the O
results O
showed O
that O
enriched O
ginger B-Plant
extract O
rhizomes O
exhibited O
the O
highest O
anti O
cancer B-Disease
activity O
on O
mcf O
7 O
cancer B-Disease
cells O
with O
ic50 O
values O
of O
34 O
8 O
and O
25 O
7 O
g O
ml O
for O
fulbaria O
and O
syedpuri O
respectively O

the O
use O
of O
ginger B-Plant
grown O
under O
elevated O
co2 O
concentration O
may O
have O
potential O
in O
the O
treatment O
and O
prevention O
of O
cancer B-Disease

projected O
effects O
of O
tobacco B-Plant
smoking O
on O
worldwide O
tuberculosis B-Disease
control O
mathematical O
modelling O
analysis O

the O
model O
estimated O
that O
aggressive O
tobacco B-Plant
control O
achieving O
a O
1 O
decrease O
in O
smoking O
prevalence O
per O
year O
down O
to O
eradication O
would O
avert O
27 O
million O
smoking O
attributable O
deaths O
from O
tuberculosis B-Disease
by O
2050 O

however O
if O
the O
prevalence O
of O
smoking O
increased O
to O
50 O
of O
adults O
as O
observed O
in O
countries O
with O
high O
tobacco B-Plant
use O
the O
model O
estimated O
that O
34 O
million O
additional O
deaths O
from O
tuberculosis B-Disease
would O
occur O
by O
2050 O

conclusions O
tobacco B-Plant
smoking O
could O
substantially O
increase O
tuberculosis B-Disease
cases O
and O
deaths O
worldwide O
in O
coming O
years O
undermining O
progress O
towards O
tuberculosis B-Disease
mortality O
targeta O
aggressive O
tobacco B-Plant
control O
could O
avert O
millions O
of O
deaths O
from O
tuberculosis B-Disease

elastase O
is O
the O
only O
currently O
identified O
target O
protein O
for O
indole O
3 O
carbinol O
i3c O
a O
naturally O
occurring O
hydrolysis O
product O
of O
glucobrassicin O
in O
cruciferous B-Plant
vegetables I-Plant
such O
as O
broccoli B-Plant
cabbage B-Plant
and O
brussels B-Plant
sprouts I-Plant
that O
induces O
a O
cell O
cycle O
arrest O
and O
apoptosis O
of O
human O
breast B-Disease
cancer I-Disease

toward O
the O
identification O
of O
communities O
with O
increased O
tobacco B-Plant
associated O
cancer B-Disease
burden O
application O
of O
spatial O
modeling O
techniques O

identifying O
areas O
with O
higher O
than O
average O
cancer B-Disease
risk O
and O
smoking O
rates O
then O
targeting O
those O
areas O
for O
intervention O
is O
one O
approach O
to O
more O
rapidly O
lower O
the O
overall O
tobacco B-Plant
disease O
burden O
in O
a O
given O
states O

our O
research O
team O
used O
spatial O
modeling O
techniques O
to O
identify O
areas O
in O
florida O
with O
higher O
than O
expected O
tobacco B-Plant
associated O
cancer B-Disease
incidence O
clusters O

materials O
and O
methods O
geocoded O
tobacco B-Plant
associated O
incident O
cancer B-Disease
data O
from O
1998 O
to O
2002 O
from O
the O
florida O
cancer O
data O
system O
were O
used O

tobacco B-Plant
associated O
cancers B-Disease
included O
lung B-Disease
esophageal B-Disease
and O
h B-Disease
n I-Disease
cancers I-Disease

satscan O
was O
used O
to O
identify O
geographic O
areas O
that O
had O
statistically O
significant O
p O
0 O
10 O
excess O
age O
adjusted O
rates O
of O
tobacco B-Plant
associated O
cancers B-Disease

however O
spatial O
analyses O
may O
be O
most O
useful O
when O
examining O
incident O
clusters O
where O
several O
tobacco B-Plant
associated O
cancer B-Disease
clusters O
overlap O

focusing O
on O
overlapping O
cancer B-Disease
clusters O
may O
help O
investigators O
identify O
priority O
areas O
for O
further O
screening O
detailed O
assessments O
of O
tobacco B-Plant
use O
and O
or O
prevention O
and O
cessation O
interventions O
to O
decrease O
risk O

epidemiological O
evidence O
shows O
that O
regular O
consumption O
of O
brassicaceae B-Plant
is O
associated O
with O
a O
reduced O
risk O
of O
cancer B-Disease
and O
heart B-Disease
disease I-Disease

coriander B-Plant
has O
been O
recommended O
for O
the O
relief O
of O
pain B-Disease
anxiety B-Disease
flatulence B-Disease
and O
loss B-Disease
of I-Disease
appetite I-Disease

in O
traditional O
medicine O
it O
is O
believed O
that O
coriander B-Plant
can O
induce O
some O
degree O
of O
amnesia B-Disease
in O
a O
child O
when O
his O
her O
mother O
uses O
coriander B-Plant
during O
the O
pregancy O

no O
modification O
in O
the O
pain B-Disease
threshold O
was O
elicited O
by O
electric O
stimuli O
both O
in O
coriander B-Plant
and O
control O
groups O

perceived O
health O
risks O
attitude O
and O
readiness O
to O
quit O
tobacco B-Plant
among O
euthymic B-Disease
bipolar I-Disease
disorder I-Disease
patients O
in O
regular O
contact O
with O
mental O
health O
services O
an O
exploratory O
study O
from O
india O

background O
patients O
with O
bipolar O
disorder O
bd B-Disease
are O
at O
higher O
risk O
of O
tobacco B-Plant
related O
harm O
compared O
with O
general O
population O

aim O
the O
study O
aims O
to O
explore O
the O
perceived O
health O
risks O
attitude O
and O
readiness O
to O
quit O
tobacco B-Plant
among O
euthymic O
bd B-Disease
patients O

the O
non O
readiness O
to O
change O
tobacco B-Plant
use O
was O
predicted O
by O
difficulty O
in O
quitting O
due O
to O
mood B-Disease
disorder I-Disease
odds O
ratio O
or O
0 O
229 O
and O
a O
higher O
perceived O
ability O
to O
quit O
or O
328 O

conclusion O
the O
knowledge O
and O
risk O
perception O
for O
tobacco B-Plant
remains O
inadequate O
even O
among O
the O
stable O
bd B-Disease
type I-Disease
i I-Disease
patients O
in O
regular O
contact O
with O
mental O
health O
services O

the O
aim O
of O
this O
review O
is O
to O
summarize O
present O
knowledge O
of O
genetic O
variation O
in O
cytochrome O
p450 O
1b1 O
cyp1b1 O
and O
2c9 O
cyp2c9 O
genes O
and O
risk O
of O
tobacco B-Plant
related O
cancer B-Disease
female O
cancer B-Disease
chronic B-Disease
obstructive I-Disease
pulmonary I-Disease
disease I-Disease
and O
ischemic B-Disease
vascular I-Disease
disease I-Disease

recently O
large O
studies O
on O
the O
association O
between O
genetic O
variation O
in O
cyp1b1 O
and O
cyp2c9 O
and O
risk O
of O
disease O
with O
considerable O
statistical O
power O
rebutted O
the O
hypotheses O
that O
these O
genetic O
variants O
affect O
risk O
of O
tobacco B-Plant
related O
cancer B-Disease
female O
cancer B-Disease
chronic B-Disease
obstructive I-Disease
pulmonary I-Disease
disease I-Disease
and O
ischemic B-Disease
vascular I-Disease
disease I-Disease

fenugreek B-Plant
a O
naturally O
occurring O
edible O
spice O
kills O
mcf O
7 O
human O
breast B-Disease
cancer I-Disease
cells O
via O
an O
apoptotic O
pathway O

trigonella B-Plant
foenum I-Plant
graecum I-Plant
fenugreek B-Plant
is O
traditionally O
applied O
to O
treat O
disorders O
such O
as O
diabetes B-Disease
high B-Disease
cholesterol I-Disease
wounds B-Disease
inflammation B-Disease
and O
gastrointestinal B-Disease
ailments I-Disease

oxyresveratrol O
is O
a O
potent O
antioxidant O
and O
free O
radical O
scavenger O
found O
in O
mulberry B-Plant
wood I-Plant
morus B-Plant
alba I-Plant
l I-Plant
with O
demonstrated O
protective O
effects O
against O
cerebral B-Disease
ischemia I-Disease

background O
olive B-Plant
oil O
consumption O
is O
associated O
with O
a O
decreased O
risk O
of O
several O
chronic B-Disease
diseases I-Disease
in O
particular O
cardiovascular B-Disease
disease I-Disease
cvd B-Disease

objective O
we O
evaluated O
the O
association O
between O
olive B-Plant
oil O
and O
overall O
and O
cause O
specific O
mortality O
in O
the O
spanish O
population O
in O
the O
european O
prospective O
investigation O
into O
cancer B-Disease
and O
nutrition O
epic O
spain O

the O
association O
between O
olive B-Plant
oil O
analyzed O
as O
a O
categorical O
and O
continuous O
variable O
and O
overall O
and O
cause O
specific O
mortality O
cvd B-Disease
cancer B-Disease
and O
other O
causes O
was O
analyzed O
by O
using O
cox O
proportional O
hazards O
regression O
models O
adjusted O
for O
potential O
confounders O

in O
comparison O
with O
nonconsumers O
the O
highest O
quartile O
of O
olive B-Plant
oil O
consumption O
was O
associated O
with O
a O
26 O
95 O
ci O
13 O
36 O
reduction O
in O
risk O
of O
overall O
mortality O
and O
a O
44 O
95 O
ci O
21 O
60 O
reduction O

in O
cvd B-Disease
for O
each O
increase O
in O
olive B-Plant
oil O
of O
10gr O
2000 O
kcal O
d O
there O
was O
a O
7 O
95 O
ci O
3 O
10 O
decreased O
risk O
of O
overall O
mortality O
and O
a O
13 O
95 O
ci O
6 O
20 O
decreased O
risk O
of O
cvd B-Disease
mortality O
no O
significant O
association O
was O
observed O
between O
olive B-Plant
oil O
and O
cancer B-Disease
mortality O

conclusions O
olive B-Plant
oil O
was O
associated O
with O
a O
decreased O
risk O
of O
overall O
mortality O
and O
an O
important O
reduction O
in O
cvd B-Disease
mortality O
in O
this O
large O
mediterranean O
cohort O

areca B-Plant
nut O
chewing O
and O
systemic B-Disease
inflammation I-Disease
evidence O
of O
a O
common O
pathway O
for O
systemic B-Disease
diseases I-Disease

diabetes B-Disease
hypertension B-Disease
cardiovascular B-Disease
diseases I-Disease
oropharyngeal B-Disease
and O
oesophageal B-Disease
cancers I-Disease
have O
been O
associated O
with O
areca B-Plant
nut O
chewing O
and O
the O
mechanism O
by O
which O
areca B-Plant
nut O
chewing O
increases O
the O
risk O
of O
systemic B-Disease
diseases I-Disease
remains O
elusive O

we O
hypothesize O
that O
systemic B-Disease
inflammation I-Disease
may O
be O
elevated O
among O
areca B-Plant
nut O
users O
which O
is O
linked O
with O
many O
systemic B-Disease
disease I-Disease

therefore O
this O
present O
study O
was O
conducted O
to O
examine O
the O
systemic B-Disease
inflammation I-Disease
among O
areca B-Plant
nut O
chewers O
and O
healthy O
control O

increase O
in O
amount O
of O
areca B-Plant
nut O
consumption O
had O
a O
significant O
dose O
response O
relationship O
with O
systemic B-Disease
inflammation I-Disease
p O
for O
trend O

areca B-Plant
nut O
chewing O
has O
a O
significant O
association O
with O
systemic B-Disease
inflammation I-Disease

further O
work O
is O
required O
to O
confirm O
that O
systemic B-Disease
inflammation I-Disease
is O
the O
main O
pathway O
by O
which O
areca B-Plant
nut O
use O
increases O
the O
risk O
of O
systemic B-Disease
diseases I-Disease

rhodiola B-Plant
crenulata I-Plant
root O
ameliorates O
derangements O
of O
glucose O
and O
lipid O
metabolism O
in O
a O
rat O
model O
of O
the O
metabolic B-Disease
syndrome I-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease

ethnopharmacological O
relevance O
rhodiola B-Plant
species O
are O
traditionally O
used O
as O
tonics O
and O
stimulants O
to O
treat O
asthenia B-Disease
suggesting O
their O
possible O
regulatory O
effect O
on O
energy O
metabolism O

materials O
and O
methods O
zucker O
diabetic B-Disease
fatty O
zdf O
rats O
were O
treated O
with O
rhodiola B-Plant
crenulata I-Plant
root O
rcr B-Plant
powder O
100 O
and O
500 O
mg O
kg O
by O
gavage O
once O
daily O
for O
4 O
weeks O

in O
addition O
the O
effects O
of O
rcr B-Plant
on O
sucrose O
induced O
acute O
hyperglycemia B-Disease
in O
mice O
and O
olive B-Plant
oil O
induced O
hypertriglyceridemia B-Disease
in O
rats O
were O
also O
examined O

however O
rcr B-Plant
minimally O
affected O
sucrose O
induced O
acute O
hyperglycemia B-Disease
in O
mice O
and O
olive B-Plant
oil O
induced O
acute O
hypertriglyceridemia B-Disease
in O
rats O

conclusions O
the O
present O
results O
demonstrate O
that O
rcr B-Plant
treatment O
improves O
metabolic O
derangements O
in O
animal O
model O
of O
the O
metabolic B-Disease
syndrome I-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease

persistent O
cigarette O
smoking O
and O
other O
tobacco B-Plant
use O
after O
a O
tobacco B-Plant
related O
cancer B-Disease
diagnosis O

these O
risks O
may O
be O
even O
higher O
among O
tobacco B-Plant
related O
cancer B-Disease
survivors O
trcs O

we O
describe O
tobacco B-Plant
use O
behaviors O
among O
trcs O
other O
cancer B-Disease
survivors O
and O
people O
without O
a O
history O
of O
cancer B-Disease

methods O
we O
used O
2009 O
behavioral O
risk O
factor O
surveillance O
system O
data O
to O
describe O
demographic O
characteristics O
smoking O
history O
current O
smoking O
prevalence O
and O
smokeless O
tobacco B-Plant
use O
among O
trcs O
other O
cancer B-Disease
survivors O
and O
people O
without O
a O
history O
of O
cancer B-Disease
cigarette O
smoking O
and O
smokeless O
tobacco B-Plant
use O
were O
calculated O
after O
adjusting O
for O
age O
sex O
race O
and O
insurance O
status O

tobacco B-Plant
related O
cancers B-Disease
were O
defined O
as O
lung O
bronchial O
pharyngeal O
laryngeal O
esophageal O
stomach O
pancreatic O
kidney O
renal O
urinary O
bladder O
cervical O
and O
acute B-Disease
myeloid I-Disease
leukemia I-Disease

smokeless O
tobacco B-Plant
use O
was O
higher O
among O
respondents O
without O
a O
history O
of O
cancer B-Disease
4 O
compared O
with O
trcs O
3 O
and O
other O
cancer B-Disease
survivors O
3 O

targeted O
smoking O
prevention O
and O
cessation O
interventions O
are O
needed O
for O
cancer B-Disease
survivors O
especially O
those O
diagnosed O
with O
a O
tobacco B-Plant
related O
cancer B-Disease

we O
provide O
the O
first O
population O
based O
report O
on O
demographic O
characteristics O
and O
tobacco B-Plant
use O
behaviors O
among O
sel O
reported O
tobacco B-Plant
related O
cancer B-Disease
survivors O

epidemiological O
studies O
suggest O
that O
cocoa B-Plant
rich O
products O
reduce O
the O
risk O
of O
cardiovascular B-Disease
disease I-Disease

epidemiological O
studies O
suggest O
that O
cocoa B-Plant
rich O
products O
reduce O
the O
risk O
of O
cardiovascular B-Disease
disease I-Disease

adverse O
effects O
including O
gastrointestinal B-Disease
complaints I-Disease
and O
distaste O
of O
the O
trial O
product O
were O
reported O
by O
5 O
of O
patients O
in O
the O
active O
cocoa B-Plant
intervention O
group O
and O
1 O
of O
patients O
in O
the O
control O
groups O

furthermore O
long O
term O
trials O
investigating O
the O
effect O
of O
cocoa B-Plant
on O
clinical O
outcomes O
are O
also O
needed O
to O
assess O
whether O
cocoa B-Plant
has O
an O
effect O
on O
cardiovascular B-Disease
events I-Disease
and O
to O
assess O
potential O
adverse O
effects O
associated O
with O
chronic O
ingestion O
of O
cocoa B-Plant
products O

aloe B-Plant
emodin O
an O
anthraquinone O
in O
vitro O
inhibits O
proliferation O
and O
induces O
apoptosis O
in O
human O
colon B-Disease
carcinoma I-Disease
cells O

the O
present O
study O
aimed O
to O
investigate O
the O
anticancer O
effect O
of O
aloe B-Plant
emodin O
an O
anthraquinone O
compound O
present O
in O
the O
leaves O
of O
aloe B-Disease
vera I-Disease
on O
two O
human O
colon B-Disease
carcinoma I-Disease
cell O
lines O
dld O
and O
widr O

colon B-Disease
carcinoma I-Disease
cells O
were O
treated O
with O
various O
concentrations O
of O
aloe B-Plant
emodin O
for O
different O
durations O

in O
addition O
exposure O
of O
colon B-Disease
carcinoma I-Disease
cells O
to O
aloe B-Plant
emodin O
suppressed O
the O
casein O
kinase O
ii O
activity O
in O
a O
time O
dependent O
manner O
and O
was O
accompanied O
by O
a O
reduced O
phosphorylation O
of O
bid O
a O
downstream O
substrate O
of O
casein O
kinase O
ii O
and O
a O
pro O
apoptotic O
molecule O

these O
findings O
showed O
that O
the O
inhibition O
of O
casein O
kinase O
ii O
activity O
the O
release O
of O
apoptosis O
inducing O
factor O
and O
cytochrome O
c O
and O
the O
caspase O
3 O
activation O
are O
involved O
in O
aloe B-Plant
emodin O
mediated O
apoptosis O
in O
colon B-Disease
carcinoma I-Disease
cells O

in O
this O
study O
we O
use O
a O
genomic O
approach O
to O
study O
the O
signaling O
processes O
associated O
with O
tobacco B-Plant
smoke O
exposure O
and O
lung B-Disease
cancer I-Disease

furthermore O
our O
findings O
suggest O
that O
the O
airway O
gene O
expression O
signatures O
derived O
in O
this O
study O
can O
provide O
novel O
insights O
into O
signaling O
pathways O
altered O
in O
the O
field O
of O
injury O
induced O
by O
tobacco B-Plant
smoke O
and O
thus O
may O
impact O
strategies O
for O
prevention O
of O
tobacco B-Plant
related O
lung B-Disease
cancer I-Disease

effects O
of O
korean O
red O
ginseng B-Plant
extracts O
on O
neural B-Disease
tube I-Disease
defects I-Disease
and O
impairment B-Disease
of I-Disease
social I-Disease
interaction I-Disease
induced O
by O
prenatal O
exposure O
to O
valproic O
acid O

using O
the O
prenatal O
valproic O
acid O
vpa O
injection O
model O
of O
autism B-Disease
spectrum I-Disease
disorder I-Disease
asd B-Disease
in O
rats O
which O
produces O
social O
impairrment O
and O
altered O
seizure B-Disease
susceptibility O
as O
in O
human O
asd B-Disease
patients O
as O
well O
as O
mild O
neural B-Disease
tube I-Disease
defects I-Disease
like O
crooked B-Disease
tail I-Disease
phenotype I-Disease
we O
examined O
whether O
chronic O
administration O
of O
red O
ginseng B-Plant
extract O
may O
rescue O
the O
social O
impairment O
and O
crooked B-Disease
tail I-Disease
phenotype I-Disease
in O
prenatally O
vpa O
exposed O
rat O
offspring O

vpa O
induced O
impairment O
in O
social O
interactions O
tested O
using O
sociability O
and O
social O
preference O
paradigms O
as O
well O
as O
crooked B-Disease
tail I-Disease
phenotypes I-Disease
were O
significantly O
improved O
by O
administration O
of O
korean O
red O
ginseng B-Plant
krg B-Plant
in O
a O
dose O
dependent O
manner O

22 O
- O
oxacalcitriol O
suppresses O
secondary B-Disease
hyperparathyroidism B-Disease
without O
inducing O
low B-Disease
bone B-Disease
turnover B-Disease
in O
dogs O
with O
renal B-Disease
failure B-Disease
. O

background O
: O
calcitriol O
therapy O
suppresses O
serum O
levels O
of O
parathyroid O
hormone O
( O
pth O
) O
in O
patients O
with O
renal B-Disease
failure B-Disease
but O
has O
several O
drawbacks O
, O
including O
hypercalcemia B-Disease
and O
/ O
or O
marked O
suppression B-Disease
of B-Disease
bone B-Disease
turnover B-Disease
, O
which O
may O
lead O
to O
adynamic B-Disease
bone B-Disease
disease B-Disease
. O

a O
new O
vitamin O
d O
analogue O
, O
22 O
- O
oxacalcitriol O
( O
oct O
) O
, O
has O
been O
shown O
to O
have O
promising O
characteristics O
. O

this O
study O
was O
undertaken O
to O
determine O
the O
effects O
of O
oct O
on O
serum O
pth O
levels O
and O
bone O
turnover O
in O
states O
of O
normal O
or O
impaired B-Disease
renal B-Disease
function B-Disease
. O

methods O
: O
sixty O
dogs O
were O
either O
nephrectomized O
( O
nx O
, O
n O
= O
38 O
) O
or O
sham O
- O
operated O
( O
sham O
, O
n O
= O
22 O
) O
. O

the O
animals O
received O
supplemental O
phosphate O
to O
enhance O
pth O
secretion O
. O

fourteen O
weeks O
after O
the O
start O
of O
phosphate O
supplementation O
, O
half O
of O
the O
nx O
and O
sham O
dogs O
received O
doses O
of O
oct O
( O
three O
times O
per O
week O
) O
; O
the O
other O
half O
were O
given O
vehicle O
for O
60 O
weeks O
. O

thereafter O
, O
the O
treatment O
modalities O
for O
a O
subset O
of O
animals O
were O
crossed O
over O
for O
an O
additional O
eight O
months O
. O

biochemical O
and O
hormonal O
indices O
of O
calcium O
and O
bone O
metabolism O
were O
measured O
throughout O
the O
study O
, O
and O
bone O
biopsies O
were O
done O
at O
baseline O
, O
60 O
weeks O
after O
oct O
or O
vehicle O
treatment O
, O
and O
at O
the O
end O
of O
the O
crossover O
period O
. O

results O
: O
in O
nx O
dogs O
, O
oct O
significantly O
decreased O
serum O
pth O
levels O
soon O
after O
the O
induction O
of O
renal B-Disease
insufficiency B-Disease
. O

in O
long O
- O
standing O
secondary B-Disease
hyperparathyroidism B-Disease
, O
oct O
( O
0 O
. O
03 O
microg O
/ O
kg O
) O
stabilized O
serum O
pth O
levels O
during O
the O
first O
months O
. O

serum O
pth O
levels O
rose O
thereafter O
, O
but O
the O
rise O
was O
less O
pronounced O
compared O
with O
baseline O
than O
the O
rise O
seen O
in O
nx O
control O
. O

these O
effects O
were O
accompanied O
by O
episodes O
of O
hypercalcemia B-Disease
and O
hyperphosphatemia B-Disease
. O

in O
animals O
with O
normal O
renal O
function O
, O
oct O
induced O
a O
transient O
decrease O
in O
serum O
pth O
levels O
at O
a O
dose O
of O
0 O
. O
1 O
microg O
/ O
kg O
, O
which O
was O
not O
sustained O
with O
lowering O
of O
the O
doses O
. O

in O
nx O
dogs O
, O
oct O
reversed O
abnormal O
bone O
formation O
, O
such O
as O
woven B-Disease
osteoid B-Disease
and O
fibrosis B-Disease
, O
but O
did O
not O
significantly O
alter O
the O
level O
of O
bone O
turnover O
. O

in O
addition O
, O
oct O
improved O
mineralization O
lag O
time O
, O
( O
that O
is O
, O
the O
rate O
at O
which O
osteoid O
mineralizes O
) O
in O
both O
nx O
and O
sham O
dogs O
. O

conclusions O
: O
these O
results O
indicate O
that O
even O
though O
oct O
does O
not O
completely O
prevent O
the O
occurrence O
of O
hypercalcemia B-Disease
in O
experimental O
dogs O
with O
renal B-Disease
insufficiency B-Disease
, O
it O
may O
be O
of O
use O
in O
the O
management O
of O
secondary B-Disease
hyperparathyroidism B-Disease
because O
it O
does O
not O
induce O
low B-Disease
bone B-Disease
turnover B-Disease
and O
, O
therefore O
, O
does O
not O
increase O
the O
risk O
of O
adynamic B-Disease
bone B-Disease
disease B-Disease
. O

hypotension B-Disease
, O
bradycardia B-Disease
, O
and O
asystole B-Disease
after O
high O
- O
dose O
intravenous O
methylprednisolone O
in O
a O
monitored O
patient O
. O

we O
report O
a O
case O
of O
hypotension B-Disease
, O
bradycardia B-Disease
, O
and O
asystole B-Disease
after O
intravenous O
administration O
of O
high O
- O
dose O
methylprednisolone O
in O
a O
73 O
- O
year O
- O
old O
patient O
who O
underwent O
electrocardiographic O
( O
ecg O
) O
monitoring O
throughout O
the O
episode O
. O

there O
was O
a O
history O
of O
ischemic B-Disease
cardiac B-Disease
disease B-Disease
9 O
years O
earlier O
. O

the O
patient O
was O
admitted O
with O
a O
pulmonary B-Disease
- B-Disease
renal B-Disease
syndrome B-Disease
with O
hemoptysis B-Disease
, O
rapidly O
progressive O
renal B-Disease
failure B-Disease
, O
and O
hypoxemia B-Disease
that O
required O
mechanical O
ventilation O
in O
the O
intensive O
care O
unit O
. O

after O
receiving O
advanced O
cardiopulmonary O
resuscitation O
, O
the O
patient O
recovered O
cardiac O
rhythm O
. O

the O
ecg O
showed O
a O
junctional O
rhythm O
without O
ventricular B-Disease
arrhythmia B-Disease
. O

this O
study O
reviews O
the O
current O
proposed O
mechanisms O
of O
sudden B-Disease
death B-Disease
after O
a O
high O
dose O
of O
intravenous O
methylprednisolone O
( O
ivmp O
) O
. O

these O
mechanisms O
are O
not O
well O
understood O
because O
, O
in O
most O
cases O
, O
the O
patients O
were O
not O
monitored O
at O
the O
moment O
of O
the O
event O
. O

rapid O
infusion O
and O
underlying O
cardiac B-Disease
disease B-Disease
were O
important O
risk O
factors O
in O
the O
case O
reported O
here O
, O
and O
the O
authors O
discount O
ventricular B-Disease
arrhythmia B-Disease
as O
the O
main O
mechanism O
. O

worsening O
of O
levodopa O
- O
induced O
dyskinesias B-Disease
by O
motor O
and O
mental O
tasks O
. O

ten O
patients O
who O
had O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
with O
disabling O
dyskinesia B-Disease
were O
included O
in O
this O
study O
to O
evaluate O
the O
role O
of O
mental O
( O
mental O
calculation O
) O
and O
motor O
( O
flexion O
/ O
extension O
of O
right O
fingers O
, O
flexion O
/ O
extension O
of O
left O
fingers O
, O
flexion O
/ O
extension O
of O
the O
neck O
, O
speaking O
aloud O
) O
tasks O
on O
the O
worsening O
of O
peak O
- O
dose O
dyskinesia B-Disease
following O
administration O
of O
an O
effective O
single O
dose O
of O
apomorphine O
. O

compared O
with O
the O
score O
at O
rest O
( O
1 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
) O
, O
a O
significant O
aggravation O
of O
the O
dyskinesia B-Disease
score O
was O
observed O
during O
speaking O
aloud O
( O
5 O
. O
2 O
+ O
/ O
- O
1 O
. O
1 O
, O
p O
< O
0 O
. O
05 O
) O
, O
movements O
of O
right O
( O
4 O
. O
5 O
+ O
/ O
- O
1 O
. O
0 O
, O
p O
< O
0 O
. O
05 O
) O
and O
left O
( O
3 O
. O
7 O
+ O
/ O
- O
0 O
. O
8 O
, O
p O
< O
0 O
. O
05 O
) O
fingers O
, O
movements O
of O
the O
neck O
( O
5 O
. O
1 O
+ O
/ O
- O
1 O
. O
0 O
, O
p O
< O
0 O
. O
05 O
) O
, O
and O
mental O
calculation O
( O
3 O
. O
1 O
+ O
/ O

- O
1 O
. O
0 O
, O
p O
< O
0 O
. O
05 O
) O
. O

these O
results O
suggest O
that O
activation O
tasks O
such O
as O
" O
speaking O
aloud O
" O
could O
be O
used O
for O
objective O
assessment O
of O
dyskinesia B-Disease
severity O
. O

urine O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
- O
- O
a O
marker O
of O
tubular O
damage O
? O

background O
: O
although O
an O
indicator O
of O
renal B-Disease
tubular B-Disease
dysfunction B-Disease
, O
an O
increased O
urinary O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
nag O
) O
activity O
might O
reflect O
increased O
lysosomal O
activity O
in O
renal O
tubular O
cells O
. O

methods O
: O
puromycin O
aminonucleoside O
( O
pan O
) O
was O
administered O
to O
sprague O
dawley O
rats O
to O
induce O
proteinuria B-Disease
. O

total O
protein O
, O
albumin O
, O
nag O
activity O
and O
protein O
electrophoretic O
pattern O
were O
assessed O
in O
daily O
urine O
samples O
for O
33 O
days O
. O

the O
morphological O
appearance O
of O
the O
kidneys O
was O
examined O
on O
days O
three O
, O
four O
, O
six O
, O
eight O
and O
thirty O
three O
and O
the O
nag O
isoenzyme O
patterns O
on O
days O
zero O
, O
four O
, O
eight O
and O
thirty O
three O
. O

results O
: O
following O
intravenous O
pan O
urine O
volume O
and O
urine O
nag O
activity O
increased O
significantly O
by O
day O
two O
, O
but O
returned O
to O
normal O
by O
day O
four O
. O

after O
day O
four O
all O
treated O
animals O
exhibited O
a O
marked O
rise O
in O
urine O
albumin O
, O
total O
protein O
excretion O
and O
nag O
activity O
. O

electrophoresis O
showed O
a O
generalised O
increase O
in O
middle O
and O
high O
molecular O
weight O
urine O
proteins O
from O
day O
four O
onwards O
. O

protein O
droplets O
first O
appeared O
prominent O
in O
tubular O
cells O
on O
day O
four O
. O

peak O
urine O
nag O
activity O
and O
a O
change O
in O
nag O
isoenzyme O
pattern O
coincided O
with O
both O
the O
peak O
proteinuria B-Disease
and O
the O
reduction O
in O
intracellular O
protein O
and O
nag O
droplets O
( O
day O
six O
onwards O
) O
. O

conclusions O
: O
this O
animal O
model O
demonstrates O
that O
an O
increase O
in O
lysosomal O
turnover O
and O
hence O
urine O
nag O
activity O
, O
occurs O
when O
increased O
protein O
is O
presented O
to O
the O
tubular O
cells O
. O

urine O
nag O
activity O
is O
thus O
a O
measure O
of O
altered O
function O
in O
the O
renal O
tubules O
and O
not O
simply O
an O
indicator O
of O
damage O
. O

cauda B-Disease
equina B-Disease
syndrome B-Disease
after O
spinal O
anaesthesia O
with O
hyperbaric O
5 O
% O
lignocaine O
: O
a O
review O
of O
six O
cases O
of O
cauda B-Disease
equina B-Disease
syndrome B-Disease
reported O
to O
the O
swedish O
pharmaceutical O
insurance O
1993 O
- O
1997 O
. O

six O
cases O
of O
cauda B-Disease
equina B-Disease
syndrome B-Disease
with O
varying O
severity O
were O
reported O
to O
the O
swedish O
pharmaceutical O
insurance O
during O
the O
period O
1993 O
- O
1997 O
. O

all O
were O
associated O
with O
spinal O
anaesthesia O
using O
hyperbaric O
5 O
% O
lignocaine O
. O

five O
cases O
had O
single O
- O
shot O
spinal O
anaesthesia O
and O
one O
had O
a O
repeat O
spinal O
anaesthetic O
due O
to O
inadequate O
block O
. O

the O
dose O
of O
hyperbaric O
5 O
% O
lignocaine O
administered O
ranged O
from O
60 O
to O
120 O
mg O
. O

three O
of O
the O
cases O
were O
most O
likely O
caused O
by O
direct O
neurotoxicity B-Disease
of O
hyperbaric O
5 O
% O
lignocaine O
. O

in O
the O
other O
3 O
cases O
, O
direct O
neurotoxicity B-Disease
was O
also O
probable O
, O
but O
unfortunately O
radiological O
investigations O
were O
not O
done O
to O
definitely O
exclude O
a O
compressive O
aetiology O
. O

all O
cases O
sustained O
permanent O
neurological B-Disease
deficits B-Disease
. O

we O
recommend O
that O
hyperbaric O
lignocaine O
should O
be O
administered O
in O
concentrations O
not O
greater O
than O
2 O
% O
and O
at O
a O
total O
dose O
preferably O
not O
exceeding O
60 O
mg O
. O

systemic O
toxicity B-Disease
following O
administration O
of O
sirolimus O
( O
formerly O
rapamycin O
) O
for O
psoriasis B-Disease
: O
association O
of O
capillary B-Disease
leak B-Disease
syndrome B-Disease
with O
apoptosis O
of O
lesional O
lymphocytes O
. O

background O
: O
sirolimus O
( O
formerly O
rapamycin O
) O
is O
an O
immunosuppressive O
agent O
that O
interferes O
with O
t O
- O
cell O
activation O
. O

after O
2 O
individuals O
with O
psoriasis B-Disease
developed O
a O
capillary B-Disease
leak B-Disease
syndrome B-Disease
following O
treatment O
with O
oral O
sirolimus O
lesional O
skin O
cells O
and O
activated O
peripheral O
blood O
cells O
were O
analyzed O
for O
induction O
of O
apoptosis O
. O

observations O
: O
a O
keratome O
skin O
specimen O
from O
1 O
patient O
with O
sirolimus O
- O
induced O
capillary B-Disease
leak B-Disease
syndrome B-Disease
had O
a O
2 O
. O
3 O
- O
fold O
increase O
in O
percentage O
of O
apoptotic O
cells O
( O
to O
48 O
% O
) O
compared O
with O
an O
unaffected O
sirolimus O
- O
treated O
patient O
with O
psoriasis B-Disease
( O
21 O
% O
) O
. O

activated O
peripheral O
blood O
t O
cells O
from O
patients O
with O
psoriasis B-Disease
tended O
to O
exhibit O
greater O
spontaneous O
or O
dexamethasone O
- O
induced O
apoptosis O
than O
did O
normal O
t O
cells O
, O
particularly O
in O
the O
presence O
of O
sirolimus O
. O

conclusions O
: O
severe O
adverse O
effects O
of O
sirolimus O
include O
fever B-Disease
, O
anemia B-Disease
, O
and O
capillary B-Disease
leak B-Disease
syndrome B-Disease
. O

these O
symptoms O
may O
be O
the O
result O
of O
drug O
- O
induced O
apoptosis O
of O
lesional O
leukocytes O
, O
especially O
activated O
t O
lymphocytes O
, O
and O
possibly O
release O
of O
inflammatory O
mediators O
. O

because O
patients O
with O
severe O
psoriasis B-Disease
may O
develop O
capillary B-Disease
leak B-Disease
from O
various O
systemic O
therapies O
, O
clinical O
monitoring O
is O
advisable O
for O
patients O
with O
inflammatory B-Disease
diseases B-Disease
who O
are O
treated O
with O
immune O
modulators O
. O

effect O
of O
lithium O
maintenance O
therapy O
on O
thyroid O
and O
parathyroid O
function O
. O

objectives O
: O
to O
assess O
changes O
induced O
by O
lithium O
maintenance O
therapy O
on O
the O
incidence O
of O
thyroid O
, O
parathyroid O
and O
ion O
alterations O
. O

these O
were O
evaluated O
with O
respect O
to O
the O
duration O
of O
lithium O
therapy O
, O
age O
, O
sex O
, O
and O
family O
history O
( O
whether O
or O
not O
the O
patient O
had O
a O
first O
- O
degree O
relative O
with O
thyroid B-Disease
disease B-Disease
) O
. O

design O
: O
prospective O
study O
. O

setting O
: O
affective O
disorders O
clinic O
at O
st O
. O

mary O
' O
s O
hospital O
, O
montreal O
. O

patients O
: O
one O
hundred O
and O
one O
patients O
( O
28 O
men O
and O
73 O
women O
) O
with O
bipolar B-Disease
disorder B-Disease
receiving O
lithium O
maintenance O
therapy O
ranging O
from O
1 O
year O
' O
s O
to O
32 O
years O
' O
duration O
. O

the O
control O
group O
consisted O
of O
82 O
patients O
with O
no O
psychiatric B-Disease
or O
endocrinological O
diagnoses O
from O
the O
hospital O
' O
s O
out O
- O
patient O
clinics O
. O

outcome O
measures O
: O
laboratory O
analyses O
of O
calcium O
, O
magnesium O
and O
thyroid O
- O
stimulating O
hormone O
levels O
performed O
before O
beginning O
lithium O
therapy O
and O
at O
biannual O
follow O
- O
up O
. O

results O
: O
hypothyroidism B-Disease
developed O
in O
40 O
patients O
, O
excluding O
8 O
patients O
who O
were O
hypothyroid B-Disease
at O
baseline O
. O

all O
patients O
having O
first O
- O
degree O
relatives O
affected O
by O
thyroid B-Disease
illness B-Disease
had O
accelerated O
onset O
of O
hypothyroidism B-Disease
( O
3 O
. O
7 O
years O
after O
onset O
of O
lithium O
therapy O
) O
compared O
with O
patients O
without O
a O
family O
history O
( O
8 O
. O
6 O
years O
after O
onset O
of O
lithium O
therapy O
) O
. O

women O
over O
60 O
years O
of O
age O
were O
more O
often O
affected O
by O
hypothyroidism B-Disease
than O
women O
under O
60 O
years O
of O
age O
( O
34 O
. O
6 O
% O
versus O
31 O
. O
9 O
% O
) O
. O

magnesium O
levels O
in O
patients O
on O
lithium O
treatment O
were O
unchanged O
from O
baseline O
levels O
. O

after O
lithium O
treatment O
, O
calcium O
levels O
were O
higher O
than O
either O
baseline O
levels O
or O
control O
levels O
. O

thus O
, O
lithium O
treatment O
counteracted O
the O
decrease O
in O
plasma O
calcium O
levels O
associated O
with O
aging O
. O

conclusions O
: O
familial O
thyroid B-Disease
illness B-Disease
is O
a O
risk O
factor O
for O
hypothyroidism B-Disease
and O
hypercalcemia B-Disease
during O
lithium O
therapy O
. O

severe O
immune O
hemolytic B-Disease
anemia B-Disease
associated O
with O
prophylactic O
use O
of O
cefotetan O
in O
obstetric O
and O
gynecologic O
procedures O
. O

second O
- O
and O
third O
- O
generation O
cephalosporins O
, O
especially O
cefotetan O
, O
are O
increasingly O
associated O
with O
severe O
, O
sometimes O
fatal O
immune O
hemolytic B-Disease
anemia B-Disease
. O

we O
noticed O
that O
10 O
of O
our O
35 O
cases O
of O
cefotetan O
- O
induced O
hemolytic B-Disease
anemias B-Disease
were O
in O
patients O
who O
had O
received O
cefotetan O
prophylactically O
for O
obstetric O
and O
gynecologic O
procedures O
. O

eight O
of O
these O
cases O
of O
severe O
immune O
hemolytic B-Disease
anemia B-Disease
are O
described O
. O

effects O
of O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
on O
hemostasis O
in O
patients O
with O
aneurysmal B-Disease
subarachnoid B-Disease
hemorrhage B-Disease
. O

platelet O
function O
is O
impaired O
by O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
with O
prominent O
anti O
- O
inflammatory O
properties O
. O

their O
safety O
in O
patients O
undergoing O
intracranial O
surgery O
is O
under O
debate O
. O

patients O
with O
aneurysmal B-Disease
subarachnoid B-Disease
hemorrhage B-Disease
( O
sah B-Disease
) O
were O
randomized O
to O
receive O
either O
ketoprofen O
, O
100 O
mg O
, O
three O
times O
a O
day O
( O
ketoprofen O
group O
, O
n O
= O
9 O
) O
or O
a O
weak O
nsaid O
, O
acetaminophen O
, O
1 O
g O
, O
three O
times O
a O
day O
( O
acetaminophen O
group O
, O
n O
= O
9 O
) O
starting O
immediately O
after O
the O
diagnosis O
of O
aneurysmal B-Disease
sah B-Disease
. O

treatment O
was O
continued O
for O
3 O
days O
postoperatively O
. O

test O
blood O
samples O
were O
taken O
before O
treatment O
and O
surgery O
as O
well O
as O
on O
the O
first O
, O
third O
, O
and O
fifth O
postoperative O
mornings O
. O

maximal O
platelet B-Disease
aggregation B-Disease
induced O
by O
6 O
microm O
of O
adenosine O
diphosphate O
decreased O
after O
administration O
of O
ketoprofen O
. O

aggregation O
was O
lower O
( O
p O
< O
. O
05 O
) O
in O
the O
ketoprofen O
group O
than O
in O
the O
acetaminophen O
group O
just O
before O
surgery O
and O
on O
the O
third O
postoperative O
day O
. O

in O
contrast O
, O
maximal O
platelet B-Disease
aggregation B-Disease
increased O
in O
the O
acetaminophen O
group O
on O
the O
third O
postoperative O
day O
as O
compared O
with O
the O
pretreatment O
platelet B-Disease
aggregation B-Disease
results O
( O
p O
< O
. O
05 O
) O
. O

one O
patient O
in O
the O
ketoprofen O
group O
developed O
a O
postoperative O
intracranial O
hematoma B-Disease
. O

coagulation O
( O
prothrombin O
time O
[ O
pt O
] O
, O
activated O
partial O
thromboplastin O
time O
[ O
appt O
] O
, O
fibrinogen O
concentration O
, O
and O
antithrombin O
iii O
[ O
at O
iii O
] O
) O
was O
comparable O
between O
the O
two O
groups O
. O

ketoprofen O
but O
not O
acetaminophen O
impaired O
platelet O
function O
in O
patients O
with O
sah B-Disease
. O

if O
ketoprofen O
is O
used O
before O
surgery O
on O
cerebral O
artery B-Disease
aneurysms B-Disease
, O
it O
may O
pose O
an O
additional O
risk O
factor O
for O
hemorrhage B-Disease
. O

nitric O
oxide O
synthase O
expression O
in O
the O
course O
of O
lead O
- O
induced O
hypertension B-Disease
. O

we O
recently O
showed O
elevated O
reactive O
oxygen O
species O
( O
ros O
) O
, O
reduced O
urinary O
excretion O
of O
no O
metabolites O
( O
nox O
) O
, O
and O
increased O
no O
sequestration O
as O
nitrotyrosine O
in O
various O
tissues O
in O
rats O
with O
lead O
- O
induced O
hypertension B-Disease
. O

this O
study O
was O
designed O
to O
discern O
whether O
the O
reduction O
in O
urinary O
nox O
in O
lead O
- O
induced O
hypertension B-Disease
is O
, O
in O
part O
, O
due O
to O
depressed O
no O
synthase O
( O
nos O
) O
expression O
. O

male O
sprague O
- O
dawley O
rats O
were O
randomly O
assigned O
to O
a O
lead O
- O
treated O
group O
( O
given O
lead O
acetate O
, O
100 O
ppm O
, O
in O
drinking O
water O
and O
regular O
rat O
chow O
) O
, O
a O
group O
given O
lead O
and O
vitamin O
e O
- O
fortified O
chow O
, O
or O
a O
normal O
control O
group O
given O
either O
regular O
food O
and O
water O
or O
vitamin O
e O
- O
fortified O
food O
for O
12 O
weeks O
. O

tail O
blood O
pressure O
, O
urinary O
nox O
excretion O
, O
plasma O
malondialdehyde O
( O
mda O
) O
, O
and O
endothelial O
and O
inducible O
nos O
( O
enos O
and O
inos O
) O
isotypes O
in O
the O
aorta O
and O
kidney O
were O
measured O
. O

the O
lead O
- O
treated O
group O
exhibited O
a O
rise O
in O
blood O
pressure O
and O
plasma O
mda O
concentration O
, O
a O
fall O
in O
urinary O
nox O
excretion O
, O
and O
a O
paradoxical O
rise O
in O
vascular O
and O
renal O
tissue O
enos O
and O
inos O
expression O
. O

vitamin O
e O
supplementation O
ameliorated O
hypertension B-Disease
, O
lowered O
plasma O
mda O
concentration O
, O
and O
raised O
urinary O
nox O
excretion O
while O
significantly O
lowering O
vascular O
, O
but O
not O
renal O
, O
tissue O
enos O
and O
inos O
expression O
. O

vitamin O
e O
supplementation O
had O
no O
effect O
on O
either O
blood O
pressure O
, O
plasma O
mda O
, O
or O
nos O
expression O
in O
the O
control O
group O
. O

the O
study O
also O
revealed O
significant O
inhibition O
of O
nos O
enzymatic O
activity O
by O
lead O
in O
cell O
- O
free O
preparations O
. O

in O
conclusion O
, O
lead O
- O
induced O
hypertension B-Disease
in O
this O
model O
was O
associated O
with O
a O
compensatory O
upregulation O
of O
renal O
and O
vascular O
enos O
and O
inos O
expression O
. O

this O
is O
, O
in O
part O
, O
due O
to O
ros O
- O
mediated O
no O
inactivation O
, O
lead O
- O
associated O
inhibition O
of O
nos O
activity O
, O
and O
perhaps O
stimulatory O
actions O
of O
increased O
shear O
stress O
associated O
with O
hypertension B-Disease
. O

glyceryl O
trinitrate O
induces O
attacks O
of O
migraine B-Disease
without B-Disease
aura B-Disease
in O
sufferers O
of O
migraine B-Disease
with B-Disease
aura B-Disease
. O

migraine B-Disease
with B-Disease
aura B-Disease
and O
migraine B-Disease
without B-Disease
aura B-Disease
have O
the O
same O
pain B-Disease
phase O
, O
thus O
indicating O
that O
migraine B-Disease
with B-Disease
aura B-Disease
and O
migraine B-Disease
without B-Disease
aura B-Disease
share O
a O
common O
pathway O
of O
nociception O
. O

in O
recent O
years O
, O
increasing O
evidence O
has O
suggested O
that O
the O
messenger O
molecule O
nitric O
oxide O
( O
no O
) O
is O
involved O
in O
pain B-Disease
mechanisms O
of O
migraine B-Disease
without B-Disease
aura B-Disease
. O

in O
order O
to O
clarify O
whether O
the O
same O
is O
true O
for O
migraine B-Disease
with B-Disease
aura B-Disease
, O
in O
the O
present O
study O
we O
examined O
the O
headache B-Disease
response O
to O
intravenous O
infusion O
of O
glyceryl O
trinitrate O
( O
gtn O
) O
( O
0 O
. O
5 O
microg O
/ O
kg O
/ O
min O
for O
20 O
min O
) O
in O
12 O
sufferers O
of O
migraine B-Disease
with B-Disease
aura B-Disease
. O

the O
specific O
aim O
was O
to O
elucidate O
whether O
an O
aura O
and O
/ O
or O
an O
attack O
of O
migraine B-Disease
without B-Disease
aura B-Disease
could O
be O
induced O
. O

fourteen O
healthy O
subjects O
served O
as O
controls O
. O

aura O
symptoms O
were O
not O
elicited O
in O
any O
subject O
. O

headache B-Disease
was O
more O
severe O
in O
migraineurs B-Disease
than O
in O
the O
controls O
during O
and O
immediately O
after O
gtn O
infusion O
( O
p O
= O
0 O
. O
037 O
) O
as O
well O
as O
during O
the O
following O
11 O
h O
( O
p O
= O
0 O
. O
008 O
) O
. O

in O
the O
controls O
, O
the O
gtn O
- O
induced O
headache B-Disease
gradually O
disappeared O
, O
whereas O
in O
migraineurs B-Disease
peak O
headache B-Disease
intensity O
occurred O
at O
a O
mean O
time O
of O
240 O
min O
post O
- O
infusion O
. O

at O
this O
time O
the O
induced O
headache B-Disease
in O
6 O
of O
12 O
migraineurs B-Disease
fulfilled O
the O
diagnostic O
criteria O
for O
migraine B-Disease
without B-Disease
aura B-Disease
of O
the O
international O
headache B-Disease
society O
. O

the O
results O
therefore O
suggest O
that O
no O
is O
involved O
in O
the O
pain B-Disease
mechanisms O
of O
migraine B-Disease
with B-Disease
aura B-Disease
. O

since O
cortical O
spreading O
depression B-Disease
has O
been O
shown O
to O
liberate O
no O
in O
animals O
, O
this O
finding O
may O
help O
our O
understanding O
of O
the O
coupling O
between O
cortical O
spreading O
depression B-Disease
and O
headache B-Disease
in O
migraine B-Disease
with B-Disease
aura B-Disease
. O

rapid O
reversal O
of O
life O
- O
threatening O
diltiazem O
- O
induced O
tetany B-Disease
with O
calcium O
chloride O
. O

we O
describe O
a O
patient O
who O
developed O
tetany B-Disease
with O
sudden O
respiratory B-Disease
arrest B-Disease
after O
the O
infusion O
of O
intravenous O
diltiazem O
. O

the O
administration O
of O
calcium O
chloride O
rapidly O
resolved O
the O
patient O
' O
s O
tetany B-Disease
with O
prompt O
recovery O
of O
respiratory O
function O
, O
averting O
the O
need O
for O
more O
aggressive O
airway O
management O
and O
ventilatory O
support O
. O

the O
emergency O
physician O
should O
be O
aware O
that O
life O
- O
threatening O
tetany B-Disease
may O
accompany O
the O
administration O
of O
intravenous O
diltiazem O
and O
that O
calcium O
chloride O
may O
be O
a O
rapid O
and O
effective O
remedy O
. O

predictors O
of O
decreased B-Disease
renal B-Disease
function B-Disease
in O
patients O
with O
heart B-Disease
failure B-Disease
during O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
: O
results O
from O
the O
studies O
of O
left B-Disease
ventricular B-Disease
dysfunction B-Disease
( O
solvd O
) O

background O
: O
although O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
reduces O
mortality O
rates O
in O
patients O
with O
congestive B-Disease
heart B-Disease
failure B-Disease
( O
chf B-Disease
) O
, O
it O
may O
also O
cause O
decreased B-Disease
renal B-Disease
function B-Disease
. O

little O
information O
is O
available O
to O
predict O
which O
patients O
are O
at O
highest O
risk O
for O
this O
complication O
. O

objective O
: O
to O
quantify O
specific O
clinical O
predictors O
of O
reduction B-Disease
in B-Disease
renal B-Disease
function B-Disease
in O
patients O
with O
chf B-Disease
who O
are O
prescribed O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
. O

method O
: O
we O
analyzed O
data O
from O
the O
studies O
of O
left B-Disease
ventricular B-Disease
dysfunction B-Disease
( O
solvd O
) O
, O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
of O
enalapril O
for O
the O
treatment O
of O
chf B-Disease
. O

there O
were O
3379 O
patients O
randomly O
assigned O
to O
enalapril O
with O
a O
median O
follow O
- O
up O
of O
974 O
days O
and O
3379 O
patients O
randomly O
assigned O
to O
placebo O
with O
a O
mean O
follow O
- O
up O
of O
967 O
days O
. O

decreased B-Disease
renal B-Disease
function B-Disease
was O
defined O
as O
a O
rise O
in O
serum O
creatinine O
> O
/ O
= O
0 O
. O
5 O
mg O
/ O
dl O
( O
44 O
micromol O
/ O
l O
) O
from O
baseline O
. O

we O
used O
time O
- O
to O
- O
event O
analysis O
to O
identify O
potential O
predictors O
of O
decrease O
in O
renal O
function O
including O
age O
, O
baseline O
ejection O
fraction O
, O
baseline O
creatinine O
, O
low O
systolic O
blood O
pressure O
( O
< O
100 O
mm O
hg O
) O
, O
history O
of O
hypertension B-Disease
, O
diabetes B-Disease
, O
and O
use O
of O
antiplatelet O
, O
diuretic O
, O
and O
beta O
- O
blocker O
therapy O
. O

results O
: O
patients O
randomly O
assigned O
to O
enalapril O
had O
a O
33 O
% O
greater O
likelihood O
of O
decreased B-Disease
renal B-Disease
function B-Disease
than O
controls O
( O
p O
= O
. O
003 O
) O
. O

by O
multivariate O
analysis O
, O
in O
both O
the O
placebo O
and O
enalapril O
groups O
older O
age O
, O
diuretic O
therapy O
, O
and O
diabetes B-Disease
were O
associated O
with O
decreased B-Disease
renal B-Disease
function B-Disease
, O
whereas O
beta O
- O
blocker O
therapy O
and O
higher O
ejection O
fraction O
were O
renoprotective O
. O

older O
age O
was O
associated O
with O
a O
greater O
risk O
of O
developing O
decreased B-Disease
renal B-Disease
function B-Disease
in O
both O
groups O
, O
but O
significantly O
more O
so O
in O
the O
enalapril O
group O
( O
enalapril O
: O
risk O
ratio O
[ O
rr O
] O
1 O
. O
42 O
per O
10 O
years O
, O
95 O
% O
confidence O
interval O
[ O
ci O
] O
1 O
. O
32 O
- O
1 O
. O
52 O
with O
enalapril O
; O
placebo O
: O
rr O
1 O
. O
18 O
, O
95 O
% O
ci O
1 O
. O
12 O
- O
1 O
. O
25 O
) O
. O

diuretic O
therapy O
was O
likewise O
associated O
with O
a O
greater O
risk O
of O
decreased B-Disease
renal B-Disease
function B-Disease
in O
the O
enalapril O
group O
( O
rr O
1 O
. O
89 O
, O
95 O
% O
ci O
1 O
. O
70 O
- O
2 O
. O
08 O
) O
than O
in O
the O
placebo O
group O
( O
rr O
1 O
. O
35 O
, O
95 O
% O
ci O
1 O
. O
09 O
- O
1 O
. O
66 O
) O
. O

conversely O
, O
enalapril O
had O
a O
relative O
renoprotective O
effect O
( O
rr O
1 O
. O
33 O
, O
95 O
% O
ci O
1 O
. O
13 O
- O
1 O
. O
53 O
) O
compared O
with O
placebo O
( O
rr O
1 O
. O
96 O
, O
95 O
% O
ci O
1 O
. O
57 O
- O
2 O
. O
44 O
) O
in O
patients O
with O
diabetes B-Disease
. O

a O
lower O
risk O
of O
renal B-Disease
impairment B-Disease
was O
seen O
in O
both O
groups O
with O
beta O
- O
blocker O
therapy O
( O
rr O
0 O
. O
70 O
, O
95 O
% O
ci O
0 O
. O
57 O
- O
0 O
. O
85 O
) O
and O
higher O
baseline O
ejection O
fraction O
( O
rr O
0 O
. O
93 O
per O
5 O
% O
increment O
, O
95 O
% O
ci O
0 O
. O
91 O
- O
0 O
. O
96 O
) O
. O

conclusions O
: O
enalapril O
use O
caused O
a O
33 O
% O
increase O
in O
the O
risk O
of O
decreased B-Disease
renal B-Disease
function B-Disease
in O
patients O
with O
chf B-Disease
. O

diuretic O
use O
and O
advanced O
age O
increased O
this O
risk O
. O

diabetes B-Disease
was O
associated O
with O
an O
increased O
risk O
of O
renal B-Disease
impairment B-Disease
in O
all O
patients O
with O
chf B-Disease
, O
but O
this O
risk O
was O
reduced O
in O
the O
enalapril O
group O
compared O
with O
the O
placebo O
group O
. O

beta O
- O
blocker O
therapy O
and O
higher O
ejection O
fraction O
were O
renoprotective O
in O
all O
patients O
regardless O
of O
therapy O
. O

hypomania B-Disease
- O
like O
syndrome O
induced O
by O
olanzapine O
. O

we O
report O
a O
female O
patient O
with O
a O
diagnosis O
of O
a O
not O
otherwise O
specified O
psychotic B-Disease
disorder B-Disease
( O
dsm O
- O
iv O
) O
who O
developed O
hypomania B-Disease
shortly O
after O
the O
introduction O
of O
olanzapine O
treatment O
. O

acetazolamide O
- O
induced O
gerstmann B-Disease
syndrome B-Disease
. O

acute O
confusion B-Disease
induced O
by O
acetazolamide O
is O
a O
well O
known O
adverse O
drug O
reaction O
in O
patients O
with O
renal B-Disease
impairment B-Disease
. O

we O
report O
a O
case O
of O
acetazolamide O
- O
induced O
gerstmann B-Disease
syndrome B-Disease
in O
a O
patient O
with O
normal O
renal O
function O
, O
to O
highlight O
predisposing O
factors O
that O
are O
frequently O
overlooked O
. O

vasopressin O
in O
the O
treatment O
of O
milrinone O
- O
induced O
hypotension B-Disease
in O
severe O
heart B-Disease
failure B-Disease
. O

the O
use O
of O
phosphodiesterase O
inhibitors O
such O
as O
milrinone O
in O
the O
treatment O
of O
severe O
heart B-Disease
failure B-Disease
is O
frequently O
restricted O
because O
they O
cause O
vasodilation O
and O
hypotension B-Disease
. O

in O
patients O
with O
decompensated O
heart B-Disease
failure B-Disease
with O
hypotension B-Disease
after O
treatment O
with O
milrinone O
, O
low O
doses O
of O
vasopressin O
restored O
blood O
pressure O
without O
inhibiting O
the O
inotropic O
effect O
of O
milrinone O
. O

treatment O
of O
tacrolimus O
- O
related O
adverse O
effects O
by O
conversion O
to O
cyclosporine O
in O
liver O
transplant O
recipients O
. O

when O
tacrolimus O
side O
effects O
persist O
despite O
dose O
reduction O
, O
conversion O
to O
cyclosporine O
- O
based O
immunosuppression O
( O
cya O
) O
is O
necessary O
. O

we O
characterized O
tacrolimus O
side O
effects O
that O
warranted O
discontinuation O
of O
the O
drug O
, O
and O
outcomes O
after O
conversion O
. O

of O
388 O
liver O
recipients O
who O
received O
tacrolimus O
as O
primary O
immunosuppression O
, O
70 O
required O
conversion O
to O
cya O
. O

we O
recorded O
indication O
for O
conversion O
, O
whether O
conversion O
was O
early O
or O
late O
after O
transplantation O
, O
tacrolimus O
dose O
and O
trough O
blood O
level O
at O
conversion O
, O
and O
incidence O
of O
rejection O
after O
conversion O
. O

conversion O
was O
early O
in O
29 O
patients O
( O
41 O
. O
4 O
% O
) O
and O
late O
in O
41 O
( O
58 O
. O
6 O
% O
) O
. O

indications O
for O
early O
conversion O
were O
neurotoxicity B-Disease
( O
20 O
) O
, O
( B-Disease
insulin B-Disease
- B-Disease
dependent B-Disease
) B-Disease
diabetes B-Disease
mellitus B-Disease
( O
iddm B-Disease
) O
( O
5 O
) O
, O
nephrotoxicity B-Disease
( O
3 O
) O
, O
gastrointestinal B-Disease
( B-Disease
gi B-Disease
) B-Disease
toxicity B-Disease
( O
6 O
) O
, O
and O
cardiomyopathy B-Disease
( O
1 O
) O
, O
and O
for O
late O
conversion O
were O
neurotoxicity B-Disease
( O
15 O
) O
, O
iddm B-Disease
( O
12 O
) O
, O
nephrotoxicity B-Disease
( O
3 O
) O
, O
gi B-Disease
toxicity B-Disease
( O
5 O
) O
, O
hepatotoxicity B-Disease
( O
6 O
) O
, O
post B-Disease
- B-Disease
transplant B-Disease

lmphoproliferate B-Disease
disease B-Disease
( O
ptld B-Disease
) O
( O
2 O
) O
, O
cardiomyopathy B-Disease
( O
1 O
) O
, O
hemolytic B-Disease
anemia B-Disease
( O
1 O
) O
, O
and O
pruritus B-Disease
( O
1 O
) O
. O

all O
early O
- O
conversion O
patients O
showed O
improvement O
/ O
resolution O
of O
symptoms O
. O

among O
late O
- O
conversion O
patients O
, O
37 O
( O
90 O
. O
2 O
% O
) O
had O
improvement O
/ O
resolution O
; O
in O
4 O
( O
9 O
. O
8 O
% O
) O
, O
adverse O
effects O
persisted O
. O

the O
overall O
rejection O
rate O
was O
30 O
% O
. O

sixty O
- O
two O
patients O
( O
88 O
. O
6 O
% O
) O
are O
alive O
with O
functioning O
grafts O
686 O
+ O
/ O
- O
362 O
days O
( O
range O
, O
154 O
- O
1433 O
days O
) O
after O
conversion O
. O

when O
tacrolimus O
side O
effects O
are O
unresponsive O
to O
dose O
reduction O
, O
conversion O
to O
cya O
can O
be O
accomplished O
safely O
, O
with O
no O
increased O
risk O
of O
rejection O
and O
excellent O
long O
- O
term O
outcome O
. O

ocular O
manifestations O
of O
juvenile B-Disease
rheumatoid B-Disease
arthritis B-Disease
. O

we O
followed O
210 O
cases O
of O
juvenile B-Disease
rheumatoid B-Disease
arthritis B-Disease
closely O
for O
eleven O
years O
. O

thirty O
- O
six O
of O
the O
210 O
patients O
( O
17 O
. O
2 O
% O
) O
developed O
iridocyclitis B-Disease
. O

iridocyclitis B-Disease
was O
seen O
most O
frequently O
in O
young O
female O
patients O
( O
0 O
to O
4 O
years O
) O
with O
the O
monoarticular O
or O
pauciatricular O
form O
of O
the O
arthritis B-Disease
. O

however O
, O
30 O
% O
of O
the O
patients O
developed O
uveitis B-Disease
after O
16 O
years O
of O
age O
. O

although O
61 O
% O
of O
patients O
had O
a O
noncontributory O
ocular O
history O
on O
entry O
, O
42 O
% O
had O
active O
uveitis B-Disease
on O
entry O
. O

our O
approach O
was O
effective O
in O
detecting O
uveitis B-Disease
in O
new O
cases O
and O
exacerbations O
of O
uveitis B-Disease
in O
established O
cases O
. O

forty O
- O
four O
percent O
of O
patients O
with O
uveitis B-Disease
had O
one O
or O
more O
identifiable O
signs O
or O
symptoms O
, O
such O
as O
red O
eye O
, O
ocular B-Disease
pain B-Disease
, O
decreased B-Disease
visual B-Disease
acuity B-Disease
, O
or O
photophobia B-Disease
, O
in O
order O
of O
decreasing O
frequency O
. O

even O
after O
early O
detection O
and O
prompt O
treatment O
, O
41 O
% O
of O
cases O
of O
uveitis B-Disease
did O
not O
respond O
to O
more O
than O
six O
months O
of O
intensive O
topical O
treatment O
with O
corticosteroids O
and O
mydriatics O
. O

despite O
this O
, O
there O
was O
a O
dramatic O
decrease O
in O
the O
50 O
% O
incidence O
of O
blinding O
complications O
of O
uveitis B-Disease
cited O
in O
earlier O
studies O
. O

cataract B-Disease
and O
band B-Disease
keratopathy B-Disease
occurred O
in O
only O
22 O
and O
13 O
% O
of O
our O
group O
, O
respectively O
. O

we O
used O
chloroquine O
or O
hydroxychloroquine O
in O
173 O
of O
210 O
cases O
and O
found O
only O
one O
case O
of O
chorioretinopathy B-Disease
attributable O
to O
these O
drugs O
. O

systemically O
administered O
corticosteroids O
were O
used O
in O
75 O
of O
210 O
cases O
; O
a O
significant O
number O
of O
posterior O
subcapsular O
cataracts B-Disease
was O
found O
. O

typical O
keratoconjunctivitis B-Disease
sicca O
developed O
in O
three O
of O
the O
uveitis B-Disease
cases O
. O

this O
association O
with O
uveitis B-Disease
and O
jra O
was O
not O
noted O
previously O
. O

surgical O
treatment O
of O
cataracts B-Disease
, O
band B-Disease
keratopathy B-Disease
, O
and O
glaucoma B-Disease
achieved O
uniformly O
discouraging O
results O
. O

cyclophosphamide O
- O
induced O
cystitis B-Disease
in O
freely O
- O
moving O
conscious O
rats O
: O
behavioral O
approach O
to O
a O
new O
model O
of O
visceral B-Disease
pain B-Disease
. O

purpose O
: O
to O
develop O
a O
model O
of O
visceral B-Disease
pain B-Disease
in O
rats O
using O
a O
behavioral O
approach O
. O

cyclophosphamide O
( O
cp O
) O
, O
an O
antitumoral O
agent O
known O
to O
produce O
toxic O
effects O
on O
the O
bladder O
wall O
through O
its O
main O
toxic O
metabolite O
acrolein O
, O
was O
used O
to O
induce O
cystitis B-Disease
. O

materials O
and O
methods O
: O
cp O
was O
administered O
at O
doses O
of O
50 O
, O
100 O
and O
200 O
mg O
. O
/ O
kg O
. O

i O
. O
p O
. O
to O
male O
rats O
, O
and O
their O
behavior O
observed O
and O
scored O
. O

the O
effects O
of O
morphine O
( O
0 O
. O
5 O
to O
4 O
mg O
. O
/ O
kg O
. O
i O
. O
v O
. O
) O
on O
cp O
- O
induced O
behavioral O
modifications O
were O
tested O
administered O
alone O
and O
after O
naloxone O
( O
1 O
mg O
. O
/ O
kg O
. O
s O
. O
c O
. O
) O
. O

in O
addition O
, O
90 O
minutes O
after O
cp O
injection O
, O
that O
is O
, O
at O
the O
time O
of O
administration O
of O
morphine O
, O
the O
bladder O
was O
removed O
in O
some O
rats O
for O
histological O
examination O
. O

finally O
, O
to O
show O
that O
the O
bladder O
is O
essential O
for O
the O
cp O
- O
induced O
behavioral O
modifications O
, O
female O
rats O
also O
received O
cp O
at O
doses O
of O
200 O
mg O
. O
/ O
kg O
. O

i O
. O
p O
. O
and O
of O
20 O
mg O
. O
by O
the O
intravesical O
route O
, O
and O
acrolein O
at O
doses O
of O
0 O
. O
5 O
mg O
. O
by O
the O
intravesical O
route O
and O
of O
5 O
mg O
. O
/ O
kg O
. O

i O
. O
v O
. O
results O
: O
cp O
dose O
- O
relatedly O
induced O
marked O
behavioral O
modifications O
in O
male O
rats O
: O
breathing O
rate O
decrease O
, O
closing O
of O
the O
eyes O
and O
occurrence O
of O
specific O
postures O
. O

morphine O
dose O
- O
dependently O
reversed O
these O
behavioral B-Disease
disorders B-Disease
. O

a O
dose O
of O
0 O
. O
5 O
mg O
. O
/ O
kg O
. O
produced O
a O
reduction O
of O
almost O
50 O
% O
of O
the O
behavioral O
score O
induced O
by O
cp O
200 O
mg O
. O
/ O
kg O
. O

this O
effect O
was O
completely O
prevented O
by O
pretreatment O
with O
naloxone O
. O

at O
the O
time O
of O
administration O
of O
morphine O
, O
histological O
modifications O
of O
the O
bladder O
wall O
, O
such O
as O
chorionic O
and O
muscle O
layer O
edema B-Disease
, O
were O
observed O
. O

in O
female O
rats O
, O
cp O
200 O
mg O
. O
/ O
kg O
. O

i O
. O
p O
. O
produced O
the O
same O
marked O
behavioral O
modifications O
as O
those O
observed O
in O
male O
rats O
. O

administered O
at O
the O
dose O
of O
20 O
mg O
. O
intravesically O
, O
cp O
did O
not O
produce O
any O
behavioral O
effects O
, O
whereas O
acrolein O
at O
0 O
. O
5 O
mg O
. O
intravesically O
induced O
behavioral O
modifications O
identical O
to O
those O
under O
cp O
200 O
mg O
. O
/ O
kg O
. O

i O
. O
p O
. O
, O
with O
the O
same O
maximal O
levels O
. O

conversely O
, O
acrolein O
5 O
mg O
. O
/ O
kg O
. O

i O
. O
v O
. O
did O
not O
produce O
any O
behavioral O
effects O
at O
all O
. O

conclusions O
: O
overall O
, O
these O
results O
indicate O
that O
this O
experimental O
model O
of O
cp O
- O
induced O
cystitis B-Disease
may O
be O
an O
interesting O
new O
behavioral O
model O
of O
inflammatory O
visceral B-Disease
pain B-Disease
, O
allowing O
a O
better O
understanding O
of O
these O
painful B-Disease
syndromes B-Disease
and O
thus O
a O
better O
therapeutic O
approach O
to O
them O
. O

prednisolone O
- O
induced O
muscle B-Disease
dysfunction B-Disease
is O
caused O
more O
by O
atrophy B-Disease
than O
by O
altered O
acetylcholine O
receptor O
expression O
. O

large O
doses O
of O
glucocorticoids O
can O
alter O
muscle O
physiology O
and O
susceptibility O
to O
neuromuscular O
blocking O
drugs O
by O
mechanisms O
not O
clearly O
understood O
. O

we O
investigated O
the O
effects O
of O
moderate O
and O
large O
doses O
of O
prednisolone O
on O
muscle O
function O
and O
pharmacology O
, O
and O
their O
relationship O
to O
changes O
in O
muscle O
size O
and O
acetylcholine O
receptor O
( O
achr O
) O
expression O
. O

with O
institutional O
approval O
, O
35 O
sprague O
- O
dawley O
rats O
were O
randomly O
allocated O
to O
receive O
daily O
subcutaneous O
doses O
of O
10 O
mg O
/ O
kg O
prednisolone O
( O
p10 O
group O
) O
, O
100 O
mg O
/ O
kg O
prednisolone O
( O
p100 O
group O
) O
, O
or O
an O
equal O
volume O
of O
saline O
( O
s O
group O
) O
for O
7 O
days O
. O

a O
fourth O
group O
of O
rats O
was O
pair O
fed O
( O
food O
restricted O
) O
with O
the O
p100 O
rats O
for O
7 O
days O
( O
fr O
group O
) O
. O

on O
day O
8 O
, O
the O
nerve O
- O
evoked O
peak O
twitch O
tensions O
, O
tetanic B-Disease
tensions O
, O
and O
fatigability O
, O
and O
the O
dose O
- O
response O
curves O
of O
d O
- O
tubocurarine O
in O
the O
tibialis O
cranialis O
muscle O
were O
measured O
in O
vivo O
and O
related O
to O
muscle O
mass O
or O
expression O
of O
achrs O
. O

rate O
of O
body O
weight O
gain O
was O
depressed O
in O
the O
p100 O
, O
fr O
, O
and O
p10 O
groups O
compared O
with O
the O
s O
group O
. O

tibialis O
muscle O
mass O
was O
smaller O
in O
the O
p100 O
group O
than O
in O
the O
p10 O
or O
s O
groups O
. O

the O
evoked O
peak O
twitch O
and O
tetanic B-Disease
tensions O
were O
less O
in O
the O
p100 O
group O
than O
in O
the O
p10 O
or O
s O
groups O
, O
however O
, O
tension O
per O
milligram O
of O
muscle O
mass O
was O
greater O
in O
the O
p100 O
group O
than O
in O
the O
s O
group O
. O

the O
50 O
% O
effective O
dose O
of O
d O
- O
tubocurarine O
( O
microg O
/ O
kg O
) O
in O
the O
tibialis O
muscle O
was O
smaller O
in O
the O
p10 O
( O
33 O
. O
6 O
+ O
/ O
- O
5 O
. O
4 O
) O
than O
in O
the O
s O
( O
61 O
. O
9 O
+ O
/ O
- O
5 O
. O
0 O
) O
or O
the O
p100 O
( O
71 O
. O
3 O
+ O
/ O
- O
9 O
. O
6 O
) O
groups O
. O

achr O
expression O
was O
less O
in O
the O
p10 O
group O
than O
in O
the O
s O
group O
. O

the O
evoked O
tensions O
correlated O
with O
muscle O
mass O
( O
r O
( O
2 O
) O
= O
0 O
. O
32 O
, O
p O
< O
0 O
. O
001 O
) O
, O
however O
, O
not O
with O
expression O
of O
achr O
. O

the O
50 O
% O
effective O
dose O
of O
d O
- O
tubocurarine O
did O
not O
correlate O
with O
muscle O
mass O
or O
achr O
expression O
. O

our O
results O
suggest O
that O
the O
neuromuscular B-Disease
dysfunction B-Disease
after O
prednisolone O
is O
dose O
- O
dependent O
, O
and O
derives O
primarily O
from O
muscle B-Disease
atrophy B-Disease
and O
derives O
less O
so O
from O
changes O
in O
achr O
expression O
. O

implications O
: O
the O
mechanisms O
by O
which O
chronic O
glucocorticoid O
therapy O
alters O
neuromuscular O
physiology O
and O
pharmacology O
are O
unclear O
. O

we O
suggest O
that O
the O
observed O
effects O
are O
dose O
- O
dependent O
and O
derive O
primarily O
from O
muscle B-Disease
atrophy B-Disease
and O
derive O
less O
from O
changes O
in O
acetylcholine O
receptor O
expression O
. O

apomorphine O
: O
an O
underutilized O
therapy O
for O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

apomorphine O
was O
the O
first O
dopaminergic O
drug O
ever O
used O
to O
treat O
symptoms O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

while O
powerful O
antiparkinsonian O
effects O
had O
been O
observed O
as O
early O
as O
1951 O
, O
the O
potential O
of O
treating O
fluctuating O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
by O
subcutaneous O
administration O
of O
apomorphine O
has O
only O
recently O
become O
the O
subject O
of O
systematic O
study O
. O

a O
number O
of O
small O
scale O
clinical O
trials O
have O
unequivocally O
shown O
that O
intermittent O
subcutaneous O
apomorphine O
injections O
produce O
antiparkinsonian O
benefit O
close O
if O
not O
identical O
to O
that O
seen O
with O
levodopa O
and O
that O
apomorphine O
rescue O
injections O
can O
reliably O
revert O
off O
- O
periods O
even O
in O
patients O
with O
complex O
on O
- O
off O
motor O
swings O
. O

continuous O
subcutaneous O
apomorphine O
infusions O
can O
reduce O
daily O
off O
- O
time O
by O
more O
than O
50 O
% O
in O
this O
group O
of O
patients O
, O
which O
appears O
to O
be O
a O
stronger O
effect O
than O
that O
generally O
seen O
with O
add O
- O
on O
therapy O
with O
oral O
dopamine O
agonists O
or O
comt O
inhibitors O
. O

extended O
follow O
- O
up O
studies O
of O
up O
to O
8 O
years O
have O
demonstrated O
long O
- O
term O
persistence O
of O
apomorphine O
efficacy O
. O

in O
addition O
, O
there O
is O
convincing O
clinical O
evidence O
that O
monotherapy O
with O
continuous O
subcutaneous O
apomorphine O
infusions O
is O
associated O
with O
marked O
reductions O
of O
preexisting O
levodopa O
- O
induced O
dyskinesias B-Disease
. O

the O
main O
side O
effects O
of O
subcutaneous O
apomorphine O
treatment O
are O
related O
to O
cutaneous O
tolerability O
problems O
, O
whereas O
sedation O
and O
psychiatric B-Disease
complications O
play O
a O
lesser O
role O
. O

given O
the O
marked O
degree O
of O
efficacy O
of O
subcutaneous O
apomorphine O
treatment O
in O
fluctuating O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
, O
this O
approach O
seems O
to O
deserve O
more O
widespread O
clinical O
use O
. O

probing O
peripheral O
and O
central O
cholinergic O
system O
responses O
. O

objective O
: O
the O
pharmacological O
response O
to O
drugs O
that O
act O
on O
the O
cholinergic O
system O
of O
the O
iris O
has O
been O
used O
to O
predict O
deficits O
in O
central O
cholinergic O
functioning O
due O
to O
diseases O
such O
as O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
, O
yet O
correlations O
between O
central O
and O
peripheral O
responses O
have O
not O
been O
properly O
studied O
. O

this O
study O
assessed O
the O
effect O
of O
normal O
aging O
on O
( O
1 O
) O
the O
tropicamide O
- O
induced O
increase O
in O
pupil O
diameter O
, O
and O
( O
2 O
) O
the O
reversal O
of O
this O
effect O
with O
pilocarpine O
. O

scopolamine O
was O
used O
as O
a O
positive O
control O
to O
detect O
age O
- O
dependent O
changes O
in O
central O
cholinergic O
functioning O
in O
the O
elderly O
. O

design O
: O
randomized O
double O
- O
blind O
controlled O
trial O
. O

participants O
: O
ten O
healthy O
elderly O
( O
mean O
age O
70 O
) O
and O
9 O
young O
( O
mean O
age O
33 O
) O
volunteers O
. O

interventions O
: O
pupil O
diameter O
was O
monitored O
using O
a O
computerized O
infrared O
pupillometer O
over O
4 O
hours O
. O

the O
study O
involved O
4 O
sessions O
. O

in O
1 O
session O
, O
tropicamide O
( O
20 O
microl O
, O
0 O
. O
01 O
% O
) O
was O
administered O
to O
one O
eye O
and O
placebo O
to O
the O
other O
. O

in O
another O
session O
, O
tropicamide O
( O
20 O
microl O
, O
0 O
. O
01 O
% O
) O
was O
administered O
to O
both O
eyes O
, O
followed O
23 O
minutes O
later O
by O
the O
application O
of O
pilocarpine O
( O
20 O
microl O
, O
0 O
. O
1 O
% O
) O
to O
one O
eye O
and O
placebo O
to O
the O
other O
. O

all O
eye O
drops O
were O
given O
in O
a O
randomized O
order O
. O

in O
2 O
separate O
sessions O
, O
a O
single O
dose O
of O
scopolamine O
( O
0 O
. O
5 O
mg O
, O
intravenously O
) O
or O
placebo O
was O
administered O
, O
and O
the O
effects O
on O
word O
recall O
were O
measured O
using O
the O
buschke O
selective O
reminding O
test O
over O
2 O
hours O
. O

outcome O
measures O
: O
pupil O
size O
at O
time O
points O
after O
administration O
of O
tropicamide O
and O
pilocarpine O
; O
scopolamine O
- O
induced O
impairment B-Disease
in B-Disease
word B-Disease
recall B-Disease
. O

results O
: O
there O
was O
no O
significant O
difference O
between O
elderly O
and O
young O
volunteers O
in O
pupillary O
response O
to O
tropicamide O
at O
any O
time O
point O
( O
p O
> O
0 O
. O
05 O
) O
. O

the O
elderly O
group O
had O
a O
significantly O
greater O
pilocarpine O
- O
induced O
net O
decrease O
in O
pupil O
size O
85 O
, O
125 O
, O
165 O
and O
215 O
minutes O
after O
administration O
, O
compared O
with O
the O
young O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

compared O
with O
the O
young O
group O
, O
the O
elderly O
group O
had O
greater O
scopolamine O
- O
induced O
impairment B-Disease
in B-Disease
word B-Disease
recall B-Disease
60 O
, O
90 O
and O
120 O
minutes O
after O
administration O
( O
p O
< O
0 O
. O
05 O
) O
. O

conclusion O
: O
there O
is O
an O
age O
- O
related O
pupillary O
response O
to O
pilocarpine O
that O
is O
not O
found O
with O
tropicamide O
. O

thus O
, O
pilocarpine O
may O
be O
useful O
to O
assess O
variations O
in O
central O
cholinergic O
function O
in O
elderly O
patients O
. O

pain B-Disease
responses O
in O
methadone O
- O
maintained O
opioid O
abusers O
. O

providing O
pain B-Disease
management O
for O
known O
opioid O
abusers O
is O
a O
challenging O
clinical O
task O
, O
in O
part O
because O
little O
is O
known O
about O
their O
pain B-Disease
experience O
and O
analgesic O
requirements O
. O

this O
study O
was O
designed O
to O
describe O
pain B-Disease
tolerance O
and O
analgesic O
response O
in O
a O
sample O
of O
opioid B-Disease
addicts B-Disease
stabilized O
in O
methadone O
- O
maintenance O
( O
mm O
) O
treatment O
( O
n O
= O
60 O
) O
in O
comparison O
to O
matched O
nondependent O
control O
subjects O
( O
n O
= O
60 O
) O
. O

by O
using O
a O
placebo O
- O
controlled O
, O
two O
- O
way O
factorial O
design O
, O
tolerance O
to O
cold O
- O
pressor O
( O
cp O
) O
pain B-Disease
was O
examined O
, O
both O
before O
and O
after O
oral O
administration O
of O
therapeutic O
doses O
of O
common O
opioid O
( O
hydromorphone O
2 O
mg O
) O
and O
nonsteroidal O
anti O
- O
inflammatory O
( O
ketorolac O
10 O
mg O
) O
analgesic O
agents O
. O

results O
showed O
that O
mm O
individuals O
were O
significantly O
less O
tolerant O
of O
cp O
pain B-Disease
than O
control O
subjects O
, O
replicating O
previous O
work O
. O

analgesic O
effects O
were O
significant O
neither O
for O
medication O
nor O
group O
. O

these O
data O
indicate O
that O
mm O
opioid O
abusers O
represent O
a O
pain B-Disease
- B-Disease
intolerant B-Disease
subset O
of O
clinical O
patients O
. O

their O
complaints O
of O
pain B-Disease
should O
be O
evaluated O
seriously O
and O
managed O
aggressively O
. O

high O
- O
dose O
methylprednisolone O
may O
do O
more O
harm O
for O
spinal B-Disease
cord B-Disease
injury B-Disease
. O

because O
of O
the O
national O
acute O
spinal B-Disease
cord B-Disease
injury B-Disease
studies O
( O
nascis O
) O
, O
high O
- O
dose O
methylprednisolone O
became O
the O
standard O
of O
care O
for O
the O
acute O
spinal B-Disease
cord B-Disease
injury B-Disease
. O

in O
the O
nascis O
, O
there O
was O
no O
mention O
regarding O
the O
possibility O
of O
acute O
corticosteroid O
myopathy B-Disease
that O
high O
- O
dose O
methylprednisolone O
may O
cause O
. O

the O
dosage O
of O
methylprednisolone O
recommended O
by O
the O
nascis O
3 O
is O
the O
highest O
dose O
of O
steroids O
ever O
being O
used O
during O
a O
2 O
- O
day O
period O
for O
any O
clinical O
condition O
. O

we O
hypothesize O
that O
it O
may O
cause O
some O
damage B-Disease
to B-Disease
the B-Disease
muscle B-Disease
of O
spinal B-Disease
cord B-Disease
injury B-Disease
patients O
. O

further O
, O
steroid O
myopathy B-Disease
recovers O
naturally O
and O
the O
neurological O
improvement O
shown O
in O
the O
nascis O
may O
be O
just O
a O
recording O
of O
this O
natural O
motor O
recovery O
from O
the O
steroid O
myopathy B-Disease
, O
instead O
of O
any O
protection O
that O
methylprednisolone O
offers O
to O
the O
spinal B-Disease
cord B-Disease
injury B-Disease
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
discussion O
considering O
the O
possibility O
that O
the O
methylprednisolone O
recommended O
by O
nascis O
may O
cause O
acute O
corticosteroid O
myopathy B-Disease
. O

conversion O
to O
rapamycin O
immunosuppression O
in O
renal O
transplant O
recipients O
: O
report O
of O
an O
initial O
experience O
. O

background O
: O
the O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
effects O
of O
rapa O
conversion O
in O
patients O
undergoing O
cyclosporine O
( O
csa O
) O
or O
tacrolimus O
( O
tac O
) O
toxicity B-Disease
. O

methods O
: O
twenty O
renal O
transplant O
recipients O
were O
switched O
to O
fixed O
dose O
rapamycin O
( O
rapa O
) O
( O
5 O
mg O
/ O
day O
) O
0 O
to O
204 O
months O
posttransplant O
. O

drug O
monitoring O
was O
not O
initially O
used O
to O
adjust O
doses O
. O

the O
indications O
for O
switch O
were O
chronic O
csa O
or O
tac O
nephrotoxicity B-Disease
( O
12 O
) O
, O
acute O
csa O
or O
tac O
toxicity B-Disease
( O
3 O
) O
, O
severe O
facial B-Disease
dysmorphism B-Disease
( O
2 O
) O
, O
posttransplant B-Disease
lymphoproliferative B-Disease
disorder B-Disease
( O
ptld B-Disease
) O
in O
remission O
( O
2 O
) O
, O
and O
hepatotoxicity B-Disease
in O
1 O
. O

follow O
- O
up O
is O
7 O
to O
24 O
months O
. O

results O
: O
in O
the O
12 O
patients O
switched O
because O
of O
chronic O
nephrotoxicity B-Disease
there O
was O
a O
significant O
decrease O
in O
serum O
creatinine O
[ O
233 O
+ O
/ O
- O
34 O
to O
210 O
+ O
/ O
- O
56 O
micromol O
/ O
liter O
( O
p O
< O
0 O
. O
05 O
) O
at O
6 O
months O
] O
. O

facial B-Disease
dysmorphism B-Disease
improved O
in O
two O
patients O
. O

no O
relapse O
of O
ptld B-Disease
was O
observed O
. O

five O
patients O
developed O
pneumonia B-Disease
( O
two O
pneumocystis B-Disease
carinii B-Disease
pneumonia B-Disease
, O
one O
infectious B-Disease
mononucleosis B-Disease
with O
polyclonal O
ptld B-Disease
lung O
infiltrate O
) O
and O
two O
had O
bronchiolitis B-Disease
obliterans B-Disease
. O

there O
were O
no O
deaths O
. O

rapa O
was O
discontinued O
in O
four O
patients O
, O
because O
of O
pneumonia B-Disease
in O
two O
, O
ptld B-Disease
in O
one O
, O
and O
oral O
aphtous B-Disease
ulcers B-Disease
in O
one O
. O

rapa O
levels O
were O
high O
( O
> O
15 O
ng O
/ O
ml O
) O
in O
7 O
of O
13 O
( O
54 O
% O
) O
patients O
. O

conclusions O
: O
rapa O
conversion O
provides O
adequate O
immunosuppression O
to O
enable O
csa O
withdrawal O
. O

however O
, O
when O
converting O
patients O
to O
rapa O
drug O
levels O
should O
be O
monitored O
to O
avoid O
over O
- O
immunosuppression O
and O
adequate O
antiviral O
and O
pneumocystis B-Disease
carinii B-Disease
pneumonia B-Disease
prophylaxis O
should O
be O
given O
. O

electro O
- O
oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients O
with O
vigabatrin O
- O
attributed O
visual B-Disease
field B-Disease
constriction B-Disease
. O

purpose O
: O
symptomatic O
visual B-Disease
field B-Disease
constriction B-Disease
thought O
to O
be O
associated O
with O
vigabatrin O
has O
been O
reported O
. O

the O
current O
study O
investigated O
the O
visual O
fields O
and O
visual O
electrophysiology O
of O
eight O
patients O
with O
known O
vigabatrin O
- O
attributed O
visual B-Disease
field B-Disease
loss B-Disease
, O
three O
of O
whom O
were O
reported O
previously O
. O

six O
of O
the O
patients O
were O
no O
longer O
receiving O
vigabatrin O
. O

methods O
: O
the O
central O
and O
peripheral O
fields O
were O
examined O
with O
the O
humphrey O
visual O
field O
analyzer O
. O

full O
visual O
electrophysiology O
, O
including O
flash O
electroretinography O
( O
erg O
) O
, O
pattern O
electroretinography O
, O
multifocal O
erg O
using O
the O
veris O
system O
, O
electro O
- O
oculography O
, O
and O
flash O
and O
pattern O
visual O
evoked O
potentials O
, O
was O
undertaken O
. O

results O
: O
seven O
patients O
showed O
marked O
visual B-Disease
field B-Disease
constriction B-Disease
with O
some O
sparing O
of O
the O
temporal O
visual O
field O
. O

the O
eighth O
exhibited O
concentric O
constriction O
. O

most O
electrophysiological O
responses O
were O
usually O
just O
within O
normal O
limits O
; O
two O
patients O
had O
subnormal O
arden O
electro O
- O
oculography O
indices O
; O
and O
one O
patient O
showed O
an O
abnormally O
delayed O
photopic O
b O
wave O
. O

however O
, O
five O
patients O
showed O
delayed O
30 O
- O
hz O
flicker O
b O
waves O
, O
and O
seven O
patients O
showed O
delayed O
oscillatory O
potentials O
. O

multifocal O
erg O
showed O
abnormalities O
that O
sometimes O
correlated O
with O
the O
visual O
field O
appearance O
and O
confirmed O
that O
the O
deficit O
occurs O
at O
the O
retinal O
level O
. O

conclusion O
: O
marked O
visual B-Disease
field B-Disease
constriction B-Disease
appears O
to O
be O
associated O
with O
vigabatrin O
therapy O
. O

the O
field O
defects O
and O
some O
electrophysiological O
abnormalities O
persist O
when O
vigabatrin O
therapy O
is O
withdrawn O
. O

myocardial B-Disease
ischemia B-Disease
due O
to O
coronary B-Disease
artery B-Disease
spasm B-Disease
during O
dobutamine O
stress O
echocardiography O
. O

dobutamine O
stress O
echocardiography O
( O
dse O
) O
is O
a O
useful O
and O
safe O
provocation O
test O
for O
myocardial B-Disease
ischemia B-Disease
. O

until O
now O
, O
the O
test O
has O
been O
focused O
only O
on O
the O
organic O
lesion O
in O
the O
coronary O
artery O
, O
and O
positive O
dse O
has O
indicated O
the O
presence O
of O
significant O
fixed O
coronary B-Disease
artery B-Disease
stenosis B-Disease
. O

the O
aim O
of O
the O
present O
study O
is O
to O
examine O
whether O
myocardial B-Disease
ischemia B-Disease
due O
to O
coronary B-Disease
spasm B-Disease
is O
induced O
by O
dobutamine O
. O

we O
performed O
dse O
on O
51 O
patients O
with O
coronary B-Disease
spastic B-Disease
angina B-Disease
but O
without O
significant O
fixed O
coronary B-Disease
artery B-Disease
stenosis B-Disease
. O

all O
patients O
had O
anginal B-Disease
attacks O
at O
rest O
with O
st O
elevation O
on O
the O
electrocardiogram O
( O
variant B-Disease
angina B-Disease
) O
. O

coronary O
spasm O
was O
induced O
by O
intracoronary O
injection O
of O
acetylcholine O
, O
and O
no O
fixed O
coronary B-Disease
artery B-Disease
stenosis B-Disease
was O
documented O
on O
angiograms O
in O
all O
patients O
. O

dse O
was O
performed O
with O
intravenous O
dobutamine O
infusion O
with O
an O
incremental O
doses O
of O
5 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
microg O
/ O
kg O
/ O
min O
every O
5 O
minutes O
. O

of O
the O
51 O
patients O
, O
7 O
patients O
showed O
asynergy O
with O
st O
elevation O
. O

all O
7 O
patients O
( O
13 O
. O
7 O
% O
) O
had O
chest B-Disease
pain B-Disease
during O
asynergy O
, O
and O
both O
chest B-Disease
pain B-Disease
and O
electrocardiographic O
changes O
were O
preceded O
by O
asynergy O
. O

these O
findings O
indicate O
that O
dobutamine O
can O
provoke O
coronary B-Disease
spasm B-Disease
in O
some O
patients O
with O
coronary B-Disease
spastic B-Disease
angina B-Disease
. O

when O
dse O
is O
performed O
to O
evaluate O
coronary B-Disease
artery B-Disease
disease B-Disease
, O
not O
only O
fixed O
coronary B-Disease
stenosis B-Disease
, O
but O
also O
coronary B-Disease
spasm B-Disease
should O
be O
considered O
as O
a O
genesis O
of O
asynergy O
. O

effect O
of O
intravenous O
metoprolol O
or O
intravenous O
metoprolol O
plus O
glucagon O
on O
dobutamine O
- O
induced O
myocardial B-Disease
ischemia B-Disease
. O

study O
objective O
: O
to O
determine O
the O
effect O
of O
metoprolol O
on O
dobutamine O
stress O
testing O
with O
technetium O
- O
99m O
sestamibi O
single O
- O
photon O
emission O
computed O
tomography O
imaging O
and O
st O
- O
segment O
monitoring O
, O
and O
to O
assess O
the O
impact O
of O
intravenous O
glucagon O
on O
metoprolol O
' O
s O
effects O
. O

design O
: O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O

setting O
: O
community O
hospital O
. O

patients O
: O
twenty O
- O
two O
patients O
with O
known O
reversible O
perfusion O
defects O
. O

intervention O
: O
patients O
underwent O
dobutamine O
stress O
tests O
per O
standard O
protocol O
. O

before O
dobutamine O
was O
begun O
, O
no O
therapy O
was O
given O
during O
the O
first O
visit O
, O
and O
patients O
were O
randomized O
on O
subsequent O
visits O
to O
receive O
metoprolol O
or O
metoprolol O
plus O
glucagon O
1 O
mg O
. O

metoprolol O
was O
dosed O
to O
achieve O
a O
resting O
predobutamine O
heart O
rate O
below O
65 O
beats O
/ O
minute O
or O
a O
total O
intravenous O
dose O
of O
20 O
mg O
. O

measurements O
and O
main O
results O
: O
metoprolol O
reduced O
maximum O
heart O
rate O
31 O
% O
, O
summed O
stress O
scores O
29 O
% O
, O
and O
summed O
difference O
scores O
43 O
% O
versus O
control O
. O

metoprolol O
plus O
glucagon O
also O
reduced O
the O
maximum O
heart O
rate O
29 O
% O
versus O
control O
. O

summed O
stress O
and O
summed O
difference O
scores O
were O
not O
significantly O
reduced O
, O
although O
they O
were O
18 O
% O
and O
30 O
% O
lower O
, O
respectively O
, O
than O
control O
. O

no O
significant O
differences O
were O
found O
in O
any O
parameter O
between O
metoprolol O
and O
metoprolol O
- O
glucagon O
. O

conclusion O
: O
during O
dobutamine O
stress O
testing O
, O
metoprolol O
attenuates O
or O
eliminates O
evidence O
of O
myocardial B-Disease
ischemia B-Disease
. O

glucagon O
1 O
mg O
, O
although O
somewhat O
effective O
, O
does O
not O
correct O
this O
effect O
to O
the O
extent O
that O
it O
can O
be O
administered O
clinically O
. O

evidence O
of O
functional O
somatotopy O
in O
gpi O
from O
results O
of O
pallidotomy O
. O

the O
objective O
of O
this O
study O
was O
to O
explore O
the O
functional O
anatomy O
of O
the O
globus O
pallidus O
internus O
( O
gpi O
) O
by O
studying O
the O
effects O
of O
unilateral O
pallidotomy O
on O
parkinsonian B-Disease
' O
off O
' O
signs O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
lid B-Disease
) O
. O

we O
found O
significant O
positive O
correlations O
between O
the O
preoperative O
levodopa O
responsiveness O
of O
motor O
signs O
and O
the O
levodopa O
responsiveness O
of O
scores O
in O
timed O
tests O
( O
core O
assessment O
program O
for O
intracerebral O
transplantations O
) O
in O
the O
contralateral O
limbs O
and O
the O
improvement O
in O
these O
scores O
after O
surgery O
, O
whereas O
there O
was O
no O
correlation O
with O
the O
improvement O
in O
lid B-Disease
. O

we O
also O
found O
a O
highly O
significant O
correlation O
( O
p O
: O
< O
0 O
. O
0001 O
, O
r O
= O
0 O
. O
8 O
) O
between O
the O
volume O
of O
the O
ventral O
lesion O
in O
the O
gpi O
and O
the O
improvement O
in O
lid B-Disease
in O
the O
contralateral O
limbs O
, O
whereas O
there O
was O
no O
correlation O
between O
the O
ventral O
volume O
and O
the O
improvement O
in O
parkinsonian B-Disease
' O
off O
' O
signs O
. O

the O
volumes O
of O
the O
total O
lesion O
cylinder O
and O
the O
dorsal O
lesion O
did O
not O
correlate O
with O
the O
outcome O
of O
either O
dyskinesias B-Disease
or O
parkinsonian B-Disease
' O
off O
' O
signs O
. O

the O
differential O
predictive O
value O
of O
levodopa O
responsiveness O
for O
the O
outcome O
of O
parkinsonian B-Disease
' O
off O
' O
signs O
and O
lid B-Disease
and O
the O
different O
correlations O
of O
ventral O
lesion O
volume O
with O
dyskinesias B-Disease
and O
parkinsonian B-Disease
' O
off O
' O
signs O
indicate O
that O
different O
anatomical O
or O
pathophysiological O
substrates O
may O
be O
responsible O
for O
the O
generation O
of O
parkinsonian B-Disease
' O
off O
' O
signs O
and O
dyskinesias B-Disease
. O

whereas O
cells O
in O
a O
wider O
area O
of O
the O
gpi O
may O
be O
implicated O
in O
parkinsonism B-Disease
, O
the O
ventral O
gpi O
seems O
to O
be O
crucial O
for O
the O
manifestation O
of O
lid B-Disease
. O

we O
suggest O
that O
our O
observations O
are O
additional O
proof O
of O
the O
functional O
somatotopy O
of O
the O
systems O
within O
the O
gpi O
that O
mediate O
parkinsonism B-Disease
and O
dyskinesias B-Disease
, O
especially O
along O
the O
dorsoventral O
trajectory O
used O
in O
pallidotomy O
. O

the O
outcome O
of O
pallidotomy O
in O
which O
the O
lesion O
involves O
the O
ventral O
and O
dorsal O
gpi O
could O
be O
the O
net O
effect O
of O
alteration O
in O
the O
activity O
of O
pathways O
which O
mediate O
different O
symptoms O
, O
and O
hence O
could O
be O
variable O
. O

screening O
for O
stimulant O
use O
in O
adult O
emergency O
department O
seizure B-Disease
patients O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
prevalence O
of O
positive O
plasma O
drug O
screening O
for O
cocaine O
or O
amphetamine O
in O
adult O
emergency O
department O
seizure B-Disease
patients O
. O

methods O
: O
this O
prospective O
study O
evaluated O
consecutive O
eligible O
seizure B-Disease
patients O
who O
had O
a O
plasma O
sample O
collected O
as O
part O
of O
their O
clinical O
evaluation O
. O

plasma O
was O
tested O
for O
amphetamine O
and O
the O
cocaine O
metabolite O
benzoylecgonine O
using O
enzyme O
- O
mediated O
immunoassay O
methodology O
. O

plasma O
samples O
with O
benzoylecgonine O
greater O
than O
150 O
ng O
/ O
ml O
or O
an O
amphetamine O
greater O
than O
500 O
ng O
/ O
ml O
were O
defined O
as O
positive O
. O

patient O
demographics O
, O
history O
of O
underlying O
drug O
or O
alcohol O
- O
related O
seizure B-Disease
disorder O
, O
estimated O
time O
from O
seizure B-Disease
to O
sample O
collection O
, O
history O
or O
suspicion O
of O
cocaine B-Disease
or B-Disease
amphetamine B-Disease
abuse B-Disease
, O
results O
of O
clinical O
urine O
testing O
for O
drugs O
of O
abuse O
, O
and O
assay O
results O
were O
recorded O
without O
patient O
identifiers O
. O

results O
: O
fourteen O
of O
248 O
( O
5 O
. O
6 O
% O
, O
95 O
% O
ci O
2 O
. O
7 O
% O
- O
8 O
. O
5 O
% O
) O
plasma O
samples O
were O
positive O
by O
immunoassay O
testing O
for O
benzoylecgonine O
and O
no O
samples O
( O
0 O
% O
, O
95 O
% O
ci O
0 O
- O
1 O
. O
2 O
% O
) O
were O
positive O
for O
amphetamine O
. O

positive O
test O
results O
were O
more O
common O
in O
patient O
visits O
where O
there O
was O
a O
history O
or O
suspicion O
of O
cocaine B-Disease
or B-Disease
amphetamine B-Disease
abuse B-Disease
( O
p O
< O
0 O
. O
0005 O
) O
. O

conclusions O
: O
during O
this O
study O
period O
, O
routine O
plasma O
screening O
for O
cocaine O
and O
amphetamines O
in O
adult O
seizure B-Disease
patients O
had O
a O
low O
yield O
. O

as O
a O
result O
, O
routine O
plasma O
screening O
would O
yield O
few O
cases O
of O
stimulant O
drug O
in O
which O
there O
was O
neither O
a O
history O
nor O
suspicion O
of O
drug B-Disease
abuse B-Disease
in O
this O
population O
. O

contribution O
of O
sodium O
valproate O
to O
the O
syndrome B-Disease
of B-Disease
inappropriate B-Disease
secretion B-Disease
of B-Disease
antidiuretic B-Disease
hormone B-Disease
. O

we O
report O
the O
case O
of O
a O
62 O
- O
year O
- O
old O
man O
who O
was O
administered O
sodium O
valproate O
( O
vpa O
) O
and O
who O
subsequently O
developed O
the O
syndrome B-Disease
of B-Disease
inappropriate B-Disease
secretion B-Disease
of B-Disease
antidiuretic B-Disease
hormone B-Disease
( O
siadh B-Disease
) O
. O

he O
had O
been O
taking O
vpa O
for O
treatment O
of O
idiopathic O
generalized O
tonic B-Disease
- B-Disease
clonic B-Disease
convulsions B-Disease
since O
he O
was O
56 O
years O
old O
. O

after O
substituting O
vpa O
with O
zonisamide O
, O
the O
serum O
sodium O
level O
returned O
to O
normal O
. O

we O
consider O
this O
episode O
of O
siadh B-Disease
to O
be O
the O
result O
of O
a O
combination O
of O
factors O
including O
a O
weakness B-Disease
of B-Disease
the B-Disease
central B-Disease
nervous B-Disease
system B-Disease
and O
the O
long O
- O
term O
administration O
of O
vpa O
. O

association O
of O
nitric O
oxide O
production O
and O
apoptosis O
in O
a O
model O
of O
experimental O
nephropathy B-Disease
. O

background O
: O
in O
recent O
studies O
increased O
amounts O
of O
nitric O
oxide O
( O
no O
) O
and O
apoptosis O
have O
been O
implicated O
in O
various O
pathological O
conditions O
in O
the O
kidney O
. O

we O
have O
studied O
the O
role O
of O
no O
and O
its O
association O
with O
apoptosis O
in O
an O
experimental O
model O
of O
nephrotic B-Disease
syndrome B-Disease
induced O
by O
a O
single O
injection O
of O
adriamycin O
( O
adr O
) O
. O

methods O
: O
the O
alteration O
in O
the O
no O
pathway O
was O
assessed O
by O
measuring O
nitrite O
levels O
in O
serum O
/ O
urine O
and O
by O
evaluating O
the O
changes O
in O
vascular O
reactivity O
of O
the O
isolated O
perfused O
rat O
kidney O
( O
iprk O
) O
system O
. O

rats O
were O
stratified O
into O
control O
groups O
and O
adr O
- O
induced O
nephropathy B-Disease
groups O
. O

these O
two O
groups O
were O
then O
divided O
into O
: O
group O
1 O
, O
animals O
receiving O
saline O
; O
and O
group O
2 O
, O
animals O
receiving O
aminoguanidine O
( O
ag O
) O
which O
is O
a O
specific O
inhibitor O
of O
inducible O
- O
no O
synthase O
. O

on O
day O
21 O
, O
rats O
were O
sacrificed O
after O
obtaining O
material O
for O
biochemical O
analysis O
. O

results O
: O
histopathological O
examination O
of O
the O
kidneys O
of O
rats O
treated O
with O
adr O
revealed O
focal O
areas O
of O
mesangial B-Disease
proliferation B-Disease
and O
mild O
tubulointerstitial B-Disease
inflammation B-Disease
. O

they O
also O
had O
significantly O
higher O
levels O
of O
proteinuria B-Disease
compared O
with O
control O
and O
treatment O
groups O
( O
p O
< O
0 O
. O
05 O
) O
. O

urine O
nitrite O
levels O
were O
significantly O
increased O
in O
the O
adr O
- O
nephropathy B-Disease
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

in O
the O
iprk O
phenylephrine O
and O
acetylcholine O
related O
responses O
were O
significantly O
impaired O
in O
the O
adr O
- O
nephropathy B-Disease
group O
. O

apoptosis O
was O
not O
detected O
in O
controls O
. O

however O
, O
in O
the O
adr O
- O
nephropathy B-Disease
group O
, O
numerous O
apoptotic O
cells O
were O
identified O
in O
the O
tubulointerstitial O
areas O
. O

double O
staining O
revealed O
numerous O
interstitial O
apoptotic O
cells O
to O
stain O
for O
ed1 O
, O
a O
marker O
for O
monocytes O
/ O
macrophages O
. O

treatment O
with O
ag O
prevented O
the O
impairment O
of O
renal O
vascular O
bed O
responses O
and O
reduced O
both O
urine O
nitrite O
levels O
and O
apoptosis O
to O
control O
levels O
. O

conclusion O
: O
we O
suggest O
that O
interactions O
between O
no O
and O
apoptosis O
are O
important O
in O
the O
pathogenesis O
of O
the O
adr O
- O
induced O
nephrosis B-Disease
. O

dual O
effects O
of O
melatonin O
on O
barbiturate O
- O
induced O
narcosis B-Disease
in O
rats O
. O

melatonin O
affects O
the O
circadian O
sleep O
/ O
wake O
cycle O
, O
but O
it O
is O
not O
clear O
whether O
it O
may O
influence O
drug O
- O
induced O
narcosis B-Disease
. O

sodium O
thiopenthal O
was O
administered O
intraperitoneally O
into O
male O
rats O
pre O
- O
treated O
with O
melatonin O
( O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mg O
/ O
kg O
) O
. O

melatonin O
pre O
- O
treatment O
affected O
in O
a O
dual O
manner O
barbiturate O
narcosis B-Disease
, O
however O
, O
no O
dose O
- O
effect O
correlation O
was O
found O
. O

in O
particular O
, O
low O
doses O
reduced O
the O
latency O
to O
and O
prolonged O
the O
duration O
of O
barbiturate O
narcosis B-Disease
. O

in O
contrast O
, O
the O
highest O
dose O
of O
melatonin O
( O
50 O
mg O
/ O
kg O
) O
caused O
a O
paradoxical O
increase O
in O
the O
latency O
and O
produced O
a O
sustained O
reduction O
of O
the O
duration O
of O
narcosis B-Disease
, O
and O
a O
reduction O
in O
mortality O
rate O
. O

melatonin O
0 O
. O
5 O
and O
5 O
mg O
/ O
kg O
influenced O
the O
duration O
but O
not O
the O
latency O
of O
ketamine O
- O
or O
diazepam O
- O
induced O
narcosis B-Disease
. O

thus O
, O
the O
dual O
action O
of O
melatonin O
on O
pharmacological O
narcosis B-Disease
seems O
to O
be O
specific O
for O
the O
barbiturate O
mechanism O
of O
action O
. O

reduced O
cardiotoxicity B-Disease
and O
preserved O
antitumor O
efficacy O
of O
liposome O
- O
encapsulated O
doxorubicin O
and O
cyclophosphamide O
compared O
with O
conventional O
doxorubicin O
and O
cyclophosphamide O
in O
a O
randomized O
, O
multicenter O
trial O
of O
metastatic O
breast B-Disease
cancer B-Disease
. O

purpose O
: O
to O
determine O
whether O
myocet O
( O
liposome O
- O
encapsulated O
doxorubicin O
; O
the O
liposome O
company O
, O
elan O
corporation O
, O
princeton O
, O
nj O
) O
in O
combination O
with O
cyclophosphamide O
significantly O
reduces O
doxorubicin O
cardiotoxicity B-Disease
while O
providing O
comparable O
antitumor O
efficacy O
in O
first O
- O
line O
treatment O
of O
metastatic O
breast B-Disease
cancer B-Disease
( O
mbc B-Disease
) O
. O

patients O
and O
methods O
: O
two O
hundred O
ninety O
- O
seven O
patients O
with O
mbc B-Disease
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomized O
to O
receive O
either O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
myocet O
( O
m O
) O
or O
conventional O
doxorubicin O
( O
a O
) O
, O
in O
combination O
with O
600 O
mg O
/ O
m O
( O
2 O
) O
of O
cyclophosphamide O
( O
c O
) O
, O
every O
3 O
weeks O
until O
disease O
progression O
or O
unacceptable O
toxicity B-Disease
. O

cardiotoxicity B-Disease
was O
defined O
by O
reductions O
in O
left O
- O
ventricular O
ejection O
fraction O
, O
assessed O
by O
serial O
multigated O
radionuclide O
angiography O
scans O
, O
or O
congestive B-Disease
heart B-Disease
failure B-Disease
( O
chf B-Disease
) O
. O

antitumor O
efficacy O
was O
assessed O
by O
objective O
tumor B-Disease
response O
rates O
( O
world O
health O
organization O
criteria O
) O
, O
time O
to O
progression O
, O
and O
survival O
. O

results O
: O
six O
percent O
of O
mc O
patients O
versus O
21 O
% O
( O
including O
five O
cases O
of O
chf B-Disease
) O
of O
ac O
patients O
developed O
cardiotoxicity B-Disease
( O
p O
= O
. O
0002 O
) O
. O

median O
cumulative O
doxorubicin O
dose O
at O
onset O
was O
more O
than O
2 O
, O
220 O
mg O
/ O
m O
( O
2 O
) O
for O
mc O
versus O
480 O
mg O
/ O
m O
( O
2 O
) O
for O
ac O
( O
p O
= O
. O
0001 O
, O
hazard O
ratio O
, O
5 O
. O
04 O
) O
. O

mc O
patients O
also O
experienced O
less O
grade O
4 O
neutropenia B-Disease
. O

antitumor O
efficacy O
of O
mc O
versus O
ac O
was O
comparable O
: O
objective O
response O
rates O
, O
43 O
% O
versus O
43 O
% O
; O
median O
time O
to O
progression O
, O
5 O
. O
1 O
% O
versus O
5 O
. O
5 O
months O
; O
median O
time O
to O
treatment O
failure O
, O
4 O
. O
6 O
versus O
4 O
. O
4 O
months O
; O
and O
median O
survival O
, O
19 O
versus O
16 O
months O
. O

conclusion O
: O
myocet O
improves O
the O
therapeutic O
index O
of O
doxorubicin O
by O
significantly O
reducing O
cardiotoxicity B-Disease
and O
grade O
4 O
neutropenia B-Disease
and O
provides O
comparable O
antitumor O
efficacy O
, O
when O
used O
in O
combination O
with O
cyclophosphamide O
as O
first O
- O
line O
therapy O
for O
mbc B-Disease
. O

the O
role O
of O
nitrergic O
system O
in O
lidocaine O
- O
induced O
convulsion B-Disease
in O
the O
mouse O
. O

the O
effects O
of O
n O
- O
nitro O
- O
l O
- O
arginine O
- O
methyl O
ester O
( O
l O
- O
name O
) O
a O
nitric O
oxide O
( O
no O
) O
synthase O
inhibitor O
and O
l O
- O
arginine O
, O
a O
no O
precursor O
, O
were O
investigated O
on O
lidocaine O
- O
induced O
convulsions B-Disease
. O

in O
the O
first O
experiment O
, O
four O
groups O
of O
mice O
received O
physiological O
saline O
( O
0 O
. O
9 O
% O
) O
, O
l O
- O
arginine O
( O
300 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
l O
- O
name O
( O
100 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
diazepam O
( O
2 O
mg O
/ O
kg O
) O
, O
respectively O
. O

thirty O
minutes O
after O
these O
injections O
, O
all O
mice O
received O
lidocaine O
( O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

in O
the O
second O
experiment O
, O
four O
groups O
of O
mice O
received O
similar O
treatment O
in O
the O
first O
experiment O
, O
and O
30 O
min O
after O
these O
injections O
, O
all O
mice O
received O
a O
higher O
dose O
of O
lidocaine O
( O
80 O
mg O
/ O
kg O
) O
. O

l O
- O
name O
( O
100 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
diazepam O
( O
2 O
mg O
/ O
kg O
) O
significantly O
decreased O
the O
incidence O
of O
lidocaine O
( O
50 O
mg O
/ O
kg O
) O
- O
induced O
convulsions B-Disease
. O

in O
contrast O
, O
the O
l O
- O
arginine O
treatment O
increased O
the O
incidence O
of O
lidocaine O
( O
80 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
- O
induced O
convulsions B-Disease
significantly O
. O

these O
results O
may O
suggest O
that O
no O
is O
a O
proconvulsant O
mediator O
in O
lidocaine O
- O
induced O
convulsions B-Disease
. O

erythropoietin O
restores O
the O
anemia B-Disease
- O
induced O
reduction O
in O
cyclophosphamide O
cytotoxicity B-Disease
in O
rat O
tumors B-Disease
. O

the O
aim O
of O
this O
study O
was O
to O
examine O
the O
impact O
of O
anemia B-Disease
prevention O
by O
recombinant O
human O
erythropoietin O
( O
rhuepo O
) O
treatment O
on O
the O
cytotoxicity B-Disease
of O
cyclophosphamide O
in O
solid O
experimental O
tumors B-Disease
. O

anemia B-Disease
was O
induced O
using O
a O
single O
dose O
of O
carboplatin O
( O
50 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
resulting O
in O
a O
long O
- O
lasting O
reduction O
( O
30 O
% O
) O
of O
the O
hemoglobin O
concentration O
. O

in O
a O
second O
group O
, O
the O
development O
of O
anemia B-Disease
was O
prevented O
by O
rhuepo O
( O
1000 O
iu O
/ O
kg O
) O
administered O
s O
. O
c O
. O
three O
times O
/ O
week O
starting O
7 O
days O
before O
carboplatin O
application O
. O

four O
days O
after O
carboplatin O
treatment O
, O
tumors B-Disease
( O
ds O
- O
sarcoma B-Disease
of O
the O
rat O
) O
were O
implanted O
s O
. O
c O
. O
onto O
the O
hind O
food O
dorsum O
. O

neither O
carboplatin O
nor O
rhuepo O
treatment O
influenced O
tumor B-Disease
growth O
rate O
per O
se O
. O

when O
tumors B-Disease
were O
treated O
with O
a O
single O
dose O
of O
cyclophosphamide O
( O
60 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
5 O
days O
after O
implantation O
, O
a O
growth O
delay O
with O
a O
subsequent O
regrowth O
of O
the O
tumors B-Disease
was O
observed O
. O

in O
the O
anemia B-Disease
group O
, O
the O
growth O
delay O
was O
significantly O
shorter O
compared O
with O
nonanemic O
controls O
( O
13 O
. O
3 O
days O
versus O
8 O
. O
6 O
days O
) O
. O

in O
the O
group O
where O
anemia B-Disease
was O
prevented O
by O
rhuepo O
treatment O
, O
growth O
delay O
was O
comparable O
with O
that O
of O
nonanemic O
controls O
( O
13 O
. O
3 O
days O
) O
. O

these O
results O
suggest O
that O
chemotherapy O
- O
induced O
anemia B-Disease
reduces O
cytotoxicity B-Disease
of O
cyclophosphamide O
in O
tumors B-Disease
, O
whereas O
correction O
of O
anemia B-Disease
by O
rhuepo O
treatment O
( O
epoetin O
alpha O
) O
increases O
the O
sensitivity O
, O
probably O
as O
a O
result O
of O
an O
improved O
oxygen O
supply O
to O
tumor B-Disease
tissue O
. O

fatal O
haemorrhagic B-Disease
myocarditis B-Disease
secondary O
to O
cyclophosphamide O
therapy O
. O

haemorrhagic B-Disease
myocarditis B-Disease
is O
a O
rare O
but O
important O
complication O
of O
cyclophosphamide O
therapy O
. O

echocardiographic O
identification O
of O
the O
disorder O
can O
be O
made O
. O

we O
believe O
that O
the O
ultrasound O
features O
of O
this O
disorder O
have O
not O
been O
previously O
reported O
. O

effects O
of O
verapamil O
on O
atrial B-Disease
fibrillation B-Disease
and O
its O
electrophysiological O
determinants O
in O
dogs O
. O

background O
: O
atrial B-Disease
tachycardia B-Disease
- O
induced O
remodeling O
promotes O
the O
occurrence O
and O
maintenance O
of O
atrial B-Disease
fibrillation B-Disease
( O
af B-Disease
) O
and O
decreases O
l O
- O
type O
ca O
( O
2 O
+ O
) O
current O
. O

there O
is O
also O
a O
clinical O
suggestion O
that O
acute O
l O
- O
type O
ca O
( O
2 O
) O
channel O
blockade O
can O
promote O
af B-Disease
, O
consistent O
with O
an O
af B-Disease
promoting O
effect O
of O
ca O
( O
2 O
+ O
) O
channel O
inhibition O
. O

methods O
: O
to O
evaluate O
the O
potential O
mechanisms O
of O
af B-Disease
promotion O
by O
ca O
( O
2 O
+ O
) O
channel O
blockers O
, O
we O
administered O
verapamil O
to O
morphine O
- O
chloralose O
anesthetized O
dogs O
. O

diltiazem O
was O
used O
as O
a O
comparison O
drug O
and O
autonomic O
blockade O
with O
atropine O
and O
nadolol O
was O
applied O
in O
some O
experiments O
. O

epicardial O
mapping O
with O
240 O
epicardial O
electrodes O
was O
used O
to O
evaluate O
activation O
during O
af B-Disease
. O

results O
: O
verapamil O
caused O
af B-Disease
promotion O
in O
six O
dogs O
, O
increasing O
mean O
duration O
of O
af B-Disease
induced O
by O
burst O
pacing O
, O
from O
8 O
+ O
/ O
- O
4 O
s O
( O
mean O
+ O
/ O
- O
s O
. O
e O
. O
) O
to O
95 O
+ O
/ O
- O
39 O
s O
( O
p O
< O
0 O
. O
01 O
vs O
. O
control O
) O
at O
a O
loading O
dose O
of O
0 O
. O
1 O
mg O
/ O
kg O
and O
228 O
+ O
/ O
- O
101 O
s O
( O
p O
< O
0 O
. O
0005 O
vs O
. O
control O
) O
at O
a O
dose O
of O
0 O
. O
2 O
mg O
/ O
kg O
. O

underlying O
electrophysiological O
mechanisms O
were O
studied O
in O
detail O
in O
five O
additional O
dogs O
under O
control O
conditions O
and O
in O
the O
presence O
of O
the O
higher O
dose O
of O
verapamil O
. O

in O
these O
experiments O
, O
verapamil O
shortened O
mean O
effective O
refractory O
period O
( O
erp O
) O
from O
122 O
+ O
/ O
- O
5 O
to O
114 O
+ O
/ O
- O
4 O
ms O
( O
p O
< O
0 O
. O
02 O
) O
at O
a O
cycle O
length O
of O
300 O
ms O
, O
decreased O
erp O
heterogeneity O
( O
from O
15 O
+ O
/ O
- O
1 O
to O
10 O
+ O
/ O
- O
1 O
% O
, O
p O
< O
0 O
. O
05 O
) O
, O
heterogeneously O
accelerated O
atrial O
conduction O
and O
decreased O
the O
cycle O
length O
of O
af B-Disease
( O
94 O
+ O
/ O
- O
4 O
to O
84 O
+ O
/ O
- O
3 O
ms O
, O
p O
< O
0 O
. O
005 O
) O
. O

diltiazem O
did O
not O
affect O
erp O
, O
af B-Disease
cycle O
length O
or O
af B-Disease
duration O
, O
but O
produced O
conduction O
acceleration O
similar O
to O
that O
caused O
by O
verapamil O
( O
n O
= O
5 O
) O
. O

in O
the O
presence O
of O
autonomic O
blockade O
, O
verapamil O
failed O
to O
promote O
af B-Disease
and O
increased O
, O
rather O
than O
decreasing O
, O
refractoriness O
. O

neither O
verapamil O
nor O
diltiazem O
affected O
atrial O
conduction O
in O
the O
presence O
of O
autonomic O
blockade O
. O

epicardial O
mapping O
suggested O
that O
verapamil O
promoted O
af B-Disease
by O
increasing O
the O
number O
of O
simultaneous O
wavefronts O
reflected O
by O
separate O
zones O
of O
reactivation O
in O
each O
cycle O
. O

conclusions O
: O
verapamil O
promotes O
af B-Disease
in O
normal O
dogs O
by O
promoting O
multiple O
circuit O
reentry O
, O
an O
effect O
dependent O
on O
intact O
autonomic O
tone O
and O
not O
shared O
by O
diltiazem O
. O

calcitonin O
gene O
- O
related O
peptide O
levels O
during O
nitric O
oxide O
- O
induced O
headache B-Disease
in O
patients O
with O
chronic O
tension B-Disease
- B-Disease
type B-Disease
headache B-Disease
. O

it O
has O
been O
proposed O
that O
nitric O
oxide O
( O
no O
) O
induced O
headache B-Disease
in O
primary B-Disease
headaches B-Disease
may O
be O
associated O
with O
release O
of O
calcitonin O
gene O
- O
related O
peptide O
( O
cgrp O
) O
. O

in O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
cgrp O
during O
headache B-Disease
induced O
by O
the O
no O
donor O
glyceryl O
trinitrate O
( O
gtn O
) O
in O
16 O
patients O
with O
chronic O
tension B-Disease
- B-Disease
type B-Disease
headache B-Disease
and O
16 O
healthy O
controls O
. O

the O
subjects O
were O
randomly O
allocated O
to O
receive O
0 O
. O
5 O
microg O
/ O
kg O
/ O
min O
gtn O
or O
placebo O
over O
20 O
min O
on O
two O
headache B-Disease
- O
free O
days O
. O

blood O
samples O
were O
collected O
at O
baseline O
, O
10 O
, O
20 O
and O
60 O
min O
after O
start O
of O
infusion O
. O

both O
patients O
and O
controls O
developed O
significantly O
stronger O
immediate O
headache B-Disease
on O
the O
gtn O
day O
than O
on O
the O
placebo O
day O
and O
the O
headache B-Disease
was O
significantly O
more O
pronounced O
in O
patients O
than O
in O
controls O
. O

there O
was O
no O
difference O
between O
the O
area O
under O
the O
cgrp O
curve O
( O
auccgrp O
) O
on O
gtn O
vs O
. O
placebo O
day O
in O
either O
patients O
( O
p O
= O
0 O
. O
65 O
) O
or O
controls O
( O
p O
= O
0 O
. O
48 O
) O
. O

the O
auccgrp O
recorded O
on O
the O
gtn O
day O
did O
not O
differ O
between O
patients O
and O
controls O
( O
p O
= O
0 O
. O
36 O
) O
. O

both O
in O
patients O
and O
controls O
, O
cgrp O
levels O
changed O
significantly O
over O
time O
, O
on O
both O
the O
gtn O
and O
placebo O
days O
( O
p O
< O
0 O
. O
05 O
) O
. O

the O
present O
study O
indicates O
that O
no O
- O
induced O
immediate O
headache B-Disease
is O
not O
associated O
with O
release O
of O
cgrp O
. O

fluconazole O
- O
induced O
torsade B-Disease
de B-Disease
pointes B-Disease
. O

objective O
: O
to O
present O
a O
case O
of O
fluconazole O
- O
associated O
torsade B-Disease
de B-Disease
pointes B-Disease
( O
tdp B-Disease
) O
and O
discuss O
fluconazole O
' O
s O
role O
in O
causing O
tdp B-Disease
. O

case O
summary O
: O
a O
68 O
- O
year O
- O
old O
white O
woman O
with O
candida O
glabrata O
isolated O
from O
a O
presacral O
abscess O
developed O
tdp B-Disease
eight O
days O
after O
commencing O
oral O
fluconazole O
the O
patient O
had O
no O
other O
risk O
factors O
for O
tdp B-Disease
, O
including O
coronary B-Disease
artery B-Disease
disease B-Disease
, O
cardiomyopathy B-Disease
, O
congestive B-Disease
heart B-Disease
failure B-Disease
, O
and O
electrolyte O
abnormalities O
there O
was O
a O
temporal O
association O
between O
the O
initiation O
of O
fluconazole O
and O
tdp B-Disease
. O

the O
tdp B-Disease
resolved O
when O
fluconazole O
was O
discontinued O
; O
however O
, O
the O
patient O
continued O
to O
have O
premature B-Disease
ventricular B-Disease
contractions B-Disease
and O
nonsustained O
ventricular B-Disease
tachycardia B-Disease
( O
nsvt B-Disease
) O
until O
six O
days O
after O
drug O
cessation O
discussion O
: O
use O
of O
the O
naranjo O
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
use O
of O
fluconazole O
and O
the O
development O
of O
tdp B-Disease
. O

the O
possible O
mechanism O
is O
depression B-Disease
of O
rapidly O
activating O
delayed O
rectifier O
potassium O
currents O
. O

in O
our O
patient O
, O
there O
was O
no O
other O
etiology O
identified O
that O
could O
explain O
qt B-Disease
prolongation B-Disease
or O
tdp B-Disease
the O
complete O
disappearance O
of O
nsvt B-Disease
and O
premature B-Disease
ventricular B-Disease
contractions B-Disease
followed O
by O
normalization O
of O
qt O
interval O
after O
the O
drug O
was O
stopped O
strongly O
suggests O
fluconazole O
as O
the O
etiology O
. O

conclusions O
: O
clinicians O
should O
be O
aware O
that O
fluconazole O
, O
even O
at O
low O
doses O
, O
may O
cause O
prolongation B-Disease
of B-Disease
the B-Disease
qt B-Disease
interval B-Disease
, O
leading O
to O
tdp B-Disease
. O

serial O
electrocardiographic O
monitoring O
may O
be O
considered O
when O
fluconazole O
is O
administered O
in O
patients O
who O
are O
at O
risk O
for O
ventricular B-Disease
arrhythmias B-Disease
. O

cutaneous B-Disease
leucocytoclastic B-Disease
vasculitis B-Disease
associated O
with O
oxacillin O
. O

a O
67 O
- O
year O
- O
old O
man O
who O
was O
treated O
with O
oxacillin O
for O
one O
week O
because O
of O
staphylococcus B-Disease
aureus B-Disease
bacteremia B-Disease
, O
developed O
renal B-Disease
failure B-Disease
and O
diffuse O
, O
symmetric O
, O
palpable O
purpuric B-Disease
lesions B-Disease
on O
his O
feet O
. O

necrotic B-Disease
blisters B-Disease
were O
noted O
on O
his O
fingers O
. O

skin O
biopsies O
showed O
findings O
diagnostic O
of O
leucocytoclastic B-Disease
vasculitis B-Disease
. O

oxacillin O
was O
discontinued O
and O
patient O
was O
treated O
with O
corticosteroids O
. O

the O
rash B-Disease
disappeared O
after O
three O
weeks O
and O
renal O
function O
returned O
to O
normal O
. O

leucocytoclastic B-Disease
vasculitis B-Disease
presents O
as O
palpable O
purpura B-Disease
of O
the O
lower O
extremities O
often O
accompanied O
by O
abdominal B-Disease
pain B-Disease
, O
arthralgia B-Disease
, O
and O
renal B-Disease
involvement B-Disease
. O

etiologic O
factors O
or O
associated O
disorders O
include O
infections B-Disease
, O
medications O
, O
collagen B-Disease
vascular B-Disease
disease B-Disease
and O
neoplasia B-Disease
. O

however O
, O
in O
half O
of O
the O
cases O
no O
etiologic O
factor O
is O
identified O
. O

usually O
it O
is O
a O
self O
- O
limited O
disorder O
, O
but O
corticosteroid O
therapy O
may O
be O
needed O
in O
life O
- O
threatening O
cases O
since O
early O
treatment O
with O
corticosteroids O
in O
severe O
cases O
can O
prevent O
complications O
. O

oxacillin O
should O
be O
included O
among O
the O
drugs O
that O
can O
cause O
leucocytoclastic B-Disease
vasculitis B-Disease
. O

the O
renal O
pathology O
in O
a O
case O
of O
lithium O
- O
induced O
diabetes B-Disease
insipidus B-Disease
. O

a O
case O
of O
lithium O
- O
induced O
diabetes B-Disease
insipidus B-Disease
is O
reported O
. O

at O
necropsy O
microscopy O
shoed O
unique O
and O
extensive O
damage O
to O
cells O
lining O
the O
distal O
nephron O
. O

it O
is O
suggested O
that O
these O
changes O
represent O
a O
specific O
toxic O
effect O
of O
lithium O
, O
reported O
here O
for O
the O
first O
time O
in O
man O
. O

cholestatic B-Disease
jaundice B-Disease
associated O
with O
the O
use O
of O
metformin O
. O

we O
report O
a O
patient O
who O
developed O
cholestatic B-Disease
jaundice B-Disease
shortly O
after O
initiation O
of O
treatment O
with O
metformin O
hydrochloride O
. O

ultrasound O
of O
the O
liver O
and O
abdominal O
ct O
were O
normal O
. O

an O
ercp O
showed O
normal O
biliary O
anatomy O
. O

a O
percutaneous O
liver O
biopsy O
was O
obtained O
showing O
marked O
cholestasis B-Disease
, O
with O
portal O
edema B-Disease
, O
ductular O
proliferation O
, O
and O
acute O
inflammation B-Disease
. O

metformin O
hydrochloride O
was O
discontinued O
, O
and O
the O
patient O
' O
s O
jaundice B-Disease
resolved O
slowly O
over O
a O
period O
of O
several O
months O
. O

given O
the O
onset O
of O
his O
jaundice B-Disease
2 O
wk O
after O
the O
initiation O
of O
metformin O
, O
we O
believe O
that O
this O
case O
represents O
an O
example O
of O
metformin O
- O
associated O
hepatotoxicity B-Disease
, O
the O
first O
such O
case O
reported O
. O

systemic O
toxicity B-Disease
and O
resuscitation O
in O
bupivacaine O
- O
, O
levobupivacaine O
- O
, O
or O
ropivacaine O
- O
infused O
rats O
. O

we O
compared O
the O
systemic O
toxicity B-Disease
of O
bupivacaine O
, O
levobupivacaine O
, O
and O
ropivacaine O
in O
anesthetized O
rats O
. O

we O
also O
compared O
the O
ability O
to O
resuscitate O
rats O
after O
lethal O
doses O
of O
these O
local O
anesthetics O
. O

bupivacaine O
, O
levobupivacaine O
, O
or O
ropivacaine O
was O
infused O
at O
a O
rate O
of O
2 O
mg O
. O

kg O
( O
- O
1 O
) O
. O

min O
( O
- O
1 O
) O
while O
electrocardiogram O
, O
electroencephalogram O
, O
and O
arterial O
pressure O
were O
continuously O
monitored O
. O

when O
asystole B-Disease
was O
recorded O
, O
drug O
infusion O
was O
stopped O
and O
a O
resuscitation O
sequence O
was O
begun O
. O

epinephrine O
0 O
. O
01 O
mg O
/ O
kg O
was O
administered O
at O
1 O
- O
min O
intervals O
while O
external O
cardiac O
compressions O
were O
applied O
. O

resuscitation O
was O
considered O
successful O
when O
a O
systolic O
arterial O
pressure O
> O
or O
= O
100 O
mm O
hg O
was O
achieved O
within O
5 O
min O
. O

the O
cumulative O
doses O
of O
levobupivacaine O
and O
ropivacaine O
that O
produced O
seizures B-Disease
were O
similar O
and O
were O
larger O
than O
those O
of O
bupivacaine O
. O

the O
cumulative O
doses O
of O
levobupivacaine O
that O
produced O
dysrhythmias B-Disease
and O
asystole B-Disease
were O
smaller O
than O
the O
corresponding O
doses O
of O
ropivacaine O
, O
but O
they O
were O
larger O
than O
those O
of O
bupivacaine O
. O

the O
number O
of O
successful O
resuscitations O
did O
not O
differ O
among O
groups O
. O

however O
, O
a O
smaller O
dose O
of O
epinephrine O
was O
required O
in O
the O
ropivacaine O
group O
than O
in O
the O
other O
groups O
. O

we O
conclude O
that O
the O
systemic O
toxicity B-Disease
of O
levobupivacaine O
is O
intermediate O
between O
that O
of O
ropivacaine O
and O
bupivacaine O
when O
administered O
at O
the O
same O
rate O
and O
that O
ropivacaine O
- O
induced O
cardiac B-Disease
arrest B-Disease
appears O
to O
be O
more O
susceptible O
to O
treatment O
than O
that O
induced O
by O
bupivacaine O
or O
levobupivacaine O
. O

amphotericin O
b O
- O
induced O
seizures B-Disease
in O
a O
patient O
with O
aids B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
multiple O
episodes O
of O
seizure B-Disease
activity O
in O
an O
aids B-Disease
patent O
following O
amphotericin O
b O
infusion O
. O

case O
summary O
: O
a O
46 O
- O
year O
- O
old O
african O
- O
american O
man O
experienced O
recurrent O
grand B-Disease
mal B-Disease
seizures B-Disease
during O
intravenous O
infusion O
of O
amphotericin O
b O
, O
then O
petit O
mal O
seizures B-Disease
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O
. O

the O
patients O
concurrent O
medications O
included O
didanosine O
, O
hydroxyzine O
, O
promethazine O
, O
hydrocortisone O
, O
and O
prochlorperazine O
. O

despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures B-Disease
persisted O
and O
occurred O
only O
during O
amphotercin O
b O
administration O
. O

discussion O
: O
aids B-Disease
and O
cryptococcal B-Disease
meningitis B-Disease
, O
both O
of O
which O
the O
patient O
had O
, O
can O
potentially O
cause O
seizures B-Disease
. O

the O
patient O
had O
a O
history O
of O
alcohol B-Disease
abuse B-Disease
; O
alcohol O
intake O
as O
well O
as O
withdrawal O
can O
also O
cause O
seizures B-Disease
. O

didanosine O
also O
has O
a O
potential O
for O
inducing O
seizures B-Disease
. O

however O
, O
these O
other O
potential O
causes O
of O
seizure B-Disease
were O
ruled O
out O
. O

the O
time O
course O
of O
events O
suggested O
that O
amphotericin O
b O
was O
the O
cause O
of O
the O
seizures B-Disease
in O
this O
aids B-Disease
patient O
. O

conclusions O
: O
amphotericin O
b O
seems O
to O
be O
the O
probable O
cause O
of O
the O
seizures B-Disease
. O

to O
date O
, O
only O
three O
cases O
of O
seizures B-Disease
associated O
with O
amphotericin O
b O
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

sirolimus O
and O
mycophenolate O
mofetil O
for O
calcineurin O
- O
free O
immunosuppression O
in O
renal O
transplant O
recipients O
. O

calcineurin O
inhibitors O
, O
such O
as O
cyclosporine O
and O
tacrolimus O
, O
have O
been O
available O
for O
almost O
20 O
years O
. O

although O
these O
drugs O
are O
highly O
effective O
and O
represent O
the O
mainstay O
of O
transplant O
immunosuppression O
, O
they O
are O
associated O
with O
acute O
and O
chronic O
nephrotoxicity B-Disease
. O

acute O
nephrotoxicity B-Disease
, O
which O
occurs O
in O
the O
early O
period O
after O
transplantation O
, O
leads O
to O
a O
higher O
rate O
of O
dialysis O
, O
and O
chronic O
nephrotoxicity B-Disease
may O
eventually O
result O
in O
graft O
loss O
. O

acute O
and O
chronic O
nephrotoxicity B-Disease
is O
becoming O
more O
common O
as O
the O
use O
of O
marginal O
kidneys O
for O
transplantation O
increases O
. O

two O
recently O
available O
immunosuppressive O
agents O
, O
mycophenolate O
mofetil O
and O
sirolimus O
( O
rapamycin O
) O
, O
have O
no O
nephrotoxicity B-Disease
. O

the O
use O
of O
these O
drugs O
in O
combination O
with O
other O
agents O
has O
led O
to O
the O
development O
of O
new O
paradigms O
of O
immunosuppressive O
therapy O
. O

this O
paper O
reviews O
the O
results O
of O
clinical O
trials O
that O
have O
investigated O
these O
new O
approaches O
to O
immunosuppression O
in O
renal O
transplant O
recipients O
. O

tolerability O
of O
nimesulide O
and O
paracetamol O
in O
patients O
with O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
. O

previous O
studies O
evaluated O
the O
tolerance O
of O
nimesulide O
and O
paracetamol O
in O
subjects O
with O
cutaneous O
, O
respiratory O
and O
anaphylactoid O
reactions O
induced O
by O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
. O

in O
this O
study O
we O
investigated O
tolerability O
and O
reliability O
of O
nimesulide O
and O
paracetamol O
in O
a O
very O
large O
number O
of O
patients O
with O
an O
exclusive O
well O
- O
documented O
history O
of O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
. O

furthermore O
, O
we O
evaluated O
whether O
some O
factors O
have O
the O
potential O
to O
increase O
the O
risk O
of O
reaction O
to O
paracetamol O
and O
nimesulide O
. O

a O
single O
- O
placebo O
- O
controlled O
oral O
challenge O
procedure O
with O
nimesulide O
or O
paracetamol O
was O
applied O
to O
829 O
patients O
with O
a O
history O
of O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
. O

a O
total O
of O
75 O
/ O
829 O
( O
9 O
. O
4 O
% O
) O
patients O
experienced O
reactions O
to O
nimesulide O
or O
paracetamol O
. O

of O
the O
715 O
patients O
tested O
with O
nimesulide O
62 O
( O
8 O
. O
6 O
% O
) O
showed O
a O
positive O
test O
, O
while O
of O
114 O
subjects O
submitted O
to O
the O
challenge O
with O
paracetamol O
, O
13 O
( O
9 O
. O
6 O
% O
) O
did O
not O
tolerate O
this O
drug O
. O

furthermore O
, O
18 O
. O
28 O
% O
of O
patients O
with O
a O
history O
of O
chronic O
urticaria B-Disease
and O
11 O
. O
8 O
% O
of O
subjects O
with O
an O
history O
of O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
or O
angioedema B-Disease
alone O
( O
with O
or O
without O
chronic O
urticaria B-Disease
) O
resulted O
to O
be O
intolerant O
to O
alternative O
drugs O
. O

taken O
together O
, O
our O
results O
confirm O
the O
good O
tolerability O
of O
nimesulide O
and O
paracetamol O
in O
patients O
who O
experienced O
urticaria B-Disease
/ O
angioedema B-Disease
caused O
by O
nsaids O
. O

however O
, O
the O
risk O
of O
reaction O
to O
these O
alternative O
study O
drugs O
is O
statistically O
increased O
by O
a O
history O
of O
chronic O
urticaria B-Disease
and O
, O
above O
all O
, O
by O
a O
history O
of O
nsaid O
- O
induced O
angioedema B-Disease
. O

comparison O
of O
aqueous O
and O
gellan O
ophthalmic O
timolol O
with O
placebo O
on O
the O
24 O
- O
hour O
heart O
rate O
response O
in O
patients O
on O
treatment O
for O
glaucoma B-Disease
. O

purpose O
: O
topical O
beta O
- O
blocker O
treatment O
is O
routine O
therapy O
in O
the O
management O
of O
patients O
with O
glaucoma B-Disease
. O

therapy O
results O
in O
systemic O
absorption O
, O
however O
, O
the O
degree O
of O
reduction O
of O
resting O
and O
peak O
heart O
rate O
has O
not O
been O
quantified O
. O

design O
: O
this O
trial O
evaluated O
the O
effect O
of O
placebo O
, O
0 O
. O
5 O
% O
aqueous O
timolol O
( O
timolol O
solution O
) O
and O
a O
0 O
. O
5 O
% O
timolol O
suspension O
that O
forms O
a O
gel O
on O
application O
to O
the O
conjunctiva O
( O
timolol O
gellan O
) O
on O
the O
24 O
- O
hour O
heart O
rate O
in O
patients O
currently O
being O
treated O
for O
glaucoma B-Disease
to O
quantify O
the O
reduction O
in O
mean O
heart O
rate O
. O

methods O
: O
forty O
- O
three O
caucasian O
patients O
with O
primary O
open B-Disease
- B-Disease
angle B-Disease
glaucoma B-Disease
or O
ocular B-Disease
hypertension B-Disease
with O
a O
mean O
( O
+ O
/ O
- O
sd O
) O
age O
of O
63 O
( O
+ O
/ O
- O
8 O
) O
years O
were O
randomized O
and O
crossed O
over O
in O
a O
double O
- O
masked O
manner O
to O
14 O
days O
of O
treatment O
with O
placebo O
( O
morning O
and O
evening O
in O
both O
eyes O
) O
, O
timolol O
solution O
( O
morning O
and O
evening O
in O
both O
eyes O
) O
, O
or O
timolol O
gellan O
( O
morning O
in O
both O
eyes O
with O
placebo O
in O
the O
evening O
) O
. O

on O
the O
13th O
day O
of O
each O
period O
, O
heart O
rate O
was O
recorded O
continuously O
during O
a O
typical O
, O
ambulant O
24 O
- O
hour O
period O
. O

results O
: O
both O
timolol O
solution O
and O
timolol O
gellan O
reduced O
the O
mean O
24 O
- O
hour O
heart O
rate O
compared O
with O
placebo O
( O
p O
< O
or O
= O
. O
001 O
) O
, O
and O
this O
reduction O
was O
most O
pronounced O
during O
the O
daytime O
( O
- O
7 O
. O
5 O
% O
change O
in O
mean O
heart O
rate O
, O
- O
5 O
. O
7 O
beats O
/ O
min O
) O
. O

timolol O
gellan O
showed O
a O
numerically O
but O
not O
significantly O
smaller O
reduction O
in O
24 O
- O
hour O
heart O
rate O
, O
compared O
with O
timolol O
solution O
. O

during O
the O
night O
, O
the O
mean O
12 O
- O
hour O
heart O
rate O
on O
placebo O
and O
timolol O
gellan O
were O
both O
significantly O
less O
than O
on O
timolol O
solution O
; O
the O
difference O
between O
solution O
and O
gellan O
treatments O
was O
statistically O
significant O
( O
p O
= O
. O
01 O
) O
. O

conclusions O
: O
both O
timolol O
solution O
and O
timolol O
gellan O
decrease O
the O
mean O
24 O
- O
hour O
heart O
rate O
compared O
with O
placebo O
. O

this O
response O
was O
most O
pronounced O
during O
the O
active O
daytime O
period O
. O

these O
data O
quantify O
the O
modest O
bradycardia B-Disease
associated O
with O
ophthalmic O
beta O
- O
blocker O
therapy O
in O
a O
typical O
patient O
population O
on O
therapy O
for O
glaucoma B-Disease
. O

although O
exercise O
performance O
was O
not O
assessed O
in O
this O
trial O
, O
reductions O
of O
this O
magnitude O
should O
not O
have O
substantial O
clinical O
consequences O
. O

management O
strategies O
for O
ribavirin O
- O
induced O
hemolytic B-Disease
anemia B-Disease
in O
the O
treatment O
of O
hepatitis B-Disease
c B-Disease
: O
clinical O
and O
economic O
implications O
. O

objectives O
: O
recently O
published O
studies O
have O
demonstrated O
increased O
efficacy O
and O
cost O
- O
effectiveness O
of O
combination O
therapy O
with O
interferon O
and O
alpha O
- O
2b O
/ O
ribavirin O
compared O
with O
interferon O
- O
alpha O
monotherapy O
in O
the O
treatment O
of O
chronic B-Disease
hepatitis B-Disease
c B-Disease
( O
chc B-Disease
) O
. O

combination O
therapy O
is O
associated O
with O
a O
clinically O
important O
adverse O
effect O
: O
ribavirin O
- O
induced O
hemolytic B-Disease
anemia B-Disease
( O
riha B-Disease
) O
. O

the O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
direct O
health O
- O
care O
costs O
and O
management O
of O
riha B-Disease
during O
treatment O
of O
chc B-Disease
in O
a O
clinical O
trial O
setting O
. O

methods O
: O
a O
systematic O
literature O
review O
was O
conducted O
to O
synthesize O
information O
on O
the O
incidence O
and O
management O
of O
riha B-Disease
. O

decision O
- O
analytic O
techniques O
were O
used O
to O
estimate O
the O
cost O
of O
treating O
riha B-Disease
. O

uncertainty O
was O
evaluated O
using O
sensitivity O
analyses O
. O

results O
: O
riha B-Disease
, O
defined O
as O
a O
reduction O
in O
hemoglobin O
to O
less O
than O
100 O
g O
/ O
l O
, O
occurs O
in O
approximately O
7 O
% O
to O
9 O
% O
of O
patients O
treated O
with O
combination O
therapy O
. O

the O
standard O
of O
care O
for O
management O
of O
riha B-Disease
is O
reduction O
or O
discontinuation O
of O
the O
ribavirin O
dosage O
. O

we O
estimated O
the O
direct O
cost O
of O
treating O
clinically O
significant O
riha B-Disease
to O
be O
170 O
per O
patient O
receiving O
combination O
therapy O
per O
48 O
- O
week O
treatment O
course O
( O
range O
68 O
- O
692 O
) O
. O

the O
results O
of O
the O
one O
- O
way O
sensitivity O
analyses O
ranged O
from O
57 O
to O
317 O
. O

in O
comparison O
, O
the O
cost O
of O
48 O
weeks O
of O
combination O
therapy O
is O
16 O
, O
459 O
. O

conclusions O
: O
the O
direct O
cost O
of O
treating O
clinically O
significant O
riha B-Disease
is O
1 O
% O
( O
170 O
/ O
16 O
, O
459 O
) O
of O
drug O
treatment O
costs O
. O

questions O
remain O
about O
the O
optimal O
dose O
of O
ribavirin O
and O
the O
incidence O
of O
riha B-Disease
in O
a O
real O
- O
world O
population O
. O

despite O
these O
uncertainties O
, O
this O
initial O
evaluation O
of O
the O
direct O
cost O
of O
treating O
riha B-Disease
provides O
an O
estimate O
of O
the O
cost O
and O
management O
implications O
of O
this O
clinically O
important O
adverse O
effect O
. O

preliminary O
efficacy O
assessment O
of O
intrathecal O
injection O
of O
an O
american O
formulation O
of O
adenosine O
in O
humans O
. O

background O
: O
preclinical O
studies O
of O
intrathecal O
adenosine O
suggest O
it O
may O
be O
effective O
in O
the O
treatment O
of O
acute B-Disease
and B-Disease
chronic B-Disease
pain B-Disease
in O
humans O
, O
and O
preliminary O
studies O
in O
volunteers O
and O
patients O
with O
a O
swedish O
formulation O
of O
adenosine O
suggests O
it O
may O
be O
effective O
in O
hypersensitivity B-Disease
states O
but O
not O
with O
acute O
noxious O
stimulation O
. O

the O
purpose O
of O
this O
study O
was O
to O
screen O
for O
efficacy O
of O
a O
different O
formulation O
of O
adenosine O
marketed O
in O
the O
us O
, O
using O
both O
acute O
noxious O
stimulation O
and O
capsaicin O
- O
evoked O
mechanical O
hypersensitivity B-Disease
. O

methods O
: O
following O
food O
and O
drug O
administration O
and O
institutional O
review O
board O
approval O
and O
written O
informed O
consent O
, O
65 O
volunteers O
were O
studied O
in O
two O
trials O
: O
an O
open O
- O
label O
, O
dose O
- O
escalating O
trial O
with O
intrathecal O
adenosine O
doses O
of O
0 O
. O
25 O
- O
2 O
. O
0 O
mg O
and O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
of O
adenosine O
, O
2 O
mg O
. O

cerebrospinal O
fluid O
was O
obtained O
for O
pharmacokinetic O
analysis O
, O
and O
pain B-Disease
ratings O
in O
response O
to O
acute O
heat O
stimuli O
and O
areas O
of O
mechanical B-Disease
hyperalgesia B-Disease
and O
allodynia B-Disease
after O
intradermal O
capsaicin O
injection O
were O
determined O
. O

results O
: O
adenosine O
produced O
no O
effect O
on O
pain B-Disease
report O
to O
acute O
noxious O
thermal O
or O
chemical O
stimulation O
but O
reduced O
mechanical B-Disease
hyperalgesia B-Disease
and O
allodynia B-Disease
from O
intradermal O
capsaicin O
injection O
for O
at O
least O
24 O
h O
. O

in O
contrast O
, O
residence O
time O
of O
adenosine O
in O
cerebrospinal O
fluid O
was O
short O
( O
< O
4 O
h O
) O
. O

conclusions O
: O
these O
results O
show O
selective O
inhibition O
by O
intrathecal O
adenosine O
of O
hypersensitivity B-Disease
, O
presumed O
to O
reflect O
central O
sensitization O
in O
humans O
after O
peripheral O
capsaicin O
injection O
. O

the O
long O
- O
lasting O
effect O
is O
consistent O
with O
that O
observed O
in O
preliminary O
reports O
of O
patients O
with O
chronic O
neuropathic B-Disease
pain B-Disease
and O
is O
not O
due O
to O
prolonged O
residence O
of O
adenosine O
in O
cerebrospinal O
fluid O
. O

delayed O
- O
onset O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

background O
: O
heparin O
- O
induced O
thrombocytopenia B-Disease
presents O
5 O
to O
12 O
days O
after O
heparin O
exposure O
, O
with O
or O
without O
arterial B-Disease
or B-Disease
venous B-Disease
thromboemboli B-Disease
. O

delayed O
recognition O
and O
treatment O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
contribute O
to O
poor O
patient O
outcomes O
. O

objective O
: O
to O
describe O
and O
increase O
awareness O
of O
a O
clinical O
scenario O
in O
which O
the O
onset O
or O
manifestations O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
are O
delayed O
. O

design O
: O
retrospective O
case O
series O
. O

setting O
: O
three O
large O
urban O
hospitals O
( O
with O
active O
cardiovascular O
surgery O
programs O
) O
. O

patients O
: O
14 O
patients O
seen O
over O
a O
3 O
- O
year O
period O
in O
whom O
heparin O
- O
induced O
thrombocytopenia B-Disease
became O
apparent O
on O
delayed O
presentation O
with O
thromboembolic B-Disease
complications O
. O

measurements O
: O
platelet O
counts O
, O
onset O
of O
objectively O
determined O
thromboembolism B-Disease
, O
results O
of O
heparin O
- O
induced O
platelet O
factor O
4 O
antibody O
tests O
, O
and O
outcomes O
. O

results O
: O
patients O
went O
home O
after O
hospitalizations O
that O
had O
included O
heparin O
exposure O
- O
- O
in O
most O
cases O
, O
with O
no O
thrombocytopenia B-Disease
recognized O
- O
- O
only O
to O
return O
to O
the O
hospital O
( O
median O
, O
day O
14 O
) O
with O
thromboembolic B-Disease
complications O
. O

thromboemboli B-Disease
were O
venous O
( O
12 O
patients O
, O
7 O
with O
pulmonary B-Disease
emboli B-Disease
) O
or O
arterial O
( O
4 O
patients O
) O
or O
both O
. O

platelet O
counts O
were O
mildly O
decreased O
in O
all O
but O
2 O
patients O
on O
second O
presentation O
. O

on O
readmission O
, O
11 O
patients O
received O
therapeutic O
heparin O
, O
which O
worsened O
the O
patients O
' O
clinical O
condition O
and O
, O
in O
all O
11 O
cases O
, O
decreased O
the O
platelet O
count O
( O
mean O
at O
readmission O
, O
143 O
x O
10 O
( O
9 O
) O
cells O
/ O
l O
; O
mean O
nadir O
after O
heparin O
re O
- O
exposure O
, O
39 O
x O
10 O
( O
9 O
) O
cells O
/ O
l O
) O
. O

results O
of O
serologic O
tests O
for O
heparin O
- O
induced O
antibodies O
were O
positive O
in O
all O
patients O
. O

subsequent O
treatments O
included O
alternative O
anticoagulants O
( O
11 O
patients O
) O
, O
thrombolytic O
drugs O
( O
3 O
patients O
) O
, O
inferior O
vena O
cava O
filters O
( O
3 O
patients O
) O
and O
, O
eventually O
, O
warfarin O
( O
11 O
patients O
) O
. O

three O
patients O
died O
. O

conclusions O
: O
delayed O
- O
onset O
heparin O
- O
induced O
thrombocytopenia B-Disease
is O
increasingly O
being O
recognized O
. O

to O
avoid O
disastrous O
outcomes O
, O
physicians O
must O
consider O
heparin O
- O
induced O
thrombocytopenia B-Disease
whenever O
a O
recently O
hospitalized O
patient O
returns O
with O
thromboembolism B-Disease
; O
therapy O
with O
alternative O
anticoagulants O
, O
not O
heparin O
, O
should O
be O
initiated O
. O

treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
with O
a O
dopamine O
agonist O
in O
children O
. O

background O
: O
risperidone O
, O
a O
potent O
antagonist O
of O
both O
serotonergic O
( O
5ht2a O
) O
and O
dopaminergic O
d2 O
receptors O
is O
associated O
with O
hyperprolactinemia B-Disease
in O
adults O
and O
children O
. O

chronically O
elevated O
prolactin O
levels O
in O
children O
with O
prolactinomas B-Disease
may O
be O
associated O
with O
arrested O
growth O
and O
development O
resulting O
in O
either O
delayed B-Disease
puberty B-Disease
or O
short O
stature O
. O

these O
possibilities O
stress O
the O
importance O
of O
developing O
a O
safe O
and O
effective O
approach O
to O
drug O
- O
induced O
hyperprolactinemia B-Disease
in O
youth O
. O

we O
report O
the O
successful O
treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
with O
cabergoline O
in O
youth O
. O

methods O
: O
we O
undertook O
a O
retrospective O
case O
review O
of O
four O
children O
with O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
treated O
with O
cabergoline O
. O

results O
: O
four O
males O
( O
age O
6 O
- O
11 O
years O
) O
with O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders B-Disease
( O
fourth O
edition O
) O
bipolar B-Disease
disorder B-Disease
or O
psychoses B-Disease
, O
with O
risperidone O
- O
induced O
elevations O
in O
serum O
prolactin O
levels O
( O
57 O
. O
5 O
- O
129 O
ng O
/ O
ml O
, O
normal O
5 O
- O
15 O
ng O
/ O
ml O
) O
, O
were O
treated O
with O
cabergoline O
( O
mean O
dose O
2 O
. O
13 O
+ O
/ O
- O
0 O
. O
09 O
mg O
/ O
week O
) O
. O

when O
serum O
prolactin O
levels O
normalized O
in O
all O
four O
subjects O
( O
mean O
11 O
. O
2 O
+ O
/ O
- O
10 O
. O
9 O
ng O
/ O
ml O
) O
, O
the O
cabergoline O
dose O
was O
reduced O
to O
1 O
mg O
/ O
week O
in O
three O
of O
four O
subjects O
. O

the O
mean O
duration O
of O
therapy O
with O
cabergoline O
was O
523 O
. O
5 O
+ O
/ O
- O
129 O
. O
7 O
days O
, O
and O
the O
mean O
duration O
of O
therapy O
with O
risperidone O
was O
788 O
. O
5 O
+ O
/ O
- O
162 O
. O
5 O
days O
. O

cabergoline O
was O
well O
tolerated O
without O
adverse O
effects O
. O

conclusions O
: O
cabergoline O
may O
be O
useful O
for O
the O
treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
in O
youth O
; O
however O
, O
further O
research O
is O
needed O
. O

acute O
cholestatic B-Disease
hepatitis B-Disease
after O
exposure O
to O
isoflurane O
. O

objective O
: O
to O
report O
a O
case O
of O
acute O
cholestatic B-Disease
hepatitis B-Disease
following O
exposure O
to O
the O
inhalational O
anesthetic O
isoflurane O
. O

case O
summary O
: O
a O
70 O
- O
year O
- O
old O
healthy O
woman O
from O
iraq O
developed O
acute O
cholestatic B-Disease
hepatitis B-Disease
3 O
weeks O
following O
repair O
of O
the O
right O
rotator O
cuff O
under O
general O
anesthesia O
. O

there O
was O
no O
evidence O
for O
viral O
, O
autoimmune O
, O
or O
metabolic O
causes O
of O
hepatitis B-Disease
. O

no O
other O
medications O
were O
involved O
except O
for O
dipyrone O
for O
analgesia B-Disease
. O

the O
alanine O
aminotransferase O
was O
elevated O
to O
a O
peak O
concentration O
of O
1533 O
u O
/ O
l O
and O
the O
serum O
bilirubin O
reached O
a O
peak O
of O
17 O
. O
0 O
mg O
/ O
dl O
. O

there O
was O
slow O
improvement O
over O
4 O
months O
. O

accidental O
reexposure O
by O
the O
patient O
to O
dipyrone O
was O
uneventful O
. O

discussion O
: O
the O
clinical O
and O
histologic O
picture O
of O
this O
case O
resembles O
halothane B-Disease
hepatitis B-Disease
, O
which O
has O
a O
significant O
mortality O
rate O
. O

conclusions O
: O
isoflurane O
, O
a O
common O
anesthetic O
agent O
, O
can O
cause O
severe O
cholestatic B-Disease
hepatitis B-Disease
. O

torsade B-Disease
de B-Disease
pointes B-Disease
induced O
by O
metoclopramide O
in O
an O
elderly O
woman O
with O
preexisting O
complete O
left B-Disease
bundle B-Disease
branch B-Disease
block B-Disease
. O

there O
is O
a O
growing O
list O
of O
drugs O
implicated O
in O
acquired O
long B-Disease
qt B-Disease
syndrome B-Disease
and O
torsade B-Disease
de B-Disease
pointes B-Disease
. O

however O
, O
the O
torsadogenic O
potential O
of O
metoclopramide O
, O
a O
commonly O
used O
antiemetic O
and O
prokinetic O
drug O
, O
has O
not O
been O
reported O
in O
the O
literature O
, O
despite O
its O
chemical O
similarity O
to O
procainamide O
. O

we O
report O
on O
a O
92 O
- O
year O
- O
old O
woman O
with O
preexisting O
complete O
left B-Disease
bundle B-Disease
branch B-Disease
block B-Disease
who O
developed O
torsade B-Disease
de B-Disease
pointes B-Disease
after O
intravenous O
and O
oral O
administration O
of O
metoclopramide O
. O

this O
patient O
also O
developed O
torsade B-Disease
de B-Disease
pointes B-Disease
when O
cisapride O
and O
erythromycin O
were O
given O
simultaneously O
. O

these O
two O
episodes O
were O
suppressed O
successfully O
after O
discontinuing O
the O
offending O
drugs O
and O
administering O
class O
ib O
drugs O
. O

this O
is O
the O
first O
documentation O
that O
metoclopramide O
provokes O
torsade B-Disease
de B-Disease
pointes B-Disease
clinically O
. O

metoclopramide O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
risk O
of O
torsade B-Disease
de B-Disease
pointes B-Disease
. O

dopamine O
d2 O
receptor O
signaling O
controls O
neuronal O
cell O
death O
induced O
by O
muscarinic O
and O
glutamatergic O
drugs O
. O

dopamine O
( O
da O
) O
, O
through O
d1 O
/ O
d2 O
receptor O
- O
mediated O
signaling O
, O
plays O
a O
major O
role O
in O
the O
control O
of O
epileptic B-Disease
seizures B-Disease
arising O
in O
the O
limbic O
system O
. O

excitotoxicity B-Disease
leading O
to O
neuronal O
cell O
death O
in O
the O
affected O
areas O
is O
a O
major O
consequence O
of O
seizures B-Disease
at O
the O
cellular O
level O
. O

in O
this O
respect O
, O
little O
is O
known O
about O
the O
role O
of O
da O
receptors O
in O
the O
occurrence O
of O
epilepsy B-Disease
- O
induced O
neuronal O
cell O
death O
. O

here O
we O
analyze O
the O
occurrence O
of O
seizures B-Disease
and O
neurotoxicity B-Disease
in O
d2r O
- O
/ O
- O
mice O
treated O
with O
the O
cholinergic O
agonist O
pilocarpine O
. O

we O
compared O
these O
results O
with O
those O
previously O
obtained O
with O
kainic O
acid O
( O
ka O
) O
, O
a O
potent O
glutamate O
agonist O
. O

importantly O
, O
d2r O
- O
/ O
- O
mice O
develop O
seizures B-Disease
at O
doses O
of O
both O
drugs O
that O
are O
not O
epileptogenic O
for O
wt O
littermates O
and O
show O
greater O
neurotoxicity B-Disease
. O

however O
, O
pilocarpine O
- O
induced O
seizures B-Disease
result O
in O
a O
more O
widespread O
neuronal O
death O
in O
both O
wt O
and O
d2r O
- O
/ O
- O
brains O
in O
comparison O
to O
ka O
. O

thus O
, O
the O
absence O
of O
d2r O
lowers O
the O
threshold O
for O
seizures B-Disease
induced O
by O
both O
glutamate O
and O
acetylcholine O
. O

moreover O
, O
the O
dopaminergic O
control O
of O
epilepsy B-Disease
- O
induced O
neurodegeneration B-Disease
seems O
to O
be O
mediated O
by O
distinct O
interactions O
of O
d2r O
signaling O
with O
these O
two O
neurotransmitters O
. O

steroid O
structure O
and O
pharmacological O
properties O
determine O
the O
anti O
- O
amnesic B-Disease
effects O
of O
pregnenolone O
sulphate O
in O
the O
passive O
avoidance O
task O
in O
rats O
. O

pregnenolone O
sulphate O
( O
pregs O
) O
has O
generated O
interest O
as O
one O
of O
the O
most O
potent O
memory O
- O
enhancing O
neurosteroids O
to O
be O
examined O
in O
rodent O
learning O
studies O
, O
with O
particular O
importance O
in O
the O
ageing O
process O
. O

the O
mechanism O
by O
which O
this O
endogenous O
steroid O
enhances O
memory O
formation O
is O
hypothesized O
to O
involve O
actions O
on O
glutamatergic O
and O
gabaergic O
systems O
. O

this O
hypothesis O
stems O
from O
findings O
that O
pregs O
is O
a O
potent O
positive O
modulator O
of O
n O
- O
methyl O
- O
d O
- O
aspartate O
receptors O
( O
nmdars O
) O
and O
a O
negative O
modulator O
of O
gamma O
- O
aminobutyric O
acid O
( O
a O
) O
receptors O
( O
gaba O
( O
a O
) O
rs O
) O
. O

moreover O
, O
pregs O
is O
able O
to O
reverse O
the O
amnesic B-Disease
- O
like O
effects O
of O
nmdar O
and O
gaba O
( O
a O
) O
r O
ligands O
. O

to O
investigate O
this O
hypothesis O
, O
the O
present O
study O
in O
rats O
examined O
the O
memory O
- O
altering O
abilities O
of O
structural O
analogs O
of O
pregs O
, O
which O
differ O
in O
their O
modulation O
of O
nmdar O
and O
/ O
or O
gaba O
( O
a O
) O
r O
function O
. O

the O
analogs O
tested O
were O
: O
11 O
- O
ketopregnenolone O
sulphate O
( O
an O
agent O
that O
is O
inactive O
at O
gaba O
( O
a O
) O
rs O
and O
nmdars O
) O
, O
epipregnanolone O
( O
[ O
3beta O
- O
hydroxy O
- O
5beta O
- O
pregnan O
- O
20 O
- O
one O
] O
sulphate O
, O
an O
inhibitor O
of O
both O
gaba O
( O
a O
) O
rs O
and O
nmdars O
) O
, O
and O
a O
newly O
synthesized O
( O
- O
) O
pregs O
enantiomer O
( O
which O
is O
identical O
to O
pregs O
in O
effects O
on O
gaba O
( O
a O
) O
rs O
and O
nmdars O
) O
. O

the O
memory O
- O
enhancing O
effects O
of O
pregs O
and O
its O
analogs O
were O
tested O
in O
the O
passive O
avoidance O
task O
using O
the O
model O
of O
scopolamine O
- O
induced O
amnesia B-Disease
. O

both O
pregs O
and O
its O
( O
- O
) O
enantiomer O
blocked O
the O
effects O
of O
scopolamine O
. O

the O
results O
show O
that O
, O
unlike O
pregs O
, O
11 O
- O
ketopregnenolone O
sulphate O
and O
epipregnanolone O
sulphate O
failed O
to O
block O
the O
effect O
of O
scopolamine O
, O
suggesting O
that O
altering O
the O
modulation O
of O
nmda O
receptors O
diminishes O
the O
memory O
- O
enhancing O
effects O
of O
pregs O
. O

moreover O
, O
enantioselectivity O
was O
demonstrated O
by O
the O
ability O
of O
natural O
pregs O
to O
be O
an O
order O
of O
magnitude O
more O
effective O
than O
its O
synthetic O
enantiomer O
in O
reversing O
scopolamine O
- O
induced O
amnesia B-Disease
. O

these O
results O
identify O
a O
novel O
neuropharmacological O
site O
for O
the O
modulation O
of O
memory O
processes O
by O
neuroactive O
steroids O
. O

activation O
of O
poly O
( O
adp O
- O
ribose O
) O
polymerase O
contributes O
to O
development O
of O
doxorubicin O
- O
induced O
heart B-Disease
failure B-Disease
. O

activation O
of O
the O
nuclear O
enzyme O
poly O
( O
adp O
- O
ribose O
) O
polymerase O
( O
parp O
) O
by O
oxidant O
- O
mediated O
dna O
damage O
is O
an O
important O
pathway O
of O
cell O
dysfunction O
and O
tissue O
injury O
in O
conditions O
associated O
with O
oxidative O
stress O
. O

increased O
oxidative O
stress O
is O
a O
major O
factor O
implicated O
in O
the O
cardiotoxicity B-Disease
of O
doxorubicin O
( O
dox O
) O
, O
a O
widely O
used O
antitumor O
anthracycline O
antibiotic O
. O

thus O
, O
we O
hypothesized O
that O
the O
activation O
of O
parp O
may O
contribute O
to O
the O
dox O
- O
induced O
cardiotoxicity B-Disease
. O

using O
a O
dual O
approach O
of O
parp O
- O
1 O
suppression O
, O
by O
genetic O
deletion O
or O
pharmacological O
inhibition O
with O
the O
phenanthridinone O
parp O
inhibitor O
pj34 O
, O
we O
now O
demonstrate O
the O
role O
of O
parp O
in O
the O
development O
of O
cardiac B-Disease
dysfunction B-Disease
induced O
by O
dox O
. O

parp O
- O
1 O
+ O
/ O
+ O
and O
parp O
- O
1 O
- O
/ O
- O
mice O
received O
a O
single O
injection O
of O
dox O
( O
25 O
mg O
/ O
kg O
i O
. O
p O
) O
. O

five O
days O
after O
dox O
administration O
, O
left O
ventricular O
performance O
was O
significantly O
depressed O
in O
parp O
- O
1 O
+ O
/ O
+ O
mice O
, O
but O
only O
to O
a O
smaller O
extent O
in O
parp O
- O
1 O
- O
/ O
- O
ones O
. O

similar O
experiments O
were O
conducted O
in O
balb O
/ O
c O
mice O
treated O
with O
pj34 O
or O
vehicle O
. O

treatment O
with O
a O
pj34 O
significantly O
improved O
cardiac B-Disease
dysfunction B-Disease
and O
increased O
the O
survival O
of O
the O
animals O
. O

in O
addition O
pj34 O
significantly O
reduced O
the O
dox O
- O
induced O
increase O
in O
the O
serum O
lactate O
dehydrogenase O
and O
creatine O
kinase O
activities O
but O
not O
metalloproteinase O
activation O
in O
the O
heart O
. O

thus O
, O
parp O
activation O
contributes O
to O
the O
cardiotoxicity B-Disease
of O
dox O
. O

parp O
inhibitors O
may O
exert O
protective O
effects O
against O
the O
development O
of O
severe O
cardiac B-Disease
complications B-Disease
associated O
with O
the O
dox O
treatment O
. O

spironolactone O
: O
is O
it O
a O
novel O
drug O
for O
the O
prevention O
of O
amphotericin O
b O
- O
related O
hypokalemia B-Disease
in O
cancer B-Disease
patients O
? O

objective O
: O
nephrotoxicity B-Disease
is O
the O
major O
adverse O
effect O
of O
amphotericin O
b O
( O
amb O
) O
, O
often O
limiting O
administration O
of O
full O
dosage O
. O

selective O
distal O
tubular O
epithelial O
toxicity B-Disease
seems O
to O
be O
responsible O
for O
the O
profound O
potassium O
wasting O
that O
is O
a O
major O
clinical O
side O
effect O
of O
treatment O
with O
amb O
. O

potassium O
depletion O
also O
potentiates O
the O
tubular O
toxicity B-Disease
of O
amb O
. O

this O
study O
was O
designed O
to O
assess O
the O
ability O
of O
spironolactone O
to O
reduce O
potassium O
requirements O
and O
to O
prevent O
hypokalemia B-Disease
in O
neutropenic B-Disease
patients O
on O
amb O
treatment O
. O

methods O
: O
in O
this O
study O
26 O
patients O
with O
various O
hematological B-Disease
disorders B-Disease
were O
randomized O
to O
receive O
either O
intravenous O
amb O
alone O
or O
amb O
and O
oral O
spironolactone O
100 O
mg O
twice O
daily O
when O
developing O
a O
proven O
or O
suspected O
fungal B-Disease
infection B-Disease
. O

results O
: O
patients O
receiving O
concomitant O
amb O
and O
spironolactone O
had O
significantly O
higher O
plasma O
potassium O
levels O
than O
those O
receiving O
amb O
alone O
( O
p O
= O
0 O
. O
0027 O
) O
. O

those O
patients O
receiving O
amb O
and O
spironolactone O
required O
significantly O
less O
potassium O
supplementation O
to O
maintain O
their O
plasma O
potassium O
within O
the O
normal O
range O
( O
p O
= O
0 O
. O
022 O
) O
. O

moreover O
, O
urinary O
potassium O
losses O
were O
significantly O
less O
in O
patients O
receiving O
amb O
and O
spironolactone O
than O
those O
receiving O
amb O
alone O
( O
p O
= O
0 O
. O
040 O
) O
. O

conclusion O
: O
this O
study O
showed O
that O
spironolactone O
can O
reduce O
potassium O
requirements O
and O
prevent O
hypokalemia B-Disease
by O
reducing O
urinary O
potassium O
loss O
in O
neutropenic B-Disease
patients O
on O
amb O
treatment O
. O

erectile B-Disease
dysfunction B-Disease
occurs O
following O
substantia O
nigra O
lesions O
in O
the O
rat O
. O

erectile O
function O
was O
assessed O
6 O
weeks O
following O
uni O
- O
and O
bilateral O
injections O
of O
6 O
- O
hydroxydopamine O
in O
the O
substantia O
nigra O
nucleus O
of O
the O
brain O
. O

behavioral O
apomorphine O
- O
induced O
penile O
erections O
were O
reduced O
( O
5 O
/ O
8 O
) O
and O
increased O
( O
3 O
/ O
8 O
) O
in O
uni O
- O
and O
bilateral O
lesioned O
animals O
. O

intracavernous O
pressures O
, O
following O
electrical O
stimulation O
of O
the O
cavernous O
nerve O
, O
decreased O
in O
lesioned O
animals O
. O

lesions O
of O
the O
substantia O
nigra O
were O
confirmed O
by O
histology O
. O

concentration O
of O
dopamine O
and O
its O
metabolites O
were O
decreased O
in O
the O
striatum O
of O
substantia O
nigra O
lesioned O
rats O
. O

lesions O
of O
the O
substantia O
nigra O
are O
therefore O
associated O
with O
erectile B-Disease
dysfunction B-Disease
in O
rats O
and O
may O
serve O
as O
a O
model O
to O
study O
erectile B-Disease
dysfunction B-Disease
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

nicotine O
potentiation O
of O
morphine O
- O
induced O
catalepsy B-Disease
in O
mice O
. O

in O
the O
present O
study O
, O
effects O
of O
nicotine O
on O
catalepsy B-Disease
induced O
by O
morphine O
in O
mice O
have O
been O
investigated O
. O

morphine O
but O
not O
nicotine O
induced O
a O
dose O
- O
dependent O
catalepsy B-Disease
. O

the O
response O
of O
morphine O
was O
potentiated O
by O
nicotine O
. O

intraperitoneal O
administration O
of O
atropine O
, O
naloxone O
, O
mecamylamine O
, O
and O
hexamethonium O
to O
mice O
reduced O
catalepsy B-Disease
induced O
by O
a O
combination O
of O
morphine O
with O
nicotine O
. O

intracerebroventricular O
injection O
of O
atropine O
, O
hexamethonium O
, O
and O
naloxone O
also O
decreased O
catalepsy B-Disease
induced O
by O
morphine O
plus O
nicotine O
. O

intraperitoneal O
administration O
of O
atropine O
, O
but O
not O
intraperitoneal O
or O
intracerebroventricular O
injection O
of O
hexamethonium O
, O
decreased O
the O
effect O
of O
a O
single O
dose O
of O
morphine O
. O

it O
was O
concluded O
that O
morphine O
catalepsy B-Disease
can O
be O
elicited O
by O
opioid O
and O
cholinergic O
receptors O
, O
and O
the O
potentiation O
of O
morphine O
induced O
by O
nicotine O
may O
also O
be O
mediated O
through O
cholinergic O
receptor O
mechanisms O
. O

force O
overflow O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

we O
assessed O
force O
coordination O
of O
the O
hand O
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
and O
its O
relationship O
to O
motor O
complications O
of O
levodopa O
therapy O
, O
particularly O
to O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
lid B-Disease
) O
. O

we O
studied O
two O
groups O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
patients O
with O
( O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
+ O
lid B-Disease
, O
n O
= O
23 O
) O
and O
without O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
- O
lid B-Disease
, O
n O
= O
10 O
) O
, O
and O
age O
- O
matched O
healthy O
controls O
. O

the O
motor O
score O
of O
the O
unified O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
rating O
scale O
, O
a O
dyskinesia B-Disease
score O
and O
force O
in O
a O
grip O
- O
lift O
paradigm O
were O
assessed O
on O
and O
off O
levodopa O
. O

a O
pathological O
increase O
of O
forces O
was O
seen O
in O
on O
- O
state O
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
+ O
lid B-Disease
only O
. O

in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
+ O
lid B-Disease
, O
the O
force O
involved O
in O
pressing O
down O
the O
object O
before O
lifting O
was O
significantly O
increased O
by O
levodopa O
( O
by O
61 O
% O
, O
p O
< O
0 O
. O
05 O
) O
. O

an O
overshooting O
of O
peak O
grip O
force O
by O
51 O
% O
( O
p O
< O
0 O
. O
05 O
) O
and O
of O
static O
grip O
force O
by O
45 O
% O
( O
p O
< O
0 O
. O
01 O
) O
was O
observed O
in O
the O
on O
- O
compared O
with O
the O
off O
- O
drug O
condition O
. O

in O
contrast O
, O
no O
excessive O
force O
was O
found O
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
- O
lid B-Disease
. O

peak O
grip O
force O
in O
on O
- O
state O
was O
140 O
% O
( O
p O
< O
0 O
. O
05 O
) O
higher O
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
+ O
lid B-Disease
than O
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
- O
lid B-Disease
, O
while O
static O
grip O
force O
was O
increased O
by O
138 O
% O
( O
p O
< O
0 O
. O
01 O
) O
between O
groups O
. O

severity O
of O
peak O
- O
dose O
dyskinesias B-Disease
was O
strongly O
correlated O
with O
grip O
force O
in O
on O
- O
state O
( O
r O
= O
0 O
. O
79 O
with O
peak O
force O
, O
p O
< O
0 O
. O
01 O
) O
. O

no O
correlation O
was O
observed O
between O
forces O
and O
the O
motor O
score O
as O
well O
as O
with O
the O
daily O
dose O
of O
dopaminergic O
medication O
. O

force O
excess O
was O
only O
observed O
in O
patients O
with O
lid B-Disease
and O
motor O
fluctuations O
. O

a O
close O
relationship O
was O
seen O
between O
the O
overshooting O
of O
forces O
and O
dyskinesias B-Disease
in O
the O
on O
- O
drug O
condition O
. O

we O
postulate O
that O
both O
lid B-Disease
and O
grip O
force O
excess O
share O
common O
pathophysiological O
mechanisms O
related O
to O
motor O
fluctuations O
. O

behavioral O
effects O
of O
mk O
- O
801 O
on O
reserpine O
- O
treated O
mice O
. O

the O
effects O
of O
dizocilpine O
( O
mk O
- O
801 O
) O
, O
a O
noncompetitive O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
antagonist O
, O
were O
studied O
on O
dopamine O
- O
related O
behaviors O
induced O
by O
reserpine O
treatments O
. O

this O
study O
focuses O
on O
behavioral O
syndromes O
that O
may O
used O
as O
models O
for O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
, O
or O
tardive B-Disease
dyskinesia B-Disease
, O
and O
its O
response O
after O
glutamatergic O
blockage O
. O

reserpine O
( O
1 O
mg O
/ O
kg O
) O
, O
administered O
once O
every O
other O
day O
for O
4 O
days O
, O
produced O
increases O
in O
orofacial B-Disease
dyskinesia B-Disease
, O
tongue O
protrusion O
and O
vacuous O
chewing O
in O
mice O
, O
which O
are O
signs O
indicative O
of O
tardive B-Disease
dyskinesia B-Disease
. O

reserpine O
also O
produced O
tremor B-Disease
and O
catalepsy B-Disease
, O
which O
are O
signs O
suggestive O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

mk O
- O
801 O
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
, O
administered O
30 O
min O
before O
the O
observation O
test O
, O
prevented O
the O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
and O
catalepsy B-Disease
induced O
by O
reserpine O
. O

however O
, O
mk O
- O
801 O
injection O
produced O
a O
significant O
increase O
of O
tremor B-Disease
in O
reserpine O
- O
treated O
mice O
. O

reserpine O
( O
1 O
mg O
/ O
kg O
) O
, O
administered O
90 O
min O
before O
the O
test O
and O
followed O
by O
apomophine O
injection O
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
5 O
min O
before O
the O
test O
, O
did O
not O
produce O
oral B-Disease
dyskinesia B-Disease
in O
mice O
. O

on O
the O
other O
hand O
, O
reserpine O
induced O
increases O
in O
tremor B-Disease
and O
catalepsy B-Disease
compared O
to O
control O
mice O
. O

mk O
- O
801 O
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
administration O
attenuated O
the O
catalepsy B-Disease
and O
tremor B-Disease
induced O
by O
reserpine O
. O

pretreatment O
with O
reserpine O
( O
1 O
mg O
/ O
kg O
) O
24 O
h O
before O
the O
observation O
test O
produced O
increases O
in O
vacuous O
chewing O
movements O
and O
tongue O
protrusion O
, O
as O
well O
as O
increases O
in O
tremor B-Disease
and O
catalepsy B-Disease
, O
whereas O
mk O
- O
801 O
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
injection O
90 O
min O
before O
the O
test O
reversed O
the O
effects O
of O
reserpine O
. O

these O
results O
show O
that O
reserpine O
produces O
different O
and O
abnormal B-Disease
movements B-Disease
, O
which O
are O
related O
to O
dose O
and O
schedule O
employed O
and O
can O
be O
considered O
as O
parkinsonian B-Disease
- O
like O
and O
tardive B-Disease
dsykinesia B-Disease
signs O
. O

the O
glutamatergic O
blockage O
produced O
by O
nmda O
can O
restore O
these O
signs O
, O
such O
as O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
, O
catalepsy B-Disease
and O
tremor B-Disease
according O
to O
the O
employed O
model O
. O

risperidone O
- O
associated O
, O
benign O
transient O
visual B-Disease
disturbances B-Disease
in O
schizophrenic B-Disease
patients O
with O
a O
past O
history O
of O
lsd O
abuse O
. O

two O
schizophrenic B-Disease
patients O
, O
who O
had O
a O
prior O
history O
of O
lsd O
abuse O
and O
who O
had O
previously O
developed O
eps B-Disease
with O
classic O
antipsychotics O
, O
were O
successfully O
treated O
with O
risperidone O
. O

they O
both O
reported O
short O
episodes O
of O
transient O
visual B-Disease
disturbances B-Disease
, O
which O
appeared O
immediately O
after O
starting O
treatment O
with O
risperidone O
. O

this O
imagery O
resembled O
visual B-Disease
disturbances B-Disease
previously O
experienced O
as O
" O
flashbacks O
" O
related O
to O
prior O
lsd O
consumption O
. O

risperidone O
administration O
was O
continued O
and O
the O
visual B-Disease
disturbances B-Disease
gradually O
wore O
off O
. O

during O
a O
six O
- O
month O
follow O
- O
up O
period O
, O
there O
was O
no O
recurrence O
of O
visual B-Disease
disturbances B-Disease
. O

this O
phenomenon O
may O
be O
interpreted O
as O
a O
benign O
, O
short O
- O
term O
and O
self O
- O
limiting O
side O
effect O
which O
does O
not O
contraindicate O
the O
use O
of O
risperidone O
or O
interfere O
with O
treatment O
. O

conclusions O
based O
on O
two O
case O
reports O
should O
be O
taken O
with O
appropriate O
caution O
. O

topiramate O
- O
induced O
nephrolithiasis B-Disease
. O

topiramate O
is O
a O
recently O
developed O
antiepileptic O
medication O
that O
is O
becoming O
more O
widely O
prescribed O
because O
of O
its O
efficacy O
in O
treating O
refractory B-Disease
seizures B-Disease
. O

urologists O
should O
be O
aware O
that O
this O
medication O
can O
cause O
metabolic B-Disease
acidosis B-Disease
in O
patients O
secondary O
to O
inhibition O
of O
carbonic O
anhydrase O
. O

in O
addition O
, O
a O
distal O
tubular O
acidification O
defect O
may O
result O
, O
thus O
impairing O
the O
normal O
compensatory O
drop O
in O
urine O
ph O
. O

these O
factors O
can O
lead O
to O
the O
development O
of O
calcium O
phosphate O
nephrolithiasis B-Disease
. O

we O
report O
the O
first O
two O
cases O
of O
topiramate O
- O
induced O
nephrolithiasis B-Disease
in O
the O
urologic O
literature O
. O

ketamine O
in O
war O
/ O
tropical O
surgery O
( O
a O
final O
tribute O
to O
the O
racemic O
mixture O
) O
. O

a O
technique O
of O
continuous O
intravenous O
anaesthesia O
with O
ketamine O
was O
used O
successfully O
during O
the O
somalia O
civil O
war O
in O
1994 O
and O
in O
north O
uganda O
in O
1999 O
for O
64 O
operations O
in O
62 O
patients O
, O
aged O
from O
6 O
weeks O
to O
70 O
years O
, O
undergoing O
limb O
and O
abdominal O
surgery O
including O
caesarian O
sections O
and O
interventions O
in O
neonates O
. O

operations O
lasting O
up O
to O
2h O
could O
be O
performed O
in O
the O
absence O
of O
sophisticated O
equipment O
such O
as O
pulse O
oximeters O
or O
ventilators O
in O
patients O
on O
spontaneous O
ventilation O
breathing O
air O
/ O
oxygen O
only O
. O

after O
premedication O
with O
diazepam O
, O
glycopyrrolate O
and O
local O
anaesthesia O
, O
and O
induction O
with O
standard O
doses O
of O
ketamine O
, O
a O
maintenance O
dose O
of O
10 O
- O
20 O
microg O
/ O
kg O
/ O
min O
of O
ketamine O
proved O
safe O
and O
effective O
. O

emphasis O
was O
placed O
on O
bedside O
clinical O
monitoring O
, O
relying O
heavily O
on O
the O
heart O
rate O
. O

diazepam O
, O
unless O
contraindicated O
or O
risky O
, O
remains O
the O
only O
necessary O
complementary O
drug O
to O
ketamine O
as O
it O
buffers O
its O
cardiovascular O
response O
and O
decreases O
the O
duration O
and O
intensity O
of O
operative O
and O
postoperative O
hallucinations B-Disease
. O

local O
anaesthetic O
blocks O
were O
useful O
in O
decreasing O
the O
requirement O
for O
postoperative O
analgesia B-Disease
. O

an O
antisialogue O
was O
usually O
unnecessary O
in O
operations O
lasting O
up O
to O
2 O
h O
, O
glycopyrrolate O
being O
the O
best O
choice O
for O
its O
lowest O
psychotropic O
and O
chronotropic O
effects O
, O
especially O
in O
a O
hot O
climate O
. O

experience O
in O
war O
/ O
tropical O
settings O
suggests O
this O
technique O
could O
be O
useful O
in O
civilian O
contexts O
such O
as O
outdoor O
life O
- O
saving O
emergency O
surgery O
or O
in O
mass O
casualties O
where O
, O
e O
. O
g O
. O
amputation O
and O
rapid O
extrication O
were O
required O
. O

intravenous O
ribavirin O
treatment O
for O
severe O
adenovirus B-Disease
disease B-Disease
in O
immunocompromised O
children O
. O

background O
: O
adenovirus O
is O
an O
important O
cause O
of O
morbidity O
and O
mortality O
in O
the O
immunocompromised O
host O
. O

the O
incidence O
of O
severe O
adenovirus B-Disease
disease B-Disease
in O
pediatrics O
is O
increasing O
in O
association O
with O
growing O
numbers O
of O
immunocompromised O
children O
, O
where O
case O
fatality O
rates O
as O
high O
as O
50 O
% O
to O
80 O
% O
have O
been O
reported O
. O

there O
are O
no O
approved O
antiviral O
agents O
with O
proven O
efficacy O
for O
the O
treatment O
of O
severe O
adenovirus B-Disease
disease B-Disease
, O
nor O
are O
there O
any O
prospective O
randomized O
, O
controlled O
trials O
of O
potentially O
useful O
anti O
- O
adenovirus O
therapies O
. O

apparent O
clinical O
success O
in O
the O
treatment O
of O
severe O
adenovirus B-Disease
disease B-Disease
is O
limited O
to O
a O
few O
case O
reports O
and O
small O
series O
. O

experience O
is O
greatest O
with O
intravenous O
ribavirin O
and O
cidofovir O
. O

ribavirin O
, O
a O
guanosine O
analogue O
, O
has O
broad O
antiviral O
activity O
against O
both O
rna O
and O
dna O
viruses O
, O
including O
documented O
activity O
against O
adenovirus O
in O
vitro O
. O

ribavirin O
is O
licensed O
in O
aerosol O
form O
for O
the O
treatment O
of O
respiratory B-Disease
syncytial B-Disease
virus B-Disease
infection B-Disease
, O
and O
orally O
in O
combination O
with O
interferon O
to O
treat O
hepatitis B-Disease
c B-Disease
. O

intravenous O
ribavirin O
is O
the O
treatment O
of O
choice O
for O
infection B-Disease
with B-Disease
hemorrhagic B-Disease
fever B-Disease
viruses B-Disease
. O

the O
most O
common O
adverse O
effect O
of O
intravenous O
ribavirin O
is O
reversible O
mild O
anemia B-Disease
. O

the O
use O
of O
cidofovir O
in O
severe O
adenovirus B-Disease
infection B-Disease
has O
been O
limited O
by O
adverse O
effects O
, O
the O
most O
significant O
of O
which O
is O
nephrotoxicity B-Disease
. O

objective O
: O
we O
report O
our O
experience O
with O
intravenous O
ribavirin O
therapy O
for O
severe O
adenovirus B-Disease
disease B-Disease
in O
a O
series O
of O
immunocompromised O
children O
and O
review O
the O
literature O
. O

design O
/ O
methods O
: O
we O
retrospectively O
reviewed O
the O
medical O
records O
of O
5 O
children O
treated O
with O
intravenous O
ribavirin O
for O
documented O
severe O
adenovirus B-Disease
disease B-Disease
. O

two O
patients O
developed O
adenovirus O
hemorrhagic B-Disease
cystitis B-Disease
after O
cardiac O
and O
bone O
marrow O
transplants O
, O
respectively O
. O

the O
bone O
marrow O
transplant O
patient O
also O
received O
intravenous O
cidofovir O
for O
progressive O
disseminated O
disease O
. O

an O
additional O
3 O
children O
developed O
adenovirus B-Disease
pneumonia B-Disease
; O
2 O
were O
neonates O
, O
1 O
of O
whom O
had O
partial O
digeorge B-Disease
syndrome B-Disease
. O

the O
remaining O
infant O
had O
recently O
undergone O
a O
cardiac O
transplant O
. O

intravenous O
ribavirin O
was O
administered O
on O
a O
compassionate O
- O
use O
protocol O
. O

results O
: O
complete O
clinical O
recovery O
followed O
later O
by O
viral O
clearance O
was O
observed O
in O
2 O
children O
: O
the O
cardiac O
transplant O
recipient O
with O
adenovirus O
hemorrhagic B-Disease
cystitis B-Disease
and O
the O
immunocompetent O
neonate O
with O
adenovirus B-Disease
pneumonia B-Disease
. O

the O
remaining O
3 O
children O
died O
of O
adenovirus B-Disease
disease B-Disease
. O

intravenous O
ribavirin O
therapy O
was O
well O
tolerated O
. O

use O
of O
cidofovir O
in O
1 O
child O
was O
associated O
with O
progressive B-Disease
renal B-Disease
failure B-Disease
and O
neutropenia B-Disease
. O

discussion O
: O
our O
series O
of O
patients O
is O
representative O
of O
the O
spectrum O
of O
immunocompromised O
children O
at O
greatest O
risk O
for O
severe O
adenovirus B-Disease
disease B-Disease
, O
namely O
solid O
- O
organ O
and O
bone O
marrow O
transplant O
recipients O
, O
neonates O
, O
and O
children O
with O
immunodeficiency B-Disease
. O

although O
intravenous O
ribavirin O
was O
not O
effective O
for O
all O
children O
with O
severe O
adenovirus B-Disease
disease B-Disease
in O
this O
series O
or O
in O
the O
literature O
, O
therapy O
is O
unlikely O
to O
be O
of O
benefit O
if O
begun O
late O
in O
the O
course O
of O
the O
infection B-Disease
. O

early O
identification O
, O
eg O
by O
polymerase O
chain O
reaction O
of O
those O
patients O
at O
risk O
of O
disseminated O
adenovirus B-Disease
disease B-Disease
may O
permit O
earlier O
antiviral O
treatment O
and O
better O
evaluation O
of O
therapeutic O
response O
. O

conclusions O
: O
two O
of O
5 O
children O
with O
severe O
adenovirus B-Disease
disease B-Disease
treated O
with O
intravenous O
ribavirin O
recovered O
. O

the O
availability O
of O
newer O
rapid O
diagnostic O
techniques O
, O
such O
as O
polymerase O
chain O
reaction O
, O
may O
make O
earlier O
, O
more O
effective O
treatment O
of O
adenovirus B-Disease
infection B-Disease
possible O
. O

given O
the O
seriousness O
and O
increasing O
prevalence O
of O
adenovirus B-Disease
disease B-Disease
in O
certain O
hosts O
, O
especially O
children O
, O
a O
large O
, O
multicenter O
clinical O
trial O
of O
potentially O
useful O
anti O
- O
adenoviral O
therapies O
, O
such O
as O
intravenous O
ribavirin O
, O
is O
clearly O
required O
to O
demonstrate O
the O
most O
effective O
and O
least O
toxic O
therapy O
. O

delayed O
asystolic B-Disease
cardiac B-Disease
arrest B-Disease
after O
diltiazem O
overdose B-Disease
; O
resuscitation O
with O
high O
dose O
intravenous O
calcium O
. O

a O
51 O
year O
old O
man O
took O
a O
mixed O
overdose B-Disease
including O
1 O
. O
8 O
- O
3 O
. O
6 O
g O
of O
diltiazem O
, O
paracetamol O
, O
aspirin O
, O
isosorbide O
nitrate O
, O
and O
alcohol O
. O

he O
initially O
presented O
to O
hospital O
after O
six O
hours O
with O
mild O
hypotension B-Disease
and O
was O
treated O
with O
activated O
charcoal O
and O
intravenous O
fluids O
. O

eighteen O
hours O
after O
the O
overdose B-Disease
he O
had O
two O
generalised O
tonic B-Disease
- B-Disease
clonic B-Disease
seizures B-Disease
. O

the O
patient O
remained O
unresponsive O
with O
junctional O
bradycardia B-Disease
, O
unrecordable O
blood O
pressure O
, O
and O
then O
became O
asystolic B-Disease
. O

he O
was O
resuscitated O
with O
high O
dose O
( O
13 O
. O
5 O
g O
) O
intravenous O
calcium O
and O
adrenaline O
( O
epinephrine O
) O
. O

he O
required O
inotropic O
support O
and O
temporary O
pacing O
over O
the O
next O
48 O
hours O
. O

this O
case O
suggests O
there O
is O
a O
role O
for O
aggressive O
high O
dose O
intravenous O
calcium O
therapy O
in O
severe O
diltiazem O
overdose B-Disease
, O
particularly O
with O
the O
onset O
of O
asystole B-Disease
. O

it O
should O
be O
considered O
early O
in O
cases O
of O
cardiac B-Disease
arrest B-Disease
after O
diltiazem O
overdose B-Disease
. O

the O
case O
also O
highlights O
the O
problems O
with O
delayed O
toxicity B-Disease
when O
whole O
bowel O
irrigation O
is O
not O
administered O
. O

low O
- O
molecular O
- O
weight O
heparin O
for O
the O
treatment O
of O
patients O
with O
mechanical O
heart O
valves O
. O

background O
: O
the O
interruption O
of O
oral O
anticoagulant O
( O
oac O
) O
administration O
is O
sometimes O
indicated O
in O
patients O
with O
mechanical O
heart O
valves O
, O
mainly O
before O
noncardiac O
surgery O
, O
non O
- O
surgical O
interventions O
, O
and O
pregnancy O
. O

unfractionated O
heparin O
( O
uh O
) O
is O
currently O
the O
substitute O
for O
selected O
patients O
. O

low O
- O
molecular O
- O
weight O
heparin O
( O
lmwh O
) O
offers O
theoretical O
advantages O
over O
uh O
, O
but O
is O
not O
currently O
considered O
in O
clinical O
guidelines O
as O
an O
alternative O
to O
uh O
in O
patients O
with O
prosthetic O
valves O
. O

hypothesis O
: O
the O
aim O
of O
the O
present O
study O
was O
to O
review O
the O
data O
accumulated O
so O
far O
on O
the O
use O
of O
lmwh O
in O
this O
patient O
population O
and O
to O
discuss O
its O
applicability O
in O
common O
practice O
. O

methods O
: O
for O
this O
paper O
, O
the O
current O
medical O
literature O
on O
lmwh O
in O
patients O
with O
mechanical O
heart O
valves O
was O
extensively O
reviewed O
. O

results O
: O
there O
were O
eight O
series O
and O
six O
case O
reports O
. O

none O
of O
the O
studies O
was O
randomized O
, O
and O
only O
one O
was O
prospective O
. O

data O
to O
establish O
the O
thromboembolic B-Disease
risk O
were O
incomplete O
. O

after O
excluding O
case O
reports O
, O
the O
following O
groups O
were O
constructed O
: O
( O
a O
) O
short O
- O
term O
administration O
, O
after O
valve O
insertion O
( O
n O
= O
212 O
) O
; O
( O
b O
) O
short O
- O
term O
, O
perioperative O
( O
noncardiac O
) O
/ O
periprocedural O
( O
n O
= O
114 O
) O
; O
( O
c O
) O
long O
- O
term O
, O
due O
to O
intolerance O
to O
oac O
( O
n O
= O
16 O
) O
; O
( O
d O
) O
long O
- O
term O
, O
in O
pregnancy O
( O
n O
= O
10 O
) O
. O

the O
incidence O
rate O
of O
thromboembolism B-Disease
was O
0 O
. O
9 O
% O
for O
all O
the O
studies O
and O
0 O
. O
5 O
, O
0 O
, O
20 O
, O
and O
0 O
% O
in O
groups O
a O
, O
b O
, O
c O
, O
and O
d O
, O
respectively O
; O
for O
hemorrhage B-Disease
, O
the O
overall O
rate O
was O
3 O
. O
4 O
% O
( O
3 O
. O
8 O
, O
2 O
. O
6 O
, O
10 O
, O
and O
0 O
% O
for O
the O
respective O
groups O
) O
. O

conclusions O
: O
in O
patients O
with O
mechanical O
heart O
valves O
, O
short O
- O
term O
lmwh O
therapy O
compares O
favorably O
with O
uh O
. O

data O
on O
mid O
- O
and O
long O
- O
term O
lmwh O
administration O
in O
these O
patients O
are O
sparse O
. O

further O
randomized O
studies O
are O
needed O
to O
confirm O
the O
safety O
and O
precise O
indications O
for O
the O
use O
of O
lmwh O
in O
patients O
with O
mechanical O
heart O
valves O
. O

cardiac B-Disease
arrest B-Disease
after O
intravenous O
metoclopramide O
- O
a O
case O
of O
five O
repeated O
injections O
of O
metoclopramide O
causing O
five O
episodes O
of O
cardiac B-Disease
arrest B-Disease
. O

we O
describe O
a O
patient O
where O
intravenous O
injection O
of O
metoclopramide O
was O
immediately O
followed O
by O
asystole B-Disease
repeatedly O
. O

the O
patient O
received O
metoclopramide O
10 O
mg O
i O
. O
v O
. O
five O
times O
during O
48 O
h O
. O

after O
interviewing O
the O
attending O
nurses O
and O
reviewing O
the O
written O
documentation O
, O
it O
is O
clear O
that O
every O
administration O
of O
metoclopramide O
was O
immediately O
( O
within O
s O
) O
followed O
by O
asystole B-Disease
. O

the O
asystole B-Disease
lasted O
15 O
- O
30 O
s O
on O
four O
occasions O
, O
on O
one O
occasion O
it O
lasted O
2 O
min O
. O

the O
patient O
received O
atropine O
0 O
. O
5 O
- O
1 O
mg O
and O
chest O
compressions O
, O
before O
sinus O
rhythm O
again O
took O
over O
. O

we O
interpret O
this O
as O
episodes O
of O
cardiac B-Disease
arrest B-Disease
caused O
by O
metoclopramide O
. O

the O
rapid O
injection O
via O
the O
central O
venous O
route O
and O
the O
concomitant O
tapering O
of O
dopamine O
infusion O
might O
have O
contributed O
in O
precipitating O
the O
adverse O
drug O
reaction O
. O

immunohistochemical O
study O
on O
inducible O
type O
of O
nitric O
oxide O
( O
inos O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
and O
tumor B-Disease
growth O
factor O
- O
beta1 O
( O
tgf O
- O
beta1 O
) O
in O
arteritis B-Disease
induced O
in O
rats O
by O
fenoldopam O
and O
theophylline O
, O
vasodilators O
. O

arteritis B-Disease
induced O
in O
rats O
by O
vasodilators O
, O
fenoldopam O
and O
theophylline O
, O
was O
examined O
immunohistochemically O
for O
expressions O
of O
inducible O
type O
of O
nitric O
oxide O
synthase O
( O
inos O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
and O
tumor B-Disease
growth O
factor O
- O
beta1 O
( O
tgf O
- O
beta1 O
) O
. O

rats O
were O
administered O
fenoldopam O
for O
24 O
hours O
by O
intravenous O
infusion O
with O
or O
without O
following O
repeated O
daily O
oral O
administrations O
of O
theophylline O
. O

irrespective O
of O
theophylline O
administration O
, O
inos O
antigens O
were O
remarkably O
abundant O
in O
ed O
- O
1 O
- O
positive O
cells O
on O
day O
5 O
and O
8 O
post O
- O
fenoldopam O
- O
infusion O
( O
dpi O
) O
; O
bfgf O
antigens O
were O
remarkably O
abundant O
in O
ed O
- O
1 O
- O
positive O
cells O
on O
1 O
and O
3 O
dpi O
; O
tgf O
- O
beta1 O
antigens O
were O
observed O
in O
ed O
- O
1 O
- O
positive O
cells O
on O
and O
after O
5 O
dpi O
. O

these O
results O
suggest O
that O
the O
peak O
expression O
of O
inos O
antigen O
was O
followed O
by O
that O
of O
bfgf O
antigen O
, O
and O
bfgf O
may O
have O
a O
suppressive O
effect O
on O
inos O
expression O
in O
these O
rat O
arteritis B-Disease
models O
. O

on O
the O
other O
hand O
, O
tgf O
- O
beta1 O
was O
not O
considered O
to O
have O
a O
suppressive O
effect O
on O
inos O
expression O
in O
these O
models O
. O

the O
striatum O
as O
a O
target O
for O
anti O
- O
rigor O
effects O
of O
an O
antagonist O
of O
mglur1 O
, O
but O
not O
an O
agonist O
of O
group O
ii O
metabotropic O
glutamate O
receptors O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
find O
out O
whether O
the O
metabotropic O
receptor O
1 O
( O
mglur1 O
) O
and O
group O
ii O
mglurs O
, O
localized O
in O
the O
striatum O
, O
are O
involved O
in O
antiparkinsonian O
- O
like O
effects O
in O
rats O
. O

haloperidol O
( O
1 O
mg O
/ O
kg O
ip O
) O
induced O
parkinsonian B-Disease
- O
like O
muscle B-Disease
rigidity B-Disease
, O
measured O
as O
an O
increased O
resistance O
of O
a O
rat O
' O
s O
hind O
foot O
to O
passive O
flexion O
and O
extension O
at O
the O
ankle O
joint O
. O

( O
rs O
) O
- O
1 O
- O
aminoindan O
- O
1 O
, O
5 O
- O
dicarboxylic O
acid O
( O
aida O
; O
0 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
potent O
and O
selective O
mglur1 O
antagonist O
, O
or O
( O
2r O
, O
4r O
) O
- O
4 O
- O
aminopyrrolidine O
- O
2 O
, O
4 O
- O
dicarboxylate O
( O
2r O
, O
4r O
- O
apdc O
; O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
selective O
group O
ii O
agonist O
, O
was O
injected O
bilaterally O
into O
the O
striatum O
of O

haloperidol O
- O
treated O
animals O
. O

aida O
in O
doses O
of O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
diminished O
the O
haloperidol O
- O
induced O
muscle B-Disease
rigidity B-Disease
. O

in O
contrast O
, O
2r O
, O
4r O
- O
apdc O
injections O
were O
ineffective O
. O

the O
present O
results O
may O
suggest O
that O
the O
blockade O
of O
striatal O
mglur1 O
, O
but O
not O
the O
stimulation O
of O
group O
ii O
mglurs O
, O
may O
ameliorate O
parkinsonian B-Disease
muscle B-Disease
rigidity B-Disease
. O

a O
phase O
ii O
study O
of O
thalidomide O
in O
advanced O
metastatic O
renal B-Disease
cell B-Disease
carcinoma B-Disease
. O

objectives O
: O
to O
evaluate O
the O
toxicity B-Disease
and O
activity O
of O
thalidomide O
in O
patients O
with O
advanced O
metastatic O
renal B-Disease
cell B-Disease
cancer B-Disease
and O
to O
measure O
changes O
of O
one O
angiogenic O
factor O
, O
vascular O
endothelial O
growth O
factor O
( O
vegf O
) O
165 O
, O
with O
therapy O
. O

patients O
and O
methods O
: O
29 O
patients O
were O
enrolled O
on O
a O
study O
of O
thalidomide O
using O
an O
intra O
- O
patient O
dose O
escalation O
schedule O
. O

patients O
began O
thalidomide O
at O
400 O
mg O
/ O
d O
and O
escalated O
as O
tolerated O
to O
1200 O
mg O
/ O
d O
by O
day O
54 O
. O

fifty O
- O
nine O
per O
cent O
of O
patients O
had O
had O
previous O
therapy O
with O
il O
- O
2 O
and O
52 O
% O
were O
performance O
status O
2 O
or O
3 O
. O

systemic O
plasma O
vegf165 O
levels O
were O
measured O
by O
dual O
monoclonal O
elisa O
in O
8 O
patients O
. O

results O
: O
24 O
patients O
were O
evaluable O
for O
response O
with O
one O
partial O
response O
of O
11 O
months O
duration O
of O
a O
patient O
with O
hepatic O
and O
pulmonary O
metastases B-Disease
( O
4 O
% O
) O
, O
one O
minor O
response O
, O
and O
2 O
patients O
stable O
for O
over O
6 O
months O
. O

somnolence B-Disease
and O
constipation B-Disease
were O
prominent O
toxicities B-Disease
and O
most O
patients O
could O
not O
tolerate O
the O
1200 O
mg O
/ O
day O
dose O
level O
. O

systemic O
plasma O
vegf165 O
levels O
did O
not O
change O
with O
therapy O
. O

conclusion O
: O
these O
results O
are O
consistent O
with O
a O
low O
level O
of O
activity O
of O
thalidomide O
in O
renal B-Disease
cell B-Disease
carcinoma B-Disease
. O

administration O
of O
doses O
over O
800 O
mg O
/ O
day O
was O
difficult O
to O
achieve O
in O
this O
patient O
population O
, O
however O
lower O
doses O
were O
practical O
. O

the O
dose O
- O
response O
relationship O
, O
if O
any O
, O
of O
thalidomide O
for O
renal B-Disease
cell B-Disease
carcinoma B-Disease
is O
unclear O
. O

can O
lidocaine O
reduce O
succinylcholine O
induced O
postoperative B-Disease
myalgia B-Disease
? O

this O
study O
was O
undertaken O
to O
determine O
the O
effect O
of O
lidocaine O
pretreatment O
on O
reduction O
of O
succinylcholine O
- O
induced O
myalgia B-Disease
in O
patients O
undergoing O
general O
anesthesia O
for O
gynecological O
surgery O
. O

one O
hundred O
and O
thirty O
- O
five O
patients O
were O
assigned O
to O
one O
of O
three O
groups O
in O
a O
prospective O
, O
double O
blind O
, O
randomized O
manner O
. O

group O
ps O
, O
the O
control O
group O
, O
received O
normal O
saline O
and O
succinylcholine O
1 O
. O
5 O
mg O
x O
kg O
( O
- O
1 O
) O
; O
group O
ls O
, O
lidocaine O
1 O
. O
5 O
mg O
x O
kg O
( O
- O
1 O
) O
and O
succinylcholine O
1 O
. O
5 O
mg O
x O
kg O
( O
- O
1 O
) O
; O
group O
pr O
, O
normal O
saline O
and O
rocuronium O
0 O
. O
6 O
mg O
x O
kg O
( O
- O
1 O
) O
. O

morphine O
0 O
. O
1 O
mg O
x O
kg O
( O
- O
1 O
) O
iv O
was O
given O
for O
premedication O
and O
all O
patients O
were O
monitored O
with O
a O
noninvasive O
blood O
pressure O
monitor O
, O
ecg O
and O
pulse O
oximetry O
. O

anesthesia O
was O
induced O
with O
5 O
mg O
. O
kg O
( O
- O
1 O
) O
thiopental O
iv O
. O
followed O
by O
succinylcholine O
( O
group O
ps O
, O
ls O
) O
or O
rocuronium O
( O
group O
pr O
) O
for O
tracheal O
intubation O
. O

following O
administration O
of O
these O
agents O
, O
the O
presence O
, O
and O
degree O
of O
fasciculation B-Disease
were O
assessed O
visually O
on O
a O
four O
point O
scale O
by O
one O
investigator O
who O
was O
blinded O
to O
the O
drug O
administered O
. O

the O
blood O
pressure O
and O
heart O
rate O
of O
each O
patient O
were O
monitored O
on O
nine O
occasions O
. O

twenty O
- O
four O
hours O
later O
, O
any O
myalgia B-Disease
experienced O
was O
assessed O
according O
to O
a O
structured O
questionaire O
and O
graded O
by O
a O
four O
point O
scale O
by O
one O
investigator O
blinded O
to O
the O
intraoperative O
management O
. O

the O
results O
indicate O
that O
muscle B-Disease
fasciculation B-Disease
was O
not O
found O
in O
group O
pr O
while O
the O
patients O
in O
group O
ls O
had O
a O
lower O
incidence O
of O
muscle B-Disease
fasciculation B-Disease
than O
those O
in O
group O
ps O
( O
p O
< O
0 O
. O
001 O
) O
. O

at O
24 O
h O
, O
the O
incidence O
of O
myalgia B-Disease
was O
higher O
in O
group O
ps O
than O
in O
group O
ls O
and O
pr O
( O
p O
< O
0 O
. O
05 O
) O
. O

a O
correlation O
was O
not O
found O
between O
the O
incidence O
of O
myalgia B-Disease
and O
the O
occurrence O
of O
muscle B-Disease
fasciculation B-Disease
. O

the O
changes O
in O
systolic O
and O
diastolic O
blood O
pressure O
and O
heart O
rate O
were O
not O
significant O
among O
the O
three O
groups O
. O

in O
conclusion O
, O
where O
succinylcholine O
is O
used O
, O
lidocaine O
is O
proven O
to O
be O
the O
useful O
pretreatment O
agent O
for O
the O
reduction O
of O
postoperative B-Disease
myalgia B-Disease
. O

reduced O
sodium O
channel O
density O
, O
altered O
voltage O
dependence O
of O
inactivation O
, O
and O
increased O
susceptibility O
to O
seizures B-Disease
in O
mice O
lacking O
sodium O
channel O
beta O
2 O
- O
subunits O
. O

sodium O
channel O
beta O
- O
subunits O
modulate O
channel O
gating O
, O
assembly O
, O
and O
cell O
surface O
expression O
in O
heterologous O
cell O
systems O
. O

we O
generated O
beta2 O
( O
- O
/ O
- O
) O
mice O
to O
investigate O
the O
role O
of O
beta2 O
in O
control O
of O
sodium O
channel O
density O
, O
localization O
, O
and O
function O
in O
neurons O
in O
vivo O
. O

measurements O
of O
[ O
( O
3 O
) O
h O
] O
saxitoxin O
( O
stx O
) O
binding O
showed O
a O
significant O
reduction O
in O
the O
level O
of O
plasma O
membrane O
sodium O
channels O
in O
beta2 O
( O
- O
/ O
- O
) O
neurons O
. O

the O
loss O
of O
beta2 O
resulted O
in O
negative O
shifts O
in O
the O
voltage O
dependence O
of O
inactivation O
as O
well O
as O
significant O
decreases O
in O
sodium O
current O
density O
in O
acutely O
dissociated O
hippocampal O
neurons O
. O

the O
integral O
of O
the O
compound O
action O
potential O
in O
optic O
nerve O
was O
significantly O
reduced O
, O
and O
the O
threshold O
for O
action O
potential O
generation O
was O
increased O
, O
indicating O
a O
reduction O
in O
the O
level O
of O
functional O
plasma O
membrane O
sodium O
channels O
. O

in O
contrast O
, O
the O
conduction O
velocity O
, O
the O
number O
and O
size O
of O
axons O
in O
the O
optic O
nerve O
, O
and O
the O
specific O
localization O
of O
na O
( O
v O
) O
1 O
. O
6 O
channels O
in O
the O
nodes O
of O
ranvier O
were O
unchanged O
. O

beta2 O
( O
- O
/ O
- O
) O
mice O
displayed O
increased O
susceptibility O
to O
seizures B-Disease
, O
as O
indicated O
by O
reduced O
latency O
and O
threshold O
for O
pilocarpine O
- O
induced O
seizures B-Disease
, O
but O
seemed O
normal O
in O
other O
neurological O
tests O
. O

our O
observations O
show O
that O
beta2 O
- O
subunits O
play O
an O
important O
role O
in O
the O
regulation O
of O
sodium O
channel O
density O
and O
function O
in O
neurons O
in O
vivo O
and O
are O
required O
for O
normal O
action O
potential O
generation O
and O
control O
of O
excitability O
. O

acute B-Disease
liver B-Disease
failure B-Disease
with O
concurrent O
bupropion O
and O
carbimazole O
therapy O
. O

objective O
: O
to O
report O
a O
case O
of O
fatal O
liver B-Disease
failure B-Disease
possibly O
associated O
with O
concurrent O
use O
of O
bupropion O
and O
carbimazole O
. O

case O
summary O
: O
a O
41 O
- O
year O
- O
old O
chinese O
man O
with O
a O
history O
of O
hyperthyroidism B-Disease
had O
been O
treated O
with O
carbimazole O
and O
propranolol O
for O
the O
past O
5 O
years O
. O

he O
received O
a O
10 O
- O
day O
course O
of O
bupropion O
as O
an O
aid O
for O
smoking O
cessation O
10 O
weeks O
prior O
to O
presentation O
. O

he O
developed O
acute B-Disease
liver B-Disease
failure B-Disease
with O
rapid O
deterioration O
of O
renal O
function O
. O

liver O
biopsy O
showed O
evidence O
of O
nonspecific O
drug B-Disease
- B-Disease
induced B-Disease
acute B-Disease
liver B-Disease
injury B-Disease
. O

his O
condition O
was O
further O
complicated O
by O
sepsis B-Disease
and O
coagulopathy B-Disease
. O

death O
resulted O
19 O
days O
after O
the O
onset O
of O
symptoms O
. O

the O
likelihood O
that O
bupropion O
induced O
hepatotoxicity B-Disease
in O
our O
patient O
was O
possible O
, O
based O
on O
the O
naranjo O
probability O
scale O
. O

discussion O
: O
although O
there O
is O
increasing O
evidence O
of O
hepatotoxicity B-Disease
induced O
by O
bupropion O
, O
this O
is O
the O
first O
case O
of O
fatality O
that O
could O
have O
resulted O
from O
acute B-Disease
liver B-Disease
failure B-Disease
in O
a O
patient O
receiving O
bupropion O
while O
on O
concomitant O
treatment O
with O
carbimazole O
. O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
acute B-Disease
liver B-Disease
insult B-Disease
induced O
by O
bupropion O
given O
concurrently O
with O
other O
hepatotoxic B-Disease
drugs O
. O

pyeloureteral O
filling O
defects O
associated O
with O
systemic O
anticoagulation O
: O
a O
case O
report O
. O

the O
etiology O
of O
pyeloureteritis B-Disease
cystica B-Disease
has O
long O
been O
attributed O
to O
chronic O
infection B-Disease
and O
inflammation B-Disease
. O

a O
case O
is O
presented O
that O
is O
unique O
in O
that O
the O
acute O
onset O
and O
the O
rapid O
resolution O
of O
pyeloureteral O
filling O
defects O
in O
this O
patient O
were O
documented O
by O
radiography O
. O

there O
is O
no O
evidence O
of O
antecedent O
or O
concurrent O
infection B-Disease
in O
this O
patient O
. O

the O
disease O
occurred O
subsequent O
to O
the O
initiation O
of O
heparin O
therapy O
for O
suspected O
pelvic O
thrombophlebitis B-Disease
and O
cleared O
rapidly O
subsequent O
to O
its O
discontinuation O
. O

the O
rate O
of O
resolution O
of O
the O
radiographic O
findings O
may O
be O
helpful O
in O
distinguishing O
between O
true O
pyeloureteritis B-Disease
cystica B-Disease
and O
submucosal B-Disease
hemorrhage B-Disease
. O

nephrotoxic B-Disease
effects O
in O
high O
- O
risk O
patients O
undergoing O
angiography O
. O

background O
: O
the O
use O
of O
iodinated O
contrast O
medium O
can O
result O
in O
nephropathy B-Disease
. O

whether O
iso O
- O
osmolar O
contrast O
medium O
is O
less O
nephrotoxic B-Disease
than O
low O
- O
osmolar O
contrast O
medium O
in O
high O
- O
risk O
patients O
is O
uncertain O
. O

methods O
: O
we O
conducted O
a O
randomized O
, O
double O
- O
blind O
, O
prospective O
, O
multicenter O
study O
comparing O
the O
nephrotoxic B-Disease
effects O
of O
an O
iso O
- O
osmolar O
, O
dimeric O
, O
nonionic O
contrast O
medium O
, O
iodixanol O
, O
with O
those O
of O
a O
low O
- O
osmolar O
, O
nonionic O
, O
monomeric O
contrast O
medium O
, O
iohexol O
. O

the O
study O
involved O
129 O
patients O
with O
diabetes B-Disease
with O
serum O
creatinine O
concentrations O
of O
1 O
. O
5 O
to O
3 O
. O
5 O
mg O
per O
deciliter O
who O
underwent O
coronary O
or O
aortofemoral O
angiography O
. O

the O
primary O
end O
point O
was O
the O
peak O
increase O
from O
base O
line O
in O
the O
creatinine O
concentration O
during O
the O
three O
days O
after O
angiography O
. O

other O
end O
points O
were O
an O
increase O
in O
the O
creatinine O
concentration O
of O
0 O
. O
5 O
mg O
per O
deciliter O
or O
more O
, O
an O
increase O
of O
1 O
. O
0 O
mg O
per O
deciliter O
or O
more O
, O
and O
a O
change O
in O
the O
creatinine O
concentration O
from O
day O
0 O
to O
day O
7 O
. O

results O
: O
the O
creatinine O
concentration O
increased O
significantly O
less O
in O
patients O
who O
received O
iodixanol O
. O

from O
day O
0 O
to O
day O
3 O
, O
the O
mean O
peak O
increase O
in O
creatinine O
was O
0 O
. O
13 O
mg O
per O
deciliter O
in O
the O
iodixanol O
group O
and O
0 O
. O
55 O
mg O
per O
deciliter O
in O
the O
iohexol O
group O
( O
p O
= O
0 O
. O
001 O
; O
the O
increase O
with O
iodixanol O
minus O
the O
increase O
with O
iohexol O
, O
- O
0 O
. O
42 O
mg O
per O
deciliter O
[ O
95 O
percent O
confidence O
interval O
, O
- O
0 O
. O
73 O
to O
- O
0 O
. O
22 O
] O
) O
. O

two O
of O
the O
64 O
patients O
in O
the O
iodixanol O
group O
( O
3 O
percent O
) O
had O
an O
increase O
in O
the O
creatinine O
concentration O
of O
0 O
. O
5 O
mg O
per O
deciliter O
or O
more O
, O
as O
compared O
with O
17 O
of O
the O
65 O
patients O
in O
the O
iohexol O
group O
( O
26 O
percent O
) O
( O
p O
= O
0 O
. O
002 O
; O
odds O
ratio O
for O
such O
an O
increase O
in O
the O
iodixanol O
group O
, O
0 O
. O
09 O
[ O
95 O
percent O
confidence O
interval O
, O
0 O
. O
02 O
to O
0 O
. O
41 O
] O
) O
. O

no O
patient O
receiving O
iodixanol O
had O
an O
increase O
of O
1 O
. O
0 O
mg O
per O
deciliter O
or O
more O
, O
but O
10 O
patients O
in O
the O
iohexol O
group O
( O
15 O
percent O
) O
did O
. O

the O
mean O
change O
in O
the O
creatinine O
concentration O
from O
day O
0 O
to O
day O
7 O
was O
0 O
. O
07 O
mg O
per O
deciliter O
in O
the O
iodixanol O
group O
and O
0 O
. O
24 O
mg O
per O
deciliter O
in O
the O
iohexol O
group O
( O
p O
= O
0 O
. O
003 O
; O
value O
in O
the O
iodixanol O
group O
minus O
the O
value O
in O
the O
iohexol O
group O
, O
- O
0 O
. O
17 O
mg O
per O
deciliter O
[ O
95 O
percent O
confidence O
interval O
, O
- O
0 O
. O
34 O
to O
- O
0 O
. O
07 O
] O
) O
. O

conclusions O
: O
nephropathy B-Disease
induced O
by O
contrast O
medium O
may O
be O
less O
likely O
to O
develop O
in O
high O
- O
risk O
patients O
when O
iodixanol O
is O
used O
rather O
than O
a O
low O
- O
osmolar O
, O
nonionic O
contrast O
medium O
. O

protective O
effect O
of O
edaravone O
against O
streptomycin O
- O
induced O
vestibulotoxicity B-Disease
in O
the O
guinea O
pig O
. O

this O
study O
investigated O
alleviation O
of O
streptomycin O
- O
induced O
vestibulotoxicity B-Disease
by O
edaravone O
in O
guinea O
pigs O
. O

edaravone O
, O
a O
free O
radical O
scavenger O
, O
has O
potent O
free O
radical O
quenching O
action O
and O
is O
used O
in O
clinical O
practice O
to O
treat O
cerebral B-Disease
infarction B-Disease
. O

streptomycin O
was O
administered O
to O
the O
inner O
ear O
by O
osmotic O
pump O
for O
24 O
h O
, O
and O
edaravone O
( O
n O
= O
8 O
) O
or O
saline O
( O
n O
= O
6 O
) O
was O
intraperitoneally O
injected O
once O
a O
day O
for O
7 O
days O
. O

we O
observed O
horizontal O
vestibulo O
- O
ocular O
reflex O
as O
a O
marker O
of O
postoperative O
vestibular O
function O
. O

animals O
injected O
with O
saline O
showed O
statistically O
smaller O
gains O
than O
those O
injected O
with O
edaravone O
. O

these O
results O
suggest O
that O
edaravone O
suppresses O
streptomycin O
- O
induced O
vestibulotoxicity B-Disease
. O

levodopa O
- O
induced O
oromandibular O
dystonia B-Disease
in O
progressive B-Disease
supranuclear B-Disease
palsy B-Disease
. O

levodopa O
- O
induced O
dyskinesias B-Disease
have O
been O
reported O
in O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
and O
multiple B-Disease
system B-Disease
atrophy B-Disease
. O

cranial O
dystonias B-Disease
are O
rare O
in O
patients O
with O
progressive B-Disease
supranuclear B-Disease
palsy B-Disease
( O
psp B-Disease
) O
. O

in O
this O
report O
we O
describe O
an O
unusual O
case O
of O
reversible O
levodopa O
- O
induced O
oromandibular B-Disease
dystonia B-Disease
( O
omd B-Disease
) O
in O
a O
psp B-Disease
patient O
to O
highlight O
the O
importance O
of O
recognizing O
this O
drug O
related O
complication O
in O
the O
management O
of O
psp B-Disease
, O
and O
discuss O
the O
possible O
underlying O
pathophysiology O
. O

case O
report O
: O
dexatrim O
( O
phenylpropanolamine O
) O
as O
a O
cause O
of O
myocardial B-Disease
infarction B-Disease
. O

phenylpropanolamine O
( O
ppa O
) O
is O
a O
sympathetic O
amine O
used O
in O
over O
- O
the O
- O
counter O
cold O
remedies O
and O
weight O
- O
control O
preparations O
worldwide O
. O

its O
use O
has O
been O
associated O
with O
hypertensive B-Disease
episodes O
and O
hemorrhagic B-Disease
strokes B-Disease
in O
younger O
women O
. O

several O
reports O
have O
linked O
the O
abuse O
of O
ppa O
with O
myocardial B-Disease
injury B-Disease
, O
especially O
when O
overdose B-Disease
is O
involved O
. O

we O
report O
here O
the O
first O
case O
of O
dexatrim O
( O
ppa O
) O
- O
induced O
myocardial B-Disease
injury B-Disease
in O
a O
young O
woman O
who O
was O
using O
it O
at O
recommended O
doses O
for O
weight O
control O
. O

in O
addition O
, O
we O
review O
the O
7 O
other O
cases O
of O
ppa O
related O
myocardial B-Disease
injury B-Disease
that O
have O
been O
reported O
so O
far O
. O

physicians O
and O
patients O
should O
be O
alert O
to O
the O
potential O
cardiac O
risk O
associated O
with O
the O
use O
of O
ppa O
, O
even O
at O
doses O
generally O
considered O
to O
be O
safe O
. O

differential O
diagnosis O
of O
high O
serum O
creatine O
kinase O
levels O
in O
systemic B-Disease
lupus B-Disease
erythematosus B-Disease
. O

we O
report O
the O
clinical O
and O
bioptic O
findings O
for O
a O
57 O
- O
year O
- O
old O
woman O
with O
severe O
chloroquine O
- O
induced O
myopathy B-Disease
. O

since O
1989 O
, O
she O
had O
been O
suffering O
from O
systemic B-Disease
lupus B-Disease
erythematosus B-Disease
( O
sle B-Disease
) O
with O
renal B-Disease
involvement B-Disease
and O
undergone O
periods O
of O
treatment O
with O
azathioprine O
and O
cyclophosphamide O
. O

additional O
therapy O
with O
chloroquine O
( O
cq O
) O
was O
started O
because O
of O
arthralgia B-Disease
. O

at O
the O
same O
time O
, O
slightly O
increased O
creatine O
kinase O
( O
ck O
) O
levels O
were O
noted O
. O

myositis B-Disease
was O
suspected O
, O
and O
the O
patient O
was O
treated O
with O
steroids O
. O

the O
ck O
increase O
persisted O
, O
however O
, O
and O
she O
developed O
progressive O
muscular B-Disease
weakness B-Disease
and O
muscular B-Disease
atrophy B-Disease
. O

routine O
controls O
revealed O
markedly O
elevated O
ck O
levels O
of O
1 O
, O
700 O
u O
/ O
l O
. O

the O
neurological O
and O
electrophysiological O
findings O
were O
not O
typical O
of O
myositis B-Disease
. O

thus O
, O
muscle O
biopsy O
of O
the O
deltoid O
muscle O
was O
performed O
in O
order O
to O
exclude O
polymyositis B-Disease
or O
toxic O
myopathy B-Disease
. O

as O
it O
revealed O
chloroquine O
- O
induced O
myopathy B-Disease
, O
medication O
was O
stopped O
. O

discriminating O
between O
primary O
sle B-Disease
- O
induced O
affection B-Disease
of B-Disease
the B-Disease
musculoskeletal B-Disease
system B-Disease
and O
drug O
- O
induced O
side O
effects O
is O
important O
for O
appropriate O
treatment O
of O
sle B-Disease
patients O
. O

seizure B-Disease
associated O
with O
sleep B-Disease
deprivation B-Disease
and O
sustained O
- O
release O
bupropion O
. O

this O
case O
report O
describes O
a O
generalized O
seizure B-Disease
associated O
with O
sustained O
- O
release O
bupropion O
use O
and O
sleep B-Disease
deprivation B-Disease
. O

the O
subject O
, O
a O
31 O
- O
year O
- O
old O
female O
smoker O
, O
was O
participating O
in O
a O
clinical O
trial O
evaluating O
an O
investigational O
medication O
for O
smoking O
cessation O
that O
used O
sustained O
- O
release O
bupropion O
as O
an O
active O
control O
. O

after O
5 O
weeks O
of O
bupropion O
use O
, O
the O
subject O
experienced O
a O
generalized O
tonic O
clonic O
seizure B-Disease
after O
staying O
up O
nearly O
all O
night O
packing O
and O
moving O
to O
a O
new O
residence O
. O

the O
patient O
had O
no O
other O
risk O
factors O
for O
seizures B-Disease
. O

we O
suggest O
that O
sleep B-Disease
deprivation B-Disease
may O
add O
to O
the O
risk O
of O
bupropion O
- O
associated O
seizures B-Disease
. O

postoperative B-Disease
myalgia B-Disease
after O
succinylcholine O
: O
no O
evidence O
for O
an O
inflammatory O
origin O
. O

a O
common O
side O
effect O
associated O
with O
succinylcholine O
is O
postoperative B-Disease
myalgia B-Disease
. O

the O
pathogenesis O
of O
this O
myalgia B-Disease
is O
still O
unclear O
; O
inflammation B-Disease
has O
been O
suggested O
but O
without O
convincing O
evidence O
. O

we O
designed O
the O
present O
study O
to O
investigate O
whether O
an O
inflammatory O
reaction O
contributes O
to O
this O
myalgia B-Disease
. O

the O
incidence O
and O
severity O
of O
succinylcholine O
- O
associated O
myalgia B-Disease
was O
determined O
in O
64 O
patients O
pretreated O
with O
saline O
or O
dexamethasone O
before O
succinylcholine O
( O
n O
= O
32 O
for O
each O
) O
. O

incidence O
and O
severity O
of O
myalgia B-Disease
did O
not O
differ O
significantly O
between O
the O
two O
groups O
: O
15 O
patients O
in O
the O
dexamethasone O
group O
complained O
of O
myalgia B-Disease
compared O
with O
18 O
patients O
in O
the O
saline O
group O
, O
and O
severe O
myalgia B-Disease
was O
reported O
by O
five O
patients O
and O
three O
patients O
, O
respectively O
( O
not O
significant O
) O
. O

at O
48 O
h O
after O
surgery O
, O
12 O
patients O
in O
both O
groups O
still O
suffered O
from O
myalgia B-Disease
( O
not O
significant O
) O
. O

in O
addition O
, O
interleukin O
- O
6 O
( O
il O
- O
6 O
) O
as O
an O
early O
marker O
of O
inflammation B-Disease
was O
assessed O
in O
a O
subgroup O
of O
10 O
patients O
pretreated O
with O
saline O
. O

we O
found O
an O
increase O
of O
il O
- O
6 O
for O
only O
three O
patients O
, O
but O
only O
one O
patient O
reported O
myalgia B-Disease
; O
no O
relationship O
between O
myalgia B-Disease
and O
the O
increase O
of O
il O
- O
6 O
was O
found O
. O

in O
conclusion O
, O
there O
is O
no O
evidence O
for O
an O
inflammatory O
origin O
of O
succinylcholine O
- O
associated O
myalgia B-Disease
. O

implications O
: O
administration O
of O
dexamethasone O
before O
succinylcholine O
was O
not O
effective O
in O
decreasing O
the O
incidence O
or O
the O
severity O
of O
succinylcholine O
- O
induced O
postoperative B-Disease
myalgia B-Disease
. O

furthermore O
, O
there O
was O
no O
significant O
relationship O
between O
postoperative B-Disease
myalgia B-Disease
and O
time O
course O
of O
interleukin O
- O
6 O
concentrations O
, O
a O
marker O
of O
inflammation B-Disease
. O

pretreatment O
with O
dexamethasone O
is O
not O
justified O
to O
prevent O
postoperative B-Disease
myalgia B-Disease
after O
succinylcholine O
. O

effect O
of O
lindane O
on O
hepatic O
and O
brain O
cytochrome O
p450s O
and O
influence O
of O
p450 O
modulation O
in O
lindane O
induced O
neurotoxicity B-Disease
. O

oral O
administration O
of O
lindane O
( O
2 O
. O
5 O
, O
5 O
, O
10 O
and O
15 O
mg O
/ O
kg O
, O
body O
weight O
) O
for O
5 O
days O
was O
found O
to O
produce O
a O
dose O
- O
dependent O
increase O
in O
the O
activity O
of O
p450 O
dependent O
7 O
- O
ethoxyresorufin O
- O
o O
- O
deethylase O
( O
erod O
) O
, O
7 O
- O
pentoxyresorufin O
- O
o O
- O
dealkylase O
( O
prod O
) O
and O
n O
- O
nitrosodimethylamine O
demethylase O
( O
ndma O
- O
d O
) O
in O
rat O
brain O
and O
liver O
. O

a O
significant O
increase O
in O
the O
hepatic O
and O
brain O
p450 O
monooxygenases O
was O
also O
observed O
when O
the O
duration O
of O
exposure O
of O
low O
dose O
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
of O
lindane O
was O
increased O
from O
5 O
days O
to O
15 O
or O
21 O
days O
. O

as O
observed O
with O
different O
doses O
, O
the O
magnitude O
of O
induction O
in O
the O
activity O
of O
p450 O
monooxygenases O
was O
several O
fold O
higher O
in O
liver O
microsomes O
when O
compared O
with O
the O
brain O
. O

western O
blotting O
studies O
have O
indicated O
that O
the O
increase O
in O
the O
p450 O
enzymes O
could O
be O
due O
to O
the O
increase O
in O
the O
expression O
of O
p450 O
1a1 O
/ O
1a2 O
, O
2b1 O
/ O
2b2 O
and O
2e1 O
isoenzymes O
. O

in O
vitro O
studies O
using O
organic O
inhibitors O
specific O
for O
individual O
p450 O
isoenzymes O
and O
antibody O
inhibition O
experiments O
have O
further O
demonstrated O
that O
the O
increase O
in O
the O
activity O
of O
prod O
, O
erod O
and O
ndma O
- O
d O
are O
due O
to O
the O
increase O
in O
the O
levels O
of O
p450 O
2b1 O
/ O
2b2 O
, O
1a1 O
/ O
1a2 O
and O
2e1 O
isoenzymes O
, O
respectively O
. O

induction O
studies O
have O
further O
shown O
that O
while O
pretreatment O
of O
3 O
- O
methylcholanthrene O
( O
mc O
) O
, O
an O
inducer O
of O
p4501a1 O
/ O
1a2 O
, O
did O
not O
produce O
any O
significant O
effect O
in O
the O
incidence O
of O
lindane O
induced O
convulsions B-Disease
, O
pretreatment O
with O
phenobarbital O
( O
pb O
) O
, O
an O
inducer O
of O
p450 O
2b1 O
/ O
2b2 O
or O
ethanol O
, O
an O
inducer O
of O
p450 O
2e1 O
catalysed O
reactions O
, O
significantly O
increased O
the O
incidence O
of O
lindane O
induced O
convulsions B-Disease
. O

similarly O
, O
when O
the O
p450 O
- O
mediated O
metabolism O
of O
lindane O
was O
blocked O
by O
cobalt O
chloride O
incidence O
of O
convulsions B-Disease
was O
increased O
in O
animals O
treated O
with O
lindane O
indicating O
that O
lindane O
per O
se O
or O
its O
metabolites O
formed O
by O
pb O
or O
ethanol O
inducible O
p450 O
isoenzymes O
are O
involved O
in O
its O
neurobehavioral O
toxicity B-Disease
. O

absolute O
and O
attributable O
risk O
of O
venous B-Disease
thromboembolism B-Disease
in O
women O
on O
combined O
cyproterone O
acetate O
and O
ethinylestradiol O
. O

objective O
: O
to O
achieve O
absolute O
risk O
estimates O
of O
venous B-Disease
thromboembolism B-Disease
( O
vte B-Disease
) O
among O
women O
on O
cyproterone O
acetate O
plus O
ethinylestradiol O
( O
cpa O
/ O
ee O
) O
, O
and O
among O
women O
on O
combined O
oral O
contraceptives O
( O
cocs O
) O
. O

methods O
: O
from O
the O
danish O
national O
register O
of O
patients O
( O
nrp O
) O
, O
1996 O
to O
1998 O
, O
the O
records O
of O
1 O
. O
1 O
million O
danish O
women O
, O
ages O
15 O
to O
44 O
years O
, O
were O
searched O
for O
evidence O
of O
vte B-Disease
. O

coc O
use O
was O
ascertained O
through O
mailed O
questionnaires O
. O

sales O
statistics O
of O
cocs O
and O
cpa O
/ O
ee O
were O
provided O
through O
danish O
drug O
statistics O
. O

results O
: O
during O
the O
time O
frame O
of O
the O
study O
, O
330 O
women O
were O
found O
to O
have O
had O
vte B-Disease
while O
on O
cocs O
. O

of O
these O
women O
, O
67 O
were O
on O
levonorgestrel O
- O
containing O
cocs O
. O

eleven O
were O
on O
cpa O
/ O
ee O
. O

the O
corresponding O
absolute O
risk O
of O
vte B-Disease
was O
3 O
. O
4 O
( O
range O
, O
3 O
. O
1 O
- O
3 O
. O
8 O
) O
per O
10 O
000 O
women O
years O
among O
the O
women O
on O
cocs O
, O
4 O
. O
2 O
( O
range O
, O
3 O
. O
2 O
- O
5 O
. O
2 O
) O
per O
10 O
000 O
women O
years O
among O
women O
on O
levonorgestrel O
- O
containing O
cocs O
, O
and O
3 O
. O
1 O
( O
range O
, O
1 O
. O
3 O
- O
4 O
. O
9 O
) O
per O
10 O
000 O
women O
years O
among O
the O
women O
on O
cpa O
/ O
ee O
. O

conclusion O
: O
our O
results O
suggest O
the O
absolute O
risk O
of O
vte B-Disease
among O
danish O
women O
on O
cocs O
is O
similar O
to O
that O
among O
women O
taking O
cpa O
/ O
ee O
. O

comparison O
of O
developmental O
toxicology O
of O
aspirin O
( O
acetylsalicylic O
acid O
) O
in O
rats O
using O
selected O
dosing O
paradigms O
. O

background O
: O
analysis O
of O
the O
literature O
for O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
suggests O
that O
a O
low O
incidence O
of O
developmental B-Disease
anomalies B-Disease
occurs O
in O
rats O
given O
nsaids O
on O
specific O
days O
during O
organogenesis O
. O

aspirin O
( O
acetylsalicylic O
acid O
[ O
asa O
] O
) O
, O
an O
irreversible O
cyclooxygenase O
1 O
and O
2 O
inhibitor O
, O
induces O
developmental B-Disease
anomalies B-Disease
when O
administered O
to O
wistar O
rats O
on O
gestational O
day O
( O
gd O
) O
9 O
, O
10 O
, O
or O
11 O
( O
kimmel O
ca O
, O
wilson O
jg O
, O
schumacher O
hj O
. O
teratology O
4 O
: O
15 O
- O
24 O
, O
1971 O
) O
. O

there O
are O
no O
published O
asa O
studies O
using O
the O
multiple O
dosing O
paradigm O
of O
gds O
6 O
to O
17 O
. O

objectives O
of O
the O
current O
study O
were O
to O
compare O
results O
between O
sprague O
- O
dawley O
( O
sd O
) O
and O
wistar O
strains O
when O
asa O
is O
administered O
on O
gd O
9 O
, O
10 O
, O
or O
11 O
; O
to O
compare O
the O
malformation O
patterns O
following O
single O
and O
multiple O
dosings O
during O
organogenesis O
in O
sd O
rats O
; O
and O
to O
test O
the O
hypothesis O
that O
maternal O
gastrointestinal B-Disease
toxicity B-Disease
confounds O
the O
detection O
of O
low O
incidence O
malformations B-Disease
with O
asa O
when O
a O
multiple O
dosing O
paradigm O
is O
used O
. O

methods O
: O
asa O
was O
administered O
as O
a O
single O
dose O
on O
gd O
9 O
( O
0 O
, O
250 O
, O
500 O
, O
or O
625 O
mg O
/ O
kg O
) O
, O
10 O
( O
0 O
, O
500 O
, O
625 O
, O
or O
750 O
mg O
/ O
kg O
) O
, O
or O
11 O
( O
0 O
, O
500 O
, O
750 O
, O
or O
1000 O
mg O
/ O
kg O
) O
and O
from O
gd O
6 O
to O
gd O
17 O
( O
0 O
, O
50 O
, O
125 O
, O
or O
250 O
mg O
/ O
kg O
a O
day O
) O
in O
the O
multiple O
dose O
study O
to O
sd O
rats O
. O

animals O
were O
killed O
on O
gd O
21 O
, O
and O
fetuses O
were O
examined O
viscerally O
. O

results O
: O
the O
literature O
evaluation O
suggested O
that O
nsaids O
induce O
ventricular B-Disease
septal B-Disease
defects B-Disease
( O
vsds B-Disease
) O
and O
midline B-Disease
defects B-Disease
( O
mds B-Disease
) O
in O
rats O
and O
diaphragmatic B-Disease
hernia B-Disease
( O
dh B-Disease
) O
, O
mds B-Disease
, O
and O
vsds B-Disease
in O
rabbits O
( O
cook O
jc O
et O
al O
. O
, O
2003 O
) O
; O
hence O
, O
the O
present O
study O
focused O
on O
these O
malformations B-Disease
, O
even O
though O
asa O
induces O
several O
other O
low O
- O
incidence O
malformations B-Disease
. O

in O
single O
dose O
studies O
, O
dh B-Disease
, O
md B-Disease
, O
and O
vsd B-Disease
were O
induced O
on O
gds O
9 O
and O
10 O
. O

vsd B-Disease
also O
was O
noted O
following O
treatment O
on O
gd O
11 O
. O

in O
contrast O
, O
dh B-Disease
and O
md B-Disease
were O
noted O
in O
the O
multiple O
dose O
study O
design O
only O
in O
the O
high O
- O
dose O
group O
, O
and O
vsd B-Disease
was O
noted O
across O
all O
dose O
groups O
. O

conclusions O
: O
high O
concordance O
in O
major O
developmental B-Disease
anomalies B-Disease
between O
wistar O
and O
sd O
rats O
were O
noted O
with O
the O
exception O
of O
vsd B-Disease
in O
the O
sd O
rats O
and O
hydrocephalus B-Disease
in O
the O
wistar O
rats O
. O

variations O
and O
malformations B-Disease
were O
similar O
when O
asa O
was O
administered O
as O
a O
single O
dose O
or O
during O
the O
period O
of O
organogenesis O
( O
gds O
6 O
to O
17 O
) O
. O

it O
was O
also O
evident O
that O
, O
by O
titrating O
the O
dose O
to O
achieve O
a O
maximum O
tolerated O
dose O
, O
malformations B-Disease
that O
normally O
occur O
at O
low O
incidence O
, O
as O
reported O
from O
previous O
single O
dose O
studies O
, O
could O
also O
be O
induced O
with O
asa O
given O
at O
multiple O
doses O
. O

reversal O
of O
central O
benzodiazepine O
effects O
by O
flumazenil O
after O
intravenous O
conscious O
sedation O
with O
diazepam O
and O
opioids O
: O
report O
of O
a O
double O
- O
blind O
multicenter O
study O
. O

the O
flumazenil O
in O
intravenous O
conscious O
sedation O
with O
diazepam O
multicenter O
study O
group O
ii O
. O

the O
efficacy O
and O
safety O
of O
a O
new O
benzodiazepine O
antagonist O
, O
flumazenil O
, O
were O
assessed O
in O
a O
double O
- O
blind O
multicenter O
study O
. O

flumazenil O
( O
mean O
dose O
, O
0 O
. O
76 O
mg O
) O
or O
placebo O
( O
mean O
dose O
, O
8 O
. O
9 O
ml O
) O
was O
administered O
intravenously O
to O
130 O
and O
67 O
patients O
, O
respectively O
, O
who O
had O
been O
given O
diazepam O
in O
conjunction O
with O
an O
opioid O
( O
fentanyl O
, O
meperidine O
, O
or O
morphine O
) O
for O
the O
induction O
and O
maintenance O
of O
intravenous O
conscious O
sedation O
for O
diagnostic O
or O
therapeutic O
surgical O
procedures O
. O

the O
group O
assessable O
for O
efficacy O
comprised O
122 O
patients O
treated O
with O
flumazenil O
and O
64 O
patients O
given O
placebo O
. O

after O
5 O
minutes O
, O
80 O
/ O
115 O
( O
70 O
% O
) O
flumazenil O
- O
treated O
patients O
, O
compared O
with O
21 O
/ O
63 O
( O
33 O
% O
) O
placebo O
- O
treated O
patients O
, O
were O
completely O
awake O
and O
alert O
, O
as O
indicated O
by O
a O
score O
of O
5 O
on O
the O
observer O
' O
s O
assessment O
of O
alertness O
/ O
sedation O
scale O
. O

ninety O
- O
five O
percent O
of O
patients O
in O
each O
group O
who O
attained O
a O
score O
of O
5 O
at O
the O
5 O
- O
minute O
assessment O
showed O
no O
loss O
of O
alertness O
throughout O
the O
180 O
- O
minute O
assessment O
period O
. O

flumazenil O
- O
treated O
patients O
also O
performed O
significantly O
better O
on O
the O
finger O
- O
to O
- O
nose O
test O
and O
the O
recall O
of O
pictures O
shown O
at O
the O
5 O
- O
minute O
assessment O
. O

flumazenil O
was O
well O
tolerated O
, O
with O
no O
serious O
adverse O
effects O
reported O
. O

thirty O
- O
nine O
( O
30 O
% O
) O
of O
flumazenil O
- O
treated O
patients O
, O
compared O
with O
17 O
( O
25 O
% O
) O
of O
placebo O
- O
treated O
patients O
had O
one O
or O
more O
drug O
- O
related O
adverse O
experiences O
. O

the O
most O
common O
adverse O
effects O
were O
nausea B-Disease
and O
vomiting B-Disease
in O
the O
flumazenil O
group O
and O
nausea B-Disease
and O
injection O
- O
site O
pain B-Disease
in O
the O
placebo O
group O
. O

flumazenil O
was O
found O
to O
promptly O
reverse O
sedation O
induced O
by O
diazepam O
in O
the O
presence O
of O
opioids O
. O

methylphenidate O
- O
induced O
obsessive B-Disease
- B-Disease
compulsive B-Disease
symptoms B-Disease
in O
an O
elderly O
man O
. O

an O
82 O
- O
year O
- O
old O
man O
with O
treatment B-Disease
- B-Disease
resistant B-Disease
depression B-Disease
and O
early O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
was O
started O
on O
methylphenidate O
. O

significant O
obsessive B-Disease
- B-Disease
compulsive B-Disease
behavior B-Disease
ensued O
but O
diminished O
over O
several O
weeks O
when O
methylphenidate O
was O
replaced O
by O
fluvoxamine O
. O

the O
patient O
had O
no O
prior O
psychiatric B-Disease
history O
, O
but O
he O
had O
a O
sister O
with O
obsessive B-Disease
- B-Disease
compulsive B-Disease
disorder B-Disease
. O

it O
appears O
that O
methylphenidate O
precipitated O
the O
patient O
' O
s O
pathological O
behavior O
. O

ciprofloxacin O
- O
induced O
acute O
interstitial B-Disease
nephritis B-Disease
and O
autoimmune B-Disease
hemolytic B-Disease
anemia B-Disease
. O

ciprofloxacin O
has O
been O
associated O
with O
several O
side O
effects O
including O
interstitial B-Disease
nephritis B-Disease
and O
hemolytic B-Disease
anemia B-Disease
. O

the O
combination O
of O
both O
side O
effects O
is O
extremely O
rare O
. O

in O
this O
report O
, O
we O
describe O
a O
case O
of O
ciprofloxacin O
- O
induced O
interstitial B-Disease
nephritis B-Disease
and O
autoimmune B-Disease
hemolytic B-Disease
anemia B-Disease
. O

hemolytic B-Disease
anemia B-Disease
improved O
after O
stopping O
the O
drug O
and O
initiation O
of O
steroid O
therapy O
. O

unfortunately O
, O
acute O
interstitial B-Disease
nephritis B-Disease
was O
irreversible O
and O
the O
patient O
developed O
end B-Disease
- B-Disease
stage B-Disease
renal B-Disease
disease B-Disease
. O

potential O
deleterious O
effect O
of O
furosemide O
in O
radiocontrast O
nephropathy B-Disease
. O

the O
purpose O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
furosemide O
in O
addition O
to O
intravenous O
fluids O
in O
the O
prevention O
of O
radiocontrast O
nephropathy B-Disease
. O

18 O
patients O
, O
referred O
to O
a O
radiocontrast O
study O
, O
considered O
at O
risk O
because O
of O
preexisting O
renal B-Disease
insufficiency B-Disease
, O
were O
enrolled O
in O
a O
prospective O
, O
randomized O
, O
controlled O
trial O
, O
performed O
at O
the O
secondary O
care O
center O
of O
a O
1 O
, O
100 O
- O
bed O
private O
university O
hospital O
. O

in O
addition O
to O
fluids O
, O
the O
treatment O
group O
received O
furosemide O
( O
mean O
dose O
110 O
mg O
) O
intravenously O
30 O
min O
prior O
to O
the O
injection O
of O
contrast O
material O
. O

the O
control O
group O
received O
fluids O
( O
mean O
3 O
liters O
) O
. O

radiological O
studies O
were O
mostly O
angiographies O
performed O
with O
both O
ionic O
and O
non O
- O
ionic O
contrast O
material O
, O
at O
an O
average O
dose O
of O
245 O
ml O
. O

renal B-Disease
function B-Disease
significantly B-Disease
deteriorated B-Disease
in O
the O
group O
pretreated O
with O
furosemide O
( O
p O
< O
0 O
. O
005 O
by O
anova O
) O
, O
with O
a O
rise O
in O
serum O
creatinine O
from O
145 O
+ O
/ O
- O
13 O
to O
182 O
+ O
/ O
- O
16 O
mumol O
/ O
l O
at O
24 O
h O
, O
while O
no O
change O
occurred O
in O
the O
control O
group O
( O
from O
141 O
+ O
/ O
- O
6 O
to O
142 O
+ O
/ O
- O
7 O
mumol O
/ O
l O
) O
. O

renal B-Disease
failure B-Disease
was O
associated O
with O
weight B-Disease
loss B-Disease
in O
the O
furosemide O
- O
treated O
group O
. O

furosemide O
may O
be O
deleterious O
in O
the O
prevention O
of O
radiocontrast O
nephropathy B-Disease
. O

progestational O
agents O
and O
blood B-Disease
coagulation B-Disease
. O

vii O
. O

thromboembolic B-Disease
and O
other O
complications O
of O
oral O
contraceptive O
therapy O
in O
relationship O
to O
pretreatment O
levels O
of O
blood B-Disease
coagulation B-Disease
factors O
: O
summary O
report O
of O
a O
ten O
- O
year O
study O
. O

during O
a O
ten O
- O
year O
period O
, O
348 O
women O
were O
studied O
for O
a O
total O
of O
5 O
, O
877 O
patient O
months O
in O
four O
separate O
studies O
relating O
oral O
contraceptives O
to O
changes O
in O
hematologic O
parameters O
. O

significant O
increases O
in O
certain O
factors O
of O
the O
blood B-Disease
coagulation B-Disease
and O
fibrinolysin O
systems O
( O
factors O
i O
, O
ii O
, O
vii O
, O
viii O
, O
ix O
, O
and O
x O
and O
plasminogen O
) O
were O
observed O
in O
the O
treated O
groups O
. O

severe O
complications O
developed O
in O
four O
patients O
. O

all O
four O
had O
an O
abnormal O
blood B-Disease
coagulation B-Disease
profile O
, O
suggesting O
" O
hypercoagulability B-Disease
" O
before O
initiation O
of O
therapy O
. O

some O
of O
these O
findings O
represented O
the O
most O
extreme O
abnormalities O
seen O
in O
the O
entire O
group O
of O
patients O
; O
some O
increased O
further O
during O
therapy O
. O

one O
of O
these O
patients O
developed O
a O
myocardial B-Disease
infarction B-Disease
before O
receiving O
any O
medication O
, O
shortly O
after O
the O
base O
- O
line O
values O
were O
obtained O
. O

one O
patient O
developed O
retinopathy B-Disease
19 O
months O
after O
she O
began O
therapy O
, O
and O
another O
developed O
thrombophlebitis B-Disease
after O
27 O
months O
of O
therapy O
. O

the O
fourth O
patient O
developed O
thrombophlebitis B-Disease
14 O
days O
after O
initiation O
of O
contraceptive O
therapy O
. O

all O
four O
patients O
were O
of O
the O
a O
or O
ab O
blood O
group O
. O

previous O
studies O
suggested O
the O
possiblility O
of O
increased O
propensity O
for O
thromboembolic B-Disease
episodes B-Disease
in O
patients O
possessing O
the O
a O
antigen O
. O

it O
appears O
from O
these O
data O
that O
hematologic O
work O
- O
ups O
may O
be O
useful O
in O
women O
who O
are O
about O
to O
start O
long O
- O
term O
oral O
contraceptive O
therapy O
. O

orthostatic B-Disease
hypotension B-Disease
occurs O
following O
alpha O
2 O
- O
adrenoceptor O
blockade O
in O
chronic O
prazosin O
- O
pretreated O
conscious O
spontaneously O
hypertensive B-Disease
rats O
. O

1 O
. O

studies O
were O
performed O
to O
evaluate O
whether O
chronic O
prazosin O
treatment O
alters O
the O
alpha O
2 O
- O
adrenoceptor O
function O
for O
orthostatic O
control O
of O
arterial O
blood O
pressure O
in O
conscious O
spontaneously O
hypertensive B-Disease
rats O
( O
shr O
) O
. O

2 O
. O

conscious O
shr O
( O
male O
300 O
- O
350 O
g O
) O
were O
subjected O
to O
90 O
degrees O
head O
- O
up O
tilts O
for O
60 O
s O
following O
acute O
administration O
of O
prazosin O
( O
0 O
. O
1 O
mg O
kg O
- O
1 O
i O
. O
p O
. O
) O
or O
rauwolscine O
( O
3 O
mg O
kg O
- O
1 O
i O
. O
v O
. O
) O
. O

orthostatic B-Disease
hypotension B-Disease
was O
determined O
by O
the O
average O
decrease O
( O
% O
) O
in O
mean O
arterial O
pressure O
( O
map O
femoral O
) O
over O
the O
60 O
- O
s O
tilt O
period O
. O

the O
basal O
map O
of O
conscious O
shr O
was O
reduced O
to O
a O
similar O
extent O
by O
prazosin O
( O
- O
23 O
% O
( O
- O
) O
- O
26 O
% O
map O
) O
and O
rauwolscine O
( O
- O
16 O
% O
( O
- O
) O
- O
33 O
% O
map O
) O
. O

however O
, O
the O
head O
- O
up O
tilt O
induced O
orthostatic B-Disease
hypotension B-Disease
in O
the O
shr O
treated O
with O
prazosin O
( O
- O
16 O
% O
map O
, O
n O
= O
6 O
) O
, O
but O
not O
in O
the O
shr O
treated O
with O
rauwolscine O
( O
less O
than O
+ O
2 O
% O
map O
, O
n O
= O
6 O
) O
. O

3 O
. O

conscious O
shr O
were O
treated O
for O
4 O
days O
with O
prazosin O
at O
2 O
mg O
kg O
- O
1 O
day O
- O
1 O
i O
. O
p O
. O
for O
chronic O
alpha O
1 O
- O
adrenoceptor O
blockade O
. O

map O
in O
conscious O
shr O
after O
chronic O
prazosin O
treatment O
was O
14 O
% O
lower O
than O
in O
the O
untreated O
shr O
( O
n O
= O
8 O
) O
. O

head O
- O
up O
tilts O
in O
these O
rats O
did O
not O
produce O
orthostatic B-Disease
hypotension B-Disease
when O
performed O
either O
prior O
to O
or O
after O
acute O
dosing O
of O
prazosin O
( O
0 O
. O
1 O
mg O
kg O
- O
1 O
i O
. O
p O
. O
) O
. O

conversely O
, O
administration O
of O
rauwolscine O
( O
3 O
mg O
kg O
- O
1 O
i O
. O
v O
. O
) O
in O
chronic O
prazosin O
treated O
shr O
decreased O
the O
basal O
map O
by O
12 O
- O
31 O
% O
( O
n O
= O
4 O
) O
, O
and O
subsequent O
tilts O
induced O
further O
drops O
of O
map O
by O
19 O
- O
23 O
% O
in O
these O
rats O
. O

4 O
. O

the O
pressor O
responses O
and O
bradycardia B-Disease
to O
the O
alpha O
1 O
- O
agonist O
cirazoline O
( O
0 O
. O
6 O
and O
2 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
, O
the O
alpha O
2 O
- O
agonist O
abbott O
- O
53693 O
( O
1 O
and O
3 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
, O
and O
noradrenaline O
( O
0 O
. O
1 O
and O
1 O
. O
0 O
micrograms O
kg O
- O
1 O
i O
. O
v O
. O
) O
were O
determined O
in O
conscious O
shr O
with O
and O
without O
chronic O
prazosin O
pretreatment O
. O

both O
the O
pressor O
and O
bradycardia B-Disease
effects O
of O
cirazoline O
were O
abolished O
in O
chronic O
prazosin O
treated O
shr O
( O
n O
= O
4 O
) O
as O
compared O
to O
the O
untreated O
shr O
( O
n O
= O
4 O
) O
. O

on O
the O
other O
hand O
, O
the O
pressor O
effects O
of O
abbott O
- O
53693 O
were O
similar O
in O
both O
groups O
of O
shr O
, O
but O
the O
accompanying O
bradycardia B-Disease
was O
greater O
in O
shr O
with O
chronic O
prazosin O
treatment O
than O
without O
such O
treatment O
. O

furthermore O
, O
the O
bradycardia B-Disease
that O
accompanied O
the O
noradrenaline O
- O
induced O
pressor O
effect O
in O
shr O
was O
similar O
with O
and O
without O
chronic O
prazosin O
treatment O
despite O
a O
47 O
- O
71 O
% O
reduction O
of O
the O
pressor O
effect O
in O
chronic O
alpha O
1 O
- O
receptor O
blocked O
shr O
. O
( O
abstract O
truncated O
at O
400 O
words O
) O

hemolytic B-Disease
- B-Disease
uremic B-Disease
syndrome B-Disease
associated O
with O
ingestion O
of O
quinine O
. O

hemolytic B-Disease
- B-Disease
uremic B-Disease
syndrome B-Disease
following O
quinine O
ingestion O
is O
a O
newly O
described O
phenomenon O
, O
with O
just O
two O
previous O
descriptions O
of O
4 O
cases O
in O
the O
literature O
. O

we O
describe O
a O
5th O
case O
. O

the O
reaction O
may O
be O
mediated O
by O
the O
presence O
of O
antibodies O
reactive O
against O
platelets O
in O
the O
presence O
of O
quinine O
. O

treatment O
has O
included O
use O
of O
plasma O
exchange O
, O
prednisone O
, O
aspirin O
, O
and O
dipyridamole O
. O

the O
patients O
have O
all O
regained O
some O
degree O
of O
renal O
function O
. O

however O
, O
it O
is O
unclear O
whether O
pharmacological O
treatment O
or O
spontaneous O
resolution O
is O
responsible O
for O
the O
improvement O
. O

quinine O
- O
associated O
hemolytic B-Disease
- B-Disease
uremic B-Disease
syndrome B-Disease
probably O
occurs O
more O
often O
than O
is O
recognized O
. O

it O
is O
important O
to O
recognize O
this O
reaction O
when O
it O
occurs O
and O
to O
avoid O
further O
quinine O
exposure O
, O
since O
the O
reaction O
seems O
to O
be O
recurrent O
. O

amnestic B-Disease
syndrome B-Disease
associated O
with O
propranolol O
toxicity B-Disease
: O
a O
case O
report O
. O

an O
elderly O
woman O
developed O
an O
alzheimer B-Disease
- O
like O
subacute O
dementia B-Disease
as O
a O
result O
of O
propranolol O
toxicity B-Disease
. O

analysis O
of O
the O
manifestations O
showed O
that O
severe O
impairment O
of O
memory O
accounted O
for O
virtually O
all O
of O
the O
abnormalities O
. O

there O
is O
evidence O
that O
cerebral O
reactions O
to O
drug O
toxicity B-Disease
can O
exhibit O
patterns O
that O
suggest O
highly O
selective O
involvement O
of O
functional O
subdivisions O
of O
the O
brain O
. O

cefotetan O
- O
induced O
immune O
hemolytic B-Disease
anemia B-Disease
. O

immune O
hemolytic B-Disease
anemia B-Disease
due O
to O
a O
drug O
- O
adsorption O
mechanism O
has O
been O
described O
primarily O
in O
patients O
receiving O
penicillins O
and O
first O
- O
generation O
cephalosporins O
. O

we O
describe O
a O
patient O
who O
developed O
anemia B-Disease
while O
receiving O
intravenous O
cefotetan O
. O

cefotetan O
- O
dependent O
antibodies O
were O
detected O
in O
the O
patient O
' O
s O
serum O
and O
in O
an O
eluate O
prepared O
from O
his O
red O
blood O
cells O
. O

the O
eluate O
also O
reacted O
weakly O
with O
red O
blood O
cells O
in O
the O
absence O
of O
cefotetan O
, O
suggesting O
the O
concomitant O
formation O
of O
warm O
- O
reactive O
autoantibodies O
. O

these O
observations O
, O
in O
conjunction O
with O
clinical O
and O
laboratory O
evidence O
of O
extravascular O
hemolysis B-Disease
, O
are O
consistent O
with O
drug O
- O
induced O
hemolytic B-Disease
anemia B-Disease
, O
possibly O
involving O
both O
drug O
- O
adsorption O
and O
autoantibody O
formation O
mechanisms O
. O

this O
case O
emphasizes O
the O
need O
for O
increased O
awareness O
of O
hemolytic O
reactions O
to O
all O
cephalosporins O
. O

use O
of O
dexamethasone O
with O
mesna O
for O
the O
prevention O
of O
ifosfamide O
- O
induced O
hemorrhagic B-Disease
cystitis B-Disease
. O

aim O
: O
hemorrhagic B-Disease
cystitis B-Disease
( O
hc B-Disease
) O
is O
a O
limiting O
side O
- O
effect O
of O
chemotherapy O
with O
ifosfamide O
( O
ifs O
) O
. O

in O
the O
study O
presented O
here O
, O
we O
investigated O
the O
use O
of O
dexamethasone O
in O
combination O
with O
mesna O
for O
the O
prevention O
of O
ifs O
- O
induced O
hc B-Disease
. O

methods O
: O
male O
wistar O
rats O
( O
150 O
- O
200 O
g O
; O
6 O
rats O
per O
group O
) O
were O
treated O
with O
saline O
or O
mesna O
5 O
min O
( O
i O
. O
p O
. O
) O
before O
and O
2 O
and O
6 O
h O
after O
( O
v O
. O
o O
. O
) O
administration O
of O
ifs O
. O

one O
, O
two O
or O
three O
doses O
of O
mesna O
were O
replaced O
with O
dexamethasone O
alone O
or O
with O
dexamethasone O
plus O
mesna O
. O

cystitis B-Disease
was O
evaluated O
24 O
h O
after O
its O
induction O
by O
the O
changes O
in O
bladder O
wet O
weight O
and O
by O
macroscopic O
and O
microscopic O
analysis O
. O

results O
: O
the O
replacement O
of O
the O
last O
dose O
or O
the O
last O
two O
doses O
of O
mesna O
with O
dexamethasone O
reduced O
the O
increase O
in O
bladder O
wet O
weight O
induced O
by O
ifs O
by O
84 O
. O
79 O
% O
and O
89 O
. O
13 O
% O
, O
respectively O
. O

in O
addition O
, O
it O
almost O
abolished O
the O
macroscopic O
and O
microscopic O
alterations O
induced O
by O
ifs O
. O

moreover O
, O
the O
addition O
of O
dexamethasone O
to O
the O
last O
two O
doses O
of O
mesna O
was O
more O
efficient O
than O
three O
doses O
of O
mesna O
alone O
when O
evaluated O
microscopically O
. O

conclusion O
: O
dexamethasone O
in O
combination O
with O
mesna O
was O
efficient O
in O
blocking O
ifs O
- O
induced O
hc B-Disease
. O

however O
, O
the O
replacement O
of O
last O
two O
doses O
of O
mesna O
with O
saline O
or O
all O
of O
the O
mesna O
doses O
with O
dexamethasone O
did O
not O
prevent O
hc B-Disease
. O

all O
- O
trans O
- O
retinoic O
acid O
- O
induced O
erythema B-Disease
nodosum B-Disease
in O
patients O
with O
acute B-Disease
promyelocytic B-Disease
leukemia B-Disease
. O

erythema B-Disease
nodosum B-Disease
associated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
atra O
) O
for O
acute B-Disease
promyelocytic B-Disease
leukemia B-Disease
( O
apl B-Disease
) O
is O
very O
rare O
. O

we O
describe O
four O
patients O
with O
classic O
apl B-Disease
who O
developed O
erythema B-Disease
nodosum B-Disease
during O
atra O
therapy O
. O

fever B-Disease
and O
subsequent O
multiple O
painful B-Disease
erythematous B-Disease
nodules B-Disease
over O
extremities O
developed O
on O
d11 O
, O
d16 O
, O
d17 O
, O
and O
d19 O
, O
respectively O
, O
after O
atra O
therapy O
. O

the O
skin O
biopsy O
taken O
from O
each O
patient O
was O
consistent O
with O
erythema B-Disease
nodosum B-Disease
. O

all O
patients O
received O
short O
course O
of O
steroids O
. O

fever B-Disease
subsided O
rapidly O
and O
the O
skin O
lesions O
regressed O
completely O
. O

all O
patients O
achieved O
complete O
remission O
without O
withdrawal O
of O
atra O
. O

atra O
seemed O
to O
be O
the O
most O
possible O
etiology O
of O
erythema B-Disease
nodosum B-Disease
in O
our O
patients O
. O

short O
- O
term O
use O
of O
steroid O
is O
very O
effective O
in O
atra O
- O
induced O
erythema B-Disease
nodosum B-Disease
. O

effect O
of O
some O
convulsants O
on O
the O
protective O
activity O
of O
loreclezole O
and O
its O
combinations O
with O
valproate O
or O
clonazepam O
in O
amygdala O
- O
kindled O
rats O
. O

loreclezole O
( O
5 O
mg O
/ O
kg O
) O
exerted O
a O
significant O
protective O
action O
in O
amygdala O
- O
kindled O
rats O
, O
reducing O
both O
seizure B-Disease
and O
afterdischarge O
durations O
. O

the O
combinations O
of O
loreclezole O
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
with O
valproate O
, O
clonazepam O
, O
or O
carbamazepine O
( O
applied O
at O
their O
subprotective O
doses O
) O
also O
exhibited O
antiseizure O
effect O
in O
this O
test O
. O

however O
, O
only O
two O
first O
combinations O
occurred O
to O
be O
of O
pharmacodynamic O
nature O
. O

among O
several O
chemoconvulsants O
, O
bicuculline O
, O
n O
- O
methyl O
- O
d O
- O
aspartic O
acid O
and O
bay O
k O
- O
8644 O
( O
the O
opener O
of O
l O
- O
type O
calcium O
channels O
) O
reversed O
the O
protective O
activity O
of O
loreclezole O
alone O
and O
its O
combination O
with O
valproate O
. O

on O
the O
other O
hand O
, O
bicuculline O
, O
aminophylline O
and O
bay O
k O
- O
8644 O
inhibited O
the O
anticonvulsive O
action O
of O
loreclezole O
combined O
with O
clonazepam O
. O

the O
results O
support O
the O
hypothesis O
that O
the O
protective O
activity O
of O
loreclezole O
and O
its O
combinations O
with O
other O
antiepileptics O
may O
involve O
potentiation O
of O
gabaergic O
neurotransmission O
and O
blockade O
of O
l O
- O
type O
of O
calcium O
channels O
. O

mitochondrial O
dna O
and O
its O
respiratory O
chain O
products O
are O
defective O
in O
doxorubicin O
nephrosis B-Disease
. O

background O
: O
doxorubicin O
induces O
a O
self O
- O
perpetuating O
nephropathy B-Disease
characterized O
by O
early O
glomerular B-Disease
and B-Disease
late B-Disease
- B-Disease
onset B-Disease
tubular B-Disease
lesions B-Disease
in O
rats O
. O

we O
investigated O
the O
potential O
role O
of O
mitochondrial B-Disease
injury B-Disease
in O
the O
onset O
of O
these O
lesions O
. O

methods O
: O
rats O
were O
treated O
with O
intravenous O
doxorubicin O
( O
1 O
mg O
kg O
( O
- O
1 O
) O
week O
( O
- O
1 O
) O
) O
for O
7 O
weeks O
and O
were O
sacrificed O
either O
1 O
week O
( O
' O
short O
- O
term O
' O
) O
or O
30 O
weeks O
( O
' O
long O
- O
term O
' O
) O
following O
the O
last O
dose O
. O

additional O
rats O
received O
a O
single O
dose O
either O
6 O
days O
or O
2 O
h O
prior O
to O
euthanasia O
. O

all O
rats O
were O
killed O
at O
48 O
weeks O
of O
age O
. O

glomerular B-Disease
and B-Disease
tubular B-Disease
injury B-Disease
was O
monitored O
and O
correlated O
to O
the O
activity O
or O
expression O
of O
respiratory O
chain O
components O
. O

finally O
, O
we O
quantified O
both O
nuclear O
and O
mitochondrial O
dna O
( O
mtdna O
) O
as O
well O
as O
superoxide O
production O
and O
the O
4834 O
base O
pair O
' O
common O
' O
mtdna O
deletion O
. O

results O
: O
the O
' O
long O
- O
term O
' O
group O
had O
significant O
glomerular B-Disease
and B-Disease
tubular B-Disease
lesions B-Disease
, O
depressed O
activities O
of O
mtdna O
- O
encoded O
nadh O
dehydrogenase O
and O
cytochrome O
- O
c O
oxidase O
( O
cox O
) O
and O
increased O
citrate O
synthase O
activity O
. O

in O
addition O
, O
expression O
of O
the O
mtdna O
- O
encoded O
cox O
subunit O
i O
was O
reduced O
and O
mtdna O
levels O
were O
decreased O
. O

in O
' O
short O
- O
term O
' O
rats O
, O
there O
were O
fewer O
tubular B-Disease
lesions B-Disease
, O
but O
similar O
numbers O
of O
glomerular B-Disease
lesions B-Disease
activity O
. O

among O
all O
animals O
, O
glomerular B-Disease
and B-Disease
tubular B-Disease
injury B-Disease
were O
inversely O
correlated O
with O
mtdna O
levels O
, O
mtdna O
- O
encoded O
respiratory O
chain O
activities O
and O
with O
the O
expression O
of O
the O
mtdna O
- O
encoded O
respiratory O
chain O
subunit O
cox O
- O
i O
. O

injury O
was O
positively O
correlated O
with O
superoxide O
production O
and O
the O
activities O
of O
nucleus O
- O
encoded O
mitochondrial O
or O
cytoplasmic O
enzymes O
. O

kidneys O
from O
the O
' O
long O
- O
term O
' O
group O
showed O
more O
mtdna O
deletions O
than O
in O
' O
short O
- O
term O
' O
animals O
and O
these O
were O
not O
observed O
in O
the O
other O
groups O
. O

conclusions O
: O
these O
results O
suggest O
an O
important O
role O
for O
quantitative O
and O
qualitative O
mtdna O
alterations O
through O
the O
reduction O
of O
mtdna O
- O
encoded O
respiratory O
chain O
function O
and O
induction O
of O
superoxide O
in O
doxorubicin O
- O
induced O
renal B-Disease
lesions B-Disease
. O

a O
randomized O
, O
placebo O
- O
controlled O
, O
crossover O
study O
of O
ephedrine O
for O
ssri O
- O
induced O
female O
sexual B-Disease
dysfunction B-Disease
. O

the O
objective O
of O
this O
study O
was O
to O
determine O
whether O
ephedrine O
, O
an O
alpha O
- O
and O
beta O
- O
adrenergic O
agonist O
previously O
shown O
to O
enhance O
genital O
blood O
flow O
in O
women O
, O
has O
beneficial O
effects O
in O
reversing O
antidepressant O
- O
induced O
sexual B-Disease
dysfunction B-Disease
. O

nineteen O
sexually B-Disease
dysfunctional B-Disease
women O
receiving O
either O
fluoxetine O
, O
sertraline O
, O
or O
paroxetine O
participated O
in O
an O
eight O
- O
week O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
study O
of O
the O
effects O
of O
ephedrine O
( O
50 O
mg O
) O
on O
self O
- O
report O
measures O
of O
sexual O
desire O
, O
arousal O
, O
orgasm O
, O
and O
sexual O
satisfaction O
. O

although O
there O
were O
significant O
improvements O
relative O
to O
baseline O
in O
sexual O
desire O
and O
orgasm O
intensity O
/ O
pleasure O
on O
50 O
mg O
ephedrine O
1 O
- O
hr O
prior O
to O
sexual O
activity O
, O
significant O
improvements O
in O
these O
measures O
, O
as O
well O
as O
in O
sexual O
arousal O
and O
orgasmic O
ability O
also O
were O
noted O
with O
placebo O
. O

these O
findings O
highlight O
the O
importance O
of O
conducting O
placebo O
- O
controlled O
trials O
for O
this O
condition O
. O

does O
hormone O
therapy O
for O
the O
treatment O
of O
breast B-Disease
cancer B-Disease
have O
a O
detrimental B-Disease
effect B-Disease
on B-Disease
memory B-Disease
and B-Disease
cognition B-Disease
? O

a O
pilot O
study O
. O

this O
pilot O
study O
examines O
whether O
hormone O
therapy O
for O
breast B-Disease
cancer B-Disease
affects O
cognition O
. O

patients O
participating O
in O
a O
randomised O
trial O
of O
anastrozole O
, O
tamoxifen O
alone O
or O
combined O
( O
atac O
) O
( O
n O
= O
94 O
) O
and O
a O
group O
of O
women O
without O
breast B-Disease
cancer B-Disease
( O
n O
= O
35 O
) O
completed O
a O
battery O
of O
neuropsychological O
measures O
. O

compared O
with O
the O
control O
group O
, O
the O
patients O
were O
impaired O
on O
a O
processing O
speed O
task O
( O
p O
= O
0 O
. O
032 O
) O
and O
on O
a O
measure O
of O
immediate O
verbal O
memory O
( O
p O
= O
0 O
. O
026 O
) O
after O
controlling O
for O
the O
use O
of O
hormone O
replacement O
therapy O
in O
both O
groups O
. O

patient O
group O
performance O
was O
not O
significantly O
related O
to O
length O
of O
treatment O
or O
measures O
of O
psychological O
morbidity O
. O

the O
results O
showed O
specific O
impairments O
in O
processing O
speed O
and O
verbal O
memory O
in O
women O
receiving O
hormonal O
therapy O
for O
the O
treatment O
of O
breast B-Disease
cancer B-Disease
. O

verbal O
memory O
may O
be O
especially O
sensitive O
to O
changes O
in O
oestrogen O
levels O
, O
a O
finding O
commonly O
reported O
in O
studies O
of O
hormone O
replacement O
therapy O
in O
healthy O
women O
. O

in O
view O
of O
the O
increased O
use O
of O
hormone O
therapies O
in O
an O
adjuvant O
and O
preventative O
setting O
their O
impact O
on O
cognitive O
functioning O
should O
be O
investigated O
more O
thoroughly O
. O

expression O
of O
p300 O
protects O
cardiac O
myocytes O
from O
apoptosis O
in O
vivo O
. O

doxorubicin O
is O
an O
anti O
- O
tumor B-Disease
agent O
that O
represses O
cardiac O
- O
specific O
gene O
expression O
and O
induces O
myocardial O
cell O
apoptosis O
. O

doxorubicin O
depletes O
cardiac O
p300 O
, O
a O
transcriptional O
coactivator O
that O
is O
required O
for O
the O
maintenance O
of O
the O
differentiated O
phenotype O
of O
cardiac O
myocytes O
. O

however O
, O
the O
role O
of O
p300 O
in O
protection O
against O
doxorubicin O
- O
induced O
apoptosis O
is O
unknown O
. O

transgenic O
mice O
overexpressing O
p300 O
in O
the O
heart O
and O
wild O
- O
type O
mice O
were O
subjected O
to O
doxorubicin O
treatment O
. O

compared O
with O
wild O
- O
type O
mice O
, O
transgenic O
mice O
exhibited O
higher O
survival O
rate O
as O
well O
as O
more O
preserved O
left O
ventricular O
function O
and O
cardiac O
expression O
of O
alpha O
- O
sarcomeric O
actin O
. O

doxorubicin O
induced O
myocardial O
cell O
apoptosis O
in O
wild O
- O
type O
mice O
but O
not O
in O
transgenic O
mice O
. O

expression O
of O
p300 O
increased O
the O
cardiac O
level O
of O
bcl O
- O
2 O
and O
mdm O
- O
2 O
, O
but O
not O
that O
of O
p53 O
or O
other O
members O
of O
the O
bcl O
- O
2 O
family O
. O

these O
findings O
demonstrate O
that O
overexpression O
of O
p300 O
protects O
cardiac O
myocytes O
from O
doxorubicin O
- O
induced O
apoptosis O
and O
reduces O
the O
extent O
of O
acute O
heart B-Disease
failure B-Disease
in O
adult O
mice O
in O
vivo O
. O

methimazole O
- O
induced O
cholestatic B-Disease
jaundice B-Disease
. O

methimazole O
is O
a O
widely O
used O
and O
generally O
well O
- O
tolerated O
antithyroid O
agent O
. O

a O
43 O
- O
year O
- O
old O
woman O
had O
severe O
jaundice B-Disease
and O
itching B-Disease
1 O
month O
after O
receiving O
methimazole O
( O
10 O
mg O
tid O
) O
and O
propranolol O
( O
20 O
mg O
tid O
) O
for O
treatment O
of O
hyperthyroidism B-Disease
. O

the O
patient O
continued O
treatment O
for O
another O
4 O
days O
after O
the O
appearance O
of O
jaundice B-Disease
until O
she O
finished O
both O
medications O
. O

when O
seen O
at O
the O
emergency O
department O
2 O
weeks O
later O
, O
she O
still O
had O
severe O
icterus B-Disease
, O
pruritus B-Disease
, O
and O
hyperbilirubinemia B-Disease
, O
formed O
mainly O
of O
the O
conjugated O
fraction O
. O

methimazole O
- O
induced O
cholestasis B-Disease
was O
diagnosed O
, O
and O
propranolol O
therapy O
was O
resumed O
. O

over O
the O
following O
9 O
days O
, O
the O
symptoms O
improved O
and O
plasma O
bilirubin O
levels O
were O
normal O
after O
12 O
weeks O
without O
methimazole O
. O

in O
rare O
cases O
within O
the O
first O
few O
weeks O
of O
therapy O
, O
this O
drug O
can O
cause O
severe O
and O
reversible O
cholestatic B-Disease
jaundice B-Disease
. O

physicians O
and O
patients O
should O
be O
aware O
of O
this O
adverse O
effect O
so O
that O
, O
upon O
occurrence O
, O
they O
can O
discontinue O
methimazole O
therapy O
and O
avoid O
unnecessary O
invasive O
procedures O
. O

atrial B-Disease
fibrillation B-Disease
following O
chemotherapy O
for O
stage O
iiie O
diffuse O
large O
b O
- O
cell O
gastric B-Disease
lymphoma B-Disease
in O
a O
patient O
with O
myotonic B-Disease
dystrophy B-Disease
( O
steinert B-Disease
' B-Disease
s B-Disease
disease B-Disease
) O
. O

the O
authors O
describe O
the O
unusual O
association O
between O
diffuse O
b O
- O
cell O
gastric B-Disease
lymphoma B-Disease
and O
myotonic B-Disease
dystrophy B-Disease
, O
the O
most O
common O
form O
of O
adult O
muscular B-Disease
dystrophy B-Disease
, O
and O
sudden O
atrial B-Disease
fibrillation B-Disease
following O
one O
cycle O
of O
doxorubicin O
- O
based O
chemotherapy O
in O
the O
same O
patient O
. O

atrial B-Disease
fibrillation B-Disease
or O
other O
cardiac B-Disease
arrhythmias B-Disease
are O
unusual O
complications O
in O
patients O
treated O
with O
chemotherapy O
. O

the O
cardiac B-Disease
toxicity B-Disease
intrinsically O
associated O
with O
the O
aggressive O
chemotherapy O
employed O
could O
function O
as O
a O
triggering O
factor O
for O
the O
arrhythmia B-Disease
in O
the O
predisposed O
myocardium O
of O
this O
patient O
. O

hypersensitivity B-Disease
immune O
reaction O
as O
a O
mechanism O
for O
dilevalol O
- O
associated O
hepatitis B-Disease
. O

objective O
: O
to O
assess O
lymphocyte O
reactivity O
to O
dilevalol O
and O
to O
serum O
containing O
putative O
ex O
vivo O
dilevalol O
antigens O
or O
metabolites O
in O
a O
case O
of O
dilevalol O
- O
induced O
liver B-Disease
injury B-Disease
. O

patient O
: O
a O
58 O
- O
year O
- O
old O
woman O
with O
a O
clinical O
diagnosis O
of O
dilevalol O
- O
induced O
liver B-Disease
injury B-Disease
. O

methods O
: O
peripheral O
blood O
mononuclear O
cells O
collected O
from O
the O
patient O
were O
cultured O
in O
the O
presence O
of O
a O
solution O
of O
dilevalol O
and O
also O
with O
sera O
collected O
from O
a O
volunteer O
before O
and O
after O
dilevalol O
intake O
. O

a O
similar O
protocol O
was O
performed O
with O
lymphocytes O
from O
a O
healthy O
subject O
. O

results O
: O
no O
lymphocyte O
proliferation O
was O
observed O
either O
in O
the O
patient O
or O
in O
the O
healthy O
volunteer O
in O
the O
presence O
of O
dilevalol O
solutions O
. O

a O
significant O
proliferative O
response O
to O
serum O
collected O
after O
dilevalol O
intake O
was O
observed O
in O
the O
case O
of O
the O
patient O
compared O
with O
the O
proliferative O
response O
to O
the O
serum O
collected O
before O
the O
drug O
intake O
. O

no O
reactivity O
was O
found O
when O
lymphocytes O
from O
the O
healthy O
subject O
were O
tested O
under O
similar O
conditions O
. O

conclusions O
: O
the O
methodology O
used O
allowed O
the O
detection O
of O
lymphocyte O
sensitization O
to O
sera O
containing O
ex O
vivo O
- O
prepared O
dilevalol O
antigens O
, O
suggesting O
the O
involvement O
of O
an O
immunologic O
mechanism O
in O
dilevalol O
- O
induced O
liver B-Disease
injury B-Disease
. O

increased O
expression O
and O
apical O
targeting O
of O
renal O
enac O
subunits O
in O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome B-Disease
in O
rats O
. O

nephrotic B-Disease
syndrome B-Disease
is O
often O
accompanied O
by O
sodium O
retention O
and O
generalized O
edema B-Disease
. O

however O
, O
the O
molecular O
basis O
for O
the O
decreased O
renal O
sodium O
excretion O
remains O
undefined O
. O

we O
hypothesized O
that O
epithelial O
na O
channel O
( O
enac O
) O
subunit O
dysregulation O
may O
be O
responsible O
for O
the O
increased O
sodium O
retention O
. O

an O
experimental O
group O
of O
rats O
was O
treated O
with O
puromycin O
aminonucleoside O
( O
pan O
; O
180 O
mg O
/ O
kg O
iv O
) O
, O
whereas O
the O
control O
group O
received O
only O
vehicle O
. O

after O
7 O
days O
, O
pan O
treatment O
induced O
significant O
proteinuria B-Disease
, O
hypoalbuminemia B-Disease
, O
decreased O
urinary O
sodium O
excretion O
, O
and O
extensive O
ascites B-Disease
. O

the O
protein O
abundance O
of O
alpha O
- O
enac O
and O
beta O
- O
enac O
was O
increased O
in O
the O
inner O
stripe O
of O
the O
outer O
medulla O
( O
isom O
) O
and O
in O
the O
inner O
medulla O
( O
im O
) O
but O
was O
not O
altered O
in O
the O
cortex O
. O

gamma O
- O
enac O
abundance O
was O
increased O
in O
the O
cortex O
, O
isom O
, O
and O
im O
. O

immunoperoxidase O
brightfield O
- O
and O
laser O
- O
scanning O
confocal O
fluorescence O
microscopy O
demonstrated O
increased O
targeting O
of O
alpha O
- O
enac O
, O
beta O
- O
enac O
, O
and O
gamma O
- O
enac O
subunits O
to O
the O
apical O
plasma O
membrane O
in O
the O
distal O
convoluted O
tubule O
( O
dct2 O
) O
, O
connecting O
tubule O
, O
and O
cortical O
and O
medullary O
collecting O
duct O
segments O
. O

immunoelectron O
microscopy O
further O
revealed O
an O
increased O
labeling O
of O
alpha O
- O
enac O
in O
the O
apical O
plasma O
membrane O
of O
cortical O
collecting O
duct O
principal O
cells O
of O
pan O
- O
treated O
rats O
, O
indicating O
enhanced O
apical O
targeting O
of O
alpha O
- O
enac O
subunits O
. O

in O
contrast O
, O
the O
protein O
abundances O
of O
na O
( O
+ O
) O
/ O
h O
( O
+ O
) O
exchanger O
type O
3 O
( O
nhe3 O
) O
, O
na O
( O
+ O
) O
- O
k O
( O
+ O
) O
- O
2cl O
( O
- O
) O
cotransporter O
( O
bsc O
- O
1 O
) O
, O
and O
thiazide O
- O
sensitive O
na O
( O
+ O
) O
- O
cl O
( O
- O
) O
cotransporter O
( O
tsc O
) O
were O
decreased O
. O

moreover O
, O
the O
abundance O
of O
the O
alpha O
( O
1 O
) O
- O
subunit O
of O
the O
na O
- O
k O
- O
atpase O
was O
decreased O
in O
the O
cortex O
and O
isom O
, O
but O
it O
remained O
unchanged O
in O
the O
im O
. O

in O
conclusion O
, O
the O
increased O
or O
sustained O
expression O
of O
enac O
subunits O
combined O
with O
increased O
apical O
targeting O
in O
the O
dct2 O
, O
connecting O
tubule O
, O
and O
collecting O
duct O
are O
likely O
to O
play O
a O
role O
in O
the O
sodium O
retention O
associated O
with O
pan O
- O
induced O
nephrotic B-Disease
syndrome B-Disease
. O

the O
decreased O
abundance O
of O
nhe3 O
, O
bsc O
- O
1 O
, O
tsc O
, O
and O
na O
- O
k O
- O
atpase O
may O
play O
a O
compensatory O
role O
to O
promote O
sodium O
excretion O
. O

pallidal O
stimulation O
: O
an O
alternative O
to O
pallidotomy O
? O

a O
resurgence O
of O
interest O
in O
the O
surgical O
treatment O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
( O
pd B-Disease
) O
came O
with O
the O
rediscovery O
of O
posteroventral O
pallidotomy O
by O
laitinen O
in O
1985 O
. O

laitinen O
' O
s O
procedure O
improved O
most O
symptoms O
in O
drug O
- O
resistant O
pd B-Disease
, O
which O
engendered O
wide O
interest O
in O
the O
neurosurgical O
community O
. O

another O
lesioning O
procedure O
, O
ventrolateral O
thalamotomy O
, O
has O
become O
a O
powerful O
alternative O
to O
stimulate O
the O
nucleus O
ventralis O
intermedius O
, O
producing O
high O
long O
- O
term O
success O
rates O
and O
low O
morbidity O
rates O
. O

pallidal O
stimulation O
has O
not O
met O
with O
the O
same O
success O
. O

according O
to O
the O
literature O
pallidotomy O
improves O
the O
" O
on O
" O
symptoms O
of O
pd B-Disease
, O
such O
as O
dyskinesias B-Disease
, O
as O
well O
as O
the O
" O
off O
" O
symptoms O
, O
such O
as O
rigidity B-Disease
, O
bradykinesia B-Disease
, O
and O
on O
- O
off O
fluctuations O
. O

pallidal O
stimulation O
improves O
bradykinesia B-Disease
and O
rigidity B-Disease
to O
a O
minor O
extent O
; O
however O
, O
its O
strength O
seems O
to O
be O
in O
improving O
levodopa O
- O
induced O
dyskinesias B-Disease
. O

stimulation O
often O
produces O
an O
improvement O
in O
the O
hyper B-Disease
- B-Disease
or B-Disease
dyskinetic B-Disease
upper O
limbs O
, O
but O
increases O
the O
" O
freezing O
" O
phenomenon O
in O
the O
lower O
limbs O
at O
the O
same O
time O
. O

considering O
the O
small O
increase O
in O
the O
patient O
' O
s O
independence O
, O
the O
high O
costs O
of O
bilateral O
implants O
, O
and O
the O
difficulty O
most O
patients O
experience O
in O
handling O
the O
devices O
, O
the O
question O
arises O
as O
to O
whether O
bilateral O
pallidal O
stimulation O
is O
a O
real O
alternative O
to O
pallidotomy O
. O

effects O
of O
the O
cyclooxygenase O
- O
2 O
specific O
inhibitor O
valdecoxib O
versus O
nonsteroidal O
antiinflammatory O
agents O
and O
placebo O
on O
cardiovascular O
thrombotic B-Disease
events O
in O
patients O
with O
arthritis B-Disease
. O

there O
have O
been O
concerns O
that O
the O
risk O
of O
cardiovascular O
thrombotic B-Disease
events O
may O
be O
higher O
with O
cyclooxygenase O
( O
cox O
) O
- O
2 O
- O
specific O
inhibitors O
than O
nonselective O
nonsteroidal O
antiinflammatory O
drugs O
( O
nsaids O
) O
. O

we O
evaluated O
cardiovascular O
event O
data O
for O
valdecoxib O
, O
a O
new O
cox O
- O
2 O
- O
specific O
inhibitor O
in O
approximately O
8000 O
patients O
with O
osteoarthritis B-Disease
and O
rheumatoid B-Disease
arthritis B-Disease
treated O
with O
this O
agent O
in O
randomized O
clinical O
trials O
. O

the O
incidence O
of O
cardiovascular O
thrombotic B-Disease
events O
( O
cardiac O
, O
cerebrovascular O
and O
peripheral O
vascular O
, O
or O
arterial O
thrombotic B-Disease
) O
was O
determined O
by O
analyzing O
pooled O
valdecoxib O
( O
10 O
- O
80 O
mg O
daily O
) O
, O
nonselective O
nsaid O
( O
diclofenac O
75 O
mg O
bid O
, O
ibuprofen O
800 O
mg O
tid O
, O
or O
naproxen O
500 O
mg O
bid O
) O
and O
placebo O
data O
from O
10 O
randomized O
osteoarthritis B-Disease
and O
rheumatoid B-Disease
arthritis B-Disease
trials O
that O
were O
6 O
- O
52 O
weeks O
in O
duration O
. O

the O
incidence O
rates O
of O
events O
were O
determined O
in O
all O
patients O
( O
n O
= O
7934 O
) O
and O
in O
users O
of O
low O
- O
dose O
( O
< O
or O
= O
325 O
mg O
daily O
) O
aspirin O
( O
n O
= O
1051 O
) O
and O
nonusers O
of O
aspirin O
( O
n O
= O
6883 O
) O
. O

crude O
and O
exposure O
- O
adjusted O
incidences O
of O
thrombotic B-Disease
events O
were O
similar O
for O
valdecoxib O
, O
nsaids O
, O
and O
placebo O
. O

the O
risk O
of O
serious O
thrombotic B-Disease
events O
was O
also O
similar O
for O
each O
valdecoxib O
dose O
. O

thrombotic B-Disease
risk O
was O
consistently O
higher O
for O
users O
of O
aspirin O
users O
than O
nonusers O
of O
aspirin O
( O
placebo O
, O
1 O
. O
4 O
% O
vs O
. O
0 O
% O
; O
valdecoxib O
, O
1 O
. O
7 O
% O
vs O
. O
0 O
. O
2 O
% O
; O
nsaids O
, O
1 O
. O
9 O
% O
vs O
. O
0 O
. O
5 O
% O
) O
. O

the O
rates O
of O
events O
in O
users O
of O
aspirin O
were O
similar O
for O
all O
3 O
treatment O
groups O
and O
across O
valdecoxib O
doses O
. O

short O
- O
and O
intermediate O
- O
term O
treatment O
with O
therapeutic O
( O
10 O
or O
20 O
mg O
daily O
) O
and O
supratherapeutic O
( O
40 O
or O
80 O
mg O
daily O
) O
valdecoxib O
doses O
was O
not O
associated O
with O
an O
increased O
incidence O
of O
thrombotic B-Disease
events O
relative O
to O
nonselective O
nsaids O
or O
placebo O
in O
osteoarthritis B-Disease
and O
rheumatoid B-Disease
arthritis B-Disease
patients O
in O
controlled O
clinical O
trials O
. O

hypersensitivity B-Disease
myocarditis B-Disease
complicating O
hypertrophic B-Disease
cardiomyopathy B-Disease
heart O
. O

the O
present O
report O
describes O
a O
case O
of O
eosinophilic B-Disease
myocarditis B-Disease
complicating O
hypertrophic B-Disease
cardiomyopathy B-Disease
. O

the O
47 O
- O
year O
- O
old O
female O
patient O
, O
known O
to O
have O
hypertrophic B-Disease
cardiomyopathy B-Disease
, O
was O
admitted O
with O
biventricular B-Disease
failure B-Disease
and O
managed O
aggressively O
with O
dobutamine O
infusion O
and O
other O
drugs O
while O
being O
assessed O
for O
heart O
transplantation O
. O

on O
transthoracic O
echocardiogram O
, O
she O
had O
moderate O
left B-Disease
ventricular B-Disease
dysfunction B-Disease
with O
regional O
variability O
and O
moderate O
mitral B-Disease
regurgitation B-Disease
. O

the O
recipient O
' O
s O
heart O
showed O
the O
features O
of O
apical O
hypertrophic B-Disease
cardiomyopathy B-Disease
and O
myocarditis B-Disease
with O
abundant O
eosinophils O
. O

myocarditis B-Disease
is O
rare O
and O
eosinophilic B-Disease
myocarditis B-Disease
is O
rarer O
. O

it O
is O
likely O
that O
the O
hypersensitivity B-Disease
( O
eosinophilic B-Disease
) O
myocarditis B-Disease
was O
related O
to O
dobutamine O
infusion O
therapy O
. O

eosinophilic B-Disease
myocarditis B-Disease
has O
been O
reported O
with O
an O
incidence O
of O
2 O
. O
4 O
% O
to O
7 O
. O
2 O
% O
in O
explanted O
hearts O
and O
may O
be O
related O
to O
multidrug O
therapy O
. O

time O
trends O
in O
warfarin O
- O
associated O
hemorrhage B-Disease
. O

the O
annual O
incidence O
of O
warfarin O
- O
related O
bleeding B-Disease
at O
brigham O
and O
women O
' O
s O
hospital O
increased O
from O
0 O
. O
97 O
/ O
1 O
, O
000 O
patient O
admissions O
in O
the O
first O
time O
period O
( O
january O
1995 O
to O
october O
1998 O
) O
to O
1 O
. O
19 O
/ O
1 O
, O
000 O
patient O
admissions O
in O
the O
second O
time O
period O
( O
november O
1998 O
to O
august O
2002 O
) O
of O
this O
study O
. O

the O
proportion O
of O
patients O
with O
major O
and O
intracranial B-Disease
bleeding B-Disease
increased O
from O
20 O
. O
2 O
% O
and O
1 O
. O
9 O
% O
, O
respectively O
, O
in O
the O
first O
time O
period O
, O
to O
33 O
. O
3 O
% O
and O
7 O
. O
8 O
% O
, O
respectively O
, O
in O
the O
second O
. O

yohimbine O
treatment O
of O
sexual B-Disease
side B-Disease
effects B-Disease
induced O
by O
serotonin O
reuptake O
blockers O
. O

background O
: O
preclinical O
and O
clinical O
studies O
suggest O
that O
yohimbine O
facilitates O
sexual O
behavior O
and O
may O
be O
helpful O
in O
the O
treatment O
of O
male B-Disease
impotence B-Disease
. O

a O
single O
case O
report O
suggests O
that O
yohimbine O
may O
be O
used O
to O
treat O
the O
sexual B-Disease
side B-Disease
effects B-Disease
of O
clomipramine O
. O

this O
study O
evaluated O
yohimbine O
as O
a O
treatment O
for O
the O
sexual B-Disease
side B-Disease
effects B-Disease
caused O
by O
serotonin O
reuptake O
blockers O
. O

method O
: O
six O
patients O
with O
either O
obsessive B-Disease
compulsive B-Disease
disorder B-Disease
, O
trichotillomania B-Disease
, O
anxiety B-Disease
, O
or O
affective B-Disease
disorders B-Disease
who O
suffered O
sexual B-Disease
side B-Disease
effects B-Disease
after O
treatment O
with O
serotonin O
reuptake O
blockers O
were O
given O
yohimbine O
on O
a O
p O
. O
r O
. O
n O
. O
basis O
in O
an O
open O
clinical O
trial O
. O

various O
doses O
of O
yohimbine O
were O
used O
to O
determine O
the O
ideal O
dose O
for O
each O
patient O
. O

results O
: O
five O
of O
the O
six O
patients O
experienced O
improved O
sexual O
functioning O
after O
taking O
yohimbine O
. O

one O
patient O
who O
failed O
to O
comply O
with O
yohimbine O
treatment O
had O
no O
therapeutic O
effects O
. O

side O
effects O
of O
yohimbine O
included O
excessive O
sweating O
, O
increased O
anxiety B-Disease
, O
and O
a O
wound O
- O
up O
feeling O
in O
some O
patients O
. O

conclusion O
: O
the O
results O
of O
this O
study O
indicate O
that O
yohimbine O
may O
be O
an O
effective O
treatment O
for O
the O
sexual B-Disease
side B-Disease
effects B-Disease
caused O
by O
serotonin O
reuptake O
blockers O
. O

future O
controlled O
studies O
are O
needed O
to O
further O
investigate O
the O
effectiveness O
and O
safety O
of O
yohimbine O
for O
this O
indication O
. O

hemorrhagic B-Disease
cystitis B-Disease
complicating O
bone O
marrow O
transplantation O
. O

hemorrhagic B-Disease
cystitis B-Disease
is O
a O
potentially O
serious O
complication O
of O
high O
- O
dose O
cyclophosphamide O
therapy O
administered O
before O
bone O
marrow O
transplantation O
. O

as O
standard O
practice O
at O
our O
institution O
, O
patients O
who O
are O
scheduled O
to O
receive O
a O
bone O
marrow O
transplant O
are O
treated O
prophylactically O
with O
forced O
hydration O
and O
bladder O
irrigation O
. O

in O
an O
attempt O
to O
obviate O
the O
inconvenience O
of O
bladder O
irrigation O
, O
we O
conducted O
a O
feasibility O
trial O
of O
uroprophylaxis O
with O
mesna O
, O
which O
neutralizes O
the O
hepatic O
metabolite O
of O
cyclophosphamide O
that O
causes O
hemorrhagic B-Disease
cystitis B-Disease
. O

of O
97 O
patients O
who O
received O
standard O
prophylaxis O
, O
4 O
had O
symptomatic O
hemorrhagic B-Disease
cystitis B-Disease
. O

in O
contrast O
, O
two O
of O
four O
consecutive O
patients O
who O
received O
mesna O
uroprophylaxis O
before O
allogeneic O
bone O
marrow O
transplantation O
had O
severe O
hemorrhagic B-Disease
cystitis B-Disease
for O
at O
least O
2 O
weeks O
. O

because O
of O
this O
suboptimal O
result O
, O
we O
resumed O
the O
use O
of O
bladder O
irrigation O
and O
forced O
hydration O
to O
minimize O
the O
risk O
of O
hemorrhagic B-Disease
cystitis B-Disease
. O

consensus O
statement O
concerning O
cardiotoxicity B-Disease
occurring O
during O
haematopoietic O
stem O
cell O
transplantation O
in O
the O
treatment O
of O
autoimmune B-Disease
diseases B-Disease
, O
with O
special O
reference O
to O
systemic B-Disease
sclerosis B-Disease
and O
multiple B-Disease
sclerosis B-Disease
. O

autologous O
haematopoietic O
stem O
cell O
transplantation O
is O
now O
a O
feasible O
and O
effective O
treatment O
for O
selected O
patients O
with O
severe O
autoimmune B-Disease
diseases B-Disease
. O

worldwide O
, O
over O
650 O
patients O
have O
been O
transplanted O
in O
the O
context O
of O
phase O
i O
and O
ii O
clinical O
trials O
. O

the O
results O
are O
encouraging O
enough O
to O
begin O
randomised O
phase O
iii O
trials O
. O

however O
, O
as O
predicted O
, O
significant O
transplant O
- O
related O
morbidity O
and O
mortality O
have O
been O
observed O
. O

this O
is O
primarily O
due O
to O
complications O
related O
to O
either O
the O
stage O
of O
the O
disease O
at O
transplant O
or O
due O
to O
infections B-Disease
. O

the O
number O
of O
deaths O
related O
to O
cardiac B-Disease
toxicity B-Disease
is O
low O
. O

however O
, O
caution O
is O
required O
when O
cyclophosphamide O
or O
anthracyclines O
such O
as O
mitoxantrone O
are O
used O
in O
patients O
with O
a O
possible O
underlying O
heart B-Disease
damage B-Disease
, O
for O
example O
, O
systemic B-Disease
sclerosis B-Disease
patients O
. O

in O
november O
2002 O
, O
a O
meeting O
was O
held O
in O
florence O
, O
bringing O
together O
a O
number O
of O
experts O
in O
various O
fields O
, O
including O
rheumatology O
, O
cardiology O
, O
neurology O
, O
pharmacology O
and O
transplantation O
medicine O
. O

the O
object O
of O
the O
meeting O
was O
to O
analyse O
existing O
data O
, O
both O
published O
or O
available O
, O
in O
the O
european O
group O
for O
blood O
and O
marrow O
transplantation O
autoimmune B-Disease
disease B-Disease
database O
, O
and O
to O
propose O
a O
safe O
approach O
to O
such O
patients O
. O

a O
full O
cardiological O
assessment O
before O
and O
during O
the O
transplant O
emerged O
as O
the O
major O
recommendation O
. O

does O
supplemental O
vitamin O
c O
increase O
cardiovascular B-Disease
disease B-Disease
risk O
in O
women O
with O
diabetes B-Disease
? O

background O
: O
vitamin O
c O
acts O
as O
a O
potent O
antioxidant O
; O
however O
, O
it O
can O
also O
be O
a O
prooxidant O
and O
glycate O
protein O
under O
certain O
circumstances O
in O
vitro O
. O

these O
observations O
led O
us O
to O
hypothesize O
that O
a O
high O
intake O
of O
vitamin O
c O
in O
diabetic B-Disease
persons O
might O
promote O
atherosclerosis B-Disease
. O

objective O
: O
the O
objective O
was O
to O
examine O
the O
relation O
between O
vitamin O
c O
intake O
and O
mortality O
from O
cardiovascular B-Disease
disease B-Disease
. O

design O
: O
we O
studied O
the O
relation O
between O
vitamin O
c O
intake O
and O
mortality O
from O
total O
cardiovascular B-Disease
disease B-Disease
( O
n O
= O
281 O
) O
, O
coronary B-Disease
artery B-Disease
disease B-Disease
( O
n O
= O
175 O
) O
, O
and O
stroke B-Disease
( O
n O
= O
57 O
) O
in O
1923 O
postmenopausal O
women O
who O
reported O
being O
diabetic B-Disease
at O
baseline O
. O

diet O
was O
assessed O
with O
a O
food O
- O
frequency O
questionnaire O
at O
baseline O
, O
and O
subjects O
initially O
free O
of O
coronary B-Disease
artery B-Disease
disease B-Disease
were O
prospectively O
followed O
for O
15 O
y O
. O

results O
: O
after O
adjustment O
for O
cardiovascular B-Disease
disease B-Disease
risk O
factors O
, O
type O
of O
diabetes B-Disease
medication O
used O
, O
duration O
of O
diabetes B-Disease
, O
and O
intakes O
of O
folate O
, O
vitamin O
e O
, O
and O
beta O
- O
carotene O
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular B-Disease
disease B-Disease
mortality O
were O
1 O
. O
0 O
, O
0 O
. O
97 O
, O
1 O
. O
11 O
, O
1 O
. O
47 O
, O
and O
1 O
. O
84 O
( O
p O
for O
trend O
< O
0 O
. O
01 O
) O
across O
quintiles O
of O
total O
vitamin O
c O
intake O
from O
food O
and O
supplements O
. O

adjusted O
relative O
risks O
of O
coronary B-Disease
artery B-Disease
disease B-Disease
were O
1 O
. O
0 O
, O
0 O
. O
81 O
, O
0 O
. O
99 O
, O
1 O
. O
26 O
, O
and O
1 O
. O
91 O
( O
p O
for O
trend O
= O
0 O
. O
01 O
) O
and O
of O
stroke B-Disease
were O
1 O
. O
0 O
, O
0 O
. O
52 O
, O
1 O
. O
23 O
, O
2 O
. O
22 O
, O
and O
2 O
. O
57 O
( O
p O
for O
trend O
< O
0 O
. O
01 O
) O
. O

when O
dietary O
and O
supplemental O
vitamin O
c O
were O
analyzed O
separately O
, O
only O
supplemental O
vitamin O
c O
showed O
a O
positive O
association O
with O
mortality O
endpoints O
. O

vitamin O
c O
intake O
was O
unrelated O
to O
mortality O
from O
cardiovascular B-Disease
disease B-Disease
in O
the O
nondiabetic O
subjects O
at O
baseline O
. O

conclusion O
: O
a O
high O
vitamin O
c O
intake O
from O
supplements O
is O
associated O
with O
an O
increased O
risk O
of O
cardiovascular B-Disease
disease B-Disease
mortality O
in O
postmenopausal O
women O
with O
diabetes B-Disease
. O

optical O
coherence O
tomography O
can O
measure O
axonal O
loss O
in O
patients O
with O
ethambutol O
- O
induced O
optic B-Disease
neuropathy B-Disease
. O

purpose O
: O
to O
map O
and O
identify O
the O
pattern O
, O
in O
vivo O
, O
of O
axonal B-Disease
degeneration B-Disease
in O
ethambutol O
- O
induced O
optic B-Disease
neuropathy B-Disease
using O
optical O
coherence O
tomography O
( O
oct O
) O
. O

ethambutol O
is O
an O
antimycobacterial O
agent O
often O
used O
to O
treat O
tuberculosis B-Disease
. O

a O
serious O
complication O
of O
ethambutol O
is O
an O
optic B-Disease
neuropathy B-Disease
that O
impairs O
visual O
acuity O
, O
contrast O
sensitivity O
, O
and O
color O
vision O
. O

however O
, O
early O
on O
, O
when O
the O
toxic O
optic B-Disease
neuropathy B-Disease
is O
mild O
and O
partly O
reversible O
, O
the O
funduscopic O
findings O
are O
often O
subtle O
and O
easy O
to O
miss O
. O

methods O
: O
three O
subjects O
with O
a O
history O
of O
ethambutol O
( O
emb O
) O
- O
induced O
optic B-Disease
neuropathy B-Disease
of O
short O
- O
, O
intermediate O
- O
, O
and O
long O
- O
term O
visual B-Disease
deficits B-Disease
were O
administered O
a O
full O
neuro O
- O
ophthalmologic O
examination O
including O
visual O
acuity O
, O
color O
vision O
, O
contrast O
sensitivity O
, O
and O
fundus O
examination O
. O

in O
addition O
, O
oct O
( O
oct O
3000 O
, O
humphrey O
- O
zeiss O
, O
dublin O
, O
ca O
) O
was O
performed O
on O
both O
eyes O
of O
each O
subject O
using O
the O
retinal O
nerve O
fiber O
layer O
( O
rnfl O
) O
analysis O
protocol O
. O

oct O
interpolates O
data O
from O
100 O
points O
around O
the O
optic O
nerve O
to O
effectively O
map O
out O
the O
rnfl O
. O

results O
: O
the O
results O
were O
compared O
to O
the O
calculated O
average O
rnfl O
of O
normal O
eyes O
accumulated O
from O
four O
prior O
studies O
using O
oct O
, O
n O
= O
661 O
. O

in O
all O
subjects O
with O
history O
of O
emb O
- O
induced O
optic B-Disease
neuropathy B-Disease
, O
there O
was O
a O
mean O
loss O
of O
72 O
% O
nerve O
fiber O
layer O
thickness O
in O
the O
temporal O
quadrant O
( O
patient O
a O
, O
with O
eventual O
recovery O
of O
visual O
acuity O
and O
fields O
, O
58 O
% O
loss O
; O
patient O
b O
, O
with O
intermediate O
visual B-Disease
deficits B-Disease
, O
68 O
% O
loss O
; O
patient O
c O
, O
with O
chronic O
visual B-Disease
deficits B-Disease
, O
90 O
% O
loss O
) O
, O
with O
an O
average O
mean O
optic O
nerve O
thickness O
of O
26 O
+ O
/ O
- O
16 O
microm O
. O

there O
was O
a O
combined O
mean O
loss O
of O
46 O
% O
of O
fibers O
from O
the O
superior O
, O
inferior O
, O
and O
nasal O
quadrants O
in O
the O
( O
six O
) O
eyes O
of O
all O
three O
subjects O
( O
mean O
average O
thickness O
of O
55 O
+ O
/ O
- O
29 O
microm O
) O
. O

in O
both O
sets O
( O
four O
) O
of O
eyes O
of O
the O
subjects O
with O
persistent O
visual B-Disease
deficits B-Disease
( O
patients O
b O
and O
c O
) O
, O
there O
was O
an O
average O
loss O
of O
79 O
% O
of O
nerve O
fiber O
thickness O
in O
the O
temporal O
quadrant O
. O

conclusions O
: O
the O
oct O
results O
in O
these O
patients O
with O
emb O
- O
induced O
optic B-Disease
neuropathy B-Disease
show O
considerable O
loss O
especially O
of O
the O
temporal O
fibers O
. O

this O
is O
consistent O
with O
prior O
histopathological O
studies O
that O
show O
predominant O
loss O
of O
parvo O
- O
cellular O
axons O
( O
or O
small O
- O
caliber O
axons O
) O
within O
the O
papillo O
- O
macular O
bundle O
in O
toxic O
or O
hereditary O
optic B-Disease
neuropathies B-Disease
. O

oct O
can O
be O
a O
valuable O
tool O
in O
the O
quantitative O
analysis O
of O
optic B-Disease
neuropathies B-Disease
. O

additionally O
, O
in O
terms O
of O
management O
of O
emb O
- O
induced O
optic B-Disease
neuropathy B-Disease
, O
it O
is O
important O
to O
properly O
manage O
ethambutol O
dosing O
in O
patients O
with O
renal B-Disease
impairment B-Disease
and O
to O
achieve O
proper O
transition O
to O
a O
maintenance O
dose O
once O
an O
appropriate O
loading O
dose O
has O
been O
reached O
. O

hypoxia B-Disease
in O
renal B-Disease
disease B-Disease
with O
proteinuria B-Disease
and O
/ O
or O
glomerular O
hypertension B-Disease
. O

despite O
the O
increasing O
need O
to O
identify O
and O
quantify O
tissue O
oxygenation O
at O
the O
cellular O
level O
, O
relatively O
few O
methods O
have O
been O
available O
. O

in O
this O
study O
, O
we O
developed O
a O
new O
hypoxia B-Disease
- O
responsive O
reporter O
vector O
using O
a O
hypoxia B-Disease
- O
responsive O
element O
of O
the O
5 O
' O
vascular O
endothelial O
growth O
factor O
untranslated O
region O
and O
generated O
a O
novel O
hypoxia B-Disease
- O
sensing O
transgenic O
rat O
. O

we O
then O
applied O
this O
animal O
model O
to O
the O
detection O
of O
tubulointerstitial O
hypoxia B-Disease
in O
the O
diseased B-Disease
kidney B-Disease
. O

with O
this O
model O
, O
we O
were O
able O
to O
identify O
diffuse O
cortical O
hypoxia B-Disease
in O
the O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome B-Disease
and O
focal O
and O
segmental O
hypoxia B-Disease
in O
the O
remnant O
kidney O
model O
. O

expression O
of O
the O
hypoxia B-Disease
- O
responsive O
transgene O
increased O
throughout O
the O
observation O
period O
, O
reaching O
2 O
. O
2 O
- O
fold O
at O
2 O
weeks O
in O
the O
puromycin O
aminonucleoside O
model O
and O
2 O
. O
6 O
- O
fold O
at O
4 O
weeks O
in O
the O
remnant O
kidney O
model O
, O
whereas O
that O
of O
vascular O
endothelial O
growth O
factor O
showed O
a O
mild O
decrease O
, O
reflecting O
distinct O
behaviors O
of O
the O
two O
genes O
. O

the O
degree O
of O
hypoxia B-Disease
showed O
a O
positive O
correlation O
with O
microscopic O
tubulointerstitial B-Disease
injury B-Disease
in O
both O
models O
. O

finally O
, O
we O
identified O
the O
localization O
of O
proliferating O
cell O
nuclear O
antigen O
- O
positive O
, O
ed O
- O
1 O
- O
positive O
, O
and O
terminal O
dutp O
nick O
- O
end O
labeled O
- O
positive O
cells O
in O
the O
hypoxic B-Disease
cortical O
area O
in O
the O
remnant O
kidney O
model O
. O

we O
propose O
here O
a O
possible O
pathological O
tie O
between O
chronic O
tubulointerstitial O
hypoxia B-Disease
and O
progressive O
glomerular B-Disease
diseases B-Disease
. O

adequate O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis B-Disease
during O
combination O
therapy O
of O
interferon O
and O
ribavirin O
for O
chronic B-Disease
hepatitis B-Disease
c B-Disease
. O

background O
: O
hemolytic B-Disease
anemia B-Disease
is O
one O
of O
the O
major O
adverse O
events O
of O
the O
combination O
therapy O
of O
interferon O
and O
ribavirin O
. O

because O
of O
ribavirin O
- O
related O
hemolytic B-Disease
anemia B-Disease
, O
dose O
reduction O
is O
a O
common O
event O
in O
this O
therapy O
. O

in O
this O
clinical O
retrospective O
cohort O
study O
we O
have O
examined O
the O
suitable O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis B-Disease
during O
combination O
therapy O
. O

methods O
: O
thirty O
- O
seven O
of O
160 O
patients O
who O
had O
hcv O
- O
genotype O
1b O
, O
had O
high O
virus O
load O
, O
and O
received O
24 O
- O
week O
combination O
therapy O
developed O
anemia B-Disease
with O
hemoglobin O
level O
< O
10 O
g O
/ O
dl O
or O
anemia B-Disease
- O
related O
signs O
during O
therapy O
. O

after O
that O
, O
these O
37 O
patients O
were O
reduced O
one O
tablet O
of O
ribavirin O
( O
200 O
mg O
) O
per O
day O
. O

after O
reduction O
of O
ribavirin O
, O
27 O
of O
37 O
patients O
could O
continue O
combination O
therapy O
for O
a O
total O
of O
24 O
weeks O
( O
group O
a O
) O
. O

however O
, O
10 O
of O
37 O
patients O
with O
reduction O
of O
ribavirin O
could O
not O
continue O
combination O
therapy O
because O
their O
< O
8 O
. O
5 O
g O
/ O
dl O
hemoglobin O
values O
decreased O
to O
or O
anemia B-Disease
- O
related O
severe O
side O
effects O
occurred O
( O
group O
b O
) O
. O

we O
assessed O
the O
final O
efficacy O
and O
safety O
after O
reduction O
of O
ribavirin O
in O
groups O
a O
and O
b O
. O

results O
: O
a O
sustained O
virological O
response O
( O
svr O
) O
was O
29 O
. O
6 O
% O
( O
8 O
/ O
27 O
) O
in O
group O
a O
and O
10 O
% O
( O
1 O
/ O
10 O
) O
in O
group O
b O
, O
respectively O
. O

a O
34 O
. O
4 O
% O
( O
12 O
/ O
27 O
) O
of O
svr O
+ O
biological O
response O
in O
group O
a O
was O
higher O
than O
10 O
% O
( O
1 O
/ O
10 O
) O
in O
group O
b O
( O
p O
= O
0 O
. O
051 O
) O
, O
with O
slight O
significance O
. O

with O
respect O
to O
hemoglobin O
level O
at O
the O
time O
of O
ribavirin O
reduction O
, O
a O
rate O
of O
continuation O
of O
therapy O
in O
patients O
with O
> O
or O
= O
10 O
g O
/ O
dl O
hemoglobin O
was O
higher O
than O
that O
in O
patients O
with O
< O
10 O
g O
/ O
dl O
( O
p O
= O
0 O
. O
036 O
) O
. O

conclusions O
: O
reduction O
of O
ribavirin O
at O
hemoglobin O
level O
> O
or O
= O
10 O
g O
/ O
dl O
is O
suitable O
in O
terms O
of O
efficacy O
and O
side O
effects O
. O

aging O
process O
of O
epithelial O
cells O
of O
the O
rat O
prostate O
lateral O
lobe O
in O
experimental O
hyperprolactinemia B-Disease
induced O
by O
haloperidol O
. O

the O
aim O
of O
the O
study O
was O
to O
examine O
the O
influence O
of O
hyperprolactinemia B-Disease
, O
induced O
by O
haloperidol O
( O
hal O
) O
on O
age O
related O
morphology O
and O
function O
changes O
of O
epithelial O
cells O
in O
rat O
prostate O
lateral O
lobe O
. O

the O
study O
was O
performed O
on O
sexually O
mature O
male O
rats O
. O

serum O
concentrations O
of O
prolactin O
( O
prl O
) O
and O
testosterone O
( O
t O
) O
were O
measured O
. O

tissue O
sections O
were O
evaluated O
with O
light O
and O
electron O
microscopy O
. O

immunohistochemical O
reactions O
for O
anti O
- O
proliferating O
cell O
nuclear O
antigen O
( O
pcna O
) O
were O
performed O
. O

in O
rats O
of O
the O
experimental O
group O
, O
the O
mean O
concentration O
of O
: O
prl O
was O
more O
than O
twice O
higher O
, O
whereas O
t O
concentration O
was O
almost O
twice O
lower O
than O
that O
in O
the O
control O
group O
. O

light O
microscopy O
visualized O
the O
following O
: O
hypertrophy B-Disease
and O
epithelium O
hyperplasia B-Disease
of O
the O
glandular O
ducts O
, O
associated O
with O
increased O
pcna O
expression O
. O

electron O
microscopy O
revealed O
changes O
in O
columnar O
epithelial O
cells O
, O
concerning O
organelles O
, O
engaged O
in O
protein O
synthesis O
and O
secretion O
. O

relation O
of O
perfusion O
defects O
observed O
with O
myocardial O
contrast O
echocardiography O
to O
the O
severity O
of O
coronary B-Disease
stenosis B-Disease
: O
correlation O
with O
thallium O
- O
201 O
single O
- O
photon O
emission O
tomography O
. O

it O
has O
been O
previously O
shown O
that O
myocardial O
contrast O
echocardiography O
is O
a O
valuable O
technique O
for O
delineating O
regions O
of O
myocardial O
underperfusion O
secondary O
to O
coronary B-Disease
occlusion B-Disease
and O
to O
critical O
coronary B-Disease
stenoses B-Disease
in O
the O
presence O
of O
hyperemic B-Disease
stimulation O
. O

the O
aim O
of O
this O
study O
was O
to O
determine O
whether O
myocardial O
contrast O
echocardiography O
performed O
with O
a O
stable O
solution O
of O
sonicated O
albumin O
could O
detect O
regions O
of O
myocardial O
underperfusion O
resulting O
from O
various O
degrees O
of O
coronary B-Disease
stenosis B-Disease
. O

the O
perfusion O
defect O
produced O
in O
16 O
open O
chest O
dogs O
was O
compared O
with O
the O
anatomic O
area O
at O
risk O
measured O
by O
the O
postmortem O
dual O
- O
perfusion O
technique O
and O
with O
thallium O
- O
201 O
single O
- O
photon O
emission O
tomography O
( O
spect O
) O
. O

during O
a O
transient O
( O
20 O
- O
s O
) O
coronary B-Disease
occlusion B-Disease
, O
a O
perfusion O
defect O
was O
observed O
with O
contrast O
echocardiography O
in O
14 O
of O
the O
15 O
dogs O
in O
which O
the O
occlusion O
was O
produced O
. O

the O
perfusion O
defect O
correlated O
significantly O
with O
the O
anatomic O
area O
at O
risk O
( O
r O
= O
0 O
. O
74 O
; O
p O
less O
than O
0 O
. O
002 O
) O
. O

during O
dipyridamole O
- O
induced O
hyperemia B-Disease
, O
12 O
of O
the O
16 O
dogs O
with O
a O
partial O
coronary B-Disease
stenosis B-Disease
had O
a O
visible O
area O
of O
hypoperfusion O
by O
contrast O
echocardiography O
. O

the O
four O
dogs O
without O
a O
perfusion O
defect O
had O
a O
stenosis O
that O
resulted O
in O
a O
mild O
( O
0 O
% O
to O
50 O
% O
) O
reduction O
in O
dipyridamole O
- O
induced O
hyperemia B-Disease
. O

the O
size O
of O
the O
perfusion O
defect O
during O
stenosis O
correlated O
significantly O
with O
the O
anatomic O
area O
at O
risk O
( O
r O
= O
0 O
. O
61 O
; O
p O
= O
0 O
. O
02 O
) O
. O

thallium O
- O
201 O
spect O
demonstrated O
a O
perfusion O
defect O
in O
all O
14 O
dogs O
analyzed O
during O
dipyridamole O
- O
induced O
hyperemia B-Disease
; O
the O
size O
of O
the O
perfusion O
defect O
correlated O
with O
the O
anatomic O
area O
at O
risk O
( O
r O
= O
0 O
. O
58 O
; O
p O
less O
than O
0 O
. O
03 O
) O
and O
with O
the O
perfusion O
defect O
by O
contrast O
echocardiography O
( O
r O
= O
0 O
. O
58 O
; O
p O
less O
than O
0 O
. O
03 O
) O
. O

thus O
, O
myocardial O
contrast O
echocardiography O
can O
be O
used O
to O
visualize O
and O
quantitate O
the O
amount O
of O
jeopardized O
myocardium O
during O
moderate O
to O
severe O
degrees O
of O
coronary B-Disease
stenosis B-Disease
. O

the O
results O
obtained O
show O
a O
correlation O
with O
the O
anatomic O
area O
at O
risk O
similar O
to O
that O
obtained O
with O
thallium O
- O
201 O
spect O
. O

the O
activation O
of O
spinal O
n O
- O
methyl O
- O
d O
- O
aspartate O
receptors O
may O
contribute O
to O
degeneration O
of O
spinal O
motor O
neurons O
induced O
by O
neuraxial O
morphine O
after O
a O
noninjurious O
interval O
of O
spinal B-Disease
cord B-Disease
ischemia B-Disease
. O

we O
investigated O
the O
relationship O
between O
the O
degeneration O
of O
spinal O
motor O
neurons O
and O
activation O
of O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptors O
after O
neuraxial O
morphine O
following O
a O
noninjurious O
interval O
of O
aortic B-Disease
occlusion B-Disease
in O
rats O
. O

spinal B-Disease
cord B-Disease
ischemia B-Disease
was O
induced O
by O
aortic B-Disease
occlusion B-Disease
for O
6 O
min O
with O
a O
balloon O
catheter O
. O

in O
a O
microdialysis O
study O
, O
10 O
mul O
of O
saline O
( O
group O
c O
; O
n O
= O
8 O
) O
or O
30 O
mug O
of O
morphine O
( O
group O
m O
; O
n O
= O
8 O
) O
was O
injected O
intrathecally O
( O
it O
) O
0 O
. O
5 O
h O
after O
reflow O
, O
and O
30 O
mug O
of O
morphine O
( O
group O
sm O
; O
n O
= O
8 O
) O
or O
10 O
mul O
of O
saline O
( O
group O
sc O
; O
n O
= O
8 O
) O
was O
injected O
it O
0 O
. O
5 O
h O
after O
sham O
operation O
. O

microdialysis O
samples O
were O
collected O
preischemia O
, O
before O
it O
injection O
, O
and O
at O
2 O
, O
4 O
, O
8 O
, O
24 O
, O
and O
48 O
h O
of O
reperfusion O
( O
after O
it O
injection O
) O
. O

second O
, O
we O
investigated O
the O
effect O
of O
it O
mk O
- O
801 O
( O
30 O
mug O
) O
on O
the O
histopathologic O
changes O
in O
the O
spinal O
cord O
after O
morphine O
- O
induced O
spastic B-Disease
paraparesis B-Disease
. O

after O
it O
morphine O
, O
the O
cerebrospinal O
fluid O
( O
csf O
) O
glutamate O
concentration O
was O
increased O
in O
group O
m O
relative O
to O
both O
baseline O
and O
group O
c O
( O
p O
< O
0 O
. O
05 O
) O
. O

this O
increase O
persisted O
for O
8 O
hrs O
. O

it O
mk O
- O
801 O
significantly O
reduced O
the O
number O
of O
dark O
- O
stained O
alpha O
- O
motoneurons O
after O
morphine O
- O
induced O
spastic B-Disease
paraparesis B-Disease
compared O
with O
the O
saline O
group O
. O

these O
data O
indicate O
that O
it O
morphine O
induces O
spastic B-Disease
paraparesis B-Disease
with O
a O
concomitant O
increase O
in O
csf O
glutamate O
, O
which O
is O
involved O
in O
nmda O
receptor O
activation O
. O

we O
suggest O
that O
opioids O
may O
be O
neurotoxic B-Disease
in O
the O
setting O
of O
spinal B-Disease
cord B-Disease
ischemia B-Disease
via O
nmda O
receptor O
activation O
. O

acute O
low B-Disease
back B-Disease
pain B-Disease
during O
intravenous O
administration O
of O
amiodarone O
: O
a O
report O
of O
two O
cases O
. O

amiodarone O
represents O
an O
effective O
antiarrhythmic O
drug O
for O
cardioversion O
of O
recent O
- O
onset O
atrial B-Disease
fibrillation B-Disease
( O
af B-Disease
) O
and O
maintenance O
of O
sinus O
rhythm O
. O

we O
briefly O
describe O
two O
patients O
suffering O
from O
recent O
- O
onset O
atrial B-Disease
fibrillation B-Disease
, O
who O
experienced O
an O
acute O
devastating O
low B-Disease
back B-Disease
pain B-Disease
a O
few O
minutes O
after O
initiation O
of O
intravenous O
amiodarone O
loading O
. O

notably O
, O
this O
side O
effect O
has O
not O
been O
ever O
reported O
in O
the O
medical O
literature O
. O

clinicians O
should O
be O
aware O
of O
this O
reaction O
since O
prompt O
termination O
of O
parenteral O
administration O
leads O
to O
complete O
resolution O
. O

quantitative O
drug O
levels O
in O
stimulant O
psychosis B-Disease
: O
relationship O
to O
symptom O
severity O
, O
catecholamines O
and O
hyperkinesia B-Disease
. O

to O
examine O
the O
relationship O
between O
quantitative O
stimulant O
drug O
levels O
, O
catecholamines O
, O
and O
psychotic B-Disease
symptoms B-Disease
, O
nineteen O
patients O
in O
a O
psychiatric B-Disease
emergency O
service O
with O
a O
diagnosis O
of O
amphetamine O
- O
or O
cocaine O
- O
induced O
psychosis B-Disease
were O
interviewed O
, O
and O
plasma O
and O
urine O
were O
collected O
for O
quantitative O
assays O
of O
stimulant O
drug O
and O
catecholamine O
metabolite O
levels O
. O

methamphetamine O
or O
amphetamine O
levels O
were O
related O
to O
several O
psychopathology O
scores O
and O
the O
global O
hyperkinesia B-Disease
rating O
. O

hva O
levels O
were O
related O
to O
global O
hyperkinesia B-Disease
but O
not O
to O
psychopathology O
ratings O
. O

although O
many O
other O
factors O
such O
as O
sensitization O
may O
play O
a O
role O
, O
intensity O
of O
stimulant O
- O
induced O
psychotic B-Disease
symptoms B-Disease
and O
stereotypies B-Disease
appears O
to O
be O
at O
least O
in O
part O
dose O
- O
related O
. O

pheochromocytoma B-Disease
unmasked O
by O
amisulpride O
and O
tiapride O
. O

objective O
: O
to O
describe O
the O
unmasking O
of O
pheochromocytoma B-Disease
in O
a O
patient O
treated O
with O
amisulpride O
and O
tiapride O
. O

case O
summary O
: O
a O
42 O
- O
year O
- O
old O
white O
man O
developed O
acute O
hypertension B-Disease
with O
severe O
headache B-Disease
and O
vomiting B-Disease
2 O
hours O
after O
the O
first O
doses O
of O
amisulpride O
100 O
mg O
and O
tiapride O
100 O
mg O
. O

both O
drugs O
were O
immediately O
discontinued O
, O
and O
the O
patient O
recovered O
after O
subsequent O
nicardipine O
and O
verapamil O
treatment O
. O

abdominal O
ultrasound O
showed O
an O
adrenal O
mass O
, O
and O
postoperative O
histologic O
examination O
confirmed O
the O
diagnosis O
of O
pheochromocytoma B-Disease
. O

discussion O
: O
drug O
- O
induced O
symptoms O
of O
pheochromocytoma B-Disease
are O
often O
associated O
with O
the O
use O
of O
substituted O
benzamide O
drugs O
, O
but O
the O
underlying O
mechanism O
is O
unknown O
. O

in O
our O
case O
, O
use O
of O
the O
naranjo O
probability O
scale O
indicated O
a O
possible O
relationship O
between O
the O
hypertensive B-Disease
crisis O
and O
amisulpride O
and O
tiapride O
therapy O
. O

conclusions O
: O
as O
of O
march O
24 O
, O
2005 O
, O
this O
is O
the O
first O
reported O
case O
of O
amisulpride O
- O
and O
tiapride O
- O
induced O
hypertensive B-Disease
crisis O
in O
a O
patient O
with O
pheochromocytoma B-Disease
. O

physicians O
and O
other O
healthcare O
professionals O
should O
be O
aware O
of O
this O
potential O
adverse O
effect O
of O
tiapride O
and O
amisulpride O
. O

minor O
neurological B-Disease
dysfunction B-Disease
, O
cognitive O
development O
, O
and O
somatic O
development O
at O
the O
age O
of O
3 O
to O
7 O
years O
after O
dexamethasone O
treatment O
in O
very O
- O
low O
birth O
- O
weight O
infants O
. O

the O
objective O
of O
this O
study O
was O
to O
assess O
minor O
neurological B-Disease
dysfunction B-Disease
, O
cognitive O
development O
, O
and O
somatic O
development O
after O
dexamethasone O
therapy O
in O
very O
- O
low O
- O
birthweight O
infants O
. O

thirty O
- O
three O
children O
after O
dexamethasone O
treatment O
were O
matched O
to O
33 O
children O
without O
dexamethasone O
treatment O
. O

data O
were O
assessed O
at O
the O
age O
of O
3 O
- O
7 O
years O
. O

dexamethasone O
was O
started O
between O
the O
7th O
and O
the O
28th O
day O
of O
life O
over O
7 O
days O
with O
a O
total O
dose O
of O
2 O
. O
35 O
mg O
/ O
kg O
/ O
day O
. O

exclusion O
criteria O
were O
asphyxia B-Disease
, O
malformations B-Disease
, O
major O
surgical O
interventions O
, O
small O
for O
gestational O
age O
, O
intraventricular O
haemorrhage B-Disease
grades O
iii O
and O
iv O
, O
periventricular B-Disease
leukomalacia B-Disease
, O
and O
severe O
psychomotor B-Disease
retardation B-Disease
. O

each O
child O
was O
examined O
by O
a O
neuropediatrician O
for O
minor O
neurological B-Disease
dysfunctions B-Disease
and O
tested O
by O
a O
psychologist O
for O
cognitive O
development O
with O
a O
kaufman O
assessment O
battery O
for O
children O
and O
a O
draw O
- O
a O
- O
man O
test O
. O

there O
were O
no O
differences O
in O
demographic O
data O
, O
growth O
, O
and O
socio O
- O
economic O
status O
between O
the O
two O
groups O
. O

fine O
motor O
skills O
and O
gross O
motor O
function O
were O
significantly O
better O
in O
the O
control O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

in O
the O
draw O
- O
a O
- O
man O
test O
, O
the O
control O
group O
showed O
better O
results O
( O
p O
< O
0 O
. O
001 O
) O
. O

there O
were O
no O
differences O
in O
development O
of O
speech O
, O
social O
development O
, O
and O
the O
kaufman O
assessment O
battery O
for O
children O
. O

after O
dexamethasone O
treatment O
, O
children O
showed O
a O
higher O
rate O
of O
minor O
neurological B-Disease
dysfunctions B-Disease
. O

neurological O
development O
was O
affected O
even O
without O
neurological O
diagnosis O
. O

further O
long O
- O
term O
follow O
- O
up O
studies O
will O
be O
necessary O
to O
fully O
evaluate O
the O
impact O
of O
dexamethasone O
on O
neurological O
and O
cognitive O
development O
. O

valproic O
acid O
i O
: O
time O
course O
of O
lipid O
peroxidation O
biomarkers O
, O
liver B-Disease
toxicity B-Disease
, O
and O
valproic O
acid O
metabolite O
levels O
in O
rats O
. O

a O
single O
dose O
of O
valproic O
acid O
( O
vpa O
) O
, O
which O
is O
a O
widely O
used O
antiepileptic O
drug O
, O
is O
associated O
with O
oxidative O
stress O
in O
rats O
, O
as O
recently O
demonstrated O
by O
elevated O
levels O
of O
15 O
- O
f O
( O
2t O
) O
- O
isoprostane O
( O
15 O
- O
f O
( O
2t O
) O
- O
isop O
) O
. O

to O
determine O
whether O
there O
was O
a O
temporal O
relationship O
between O
vpa O
- O
associated O
oxidative O
stress O
and O
hepatotoxicity B-Disease
, O
adult O
male O
sprague O
- O
dawley O
rats O
were O
treated O
ip O
with O
vpa O
( O
500 O
mg O
/ O
kg O
) O
or O
0 O
. O
9 O
% O
saline O
( O
vehicle O
) O
once O
daily O
for O
2 O
, O
4 O
, O
7 O
, O
10 O
, O
or O
14 O
days O
. O

oxidative O
stress O
was O
assessed O
by O
determining O
plasma O
and O
liver O
levels O
of O
15 O
- O
f O
( O
2t O
) O
- O
isop O
, O
lipid O
hydroperoxides O
( O
lpo O
) O
, O
and O
thiobarbituric O
acid O
reactive O
substances O
( O
tbars O
) O
. O

plasma O
and O
liver O
15 O
- O
f O
( O
2t O
) O
- O
isop O
were O
elevated O
and O
reached O
a O
plateau O
after O
day O
2 O
of O
vpa O
treatment O
compared O
to O
control O
. O

liver O
lpo O
levels O
were O
not O
elevated O
until O
day O
7 O
of O
treatment O
( O
1 O
. O
8 O
- O
fold O
versus O
control O
, O
p O
< O
0 O
. O
05 O
) O
. O

liver O
and O
plasma O
tbars O
were O
not O
increased O
until O
14 O
days O
( O
2 O
- O
fold O
vs O
. O
control O
, O
p O
< O
0 O
. O
05 O
) O
. O

liver B-Disease
toxicity B-Disease
was O
evaluated O
based O
on O
serum O
levels O
of O
alpha O
- O
glutathione O
s O
- O
transferase O
( O
alpha O
- O
gst O
) O
and O
by O
histology O
. O

serum O
alpha O
- O
gst O
levels O
were O
significantly O
elevated O
by O
day O
4 O
, O
which O
corresponded O
to O
hepatotoxicity B-Disease
as O
shown O
by O
the O
increasing O
incidence O
of O
inflammation B-Disease
of O
the O
liver O
capsule O
, O
necrosis B-Disease
, O
and O
steatosis B-Disease
throughout O
the O
study O
. O

the O
liver O
levels O
of O
beta O
- O
oxidation O
metabolites O
of O
vpa O
were O
decreased O
by O
day O
14 O
, O
while O
the O
levels O
of O
4 O
- O
ene O
- O
vpa O
and O
( O
e O
) O
- O
2 O
, O
4 O
- O
diene O
- O
vpa O
were O
not O
elevated O
throughout O
the O
study O
. O

overall O
, O
these O
findings O
indicate O
that O
vpa O
treatment O
results O
in O
oxidative O
stress O
, O
as O
measured O
by O
levels O
of O
15 O
- O
f O
( O
2t O
) O
- O
isop O
, O
which O
precedes O
the O
onset O
of O
necrosis B-Disease
, O
steatosis B-Disease
, O
and O
elevated O
levels O
of O
serum O
alpha O
- O
gst O
. O

assessment O
of O
perinatal O
hepatitis B-Disease
b B-Disease
and O
rubella B-Disease
prevention O
in O
new O
hampshire O
delivery O
hospitals O
. O

objective O
: O
to O
evaluate O
current O
performance O
on O
recommended O
perinatal O
hepatitis B-Disease
b B-Disease
and O
rubella B-Disease
prevention O
practices O
in O
new O
hampshire O
. O

methods O
: O
data O
were O
extracted O
from O
2021 O
paired O
mother O
- O
infant O
records O
for O
the O
year O
2000 O
birth O
cohort O
in O
new O
hampshire O
' O
s O
25 O
delivery O
hospitals O
. O

assessment O
was O
done O
on O
the O
following O
: O
prenatal O
screening O
for O
hepatitis B-Disease
b B-Disease
and O
rubella B-Disease
, O
administration O
of O
the O
hepatitis B-Disease
b B-Disease
vaccine O
birth O
dose O
to O
all O
infants O
, O
administration O
of O
hepatitis B-Disease
b B-Disease
immune O
globulin O
to O
infants O
who O
were O
born O
to O
hepatitis O
b O
surface O
antigen O
- O
positive O
mothers O
, O
rubella B-Disease
immunity O
, O
and O
administration O
of O
in O
- O
hospital O
postpartum O
rubella B-Disease
vaccine O
to O
rubella B-Disease
nonimmune O
women O
. O

results O
: O
prenatal O
screening O
rates O
for O
hepatitis B-Disease
b B-Disease
( O
98 O
. O
8 O
% O
) O
and O
rubella B-Disease
( O
99 O
. O
4 O
% O
) O
were O
high O
. O

hepatitis B-Disease
b B-Disease
vaccine O
birth O
dose O
was O
administered O
to O
76 O
. O
2 O
% O
of O
all O
infants O
. O

all O
infants O
who O
were O
born O
to O
hepatitis O
b O
surface O
antigen O
- O
positive O
mothers O
also O
received O
hepatitis B-Disease
b B-Disease
immune O
globulin O
. O

multivariate O
logistic O
regression O
showed O
that O
the O
month O
of O
delivery O
and O
infant O
birth O
weight O
were O
independent O
predictors O
of O
hepatitis B-Disease
b B-Disease
vaccination O
. O

the O
proportion O
of O
infants O
who O
were O
vaccinated O
in O
january O
and O
february O
2000 O
( O
48 O
. O
5 O
% O
and O
67 O
. O
5 O
% O
, O
respectively O
) O
was O
less O
than O
any O
other O
months O
, O
whereas O
the O
proportion O
who O
were O
vaccinated O
in O
december O
2000 O
( O
88 O
. O
2 O
% O
) O
was O
the O
highest O
. O

women O
who O
were O
born O
between O
1971 O
and O
1975 O
had O
the O
highest O
rate O
of O
rubella B-Disease
nonimmunity O
( O
9 O
. O
5 O
% O
) O
. O

in O
- O
hospital O
postpartum O
rubella B-Disease
vaccine O
administration O
was O
documented O
for O
75 O
. O
6 O
% O
of O
nonimmune O
women O
. O

conclusion O
: O
this O
study O
documents O
good O
compliance O
in O
new O
hampshire O
' O
s O
birthing O
hospitals O
with O
national O
guidelines O
for O
perinatal O
hepatitis B-Disease
b B-Disease
and O
rubella B-Disease
prevention O
and O
highlights O
potential O
areas O
for O
improvement O
. O

succinylcholine O
- O
induced O
masseter B-Disease
muscle B-Disease
rigidity B-Disease
during O
bronchoscopic O
removal O
of O
a O
tracheal O
foreign O
body O
. O

masseter B-Disease
muscle B-Disease
rigidity B-Disease
during O
general O
anesthesia O
is O
considered O
an O
early O
warning O
sign O
of O
a O
possible O
episode O
of O
malignant B-Disease
hyperthermia B-Disease
. O

the O
decision O
whether O
to O
continue O
or O
discontinue O
the O
procedure O
depends O
on O
the O
urgency O
of O
the O
surgery O
and O
severity O
of O
masseter B-Disease
muscle B-Disease
rigidity B-Disease
. O

here O
, O
we O
describe O
a O
case O
of O
severe O
masseter B-Disease
muscle B-Disease
rigidity B-Disease
( O
jaw B-Disease
of B-Disease
steel B-Disease
) O
after O
succinylcholine O
( O
sch O
) O
administration O
during O
general O
anesthetic O
management O
for O
rigid O
bronchoscopic O
removal O
of O
a O
tracheal O
foreign O
body O
. O

anesthesia O
was O
continued O
uneventfully O
with O
propofol O
infusion O
while O
all O
facilities O
were O
available O
to O
detect O
and O
treat O
malignant B-Disease
hyperthermia B-Disease
. O

dexrazoxane O
protects O
against O
myelosuppression B-Disease
from O
the O
dna O
cleavage O
- O
enhancing O
drugs O
etoposide O
and O
daunorubicin O
but O
not O
doxorubicin O
. O

purpose O
: O
the O
anthracyclines O
daunorubicin O
and O
doxorubicin O
and O
the O
epipodophyllotoxin O
etoposide O
are O
potent O
dna O
cleavage O
- O
enhancing O
drugs O
that O
are O
widely O
used O
in O
clinical O
oncology O
; O
however O
, O
myelosuppression B-Disease
and O
cardiac B-Disease
toxicity B-Disease
limit O
their O
use O
. O

dexrazoxane O
( O
icrf O
- O
187 O
) O
is O
recommended O
for O
protection O
against O
anthracycline O
- O
induced O
cardiotoxicity B-Disease
. O

experimental O
design O
: O
because O
of O
their O
widespread O
use O
, O
the O
hematologic B-Disease
toxicity B-Disease
following O
coadministration O
of O
dexrazoxane O
and O
these O
three O
structurally O
different O
dna O
cleavage O
enhancers O
was O
investigated O
: O
sensitivity O
of O
human O
and O
murine O
blood O
progenitor O
cells O
to O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
+ O
/ O
- O
dexrazoxane O
was O
determined O
in O
granulocyte O
- O
macrophage O
colony O
forming O
assays O
. O

likewise O
, O
in O
vivo O
, O
b6d2f1 O
mice O
were O
treated O
with O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
, O
with O
or O
without O
dexrazoxane O
over O
a O
wide O
range O
of O
doses O
: O
posttreatment O
, O
a O
full O
hematologic O
evaluation O
was O
done O
. O

results O
: O
nontoxic O
doses O
of O
dexrazoxane O
reduced O
myelosuppression B-Disease
and O
weight B-Disease
loss B-Disease
from O
daunorubicin O
and O
etoposide O
in O
mice O
and O
antagonized O
their O
antiproliferative O
effects O
in O
the O
colony O
assay O
; O
however O
, O
dexrazoxane O
neither O
reduced O
myelosuppression B-Disease
, O
weight B-Disease
loss B-Disease
, O
nor O
the O
in O
vitro O
cytotoxicity B-Disease
from O
doxorubicin O
. O

conclusion O
: O
although O
our O
findings O
support O
the O
observation O
that O
dexrazoxane O
reduces O
neither O
hematologic O
activity O
nor O
antitumor O
activity O
from O
doxorubicin O
clinically O
, O
the O
potent O
antagonism O
of O
daunorubicin O
activity O
raises O
concern O
; O
a O
possible O
interference O
with O
anticancer O
efficacy O
certainly O
would O
call O
for O
renewed O
attention O
. O

our O
data O
also O
suggest O
that O
significant O
etoposide O
dose O
escalation O
is O
perhaps O
possible O
by O
the O
use O
of O
dexrazoxane O
. O

clinical O
trials O
in O
patients O
with O
brain O
metastases B-Disease
combining O
dexrazoxane O
and O
high O
doses O
of O
etoposide O
is O
ongoing O
with O
the O
aim O
of O
improving O
efficacy O
without O
aggravating O
hematologic B-Disease
toxicity B-Disease
. O

if O
successful O
, O
this O
represents O
an O
exciting O
mechanism O
for O
pharmacologic O
regulation O
of O
side O
effects O
from O
cytotoxic O
chemotherapy O
. O

assessment O
of O
the O
onset O
and O
persistence O
of O
amnesia B-Disease
during O
procedural O
sedation O
with O
propofol O
. O

objectives O
: O
to O
assess O
patients O
' O
ability O
to O
repeat O
and O
recall O
words O
presented O
to O
them O
while O
undergoing O
procedural O
sedation O
with O
propofol O
, O
and O
correlate O
their O
recall O
with O
their O
level O
of O
awareness O
as O
measured O
by O
bispectral O
index O
( O
bis O
) O
monitoring O
. O

methods O
: O
this O
was O
a O
prospective O
, O
single O
- O
intervention O
study O
of O
consenting O
adult O
patients O
undergoing O
procedural O
sedation O
with O
propofol O
between O
december O
28 O
, O
2002 O
, O
and O
october O
31 O
, O
2003 O
. O

bis O
monitoring O
was O
initiated O
starting O
3 O
minutes O
before O
the O
procedure O
and O
continuing O
until O
the O
patient O
had O
regained O
baseline O
mental O
status O
. O

at O
1 O
- O
minute O
intervals O
during O
the O
procedural O
sedation O
, O
until O
the O
patient O
regained O
baseline O
mental O
status O
at O
the O
end O
of O
the O
procedure O
, O
a O
word O
from O
a O
standardized O
list O
was O
read O
aloud O
, O
and O
the O
patient O
was O
asked O
to O
immediately O
repeat O
the O
word O
to O
the O
investigator O
. O

the O
bis O
score O
at O
the O
time O
the O
word O
was O
read O
and O
the O
patient O
' O
s O
ability O
to O
repeat O
the O
word O
were O
recorded O
. O

after O
the O
procedure O
, O
the O
patient O
was O
asked O
to O
state O
all O
of O
the O
words O
from O
the O
list O
that O
he O
or O
she O
could O
recall O
, O
and O
to O
identify O
the O
last O
word O
recalled O
from O
prior O
to O
the O
start O
of O
the O
procedure O
and O
the O
first O
word O
recalled O
from O
after O
the O
procedure O
was O
completed O
. O

results O
: O
seventy O
- O
five O
consenting O
patients O
were O
enrolled O
; O
one O
patient O
was O
excluded O
from O
data O
analysis O
for O
a O
protocol O
violation O
. O

no O
serious O
adverse O
events O
were O
noted O
during O
the O
procedural O
sedations O
. O

the O
mean O
( O
+ O
/ O
- O
standard O
deviation O
) O
time O
of O
data O
collection O
was O
16 O
. O
4 O
minutes O
( O
+ O
/ O
- O
7 O
. O
1 O
; O
range O
5 O
to O
34 O
minutes O
) O
. O

the O
mean O
initial O
( O
preprocedure O
) O
bis O
score O
was O
97 O
. O
1 O
( O
+ O
/ O
- O
2 O
. O
3 O
; O
range O
92 O
to O
99 O
) O
. O

the O
mean O
lowest O
bis O
score O
occurring O
during O
these O
procedural O
sedations O
was O
66 O
. O
9 O
( O
+ O
/ O
- O
14 O
. O
4 O
; O
range O
33 O
to O
91 O
) O
. O

the O
mean O
lowest O
bis O
score O
corresponding O
to O
the O
ability O
of O
the O
patient O
to O
immediately O
repeat O
words O
read O
from O
the O
list O
was O
77 O
. O
1 O
( O
95 O
% O
ci O
= O
74 O
. O
3 O
to O
80 O
. O
0 O
) O
. O

the O
mean O
highest O
bis O
score O
corresponding O
to O
the O
inability B-Disease
to B-Disease
repeat B-Disease
words B-Disease
was O
81 O
. O
5 O
( O
95 O
% O
ci O
= O
78 O
. O
1 O
to O
84 O
. O
8 O
) O
. O

the O
mean O
bis O
score O
corresponding O
to O
the O
last O
word O
recalled O
from O
prior O
to O
the O
initiation O
of O
the O
sedation O
was O
96 O
. O
7 O
( O
+ O
/ O
- O
2 O
. O
4 O
; O
range O
84 O
to O
98 O
) O
. O

the O
mean O
bis O
score O
corresponding O
to O
the O
first O
word O
recalled O
after O
the O
procedure O
was O
completed O
was O
91 O
. O
2 O
( O
95 O
% O
ci O
= O
88 O
. O
1 O
to O
94 O
. O
3 O
) O
. O

all O
patients O
recalled O
at O
least O
one O
word O
that O
had O
been O
read O
to O
them O
during O
the O
protocol O
. O

the O
mean O
lowest O
bis O
score O
for O
any O
recalled O
word O
was O
91 O
. O
5 O
( O
+ O
/ O
- O
11 O
. O
1 O
; O
range O
79 O
to O
98 O
) O
, O
and O
no O
words O
were O
recalled O
when O
the O
corresponding O
bis O
score O
was O
less O
than O
90 O
. O

conclusions O
: O
there O
is O
a O
range O
of O
bis O
scores O
during O
which O
sedated O
patients O
are O
able O
to O
repeat O
words O
read O
to O
them O
but O
are O
not O
able O
to O
subsequently O
recall O
these O
words O
. O

furthermore O
, O
patients O
had O
no O
recall O
of O
words O
repeated O
prior O
to O
procedural O
sedation O
in O
bis O
ranges O
associated O
with O
recall O
after O
procedural O
sedation O
, O
suggestive O
of O
retrograde B-Disease
amnesia B-Disease
. O

amiodarone O
pulmonary B-Disease
toxicity B-Disease
. O

amiodarone O
is O
an O
effective O
antiarrhythmic O
agent O
whose O
utility O
is O
limited O
by O
many O
side O
- O
effects O
, O
the O
most O
problematic O
being O
pneumonitis B-Disease
. O

the O
pulmonary B-Disease
toxicity B-Disease
of O
amiodarone O
is O
thought O
to O
result O
from O
direct O
injury O
related O
to O
the O
intracellular O
accumulation O
of O
phospholipid O
and O
t O
cell O
- O
mediated O
hypersensitivity B-Disease
pneumonitis B-Disease
. O

the O
clinical O
and O
radiographic O
features O
of O
amiodarone O
- O
induced O
pulmonary B-Disease
toxicity B-Disease
are O
characteristic O
but O
nonspecific O
. O

the O
diagnosis O
depends O
on O
exclusion O
of O
other O
entities O
, O
such O
as O
heart B-Disease
failure B-Disease
, O
infection B-Disease
, O
and O
malignancy B-Disease
. O

while O
withdrawal O
of O
amiodarone O
leads O
to O
clinical O
improvement O
in O
majority O
of O
cases O
, O
this O
is O
not O
always O
possible O
or O
advisable O
. O

dose O
reduction O
or O
concomitant O
steroid O
therapy O
may O
have O
a O
role O
in O
selected O
patients O
. O

two O
prodrugs O
of O
potent O
and O
selective O
glur5 O
kainate O
receptor O
antagonists O
actives O
in O
three O
animal O
models O
of O
pain B-Disease
. O

amino O
acids O
5 O
and O
7 O
, O
two O
potent O
and O
selective O
competitive O
glur5 O
ka O
receptor O
antagonists O
, O
exhibited O
high O
glur5 O
receptor O
affinity O
over O
other O
glutamate O
receptors O
. O

their O
ester O
prodrugs O
6 O
and O
8 O
were O
orally O
active O
in O
three O
models O
of O
pain B-Disease
: O
reversal O
of O
formalin O
- O
induced O
paw O
licking O
, O
carrageenan O
- O
induced O
thermal B-Disease
hyperalgesia B-Disease
, O
and O
capsaicin O
- O
induced O
mechanical B-Disease
hyperalgesia B-Disease
. O

possible O
azithromycin O
- O
associated O
hiccups B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
persistent O
hiccups B-Disease
associated O
by O
azithromycin O
therapy O
. O

case O
summary O
: O
a O
76 O
- O
year O
- O
old O
man O
presented O
with O
persistent O
hiccups B-Disease
after O
beginning O
azithromycin O
for O
the O
treatment O
of O
pharyngitis B-Disease
. O

hiccups B-Disease
were O
persistent O
and O
exhausting O
. O

discontinuation O
of O
azithromycin O
and O
therapy O
with O
baclofen O
finally O
resolved O
hiccups B-Disease
. O

no O
organic O
cause O
of O
hiccups B-Disease
was O
identified O
despite O
extensive O
investigation O
. O

discussion O
: O
pharmacotherapeutic O
agents O
have O
been O
uncommonly O
associated O
with O
hiccups B-Disease
. O

corticosteroids O
( O
dexamethasone O
and O
methylprednisolone O
) O
, O
benzodiazepines O
( O
midazolam O
) O
and O
general O
anaesthesia O
have O
been O
the O
specific O
agents O
mentioned O
most O
frequently O
in O
the O
literature O
as O
being O
associated O
with O
the O
development O
of O
hiccups B-Disease
. O

few O
cases O
of O
drug O
- O
induced O
hiccups B-Disease
have O
been O
reported O
related O
to O
macrolide O
antimicrobials O
. O

using O
the O
naranjo O
adverse O
effect O
reaction O
probability O
scale O
this O
event O
could O
be O
classified O
as O
possible O
( O
score O
5 O
points O
) O
, O
mostly O
because O
of O
the O
close O
temporal O
sequence O
, O
previous O
reports O
on O
this O
reaction O
with O
other O
macrolides O
and O
the O
absence O
of O
any O
alternative O
explanation O
for O
hiccups B-Disease
. O

our O
hypothesis O
is O
that O
a O
vagal O
mechanism O
mediated O
by O
azithromycin O
could O
be O
the O
pathogenesis O
of O
hiccups B-Disease
in O
our O
patient O
. O

conclusions O
: O
diagnosis O
of O
drug O
- O
induced O
hiccups B-Disease
is O
difficult O
and O
often O
achieved O
only O
by O
a O
process O
of O
elimination O
. O

however O
, O
macrolide O
antimicrobials O
have O
been O
reported O
to O
be O
associated O
with O
hiccups B-Disease
and O
vagal O
mechanism O
could O
explain O
the O
development O
of O
this O
side O
- O
effect O
. O

calcium O
carbonate O
toxicity B-Disease
: O
the O
updated O
milk B-Disease
- B-Disease
alkali B-Disease
syndrome B-Disease
; O
report O
of O
3 O
cases O
and O
review O
of O
the O
literature O
. O

objective O
: O
to O
describe O
3 O
patients O
with O
calcium O
carbonate O
- O
induced O
hypercalcemia B-Disease
and O
gain O
insights O
into O
the O
cause O
and O
management O
of O
the O
milk B-Disease
- B-Disease
alkali B-Disease
syndrome B-Disease
. O

methods O
: O
we O
report O
the O
clinical O
and O
laboratory O
data O
in O
3 O
patients O
who O
presented O
with O
severe O
hypercalcemia B-Disease
( O
corrected O
serum O
calcium O
> O
or O
= O
14 O
mg O
/ O
dl O
) O
and O
review O
the O
pertinent O
literature O
on O
milk B-Disease
- B-Disease
alkali B-Disease
syndrome B-Disease
. O

results O
: O
the O
3 O
patients O
had O
acute B-Disease
renal B-Disease
insufficiency B-Disease
, O
relative O
metabolic B-Disease
alkalosis B-Disease
, O
and O
low O
parathyroid O
hormone O
( O
pth O
) O
, O
pth O
- O
related O
peptide O
, O
and O
1 O
, O
25 O
- O
dihydroxyvitamin O
d O
concentrations O
. O

no O
malignant O
lesion O
was O
found O
. O

treatment O
included O
aggressive O
hydration O
and O
varied O
amounts O
of O
furosemide O
. O

the O
2 O
patients O
with O
the O
higher O
serum O
calcium O
concentrations O
received O
pamidronate O
intravenously O
( O
60 O
and O
30 O
mg O
, O
respectively O
) O
, O
which O
caused O
severe O
hypocalcemia B-Disease
. O

of O
the O
3 O
patients O
, O
2 O
were O
ingesting O
acceptable O
doses O
of O
elemental O
calcium O
( O
1 O
g O
and O
2 O
g O
daily O
, O
respectively O
) O
in O
the O
form O
of O
calcium O
carbonate O
. O

in O
addition O
to O
our O
highlighted O
cases O
, O
we O
review O
the O
history O
, O
classification O
, O
pathophysiologic O
features O
, O
and O
treatment O
of O
milk B-Disease
- B-Disease
alkali B-Disease
syndrome B-Disease
and O
summarize O
the O
cases O
reported O
from O
early O
1995 O
to O
november O
2003 O
. O

conclusion O
: O
milk B-Disease
- B-Disease
alkali B-Disease
syndrome B-Disease
may O
be O
a O
common O
cause O
of O
unexplained O
hypercalcemia B-Disease
and O
can O
be O
precipitated O
by O
small O
amounts O
of O
orally O
ingested O
calcium O
carbonate O
in O
susceptible O
persons O
. O

treatment O
with O
hydration O
, O
furosemide O
, O
and O
discontinuation O
of O
the O
calcium O
and O
vitamin O
d O
source O
is O
adequate O
. O

pamidronate O
treatment O
is O
associated O
with O
considerable O
risk O
for O
hypocalcemia B-Disease
, O
even O
in O
cases O
of O
initially O
severe O
hypercalcemia B-Disease
. O

warfarin O
- O
induced O
leukocytoclastic B-Disease
vasculitis B-Disease
. O

skin O
reactions O
associated O
with O
oral O
coumarin O
- O
derived O
anticoagulants O
are O
an O
uncommon O
occurrence O
. O

leukocytoclastic B-Disease
vasculitis B-Disease
( O
lv B-Disease
) O
is O
primarily O
a O
cutaneous B-Disease
small B-Disease
vessel B-Disease
vasculitis B-Disease
, O
though O
systemic O
involvement O
may O
be O
encountered O
. O

we O
report O
4 O
patients O
with O
late O
- O
onset O
lv B-Disease
probably O
due O
to O
warfarin O
. O

all O
4 O
patients O
presented O
with O
skin B-Disease
eruptions B-Disease
that O
developed O
after O
receiving O
warfarin O
for O
several O
years O
. O

the O
results O
of O
skin B-Disease
lesion B-Disease
biopsies O
were O
available O
in O
3 O
patients O
, O
confirming O
lv B-Disease
cutaneous B-Disease
lesions B-Disease
resolved O
in O
all O
patients O
after O
warfarin O
was O
discontinued O
. O

in O
2 O
of O
the O
4 O
patients O
, O
rechallenge O
with O
warfarin O
led O
to O
recurrence O
of O
the O
lesions O
. O

lv B-Disease
may O
be O
a O
late O
- O
onset O
adverse O
reaction O
associated O
with O
warfarin O
therapy O
. O

cocaine O
- O
induced O
brainstem O
seizures B-Disease
and O
behavior O
. O

a O
variety O
of O
abnormal O
sensory O
/ O
motor O
behaviors O
associated O
with O
electrical O
discharges O
recorded O
from O
the O
bilateral O
brainstem O
were O
induced O
in O
adult O
wky O
rats O
by O
mechanical O
( O
electrode O
implants O
) O
and O
dc O
electrical O
current O
stimulations O
and O
by O
acute O
and O
chronic O
administration O
of O
cocaine O
. O

the O
electrode O
implant O
implicated O
one O
side O
or O
the O
other O
of O
the O
reticular O
system O
of O
the O
brainstem O
but O
subjects O
were O
not O
incapacitated O
by O
the O
stimulations O
. O

cocaine O
( O
40 O
mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
for O
an O
acute O
experiment O
and O
subsequent O
20 O
mg O
/ O
kg O
doses O
twice O
daily O
for O
3 O
days O
in O
a O
chronic O
study O
. O

cocaine O
generated O
more O
abnormal O
behaviors O
in O
the O
brainstem O
perturbation O
group O
, O
especially O
the O
electrically O
perturbated O
subjects O
. O

the O
abnormal O
behaviors O
were O
yawning O
, O
retrocollis O
, O
hyperactivity B-Disease
, O
hypersensitivity B-Disease
, O
" O
beating O
drum O
" O
behavior O
, O
squealing O
, O
head O
bobbing O
, O
circling O
, O
sniffing O
, O
abnormal O
posturing O
, O
and O
facial O
twitching O
. O

shifts O
in O
the O
power O
frequency O
spectra O
of O
the O
discharge O
patterns O
were O
noted O
between O
quiet O
and O
pacing O
behavioral O
states O
. O

hypersensitivity B-Disease
to O
various O
auditory O
, O
tactile O
, O
and O
visual O
stimulation O
was O
present O
and O
shifts O
in O
the O
brainstem O
ambient O
power O
spectral O
frequency O
occurred O
in O
response O
to O
tactile O
stimulation O
. O

these O
findings O
suggest O
that O
the O
brainstem O
generates O
and O
propagates O
pathological O
discharges O
that O
can O
be O
elicited O
by O
mechanical O
and O
dc O
electrical O
perturbation O
. O

cocaine O
was O
found O
to O
activate O
the O
discharge O
system O
and O
thus O
induce O
abnormal O
behaviors O
that O
are O
generated O
at O
the O
discharge O
site O
and O
at O
distant O
sites O
to O
which O
the O
discharge O
propagates O
. O

cognitive O
functions O
may O
also O
be O
involved O
since O
dopaminergic O
and O
serotonergic O
cellular O
elements O
at O
the O
brainstem O
level O
are O
also O
implicated O
. O

rtms O
of O
supplementary O
motor O
area O
modulates O
therapy O
- O
induced O
dyskinesias B-Disease
in O
parkinson B-Disease
disease B-Disease
. O

the O
neural O
mechanisms O
and O
circuitry O
involved O
in O
levodopa O
- O
induced O
dyskinesia B-Disease
are O
unclear O
. O

using O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rtms O
) O
over O
the O
supplementary O
motor O
area O
( O
sma O
) O
in O
a O
group O
of O
patients O
with O
advanced O
parkinson B-Disease
disease B-Disease
, O
the O
authors O
investigated O
whether O
modulation O
of O
sma O
excitability O
may O
result O
in O
a O
modification O
of O
a O
dyskinetic B-Disease
state O
induced O
by O
continuous O
apomorphine O
infusion O
. O

rtms O
at O
1 O
hz O
was O
observed O
to O
markedly O
reduce O
drug B-Disease
- B-Disease
induced B-Disease
dyskinesias B-Disease
, O
whereas O
5 O
- O
hz O
rtms O
induced O
a O
slight O
but O
not O
significant O
increase O
. O

intracavitary O
chemotherapy O
( O
paclitaxel O
/ O
carboplatin O
liquid O
crystalline O
cubic O
phases O
) O
for O
recurrent O
glioblastoma B-Disease
- O
- O
clinical O
observations O
. O

human O
malignant O
brain B-Disease
tumors B-Disease
have O
a O
poor O
prognosis O
in O
spite O
of O
surgery O
and O
radiation O
therapy O
. O

cubic O
phases O
consist O
of O
curved O
biocontinuous O
lipid O
bilayers O
, O
separating O
two O
congruent O
networks O
of O
water O
channels O
. O

used O
as O
a O
host O
for O
cytotoxic O
drugs O
, O
the O
gel O
- O
like O
matrix O
can O
easily O
be O
applied O
to O
the O
walls O
of O
a O
surgical O
resection O
cavity O
. O

for O
human O
glioblastoma B-Disease
recurrences O
, O
the O
feasibility O
, O
safety O
, O
and O
short O
- O
term O
effects O
of O
a O
surgical O
intracavitary O
application O
of O
paclitaxel O
and O
carboplatin O
encapsulated O
by O
liquid O
crystalline O
cubic O
phases O
are O
examined O
in O
a O
pilot O
study O
. O

a O
total O
of O
12 O
patients O
with O
a O
recurrence O
of O
a O
glioblastoma B-Disease
multiforme O
underwent O
re O
- O
resection O
and O
received O
an O
intracavitary O
application O
of O
paclitaxel O
and O
carboplatin O
cubic O
phases O
in O
different O
dosages O
. O

six O
of O
the O
patients O
received O
more O
than O
15 O
mg O
paclitaxel O
and O
suffered O
from O
moderate O
to O
severe O
brain B-Disease
edema B-Disease
, O
while O
the O
remaining O
patients O
received O
only O
a O
total O
of O
15 O
mg O
paclitaxel O
. O

in O
the O
latter O
group O
, O
brain B-Disease
edema B-Disease
was O
markedly O
reduced O
and O
dealt O
medically O
. O

intracavitary O
chemotherapy O
in O
recurrent O
glioblastoma B-Disease
using O
cubic O
phases O
is O
feasible O
and O
safe O
, O
yet O
the O
clinical O
benefit O
remains O
to O
be O
examined O
in O
a O
clinical O
phase O
ii O
study O
. O

lamotrigine O
associated O
with O
exacerbation O
or O
de O
novo O
myoclonus B-Disease
in O
idiopathic B-Disease
generalized B-Disease
epilepsies B-Disease
. O

five O
patients O
with O
idiopathic B-Disease
generalized B-Disease
epilepsies B-Disease
( O
ige B-Disease
) O
treated O
with O
lamotrigine O
( O
ltg O
) O
experienced O
exacerbation O
or O
de O
novo O
appearance O
of O
myoclonic B-Disease
jerks B-Disease
( O
mj B-Disease
) O
. O

in O
three O
patients O
, O
ltg O
exacerbated O
mj B-Disease
in O
a O
dose O
- O
dependent O
manner O
with O
early O
aggravation O
during O
titration O
. O

mj B-Disease
disappeared O
when O
ltg O
dose O
was O
decreased O
by O
25 O
to O
50 O
% O
. O

in O
two O
patients O
, O
ltg O
exacerbated O
mj B-Disease
in O
a O
delayed O
but O
more O
severe O
manner O
, O
with O
myoclonic B-Disease
status B-Disease
that O
only O
ceased O
after O
ltg O
withdrawal O
. O

absence O
of O
acute O
cerebral O
vasoconstriction O
after O
cocaine O
- O
associated O
subarachnoid B-Disease
hemorrhage B-Disease
. O

introduction O
: O
cocaine O
use O
has O
been O
associated O
with O
neurovascular B-Disease
complications B-Disease
, O
including O
arterial O
vasoconstriction O
and O
vasculitis B-Disease
. O

however O
, O
there O
are O
few O
studies O
of O
angiographic O
effects O
of O
cocaine O
on O
human O
cerebral O
arteries O
. O

information O
on O
these O
effects O
could O
be O
obtained O
from O
angiograms O
of O
patients O
with O
cocaine O
- O
associated O
subarachnoid B-Disease
hemorrhage B-Disease
( O
sah B-Disease
) O
who O
underwent O
angiography O
shortly O
after O
cocaine O
use O
. O

methods O
: O
we O
screened O
patients O
with O
sah B-Disease
retrospectively O
and O
identified O
those O
with O
positive O
urine O
toxicology O
for O
cocaine O
or O
its O
metabolites O
. O

quantitative O
arterial O
diameter O
measurements O
from O
angiograms O
of O
these O
patients O
were O
compared O
to O
measurements O
from O
control O
patients O
with O
sah B-Disease
who O
were O
matched O
for O
factors O
known O
to O
influence O
arterial O
diameter O
. O

qualitative O
comparisons O
of O
small O
artery O
changes O
also O
were O
made O
. O

results O
: O
thirteen O
patients O
with O
positive O
cocaine O
toxicology O
were O
compared O
to O
26 O
controls O
. O

there O
were O
no O
significant O
differences O
between O
groups O
in O
the O
mean O
diameters O
of O
the O
intradural O
internal O
carotid O
, O
sphenoidal O
segment O
of O
the O
middle O
cerebral O
, O
precommunicating O
segment O
of O
the O
anterior O
cerebral O
, O
or O
basilar O
arteries O
( O
p O
greater O
than O
0 O
. O
05 O
for O
all O
comparisons O
, O
unpaired O
t O
- O
tests O
) O
. O

there O
also O
were O
no O
significant O
differences O
between O
groups O
when O
expressing O
diameters O
as O
the O
sum O
of O
the O
precommunicating O
segment O
of O
the O
anterior O
cerebral O
+ O
sphenoidal O
segment O
of O
the O
middle O
cerebral O
+ O
supraclinoid O
internal O
carotid O
artery O
+ O
basilar O
artery O
divided O
by O
the O
diameter O
of O
the O
petrous O
internal O
carotid O
artery O
( O
p O
greater O
than O
0 O
. O
05 O
, O
unpaired O
t O
- O
tests O
) O
. O

qualitative O
assessments O
showed O
two O
arterial O
irregularities O
in O
the O
distal O
vasculature O
in O
each O
group O
. O

conclusion O
: O
no O
quantitative O
evidence O
for O
narrowing O
of O
large O
cerebral O
arteries O
or O
qualitative O
angiographic O
evidence O
for O
distal O
narrowing O
or O
vasculitis B-Disease
could O
be O
found O
in O
patients O
who O
underwent O
angiography O
after O
aneurysmal B-Disease
sah B-Disease
associated O
with O
cocaine O
use O
. O

methamphetamine O
causes O
alterations O
in O
the O
map O
kinase O
- O
related O
pathways O
in O
the O
brains O
of O
mice O
that O
display O
increased O
aggressiveness B-Disease
. O

aggressive B-Disease
behaviors B-Disease
have O
been O
reported O
in O
patients O
who O
suffer O
from O
some O
psychiatric B-Disease
disorders B-Disease
, O
and O
are O
common O
in O
methamphetamine O
( O
meth O
) O
abusers O
. O

herein O
, O
we O
report O
that O
multiple O
( O
but O
not O
single O
) O
injections O
of O
meth O
significantly O
increased O
aggressiveness B-Disease
in O
male O
cd O
- O
1 O
mice O
. O

this O
increase O
in O
aggressiveness B-Disease
was O
not O
secondary O
to O
meth O
- O
induced O
hyperactivity B-Disease
. O

analysis O
of O
protein O
expression O
using O
antibody O
microarrays O
and O
western O
blotting O
revealed O
differential O
changes O
in O
map O
kinase O
- O
related O
pathways O
after O
multiple O
and O
single O
meth O
injections O
. O

there O
were O
statistically O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decreases O
in O
mek1 O
, O
erk2p O
, O
gsk3alpha O
, O
14 O
- O
3 O
- O
3e O
, O
and O
mek7 O
in O
the O
striata O
of O
mice O
after O
multiple O
injections O
of O
meth O
. O

mek1 O
was O
significantly O
decreased O
also O
after O
a O
single O
injection O
of O
meth O
, O
but O
to O
a O
much O
lesser O
degree O
than O
after O
multiple O
injections O
of O
meth O
. O

in O
the O
frontal O
cortex O
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
gsk3alpha O
after O
multiple O
( O
but O
not O
single O
) O
injections O
of O
meth O
. O

these O
findings O
suggest O
that O
alterations O
in O
map O
kinase O
- O
related O
pathways O
in O
the O
prefronto O
- O
striatal O
circuitries O
might O
be O
involved O
in O
the O
manifestation O
of O
aggressive B-Disease
behaviors B-Disease
in O
mice O
. O

amisulpride O
related O
tic B-Disease
- B-Disease
like B-Disease
symptoms B-Disease
in O
an O
adolescent O
schizophrenic B-Disease
. O

tic B-Disease
disorders B-Disease
can O
be O
effectively O
treated O
by O
atypical O
antipsychotics O
such O
as O
risperidone O
, O
olanzapine O
and O
ziprasidone O
. O

however O
, O
there O
are O
two O
case O
reports O
that O
show O
tic B-Disease
- B-Disease
like B-Disease
symptoms B-Disease
, O
including O
motor O
and O
phonic O
variants O
, O
occurring O
during O
treatment O
with O
quetiapine O
or O
clozapine O
. O

we O
present O
a O
15 O
- O
year O
- O
old O
girl O
schizophrenic B-Disease
who O
developed O
frequent O
involuntary B-Disease
eye B-Disease
- B-Disease
blinking B-Disease
movements B-Disease
after O
5 O
months O
of O
amisulpride O
treatment O
( O
1000 O
mg O
per O
day O
) O
. O

the O
tic B-Disease
- B-Disease
like B-Disease
symptoms B-Disease
resolved O
completely O
after O
we O
reduced O
the O
dose O
of O
amisulpride O
down O
to O
800 O
mg O
per O
day O
. O

however O
, O
her O
psychosis B-Disease
recurred O
after O
the O
dose O
reduction O
. O

we O
then O
placed O
her O
on O
an O
additional O
100 O
mg O
per O
day O
of O
quetiapine O
. O

she O
has O
been O
in O
complete O
remission O
under O
the O
combined O
medications O
for O
more O
than O
one O
year O
and O
maintains O
a O
fair O
role O
function O
. O

no O
more O
tic B-Disease
- B-Disease
like B-Disease
symptoms B-Disease
or O
other O
side O
effects O
have O
been O
reported O
. O

together O
with O
previously O
reported O
cases O
, O
our O
patient O
suggests O
that O
tic B-Disease
- B-Disease
like B-Disease
symptoms B-Disease
might O
occur O
in O
certain O
vulnerable O
individuals O
during O
treatment O
with O
atypical O
antipsychotics O
such O
as O
quetiapine O
, O
clozapine O
, O
or O
amisulpride O
. O

chloroquine O
related O
complete O
heart B-Disease
block B-Disease
with O
blindness B-Disease
: O
case O
report O
. O

a O
27 O
- O
year O
old O
african O
woman O
with O
history O
of O
regular O
chloroquine O
ingestion O
presented O
with O
progressive O
deterioration B-Disease
of B-Disease
vision B-Disease
, O
easy O
fatiguability B-Disease
, O
dyspnoea B-Disease
, O
dizziness B-Disease
progressing O
to O
syncopal B-Disease
attacks B-Disease
. O

ophthalmological O
assessment O
revealed O
features O
of O
chloroquine O
retinopathy B-Disease
, O
cardiac O
assessment O
revealed O
features O
of O
heart B-Disease
failure B-Disease
and O
a O
complete O
heart B-Disease
block B-Disease
with O
right B-Disease
bundle B-Disease
branch B-Disease
block B-Disease
pattern O
. O

the O
heart B-Disease
block B-Disease
was O
treated O
by O
pacemaker O
insertion O
and O
the O
heart B-Disease
failure B-Disease
resolved O
spontaneously O
following O
chloroquine O
discontinuation O
. O

she O
however O
remains O
blind B-Disease
. O

effects O
of O
suprofen O
on O
the O
isolated O
perfused O
rat O
kidney O
. O

although O
suprofen O
has O
been O
associated O
with O
the O
development O
of O
acute B-Disease
renal B-Disease
failure B-Disease
in O
greater O
than O
100 O
subjects O
, O
the O
mechanism O
of O
damage O
remains O
unclear O
. O

the O
direct O
nephrotoxic B-Disease
effects O
of O
a O
single O
dose O
of O
15 O
mg O
of O
suprofen O
were O
compared O
in O
the O
recirculating O
isolated O
rat O
kidney O
perfused O
with O
cell O
- O
free O
buffer O
with O
or O
without O
the O
addition O
of O
5 O
mg O
/ O
dl O
of O
uric O
acid O
. O

there O
were O
no O
significant O
differences O
in O
renal O
sodium O
excretion O
, O
oxygen O
consumption O
, O
or O
urinary O
flow O
rates O
in O
kidneys O
perfused O
with O
suprofen O
compared O
with O
the O
drug O
- O
free O
control O
groups O
. O

in O
contrast O
, O
a O
significant O
decline O
in O
glomerular O
filtration O
rate O
was O
found O
after O
the O
introduction O
of O
suprofen O
to O
the O
kidney O
perfused O
with O
uric O
acid O
; O
no O
changes O
were O
found O
with O
suprofen O
in O
the O
absence O
of O
uric O
acid O
. O

a O
significant O
decrease O
in O
the O
baseline O
excretion O
rate O
of O
uric O
acid O
was O
found O
in O
rats O
given O
suprofen O
, O
compared O
with O
drug O
- O
free O
controls O
. O

however O
, O
the O
fractional O
excretion O
of O
uric O
acid O
was O
unchanged O
between O
the O
groups O
over O
the O
experimental O
period O
. O

in O
summary O
, O
suprofen O
causes O
acute B-Disease
declines B-Disease
in B-Disease
renal B-Disease
function B-Disease
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric O
acid O
. O

microinjection O
of O
ritanserin O
into O
the O
ca1 O
region O
of O
hippocampus O
improves O
scopolamine O
- O
induced O
amnesia B-Disease
in O
adult O
male O
rats O
. O

the O
effect O
of O
ritanserin O
( O
5 O
- O
ht2 O
antagonist O
) O
on O
scopolamine O
( O
muscarinic O
cholinergic O
antagonist O
) O
- O
induced O
amnesia B-Disease
in O
morris O
water O
maze O
( O
mwm O
) O
was O
investigated O
. O

rats O
were O
divided O
into O
eight O
groups O
and O
bilaterally O
cannulated O
into O
ca1 O
region O
of O
the O
hippocampus O
. O

one O
week O
later O
, O
they O
received O
repeatedly O
vehicles O
( O
saline O
, O
dmso O
, O
saline O
+ O
dmso O
) O
, O
scopolamine O
( O
2 O
microg O
/ O
0 O
. O
5 O
microl O
saline O
/ O
side O
; O
30 O
min O
before O
training O
) O
, O
ritanserin O
( O
2 O
, O
4 O
and O
8 O
microg O
/ O
0 O
. O
5 O
microl O
dmso O
/ O
side O
; O
20 O
min O
before O
training O
) O
and O
scopolamine O
( O
2 O
microg O
/ O
0 O
. O
5 O
microl O
; O
30 O
min O
before O
ritanserin O
injection O
) O
+ O
ritanserin O
( O
4 O
microg O
/ O
0 O
. O
5 O
microl O
dmso O
) O
through O
cannulae O
each O
day O
. O

animals O
were O
tested O
for O
four O
consecutive O
days O
( O
4 O
trial O
/ O
day O
) O
in O
mwm O
during O
which O
the O
position O
of O
hidden O
platform O
was O
unchanged O
. O

in O
the O
fifth O
day O
, O
the O
platform O
was O
elevated O
above O
the O
water O
surface O
in O
another O
position O
to O
evaluate O
the O
function O
of O
motor O
, O
motivational O
and O
visual O
systems O
. O

the O
results O
showed O
a O
significant O
increase O
in O
escape O
latencies O
and O
traveled O
distances O
to O
find O
platform O
in O
scopolamine O
- O
treated O
group O
as O
compared O
to O
saline O
group O
. O

ritanserin O
- O
treated O
rats O
( O
4 O
microg O
/ O
0 O
. O
5 O
microl O
/ O
side O
) O
showed O
a O
significant O
decrease O
in O
the O
mentioned O
parameters O
as O
compared O
to O
dmso O
- O
treated O
group O
. O

however O
, O
scopolamine O
and O
ritanserin O
co O
- O
administration O
resulted O
in O
a O
significant O
decrease O
in O
escape O
latencies O
and O
traveled O
distances O
as O
compared O
to O
the O
scopolamine O
- O
treated O
rats O
. O

our O
findings O
show O
that O
microinjection O
of O
ritanserin O
into O
the O
ca1 O
region O
of O
the O
hippocampus O
improves O
the O
scopolamine O
- O
induced O
amnesia B-Disease
. O

ptu O
- O
associated O
vasculitis B-Disease
in O
a O
girl O
with O
turner B-Disease
syndrome B-Disease
and O
graves B-Disease
' B-Disease
disease B-Disease
. O

palpable O
purpura B-Disease
is O
a O
concerning O
clinical O
finding O
in O
pediatric O
patients O
and O
can O
have O
many O
causes O
, O
including O
infectious O
and O
autoimmune O
processes O
. O

a O
rare O
cause O
, O
drug O
- O
induced O
vasculitis B-Disease
, O
may O
result O
from O
the O
production O
of O
antineutrophil O
cytoplasmic O
antibodies O
( O
ancas O
) O
in O
response O
to O
a O
medication O
. O

we O
report O
a O
girl O
with O
turner B-Disease
syndrome B-Disease
and O
graves B-Disease
' B-Disease
disease B-Disease
who O
presented O
with O
palpable O
purpuric B-Disease
lesions B-Disease
. O

the O
diagnosis O
of O
propylthiouracil O
( O
ptu O
) O
- O
associated O
vasculitis B-Disease
was O
made O
by O
observation O
of O
consistent O
clinical O
features O
, O
the O
detection O
of O
elevated O
ana O
and O
anca O
in O
the O
blood O
, O
and O
the O
observed O
clinical O
resolution O
of O
symptoms O
following O
withdrawal O
of O
ptu O
. O

subsequent O
treatment O
of O
persistent O
hyperthyroidism B-Disease
with O
radioablation O
did O
not O
result O
in O
an O
exacerbation O
of O
the O
vasculitis B-Disease
, O
a O
complication O
described O
in O
prior O
case O
reports O
. O

daidzein O
activates O
choline O
acetyltransferase O
from O
mc O
- O
ixc O
cells O
and O
improves O
drug O
- O
induced O
amnesia B-Disease
. O

the O
choline O
acetyltransferase O
( O
chat O
) O
activator O
, O
which O
enhances O
cholinergic O
transmission O
via O
an O
augmentation O
of O
the O
enzymatic O
production O
of O
acetylcholine O
( O
ach O
) O
, O
is O
an O
important O
factor O
in O
the O
treatment O
of O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
( O
ad B-Disease
) O
. O

methanolic O
extracts O
from O
pueraria O
thunbergiana O
exhibited O
an O
activation O
effect O
( O
46 O
% O
) O
on O
chat O
in O
vitro O
. O

via O
the O
sequential O
isolation O
of O
pueraria O
thunbergiana O
, O
the O
active O
component O
was O
ultimately O
identified O
as O
daidzein O
( O
4 O
' O
, O
7 O
- O
dihydroxy O
- O
isoflavone O
) O
. O

in O
order O
to O
investigate O
the O
effects O
of O
daidzein O
from O
pueraria O
thunbergiana O
on O
scopolamine O
- O
induced O
impairments B-Disease
of B-Disease
learning B-Disease
and B-Disease
memory B-Disease
, O
we O
conducted O
a O
series O
of O
in O
vivo O
tests O
. O

administration O
of O
daidzein O
( O
4 O
. O
5 O
mg O
/ O
kg O
body O
weight O
) O
to O
mice O
was O
shown O
significantly O
to O
reverse O
scopolamine O
- O
induced O
amnesia B-Disease
, O
according O
to O
the O
results O
of O
a O
y O
- O
maze O
test O
. O

injections O
of O
scopolamine O
into O
mice O
resulted O
in O
impaired O
performance O
on O
y O
- O
maze O
tests O
( O
a O
37 O
% O
decreases O
in O
alternation O
behavior O
) O
. O

by O
way O
of O
contrast O
, O
mice O
treated O
with O
daidzein O
prior O
to O
the O
scopolamine O
injections O
were O
noticeably O
protected O
from O
this O
performance O
impairment O
( O
an O
approximately O
12 O
% O
- O
21 O
% O
decrease O
in O
alternation O
behavior O
) O
. O

these O
results O
indicate O
that O
daidzein O
might O
play O
a O
role O
in O
acetylcholine O
biosynthesis O
as O
a O
chat O
activator O
, O
and O
that O
it O
also O
ameliorates O
scopolamine O
- O
induced O
amnesia B-Disease
. O

urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
thai O
women O
with O
overactive B-Disease
bladder B-Disease
after O
tolterodine O
treatment O
. O

objectives O
: O
to O
study O
the O
urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
thai O
women O
with O
overactive B-Disease
bladder B-Disease
( O
oab B-Disease
) O
after O
tolterodine O
treatment O
. O

material O
and O
method O
: O
thirty O
women O
( O
aged O
30 O
- O
77 O
years O
) O
diagnosed O
as O
having O
oab B-Disease
at O
the O
gynecology O
clinic O
, O
king O
chulalongkorn O
memorial O
hospital O
from O
january O
to O
april O
2004 O
were O
included O
in O
the O
present O
study O
. O

tolterodine O
2 O
mg O
, O
twice O
daily O
was O
given O
. O

after O
8 O
weeks O
treatment O
, O
changes O
in O
micturition O
diary O
variables O
and O
tolerability O
were O
determined O
. O

short O
form O
36 O
( O
sf36 O
) O
questionaires O
( O
thai O
version O
) O
were O
given O
before O
and O
after O
8 O
weeks O
of O
treatment O
. O

results O
: O
at O
8 O
weeks O
, O
all O
micturition O
per O
day O
decreased O
from O
16 O
. O

7 O
+ O
/ O
- O
5 O
. O

3 O
to O
6 O
. O

7 O
+ O
/ O
- O
2 O
. O
4 O
times O
per O
day O
. O

the O
number O
of O
nocturia B-Disease
episodes O
decreased O
from O
5 O
. O
4 O
+ O
/ O
- O
4 O
. O
2 O
to O
1 O
. O
1 O
+ O
/ O
- O
1 O
. O
0 O
times O
per O
night O
. O

the O
most O
common O
side O
effect O
was O
dry B-Disease
month B-Disease
in O
5 O
cases O
( O
16 O
. O
7 O
% O
) O
with O
2 O
cases O
reporting O
a O
moderate O
degree O
and O
1 O
case O
with O
severe O
degree O
. O

only O
one O
case O
( O
3 O
. O
3 O
% O
) O
withdrew O
from O
the O
present O
study O
due O
to O
a O
severe O
dry B-Disease
mouth B-Disease
. O

the O
sf O
- O
36 O
scores O
changed O
significantly O
in O
the O
domains O
of O
physical O
functioning O
, O
role O
function O
emotional O
, O
social O
function O
and O
mental O
heath O
. O

conclusion O
: O
tolterodine O
was O
well O
tolerated O
and O
its O
effects O
improved O
the O
quality O
of O
life O
in O
thai O
women O
with O
oab B-Disease
. O

remifentanil O
pretreatment O
reduces O
myoclonus B-Disease
after O
etomidate O
. O

study O
objective O
: O
the O
aim O
of O
the O
study O
was O
to O
compare O
the O
effect O
of O
pretreatment O
with O
remifentanil O
1 O
microg O
/ O
kg O
and O
the O
effect O
of O
gender O
on O
the O
incidence O
of O
myoclonus B-Disease
after O
anesthesia O
induction O
with O
etomidate O
. O

design O
: O
this O
was O
a O
randomized O
, O
double O
- O
blind O
study O
. O

setting O
: O
the O
study O
was O
conducted O
at O
a O
university O
hospital O
. O

patients O
: O
sixty O
patients O
were O
pretreated O
in O
a O
randomized O
double O
- O
blinded O
fashion O
with O
remifentanil O
1 O
microg O
/ O
kg O
or O
placebo O
. O

two O
minutes O
after O
remifentanil O
or O
placebo O
injection O
, O
etomidate O
0 O
. O
3 O
mg O
/ O
kg O
was O
given O
. O

measurements O
: O
myoclonus B-Disease
was O
recorded O
with O
a O
scale O
of O
0 O
to O
3 O
. O

the O
grade O
of O
sedation O
( O
none O
, O
mild O
, O
moderate O
, O
severe O
) O
, O
nausea B-Disease
, O
pruritus B-Disease
, O
and O
apnea B-Disease
were O
recorded O
after O
injection O
of O
both O
drugs O
. O

main O
results O
: O
the O
incidence O
of O
myoclonus B-Disease
was O
significantly O
lower O
in O
the O
remifentanil O
group O
( O
6 O
. O
7 O
% O
) O
than O
in O
the O
placebo O
group O
( O
70 O
% O
) O
( O
p O
< O
0 O
. O
001 O
) O
. O

none O
of O
the O
patients O
experienced O
sedation O
, O
apnea B-Disease
, O
nausea B-Disease
, O
or O
pruritus B-Disease
after O
injection O
of O
both O
drugs O
. O

in O
the O
placebo O
group O
, O
male O
patients O
were O
associated O
with O
significantly O
increased O
incidence O
of O
myoclonus B-Disease
after O
etomidate O
administration O
. O

conclusion O
: O
pretreatment O
with O
remifentanil O
1 O
microg O
/ O
kg O
reduced O
myoclonus B-Disease
after O
etomidate O
induction O
without O
side O
effects O
such O
as O
sedation O
, O
apnea B-Disease
, O
nausea B-Disease
, O
or O
pruritus B-Disease
. O

men O
experience O
increased O
incidence O
of O
myoclonus B-Disease
than O
women O
after O
etomidate O
administration O
. O

memory O
function O
and O
serotonin O
transporter O
promoter O
gene O
polymorphism O
in O
ecstasy O
( O
mdma O
) O
users O
. O

although O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
( O
mdma O
or O
ecstasy O
) O
has O
been O
shown O
to O
damage O
brain O
serotonin O
( O
5 O
- O
ht O
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long O
- O
term O
consequences O
of O
mdma O
- O
induced O
5 O
- O
ht O
neurotoxic B-Disease
lesions B-Disease
on O
functions O
in O
which O
5 O
- O
ht O
is O
involved O
, O
such O
as O
cognitive O
function O
. O

because O
5 O
- O
ht O
transporters O
play O
a O
key O
element O
in O
the O
regulation O
of O
synaptic O
5 O
- O
ht O
transmission O
it O
may O
be O
important O
to O
control O
for O
the O
potential O
covariance O
effect O
of O
a O
polymorphism O
in O
the O
5 O
- O
ht O
transporter O
promoter O
gene O
region O
( O
5 O
- O
httlpr O
) O
when O
studying O
the O
effects O
of O
mdma O
as O
well O
as O
cognitive O
functioning O
. O

the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
effects O
of O
moderate O
and O
heavy O
mdma O
use O
on O
cognitive O
function O
, O
as O
well O
as O
the O
effects O
of O
long O
- O
term O
abstention O
from O
mdma O
, O
in O
subjects O
genotyped O
for O
5 O
- O
httlpr O
. O

a O
second O
aim O
of O
the O
study O
was O
to O
determine O
whether O
these O
effects O
differ O
for O
females O
and O
males O
. O

fifteen O
moderate O
mdma O
users O
( O
< O
55 O
lifetime O
tablets O
) O
, O
22 O
heavy O
mdma O
+ O
users O
( O
> O
55 O
lifetime O
tablets O
) O
, O
16 O
ex O
- O
mdma O
+ O
users O
( O
last O
tablet O
> O
1 O
year O
ago O
) O
and O
13 O
controls O
were O
compared O
on O
a O
battery O
of O
neuropsychological O
tests O
. O

dna O
from O
peripheral O
nuclear O
blood O
cells O
was O
genotyped O
for O
5 O
- O
httlpr O
using O
standard O
polymerase O
chain O
reaction O
methods O
. O
a O
significant O
group O
effect O
was O
observed O
only O
on O
memory O
function O
tasks O
( O
p O
= O
0 O
. O
04 O
) O
but O
not O
on O
reaction O
times O
( O
p O
= O
0 O
. O
61 O
) O
or O
attention O
/ O
executive O
functioning O
( O
p O
= O
0 O
. O
59 O
) O
. O

heavy O
and O
ex O
- O
mdma O
+ O
users O
performed O
significantly O
poorer O
on O
memory O
tasks O
than O
controls O
. O

in O
contrast O
, O
no O
evidence O
of O
memory B-Disease
impairment B-Disease
was O
observed O
in O
moderate O
mdma O
users O
. O

no O
significant O
effect O
of O
5 O
- O
httlpr O
or O
gender O
was O
observed O
. O

while O
the O
use O
of O
mdma O
in O
quantities O
that O
may O
be O
considered O
" O
moderate O
" O
is O
not O
associated O
with O
impaired B-Disease
memory B-Disease
functioning B-Disease
, O
heavy O
use O
of O
mdma O
use O
may O
lead O
to O
long O
lasting O
memory B-Disease
impairments B-Disease
. O

no O
effect O
of O
5 O
- O
httlpr O
or O
gender O
on O
memory O
function O
or O
mdma O
use O
was O
observed O
. O

role O
of O
mangiferin O
on O
biochemical O
alterations O
and O
antioxidant O
status O
in O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction B-Disease
in O
rats O
. O

the O
current O
study O
dealt O
with O
the O
protective O
role O
of O
mangiferin O
, O
a O
polyphenol O
from O
mangifera O
indica O
linn O
. O

( O
anacardiaceae O
) O
, O
on O
isoproterenol O
( O
isph O
) O
- O
induced O
myocardial B-Disease
infarction B-Disease
( O
mi B-Disease
) O
in O
rats O
through O
its O
antioxidative O
mechanism O
. O

subcutaneous O
injection O
of O
isph O
( O
200 O
mg O
/ O
kg O
body O
weight O
in O
1 O
ml O
saline O
) O
to O
rats O
for O
2 O
consecutive O
days O
caused O
myocardial B-Disease
damage B-Disease
in O
rat O
heart O
, O
which O
was O
determined O
by O
the O
increased O
activity O
of O
serum O
lactate O
dehydrogenase O
( O
ldh O
) O
and O
creatine O
phosphokinase O
isoenzymes O
( O
ck O
- O
mb O
) O
, O
increased O
uric O
acid O
level O
and O
reduced O
plasma O
iron O
binding O
capacity O
. O

the O
protective O
role O
of O
mangiferin O
was O
analyzed O
by O
triphenyl O
tetrazolium O
chloride O
( O
ttc O
) O
test O
used O
for O
macroscopic O
enzyme O
mapping O
assay O
of O
the O
ischemic B-Disease
myocardium B-Disease
. O

the O
heart O
tissue O
antioxidant O
enzymes O
such O
as O
superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
, O
glutathione O
transferase O
and O
glutathione O
reductase O
activities O
, O
non O
- O
enzymic O
antioxidants O
such O
as O
cerruloplasmin O
, O
vitamin O
c O
, O
vitamin O
e O
and O
glutathione O
levels O
were O
altered O
in O
mi B-Disease
rats O
. O

upon O
pretreatment O
with O
mangiferin O
( O
100 O
mg O
/ O
kg O
body O
weight O
suspended O
in O
2 O
ml O
of O
dimethyl O
sulphoxide O
) O
given O
intraperitoneally O
for O
28 O
days O
to O
mi B-Disease
rats O
protected O
the O
above O
- O
mentioned O
parameters O
to O
fall O
from O
the O
normal O
levels O
. O

activities O
of O
heart O
tissue O
enzymic O
antioxidants O
and O
serum O
non O
- O
enzymic O
antioxidants O
levels O
rose O
significantly O
upon O
mangiferin O
administration O
as O
compared O
to O
isph O
- O
induced O
mi B-Disease
rats O
. O

from O
the O
present O
study O
it O
is O
concluded O
that O
mangiferin O
exerts O
a O
beneficial O
effect O
against O
isph O
- O
induced O
mi B-Disease
due O
to O
its O
antioxidant O
potential O
, O
which O
regulated O
the O
tissues O
defense O
system O
against O
cardiac B-Disease
damage B-Disease
. O

cardiovascular O
risk O
with O
cyclooxygenase O
inhibitors O
: O
general O
problem O
with O
substance O
specific O
differences O
? O

randomised O
clinical O
trials O
and O
observational O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial B-Disease
infarction B-Disease
, O
stroke B-Disease
, O
hypertension B-Disease
and O
heart B-Disease
failure B-Disease
during O
treatment O
with O
cyclooxygenase O
inhibitors O
. O

adverse O
cardiovascular O
effects O
occurred O
mainly O
, O
but O
not O
exclusively O
, O
in O
patients O
with O
concomitant O
risk O
factors O
. O

cyclooxygenase O
inhibitors O
cause O
complex O
changes O
in O
renal O
, O
vascular O
and O
cardiac O
prostanoid O
profiles O
thereby O
increasing O
vascular O
resistance O
and O
fluid O
retention O
. O

the O
incidence O
of O
cardiovascular O
adverse O
events O
tends O
to O
increase O
with O
the O
daily O
dose O
and O
total O
exposure O
time O
. O

a O
comparison O
of O
individual O
selective O
and O
unselective O
cyclooxygenase O
inhibitors O
suggests O
substance O
- O
specific O
differences O
, O
which O
may O
depend O
on O
differences O
in O
pharmacokinetic O
parameters O
or O
inhibitory O
potency O
and O
may O
be O
contributed O
by O
prostaglandin O
- O
independent O
effects O
. O

diagnostic O
markers O
such O
as O
n O
- O
terminal O
pro O
brain O
natriuretic O
peptide O
( O
nt O
- O
probnp O
) O
or O
high O
- O
sensitive O
c O
- O
reactive O
protein O
might O
help O
in O
the O
early O
identification O
of O
patients O
at O
risk O
, O
thus O
avoiding O
the O
occurrence O
of O
serious O
cardiovascular B-Disease
toxicity B-Disease
. O

pilocarpine O
seizures B-Disease
cause O
age O
- O
dependent O
impairment B-Disease
in B-Disease
auditory B-Disease
location B-Disease
discrimination B-Disease
. O

children O
who O
have O
status B-Disease
epilepticus B-Disease
have O
continuous O
or O
rapidly O
repeating O
seizures B-Disease
that O
may O
be O
life O
- O
threatening O
and O
may O
cause O
life O
- O
long O
changes O
in O
brain O
and O
behavior O
. O

the O
extent O
to O
which O
status B-Disease
epilepticus B-Disease
causes O
deficits B-Disease
in B-Disease
auditory B-Disease
discrimination B-Disease
is O
unknown O
. O

a O
naturalistic O
auditory O
location O
discrimination O
method O
was O
used O
to O
evaluate O
this O
question O
using O
an O
animal O
model O
of O
status B-Disease
epilepticus B-Disease
. O

male O
sprague O
- O
dawley O
rats O
were O
injected O
with O
saline O
on O
postnatal O
day O
( O
p O
) O
20 O
, O
or O
a O
convulsant O
dose O
of O
pilocarpine O
on O
p20 O
or O
p45 O
. O

pilocarpine O
on O
either O
day O
induced O
status B-Disease
epilepticus B-Disease
; O
status B-Disease
epilepticus B-Disease
at O
p45 O
resulted O
in O
ca3 O
cell O
loss O
and O
spontaneous O
seizures B-Disease
, O
whereas O
p20 O
rats O
had O
no O
cell O
loss O
or O
spontaneous O
seizures B-Disease
. O

mature O
rats O
were O
trained O
with O
sound O
- O
source O
location O
and O
sound O
- O
silence O
discriminations O
. O

control O
( O
saline O
p20 O
) O
rats O
acquired O
both O
discriminations O
immediately O
. O

in O
status B-Disease
epilepticus B-Disease
( O
p20 O
) O
rats O
, O
acquisition O
of O
the O
sound O
- O
source O
location O
discrimination O
was O
moderately O
impaired O
. O

status B-Disease
epilepticus B-Disease
( O
p45 O
) O
rats O
failed O
to O
acquire O
either O
sound O
- O
source O
location O
or O
sound O
- O
silence O
discriminations O
. O

status B-Disease
epilepticus B-Disease
in O
rat O
causes O
an O
age O
- O
dependent O
, O
long O
- O
term O
impairment B-Disease
in B-Disease
auditory B-Disease
discrimination B-Disease
. O

this O
impairment O
may O
explain O
one O
cause O
of O
impaired B-Disease
auditory B-Disease
location B-Disease
discrimination B-Disease
in O
humans O
. O

nerve O
growth O
factor O
and O
prostaglandins O
in O
the O
urine O
of O
female O
patients O
with O
overactive B-Disease
bladder B-Disease
. O

purpose O
: O
ngf O
and O
pgs O
in O
the O
bladder O
can O
be O
affected O
by O
pathological O
changes O
in O
the O
bladder O
and O
these O
changes O
can O
be O
detected O
in O
urine O
. O

we O
investigated O
changes O
in O
urinary O
ngf O
and O
pgs O
in O
women O
with O
oab B-Disease
. O

materials O
and O
methods O
: O
the O
study O
groups O
included O
65 O
women O
with O
oab B-Disease
and O
20 O
without O
bladder O
symptoms O
who O
served O
as O
controls O
. O

evaluation O
included O
patient O
history O
, O
urinalysis O
, O
a O
voiding O
diary O
and O
urodynamic O
studies O
. O

urine O
samples O
were O
collected O
. O

ngf O
, O
pge2 O
, O
pgf2alpha O
and O
pgi2 O
were O
measured O
using O
enzyme O
- O
linked O
immunosorbent O
assay O
and O
compared O
between O
the O
groups O
. O

in O
addition O
, O
correlations O
between O
urinary O
ngf O
and O
pg O
, O
and O
urodynamic O
parameters O
in O
patients O
with O
oab B-Disease
were O
examined O
. O

results O
: O
urinary O
ngf O
, O
pge2 O
and O
pgf2alpha O
were O
significantly O
increased O
in O
patients O
with O
oab B-Disease
compared O
with O
controls O
( O
p O
< O
0 O
. O
05 O
) O
. O

however O
, O
urinary O
pgi2 O
was O
not O
different O
between O
controls O
and O
patients O
with O
oab B-Disease
. O

in O
patients O
with O
oab B-Disease
urinary O
pge2 O
positively O
correlated O
with O
volume O
at O
first O
desire O
to O
void O
and O
maximum O
cystometric O
capacity O
( O
p O
< O
0 O
. O
05 O
) O
. O

urinary O
ngf O
, O
pgf2alpha O
and O
pgi2 O
did O
not O
correlate O
with O
urodynamic O
parameters O
in O
patients O
with O
oab B-Disease
. O

conclusions O
: O
ngf O
and O
pgs O
have O
important O
roles O
in O
the O
development O
of O
oab B-Disease
symptoms O
in O
female O
patients O
. O

urinary O
levels O
of O
these O
factors O
may O
be O
used O
as O
markers O
to O
evaluate O
oab B-Disease
symptoms O
. O

definition O
and O
management O
of O
anemia B-Disease
in O
patients O
infected B-Disease
with B-Disease
hepatitis B-Disease
c B-Disease
virus B-Disease
. O

chronic B-Disease
infection B-Disease
with B-Disease
hepatitis B-Disease
c B-Disease
virus B-Disease
( O
hcv O
) O
can O
progress O
to O
cirrhosis B-Disease
, O
hepatocellular B-Disease
carcinoma B-Disease
, O
and O
end B-Disease
- B-Disease
stage B-Disease
liver B-Disease
disease B-Disease
. O

the O
current O
best O
treatment O
for O
hcv B-Disease
infection B-Disease
is O
combination O
therapy O
with O
pegylated O
interferon O
and O
ribavirin O
. O

although O
this O
regimen O
produces O
sustained O
virologic O
responses O
( O
svrs O
) O
in O
approximately O
50 O
% O
of O
patients O
, O
it O
can O
be O
associated O
with O
a O
potentially O
dose O
- O
limiting O
hemolytic B-Disease
anemia B-Disease
. O

hemoglobin O
concentrations O
decrease O
mainly O
as O
a O
result O
of O
ribavirin O
- O
induced O
hemolysis B-Disease
, O
and O
this O
anemia B-Disease
can O
be O
problematic O
in O
patients O
with O
hcv B-Disease
infection B-Disease
, O
especially O
those O
who O
have O
comorbid O
renal B-Disease
or B-Disease
cardiovascular B-Disease
disorders B-Disease
. O

in O
general O
, O
anemia B-Disease
can O
increase O
the O
risk O
of O
morbidity O
and O
mortality O
, O
and O
may O
have O
negative O
effects O
on O
cerebral O
function O
and O
quality O
of O
life O
. O

although O
ribavirin O
- O
associated O
anemia B-Disease
can O
be O
reversed O
by O
dose O
reduction O
or O
discontinuation O
, O
this O
approach O
compromises O
outcomes O
by O
significantly O
decreasing O
svr O
rates O
. O

recombinant O
human O
erythropoietin O
has O
been O
used O
to O
manage O
ribavirin O
- O
associated O
anemia B-Disease
but O
has O
other O
potential O
disadvantages O
. O

viramidine O
, O
a O
liver O
- O
targeting O
prodrug O
of O
ribavirin O
, O
has O
the O
potential O
to O
maintain O
the O
virologic O
efficacy O
of O
ribavirin O
while O
decreasing O
the O
risk O
of O
hemolytic B-Disease
anemia B-Disease
in O
patients O
with O
chronic B-Disease
hepatitis B-Disease
c B-Disease
. O

impact O
of O
alcohol O
exposure O
after O
pregnancy O
recognition O
on O
ultrasonographic O
fetal O
growth O
measures O
. O

background O
: O
more O
than O
3 O
decades O
after O
jones O
and O
smith O
( O
1973 O
) O
reported O
on O
the O
devastation O
caused O
by O
alcohol O
exposure O
on O
fetal O
development O
, O
the O
rates O
of O
heavy O
drinking O
during O
pregnancy O
remain O
relatively O
unchanged O
. O

early O
identification O
of O
fetal O
alcohol O
exposure O
and O
maternal O
abstinence O
led O
to O
better O
infant O
outcomes O
. O

this O
study O
examined O
the O
utility O
of O
biometry O
for O
detecting O
alcohol O
- O
related O
fetal O
growth B-Disease
impairment B-Disease
. O

methods O
: O
we O
obtained O
fetal O
ultrasound O
measures O
from O
routine O
ultrasound O
examinations O
for O
167 O
pregnant O
hazardous O
drinkers O
who O
were O
enrolled O
in O
a O
brief O
alcohol O
intervention O
study O
. O

the O
fetal O
measures O
for O
women O
who O
quit O
after O
learning O
of O
their O
pregnancies O
were O
compared O
with O
measures O
for O
women O
who O
continued O
some O
drinking O
throughout O
the O
course O
of O
their O
pregnancies O
. O

because O
intensity O
of O
alcohol O
consumption O
is O
associated O
with O
poorer O
fetal O
outcomes O
, O
separate O
analyses O
were O
conducted O
for O
the O
heavy O
( O
average O
of O
> O
or O
= O
5 O
drinks O
per O
drinking O
day O
) O
alcohol O
consumers O
. O

fetal O
measures O
from O
the O
heavy O
- O
exposed O
fetuses O
were O
also O
compared O
with O
measures O
from O
a O
nondrinking O
group O
that O
was O
representative O
of O
normal O
, O
uncomplicated O
pregnancies O
from O
our O
clinics O
. O

analyses O
of O
covariance O
were O
used O
to O
determine O
whether O
there O
were O
differences O
between O
groups O
after O
controlling O
for O
influences O
of O
gestational O
age O
and O
drug B-Disease
abuse B-Disease
. O

results O
: O
nearly O
half O
of O
the O
pregnant O
drinkers O
abstained O
after O
learning O
of O
their O
pregnancies O
. O

when O
women O
reportedly O
quit O
drinking O
early O
in O
their O
pregnancies O
, O
fetal O
growth O
measures O
were O
not O
significantly O
different O
from O
a O
non O
- O
alcohol O
- O
exposed O
group O
, O
regardless O
of O
prior O
drinking O
patterns O
. O

any O
alcohol O
consumption O
postpregnancy O
recognition O
among O
the O
heavy O
drinkers O
resulted O
in O
reduced B-Disease
cerebellar B-Disease
growth B-Disease
as O
well O
as O
decreased B-Disease
cranial B-Disease
to B-Disease
body B-Disease
growth B-Disease
in O
comparison O
with O
women O
who O
either O
quit O
drinking O
or O
who O
were O
nondrinkers O
. O

amphetamine O
abuse O
was O
predictive O
of O
larger O
cranial O
to O
body O
growth O
ratios O
. O

conclusions O
: O
alterations O
in O
fetal O
biometric O
measurements O
were O
observed O
among O
the O
heavy O
drinkers O
only O
when O
they O
continued O
drinking O
after O
becoming O
aware O
of O
their O
pregnancies O
. O

although O
the O
reliance O
on O
self O
- O
reported O
drinking O
is O
a O
limitation O
in O
this O
study O
, O
these O
findings O
support O
the O
benefits O
of O
early O
abstinence O
and O
the O
potential O
for O
ultrasound O
examinations O
in O
the O
detection O
of O
fetal O
alcohol O
effects O
. O

ethambutol O
- O
associated O
optic B-Disease
neuropathy B-Disease
. O

introduction O
: O
ethambutol O
is O
used O
in O
the O
treatment O
of O
tuberculosis B-Disease
, O
which O
is O
still O
prevalent O
in O
southeast O
asia O
, O
and O
can O
be O
associated O
with O
permanent O
visual B-Disease
loss B-Disease
. O

we O
report O
3 O
cases O
which O
presented O
with O
bitemporal B-Disease
hemianopia B-Disease
. O

clinical O
picture O
: O
three O
patients O
with O
ethambutol O
- O
associated O
toxic O
optic B-Disease
neuropathy B-Disease
are O
described O
. O

all O
3 O
patients O
had O
loss B-Disease
of B-Disease
central B-Disease
visual B-Disease
acuity B-Disease
, B-Disease
colour B-Disease
vision B-Disease
( B-Disease
ishihara B-Disease
) B-Disease
and B-Disease
visual B-Disease
field B-Disease
. O

the O
visual B-Disease
field B-Disease
loss B-Disease
had O
a O
bitemporal O
flavour O
, O
suggesting O
involvement O
of O
the O
optic O
chiasm O
. O

treatment O
: O
despite O
stopping O
ethambutol O
on O
diagnosis O
, O
visual O
function O
continued O
to O
deteriorate O
for O
a O
few O
months O
. O

subsequent O
improvement O
was O
mild O
in O
2 O
cases O
. O

in O
the O
third O
case O
, O
visual O
acuity O
and O
colour O
vision O
normalised O
but O
the O
optic O
discs O
were O
pale O
. O

outcome O
: O
all O
3 O
patients O
had O
some O
permanent O
loss B-Disease
of B-Disease
visual B-Disease
function B-Disease
. O

conclusions O
: O
ethambutol O
usage O
is O
associated O
with O
permanent O
visual B-Disease
loss B-Disease
and O
should O
be O
avoided O
if O
possible O
or O
used O
with O
caution O
and O
proper O
ophthalmological O
follow O
- O
up O
. O

the O
author O
postulates O
that O
in O
cases O
of O
ethambutol O
associated O
chiasmopathy O
, O
ethambutol O
may O
initially O
affect O
the O
optic O
nerves O
and O
subsequently O
progress O
to O
involve O
the O
optic O
chiasm O
. O

possible O
neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
related O
to O
concomitant O
treatment O
with O
paroxetine O
and O
alprazolam O
. O

a O
74 O
- O
year O
- O
old O
man O
with O
depressive B-Disease
symptoms B-Disease
was O
admitted O
to O
a O
psychiatric B-Disease
hospital O
due O
to O
insomnia B-Disease
, O
loss B-Disease
of B-Disease
appetite B-Disease
, O
exhaustion O
, O
and O
agitation B-Disease
. O

medical O
treatment O
was O
initiated O
at O
a O
daily O
dose O
of O
20 O
mg O
paroxetine O
and O
1 O
. O
2 O
mg O
alprazolam O
. O

on O
the O
10th O
day O
of O
paroxetine O
and O
alprazolam O
treatment O
, O
the O
patient O
exhibited O
marked O
psychomotor B-Disease
retardation B-Disease
, O
disorientation O
, O
and O
severe O
muscle B-Disease
rigidity B-Disease
with O
tremors B-Disease
. O

the O
patient O
had O
a O
fever B-Disease
( O
38 O
. O
2 O
degrees O
c O
) O
, O
fluctuating O
blood O
pressure O
( O
between O
165 O
/ O
90 O
and O
130 O
/ O
70 O
mg O
mm O
hg O
) O
, O
and O
severe O
extrapyramidal B-Disease
symptoms B-Disease
. O

laboratory O
tests O
showed O
an O
elevation O
of O
creatine O
phosphokinase O
( O
2218 O
iu O
/ O
l O
) O
, O
aspartate O
aminotransferase O
( O
134 O
iu O
/ O
l O
) O
, O
alanine O
aminotransferase O
( O
78 O
iu O
/ O
l O
) O
, O
and O
bun O
( O
27 O
. O
9 O
mg O
/ O
ml O
) O
levels O
. O

the O
patient O
received O
bromocriptine O
and O
diazepam O
to O
treat O
his O
symptoms O
. O

7 O
days O
later O
, O
the O
fever B-Disease
disappeared O
and O
the O
patient O
' O
s O
serum O
cpk O
levels O
were O
normalized O
( O
175 O
iu O
/ O
l O
) O
. O

this O
patient O
presented O
with O
symptoms O
of O
neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
( O
nms B-Disease
) O
, O
thus O
demonstrating O
that O
nms B-Disease
- O
like O
symptoms O
can O
occur O
after O
combined O
paroxetine O
and O
alprazolam O
treatment O
. O

the O
adverse O
drug O
reaction O
score O
obtained O
by O
the O
naranjo O
algorithm O
was O
6 O
in O
our O
case O
, O
indicating O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
nms B-Disease
- O
like O
adverse O
symptoms O
and O
the O
combined O
treatment O
used O
in O
this O
case O
. O

the O
involvement O
of O
physiologic O
and O
environmental O
aspects O
specific O
to O
this O
patient O
was O
suspected O
. O

several O
risk O
factors O
for O
nms B-Disease
should O
be O
noted O
in O
elderly O
depressive B-Disease
patients O
whose O
symptoms O
often O
include O
dehydration B-Disease
, O
agitation B-Disease
, O
malnutrition B-Disease
, O
and O
exhaustion O
. O

careful O
therapeutic O
intervention O
is O
necessary O
in O
cases O
involving O
elderly O
patients O
who O
suffer O
from O
depression B-Disease
. O

down O
- O
regulation O
of O
norepinephrine O
transporter O
function O
induced O
by O
chronic O
administration O
of O
desipramine O
linking O
to O
the O
alteration O
of O
sensitivity O
of O
local O
- O
anesthetics O
- O
induced O
convulsions B-Disease
and O
the O
counteraction O
by O
co O
- O
administration O
with O
local O
anesthetics O
. O

alterations O
of O
norepinephrine O
transporter O
( O
net O
) O
function O
by O
chronic O
inhibition O
of O
net O
in O
relation O
to O
sensitization O
to O
seizures B-Disease
induce O
by O
cocaine O
and O
local O
anesthetics O
were O
studied O
in O
mice O
. O

daily O
administration O
of O
desipramine O
, O
an O
inhibitor O
of O
the O
net O
, O
for O
5 O
days O
decreased O
[ O
( O
3 O
) O
h O
] O
norepinephrine O
uptake O
in O
the O
p2 O
fractions O
of O
hippocampus O
but O
not O
cortex O
, O
striatum O
or O
amygdalae O
. O

co O
- O
administration O
of O
lidocaine O
, O
bupivacaine O
or O
tricaine O
with O
desipramine O
reversed O
this O
effect O
. O

daily O
treatment O
of O
cocaine O
increased O
[ O
( O
3 O
) O
h O
] O
norepinephrine O
uptake O
into O
the O
hippocampus O
. O

daily O
administration O
of O
desipramine O
increased O
the O
incidence O
of O
appearance O
of O
lidocaine O
- O
induced O
convulsions B-Disease
and O
decreased O
that O
of O
cocaine O
- O
induced O
convulsions B-Disease
. O

co O
- O
administration O
of O
lidocaine O
with O
desipramine O
reversed O
the O
changes O
of O
convulsive B-Disease
activity O
of O
lidocaine O
and O
cocaine O
induced O
by O
repeated O
administration O
of O
desipramine O
. O

these O
results O
suggest O
that O
down O
- O
regulation O
of O
hippocampal O
net O
induced O
by O
chronic O
administration O
of O
desipramine O
may O
be O
relevant O
to O
desipramine O
- O
induced O
sensitization O
of O
lidocaine O
convulsions B-Disease
. O

inhibition O
of O
na O
( O
+ O
) O
channels O
by O
local O
anesthetics O
may O
regulate O
desipramine O
- O
induced O
down O
- O
regulation O
of O
net O
function O
. O

repeated O
administration O
of O
cocaine O
induces O
up O
- O
regulation O
of O
hippocampal O
net O
function O
. O

desipramine O
- O
induced O
sensitization O
of O
lidocaine O
seizures B-Disease
may O
have O
a O
mechanism O
distinct O
from O
kindling O
resulting O
from O
repeated O
administration O
of O
cocaine O
. O

atorvastatin O
prevented O
and O
reversed O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
the O
rat O
. O

to O
assess O
the O
antioxidant O
effects O
of O
atorvastatin O
( O
atorva O
) O
on O
dexamethasone O
( O
dex O
) O
- O
induced O
hypertension B-Disease
, O
60 O
male O
sprague O
- O
dawley O
rats O
were O
treated O
with O
atorva O
30 O
mg O
/ O
kg O
/ O
day O
or O
tap O
water O
for O
15 O
days O
. O

dex O
increased O
systolic O
blood O
pressure O
( O
sbp O
) O
from O
109 O
+ O
/ O
- O
1 O
. O
8 O
to O
135 O
+ O
/ O
- O
0 O
. O
6 O
mmhg O
and O
plasma O
superoxide O
( O
5711 O
+ O
/ O
- O
284 O
. O
9 O
saline O
, O
7931 O
+ O
/ O
- O
392 O
. O
8 O
u O
/ O
ml O
dex O
, O
p O
< O
0 O
. O
001 O
) O
. O

in O
this O
prevention O
study O
, O
sbp O
in O
the O
atorva O
+ O
dex O
group O
was O
increased O
from O
115 O
+ O
/ O
- O
0 O
. O
4 O
to O
124 O
+ O
/ O
- O
1 O
. O
5 O
mmhg O
, O
but O
this O
was O
significantly O
lower O
than O
in O
the O
dex O
- O
only O
group O
( O
p O
' O
< O
0 O
. O
05 O
) O
. O

atorva O
reversed O
dex O
- O
induced O
hypertension B-Disease
( O
129 O
+ O
/ O
- O
0 O
. O
6 O
mmhg O
, O
vs O
. O
135 O
+ O
/ O
- O
0 O
. O
6 O
mmhg O
p O
' O
< O
0 O
. O
05 O
) O
and O
decreased O
plasma O
superoxide O
( O
7931 O
+ O
/ O
- O
392 O
. O
8 O
dex O
, O
1187 O
+ O
/ O
- O
441 O
. O
2 O
atorva O
+ O
dex O
, O
p O
< O
0 O
. O
0001 O
) O
. O

plasma O
nitrate O
/ O
nitrite O
( O
nox O
) O
was O
decreased O
in O
dex O
- O
treated O
rats O
compared O
to O
saline O
- O
treated O
rats O
( O
11 O
. O
2 O
+ O
/ O
- O
1 O
. O
08 O
microm O
, O
15 O
. O
3 O
+ O
/ O
- O
1 O
. O
17 O
microm O
, O
respectively O
, O
p O
< O
0 O
. O
05 O
) O
. O

atorva O
affected O
neither O
plasma O
nox O
nor O
thymus O
weight O
. O

thus O
, O
atorvastatin O
prevented O
and O
reversed O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
the O
rat O
. O

peripheral B-Disease
neuropathy B-Disease
caused O
by O
high O
- O
dose O
cytosine O
arabinoside O
treatment O
in O
a O
patient O
with O
acute B-Disease
myeloid B-Disease
leukemia B-Disease
. O

the O
central O
nervous O
system O
toxicity B-Disease
of O
high O
- O
dose O
cytosine O
arabinoside O
is O
well O
recognized O
, O
but O
the O
toxicity B-Disease
of O
cytosine O
arabinoside O
in O
the O
peripheral O
nervous O
system O
has O
been O
infrequently O
reported O
. O

a O
49 O
- O
year O
- O
old O
japanese O
man O
was O
diagnosed O
with O
acute B-Disease
myeloid B-Disease
leukemia B-Disease
. O

after O
he O
achieved O
complete O
remission O
, O
he O
received O
high O
- O
dose O
cytosine O
arabinoside O
treatment O
( O
2 O
g O
/ O
m2 O
twice O
a O
day O
for O
5 O
days O
; O
total O
, O
20 O
g O
/ O
m2 O
) O
as O
consolidation O
therapy O
. O

the O
first O
course O
of O
high O
- O
dose O
cytosine O
arabinoside O
resulted O
in O
no O
unusual O
symptoms O
, O
but O
on O
day O
21 O
of O
the O
second O
course O
of O
treatment O
, O
the O
patient O
complained O
of O
numbness B-Disease
in O
his O
right O
foot O
. O

electromyogram O
and O
nerve O
- O
conduction O
studies O
showed O
peripheral B-Disease
neuropathy B-Disease
in O
both O
peroneal O
nerves O
. O

this O
neuropathy B-Disease
was O
gradually O
resolving O
; O
however O
, O
after O
the O
patient O
received O
allogeneic O
bone O
marrow O
transplantation O
, O
the O
symptoms O
worsened O
, O
with O
the O
development O
of O
graft B-Disease
- B-Disease
versus B-Disease
- B-Disease
host B-Disease
disease B-Disease
, O
and O
the O
symptoms O
subsequently O
responded O
to O
methylprednisolone O
. O

although O
the O
mechanisms O
of O
peripheral B-Disease
neuropathy B-Disease
are O
still O
unclear O
, O
high O
- O
dose O
cytosine O
arabinoside O
is O
a O
therapy O
that O
is O
potentially O
toxic O
to O
the O
peripheral O
nervous O
system O
, O
and O
auto O
/ O
alloimmunity O
may O
play O
an O
important O
role O
in O
these O
mechanisms O
. O

effect O
of O
alpha O
- O
tocopherol O
and O
deferoxamine O
on O
methamphetamine O
- O
induced O
neurotoxicity B-Disease
. O

methamphetamine O
( O
ma O
) O
- O
induced O
dopaminergic O
neurotoxicity B-Disease
is O
believed O
to O
be O
associated O
with O
the O
increased O
formation O
of O
free O
radicals O
. O

this O
study O
examined O
the O
effect O
of O
alpha O
- O
tocopherol O
( O
alpha O
- O
tc O
) O
, O
a O
scavenger O
of O
reactive O
oxygen O
species O
, O
and O
deferoxamine O
( O
dfo O
) O
, O
an O
iron O
chelator O
, O
on O
the O
ma O
- O
induced O
neurotoxicity B-Disease
. O

male O
rats O
were O
treated O
with O
ma O
( O
10 O
mg O
/ O
kg O
, O
every O
2 O
h O
for O
four O
injections O
) O
. O

the O
rat O
received O
either O
alpha O
- O
tc O
( O
20 O
mg O
/ O
kg O
) O
intraperitoneally O
for O
3 O
days O
and O
30 O
min O
prior O
to O
ma O
administration O
or O
dfo O
( O
50 O
mg O
/ O
kg O
) O
subcutaneously O
30 O
min O
before O
ma O
administration O
. O

the O
concentrations O
of O
dopamine O
( O
da O
) O
, O
serotonin O
and O
their O
metabolites O
decreased O
significantly O
after O
ma O
administration O
, O
which O
was O
inhibited O
by O
the O
alpha O
- O
tc O
and O
dfo O
pretreatment O
. O

alpha O
- O
tc O
and O
dfo O
attenuated O
the O
ma O
- O
induced O
hyperthermia B-Disease
as O
well O
as O
the O
alterations O
in O
the O
locomotor O
activity O
. O

the O
level O
of O
lipid O
peroxidation O
was O
higher O
and O
the O
reduced O
glutathione O
concentration O
was O
lower O
in O
the O
ma O
- O
treated O
rats O
. O

these O
changes O
were O
significantly O
attenuated O
by O
alpha O
- O
tc O
and O
dfo O
. O

this O
suggests O
that O
alpha O
- O
tc O
and O
dfo O
ameliorate O
the O
ma O
- O
induced O
neuronal B-Disease
damage B-Disease
by O
decreasing O
the O
level O
of O
oxidative O
stress O
. O

blockade O
of O
both O
d O
- O
1 O
and O
d O
- O
2 O
dopamine O
receptors O
may O
induce O
catalepsy B-Disease
in O
mice O
. O

1 O
. O

the O
catalepsy B-Disease
induced O
by O
dopamine O
antagonists O
has O
been O
tested O
and O
the O
possible O
dopamine O
subtypes O
involved O
in O
catalepsy B-Disease
was O
determined O
. O

2 O
. O

dopamine O
antagonist O
fluphenazine O
, O
d O
- O
1 O
antagonist O
sch O
23390 O
or O
d O
- O
2 O
antagonist O
sulpiride O
induced O
catalepsy B-Disease
. O

the O
effect O
of O
fluphenazine O
and O
sulpiride O
was O
dose O
- O
dependent O
. O

combination O
of O
sch O
23390 O
with O
sulpiride O
did O
not O
induce O
catalepsy B-Disease
potentiation O
. O

3 O
. O

d O
- O
1 O
agonist O
skf O
38393 O
or O
d O
- O
2 O
agonist O
quinpirole O
decreased O
the O
catalepsy B-Disease
induced O
by O
fluphenazine O
, O
sch O
23390 O
or O
sulpiride O
. O

4 O
. O

combination O
of O
skf O
38393 O
with O
quinpirole O
did O
not O
cause O
potentiated O
inhibitory O
effect O
on O
catalepsy B-Disease
induced O
by O
dopamine O
antagonists O
. O

5 O
. O

the O
data O
may O
indicate O
that O
although O
d O
- O
2 O
receptor O
blockade O
is O
involved O
in O
catalepsy B-Disease
, O
the O
d O
- O
1 O
receptor O
may O
plan O
a O
role O
. O

sustained O
clinical O
improvement O
of O
a O
patient O
with O
decompensated O
hepatitis B-Disease
b B-Disease
virus O
- O
related O
cirrhosis B-Disease
after O
treatment O
with O
lamivudine O
monotherapy O
. O

hepatitis B-Disease
b B-Disease
virus B-Disease
( B-Disease
hbv B-Disease
) B-Disease
infection B-Disease
, O
which O
causes O
liver B-Disease
cirrhosis B-Disease
and O
hepatocellular B-Disease
carcinoma B-Disease
, O
remains O
a O
major O
health O
problem O
in O
asian O
countries O
. O

recent O
development O
of O
vaccine O
for O
prevention O
is O
reported O
to O
be O
successful O
in O
reducing O
the O
size O
of O
chronically O
infected O
carriers O
, O
although O
the O
standard O
medical O
therapies O
have O
not O
been O
established O
up O
to O
now O
. O

in O
this O
report O
, O
we O
encountered O
a O
patient O
with O
decompensated O
hbv O
- O
related O
cirrhosis B-Disease
who O
exhibited O
the O
dramatic O
improvements O
after O
antiviral O
therapy O
. O

the O
patient O
was O
a O
50 O
- O
year O
- O
old O
woman O
. O

previous O
conventional O
medical O
treatments O
were O
not O
effective O
for O
this O
patient O
, O
thus O
this O
patient O
had O
been O
referred O
to O
our O
hospital O
. O

however O
, O
the O
administration O
of O
lamivudine O
, O
a O
reverse O
transcriptase O
inhibitor O
, O
for O
23 O
months O
dramatically O
improved O
her O
liver O
severity O
. O

during O
this O
period O
, O
no O
drug O
resistant O
mutant O
hbv O
emerged O
, O
and O
the O
serum O
hbv O
- O
dna O
level O
was O
continuously O
suppressed O
. O

these O
virological O
responses O
were O
also O
maintained O
even O
after O
the O
antiviral O
therapy O
was O
discontinued O
. O

moreover O
, O
both O
hepatitis O
b O
surface O
antigen O
and O
e O
antigen O
were O
observed O
to O
have O
disappeared O
in O
this O
patient O
. O

the O
administration O
of O
lamivudine O
to O
patients O
with O
hbv O
- O
related O
cirrhosis B-Disease
, O
like O
our O
present O
case O
, O
should O
be O
considered O
as O
an O
initial O
medical O
therapeutic O
option O
, O
especially O
in O
countries O
where O
liver O
transplantation O
is O
not O
reliably O
available O
. O

antiarrhythmic O
effects O
of O
optical O
isomers O
of O
cibenzoline O
on O
canine O
ventricular B-Disease
arrhythmias B-Disease
. O

antiarrhythmic O
effects O
of O
( O
+ O
) O
- O
cibenzoline O
and O
( O
- O
) O
- O
cibenzoline O
were O
examined O
using O
two O
canine O
ventricular B-Disease
arrhythmia B-Disease
models O
. O

digitalis O
arrhythmia B-Disease
, O
which O
is O
suppressed O
by O
na O
channel O
blockers O
, O
was O
induced O
by O
intermittent O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
ouabain O
in O
pentobarbital O
- O
anesthetized O
dogs O
. O

adrenaline B-Disease
arrhythmia B-Disease
, O
which O
is O
suppressed O
by O
ca O
channel O
blockers O
, O
was O
induced O
by O
adrenaline O
infusion O
in O
halothane O
- O
anesthetized O
dogs O
. O

ten O
and O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
( O
+ O
) O
- O
cibenzoline O
suppressed O
digitalis O
- O
and O
adrenaline O
- O
induced O
arrhythmias B-Disease
, O
respectively O
. O

the O
minimum O
effective O
plasma O
concentrations O
of O
( O
+ O
) O
- O
cibenzoline O
for O
digitalis O
- O
and O
adrenaline O
- O
induced O
arrhythmias B-Disease
were O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
4 O
and O
2 O
. O
0 O
+ O
/ O
- O
0 O
. O
6 O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
sd O
, O
n O
= O
6 O
) O
. O

a O
lower O
dose O
of O
1 O
mg O
/ O
kg O
i O
. O
v O
. O
of O
( O
- O
) O
- O
cibenzoline O
suppressed O
the O
digitalis O
- O
induced O
arrhythmia B-Disease
, O
whereas O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
was O
needed O
to O
suppress O
adrenaline O
- O
induced O
arrhythmias B-Disease
. O

the O
minimum O
effective O
plasma O
concentrations O
of O
( O
- O
) O
- O
cibenzoline O
for O
digitalis O
- O
and O
adrenaline O
- O
induced O
arrhythmia B-Disease
were O
0 O
. O
06 O
+ O
/ O
- O
0 O
. O
04 O
and O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
sd O
, O
n O
= O
6 O
) O
. O

the O
stronger O
antiarrhythmic O
effect O
of O
( O
- O
) O
- O
cibenzoline O
indicates O
that O
( O
- O
) O
- O
isomer O
may O
have O
an O
effect O
nearly O
5 O
- O
20 O
times O
stronger O
in O
suppressing O
na O
channels O
, O
but O
effects O
of O
both O
drugs O
on O
ca O
channels O
may O
be O
almost O
equipotent O
. O

passage O
of O
mannitol O
into O
the O
brain O
around O
gliomas B-Disease
: O
a O
potential O
cause O
of O
rebound O
phenomenon O
. O

a O
study O
on O
21 O
patients O
. O

aim O
: O
widespread O
use O
of O
mannitol O
to O
reduce O
brain B-Disease
edema B-Disease
and O
lower O
elevated B-Disease
icp B-Disease
in O
brain B-Disease
tumor B-Disease
patients O
continues O
to O
be O
afflicted O
by O
the O
so O
- O
called O
rebound O
phenomenon O
. O

leakage O
of O
mannitol O
into O
the O
brain O
parenchyma O
through O
an O
altered O
bbb O
and O
secondary O
reversal O
of O
osmotic O
gradient O
is O
considered O
the O
major O
cause O
of O
rebound O
. O

this O
has O
only O
been O
demonstrated O
experimentally O
in O
animals O
. O

as O
a O
contribution O
to O
this O
issue O
we O
decided O
to O
research O
the O
possible O
passage O
of O
mannitol O
into O
the O
brain O
after O
administration O
to O
21 O
brain B-Disease
tumor B-Disease
patients O
. O

methods O
: O
mannitol O
( O
18 O
% O
solution O
; O
1 O
g O
/ O
kg O
) O
was O
administered O
as O
a O
bolus O
to O
patients O
( O
ten O
had O
malignant B-Disease
glioma B-Disease
, O
seven O
brain O
metastases B-Disease
and O
four O
meningioma B-Disease
) O
about O
30 O
minutes O
before O
craniotomy O
. O

during O
resection O
, O
a O
sample O
of O
the O
surrounding O
edematous B-Disease
white O
matter O
was O
taken O
at O
the O
same O
time O
as O
a O
10 O
ml O
venous O
blood O
sample O
. O

mannitol O
concentrations O
were O
measured O
in O
plasma O
and O
white O
matter O
by O
a O
modified O
version O
of O
the O
enzyme O
assay O
of O
blonquist O
et O
al O
. O

results O
: O
in O
most O
glioma B-Disease
patients O
, O
mannitol O
concentrations O
in O
white O
matter O
were O
2 O
to O
6 O
times O
higher O
than O
in O
plasma O
( O
mean O
3 O
. O
5 O
times O
) O
. O

in O
meningioma B-Disease
and O
metastases B-Disease
patients O
plasma O
concentrations O
of O
mannitol O
were O
higher O
than O
white O
matter O
concentrations O
except O
in O
three O
cases O
with O
infiltration O
by O
neoplastic O
cells O
. O

conclusions O
: O
the O
results O
of O
our O
study O
show O
that O
even O
after O
a O
single O
bolus O
, O
mannitol O
may O
leak O
through O
the O
altered O
bbb O
near O
gliomas B-Disease
, O
reversing O
the O
initial O
plasma O
- O
to O
- O
blood O
osmotic O
gradient O
, O
aggravating O
peritumoral O
edema B-Disease
and O
promoting O
rebound O
of O
icp O
. O

placebo O
- O
level O
incidence O
of O
extrapyramidal B-Disease
symptoms B-Disease
( O
eps B-Disease
) O
with O
quetiapine O
in O
controlled O
studies O
of O
patients O
with O
bipolar B-Disease
mania B-Disease
. O

objectives O
: O
to O
evaluate O
extrapyramidal B-Disease
symptoms B-Disease
( O
eps B-Disease
) O
, O
including O
akathisia B-Disease
, O
with O
quetiapine O
in O
patients O
with O
bipolar B-Disease
mania B-Disease
. O

methods O
: O
data O
were O
analyzed O
from O
four O
similarly O
designed O
, O
randomized O
, O
double O
- O
blind O
, O
3 O
- O
to O
12 O
- O
week O
studies O
. O

two O
studies O
evaluated O
quetiapine O
monotherapy O
( O
up O
to O
800 O
mg O
/ O
day O
) O
( O
n O
= O
209 O
) O
versus O
placebo O
( O
n O
= O
198 O
) O
, O
with O
lithium O
or O
haloperidol O
monotherapy O
as O
respective O
active O
controls O
. O

two O
studies O
evaluated O
quetiapine O
( O
up O
to O
800 O
mg O
/ O
day O
) O
in O
combination O
with O
a O
mood O
stabilizer O
( O
lithium O
or O
divalproex O
, O
qtp O
+ O
li O
/ O
dvp O
) O
( O
n O
= O
196 O
) O
compared O
to O
placebo O
and O
mood O
stabilizer O
( O
pbo O
+ O
li O
/ O
dvp O
) O
( O
n O
= O
203 O
) O
. O

extrapyramidal B-Disease
symptoms B-Disease
were O
evaluated O
using O
the O
simpson O
- O
angus O
scale O
( O
sas O
) O
, O
the O
barnes O
akathisia O
rating O
scale O
( O
bars O
) O
, O
adverse O
event O
reports O
and O
anticholinergic O
drug O
usage O
. O

results O
: O
the O
incidence O
of O
eps B-Disease
- O
related O
adverse O
events O
, O
including O
akathisia B-Disease
, O
was O
no O
different O
with O
quetiapine O
monotherapy O
( O
12 O
. O
9 O
% O
) O
than O
with O
placebo O
( O
13 O
. O
1 O
% O
) O
. O

similarly O
, O
eps B-Disease
- O
related O
adverse O
events O
with O
qtp O
+ O
li O
/ O
dvp O
( O
21 O
. O
4 O
% O
) O
were O
no O
different O
than O
with O
pbo O
+ O
li O
/ O
dvp O
( O
19 O
. O
2 O
% O
) O
. O

adverse O
events O
related O
to O
eps B-Disease
occurred O
in O
59 O
. O
6 O
% O
of O
patients O
treated O
with O
haloperidol O
( O
n O
= O
99 O
) O
monotherapy O
, O
whereas O
26 O
. O
5 O
% O
of O
patients O
treated O
with O
lithium O
( O
n O
= O
98 O
) O
monotherapy O
experienced O
adverse O
events O
related O
to O
eps B-Disease
. O

the O
incidence O
of O
akathisia B-Disease
was O
low O
and O
similar O
with O
quetiapine O
monotherapy O
( O
3 O
. O
3 O
% O
) O
and O
placebo O
( O
6 O
. O
1 O
% O
) O
, O
and O
with O
qtp O
+ O
li O
/ O
dvp O
( O
3 O
. O
6 O
% O
) O
and O
pbo O
+ O
li O
/ O
dvp O
( O
4 O
. O
9 O
% O
) O
. O

lithium O
was O
associated O
with O
a O
significantly O
higher O
incidence O
( O
p O
< O
0 O
. O
05 O
) O
of O
tremor B-Disease
( O
18 O
. O
4 O
% O
) O
than O
quetiapine O
( O
5 O
. O
6 O
% O
) O
; O
cerebellar O
tremor B-Disease
, O
which O
is O
a O
known O
adverse O
effect O
of O
lithium O
, O
may O
have O
contributed O
to O
the O
elevated O
rate O
of O
tremor B-Disease
in O
patients O
receiving O
lithium O
therapy O
. O

haloperidol O
induced O
a O
significantly O
higher O
incidence O
( O
p O
< O
0 O
. O
001 O
) O
of O
akathisia B-Disease
( O
33 O
. O
3 O
% O
versus O
5 O
. O
9 O
% O
) O
, O
tremor B-Disease
( O
30 O
. O
3 O
% O
versus O
7 O
. O
8 O
% O
) O
, O
and O
extrapyramidal B-Disease
syndrome B-Disease
( O
35 O
. O
4 O
% O
versus O
5 O
. O
9 O
% O
) O
than O
quetiapine O
. O

no O
significant O
differences O
were O
observed O
between O
quetiapine O
and O
placebo O
on O
sas O
and O
bars O
scores O
. O

anticholinergic O
use O
was O
low O
and O
similar O
with O
quetiapine O
or O
placebo O
. O

conclusions O
: O
in O
bipolar B-Disease
mania B-Disease
, O
the O
incidence O
of O
eps B-Disease
, O
including O
akathisia B-Disease
, O
with O
quetiapine O
therapy O
is O
similar O
to O
that O
with O
placebo O
. O

is O
phenytoin O
administration O
safe O
in O
a O
hypothermic B-Disease
child O
? O

a O
male O
neonate O
with O
a O
chiari B-Disease
malformation B-Disease
and O
a O
leaking O
myelomeningocoele O
underwent O
ventriculoperitoneal O
shunt O
insertion O
followed O
by O
repair O
of O
myelomeningocoele O
. O

during O
anaesthesia O
and O
surgery O
, O
he O
inadvertently O
became O
moderately O
hypothermic B-Disease
. O

intravenous O
phenytoin O
was O
administered O
during O
the O
later O
part O
of O
the O
surgery O
for O
seizure B-Disease
prophylaxis O
. O

following O
phenytoin O
administration O
, O
the O
patient O
developed O
acute O
severe O
bradycardia B-Disease
, O
refractory O
to O
atropine O
and O
adrenaline O
. O

the O
cardiac O
depressant O
actions O
of O
phenytoin O
and O
hypothermia B-Disease
can O
be O
additive O
. O

administration O
of O
phenytoin O
in O
the O
presence O
of O
hypothermia B-Disease
may O
lead O
to O
an O
adverse O
cardiac O
event O
in O
children O
. O

as O
phenytoin O
is O
a O
commonly O
used O
drug O
, O
clinicians O
need O
to O
be O
aware O
of O
this O
interaction O
. O

valproate O
- O
induced O
chorea B-Disease
and O
encephalopathy B-Disease
in O
atypical O
nonketotic B-Disease
hyperglycinemia B-Disease
. O

nonketotic B-Disease
hyperglycinemia B-Disease
is O
a O
disorder B-Disease
of B-Disease
amino B-Disease
acid B-Disease
metabolism B-Disease
in O
which O
a O
defect O
in O
the O
glycine O
cleavage O
system O
leads O
to O
an O
accumulation O
of O
glycine O
in O
the O
brain O
and O
other O
body O
compartments O
. O

in O
the O
classical O
form O
it O
presents O
as O
neonatal O
apnea B-Disease
, O
intractable O
seizures B-Disease
, O
and O
hypotonia B-Disease
, O
followed O
by O
significant O
psychomotor B-Disease
retardation B-Disease
. O

an O
important O
subset O
of O
children O
with O
nonketotic B-Disease
hyperglycinemia B-Disease
are O
atypical O
variants O
who O
present O
in O
a O
heterogeneous O
manner O
. O

this O
report O
describes O
a O
patient O
with O
mild O
language B-Disease
delay B-Disease
and O
mental B-Disease
retardation B-Disease
, O
who O
was O
found O
to O
have O
nonketotic B-Disease
hyperglycinemia B-Disease
following O
her O
presentation O
with O
acute O
encephalopathy B-Disease
and O
chorea B-Disease
shortly O
after O
initiation O
of O
valproate O
therapy O
. O

delayed O
institution O
of O
hypertension B-Disease
during O
focal O
cerebral B-Disease
ischemia B-Disease
: O
effect O
on O
brain B-Disease
edema B-Disease
. O

the O
effect O
of O
induced O
hypertension B-Disease
instituted O
after O
a O
2 O
- O
h O
delay O
following O
middle B-Disease
cerebral B-Disease
artery B-Disease
occlusion B-Disease
( O
mcao B-Disease
) O
on O
brain B-Disease
edema B-Disease
formation O
and O
histochemical O
injury O
was O
studied O
. O

under O
isoflurane O
anesthesia O
, O
the O
mca O
of O
14 O
spontaneously O
hypertensive B-Disease
rats O
was O
occluded O
. O

in O
the O
control O
group O
( O
n O
= O
7 O
) O
, O
the O
mean O
arterial O
pressure O
( O
map O
) O
was O
not O
manipulated O
. O

in O
the O
hypertensive B-Disease
group O
( O
n O
= O
7 O
) O
, O
the O
map O
was O
elevated O
by O
25 O
- O
30 O
mm O
hg O
beginning O
2 O
h O
after O
mcao B-Disease
. O

four O
hours O
after O
mcao B-Disease
, O
the O
rats O
were O
killed O
and O
the O
brains O
harvested O
. O

the O
brains O
were O
sectioned O
along O
coronal O
planes O
spanning O
the O
distribution O
of O
ischemia B-Disease
produced O
by O
mcao B-Disease
. O

specific O
gravity O
( O
sg O
) O
was O
determined O
in O
the O
subcortex O
and O
in O
two O
sites O
in O
the O
cortex O
( O
core O
and O
periphery O
of O
the O
ischemic B-Disease
territory O
) O
. O

the O
extent O
of O
neuronal B-Disease
injury B-Disease
was O
determined O
by O
2 O
, O
3 O
, O
5 O
- O
triphenyltetrazolium O
staining O
. O

in O
the O
ischemic B-Disease
core O
, O
there O
was O
no O
difference O
in O
sg O
in O
the O
subcortex O
and O
cortex O
in O
the O
two O
groups O
. O

in O
the O
periphery O
of O
the O
ischemic B-Disease
territory O
, O
sg O
in O
the O
cortex O
was O
greater O
( O
less O
edema B-Disease
accumulation O
) O
in O
the O
hypertensive B-Disease
group O
( O
1 O
. O
041 O
+ O
/ O
- O
0 O
. O
001 O
vs O
1 O
. O
039 O
+ O
/ O
- O
0 O
. O
001 O
, O
p O
less O
than O
0 O
. O
05 O
) O
. O

the O
area O
of O
histochemical O
injury O
( O
as O
a O
percent O
of O
the O
cross O
- O
sectional O
area O
of O
the O
hemisphere O
) O
was O
less O
in O
the O
hypertensive B-Disease
group O
( O
33 O
+ O
/ O
- O
3 O
% O
vs O
21 O
+ O
/ O
- O
2 O
% O
, O
p O
less O
than O
0 O
. O
05 O
) O
. O

the O
data O
indicate O
that O
phenylephrine O
- O
induced O
hypertension B-Disease
instituted O
2 O
h O
after O
mcao B-Disease
does O
not O
aggravate O
edema B-Disease
in O
the O
ischemic B-Disease
core O
, O
that O
it O
improves O
edema B-Disease
in O
the O
periphery O
of O
the O
ischemic B-Disease
territory O
, O
and O
that O
it O
reduces O
the O
area O
of O
histochemical O
neuronal B-Disease
dysfunction B-Disease
. O

behavioral O
effects O
of O
pubertal O
anabolic O
androgenic O
steroid O
exposure O
in O
male O
rats O
with O
low O
serotonin O
. O

the O
goal O
of O
this O
study O
was O
to O
assess O
the O
interactive O
effects O
of O
chronic O
anabolic O
androgenic O
steroid O
( O
aas O
) O
exposure O
and O
brain O
serotonin O
( O
5 O
- O
hydroxytryptamine O
, O
5 O
- O
ht O
) O
depletion O
on O
behavior O
of O
pubertal O
male O
rats O
. O

serotonin O
was O
depleted O
beginning O
on O
postnatal O
day O
26 O
with O
parachlorophenylalanine O
( O
pcpa O
100 O
mg O
/ O
kg O
, O
every O
other O
day O
) O
; O
controls O
received O
saline O
. O

at O
puberty O
( O
p40 O
) O
, O
half O
the O
pcpa O
- O
treated O
rats O
and O
half O
the O
saline O
- O
treated O
rats O
began O
treatment O
with O
testosterone O
( O
t O
, O
5 O
mg O
/ O
kg O
, O
5 O
days O
/ O
week O
) O
. O

behavioral O
measures O
included O
locomotion O
, O
irritability B-Disease
, O
copulation O
, O
partner O
preference O
, O
and O
aggression B-Disease
. O

animals O
were O
tested O
for O
aggression B-Disease
in O
their O
home O
cage O
, O
both O
with O
and O
without O
physical O
provocation O
( O
mild O
tail O
pinch O
) O
. O

brain O
levels O
of O
5 O
- O
ht O
and O
its O
metabolite O
, O
5 O
- O
hydroxyindoleacetic O
acid O
( O
5 O
- O
hiaa O
) O
, O
were O
determined O
using O
hplc O
. O

pcpa O
significantly O
and O
substantially O
depleted O
5 O
- O
ht O
and O
5 O
- O
hiaa O
in O
all O
brain O
regions O
examined O
. O

chronic O
t O
treatment O
significantly O
decreased O
5 O
- O
ht O
and O
5 O
- O
hiaa O
in O
certain O
brain O
areas O
, O
but O
to O
a O
much O
lesser O
extent O
than O
pcpa O
. O

chronic O
exposure O
to O
pcpa O
alone O
significantly O
decreased O
locomotor O
activity O
and O
increased O
irritability B-Disease
but O
had O
no O
effect O
on O
sexual O
behavior O
, O
partner O
preference O
, O
or O
aggression B-Disease
. O

t O
alone O
had O
no O
effect O
on O
locomotion O
, O
irritability B-Disease
, O
or O
sexual O
behavior O
but O
increased O
partner O
preference O
and O
aggression B-Disease
. O

the O
most O
striking O
effect O
of O
combining O
t O
+ O
pcpa O
was O
a O
significant O
increase O
in O
attack O
frequency O
as O
well O
as O
a O
significant O
decrease O
in O
the O
latency O
to O
attack O
, O
particularly O
following O
physical O
provocation O
. O

based O
on O
these O
data O
, O
it O
can O
be O
speculated O
that O
pubertal O
aas O
users O
with O
low O
central O
5 O
- O
ht O
may O
be O
especially O
prone O
to O
exhibit O
aggressive B-Disease
behavior B-Disease
. O

effects O
of O
umb24 O
and O
( O
+ O
/ O
- O
) O
- O
sm O
21 O
, O
putative O
sigma2 O
- O
preferring O
antagonists O
, O
on O
behavioral O
toxic O
and O
stimulant O
effects O
of O
cocaine O
in O
mice O
. O

earlier O
studies O
have O
demonstrated O
that O
antagonism O
of O
sigma1 O
receptors O
attenuates O
the O
convulsive B-Disease
, O
lethal O
, O
locomotor O
stimulatory O
and O
rewarding O
actions O
of O
cocaine O
in O
mice O
. O

in O
contrast O
, O
the O
contribution O
of O
sigma2 O
receptors O
is O
unclear O
because O
experimental O
tools O
to O
selectively O
target O
this O
subtype O
are O
unavailable O
. O

to O
begin O
addressing O
this O
need O
, O
we O
characterized O
umb24 O
( O
1 O
- O
( O
2 O
- O
phenethyl O
) O
- O
4 O
- O
( O
2 O
- O
pyridyl O
) O
- O
piperazine O
) O
and O
( O
+ O
/ O
- O
) O
- O
sm O
21 O
( O
3alpha O
- O
tropanyl O
- O
2 O
- O
( O
4 O
- O
chorophenoxy O
) O
butyrate O
) O
in O
receptor O
binding O
and O
behavioral O
studies O
. O

receptor O
binding O
studies O
confirmed O
that O
umb24 O
and O
( O
+ O
/ O
- O
) O
- O
sm O
21 O
display O
preferential O
affinity O
for O
sigma2 O
over O
sigma1 O
receptors O
. O

in O
behavioral O
studies O
, O
pretreatment O
of O
swiss O
webster O
mice O
with O
umb24 O
or O
( O
+ O
/ O
- O
) O
- O
sm O
21 O
significantly O
attenuated O
cocaine O
- O
induced O
convulsions B-Disease
and O
locomotor O
activity O
, O
but O
not O
lethality O
. O

when O
administered O
alone O
, O
( O
+ O
/ O
- O
) O
- O
sm O
21 O
produced O
no O
significant O
effects O
compared O
to O
control O
injections O
of O
saline O
, O
but O
umb24 O
had O
locomotor O
depressant O
actions O
. O

together O
, O
the O
data O
suggest O
that O
sigma2 O
receptor O
antagonists O
have O
the O
potential O
to O
attenuate O
some O
of O
the O
behavioral O
effects O
of O
cocaine O
, O
and O
further O
development O
of O
more O
selective O
, O
high O
affinity O
ligands O
are O
warranted O
. O

cardiac B-Disease
arrest B-Disease
in O
a O
child O
with O
cerebral B-Disease
palsy B-Disease
undergoing O
sevoflurane O
induction O
of O
anesthesia O
after O
preoperative O
clonidine O
. O

clonidine O
is O
a O
frequently O
administered O
alpha2 O
- O
adrenergic O
agonist O
which O
can O
decrease O
heart O
rate O
and O
blood O
pressure O
. O

we O
present O
a O
case O
of O
a O
5 O
- O
year O
- O
old O
child O
with O
cerebral B-Disease
palsy B-Disease
and O
seizure B-Disease
disorder B-Disease
, O
receiving O
clonidine O
for O
restlessness B-Disease
, O
who O
presented O
for O
placement O
of O
a O
baclofen O
pump O
. O

without O
the O
knowledge O
of O
the O
medical O
personnel O
, O
the O
patient O
' O
s O
mother O
administered O
three O
doses O
of O
clonidine O
during O
the O
evening O
before O
and O
morning O
of O
surgery O
to O
reduce O
anxiety B-Disease
. O

during O
induction O
of O
anesthesia O
, O
the O
patient O
developed O
bradycardia B-Disease
and O
hypotension B-Disease
requiring O
cardiac O
resuscitation O
. O

there O
are O
no O
previous O
reports O
of O
clonidine O
- O
associated O
cardiac B-Disease
arrest B-Disease
in O
a O
child O
undergoing O
induction O
of O
anesthesia O
. O

angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitor O
- O
associated O
angioedema B-Disease
of O
the O
stomach O
and O
small O
intestine O
: O
a O
case O
report O
. O

this O
is O
a O
case O
report O
on O
a O
45 O
- O
year O
old O
african O
- O
american O
female O
with O
newly O
diagnosed O
hypertension B-Disease
, O
who O
was O
started O
on O
a O
combination O
pill O
of O
amlodipine O
/ O
benazapril O
10 O
/ O
5 O
mg O
. O

the O
very O
next O
day O
, O
she O
presented O
at O
the O
emergency O
room O
( O
er O
) O
with O
abdominal B-Disease
pain B-Disease
, O
nausea B-Disease
and O
vomiting B-Disease
. O

physical O
exam O
, O
complete O
metabolic O
panel O
, O
and O
hemogram O
were O
in O
the O
normal O
range O
. O

she O
was O
discharged O
from O
the O
er O
after O
a O
few O
hours O
of O
treatment O
with O
fluid O
and O
analgesics O
. O

however O
, O
she O
returned O
to O
the O
er O
the O
next O
day O
with O
the O
same O
complaints O
. O

this O
time O
the O
physical O
exam O
was O
significant O
for O
a O
distended O
abdomen O
with O
dullness O
to O
percussion O
. O

ct O
scan O
of O
the O
abdomen O
revealed O
markedly O
thickened O
antrum O
of O
the O
stomach O
, O
duodenum O
and O
jejunum O
, O
along O
with O
fluid O
in O
the O
abdominal O
and O
pelvic O
cavity O
. O

angiotensin O
- O
converting O
enzyme O
inhibitor O
( O
acei O
) O
- O
induced O
angioedema B-Disease
was O
suspected O
, O
and O
anti O
- O
hypertensive B-Disease
medications O
were O
discontinued O
. O

her O
symptoms O
improved O
within O
the O
next O
24 O
hours O
, O
and O
repeat O
ct O
after O
72 O
hours O
revealed O
marked O
improvement O
in O
stomach O
and O
small O
bowel O
thickening O
and O
resolution O
of O
ascites B-Disease
. O

the O
recognition O
of O
angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
and O
angiotensin O
receptor O
blocker O
( O
arb O
) O
intestinal B-Disease
angioedema B-Disease
constitutes O
a O
challenge O
to O
primary O
care O
physicians O
, O
internists O
, O
emergency O
room O
personal O
and O
surgeons O
. O

carbamazepine O
- O
induced O
cardiac B-Disease
dysfunction B-Disease
. O

characterization O
of O
two O
distinct O
clinical O
syndromes O
. O

a O
patient O
with O
sinus O
bradycardia B-Disease
and O
atrioventricular B-Disease
block B-Disease
, O
induced O
by O
carbamazepine O
, O
prompted O
an O
extensive O
literature O
review O
of O
all O
previously O
reported O
cases O
. O

from O
the O
analysis O
of O
these O
cases O
, O
two O
distinct O
forms O
of O
carbamazepine O
- O
associated O
cardiac B-Disease
dysfunction B-Disease
emerged O
. O

one O
patient O
group O
developed O
sinus B-Disease
tachycardias B-Disease
in O
the O
setting O
of O
a O
massive O
carbamazepine O
overdose B-Disease
. O

the O
second O
group O
consisted O
almost O
exclusively O
of O
elderly O
women O
who O
developed O
potentially O
life O
- O
threatening O
bradyarrhythmias B-Disease
or O
atrioventricular B-Disease
conduction B-Disease
delay B-Disease
, O
associated O
with O
either O
therapeutic O
or O
modestly O
elevated O
carbamazepine O
serum O
levels O
. O

because O
carbamazepine O
is O
widely O
used O
in O
the O
treatment O
of O
many O
neurologic O
and O
psychiatric B-Disease
conditions O
, O
the O
recognition O
of O
the O
latter O
syndrome O
has O
important O
implications O
for O
the O
use O
of O
this O
drug O
in O
elderly O
patients O
. O

detection O
of O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
in O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
with O
iodine O
- O
125 O
- O
metaiodobenzylguanidine O
. O

radiolabeled O
metaiodobenzylguanidine O
( O
mibg O
) O
, O
an O
analog O
of O
norepinephrine O
( O
ne O
) O
, O
serves O
as O
an O
index O
of O
adrenergic O
neuron O
integrity O
and O
function O
. O

using O
a O
rat O
model O
of O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
, O
we O
tested O
the O
hypothesis O
that O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
may O
appear O
and O
be O
exacerbated O
dose O
- O
dependently O
in O
adriamycin O
cardiomyopathy B-Disease
. O

the O
degree O
of O
vacuolar B-Disease
degeneration B-Disease
of B-Disease
myocardial B-Disease
cells B-Disease
was O
analyzed O
in O
relation O
to O
the O
duration O
of O
adriamycin O
treatment O
( O
2 O
mg O
/ O
kg O
, O
once O
a O
week O
) O
. O

there O
were O
no O
abnormalities O
or O
only O
isolated O
degeneration O
in O
the O
1 O
- O
or O
2 O
- O
wk O
treatment O
groups O
, O
isolated O
or O
scattered O
degeneration O
in O
half O
of O
the O
3 O
- O
wk O
group O
, O
frequent O
scattered O
degeneration O
in O
the O
4 O
- O
wk O
group O
, O
scattered O
or O
focal O
degeneration O
in O
the O
5 O
- O
wk O
group O
, O
and O
extensive O
degeneration O
in O
the O
8 O
- O
wk O
group O
. O

myocardial O
accumulation O
of O
[ O
125i O
] O
mibg O
4 O
hr O
after O
intravenous O
injection O
did O
not O
differ O
between O
the O
controls O
and O
the O
groups O
treated O
3 O
wk O
or O
less O
. O

however O
, O
the O
4 O
- O
wk O
group O
had O
a O
slightly O
lower O
accumulation O
in O
the O
right O
ventricular O
wall O
( O
82 O
% O
of O
the O
control O
) O
and O
significantly O
lower O
accumulation O
in O
the O
left O
ventricular O
wall O
( O
about O
66 O
% O
of O
the O
control O
: O
p O
less O
than O
0 O
. O
05 O
) O
. O

in O
the O
5 O
- O
wk O
group O
, O
mibg O
accumulation O
in O
the O
right O
and O
left O
ventricular O
wall O
was O
35 O
% O
and O
27 O
% O
of O
that O
in O
controls O
, O
respectively O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

in O
the O
8 O
- O
wk O
group O
, O
mibg O
accumulation O
in O
the O
right O
and O
left O
ventricular O
wall O
was O
18 O
% O
and O
14 O
% O
of O
that O
in O
controls O
, O
respectively O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

thus O
, O
mibg O
accumulation O
in O
the O
myocardium O
decreased O
in O
an O
adriamycin O
dose O
- O
dependent O
manner O
. O

the O
appearance O
of O
impaired O
cardiac O
adrenergic O
neuron O
activity O
in O
the O
presence O
of O
slight O
myocardial B-Disease
impairment B-Disease
( O
scattered O
or O
focal O
vacuolar B-Disease
degeneration B-Disease
) O
indicates O
that O
mibg O
scintigraphy O
may O
be O
a O
useful O
method O
for O
detection O
of O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
. O

syncope B-Disease
and O
qt B-Disease
prolongation B-Disease
among O
patients O
treated O
with O
methadone O
for O
heroin O
dependence O
in O
the O
city O
of O
copenhagen O
. O

background O
: O
methadone O
is O
prescribed O
to O
heroin O
addicts O
to O
decrease O
illicit O
opioid O
use O
. O

prolongation O
of O
the O
qt O
interval O
in O
the O
ecg O
of O
patients O
with O
torsade B-Disease
de B-Disease
pointes B-Disease
( O
tdp B-Disease
) O
has O
been O
reported O
in O
methadone O
users O
. O

as O
heroin O
addicts O
sometimes O
faint O
while O
using O
illicit O
drugs O
, O
doctors O
might O
attribute O
too O
many O
episodes O
of O
syncope B-Disease
to O
illicit O
drug O
use O
and O
thereby O
underestimate O
the O
incidence O
of O
tdp B-Disease
in O
this O
special O
population O
, O
and O
the O
high O
mortality O
in O
this O
population O
may O
, O
in O
part O
, O
be O
caused O
by O
the O
proarrhythmic O
effect O
of O
methadone O
. O

methods O
: O
in O
this O
cross O
- O
sectional O
study O
interview O
, O
ecgs O
and O
blood O
samples O
were O
collected O
in O
a O
population O
of O
adult O
heroin O
addicts O
treated O
with O
methadone O
or O
buprenorphine O
on O
a O
daily O
basis O
. O

of O
the O
patients O
at O
the O
drug O
addiction O
service O
in O
the O
municipal O
of O
copenhagen O
, O
450 O
( O
approximately O
52 O
% O
) O
were O
included O
. O

the O
qt O
interval O
was O
estimated O
from O
12 O
lead O
ecgs O
. O

all O
participants O
were O
interviewed O
about O
any O
experience O
of O
syncope B-Disease
. O

the O
association O
between O
opioid O
dose O
and O
qt O
, O
and O
methadone O
dose O
and O
reporting O
of O
syncope B-Disease
was O
assessed O
using O
multivariate O
linear O
regression O
and O
logistic O
regression O
, O
respectively O
. O

results O
: O
methadone O
dose O
was O
associated O
with O
longer O
qt O
interval O
of O
0 O
. O
140 O
ms O
/ O
mg O
( O
p O
= O
0 O
. O
002 O
) O
. O

no O
association O
between O
buprenorphine O
and O
qtc O
was O
found O
. O

among O
the O
subjects O
treated O
with O
methadone O
, O
28 O
% O
men O
and O
32 O
% O
women O
had O
prolonged B-Disease
qtc B-Disease
interval B-Disease
. O

none O
of O
the O
subjects O
treated O
with O
buprenorphine O
had O
qtc O
interval O
> O
0 O
. O
440 O
s O
( O
( O
1 O
/ O
2 O
) O
) O
. O

a O
50 O
mg O
higher O
methadone O
dose O
was O
associated O
with O
a O
1 O
. O
2 O
( O
95 O
% O
ci O
1 O
. O
1 O
to O
1 O
. O
4 O
) O
times O
higher O
odds O
for O
syncope B-Disease
. O

conclusions O
: O
methadone O
is O
associated O
with O
qt B-Disease
prolongation B-Disease
and O
higher O
reporting O
of O
syncope B-Disease
in O
a O
population O
of O
heroin O
addicts O
. O

neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
induced O
by O
ziprasidone O
on O
the O
second O
day O
of O
treatment O
. O

neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
( O
nms B-Disease
) O
is O
the O
rarest O
and O
most O
serious O
of O
the O
neuroleptic O
- O
induced O
movement B-Disease
disorders B-Disease
. O

we O
describe O
a O
case O
of O
neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
( O
nms B-Disease
) O
associated O
with O
the O
use O
of O
ziprasidone O
. O

although O
conventional O
neuroleptics O
are O
more O
frequently O
associated O
with O
nms B-Disease
, O
atypical O
antipsychotic O
drugs O
like O
ziprasidone O
may O
also O
be O
a O
cause O
. O

the O
patient O
is O
a O
24 O
- O
year O
- O
old O
male O
with O
a O
history O
of O
schizophrenia B-Disease
who O
developed O
signs O
and O
symptoms O
of O
nms B-Disease
after O
2 O
days O
of O
treatment O
with O
an O
80 O
- O
mg O
/ O
day O
dose O
of O
orally O
administrated O
ziprasidone O
. O

this O
case O
is O
the O
earliest O
( O
second O
day O
of O
treatment O
) O
nms B-Disease
due O
to O
ziprasidone O
reported O
in O
the O
literature O
. O

peripheral O
iron O
dextran O
induced O
degeneration B-Disease
of B-Disease
dopaminergic B-Disease
neurons B-Disease
in O
rat O
substantia O
nigra O
. O

iron O
accumulation O
is O
considered O
to O
be O
involved O
in O
the O
pathogenesis O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

to O
demonstrate O
the O
relationship O
between O
peripheral O
iron O
overload O
and O
dopaminergic O
neuron O
loss O
in O
rat O
substantia O
nigra O
( O
sn O
) O
, O
in O
the O
present O
study O
we O
used O
fast O
cyclic O
voltammetry O
, O
tyrosine O
hydroxylase O
( O
th O
) O
immunohistochemistry O
, O
perls O
' O
iron O
staining O
, O
and O
high O
performance O
liquid O
chromatography O
- O
electrochemical O
detection O
to O
study O
the O
degeneration B-Disease
of B-Disease
dopaminergic B-Disease
neurons B-Disease
and O
increased O
iron O
content O
in O
the O
sn O
of O
iron O
dextran O
overloaded O
animals O
. O

the O
findings O
showed O
that O
peripheral O
iron O
dextran O
overload O
increased O
the O
iron O
staining O
positive O
cells O
and O
reduced O
the O
number O
of O
th O
- O
immunoreactive O
neurons O
in O
the O
sn O
. O

as O
a O
result O
, O
dopamine O
release O
and O
content O
, O
as O
well O
as O
its O
metabolites O
contents O
were O
decreased O
in O
caudate O
putamen O
. O

even O
more O
dramatic O
changes O
were O
found O
in O
chronic O
overload O
group O
. O

these O
results O
suggest O
that O
peripheral O
iron O
dextran O
can O
increase O
the O
iron O
level O
in O
the O
sn O
, O
where O
excessive O
iron O
causes O
the O
degeneration B-Disease
of B-Disease
dopaminergic B-Disease
neurons B-Disease
. O

the O
chronic O
iron O
overload O
may O
be O
more O
destructive O
to O
dopaminergic O
neurons O
than O
the O
acute O
iron O
overload O
. O

attenuated O
disruption O
of O
prepulse O
inhibition O
by O
dopaminergic O
stimulation O
after O
maternal O
deprivation O
and O
adolescent O
corticosterone O
treatment O
in O
rats O
. O

the O
development O
of O
schizophrenia B-Disease
may O
include O
an O
early O
neurodevelopmental O
stress O
component O
which O
increases O
vulnerability O
to O
later O
stressful O
life O
events O
, O
in O
combination O
leading O
to O
overt O
disease O
. O

we O
investigated O
the O
effect O
of O
an O
early O
stress O
, O
in O
the O
form O
of O
maternal O
deprivation O
, O
combined O
with O
a O
later O
stress O
, O
simulated O
by O
chronic O
periadolescent O
corticosterone O
treatment O
, O
on O
behaviour O
in O
rats O
. O

acute O
treatment O
with O
apomorphine O
caused O
disruption O
of O
prepulse O
inhibition O
( O
ppi O
) O
in O
controls O
and O
in O
rats O
that O
had O
undergone O
either O
maternal O
deprivation O
or O
corticosterone O
treatment O
, O
but O
was O
surprisingly O
absent O
in O
rats O
that O
had O
undergone O
the O
combined O
early O
and O
late O
stress O
. O

amphetamine O
treatment O
significantly O
disrupted O
ppi O
in O
both O
non O
- O
deprived O
groups O
, O
but O
was O
absent O
in O
both O
maternally O
deprived O
groups O
. O

the O
serotonin O
- O
1a O
receptor O
agonist O
, O
8 O
- O
oh O
- O
dpat O
, O
induced O
a O
significant O
disruption O
of O
ppi O
in O
all O
groups O
. O

amphetamine O
- O
induced O
locomotor B-Disease
hyperactivity B-Disease
was O
similar O
in O
all O
groups O
. O

these O
results O
show O
an O
inhibitory O
interaction O
of O
early O
stress O
, O
caused O
by O
maternal O
deprivation O
, O
combined O
with O
' O
adolescent O
' O
stress O
, O
simulated O
by O
corticosterone O
treatment O
, O
on O
dopaminergic O
regulation O
of O
ppi O
. O

the O
altered O
effects O
of O
apomorphine O
and O
amphetamine O
could O
indicate O
differential O
changes O
in O
dopamine O
receptor O
signalling O
leading O
to O
functional O
desensitisation O
, O
or O
altered O
modulation O
of O
sensory O
gating O
in O
the O
nucleus O
accumbens O
by O
limbic O
structures O
such O
as O
the O
hippocampus O
. O

an O
extremely O
rare O
case O
of O
delusional B-Disease
parasitosis B-Disease
in O
a O
chronic B-Disease
hepatitis B-Disease
c B-Disease
patient O
during O
pegylated O
interferon O
alpha O
- O
2b O
and O
ribavirin O
treatment O
. O

during O
treatment O
of O
chronic B-Disease
hepatitis B-Disease
c B-Disease
patients O
with O
interferon O
and O
ribavirin O
, O
a O
lot O
of O
side O
effects O
are O
described O
. O

twenty O
- O
three O
percent O
to O
44 O
% O
of O
patients O
develop O
depression B-Disease
. O

a O
minority O
of O
patients O
evolve O
to O
psychosis B-Disease
. O

to O
the O
best O
of O
our O
knowledge O
, O
no O
cases O
of O
psychogenic B-Disease
parasitosis B-Disease
occurring O
during O
interferon O
therapy O
have O
been O
described O
in O
the O
literature O
. O

we O
present O
a O
49 O
- O
year O
- O
old O
woman O
who O
developed O
a O
delusional B-Disease
parasitosis B-Disease
during O
treatment O
with O
pegylated O
interferon O
alpha O
- O
2b O
weekly O
and O
ribavirin O
. O

she O
complained O
of O
seeing O
parasites O
and O
the O
larvae O
of O
fleas O
in O
her O
stools O
. O

this O
could O
not O
be O
confirmed O
by O
any O
technical O
examination O
. O

all O
the O
complaints O
disappeared O
after O
stopping O
pegylated O
interferon O
alpha O
- O
2b O
and O
reappeared O
after O
restarting O
it O
. O

she O
had O
a O
complete O
sustained O
viral O
response O
. O

hepatonecrosis B-Disease
and O
cholangitis B-Disease
related O
to O
long O
- O
term O
phenobarbital O
therapy O
: O
an O
autopsy O
report O
of O
two O
patients O
. O

phenobarbital O
( O
pb O
) O
has O
a O
reputation O
for O
safety O
, O
and O
it O
is O
commonly O
believed O
that O
pb O
- O
related O
increases O
in O
serum O
aminotransferase O
levels O
do O
not O
indicate O
or O
predict O
the O
development O
of O
significant O
chronic O
liver B-Disease
disease B-Disease
. O

here O
we O
report O
of O
two O
adult O
patients O
with O
a O
long O
history O
of O
epilepsy B-Disease
treated O
with O
pb O
who O
died O
suddenly O
: O
one O
as O
consequence O
of O
cardiac B-Disease
arrest B-Disease
, O
the O
other O
of O
acute O
bronchopneumonia B-Disease
. O

at O
autopsy O
, O
analysis O
of O
liver O
parenchyma O
revealed O
rich O
portal O
inflammatory O
infiltrate O
, O
which O
consisted O
of O
mixed O
eosinophil O
and O
monocyte O
cells O
, O
associated O
with O
several O
foci O
of O
necrosis B-Disease
surrounded O
by O
a O
hard O
ring O
of O
non O
- O
specific O
granulomatous O
tissue O
. O

inflammatory O
reactions O
of O
internal O
and O
external O
hepatic O
biliary O
ducts O
were O
also O
seen O
. O

our O
findings O
illustrate O
that O
pb O
may O
be O
associated O
with O
chronic O
liver B-Disease
damage B-Disease
, O
which O
may O
lead O
to O
more O
serious O
and O
deleterious O
consequences O
. O

for O
this O
reason O
, O
each O
clinician O
should O
recognize O
this O
entity O
in O
the O
differential O
diagnosis O
of O
pb O
- O
related O
asymptomatic O
chronic B-Disease
hepatic B-Disease
enzyme B-Disease
dysfunction B-Disease
. O

delayed O
leukoencephalopathy B-Disease
with O
stroke B-Disease
- O
like O
presentation O
in O
chemotherapy O
recipients O
. O

background O
: O
a O
transient O
leukoencephalopathy B-Disease
mimicking O
cerebrovascular B-Disease
accident B-Disease
has O
been O
described O
as O
a O
complication O
of O
chemotherapy O
, O
most O
commonly O
in O
recipients O
of O
intrathecal O
methotrexate O
for O
childhood O
leukaemia B-Disease
. O

recently O
published O
neuroimaging O
data O
suggest O
a O
common O
pathophysiology O
associated O
with O
a O
variety O
of O
chemotherapy O
agents O
and O
modes O
of O
administration O
. O

methods O
: O
we O
reviewed O
the O
medical O
literature O
for O
single O
reports O
and O
case O
series O
of O
patients O
presenting O
with O
stroke B-Disease
- O
like O
episodes O
while O
receiving O
systemic O
or O
intrathecal O
chemotherapy O
. O

we O
only O
included O
studies O
providing O
detailed O
neuroimaging O
data O
. O

patients O
with O
cerebrovascular B-Disease
accidents B-Disease
were O
excluded O
. O

results O
: O
we O
identified O
27 O
reports O
of O
toxic O
leukoencephalopathy B-Disease
in O
patients O
treated O
with O
methotrexate O
( O
intrathecal O
, O
systemic O
) O
, O
5 O
- O
fluorouracil O
and O
its O
derivative O
carmofur O
, O
and O
capecitabine O
. O

diffusion O
weighted O
imaging O
( O
dwi O
) O
of O
all O
patients O
revealed O
well O
demarcated O
hyperintense O
lesions B-Disease
within B-Disease
the B-Disease
subcortical B-Disease
white B-Disease
matter B-Disease
of O
the O
cerebral O
hemispheres O
and O
the O
corpus O
callosum O
, O
corresponding O
to O
areas O
of O
decreased O
proton O
diffusion O
on O
apparent O
diffusion O
coefficient O
( O
adc O
) O
maps O
( O
available O
in O
21 O
/ O
27 O
patients O
) O
. O

lesions O
exceeded O
the O
confines O
of O
adjacent O
vascular O
territories O
. O

complete O
resolution O
of O
symptoms O
within O
1 O
- O
4 O
days O
was O
accompanied O
by O
normalisation O
of O
adc O
abnormalities O
. O

however O
, O
fluid O
attenuated O
inversion O
recovery O
( O
flair O
) O
sequences O
frequently O
revealed O
persistent O
white B-Disease
matter B-Disease
abnormalities B-Disease
. O

conclusions O
: O
several O
pathophysiological O
models O
of O
delayed O
leukoencephalopathy B-Disease
after O
exposure O
to O
intrathecal O
or O
systemic O
chemotherapy O
have O
been O
proposed O
. O

dwi O
findings O
in O
this O
cohort O
are O
indicative O
of O
cytotoxic B-Disease
oedema B-Disease
within B-Disease
cerebral B-Disease
white B-Disease
matter B-Disease
and O
lend O
support O
to O
an O
at O
least O
partially O
reversible O
metabolic O
derangement O
as O
the O
basis O
for O
this O
syndrome O
. O

prenatal O
exposure O
to O
fluoxetine O
induces O
fetal B-Disease
pulmonary B-Disease
hypertension B-Disease
in O
the O
rat O
. O

rationale O
: O
fluoxetine O
is O
a O
selective O
serotonin O
reuptake O
inhibitor O
antidepressant O
widely O
used O
by O
pregnant O
women O
. O

epidemiological O
data O
suggest O
that O
fluoxetine O
exposure O
prenatally O
increases O
the O
prevalence O
of O
persistent O
pulmonary B-Disease
hypertension B-Disease
syndrome B-Disease
of O
the O
newborn O
. O

the O
mechanism O
responsible O
for O
this O
effect O
is O
unclear O
and O
paradoxical O
, O
considering O
the O
current O
evidence O
of O
a O
pulmonary B-Disease
hypertension B-Disease
protective O
fluoxetine O
effect O
in O
adult O
rodents O
. O

objectives O
: O
to O
evaluate O
the O
fluoxetine O
effect O
on O
fetal O
rat O
pulmonary O
vascular O
smooth O
muscle O
mechanical O
properties O
and O
cell O
proliferation O
rate O
. O

methods O
: O
pregnant O
rats O
were O
treated O
with O
fluoxetine O
( O
10 O
mg O
/ O
kg O
) O
from O
day O
11 O
through O
day O
21 O
of O
gestation O
. O

measurements O
and O
main O
results O
: O
fetuses O
were O
delivered O
by O
cesarean O
section O
. O

as O
compared O
with O
controls O
, O
fluoxetine O
exposure O
resulted O
in O
fetal B-Disease
pulmonary B-Disease
hypertension B-Disease
as O
evidenced O
by O
an O
increase O
in O
the O
weight O
ratio O
of O
the O
right O
ventricle O
to O
the O
left O
ventricle O
plus O
septum O
( O
p O
= O
0 O
. O
02 O
) O
and O
by O
an O
increase O
in O
pulmonary O
arterial O
medial O
thickness O
( O
p O
< O
0 O
. O
01 O
) O
. O

postnatal O
mortality O
was O
increased O
among O
experimental O
animals O
, O
and O
arterial O
oxygen O
saturation O
was O
96 O
+ O
/ O
- O
1 O
% O
in O
1 O
- O
day O
- O
old O
control O
animals O
and O
significantly O
lower O
( O
p O
< O
0 O
. O
01 O
) O
in O
fluoxetine O
- O
exposed O
pups O
( O
79 O
+ O
/ O
- O
2 O
% O
) O
. O

in O
vitro O
, O
fluoxetine O
induced O
pulmonary O
arterial O
muscle O
contraction O
in O
fetal O
, O
but O
not O
adult O
, O
animals O
( O
p O
< O
0 O
. O
01 O
) O
and O
reduced O
serotonin O
- O
induced O
contraction O
at O
both O
ages O
( O
p O
< O
0 O
. O
01 O
) O
. O

after O
in O
utero O
exposure O
to O
a O
low O
fluoxetine O
concentration O
the O
pulmonary O
arterial O
smooth O
muscle O
cell O
proliferation O
rate O
was O
significantly O
increased O
in O
fetal O
, O
but O
not O
adult O
, O
cells O
( O
p O
< O
0 O
. O
01 O
) O
. O

conclusions O
: O
in O
contrast O
to O
the O
adult O
, O
fluoxetine O
exposure O
in O
utero O
induces O
pulmonary B-Disease
hypertension B-Disease
in O
the O
fetal O
rat O
as O
a O
result O
of O
a O
developmentally O
regulated O
increase O
in O
pulmonary O
vascular O
smooth O
muscle O
proliferation O
. O

disulfiram O
- O
induced O
transient O
optic B-Disease
and B-Disease
peripheral B-Disease
neuropathy B-Disease
: O
a O
case O
report O
. O

aim O
: O
to O
report O
a O
case O
of O
optic B-Disease
and B-Disease
peripheral B-Disease
neuropathy B-Disease
after O
chronic O
use O
of O
disulfiram O
for O
alcohol B-Disease
dependence B-Disease
management O
. O

materials O
and O
methods O
: O
a O
case O
report O
. O

results O
: O
a O
57 O
- O
year O
- O
old O
male O
presented O
with O
gradual O
loss B-Disease
of B-Disease
vision B-Disease
in O
both O
eyes O
with O
intermittent O
headaches B-Disease
for O
2 O
months O
. O

he O
also O
complained O
of O
paraesthesia B-Disease
with O
numbness B-Disease
in O
both O
feet O
. O

his O
vision O
was O
6 O
/ O
15 O
and O
2 O
/ O
60 O
in O
the O
right O
and O
left O
eyes O
, O
respectively O
. O

fundoscopy O
revealed O
bilaterally O
swollen O
optic O
nerve O
heads O
. O

visual O
field O
testing O
confirmed O
bilateral O
central O
- O
caecal O
scotomata B-Disease
. O

he O
had O
been O
taking O
disulfiram O
for O
alcohol B-Disease
dependence B-Disease
for O
the O
preceding O
3 O
years O
. O

disulfiram O
discontinuation O
lead O
to O
an O
immediate O
symptomatic O
improvement O
. O

conclusion O
: O
physicians O
initiating O
long O
- O
term O
disulfiram O
therapy O
should O
be O
aware O
of O
these O
adverse O
effects O
. O

they O
should O
recommend O
annual O
ophthalmic O
reviews O
with O
visual O
field O
testing O
. O

patients O
should O
be O
reassured O
with O
respect O
to O
the O
reversibility O
of O
these O
adverse O
effects O
. O

intraocular O
pressure O
in O
patients O
with O
uveitis B-Disease
treated O
with O
fluocinolone O
acetonide O
implants O
. O

objective O
: O
to O
report O
the O
incidence O
and O
management O
of O
elevated B-Disease
intraocular B-Disease
pressure B-Disease
( O
iop O
) O
in O
patients O
with O
uveitis B-Disease
treated O
with O
the O
fluocinolone O
acetonide O
( O
fa O
) O
intravitreal O
implant O
. O

design O
: O
pooled O
data O
from O
3 O
multicenter O
, O
double O
- O
masked O
, O
randomized O
, O
controlled O
, O
phase O
2b O
/ O
3 O
clinical O
trials O
evaluating O
the O
safety O
and O
efficacy O
of O
the O
0 O
. O
59 O
- O
mg O
or O
2 O
. O
1 O
- O
mg O
fa O
intravitreal O
implant O
or O
standard O
therapy O
were O
analyzed O
. O

results O
: O
during O
the O
3 O
- O
year O
follow O
- O
up O
, O
71 O
. O
0 O
% O
of O
implanted O
eyes O
had O
an O
iop O
increase O
of O
10 O
mm O
hg O
or O
more O
than O
baseline O
and O
55 O
. O
1 O
% O
, O
24 O
. O
7 O
% O
, O
and O
6 O
. O
2 O
% O
of O
eyes O
reached O
an O
iop O
of O
30 O
mm O
hg O
or O
more O
, O
40 O
mm O
hg O
or O
more O
, O
and O
50 O
mm O
hg O
or O
more O
, O
respectively O
. O

topical O
iop O
- O
lowering O
medication O
was O
administered O
in O
74 O
. O
8 O
% O
of O
implanted O
eyes O
, O
and O
iop O
- O
lowering O
surgeries O
, O
most O
of O
which O
were O
trabeculectomies O
( O
76 O
. O
2 O
% O
) O
, O
were O
performed O
on O
36 O
. O
6 O
% O
of O
implanted O
eyes O
. O

intraocular O
pressure O
- O
lowering O
surgeries O
were O
considered O
a O
success O
( O
postoperative O
iop O
of O
6 O
- O
21 O
mm O
hg O
with O
or O
without O
additional O
iop O
- O
lowering O
medication O
) O
in O
85 O
. O
1 O
% O
of O
eyes O
at O
1 O
year O
. O

the O
rate O
of O
hypotony B-Disease
( O
iop O
< O
/ O
= O
5 O
mm O
hg O
) O
following O
iop O
- O
lowering O
surgery O
( O
42 O
. O
5 O
% O
) O
was O
not O
different O
from O
that O
of O
implanted O
eyes O
not O
subjected O
to O
surgery O
( O
35 O
. O
4 O
% O
) O
( O
p O
= O
. O
09 O
) O
. O

conclusion O
: O
elevated O
iop O
is O
a O
significant O
complication O
with O
the O
fa O
intravitreal O
implant O
but O
may O
be O
controlled O
with O
medication O
and O
surgery O
. O

myocardial O
fas O
ligand O
expression O
increases O
susceptibility O
to O
azt O
- O
induced O
cardiomyopathy B-Disease
. O

background O
: O
dilated B-Disease
cardiomyopathy B-Disease
( O
dcm B-Disease
) O
and O
myocarditis B-Disease
occur O
in O
many O
hiv B-Disease
- B-Disease
infected B-Disease
individuals O
, O
resulting O
in O
symptomatic O
heart B-Disease
failure B-Disease
in O
up O
to O
5 O
% O
of O
patients O
. O

highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
has O
significantly O
reduced O
morbidity O
and O
mortality O
of O
acquired B-Disease
immunodeficiency B-Disease
syndrome B-Disease
( O
aids B-Disease
) O
, O
but O
has O
resulted O
in O
an O
increase O
in O
cardiac B-Disease
and B-Disease
skeletal B-Disease
myopathies B-Disease
. O

methods O
and O
results O
: O
in O
order O
to O
investigate O
whether O
the O
haart O
component O
zidovudine O
( O
3 O
' O
- O
azido O
- O
2 O
' O
, O
3 O
' O
- O
deoxythymidine O
; O
azt O
) O
triggers O
the O
fas O
- O
dependent O
cell O
- O
death O
pathway O
and O
cause O
cytoskeletal O
disruption O
in O
a O
murine O
model O
of O
dcm B-Disease
, O
8 O
- O
week O
- O
old O
transgenic O
( O
expressing O
fas O
ligand O
in O
the O
myocardium O
: O
fasl O
tg O
) O
and O
non O
- O
transgenic O
( O
ntg O
) O
mice O
received O
water O
ad O
libitum O
containing O
different O
concentrations O
of O
azt O
( O
0 O
, O
0 O
. O
07 O
, O

0 O
. O
2 O
, O
and O
0 O
. O
7 O
mg O
/ O
ml O
) O
. O

after O
6 O
weeks O
, O
cardiac O
function O
was O
assessed O
by O
echocardiography O
and O
morphology O
was O
assessed O
by O
histopathologic O
and O
immunohistochemical O
methods O
. O

ntg O
and O
untreated O
fasl O
tg O
mice O
showed O
little O
or O
no O
change O
in O
cardiac O
structure O
or O
function O
. O

in O
contrast O
, O
azt O
- O
treated O
fasl O
tg O
mice O
developed O
cardiac B-Disease
dilation B-Disease
and O
depressed O
cardiac O
function O
in O
a O
dose O
- O
dependent O
manner O
, O
with O
concomitant O
inflammatory O
infiltration O
of O
both O
ventricles O
. O

these O
changes O
were O
associated O
with O
an O
increased O
sarcolemmal O
expression O
of O
fas O
and O
fasl O
, O
as O
well O
as O
increased O
activation O
of O
caspase O
3 O
, O
translocation O
of O
calpain O
1 O
to O
the O
sarcolemma O
and O
sarcomere O
, O
and O
increased O
numbers O
of O
cells O
undergoing O
apoptosis O
. O

these O
were O
associated O
with O
changes O
in O
dystrophin O
and O
cardiac O
troponin O
i O
localization O
, O
as O
well O
as O
loss O
of O
sarcolemmal O
integrity O
. O

conclusions O
: O
the O
expression O
of O
fas O
ligand O
in O
the O
myocardium O
, O
as O
identified O
in O
hiv O
- O
positive O
patients O
, O
might O
increase O
the O
susceptibility O
to O
haart O
- O
induced O
cardiomyopathy B-Disease
due O
to O
activation O
of O
apoptotic O
pathways O
, O
resulting O
in O
cardiac B-Disease
dilation B-Disease
and B-Disease
dysfunction B-Disease
. O

gastrointestinal O
tolerability O
of O
etoricoxib O
in O
rheumatoid B-Disease
arthritis B-Disease
patients O
: O
results O
of O
the O
etoricoxib O
vs O
diclofenac O
sodium O
gastrointestinal O
tolerability O
and O
effectiveness O
trial O
( O
edge O
- O
ii O
) O
. O

objective O
: O
a O
randomised O
, O
double O
- O
blind O
study O
to O
compare O
the O
gastrointestinal O
( O
gi O
) O
tolerability O
, O
safety O
and O
efficacy O
of O
etoricoxib O
and O
diclofenac O
in O
patients O
with O
rheumatoid B-Disease
arthritis B-Disease
( O
ra B-Disease
) O
. O

patients O
and O
methods O
: O
a O
total O
of O
4086 O
patients O
( O
mean O
age O
60 O
. O
8 O
years O
) O
diagnosed O
with O
ra B-Disease
were O
enrolled O
and O
received O
etoricoxib O
90 O
mg O
daily O
( O
n O
= O
2032 O
) O
or O
diclofenac O
75 O
mg O
twice O
daily O
( O
n O
= O
2054 O
) O
. O

use O
of O
gastroprotective O
agents O
and O
low O
- O
dose O
aspirin O
was O
allowed O
. O

the O
prespecified O
primary O
end O
point O
consisted O
of O
the O
cumulative O
rate O
of O
patient O
discontinuations O
due O
to O
clinical O
and O
laboratory O
gi O
adverse O
experiences O
( O
aes O
) O
. O

general O
safety O
was O
also O
assessed O
, O
including O
adjudicated O
thrombotic B-Disease
cardiovascular B-Disease
event O
data O
. O

efficacy O
was O
evaluated O
using O
the O
patient O
global O
assessment O
of O
disease O
status O
( O
pgads O
; O
0 O
- O
4 O
point O
scale O
) O
. O

results O
: O
mean O
( O
sd O
; O
maximum O
) O
duration O
of O
treatment O
was O
19 O
. O
3 O
( O
10 O
. O
3 O
; O
32 O
. O
9 O
) O
and O
19 O
. O
1 O
( O
10 O
. O
4 O
; O
33 O
. O
1 O
) O
months O
in O
the O
etoricoxib O
and O
diclofenac O
groups O
, O
respectively O
. O

the O
cumulative O
discontinuation O
rate O
due O
to O
gi B-Disease
aes B-Disease
was O
significantly O
lower O
with O
etoricoxib O
than O
diclofenac O
( O
5 O
. O
2 O
vs O
8 O
. O
5 O
events O
per O
100 O
patient O
- O
years O
, O
respectively O
; O
hazard O
ratio O
0 O
. O
62 O
( O
95 O
% O
ci O
: O
0 O
. O
47 O
, O
0 O
. O
81 O
; O
p O
< O
or O
= O
0 O
. O
001 O
) O
) O
. O

the O
incidence O
of O
discontinuations O
for O
hypertension B-Disease
- O
related O
and O
oedema B-Disease
- O
related O
aes O
were O
significantly O
higher O
with O
etoricoxib O
( O
2 O
. O
5 O
% O
and O
1 O
. O
1 O
% O
respectively O
) O
compared O
with O
diclofenac O
( O
1 O
. O
5 O
% O
and O
0 O
. O
4 O
% O
respectively O
; O
p O
< O
0 O
. O
001 O
for O
hypertension B-Disease
and O
p O
< O
0 O
. O
01 O
for O
oedema B-Disease
) O
. O

etoricoxib O
and O
diclofenac O
treatment O
resulted O
in O
similar O
efficacy O
( O
pgads O
mean O
changes O
from O
baseline O
- O
0 O
. O
62 O
vs O
- O
0 O
. O
58 O
, O
respectively O
) O
. O

conclusions O
: O
etoricoxib O
90 O
mg O
demonstrated O
a O
significantly O
lower O
risk O
for O
discontinuing O
treatment O
due O
to O
gi B-Disease
aes B-Disease
compared O
with O
diclofenac O
150 O
mg O
. O

discontinuations O
from O
renovascular O
aes O
, O
although O
less O
common O
than O
discontinuations O
from O
gi B-Disease
aes B-Disease
, O
were O
significantly O
higher O
with O
etoricoxib O
. O

anxiogenic O
potential O
of O
ciprofloxacin O
and O
norfloxacin O
in O
rats O
. O

introduction O
: O
the O
possible O
anxiogenic O
effects O
of O
fluoroquinolones O
, O
namely O
ciprofloxacin O
and O
norfloxacin O
, O
were O
investigated O
in O
adult O
charles O
foster O
albino O
rats O
of O
either O
sex O
, O
weighing O
150 O
- O
200 O
g O
. O

methods O
: O
the O
drugs O
were O
given O
orally O
, O
in O
doses O
of O
50 O
mg O
/ O
kg O
for O
five O
consecutive O
days O
and O
the O
experiments O
were O
performed O
on O
the O
fifth O
day O
. O

the O
tests O
included O
open O
- O
field O
exploratory O
behaviour O
, O
elevated O
plus O
maze O
and O
elevated O
zero O
maze O
, O
social O
interaction O
and O
novelty O
- O
suppressed O
feeding O
latency O
behaviour O
. O

results O
: O
the O
results O
indicate O
that O
ciprofloxacin O
- O
and O
norfloxacin O
- O
treated O
rats O
showed O
anxious B-Disease
behaviour B-Disease
in O
comparison O
to O
control O
rats O
in O
all O
the O
parameters O
studied O
. O

however O
, O
ciprofloxacin O
- O
and O
norfloxacin O
- O
treated O
rats O
did O
not O
differ O
significantly O
from O
each O
other O
in O
various O
behavioural O
parameters O
. O

conclusion O
: O
the O
present O
experimental O
findings O
substantiate O
the O
clinically O
observed O
anxiogenic O
potential O
of O
ciprofloxacin O
and O
norfloxacin O
. O

reduction O
of O
pain B-Disease
during O
induction O
with O
target O
- O
controlled O
propofol O
and O
remifentanil O
. O

background O
: O
pain B-Disease
on O
injection O
of O
propofol O
is O
unpleasant O
. O

we O
hypothesized O
that O
propofol O
infusion O
pain B-Disease
might O
be O
prevented O
by O
infusing O
remifentanil O
before O
starting O
the O
propofol O
infusion O
in O
a O
clinical O
setting O
where O
target O
- O
controlled O
infusions O
( O
tci O
) O
of O
both O
drugs O
were O
used O
. O

a O
prospective O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
was O
performed O
to O
determine O
the O
effect O
- O
site O
concentration O
( O
ce O
) O
of O
remifentanil O
to O
prevent O
the O
pain B-Disease
without O
producing O
complications O
. O

methods O
: O
a O
total O
of O
128 O
patients O
undergoing O
general O
surgery O
were O
randomly O
allocated O
to O
receive O
normal O
saline O
( O
control O
) O
or O
remifentanil O
to O
a O
target O
ce O
of O
2 O
ng O
ml O
( O
- O
1 O
) O
( O
r2 O
) O
, O
4 O
ng O
ml O
( O
- O
1 O
) O
( O
r4 O
) O
, O
or O
6 O
ng O
ml O
( O
- O
1 O
) O
( O
r6 O
) O
administered O
via O
tci O
. O

after O
the O
target O
ce O
was O
achieved O
, O
the O
infusion O
of O
propofol O
was O
started O
. O

remifentanil O
- O
related O
complications O
were O
assessed O
during O
the O
remifentanil O
infusion O
, O
and O
pain B-Disease
caused O
by O
propofol O
was O
evaluated O
using O
a O
four O
- O
point O
scale O
during O
the O
propofol O
infusion O
. O

results O
: O
the O
incidence O
of O
pain B-Disease
was O
significantly O
lower O
in O
groups O
r4 O
and O
r6 O
than O
in O
the O
control O
and O
r2 O
groups O
( O
12 O
/ O
32 O
and O
6 O
/ O
31 O
vs O
26 O
/ O
31 O
and O
25 O
/ O
32 O
, O
respectively O
, O
p O
< O
0 O
. O
001 O
) O
. O

pain B-Disease
was O
less O
severe O
in O
groups O
r4 O
and O
r6 O
than O
in O
the O
control O
and O
r2 O
groups O
( O
p O
< O
0 O
. O
001 O
) O
. O

however O
, O
both O
incidence O
and O
severity O
of O
pain B-Disease
were O
not O
different O
between O
groups O
r4 O
and O
r6 O
. O

no O
significant O
complications O
were O
observed O
during O
the O
study O
. O

conclusions O
: O
during O
induction O
of O
anaesthesia O
with O
tci O
of O
propofol O
and O
remifentanil O
, O
a O
significant O
reduction O
in O
propofol O
infusion O
pain B-Disease
was O
achieved O
without O
significant O
complications O
by O
prior O
administration O
of O
remifentanil O
at O
a O
target O
ce O
of O
4 O
ng O
ml O
( O
- O
1 O
) O
. O

dexmedetomidine O
and O
cardiac O
protection O
for O
non O
- O
cardiac O
surgery O
: O
a O
meta O
- O
analysis O
of O
randomised O
controlled O
trials O
. O

we O
conducted O
a O
systematic O
review O
of O
the O
effects O
of O
dexmedetomidine O
on O
cardiac O
outcomes O
following O
non O
- O
cardiac O
surgery O
. O

we O
included O
prospective O
, O
randomised O
peri O
- O
operative O
studies O
of O
dexmedetomidine O
that O
reported O
mortality O
, O
cardiac O
morbidity O
or O
adverse O
drug O
events O
. O

a O
pubmed O
central O
and O
embase O
search O
was O
conducted O
up O
to O
july O
2007 O
. O

the O
reference O
lists O
of O
identified O
papers O
were O
examined O
for O
further O
trials O
. O

of O
425 O
studies O
identified O
, O
20 O
were O
included O
in O
the O
meta O
- O
analysis O
( O
840 O
patients O
) O
. O

dexmedetomidine O
was O
associated O
with O
a O
trend O
towards O
improved O
cardiac O
outcomes O
; O
all O
- O
cause O
mortality O
( O
or O
0 O
. O
27 O
, O
95 O
% O
ci O
0 O
. O
01 O
- O
7 O
. O
13 O
, O
p O
= O
0 O
. O
44 O
) O
, O
non O
- O
fatal O
myocardial B-Disease
infarction B-Disease
( O
or O
0 O
. O
26 O
, O
95 O
% O
ci O
0 O
. O
04 O
- O
1 O
. O
60 O
, O
p O
= O
0 O
. O
14 O
) O
, O
and O
myocardial B-Disease
ischaemia B-Disease
( O
or O
0 O
. O
65 O
, O
95 O
% O
ci O
0 O
. O
26 O
- O
1 O
. O
63 O
, O
p O
= O
0 O
. O
36 O
) O
. O

peri O
- O
operative O
hypotension B-Disease
( O
26 O
% O
, O
or O
3 O
. O
80 O
, O
95 O
% O
ci O
1 O
. O
91 O
- O
7 O
. O
54 O
, O
p O
= O
0 O
. O
0001 O
) O
and O
bradycardia B-Disease
( O
17 O
% O
, O
or O
5 O
. O
45 O
, O
95 O
% O
ci O
2 O
. O
98 O
- O
9 O
. O
95 O
, O
p O
< O
0 O
. O
00001 O
) O
were O
significantly O
increased O
. O

an O
anticholinergic O
did O
not O
reduce O
the O
incidence O
of O
bradycardia B-Disease
( O
p O
= O
0 O
. O
43 O
) O
. O

a O
randomised O
placebo O
- O
controlled O
trial O
of O
dexmedetomidine O
is O
warranted O
. O

myocardial B-Disease
infarction B-Disease
in O
pregnancy O
associated O
with O
clomiphene O
citrate O
for O
ovulation O
induction O
: O
a O
case O
report O
. O

background O
: O
clomiphene O
citrate O
( O
cc O
) O
is O
commonly O
prescribed O
for O
ovulation O
induction O
. O

it O
is O
considered O
safe O
, O
with O
minimal O
side O
effects O
. O

thromboembolism B-Disease
is O
a O
rare O
but O
life O
- O
threatening O
complication O
that O
has O
been O
reported O
after O
ovulation O
induction O
with O
cc O
. O

spontaneous O
coronary B-Disease
thrombosis B-Disease
or O
thromboembolism B-Disease
with O
subsequent O
clot O
lysis O
has O
been O
suggested O
as O
one O
of O
the O
most O
common O
causes O
of O
myocardial B-Disease
infarction B-Disease
( O
mi B-Disease
) O
during O
pregnancy O
, O
with O
a O
subsequently O
normal O
coronary O
angiogram O
. O

case O
: O
a O
33 O
- O
year O
- O
old O
woman O
with O
a O
5 O
- O
week O
gestation O
had O
recently O
received O
cc O
for O
ovulation O
induction O
and O
presented O
with O
chest B-Disease
pain B-Disease
. O

an O
electrocardiogram O
showed O
a O
lateral O
and O
anterior O
wall O
myocardial B-Disease
infarction B-Disease
. O

cardiac O
enzymes O
showed O
a O
peak O
rise O
in O
troponin O
i O
to O
9 O
. O
10 O
ng O
/ O
ml O
. O

an O
initial O
exercise O
stress O
test O
was O
normal O
. O

at O
the O
time O
of O
admission O
, O
the O
patient O
was O
at O
high O
risk O
of O
radiation B-Disease
injury B-Disease
to O
the O
fetus O
, O
so O
a O
coronary O
angiogram O
was O
postponed O
until O
the O
second O
trimester O
. O

it O
showed O
normal O
coronary O
vessels O
. O

conclusion O
: O
this O
appears O
to O
be O
the O
first O
reported O
case O
documenting O
a O
possible O
association O
between O
cc O
and O
myocardial B-Disease
infarction B-Disease
. O

thrombosis B-Disease
might O
be O
a O
rare O
but O
hazardous O
complication O
of O
cc O
. O

given O
this O
life O
- O
threatening O
complication O
, O
appropriate O
prophylactic O
measures O
should O
be O
used O
in O
high O
- O
risk O
woman O
undergoing O
ovarian O
stimulation O
. O

reverse O
or O
inverted O
left B-Disease
ventricular B-Disease
apical B-Disease
ballooning B-Disease
syndrome B-Disease
( O
reverse O
takotsubo B-Disease
cardiomyopathy B-Disease
) O
in O
a O
young O
woman O
in O
the O
setting O
of O
amphetamine O
use O
. O

transient O
left B-Disease
ventricular B-Disease
apical B-Disease
ballooning B-Disease
syndrome B-Disease
was O
first O
described O
in O
japan O
as O
" O
takotsubo B-Disease
cardiomyopathy B-Disease
. O
" O
this O
syndrome O
has O
been O
identified O
in O
many O
other O
countries O
. O

many O
variations O
of O
this O
syndrome O
have O
been O
recently O
described O
in O
the O
literature O
. O

one O
of O
the O
rarest O
is O
the O
reverse O
type O
of O
this O
syndrome O
, O
with O
hyperdynamic O
apex O
and O
complete O
akinesia B-Disease
of O
the O
base O
( O
as O
opposed O
to O
the O
classic O
apical B-Disease
ballooning B-Disease
) O
. O

in O
this O
article O
, O
we O
report O
an O
interesting O
case O
of O
a O
young O
woman O
who O
presented O
with O
this O
rare O
type O
of O
reverse O
apical B-Disease
ballooning B-Disease
syndrome B-Disease
occurring O
after O
amphetamine O
use O
. O

this O
report O
is O
followed O
by O
review O
of O
the O
literature O
. O

results O
of O
a O
comparative O
, O
phase O
iii O
, O
12 O
- O
week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double O
- O
blind O
assessment O
of O
the O
efficacy O
and O
tolerability O
of O
a O
fixed O
- O
dose O
combination O
of O
telmisartan O
and O
amlodipine O
versus O
amlodipine O
monotherapy O
in O
indian O
adults O
with O
stage O
ii O
hypertension B-Disease
. O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
a O
new O
fixed O
- O
dose O
combination O
( O
fdc O
) O
of O
telmisartan O
40 O
mg O
+ O
amlodipine O
5 O
mg O
( O
t O
+ O
a O
) O
compared O
with O
amlodipine O
5 O
- O
mg O
monotherapy O
( O
a O
) O
in O
adult O
indian O
patients O
with O
stage O
ii O
hypertension B-Disease
. O

methods O
: O
this O
comparative O
, O
phase O
iii O
, O
12 O
- O
week O
, O
multicenter O
, O
prospective O
, O
randomized O
, O
double O
- O
blind O
study O
was O
conducted O
in O
indian O
patients O
aged O
18 O
to O
65 O
years O
with O
established O
stage O
ii O
hypertension B-Disease
. O

patients O
were O
treated O
with O
oral O
fdc O
of O
t O
+ O
a O
or O
a O
qd O
before O
breakfast O
for O
12 O
weeks O
; O
blood O
pressure O
( O
bp O
) O
and O
heart O
rate O
were O
measured O
in O
the O
sitting O
position O
. O

primary O
efficacy O
end O
points O
were O
reduction O
in O
clinical O
systolic O
bp O
( O
sbp O
) O
/ O
diastolic O
bp O
( O
dbp O
) O
from O
baseline O
to O
study O
end O
and O
number O
of O
responders O
( O
ie O
, O
patients O
who O
achieved O
target O
sbp O
/ O
dbp O
< O
130 O
/ O
< O
80 O
mm O
hg O
) O
at O
end O
of O
study O
. O

tolerability O
was O
assessed O
by O
treatment O
- O
emergent O
adverse O
events O
, O
identified O
using O
physical O
examination O
, O
laboratory O
analysis O
, O
and O
electrocardiography O
. O

results O
: O
a O
total O
of O
210 O
patients O
were O
enrolled O
in O
the O
study O
; O
203 O
patients O
( O
143 O
men O
, O
60 O
women O
) O
completed O
the O
study O
while O
7 O
were O
lost O
to O
follow O
- O
up O
( O
4 O
patients O
in O
the O
t O
+ O
a O
group O
and O
3 O
in O
the O
a O
group O
) O
and O
considered O
with O
- O
drawn O
. O

at O
study O
end O
, O
statistically O
significant O
percentage O
reductions O
from O
baseline O
within O
groups O
and O
between O
groups O
were O
observed O
in O
sbp O
( O
t O
+ O
a O
[ O
- O
27 O
. O
4 O
% O
] O
; O
a O
[ O
- O
16 O
. O
6 O
% O
] O
) O
and O
dbp O
( O
t O
+ O
a O
[ O
- O
20 O
. O
1 O
% O
] O
; O
a O
[ O
- O
13 O
. O
3 O
% O
] O
) O
( O
all O
, O
p O
< O
0 O
. O
05 O
) O
. O

response O
rates O
were O
87 O
. O
3 O
% O
( O
89 O
/ O
102 O
) O
in O
the O
t O
+ O
a O
group O
and O
69 O
. O
3 O
% O
( O
70 O
/ O
101 O
) O
in O
the O
a O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

the O
prevalences O
of O
adverse O
events O
were O
not O
significantly O
different O
between O
the O
2 O
treatment O
groups O
( O
t O
+ O
a O
, O
16 O
. O
0 O
% O
[ O
17 O
/ O
106 O
] O
; O
a O
, O
15 O
. O
4 O
% O
[ O
16 O
/ O
104 O
] O
) O
. O

peripheral O
edema B-Disease
was O
reported O
in O
8 O
. O
5 O
% O
patients O
( O
9 O
/ O
106 O
) O
in O
the O
t O
+ O
a O
group O
compared O
with O
13 O
. O
5 O
% O
( O
14 O
/ O
104 O
) O
in O
the O
a O
group O
, O
and O
cough B-Disease
was O
reported O
in O
3 O
. O
8 O
% O
patients O
( O
4 O
/ O
106 O
) O
in O
the O
t O
+ O
a O
group O
and O
1 O
. O
0 O
% O
( O
1 O
/ O
104 O
) O
patients O
in O
the O
a O
group O
; O
these O
differences O
did O
not O
reach O
statistical O
significance O
. O

the O
incidences O
of O
headache B-Disease
, O
dizziness B-Disease
, O
and O
diarrhea B-Disease
were O
similar O
between O
the O
2 O
groups O
. O

conclusions O
: O
among O
these O
indian O
patients O
with O
stage O
ii O
hypertension B-Disease
, O
the O
fdc O
of O
t O
+ O
a O
was O
found O
to O
be O
significantly O
more O
effective O
, O
with O
regard O
to O
bp O
reductions O
, O
than O
a O
, O
and O
both O
treatments O
were O
well O
tolerated O
. O

increased O
mental B-Disease
slowing B-Disease
associated O
with O
the O
apoe O
epsilon4 O
allele O
after O
trihexyphenidyl O
oral O
anticholinergic O
challenge O
in O
healthy O
elderly O
. O

objectives O
: O
the O
objectives O
of O
this O
study O
were O
to O
examine O
the O
relationship O
between O
apoe O
epsilon4 O
and O
subjective O
effects O
of O
trihexyphenidyl O
on O
measures O
reflecting O
sedation O
and O
confusion B-Disease
and O
to O
investigate O
the O
relationship O
between O
trihexyphenidyl O
- O
induced O
subjective O
effects O
and O
objective O
memory O
performance O
. O

methods O
: O
this O
study O
comprised O
24 O
cognitively O
intact O
, O
health O
elderly O
adults O
( O
12 O
apoe O
epsilon4 O
carriers O
) O
at O
an O
outpatient O
geriatric O
psychiatry O
research O
clinic O
. O

this O
was O
a O
randomized O
, O
double O
blind O
, O
placebo O
- O
controlled O
, O
three O
- O
way O
, O
crossover O
experimental O
design O
. O

all O
participants O
received O
1 O
. O
0 O
mg O
or O
2 O
. O
0 O
mg O
trihexyphenidyl O
or O
placebo O
administered O
in O
counterbalanced O
sequences O
over O
a O
period O
of O
three O
consecutive O
weeks O
. O

bond O
and O
lader O
' O
s O
visual O
analog O
scales O
and O
alternate O
versions O
of O
the O
buschke O
selective O
reminding O
test O
were O
administered O
in O
a O
repeated O
measures O
design O
at O
baseline O
, O
1 O
, O
2 O
. O
5 O
, O
and O
5 O
hours O
postdrug O
administration O
. O

results O
: O
a O
2 O
. O
0 O
- O
mg O
oral O
dose O
of O
trihexyphenidyl O
resulted O
in O
increased O
subjective O
ratings O
of O
mental B-Disease
slowness B-Disease
in O
carriers O
of O
the O
apoe O
epsilon4 O
allele O
only O
. O

drug O
effects O
as O
determined O
by O
difference O
scores O
between O
2 O
. O
0 O
mg O
trihexyphenidyl O
and O
placebo O
on O
ratings O
of O
mental B-Disease
slowness B-Disease
significantly O
correlated O
with O
total O
and O
delayed O
recall O
on O
the O
buschke O
selective O
reminding O
test O
in O
carriers O
of O
the O
apoe O
epsilon4 O
allele O
only O
. O

however O
, O
no O
significant O
effects O
were O
found O
with O
other O
visual O
analog O
scales O
reflecting O
subjective O
sedation O
and O
clear O
- O
headedness O
. O

conclusion O
: O
the O
epsilon4 O
allele O
in O
healthy O
elderly O
was O
associated O
with O
increased O
subjective O
mental B-Disease
slowing B-Disease
after O
trihexyphenidyl O
anticholinergic O
challenge O
. O

an O
evaluation O
of O
amikacin O
nephrotoxicity B-Disease
in O
the O
hematology O
/ O
oncology O
population O
. O

amikacin O
is O
an O
aminoglycoside O
commonly O
used O
to O
provide O
empirical O
double O
gram O
- O
negative O
treatment O
for O
febrile B-Disease
neutropenia B-Disease
and O
other O
suspected O
infections B-Disease
. O

strategies O
of O
extended O
- O
interval O
and O
conventional O
dosing O
have O
been O
utilized O
extensively O
in O
the O
general O
medical O
population O
; O
however O
, O
data O
are O
lacking O
to O
support O
a O
dosing O
strategy O
in O
the O
hematology O
/ O
oncology O
population O
. O

to O
evaluate O
amikacin O
- O
associated O
nephrotoxicity B-Disease
in O
an O
adult O
hematology O
/ O
oncology O
population O
, O
a O
prospective O
, O
randomized O
, O
open O
- O
label O
trial O
was O
conducted O
at O
a O
university O
- O
affiliated O
medical O
center O
. O

forty O
patients O
with O
a O
diagnosis O
consistent O
with O
a O
hematologic B-Disease
/ B-Disease
oncologic B-Disease
disorder B-Disease
that O
required O
treatment O
with O
an O
aminoglycoside O
were O
randomized O
to O
either O
conventional O
or O
extended O
- O
interval O
amikacin O
. O

the O
occurrence O
of O
nephrotoxicity B-Disease
by O
means O
of O
an O
increase O
in O
serum O
creatinine O
and O
evaluation O
of O
efficacy O
via O
amikacin O
serum O
concentrations O
with O
respective O
pathogens O
were O
assessed O
. O

the O
occurrence O
of O
nephrotoxicity B-Disease
was O
similar O
between O
the O
conventional O
and O
extended O
- O
interval O
groups O
, O
at O
10 O
% O
and O
5 O
% O
, O
respectively O
( O
p O
= O
1 O
. O
00 O
) O
. O

six O
patients O
in O
the O
conventional O
group O
had O
a O
positive O
culture O
, O
compared O
with O
none O
in O
the O
extended O
- O
interval O
group O
( O
p O
= O
0 O
. O
002 O
) O
. O

the O
occurrence O
of O
nephrotoxicity B-Disease
was O
similar O
between O
the O
two O
dosing O
regimens O
, O
but O
the O
distribution O
of O
risk O
factors O
was O
variable O
between O
the O
two O
groups O
. O

efficacy O
could O
not O
be O
assessed O
. O

high O
dose O
dexmedetomidine O
as O
the O
sole O
sedative O
for O
pediatric O
mri O
. O

objective O
: O
this O
large O
- O
scale O
retrospective O
review O
evaluates O
the O
sedation O
profile O
of O
dexmedetomidine O
. O

aim O
: O
to O
determine O
the O
hemodynamic O
responses O
, O
efficacy O
and O
adverse O
events O
associated O
with O
the O
use O
of O
high O
dose O
dexmedetomidine O
as O
the O
sole O
sedative O
for O
magnetic O
resonance O
imaging O
( O
mri O
) O
studies O
. O

background O
: O
dexmedetomidine O
has O
been O
used O
at O
our O
institution O
since O
2005 O
to O
provide O
sedation O
for O
pediatric O
radiological O
imaging O
studies O
. O

over O
time O
, O
an O
effective O
protocol O
utilizing O
high O
dose O
dexmedetomidine O
as O
the O
sole O
sedative O
agent O
has O
evolved O
. O

methods O
/ O
materials O
: O
as O
part O
of O
the O
ongoing O
quality O
assurance O
process O
, O
data O
on O
all O
sedations O
are O
reviewed O
monthly O
and O
protocols O
modified O
as O
needed O
. O

data O
were O
analyzed O
from O
all O
747 O
consecutive O
patients O
who O
received O
dexmedetomidine O
for O
mri O
sedation O
from O
april O
2005 O
to O
april O
2007 O
. O

results O
: O
since O
2005 O
, O
the O
10 O
- O
min O
loading O
dose O
of O
our O
dexmedetomidine O
protocol O
increased O
from O
2 O
to O
3 O
microg O
. O
kg O
( O
- O
1 O
) O
, O
and O
the O
infusion O
rate O
increased O
from O
1 O
to O
1 O
. O
5 O
to O
2 O
microg O
. O
kg O
( O
- O
1 O
) O
. O
h O
( O
- O
1 O
) O
. O

the O
current O
sedation O
protocol O
progressively O
increased O
the O
rate O
of O
successful O
sedation O
( O
able O
to O
complete O
the O
imaging O
study O
) O
when O
using O
dexmedetomidine O
alone O
from O
91 O
. O
8 O
% O
to O
97 O
. O
6 O
% O
( O
p O
= O
0 O
. O
009 O
) O
, O
reducing O
the O
requirement O
for O
adjuvant O
pentobarbital O
in O
the O
event O
of O
sedation O
failure O
with O
dexmedetomidine O
alone O
and O
decreased O
the O
mean O
recovery O
time O
by O
10 O
min O
( O
p O
< O
0 O
. O
001 O
) O
. O

although O
dexmedetomidine O
sedation O
was O
associated O
with O
a O
16 O
% O
incidence O
of O
bradycardia B-Disease
, O
all O
concomitant O
mean O
arterial O
blood O
pressures O
were O
within O
20 O
% O
of O
age O
- O
adjusted O
normal O
range O
and O
oxygen O
saturations O
were O
95 O
% O
or O
higher O
. O

conclusion O
: O
dexmedetomidine O
in O
high O
doses O
provides O
adequate O
sedation O
for O
pediatric O
mri O
studies O
. O

while O
use O
of O
high O
dose O
dexmedetomidine O
is O
associated O
with O
decreases O
in O
heart O
rate O
and O
blood O
pressure O
outside O
the O
established O
' O
awake O
' O
norms O
, O
this O
deviation O
is O
generally O
within O
20 O
% O
of O
norms O
, O
and O
is O
not O
associated O
with O
adverse O
sequelae O
. O

dexmedetomidine O
is O
useful O
as O
the O
sole O
sedative O
for O
pediatric O
mri O
. O

hepatotoxicity B-Disease
associated O
with O
sulfasalazine O
in O
inflammatory O
arthritis B-Disease
: O
a O
case O
series O
from O
a O
local O
surveillance O
of O
serious O
adverse O
events O
. O

background O
: O
spontaneous O
reporting O
systems O
for O
adverse O
drug O
reactions O
( O
adrs O
) O
are O
handicapped O
by O
under O
- O
reporting O
and O
limited O
detail O
on O
individual O
cases O
. O

we O
report O
an O
investigation O
from O
a O
local O
surveillance O
for O
serious O
adverse O
drug O
reactions O
associated O
with O
disease O
modifying O
anti O
- O
rheumatic O
drugs O
that O
was O
triggered O
by O
the O
occurrence O
of O
liver B-Disease
failure B-Disease
in O
two O
of O
our O
patients O
. O

methods O
: O
serious O
adr O
reports O
have O
been O
solicited O
from O
local O
clinicians O
by O
regular O
postcards O
over O
the O
past O
seven O
years O
. O

patients O
' O
, O
who O
had O
hepatotoxicity B-Disease
on O
sulfasalazine O
and O
met O
a O
definition O
of O
a O
serious O
adr O
, O
were O
identified O
. O

two O
clinicians O
reviewed O
structured O
case O
reports O
and O
assessed O
causality O
by O
consensus O
and O
by O
using O
a O
causality O
assessment O
instrument O
. O

the O
likely O
frequency O
of O
hepatotoxicity B-Disease
with O
sulfasalazine O
was O
estimated O
by O
making O
a O
series O
of O
conservative O
assumptions O
. O

results O
: O
ten O
cases O
were O
identified O
: O
eight O
occurred O
during O
surveillance O
. O

eight O
patients O
were O
hospitalised O
, O
two O
in O
hepatic B-Disease
failure B-Disease
- O
one O
died O
after O
a O
liver O
transplant O
. O

all O
but O
one O
event O
occurred O
within O
6 O
weeks O
of O
treatment O
. O

seven O
patients O
had O
a O
skin B-Disease
rash B-Disease
, O
three O
eosinophilia B-Disease
and O
one O
interstitial B-Disease
nephritis B-Disease
. O

five O
patients O
were O
of O
black O
british O
of O
african O
or O
caribbean O
descent O
. O

liver O
enzymes O
showed O
a O
hepatocellular O
pattern O
in O
four O
cases O
and O
a O
mixed O
pattern O
in O
six O
. O

drug O
- O
related O
hepatotoxicity B-Disease
was O
judged O
probable O
or O
highly O
probable O
in O
8 O
patients O
. O

the O
likely O
frequency O
of O
serious O
hepatotoxicity B-Disease
with O
sulfasalazine O
was O
estimated O
at O
0 O
. O
4 O
% O
of O
treated O
patients O
. O

conclusion O
: O
serious O
hepatotoxicity B-Disease
associated O
with O
sulfasalazine O
appears O
to O
be O
under O
- O
appreciated O
and O
intensive O
monitoring O
and O
vigilance O
in O
the O
first O
6 O
weeks O
of O
treatment O
is O
especially O
important O
. O

complete O
atrioventricular B-Disease
block B-Disease
secondary O
to O
lithium O
therapy O
. O

sinus B-Disease
node B-Disease
dysfunction B-Disease
has O
been O
reported O
most O
frequently O
among O
the O
adverse O
cardiovascular O
effects O
of O
lithium O
. O

in O
the O
present O
case O
, O
complete O
atrioventricular B-Disease
( B-Disease
av B-Disease
) B-Disease
block B-Disease
with O
syncopal B-Disease
attacks B-Disease
developed O
secondary O
to O
lithium O
therapy O
, O
necessitating O
permanent O
pacemaker O
implantation O
. O

serum O
lithium O
levels O
remained O
under O
or O
within O
the O
therapeutic O
range O
during O
the O
syncopal B-Disease
attacks B-Disease
. O

lithium O
should O
be O
used O
with O
extreme O
caution O
, O
especially O
in O
patients O
with O
mild O
disturbance O
of O
av O
conduction O
. O

exaggerated O
expression O
of O
inflammatory O
mediators O
in O
vasoactive O
intestinal O
polypeptide O
knockout O
( O
vip O
- O
/ O
- O
) O
mice O
with O
cyclophosphamide O
( O
cyp O
) O
- O
induced O
cystitis B-Disease
. O

vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
is O
an O
immunomodulatory O
neuropeptide O
distributed O
in O
micturition O
pathways O
. O

vip O
( O
- O
/ O
- O
) O
mice O
exhibit O
altered O
bladder O
function O
and O
neurochemical O
properties O
in O
micturition O
pathways O
after O
cyclophosphamide O
( O
cyp O
) O
- O
induced O
cystitis B-Disease
. O

given O
vip O
' O
s O
role O
as O
an O
anti O
- O
inflammatory O
mediator O
, O
we O
hypothesized O
that O
vip O
( O
- O
/ O
- O
) O
mice O
would O
exhibit O
enhanced O
inflammatory O
mediator O
expression O
after O
cystitis B-Disease
. O

a O
mouse O
inflammatory O
cytokine O
and O
receptor O
rt2 O
profiler O
array O
was O
used O
to O
determine O
regulated O
transcripts O
in O
the O
urinary O
bladder O
of O
wild O
type O
( O
wt O
) O
and O
vip O
( O
- O
/ O
- O
) O
mice O
with O
or O
without O
cyp O
- O
induced O
cystitis B-Disease
( O
150 O
mg O
/ O
kg O
; O
i O
. O
p O
. O
; O
48 O
h O
) O
. O

four O
binary O
comparisons O
were O
made O
: O
wt O
control O
versus O
cyp O
treatment O
( O
48 O
h O
) O
, O
vip O
( O
- O
/ O
- O
) O
control O
versus O
cyp O
treatment O
( O
48 O
h O
) O
, O
wt O
control O
versus O
vip O
( O
- O
/ O
- O
) O
control O
, O
and O
wt O
with O
cyp O
treatment O
( O
48 O
h O
) O
versus O
vip O
( O
- O
/ O
- O
) O
with O
cyp O
treatment O
( O
48 O
h O
) O
. O

the O
genes O
presented O
represent O
( O
1 O
) O
greater O
than O
1 O
. O
5 O
- O
fold O
change O
in O
either O
direction O
and O
( O
2 O
) O
the O
p O
value O
is O
less O
than O
0 O
. O
05 O
for O
the O
comparison O
being O
made O
. O

several O
regulated O
genes O
were O
validated O
using O
enzyme O
- O
linked O
immunoassays O
including O
il O
- O
1beta O
and O
cxcl1 O
. O

cyp O
treatment O
significantly O
( O
p O
< O
or O
= O
0 O
. O
001 O
) O
increased O
expression O
of O
cxcl1 O
and O
il O
- O
1beta O
in O
the O
urinary O
bladder O
of O
wt O
and O
vip O
( O
- O
/ O
- O
) O
mice O
, O
but O
expression O
in O
vip O
( O
- O
/ O
- O
) O
mice O
with O
cyp O
treatment O
was O
significantly O
( O
p O
< O
or O
= O
0 O
. O
001 O
) O
greater O
( O
4 O
. O
2 O
- O
to O
13 O
- O
fold O
increase O
) O
than O
that O
observed O
in O
wt O
urinary O
bladder O
( O
3 O
. O
6 O
- O
to O
5 O
- O
fold O
increase O
) O
. O

the O
data O
suggest O
that O
in O
vip O
( O
- O
/ O
- O
) O
mice O
with O
bladder B-Disease
inflammation B-Disease
, O
inflammatory O
mediators O
are O
increased O
above O
that O
observed O
in O
wt O
with O
cyp O
. O

this O
shift O
in O
balance O
may O
contribute O
to O
increased O
bladder B-Disease
dysfunction B-Disease
in O
vip O
( O
- O
/ O
- O
) O
mice O
with O
bladder B-Disease
inflammation B-Disease
and O
altered O
neurochemical O
expression O
in O
micturition O
pathways O
. O

debrisoquine O
phenotype O
and O
the O
pharmacokinetics O
and O
beta O
- O
2 O
receptor O
pharmacodynamics O
of O
metoprolol O
and O
its O
enantiomers O
. O

the O
metabolism O
of O
the O
cardioselective O
beta O
- O
blocker O
metoprolol O
is O
under O
genetic O
control O
of O
the O
debrisoquine O
/ O
sparteine O
type O
. O

the O
two O
metabolic O
phenotypes O
, O
extensive O
( O
em O
) O
and O
poor O
metabolizers O
( O
pm O
) O
, O
show O
different O
stereoselective O
metabolism O
, O
resulting O
in O
apparently O
higher O
beta O
- O
1 O
adrenoceptor O
antagonistic O
potency O
of O
racemic O
metoprolol O
in O
ems O
. O

we O
investigated O
if O
the O
latter O
also O
applies O
to O
the O
beta O
- O
2 O
adrenoceptor O
antagonism O
by O
metoprolol O
. O

the O
drug O
effect O
studied O
was O
the O
antagonism O
by O
metoprolol O
of O
terbutaline O
- O
induced O
hypokalemia B-Disease
. O

by O
using O
pharmacokinetic O
pharmacodynamic O
modeling O
the O
pharmacodynamics O
of O
racemic O
metoprolol O
and O
the O
active O
s O
- O
isomer O
, O
were O
quantitated O
in O
ems O
and O
pms O
in O
terms O
of O
ic50 O
values O
, O
representing O
metoprolol O
plasma O
concentrations O
resulting O
in O
half O
- O
maximum O
receptor O
occupancy O
. O

six O
ems O
received O
0 O
. O
5 O
mg O
of O
terbutaline O
s O
. O
c O
. O
on O
two O
different O
occasions O
: O
1 O
) O
1 O
hr O
after O
administration O
of O
a O
placebo O
and O
2 O
) O
1 O
hr O
after O
150 O
mg O
of O
metoprolol O
p O
. O
o O
. O

five O
pms O
were O
studied O
according O
to O
the O
same O
protocol O
, O
except O
for O
a O
higher O
terbutaline O
dose O
( O
0 O
. O
75 O
mg O
) O
on O
day O
2 O
. O

blood O
samples O
for O
the O
analysis O
of O
plasma O
potassium O
, O
terbutaline O
, O
metoprolol O
( O
racemic O
, O
r O
- O
and O
s O
- O
isomer O
) O
, O
and O
alpha O
- O
hydroxymetoprolol O
concentrations O
were O
taken O
at O
regular O
time O
intervals O
, O
during O
8 O
hr O
after O
metoprolol O
. O

in O
pms O
, O
metoprolol O
increased O
the O
terbutaline O
area O
under O
the O
plasma O
concentration O
vs O
. O
time O
curve O
( O
+ O
67 O
% O
) O
. O

higher O
metoprolol O
/ O
alpha O
- O
hydroxymetoprolol O
ratios O
in O
pms O
were O
predictive O
for O
higher O
r O
- O
/ O
s O
- O
isomer O
ratios O
of O
unchanged O
drug O
. O

there O
was O
a O
difference O
in O
metoprolol O
potency O
with O
higher O
racemic O
metoprolol O
ic50 O
values O
in O
pms O
( O
72 O
+ O
/ O
- O
7 O
ng O
. O
ml O
- O
1 O
) O
than O
ems O
( O
42 O
+ O
/ O
- O
8 O
ng O
. O
ml O
- O
1 O
, O
p O
less O
than O
. O
001 O
) O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

the O
hemodynamics O
of O
oxytocin O
and O
other O
vasoactive O
agents O
during O
neuraxial O
anesthesia O
for O
cesarean O
delivery O
: O
findings O
in O
six O
cases O
. O

oxytocin O
is O
a O
commonly O
used O
uterotonic O
that O
can O
cause O
significant O
and O
even O
fatal O
hypotension B-Disease
, O
particularly O
when O
given O
as O
a O
bolus O
. O

the O
resulting O
hypotension B-Disease
can O
be O
produced O
by O
a O
decrease O
in O
systemic O
vascular O
resistance O
or O
cardiac O
output O
through O
a O
decrease O
in O
venous O
return O
. O

parturients O
with O
normal O
volume O
status O
, O
heart O
valves O
and O
pulmonary O
vasculature O
most O
often O
respond O
to O
this O
hypotension B-Disease
with O
a O
compensatory O
increase O
in O
heart O
rate O
and O
stroke B-Disease
volume O
. O

oxytocin O
- O
induced O
hypotension B-Disease
at O
cesarean O
delivery O
may O
be O
incorrectly O
attributed O
to O
blood B-Disease
loss B-Disease
. O

pulse O
power O
analysis O
( O
also O
called O
" O
pulse O
contour O
analysis O
" O
) O
of O
an O
arterial O
pressure O
wave O
form O
allows O
continuous O
evaluation O
of O
systemic O
vascular O
resistance O
and O
cardiac O
output O
in O
real O
time O
, O
thereby O
elucidating O
the O
causative O
factors O
behind O
changes O
in O
blood O
pressure O
. O

pulse O
power O
analysis O
was O
conducted O
in O
six O
cases O
of O
cesarean O
delivery O
performed O
under O
neuraxial O
anesthesia O
. O

hypotension B-Disease
in O
response O
to O
oxytocin O
was O
associated O
with O
a O
decrease O
in O
systemic O
vascular O
resistance O
and O
a O
compensatory O
increase O
in O
stroke B-Disease
volume O
, O
heart O
rate O
and O
cardiac O
output O
. O

pulse O
power O
analysis O
may O
be O
helpful O
in O
determining O
the O
etiology O
of O
and O
treating O
hypotension B-Disease
during O
cesarean O
delivery O
under O
neuraxial O
anesthesia O
. O

protective O
effects O
of O
antithrombin O
on O
puromycin O
aminonucleoside O
nephrosis B-Disease
in O
rats O
. O

we O
investigated O
the O
effects O
of O
antithrombin O
, O
a O
plasma O
inhibitor O
of O
coagulation O
factors O
, O
in O
rats O
with O
puromycin O
aminonucleoside O
- O
induced O
nephrosis B-Disease
, O
which O
is O
an O
experimental O
model O
of O
human O
nephrotic B-Disease
syndrome B-Disease
. O

antithrombin O
( O
50 O
or O
500 O
iu O
/ O
kg O
/ O
i O
. O
v O
. O
) O
was O
administered O
to O
rats O
once O
a O
day O
for O
10 O
days O
immediately O
after O
the O
injection O
of O
puromycin O
aminonucleoside O
( O
50 O
mg O
/ O
kg O
/ O
i O
. O
v O
. O
) O
. O

treatment O
with O
antithrombin O
attenuated O
the O
puromycin O
aminonucleoside O
- O
induced O
hematological B-Disease
abnormalities B-Disease
. O

puromycin O
aminonucleoside O
- O
induced O
renal B-Disease
dysfunction B-Disease
and O
hyperlipidemia B-Disease
were O
also O
suppressed O
. O

histopathological O
examination O
revealed O
severe O
renal B-Disease
damage B-Disease
such O
as O
proteinaceous O
casts O
in O
tubuli O
and O
tubular O
expansion O
in O
the O
kidney O
of O
control O
rats O
, O
while O
an O
improvement O
of O
the O
damage O
was O
seen O
in O
antithrombin O
- O
treated O
rats O
. O

in O
addition O
, O
antithrombin O
treatment O
markedly O
suppressed O
puromycin O
aminonucleoside O
- O
induced O
apoptosis O
of O
renal O
tubular O
epithelial O
cells O
. O

furthermore O
, O
puromycin O
aminonucleoside O
- O
induced O
increases O
in O
renal O
cytokine O
content O
were O
also O
decreased O
. O

these O
findings O
suggest O
that O
thrombin O
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome B-Disease
. O

treatment O
with O
antithrombin O
may O
be O
clinically O
effective O
in O
patients O
with O
nephrotic B-Disease
syndrome B-Disease
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
after O
liver O
transplantation O
. O

background O
: O
unfractionated O
heparin O
sodium O
( O
ufh O
) O
or O
low O
- O
molecular O
weight O
heparin O
( O
lmwh O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis B-Disease
after O
liver O
transplantation O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
is O
an O
adverse O
immune O
- O
mediated O
reaction O
to O
heparin O
, O
resulting O
in O
platelet O
count O
decreases O
of O
more O
than O
50 O
% O
. O

the O
frequencies O
of O
hit B-Disease
after O
liver O
transplantation O
and O
platelet O
factor O
4 O
/ O
heparin O
- O
reactive O
antibody O
( O
hit B-Disease
antibody O
) O
positivity O
in O
liver O
transplantation O
patients O
, O
however O
, O
are O
unknown O
. O

patients O
and O
methods O
: O
the O
32 O
men O
and O
20 O
women O
underwent O
living O
donor O
liver O
transplantation O
. O

we O
started O
lmwh O
( O
25 O
iu O
/ O
kg O
/ O
h O
) O
on O
postoperative O
day O
( O
pod O
) O
1 O
, O
switching O
to O
ufh O
( O
5000 O
u O
/ O
d O
) O
on O
pod O
2 O
or O
3 O
. O

the O
dose O
of O
ufh O
was O
changed O
according O
to O
the O
activated O
clotting O
time O
level O
. O

hit B-Disease
antibody O
levels O
were O
measured O
the O
day O
before O
surgery O
and O
on O
pod O
7 O
and O
14 O
. O

platelet O
count O
was O
measured O
daily O
for O
3 O
weeks O
. O

results O
: O
the O
average O
platelet O
counts O
preoperatively O
, O
and O
on O
pod O
7 O
, O
14 O
, O
and O
21 O
were O
65 O
, O
88 O
, O
149 O
, O
and O
169 O
x O
10 O
( O
9 O
) O
/ O
l O
, O
respectively O
. O

two O
patients O
developed O
hepatic O
artery O
thrombosis B-Disease
on O
pod O
11 O
and O
19 O
, O
respectively O
, O
although O
they O
were O
hit B-Disease
antibody O
- O
negative O
and O
their O
platelet O
counts O
were O
stable O
. O

in O
2 O
other O
patients O
, O
the O
platelet O
count O
decreased O
suddenly O
from O
107 O
x O
10 O
( O
9 O
) O
/ O
l O
on O
pod O
4 O
to O
65 O
x O
10 O
( O
9 O
) O
/ O
l O
on O
pod O
6 O
and O
from O
76 O
x O
10 O
( O
9 O
) O
/ O
l O
on O
pod O
7 O
to O
33 O
x O
10 O
( O
9 O
) O
/ O
l O
on O
pod O
9 O
, O
respectively O
. O

the O
heparin O
- O
induced O
platelet B-Disease
aggregation B-Disease
test O
was O
negative O
in O
these O
patients O
. O

the O
percentage O
of O
hit B-Disease
antibody O
- O
positive O
patients O
was O
0 O
. O
5 O
% O
preoperatively O
, O
5 O
. O
6 O
% O
on O
pod O
7 O
, O
and O
5 O
. O
6 O
% O
on O
pod O
14 O
. O

none O
of O
the O
subjects O
/ O
patients O
developed O
ufh O
- O
related O
hit B-Disease
. O

conclusions O
: O
in O
our O
series O
, O
the O
occurrence O
of O
hit B-Disease
after O
liver O
transplantation O
was O
uncommon O
. O

doxorubicin O
cardiomyopathy B-Disease
- O
induced O
inflammation B-Disease
and O
apoptosis O
are O
attenuated O
by O
gene O
deletion O
of O
the O
kinin O
b1 O
receptor O
. O

clinical O
use O
of O
the O
anthracycline O
doxorubicin O
( O
dox O
) O
is O
limited O
by O
its O
cardiotoxic B-Disease
effects O
, O
which O
are O
attributed O
to O
the O
induction O
of O
apoptosis O
. O

to O
elucidate O
the O
possible O
role O
of O
the O
kinin O
b1 O
receptor O
( O
b1r O
) O
during O
the O
development O
of O
dox O
cardiomyopathy B-Disease
, O
we O
studied O
b1r O
knockout O
mice O
( O
b1r O
( O
- O
/ O
- O
) O
) O
by O
investigating O
cardiac O
inflammation B-Disease
and O
apoptosis O
after O
induction O
of O
dox O
- O
induced O
cardiomyopathy B-Disease
. O

dox O
control O
mice O
showed O
cardiac B-Disease
dysfunction B-Disease
measured O
by O
pressure O
- O
volume O
loops O
in O
vivo O
. O

this O
was O
associated O
with O
a O
reduced O
activation O
state O
of O
akt O
, O
as O
well O
as O
an O
increased O
bax O
/ O
bcl2 O
ratio O
in O
western O
blots O
, O
indicating O
cardiac B-Disease
apoptosis B-Disease
. O

furthermore O
, O
mrna O
levels O
of O
the O
proinflammatory O
cytokine O
interleukin O
6 O
were O
increased O
in O
the O
cardiac O
tissue O
. O

in O
dox O
b1r O
( O
- O
/ O
- O
) O
mice O
, O
cardiac B-Disease
dysfunction B-Disease
was O
improved O
compared O
to O
dox O
control O
mice O
, O
which O
was O
associated O
with O
normalization O
of O
the O
bax O
/ O
bcl O
- O
2 O
ratio O
and O
interleukin O
6 O
, O
as O
well O
as O
akt O
activation O
state O
. O

these O
findings O
suggest O
that O
b1r O
is O
detrimental O
in O
dox O
cardiomyopathy B-Disease
in O
that O
it O
mediates O
the O
inflammatory O
response O
and O
apoptosis O
. O

these O
insights O
might O
have O
useful O
implications O
for O
future O
studies O
utilizing O
b1r O
antagonists O
for O
treatment O
of O
human O
dox O
cardiomyopathy B-Disease
. O

detailed O
spectral O
profile O
analysis O
of O
penicillin O
- O
induced O
epileptiform B-Disease
activity B-Disease
in O
anesthetized O
rats O
. O

penicillin O
model O
is O
a O
widely O
used O
experimental O
model O
for O
epilepsy B-Disease
research O
. O

in O
the O
present O
study O
we O
aimed O
to O
portray O
a O
detailed O
spectral O
analysis O
of O
penicillin O
- O
induced O
epileptiform B-Disease
activity B-Disease
in O
comparison O
with O
basal O
brain O
activity O
in O
anesthetized O
wistar O
rats O
. O

male O
wistar O
rats O
were O
anesthetized O
with O
i O
. O
p O
. O
urethane O
and O
connected O
to O
an O
electrocorticogram O
setup O
. O

after O
a O
short O
period O
of O
basal O
activity O
recording O
, O
epileptic B-Disease
focus O
was O
induced O
by O
injecting O
400iu O
/ O
2 O
microl O
penicillin O
- O
g O
potassium O
into O
the O
left O
lateral O
ventricle O
while O
the O
cortical O
activity O
was O
continuously O
recorded O
. O

basal O
activity O
, O
latent O
period O
and O
the O
penicillin O
- O
induced O
epileptiform B-Disease
activity B-Disease
periods O
were O
then O
analyzed O
using O
both O
conventional O
methods O
and O
spectral O
analysis O
. O

spectral O
analyses O
were O
conducted O
by O
dividing O
the O
whole O
spectrum O
into O
different O
frequency O
bands O
including O
delta O
, O
theta O
( O
slow O
and O
fast O
) O
, O
alpha O
- O
sigma O
, O
beta O
( O
1 O
and O
2 O
) O
and O
gamma O
( O
1 O
and O
2 O
) O
bands O
. O

our O
results O
show O
that O
the O
most O
affected O
frequency O
bands O
were O
delta O
, O
theta O
, O
beta O
- O
2 O
and O
gamma O
- O
2 O
bands O
during O
the O
epileptiform B-Disease
activity B-Disease
and O
there O
were O
marked O
differences O
in O
terms O
of O
spectral O
densities O
between O
three O
investigated O
episodes O
( O
basal O
activity O
, O
latent O
period O
and O
epileptiform B-Disease
activity B-Disease
) O
. O

our O
results O
may O
help O
to O
analyze O
novel O
data O
obtained O
using O
similar O
experimental O
models O
and O
the O
simple O
analysis O
method O
described O
here O
can O
be O
used O
in O
similar O
studies O
to O
investigate O
the O
basic O
neuronal O
mechanism O
of O
this O
or O
other O
types O
of O
experimental O
epilepsies B-Disease
. O

high O
fat O
diet O
- O
fed O
obese B-Disease
rats O
are O
highly O
sensitive O
to O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

often O
, O
chemotherapy O
by O
doxorubicin O
( O
adriamycin O
) O
is O
limited O
due O
to O
life O
threatening O
cardiotoxicity B-Disease
in O
patients O
during O
and O
posttherapy O
. O

recently O
, O
we O
have O
shown O
that O
moderate O
diet O
restriction O
remarkably O
protects O
against O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

this O
cardioprotection O
is O
accompanied O
by O
decreased O
cardiac O
oxidative O
stress O
and O
triglycerides O
and O
increased O
cardiac O
fatty O
- O
acid O
oxidation O
, O
atp O
synthesis O
, O
and O
upregulated O
jak O
/ O
stat3 O
pathway O
. O

in O
the O
current O
study O
, O
we O
investigated O
whether O
a O
physiological O
intervention O
by O
feeding O
40 O
% O
high O
fat O
diet O
( O
hfd O
) O
, O
which O
induces O
obesity B-Disease
in O
male O
sprague O
- O
dawley O
rats O
( O
250 O
- O
275 O
g O
) O
, O
sensitizes O
to O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

a O
ld O
( O
10 O
) O
dose O
( O
8 O
mg O
doxorubicin O
/ O
kg O
, O
ip O
) O
administered O
on O
day O
43 O
of O
the O
hfd O
feeding O
regimen O
led O
to O
higher O
cardiotoxicity B-Disease
, O
cardiac B-Disease
dysfunction B-Disease
, O
lipid O
peroxidation O
, O
and O
80 O
% O
mortality O
in O
the O
obese B-Disease
( O
ob B-Disease
) O
rats O
in O
the O
absence O
of O
any O
significant O
renal B-Disease
or B-Disease
hepatic B-Disease
toxicity B-Disease
. O

doxorubicin O
toxicokinetics O
studies O
revealed O
no O
change O
in O
accumulation O
of O
doxorubicin O
and O
doxorubicinol O
( O
toxic O
metabolite O
) O
in O
the O
normal O
diet O
- O
fed O
( O
nd O
) O
and O
ob B-Disease
hearts O
. O

mechanistic O
studies O
revealed O
that O
ob B-Disease
rats O
are O
sensitized O
due O
to O
: O
( O
1 O
) O
higher O
oxyradical O
stress O
leading O
to O
upregulation O
of O
uncoupling O
proteins O
2 O
and O
3 O
, O
( O
2 O
) O
downregulation O
of O
cardiac O
peroxisome O
proliferators O
activated O
receptor O
- O
alpha O
, O
( O
3 O
) O
decreased O
plasma O
adiponectin O
levels O
, O
( O
4 O
) O
decreased O
cardiac O
fatty O
- O
acid O
oxidation O
( O
666 O
. O
9 O
+ O
/ O
- O
14 O
. O
0 O
nmol O
/ O
min O
/ O
g O
heart O
in O
nd O
versus O
400 O
. O
2 O
+ O
/ O
- O
11 O
. O
8 O
nmol O
/ O
min O
/ O
g O
heart O
in O
ob B-Disease
) O
, O
( O
5 O

) O
decreased O
mitochondrial O
amp O
- O
alpha2 O
protein O
kinase O
, O
and O
( O
6 O
) O
86 O
% O
drop O
in O
cardiac O
atp O
levels O
accompanied O
by O
decreased O
atp O
/ O
adp O
ratio O
after O
doxorubicin O
administration O
. O

decreased O
cardiac O
erythropoietin O
and O
increased O
socs3 O
further O
downregulated O
the O
cardioprotective O
jak O
/ O
stat3 O
pathway O
. O

in O
conclusion O
, O
hfd O
- O
induced O
obese B-Disease
rats O
are O
highly O
sensitized O
to O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
by O
substantially O
downregulating O
cardiac O
mitochondrial O
atp O
generation O
, O
increasing O
oxidative O
stress O
and O
downregulating O
the O
jak O
/ O
stat3 O
pathway O
. O

isoproterenol O
induces O
primary O
loss O
of O
dystrophin O
in O
rat O
hearts O
: O
correlation O
with O
myocardial B-Disease
injury B-Disease
. O

the O
mechanism O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
damage B-Disease
is O
unknown O
, O
but O
a O
mismatch O
of O
oxygen O
supply O
vs O
. O
demand O
following O
coronary O
hypotension B-Disease
and O
myocardial B-Disease
hyperactivity B-Disease
is O
the O
best O
explanation O
for O
the O
complex O
morphological O
alterations O
observed O
. O

severe O
alterations O
in O
the O
structural O
integrity O
of O
the O
sarcolemma O
of O
cardiomyocytes O
have O
been O
demonstrated O
to O
be O
caused O
by O
isoproterenol O
. O

taking O
into O
account O
that O
the O
sarcolemmal O
integrity O
is O
stabilized O
by O
the O
dystrophin O
- O
glycoprotein O
complex O
( O
dgc O
) O
that O
connects O
actin O
and O
laminin O
in O
contractile O
machinery O
and O
extracellular O
matrix O
and O
by O
integrins O
, O
this O
study O
tests O
the O
hypothesis O
that O
isoproterenol O
affects O
sarcolemmal O
stability O
through O
changes O
in O
the O
dgc O
and O
integrins O
. O

we O
found O
different O
sensitivity O
of O
the O
dgc O
and O
integrin O
to O
isoproterenol O
subcutaneous O
administration O
. O

immunofluorescent O
staining O
revealed O
that O
dystrophin O
is O
the O
most O
sensitive O
among O
the O
structures O
connecting O
the O
actin O
in O
the O
cardiomyocyte O
cytoskeleton O
and O
the O
extracellular O
matrix O
. O

the O
sarcomeric O
actin O
dissolution O
occurred O
after O
the O
reduction O
or O
loss O
of O
dystrophin O
. O

subsequently O
, O
after O
lysis O
of O
myofilaments O
, O
gamma O
- O
sarcoglycan O
, O
beta O
- O
dystroglycan O
, O
beta1 O
- O
integrin O
, O
and O
laminin O
alpha O
- O
2 O
expressions O
were O
reduced O
followed O
by O
their O
breakdown O
, O
as O
epiphenomena O
of O
the O
myocytolytic O
process O
. O

in O
conclusion O
, O
administration O
of O
isoproterenol O
to O
rats O
results O
in O
primary O
loss O
of O
dystrophin O
, O
the O
most O
sensitive O
among O
the O
structural O
proteins O
that O
form O
the O
dgc O
that O
connects O
the O
extracellular O
matrix O
and O
the O
cytoskeleton O
in O
cardiomyocyte O
. O

these O
changes O
, O
related O
to O
ischaemic B-Disease
injury B-Disease
, O
explain O
the O
severe O
alterations O
in O
the O
structural O
integrity O
of O
the O
sarcolemma O
of O
cardiomyocytes O
and O
hence O
severe O
and O
irreversible O
injury O
induced O
by O
isoproterenol O
. O

etiologic O
factors O
in O
the O
pathogenesis O
of O
liver B-Disease
tumors B-Disease
associated O
with O
oral O
contraceptives O
. O

within O
the O
last O
several O
years O
, O
previously O
rare O
liver B-Disease
tumors B-Disease
have O
been O
seen O
in O
young O
women O
using O
oral O
contraceptive O
steroids O
. O

the O
registry O
for O
liver B-Disease
tumors B-Disease
associated O
with O
oral O
contraceptives O
at O
the O
university O
of O
california O
, O
irvine O
, O
has O
clearly O
identified O
27 O
cases O
. O

the O
recent O
literature O
contains O
44 O
case O
reports O
. O

common O
to O
these O
71 O
cases O
has O
been O
a O
histopathologic O
diagnosis O
of O
focal B-Disease
nodular B-Disease
hyperplasia B-Disease
, O
adenoma B-Disease
, O
hamartoma B-Disease
, O
and O
hepatoma B-Disease
. O

significant O
statistical O
etiologic O
factors O
include O
prolonged O
uninterrupted O
usage O
of O
oral O
contraceptive O
steroids O
. O

eight O
deaths O
and O
liver O
rupture B-Disease
in O
18 O
patients O
attest O
to O
the O
seriousness O
of O
this O
new O
potentially O
lethal O
adverse O
phenomenon O
. O

ifosfamide O
continuous O
infusion O
without O
mesna O
. O

a O
phase O
i O
trial O
of O
a O
14 O
- O
day O
cycle O
. O

twenty O
patients O
received O
27 O
courses O
of O
ifosfamide O
administered O
as O
a O
24 O
- O
hour O
continuous O
infusion O
for O
14 O
days O
without O
mesna O
. O

the O
goal O
of O
the O
study O
was O
to O
deliver O
a O
dose O
rate O
and O
total O
cumulative O
dose O
of O
ifosfamide O
that O
would O
be O
comparable O
to O
standard O
bolus O
or O
short O
- O
term O
infusions O
administered O
with O
mesna O
. O

dose O
escalations O
proceeded O
from O
200 O
to O
300 O
, O
400 O
, O
450 O
, O
500 O
, O
and O
550 O
mg O
/ O
m2 O
/ O
d O
. O

four O
patients O
developed O
transient O
microscopic O
hematuria B-Disease
at O
400 O
, O
450 O
, O
and O
500 O
mg O
/ O
m2 O
/ O
d O
. O

there O
were O
no O
instances O
of O
macroscopic O
hematuria B-Disease
. O

at O
550 O
mg O
/ O
m2 O
/ O
d O
, O
three O
patients O
experienced O
nonurologic O
toxicity B-Disease
; O
confusion B-Disease
( O
1 O
) O
, O
nausea B-Disease
( O
1 O
) O
, O
and O
grade O
2 O
leukopenia B-Disease
( O
1 O
) O
. O

the O
recommended O
dose O
of O
500 O
mg O
/ O
m2 O
/ O
d O
delivers O
a O
total O
dose O
of O
7 O
g O
/ O
m2 O
per O
cycle O
, O
which O
is O
comparable O
to O
that O
delivered O
in O
clinical O
practice O
for O
bolus O
or O
short O
- O
term O
infusion O
. O

because O
few O
patients O
received O
multiple O
courses O
over O
time O
, O
the O
cumulative O
effects O
are O
indeterminate O
in O
the O
present O
trial O
. O

the O
frequency O
and O
predictability O
of O
hematuria B-Disease
are O
not O
precise O
, O
and O
at O
least O
daily O
monitoring O
by O
urine O
hematest O
is O
essential O
, O
adding O
mesna O
to O
the O
infusate O
in O
patients O
with O
persistent O
hematuria B-Disease
. O

the O
protracted O
infusion O
schedule O
for O
ifosfamide O
permits O
convenient O
outpatient O
administration O
without O
mesna O
and O
reduces O
the O
drug O
cost O
of O
clinical O
usage O
of O
this O
agent O
by O
up O
to O
890 O
per O
cycle O
. O

clinical O
activity O
was O
demonstrated O
in O
a O
single O
patient O
, O
but O
a O
comparative O
trial O
of O
standard O
bolus O
schedules O
with O
the O
protracted O
infusion O
schedule O
will O
be O
necessary O
to O
determine O
if O
the O
clinical O
effectiveness O
of O
the O
drug O
is O
maintained O
. O

a O
case O
of O
ventricular B-Disease
tachycardia B-Disease
related O
to O
caffeine O
pretreatment O
. O

suboptimal O
seizure B-Disease
duration O
is O
commonly O
encountered O
in O
electroconvulsive O
therapy O
practice O
, O
especially O
in O
older O
patients O
with O
higher O
seizure B-Disease
thresholds O
. O

intravenous O
caffeine O
is O
commonly O
used O
to O
improve O
seizure B-Disease
duration O
and O
quality O
in O
such O
patients O
and O
is O
generally O
well O
tolerated O
aside O
from O
occasional O
reports O
of O
relatively O
benign O
ventricular B-Disease
ectopy B-Disease
. O

we O
describe O
a O
patient O
with O
no O
previous O
history O
of O
cardiac B-Disease
disease B-Disease
or O
arrhythmia B-Disease
who O
developed O
sustained O
bigeminy O
and O
2 O
brief O
runs O
of O
ventricular B-Disease
tachycardia B-Disease
after O
caffeine O
administration O
. O

although O
intravenous O
caffeine O
is O
generally O
well O
tolerated O
, O
the O
clinician O
should O
be O
aware O
of O
the O
potential O
for O
unpredictable O
and O
serious O
ventricular B-Disease
arrhythmias B-Disease
. O

fatal O
haemopericardium B-Disease
and O
gastrointestinal B-Disease
haemorrhage B-Disease
due O
to O
possible O
interaction O
of O
cranberry O
juice O
with O
warfarin O
. O

we O
report O
a O
case O
of O
fatal O
internal O
haemorrhage B-Disease
in O
an O
elderly O
man O
who O
consumed O
only O
cranberry O
juice O
for O
two O
weeks O
while O
maintaining O
his O
usual O
dosage O
of O
warfarin O
. O

we O
propose O
that O
naturally O
occurring O
compounds O
such O
as O
flavonoids O
, O
which O
are O
present O
in O
fruit O
juices O
, O
may O
increase O
the O
potency O
of O
warfarin O
by O
competing O
for O
the O
enzymes O
that O
normally O
inactivate O
warfarin O
. O

while O
traditionally O
regarded O
as O
foodstuffs O
, O
consumption O
of O
fruit O
juices O
should O
be O
considered O
when O
patients O
develop O
adverse O
drug O
reactions O
. O

effect O
of O
increasing O
intraperitoneal O
infusion O
rates O
on O
bupropion O
hydrochloride O
- O
induced O
seizures B-Disease
in O
mice O
. O

background O
: O
it O
is O
not O
known O
if O
there O
is O
a O
relationship O
between O
input O
rate O
and O
incidence O
of O
bupropion O
- O
induced O
seizures B-Disease
. O

this O
is O
important O
, O
since O
different O
controlled O
release O
formulations O
of O
bupropion O
release O
the O
active O
drug O
at O
different O
rates O
. O

methods O
: O
we O
investigated O
the O
effect O
of O
varying O
the O
intraperitoneal O
infusion O
rates O
of O
bupropion O
hcl O
120 O
mg O
/ O
kg O
, O
a O
known O
convulsive B-Disease
dose O
50 O
( O
cd50 O
) O
, O
on O
the O
incidence O
and O
severity O
of O
bupropion O
- O
induced O
convulsions B-Disease
in O
the O
swiss O
albino O
mice O
. O

a O
total O
of O
69 O
mice O
, O
approximately O
7 O
weeks O
of O
age O
, O
and O
weighing O
21 O
. O
0 O
to O
29 O
. O
1 O
g O
were O
randomly O
assigned O
to O
bupropion O
hcl O
120 O
mg O
/ O
kg O
treatment O
by O
intraperitoneal O
( O
ip O
) O
administration O
in O
7 O
groups O
( O
9 O
to O
10 O
animals O
per O
group O
) O
. O

bupropion O
hcl O
was O
infused O
through O
a O
surgically O
implanted O
ip O
dosing O
catheter O
with O
infusions O
in O
each O
group O
of O
0 O
min O
, O
15 O
min O
, O
30 O
min O
, O
60 O
min O
, O
90 O
min O
, O
120 O
min O
, O
and O
240 O
min O
. O

the O
number O
, O
time O
of O
onset O
, O
duration O
and O
the O
intensity O
of O
the O
convulsions B-Disease
or O
absence O
of O
convulsions B-Disease
were O
recorded O
. O

results O
: O
the O
results O
showed O
that O
ip O
administration O
of O
bupropion O
hcl O
120 O
mg O
/ O
kg O
by O
bolus O
injection O
induced O
convulsions B-Disease
in O
6 O
out O
of O
10 O
mice O
( O
60 O
% O
of O
convulsing O
mice O
) O
in O
group O
1 O
. O

logistic O
regression O
analysis O
revealed O
that O
infusion O
time O
was O
significant O
( O
p O
= O
0 O
. O
0004 O
; O
odds O
ratio O
= O
0 O
. O
974 O
) O
and O
increasing O
the O
ip O
infusion O
time O
of O
bupropion O
hcl O
120 O
mg O
/ O
kg O
was O
associated O
with O
a O
91 O
% O
reduced O
odds O
of O
convulsions B-Disease
at O
infusion O
times O
of O
15 O
to O
90 O
min O
compared O
to O
bolus O
injection O
. O

further O
increase O
in O
infusion O
time O
resulted O
in O
further O
reduction O
in O
the O
odds O
of O
convulsions B-Disease
to O
99 O
. O
8 O
% O
reduction O
at O
240 O
min O
. O

conclusion O
: O
in O
conclusion O
, O
the O
demonstration O
of O
an O
inverse O
relationship O
between O
infusion O
time O
of O
a O
fixed O
and O
convulsive B-Disease
dose O
of O
bupropion O
and O
the O
risk O
of O
convulsions B-Disease
in O
a O
prospective O
study O
is O
novel O
. O

graft B-Disease
- B-Disease
versus B-Disease
- B-Disease
host B-Disease
disease B-Disease
prophylaxis O
with O
everolimus O
and O
tacrolimus O
is O
associated O
with O
a O
high O
incidence O
of O
sinusoidal B-Disease
obstruction B-Disease
syndrome B-Disease
and O
microangiopathy B-Disease
: O
results O
of O
the O
evtac O
trial O
. O

a O
calcineurin O
inhibitor O
combined O
with O
methotrexate O
is O
the O
standard O
prophylaxis O
for O
graft B-Disease
- B-Disease
versus B-Disease
- B-Disease
host B-Disease
disease B-Disease
( O
gvhd B-Disease
) O
after O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
hsct O
) O
. O

everolimus O
, O
a O
derivative O
of O
sirolimus O
, O
seems O
to O
mediate O
antileukemia O
effects O
. O

we O
report O
on O
a O
combination O
of O
everolimus O
and O
tacrolimus O
in O
24 O
patients O
( O
median O
age O
, O
62 O
years O
) O
with O
either O
myelodysplastic B-Disease
syndrome B-Disease
( O
mds B-Disease
; O
n O
= O
17 O
) O
or O
acute B-Disease
myeloid B-Disease
leukemia B-Disease
( O
aml B-Disease
; O
n O
= O
7 O
) O
undergoing O
intensive O
conditioning O
followed O
by O
hsct O
from O
related O
( O
n O
= O
4 O
) O
or O
unrelated O
( O
n O
= O
20 O
) O
donors O
. O

all O
patients O
engrafted O
, O
and O
only O
1 O
patient O
experienced O
grade O
iv O
mucositis B-Disease
. O

nine O
patients O
( O
37 O
% O
) O
developed O
acute O
grade O
ii O
- O
iv O
gvhd B-Disease
, O
and O
11 O
of O
17 O
evaluable O
patients O
( O
64 O
% O
) O
developed O
chronic O
extensive O
gvhd B-Disease
. O

transplantation B-Disease
- B-Disease
associated B-Disease
microangiopathy B-Disease
( O
tma B-Disease
) O
occurred O
in O
7 O
patients O
( O
29 O
% O
) O
, O
with O
2 O
cases O
of O
acute B-Disease
renal B-Disease
failure B-Disease
. O

the O
study O
was O
terminated O
prematurely O
because O
an O
additional O
6 O
patients O
( O
25 O
% O
) O
developed O
sinusoidal B-Disease
obstruction B-Disease
syndrome B-Disease
( O
sos B-Disease
) O
, O
which O
was O
fatal O
in O
2 O
cases O
. O

with O
a O
median O
follow O
- O
up O
of O
26 O
months O
, O
the O
2 O
- O
year O
overall O
survival O
rate O
was O
47 O
% O
. O

although O
this O
new O
combination O
appears O
to O
be O
effective O
as O
a O
prophylactic O
regimen O
for O
acute O
gvhd B-Disease
, O
the O
incidence O
of O
tma B-Disease
and O
sos B-Disease
is O
considerably O
higher O
than O
seen O
with O
other O
regimens O
. O

longitudinal O
assessment O
of O
air O
conduction O
audiograms O
in O
a O
phase O
iii O
clinical O
trial O
of O
difluoromethylornithine O
and O
sulindac O
for O
prevention O
of O
sporadic O
colorectal B-Disease
adenomas B-Disease
. O

a O
phase O
iii O
clinical O
trial O
assessed O
the O
recurrence O
of O
adenomatous B-Disease
polyps B-Disease
after O
treatment O
for O
36 O
months O
with O
difluoromethylornithine O
( O
dfmo O
) O
plus O
sulindac O
or O
matched O
placebos O
. O

temporary O
hearing B-Disease
loss B-Disease
is O
a O
known O
toxicity B-Disease
of O
treatment O
with O
dfmo O
, O
thus O
a O
comprehensive O
approach O
was O
developed O
to O
analyze O
serial O
air O
conduction O
audiograms O
. O

the O
generalized O
estimating O
equation O
method O
estimated O
the O
mean O
difference O
between O
treatment O
arms O
with O
regard O
to O
change O
in O
air O
conduction O
pure O
tone O
thresholds O
while O
accounting O
for O
within O
- O
subject O
correlation O
due O
to O
repeated O
measurements O
at O
frequencies O
. O

based O
on O
290 O
subjects O
, O
there O
was O
an O
average O
difference O
of O
0 O
. O
50 O
db O
between O
subjects O
treated O
with O
dfmo O
plus O
sulindac O
compared O
with O
those O
treated O
with O
placebo O
( O
95 O
% O
confidence O
interval O
, O
- O
0 O
. O
64 O
to O
1 O
. O
63 O
db O
; O
p O
= O
0 O
. O
39 O
) O
, O
adjusted O
for O
baseline O
values O
, O
age O
, O
and O
frequencies O
. O

in O
the O
normal O
speech O
range O
of O
500 O
to O
3 O
, O
000 O
hz O
, O
an O
estimated O
difference O
of O
0 O
. O
99 O
db O
( O
- O
0 O
. O
17 O
to O
2 O
. O
14 O
db O
; O
p O
= O
0 O
. O
09 O
) O
was O
detected O
. O

dose O
intensity O
did O
not O
add O
information O
to O
models O
. O

there O
were O
14 O
of O
151 O
( O
9 O
. O
3 O
% O
) O
in O
the O
dfmo O
plus O
sulindac O
group O
and O
4 O
of O
139 O
( O
2 O
. O
9 O
% O
) O
in O
the O
placebo O
group O
who O
experienced O
at O
least O
15 O
db O
hearing O
reduction O
from O
baseline O
in O
2 O
or O
more O
consecutive O
frequencies O
across O
the O
entire O
range O
tested O
( O
p O
= O
0 O
. O
02 O
) O
. O

follow O
- O
up O
air O
conduction O
done O
at O
least O
6 O
months O
after O
end O
of O
treatment O
showed O
an O
adjusted O
mean O
difference O
in O
hearing O
thresholds O
of O
1 O
. O
08 O
db O
( O
- O
0 O
. O
81 O
to O
2 O
. O
96 O
db O
; O
p O
= O
0 O
. O
26 O
) O
between O
treatment O
arms O
. O

there O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
subjects O
in O
the O
dfmo O
plus O
sulindac O
group O
who O
experienced O
clinically O
significant O
hearing B-Disease
loss B-Disease
compared O
with O
the O
placebo O
group O
. O

the O
estimated O
attributable O
risk O
of O
ototoxicity B-Disease
from O
exposure O
to O
the O
drug O
is O
8 O
. O
4 O
% O
( O
95 O
% O
confidence O
interval O
, O
- O
2 O
. O
0 O
% O
to O
18 O
. O
8 O
% O
; O
p O
= O
0 O
. O
12 O
) O
. O

there O
is O
a O
< O
2 O
db O
difference O
in O
mean O
threshold O
for O
patients O
treated O
with O
dfmo O
plus O
sulindac O
compared O
with O
those O
treated O
with O
placebo O
. O

proteinase O
3 O
- O
antineutrophil O
cytoplasmic O
antibody O
- O
( O
pr3 O
- O
anca O
) O
positive O
necrotizing O
glomerulonephritis B-Disease
after O
restarting O
sulphasalazine O
treatment O
. O

a O
59 O
- O
year O
- O
old O
woman O
with O
ulcerative B-Disease
colitis B-Disease
developed O
red B-Disease
eyes B-Disease
, O
pleural B-Disease
effusion B-Disease
, O
eosinophilia B-Disease
and O
urinary B-Disease
abnormalities B-Disease
after O
restarting O
of O
sulphasalazine O
treatment O
. O

light O
microscopy O
of O
a O
kidney O
biopsy O
revealed O
segmental B-Disease
necrotizing B-Disease
glomerulonephritis B-Disease
without O
deposition O
of O
immunoglobulin O
or O
complement O
. O

proteinase O
3 O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
pr3 O
- O
anca O
) O
titer O
was O
elevated O
at O
183 O
elisa O
units O
( O
eu O
) O
in O
sera O
( O
normal O
range O
less O
than O
10 O
eu O
) O
, O
myeloperoxidase O
- O
anca O
was O
negative O
. O

pr3 O
- O
anca O
titer O
was O
250 O
and O
1 O
, O
070 O
eu O
in O
pleural B-Disease
effusions B-Disease
on O
right O
and O
left O
side O
, O
respectively O
. O

although O
cessation O
of O
sulphasalazine O
treatment O
resulted O
in O
improvements O
in O
fever B-Disease
, O
red B-Disease
eyes B-Disease
, O
chest B-Disease
pain B-Disease
, O
titer O
of O
c O
- O
reactive O
protein O
and O
volume O
of O
the O
pleural B-Disease
effusions B-Disease
, O
we O
initiated O
steroid O
therapy O
, O
because O
pr3 O
- O
anca O
titer O
rose O
to O
320 O
eu O
, O
eosinophil O
count O
increased O
to O
1 O
, O
100 O
cells O
/ O
microl O
, O
and O
the O
pleural B-Disease
effusion B-Disease
remained O
. O

one O
month O
after O
steroid O
therapy O
, O
the O
pleural B-Disease
effusion B-Disease
disappeared O
, O
and O
pr3 O
- O
anca O
titer O
normalized O
3 O
months O
later O
. O

this O
case O
suggests O
that O
sulphasalazine O
can O
induce O
pr3 O
- O
anca O
- O
positive O
necrotizing O
glomerulonephritis B-Disease
. O

comparison O
of O
unilateral O
pallidotomy O
and O
subthalamotomy O
findings O
in O
advanced O
idiopathic B-Disease
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

a O
prospective O
, O
randomized O
, O
double O
- O
blind O
pilot O
study O
to O
compare O
the O
results O
of O
stereotactic O
unilateral O
pallidotomy O
and O
subthalamotomy O
in O
advanced O
idiopathic B-Disease
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
( O
pd B-Disease
) O
refractory O
to O
medical O
treatment O
was O
designed O
. O

ten O
consecutive O
patients O
( O
mean O
age O
, O
58 O
. O
4 O
+ O
/ O
- O
6 O
. O
8 O
years O
; O
7 O
men O
, O
3 O
women O
) O
with O
similar O
characteristics O
at O
the O
duration O
of O
disease O
( O
mean O
disease O
time O
, O
8 O
. O
4 O
+ O
/ O
- O
3 O
. O
5 O
years O
) O
, O
disabling O
motor O
fluctuations O
( O
hoehn O
_ O
yahr O
stage O
3 O
- O
5 O
in O
off O
- O
drug O
phases O
) O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
were O
selected O
. O

all O
patients O
had O
bilateral O
symptoms O
and O
their O
levodopa O
equivalent O
dosing O
were O
analysed O
. O

six O
patients O
were O
operated O
on O
in O
the O
globus O
pallidus O
interna O
( O
gpi O
) O
and O
four O
in O
the O
subthalamic O
nucleus O
( O
stn O
) O
. O

clinical O
evaluation O
included O
the O
use O
of O
the O
unified O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
rating O
scale O
( O
updrs O
) O
, O
hoehn O
_ O
yahr O
score O
and O
schwab O
england O
activities O
of O
daily O
living O
( O
adl O
) O
score O
in O
' O
on O
' O
- O
and O
' O
off O
' O
- O
drug O
conditions O
before O
surgery O
and O
6 O
months O
after O
surgery O
. O

there O
was O
statistically O
significant O
improvement O
in O
all O
contralateral O
major O
parkinsonian B-Disease
motor O
signs O
in O
all O
patients O
followed O
for O
6 O
months O
. O

levodopa O
equivalent O
daily O
intake O
was O
significantly O
reduced O
in O
the O
stn O
group O
. O

changes O
in O
updrs O
, O
hoehn O
_ O
yahr O
and O
schwab O
england O
adl O
scores O
were O
similar O
in O
both O
groups O
. O

cognitive O
functions O
were O
unchanged O
in O
both O
groups O
. O

complications O
were O
observed O
in O
two O
patients O
: O
one O
had O
a O
left O
homonymous B-Disease
hemianopsia B-Disease
after O
pallidotomy O
and O
another O
one O
developed O
left O
hemiballistic O
movements O
3 O
days O
after O
subthalamotomy O
which O
partly O
improved O
within O
1 O
month O
with O
valproate O
1000 O
mg O
/ O
day O
. O

the O
findings O
of O
this O
study O
suggest O
that O
lesions O
of O
the O
unilateral O
stn O
and O
gpi O
are O
equally O
effective O
treatment O
for O
patients O
with O
advanced O
pd B-Disease
refractory O
to O
medical O
treatment O
. O

dsmm O
xi O
study O
: O
dose O
definition O
for O
intravenous O
cyclophosphamide O
in O
combination O
with O
bortezomib O
/ O
dexamethasone O
for O
remission O
induction O
in O
patients O
with O
newly O
diagnosed O
myeloma B-Disease
. O

a O
clinical O
trial O
was O
initiated O
to O
evaluate O
the O
recommended O
dose O
of O
cyclophosphamide O
in O
combination O
with O
bortezomib O
and O
dexamethasone O
as O
induction O
treatment O
before O
stem O
cell O
transplantation O
for O
younger O
patients O
with O
newly O
diagnosed O
multiple B-Disease
myeloma B-Disease
( O
mm B-Disease
) O
. O

thirty O
patients O
were O
treated O
with O
three O
21 O
- O
day O
cycles O
of O
bortezomib O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
plus O
dexamethasone O
40 O
mg O
on O
the O
day O
of O
bortezomib O
injection O
and O
the O
day O
after O
plus O
cyclophosphamide O
at O
900 O
, O
1 O
, O
200 O
, O
or O
1 O
, O
500 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
. O

the O
maximum O
tolerated O
dose O
of O
cyclophosphamide O
was O
defined O
as O
900 O
mg O
/ O
m O
( O
2 O
) O
. O

at O
this O
dose O
level O
, O
92 O
% O
of O
patients O
achieved O
at O
least O
a O
partial O
response O
. O

the O
overall O
response O
rate O
[ O
complete O
response O
( O
cr O
) O
plus O
partial O
response O
( O
pr O
) O
] O
across O
all O
dose O
levels O
was O
77 O
% O
, O
with O
a O
10 O
% O
cr O
rate O
. O

no O
patient O
experienced O
progressive O
disease O
. O

the O
most O
frequent O
adverse O
events O
were O
hematological B-Disease
and B-Disease
gastrointestinal B-Disease
toxicities B-Disease
as O
well O
as O
neuropathy B-Disease
. O

the O
results O
suggest O
that O
bortezomib O
in O
combination O
with O
cyclophosphamide O
at O
900 O
mg O
/ O
m O
( O
2 O
) O
and O
dexamethasone O
is O
an O
effective O
induction O
treatment O
for O
patients O
with O
newly O
diagnosed O
mm B-Disease
that O
warrants O
further O
investigation O
. O

naloxone O
reversal O
of O
hypotension B-Disease
due O
to O
captopril O
overdose B-Disease
. O

the O
hemodynamic O
effects O
of O
captopril O
and O
other O
angiotensin O
- O
converting O
enzyme O
inhibitors O
may O
be O
mediated O
by O
the O
endogenous O
opioid O
system O
. O

the O
opioid O
antagonist O
naloxone O
has O
been O
shown O
to O
block O
or O
reverse O
the O
hypotensive B-Disease
actions O
of O
captopril O
. O

we O
report O
a O
case O
of O
an O
intentional O
captopril O
overdose B-Disease
, O
manifested O
by O
marked O
hypotension B-Disease
, O
that O
resolved O
promptly O
with O
the O
administration O
of O
naloxone O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
captopril O
- O
induced O
hypotension B-Disease
treated O
with O
naloxone O
. O

our O
experience O
demonstrates O
a O
possible O
role O
of O
naloxone O
in O
the O
reversal O
of O
hypotension B-Disease
resulting O
from O
captopril O
. O

identification O
of O
a O
simple O
and O
sensitive O
microplate O
method O
for O
the O
detection O
of O
oversulfated O
chondroitin O
sulfate O
in O
heparin O
products O
. O

heparin O
is O
a O
commonly O
implemented O
anticoagulant O
used O
to O
treat O
critically O
ill O
patients O
. O

recently O
, O
a O
number O
of O
commercial O
lots O
of O
heparin O
products O
were O
found O
to O
be O
contaminated O
with O
an O
oversulfated O
chondroitin O
sulfate O
( O
oscs O
) O
derivative O
that O
could O
elicit O
a O
hypotensive B-Disease
response O
in O
pigs O
following O
a O
single O
high O
- O
dose O
infusion O
. O

using O
both O
contaminated O
heparin O
products O
and O
the O
synthetically O
produced O
derivative O
, O
we O
showed O
that O
the O
oscs O
produces O
dose O
- O
dependent O
hypotension B-Disease
in O
pigs O
. O

the O
no O
observed O
effect O
level O
( O
noel O
) O
for O
this O
contaminant O
appears O
to O
be O
approximately O
1mg O
/ O
kg O
, O
corresponding O
to O
a O
contamination O
level O
of O
approximately O
3 O
% O
. O

we O
also O
demonstrated O
that O
oscs O
can O
be O
identified O
in O
heparin O
products O
using O
a O
simple O
, O
inexpensive O
, O
commercially O
available O
heparin O
enzyme O
immunoassay O
( O
eia O
) O
kit O
that O
has O
a O
limit O
of O
detection O
of O
approximately O
0 O
. O
1 O
% O
, O
well O
below O
the O
noel O
. O

this O
kit O
may O
provide O
a O
useful O
method O
to O
test O
heparin O
products O
for O
contamination O
with O
oversulfated O
gag O
derivatives O
. O

5 O
flourouracil O
- O
induced O
apical B-Disease
ballooning B-Disease
syndrome B-Disease
: O
a O
case O
report O
. O

the O
apical B-Disease
ballooning B-Disease
syndrome B-Disease
( O
abs B-Disease
) O
is O
a O
recently O
described O
stress O
- O
mediated O
acute B-Disease
cardiac B-Disease
syndrome B-Disease
characterized O
by O
transient O
wall O
- O
motion O
abnormalities O
involving O
the O
apex O
and O
midventricle O
with O
hyperkinesis B-Disease
of O
the O
basal O
left O
ventricular O
( O
lv O
) O
segments O
without O
obstructive O
epicardial B-Disease
coronary B-Disease
disease B-Disease
. O

cardiotoxicity B-Disease
is O
not O
an O
uncommon O
adverse O
effect O
of O
chemotherapeutic O
agents O
. O

however O
, O
there O
are O
no O
reports O
of O
abs B-Disease
secondary O
to O
chemotherapeutic O
agents O
. O

we O
describe O
the O
case O
of O
a O
woman O
who O
developed O
the O
syndrome O
after O
chemotherapy O
for O
metastatic O
cancer B-Disease
. O

a O
79 O
- O
year O
- O
old O
woman O
presented O
with O
typical O
ischemic B-Disease
chest B-Disease
pain B-Disease
, O
elevated O
cardiac O
enzymes O
with O
significant O
st O
- O
segment O
abnormalities O
on O
her O
electrocardiogram O
. O

she O
underwent O
recent O
chemotherapy O
with O
fluorouracil O
for O
metastatic O
colorectal B-Disease
cancer B-Disease
. O

echocardiography O
revealed O
a O
wall O
- O
motion O
abnormality O
involving O
the O
apical O
and O
periapical O
segments O
which O
appeared O
akinetic B-Disease
. O

coronary O
angiography O
revealed O
no O
obstructive O
coronary O
lesions O
. O

the O
patient O
was O
stabilized O
with O
medical O
therapy O
. O

four O
weeks O
later O
she O
remained O
completely O
asymptomatic O
. O

echocardiogram O
revealed O
a O
normal O
ejection O
fraction O
and O
a O
resolution O
of O
the O
apical O
akinesis B-Disease
. O

pathogenetic O
mechanisms O
of O
cardiac B-Disease
complications B-Disease
in O
cancer B-Disease
patients O
undergoing O
chemotherapy O
include O
coronary B-Disease
vasospasm B-Disease
, O
endothelial O
damage O
and O
consequent O
thrombus B-Disease
formation O
. O

in O
our O
patient O
, O
both O
supraphysiologic O
levels O
of O
plasma O
catecholamines O
and O
stress O
related O
neuropeptides O
caused O
by O
cancer B-Disease
diagnosis O
as O
well O
as O
chemotherapy O
may O
have O
contributed O
the O
development O
of O
abs B-Disease
. O

rapid O
reversal O
of O
anticoagulation O
reduces O
hemorrhage B-Disease
volume O
in O
a O
mouse O
model O
of O
warfarin O
- O
associated O
intracerebral B-Disease
hemorrhage B-Disease
. O

warfarin O
- O
associated O
intracerebral B-Disease
hemorrhage B-Disease
( O
w O
- O
ich B-Disease
) O
is O
a O
severe O
type O
of O
stroke B-Disease
. O

there O
is O
no O
consensus O
on O
the O
optimal O
treatment O
for O
w O
- O
ich B-Disease
. O

using O
a O
mouse O
model O
, O
we O
tested O
whether O
the O
rapid O
reversal O
of O
anticoagulation O
using O
human O
prothrombin O
complex O
concentrate O
( O
pcc O
) O
can O
reduce O
hemorrhagic O
blood O
volume O
. O

male O
cd O
- O
1 O
mice O
were O
treated O
with O
warfarin O
( O
2 O
mg O
/ O
kg O
over O
24 O
h O
) O
, O
resulting O
in O
a O
mean O
( O
+ O
/ O
- O
s O
. O
d O
. O
) O
international O
normalized O
ratio O
of O
3 O
. O
5 O
+ O
/ O
- O
0 O
. O
9 O
. O

first O
, O
we O
showed O
that O
an O
intravenous O
administration O
of O
human O
pcc O
rapidly O
reversed O
anticoagulation O
in O
mice O
. O

second O
, O
a O
stereotactic O
injection O
of O
collagenase O
was O
administered O
to O
induce O
hemorrhage B-Disease
in O
the O
right O
striatum O
. O

forty O
- O
five O
minutes O
later O
, O
the O
animals O
were O
randomly O
treated O
with O
pcc O
( O
100 O
u O
/ O
kg O
) O
or O
saline O
i O
. O
v O
. O
( O
n O
= O
12 O
per O
group O
) O
. O

twenty O
- O
four O
hours O
after O
hemorrhage B-Disease
induction O
, O
hemorrhagic O
blood O
volume O
was O
quantified O
using O
a O
photometric O
hemoglobin O
assay O
. O

the O
mean O
hemorrhagic O
blood O
volume O
was O
reduced O
in O
pcc O
- O
treated O
animals O
( O
6 O
. O
5 O
+ O
/ O
- O
3 O
. O
1 O
microl O
) O
compared O
with O
saline O
controls O
( O
15 O
. O
3 O
+ O
/ O
- O
11 O
. O
2 O
microl O
, O
p O
= O
0 O
. O
015 O
) O
. O

in O
the O
saline O
group O
, O
45 O
% O
of O
the O
mice O
developed O
large O
hematomas B-Disease
( O
i O
. O
e O
. O
, O
> O
15 O
microl O
) O
. O

in O
contrast O
, O
such O
extensive O
lesions O
were O
never O
found O
in O
the O
pcc O
group O
. O

we O
provide O
experimental O
data O
suggesting O
pcc O
to O
be O
an O
effective O
acute O
treatment O
for O
w O
- O
ich B-Disease
in O
terms O
of O
reducing O
hemorrhagic O
blood O
volume O
. O

future O
studies O
are O
needed O
to O
assess O
the O
therapeutic O
potential O
emerging O
from O
our O
finding O
for O
human O
w O
- O
ich B-Disease
. O

long O
term O
hormone O
therapy O
for O
perimenopausal O
and O
postmenopausal O
women O
. O

background O
: O
hormone O
therapy O
( O
ht O
) O
is O
widely O
used O
for O
controlling O
menopausal O
symptoms O
and O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B-Disease
disease B-Disease
, O
osteoporosis B-Disease
and O
dementia B-Disease
in O
older O
women O
. O

this O
is O
an O
updated O
version O
of O
the O
original O
cochrane O
review O
first O
published O
in O
2005 O
. O

objectives O
: O
to O
assess O
the O
effect O
of O
long O
- O
term O
ht O
on O
mortality O
, O
cardiovascular O
outcomes O
, O
cancer B-Disease
, O
gallbladder B-Disease
disease B-Disease
, O
cognition O
, O
fractures B-Disease
and O
quality O
of O
life O
. O

search O
strategy O
: O
we O
searched O
the O
following O
databases O
to O
november O
2007 O
: O
trials O
register O
of O
the O
cochrane O
menstrual B-Disease
disorders B-Disease
and O
subfertility O
group O
, O
cochrane O
central O
register O
of O
controlled O
trials O
, O
medline O
, O
embase O
, O
biological O
abstracts O
. O

also O
relevant O
non O
- O
indexed O
journals O
and O
conference O
abstracts O
. O

selection O
criteria O
: O
randomised O
double O
- O
blind O
trials O
of O
ht O
versus O
placebo O
, O
taken O
for O
at O
least O
one O
year O
by O
perimenopausal O
or O
postmenopausal O
women O
. O

ht O
included O
oestrogens O
, O
with O
or O
without O
progestogens O
, O
via O
oral O
, O
transdermal O
, O
subcutaneous O
or O
transnasal O
routes O
. O

data O
collection O
and O
analysis O
: O
two O
authors O
independently O
assessed O
trial O
quality O
and O
extracted O
data O
. O

main O
results O
: O
nineteen O
trials O
involving O
41 O
, O
904 O
women O
were O
included O
. O

in O
relatively O
healthy O
women O
, O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thrombo B-Disease
- B-Disease
embolism B-Disease
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B-Disease
( O
after O
three O
years O
) O
, O
breast B-Disease
cancer B-Disease
and O
gallbladder B-Disease
disease B-Disease
. O

long O
- O
term O
oestrogen O
- O
only O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thrombo B-Disease
- B-Disease
embolism B-Disease
, O
stroke B-Disease
and O
gallbladder B-Disease
disease B-Disease
( O
after O
one O
to O
two O
years O
, O
three O
years O
and O
seven O
years O
' O
use O
respectively O
) O
, O
but O
did O
not O
significantly O
increase O
the O
risk O
of O
breast B-Disease
cancer B-Disease
. O

the O
only O
statistically O
significant O
benefits O
of O
ht O
were O
a O
decreased O
incidence O
of O
fractures B-Disease
and O
( O
for O
combined O
ht O
) O
colon B-Disease
cancer B-Disease
, O
with O
long O
- O
term O
use O
. O

among O
women O
aged O
over O
65 O
who O
were O
relatively O
healthy O
( O
i O
. O
e O
. O
generally O
fit O
, O
without O
overt O
disease O
) O
and O
taking O
continuous O
combined O
ht O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B-Disease
. O

among O
women O
with O
cardiovascular B-Disease
disease B-Disease
, O
long O
- O
term O
use O
of O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thrombo B-Disease
- B-Disease
embolism B-Disease
. O
one O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
old O
women O
taking O
combined O
continuous O
ht O
and O
1637 O
taking O
oestrogen O
- O
only O
ht O
, O
versus O
similar O
- O
sized O
placebo O
groups O
. O

the O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B-Disease
thrombo B-Disease
- B-Disease
embolism B-Disease
in O
women O
taking O
combined O
continuous O
ht O
: O
their O
absolute O
risk O
remained O
low O
, O
at O
less O
than O
1 O
/ O
500 O
. O

however O
, O
this O
study O
was O
not O
powered O
to O
detect O
differences O
between O
groups O
of O
younger O
women O
. O

authors O
' O
conclusions O
: O
ht O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic O
disease O
. O

we O
need O
more O
evidence O
on O
the O
safety O
of O
ht O
for O
menopausal O
symptom O
control O
, O
though O
short O
- O
term O
use O
appears O
to O
be O
relatively O
safe O
for O
healthy O
younger O
women O
. O

acute B-Disease
renal B-Disease
failure B-Disease
in O
patients O
with O
aids B-Disease
on O
tenofovir O
while O
receiving O
prolonged O
vancomycin O
course O
for O
osteomyelitis B-Disease
. O

renal B-Disease
failure B-Disease
developed O
after O
a O
prolonged O
course O
of O
vancomycin O
therapy O
in O
2 O
patients O
who O
were O
receiving O
tenofovir O
disoproxil O
fumarate O
as O
part O
of O
an O
antiretroviral O
regimen O
. O

tenofovir O
has O
been O
implicated O
in O
the O
development O
of O
fanconi B-Disease
syndrome B-Disease
and O
renal B-Disease
insufficiency B-Disease
because O
of O
its O
effects O
on O
the O
proximal O
renal O
tubule O
. O

vancomycin O
nephrotoxicity B-Disease
is O
infrequent O
but O
may O
result O
from O
coadministration O
with O
a O
nephrotoxic B-Disease
agent O
. O

clinicians O
should O
be O
aware O
that O
tenofovir O
may O
raise O
the O
risk O
of O
renal B-Disease
failure B-Disease
during O
prolonged O
administration O
of O
vancomycin O
. O

recurrent O
dysosmia B-Disease
induced O
by O
pyrazinamide O
. O

pyrazinamide O
can O
have O
adverse O
effects O
such O
as O
hepatic B-Disease
toxicity B-Disease
, O
hyperuricemia B-Disease
or O
digestive O
disorders O
. O

in O
rare O
cases O
, O
alterations O
in O
taste O
and O
smell O
function O
have O
been O
reported O
for O
pyrazinamide O
when O
combined O
with O
other O
drugs O
. O

we O
report O
a O
case O
of O
reversible O
olfactory B-Disease
disorder B-Disease
related O
to O
pyrazinamide O
in O
a O
woman O
, O
with O
a O
positive O
rechallenge O
. O

the O
patient O
presented O
every O
day O
a O
sensation O
of O
smelling O
something O
burning O
15 O
min O
after O
drug O
intake O
. O

dysosmia B-Disease
disappeared O
completely O
after O
pyrazinamide O
withdrawal O
and O
recurred O
after O
its O
rechallenge O
. O

the O
case O
was O
reported O
to O
the O
tunisian O
centre O
of O
pharmacovigilance O
. O

mice O
lacking O
mpges O
- O
1 O
are O
resistant O
to O
lithium O
- O
induced O
polyuria B-Disease
. O

cyclooxygenase O
- O
2 O
activity O
is O
required O
for O
the O
development O
of O
lithium O
- O
induced O
polyuria B-Disease
. O

however O
, O
the O
involvement O
of O
a O
specific O
, O
terminal O
prostaglandin O
( O
pg O
) O
isomerase O
has O
not O
been O
evaluated O
. O

the O
present O
study O
was O
undertaken O
to O
assess O
lithium O
- O
induced O
polyuria B-Disease
in O
mice O
deficient O
in O
microsomal O
prostaglandin O
e O
synthase O
- O
1 O
( O
mpges O
- O
1 O
) O
. O

a O
2 O
- O
wk O
administration O
of O
licl O
( O
4 O
mmol O
. O
kg O
( O
- O
1 O
) O
. O
day O
( O
- O
1 O
) O
ip O
) O
in O
mpges O
- O
1 O
+ O
/ O
+ O
mice O
led O
to O
a O
marked O
polyuria B-Disease
with O
hyposmotic O
urine O
. O

this O
was O
associated O
with O
elevated O
renal O
mpges O
- O
1 O
protein O
expression O
and O
increased O
urine O
pge O
( O
2 O
) O
excretion O
. O

in O
contrast O
, O
mpges O
- O
1 O
- O
/ O
- O
mice O
were O
largely O
resistant O
to O
lithium O
- O
induced O
polyuria B-Disease
and O
a O
urine O
concentrating O
defect O
, O
accompanied O
by O
nearly O
complete O
blockade O
of O
high O
urine O
pge O
( O
2 O
) O
and O
camp O
output O
. O

immunoblotting O
, O
immunohistochemistry O
, O
and O
quantitative O
( O
q O
) O
rt O
- O
pcr O
consistently O
detected O
a O
significant O
decrease O
in O
aquaporin O
- O
2 O
( O
aqp2 O
) O
protein O
expression O
in O
both O
the O
renal O
cortex O
and O
medulla O
of O
lithium O
- O
treated O
+ O
/ O
+ O
mice O
. O

this O
decrease O
was O
significantly O
attenuated O
in O
the O
- O
/ O
- O
mice O
. O

qrt O
- O
pcr O
detected O
similar O
patterns O
of O
changes O
in O
aqp2 O
mrna O
in O
the O
medulla O
but O
not O
in O
the O
cortex O
. O

similarly O
, O
the O
total O
protein O
abundance O
of O
the O
na O
- O
k O
- O
2cl O
cotransporter O
( O
nkcc2 O
) O
in O
the O
medulla O
but O
not O
in O
the O
cortex O
of O
the O
+ O
/ O
+ O
mice O
was O
significantly O
reduced O
by O
lithium O
treatment O
. O

in O
contrast O
, O
the O
dowregulation O
of O
renal O
medullary O
nkcc2 O
expression O
was O
significantly O
attenuated O
in O
the O
- O
/ O
- O
mice O
. O

we O
conclude O
that O
mpges O
- O
1 O
- O
derived O
pge O
( O
2 O
) O
mediates O
lithium O
- O
induced O
polyuria B-Disease
likely O
via O
inhibition O
of O
aqp2 O
and O
nkcc2 O
expression O
. O

preservation O
of O
renal O
blood O
flow O
during O
hypotension B-Disease
induced O
with O
fenoldopam O
in O
dogs O
. O

the O
introduction O
of O
drugs O
that O
could O
induce O
hypotension B-Disease
with O
different O
pharmacological O
actions O
would O
be O
advantageous O
because O
side O
effects O
unique O
to O
a O
specific O
drug O
could O
be O
minimized O
by O
selecting O
appropriate O
therapy O
. O

specific O
dopamine O
- O
1 O
, O
( O
da1 O
) O
and O
dopamine O
- O
2 O
( O
da2 O
) O
receptor O
agonists O
are O
now O
under O
clinical O
investigation O
. O

fenoldopam O
mesylate O
is O
a O
specific O
da1 O
receptor O
agonist O
that O
lowers O
blood O
pressure O
by O
vasodilatation O
. O

the O
hypothesis O
that O
fenoldopam O
could O
be O
used O
to O
induce O
hypotension B-Disease
and O
preserve O
blood O
flow O
to O
the O
kidney O
was O
tested O
. O

systemic O
aortic O
blood O
pressure O
and O
renal O
blood O
flow O
were O
measured O
continuously O
with O
a O
carotid O
arterial O
catheter O
and O
an O
electromagnetic O
flow O
probe O
respectively O
, O
in O
order O
to O
compare O
the O
cardiovascular O
and O
renal O
vascular O
effects O
of O
fenoldopam O
and O
sodium O
nitroprusside O
in O
ten O
dogs O
under O
halothane O
general O
anaesthesia O
. O

mean O
arterial O
pressure O
was O
decreased O
30 O
+ O
/ O
- O
8 O
per O
cent O
from O
control O
with O
infusion O
of O
fenoldopam O
( O
3 O
. O
4 O
+ O
/ O
- O
2 O
. O
0 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
) O
and O
34 O
+ O
/ O
- O
4 O
per O
cent O
with O
infusion O
of O
sodium O
nitroprusside O
( O
5 O
. O
9 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
) O
( O
ns O
) O
. O

renal O
blood O
flow O
( O
rbf O
) O
increased O
during O
fenoldopam O
- O
induced O
hypotension B-Disease
11 O
+ O
/ O
- O
7 O
per O
cent O
and O
decreased O
21 O
+ O
/ O
- O
8 O
per O
cent O
during O
sodium O
nitroprusside O
- O
induced O
hypotension B-Disease
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

sodium O
nitroprusside O
is O
a O
non O
- O
selective O
arteriolar O
and O
venous O
vasodilator O
that O
can O
produce O
redistribution O
of O
blood O
flow O
away O
from O
the O
kidney O
during O
induced O
hypotension B-Disease
. O

fenoldopam O
is O
a O
selective O
dopamine O
- O
1 O
( O
da1 O
) O
receptor O
agonist O
that O
causes O
vasodilatation O
to O
the O
kidney O
and O
other O
organs O
with O
da1 O
receptors O
and O
preserves O
blood O
flow O
to O
the O
kidney O
during O
induced O
hypotension B-Disease
. O

seizures B-Disease
associated O
with O
levofloxacin O
: O
case O
presentation O
and O
literature O
review O
. O

purpose O
: O
we O
present O
a O
case O
of O
a O
patient O
who O
developed O
seizures B-Disease
shortly O
after O
initiating O
treatment O
with O
levofloxacin O
and O
to O
discuss O
the O
potential O
drug O
- O
drug O
interactions O
related O
to O
the O
inhibition O
of O
cytochrome O
p450 O
( O
cyp O
) O
1a2 O
in O
this O
case O
, O
as O
well O
as O
in O
other O
cases O
, O
of O
levofloxacin O
- O
induced O
seizures B-Disease
. O

methods O
: O
several O
biomedical O
databases O
were O
searched O
including O
medline O
, O
cochrane O
and O
ovid O
. O

the O
main O
search O
terms O
utilized O
were O
case O
report O
and O
levofloxacin O
. O

the O
search O
was O
limited O
to O
studies O
published O
in O
english O
. O

results O
: O
six O
cases O
of O
levofloxacin O
- O
induced O
seizures B-Disease
have O
been O
reported O
in O
the O
literature O
. O

drug O
- O
drug O
interactions O
related O
to O
the O
inhibition O
of O
cyp1a2 O
by O
levofloxacin O
are O
likely O
involved O
in O
the O
clinical O
outcome O
of O
these O
cases O
. O

conclusions O
: O
clinicians O
are O
exhorted O
to O
pay O
close O
attention O
when O
initiating O
levofloxacin O
therapy O
in O
patients O
taking O
medications O
with O
epileptogenic O
properties O
that O
are O
cyp1a2 O
substrates O
. O

dextran O
- O
etodolac O
conjugates O
: O
synthesis O
, O
in O
vitro O
and O
in O
vivo O
evaluation O
. O

etodolac O
( O
e O
) O
, O
is O
a O
non O
- O
narcotic O
analgesic O
and O
antiinflammatory O
drug O
. O

a O
biodegradable O
polymer O
dextran O
has O
been O
utilized O
as O
a O
carrier O
for O
synthesis O
of O
etodolac O
- O
dextran O
conjugates O
( O
ed O
) O
to O
improve O
its O
aqueous O
solubility O
and O
reduce O
gastrointestinal O
side O
effects O
. O

an O
activated O
moiety O
, O
i O
. O
e O
. O
n O
- O
acylimidazole O
derivative O
of O
etodolac O
( O
eai O
) O
, O
was O
condensed O
with O
the O
polysaccharide O
polymer O
dextran O
of O
different O
molecular O
weights O
( O
40000 O
, O
60000 O
, O
110000 O
and O
200000 O
) O
. O

ir O
spectral O
data O
confirmed O
formation O
of O
ester O
bonding O
in O
the O
conjugates O
. O

etodolac O
contents O
were O
evaluated O
by O
uv O
- O
spectrophotometric O
analysis O
. O

the O
molecular O
weights O
were O
determined O
by O
measuring O
viscosity O
using O
the O
mark O
- O
howink O
- O
sakurada O
equation O
. O

in O
vitro O
hydrolysis O
of O
ed O
was O
done O
in O
aqueous O
buffers O
( O
ph O
1 O
. O
2 O
, O
7 O
. O
4 O
, O
9 O
) O
and O
in O
80 O
% O
( O
v O
/ O
v O
) O
human O
plasma O
( O
ph O
7 O
. O
4 O
) O
. O

at O
ph O
9 O
, O
a O
higher O
rate O
of O
etodolac O
release O
from O
ed O
was O
observed O
as O
compared O
to O
aqueous O
buffer O
of O
ph O
7 O
. O
4 O
and O
80 O
% O
human O
plasma O
( O
ph O
7 O
. O
4 O
) O
, O
following O
first O
- O
order O
kinetics O
. O

in O
vivo O
investigations O
were O
performed O
in O
animals O
. O

acute O
analgesic O
and O
antiinflammatory O
activities O
were O
ascertained O
using O
acetic O
acid O
induced O
writhing B-Disease
model O
( O
mice O
) O
and O
carrageenan O
- O
induced O
rat O
paw O
edema B-Disease
model O
, O
respectively O
. O

in O
comparison O
to O
control O
, O
e O
and O
ed1 O
- O
ed4 O
showed O
highly O
significant O
analgesic O
and O
antiinflammatory O
activities O
( O
p O
< O
0 O
. O
001 O
) O
. O

biological O
evaluation O
suggested O
that O
conjugates O
( O
ed1 O
- O
ed4 O
) O
retained O
comparable O
analgesic O
and O
antiinflammatory O
activities O
with O
remarkably O
reduced O
ulcerogenicity O
as O
compared O
to O
their O
parent O
drug O
- O
- O
etodolac O
. O

the O
antiarrhythmic O
effect O
and O
possible O
ionic O
mechanisms O
of O
pilocarpine O
on O
animal O
models O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
pilocarpine O
and O
explore O
the O
underlying O
ionic O
mechanism O
, O
using O
both O
aconitine O
- O
induced O
rat O
and O
ouabain O
- O
induced O
guinea O
pig O
arrhythmia B-Disease
models O
. O

confocal O
microscopy O
was O
used O
to O
measure O
intracellular O
free O
- O
calcium O
concentrations O
( O
[ O
ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
) O
in O
isolated O
myocytes O
. O

the O
current O
data O
showed O
that O
pilocarpine O
significantly O
delayed O
onset O
of O
arrhythmias B-Disease
, O
decreased O
the O
time O
course O
of O
ventricular B-Disease
tachycardia B-Disease
and B-Disease
fibrillation B-Disease
, O
reduced O
arrhythmia B-Disease
score O
, O
and O
increased O
the O
survival O
time O
of O
arrhythmic B-Disease
rats O
and O
guinea O
pigs O
. O

[ O
ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
overload O
induced O
by O
aconitine O
or O
ouabain O
was O
reduced O
in O
isolated O
myocytes O
pretreated O
with O
pilocarpine O
. O

moreover O
, O
m O
( O
3 O
) O
- O
muscarinic O
acetylcholine O
receptor O
( O
machr O
) O
antagonist O
4 O
- O
damp O
( O
4 O
- O
diphenylacetoxy O
- O
n O
- O
methylpiperidine O
- O
methiodide O
) O
partially O
abolished O
the O
beneficial O
effects O
of O
pilocarpine O
. O

these O
data O
suggest O
that O
pilocarpine O
produced O
antiarrhythmic O
actions O
on O
arrhythmic B-Disease
rat O
and O
guinea O
pig O
models O
induced O
by O
aconitine O
or O
ouabain O
via O
stimulating O
the O
cardiac O
m O
( O
3 O
) O
- O
machr O
. O

the O
mechanism O
may O
be O
related O
to O
the O
improvement O
of O
ca O
( O
2 O
+ O
) O
handling O
. O

effect O
of O
hibiscus O
rosa O
sinensis O
on O
reserpine O
- O
induced O
neurobehavioral O
and O
biochemical O
alterations O
in O
rats O
. O

effect O
of O
methanolic O
extract O
of O
hibiscus O
rosa O
sinensis O
( O
100 O
- O
300 O
mg O
/ O
kg O
) O
was O
studied O
on O
reserpine O
- O
induced O
orofacial O
dyskinesia B-Disease
and O
neurochemical O
alterations O
. O

the O
rats O
were O
treated O
with O
intraperitoneal O
reserpine O
( O
1 O
mg O
/ O
kg O
, O
ip O
) O
for O
3 O
days O
every O
other O
day O
. O

on O
day O
5 O
, O
vacuous O
chewing O
movements O
and O
tongue O
protrusions O
were O
counted O
for O
5 O
min O
. O

reserpine O
treated O
rats O
significantly O
developed O
vacuous O
chewing O
movements O
and O
tongue O
protrusions O
however O
, O
coadministration O
of O
hibiscus O
rosa O
sinensis O
roots O
extract O
( O
100 O
, O
200 O
and O
300 O
mg O
/ O
kg O
, O
per O
orally O
) O
attenuated O
the O
effects O
. O

biochemical O
analysis O
of O
brain O
revealed O
that O
the O
reserpine O
treatment O
significantly O
increased O
lipid O
peroxidation O
and O
decreased O
levels O
of O
superoxide O
dismutase O
( O
sod O
) O
, O
catalase O
( O
cat O
) O
and O
glutathione O
reductase O
( O
gsh O
) O
, O
an O
index O
of O
oxidative O
stress O
process O
. O

coadministration O
of O
extract O
significantly O
reduced O
the O
lipid O
peroxidation O
and O
reversed O
the O
decrease O
in O
brain O
sod O
, O
cat O
and O
gsh O
levels O
. O

the O
results O
of O
the O
present O
study O
suggested O
that O
hibiscus O
rosa O
sinensis O
had O
a O
protective O
role O
against O
reserpine O
- O
induced O
orofacial O
dyskinesia B-Disease
and O
oxidative O
stress O
. O

dynamic O
response O
of O
blood O
vessel O
in O
acute B-Disease
renal B-Disease
failure B-Disease
. O

in O
this O
study O
we O
postulated O
that O
during O
acute B-Disease
renal B-Disease
failure B-Disease
induced O
by O
gentamicin O
the O
transient O
or O
dynamic O
response O
of O
blood O
vessels O
could O
be O
affected O
, O
and O
that O
antioxidants O
can O
prevent O
the O
changes O
in O
dynamic O
responses O
of O
blood O
vessels O
. O

the O
new O
approach O
to O
ex O
vivo O
blood O
vessel O
experiments O
in O
which O
not O
only O
the O
end O
points O
of O
vessels O
response O
within O
the O
time O
interval O
is O
considered O
, O
but O
also O
dynamics O
of O
this O
response O
, O
was O
used O
in O
this O
paper O
. O

our O
results O
confirm O
the O
alteration O
in O
dynamic O
response O
of O
blood O
vessels O
during O
the O
change O
of O
pressure O
in O
gentamicin O
- O
treated O
animals O
. O

the O
beneficial O
effects O
of O
vitamin O
c O
administration O
to O
gentamicin O
- O
treated O
animals O
are O
also O
confirmed O
through O
: O
lower O
level O
of O
blood O
urea O
and O
creatinine O
and O
higher O
level O
of O
potassium O
. O

the O
pressure O
dynamic O
responses O
of O
isolated O
blood O
vessels O
show O
a O
faster O
pressure O
change O
in O
gentamicin O
- O
treated O
animals O
( O
8 O
. O
07 O
+ O
/ O
- O
1 O
. O
7 O
s O
vs O
. O
5 O
. O
64 O
+ O
/ O
- O
0 O
. O
18 O
s O
) O
. O

vitamin O
c O
administration O
induced O
slowdown O
of O
pressure O
change O
back O
to O
the O
control O
values O
. O

the O
pressure O
dynamic O
properties O
, O
quantitatively O
defined O
by O
comparative O
pressure O
dynamic O
and O
total O
pressure O
dynamic O
, O
confirm O
the O
alteration O
in O
dynamic O
response O
of O
blood O
vessels O
during O
the O
change O
of O
pressure O
in O
gentamicin O
- O
treated O
animals O
and O
beneficial O
effects O
of O
vitamin O
c O
administration O
. O

reversible O
myocardial B-Disease
hypertrophy B-Disease
induced O
by O
tacrolimus O
in O
a O
pediatric O
heart O
transplant O
recipient O
: O
case O
report O
. O

tacrolimus O
is O
a O
potent O
immunosuppressant O
that O
is O
frequently O
used O
in O
organ O
transplantation O
. O

however O
, O
adverse O
effects O
include O
cardiac B-Disease
toxicity B-Disease
. O

herein O
we O
describe O
transient O
myocardial B-Disease
hypertrophy B-Disease
induced O
by O
tacrolimus O
after O
heart O
transplantation O
. O

the O
hypertrophy B-Disease
caused O
no O
clinical O
symptoms O
but O
was O
noted O
because O
of O
elevation O
of O
plasma O
brain O
natriuretic O
peptide O
concentration O
and O
confirmed O
at O
echocardiography O
. O

initially O
, O
allograft O
rejection O
was O
feared O
; O
however O
, O
myocardial O
biopsy O
samples O
revealed O
only O
interstitial O
edema B-Disease
and O
mild O
myocardial B-Disease
hypertrophy B-Disease
; O
neither O
cellular O
nor O
humoral O
rejection O
was O
detected O
. O

the O
blood O
tacrolimus O
concentration O
was O
higher O
than O
usual O
at O
that O
time O
; O
thus O
, O
tacrolimus O
dosage O
was O
reduced O
. O

myocardial B-Disease
hypertrophy B-Disease
completely O
resolved O
upon O
reducing O
the O
target O
concentration O
of O
tacrolimus O
and O
did O
not O
recur O
, O
as O
confirmed O
at O
echocardiography O
and O
myocardial O
biopsy O
. O

thus O
, O
we O
conclude O
that O
tacrolimus O
induces O
reversible O
myocardial B-Disease
hypertrophy B-Disease
. O

in O
patients O
receiving O
tacrolimus O
therapy O
, O
blood O
concentration O
should O
be O
carefully O
controlled O
and O
extreme O
attention O
paid O
to O
cardiac O
involvement O
. O

nimodipine O
prevents O
memory B-Disease
impairment B-Disease
caused O
by O
nitroglycerin O
- O
induced O
hypotension B-Disease
in O
adult O
mice O
. O

background O
: O
hypotension B-Disease
and O
a O
resultant O
decrease O
in O
cerebral O
blood O
flow O
have O
been O
implicated O
in O
the O
development O
of O
cognitive B-Disease
dysfunction B-Disease
. O

we O
tested O
the O
hypothesis O
that O
nimodipine O
( O
nimo O
) O
administered O
at O
the O
onset O
of O
nitroglycerin O
( O
ntg O
) O
- O
induced O
hypotension B-Disease
would O
preserve O
long O
- O
term O
associative O
memory O
. O

methods O
: O
the O
passive O
avoidance O
( O
pa O
) O
paradigm O
was O
used O
to O
assess O
memory O
retention O
. O

for O
pa O
training O
, O
latencies O
( O
seconds O
) O
were O
recorded O
for O
entry O
from O
a O
suspended O
platform O
into O
a O
plexiglas O
tube O
where O
a O
shock O
was O
automatically O
delivered O
. O

latencies O
were O
recorded O
48 O
h O
later O
for O
a O
testing O
trial O
. O

ninety O
- O
six O
swiss O
- O
webster O
mice O
( O
30 O
- O
35 O
g O
, O
6 O
- O
8 O
wk O
) O
, O
were O
randomized O
into O
6 O
groups O
1 O
) O
saline O
( O
control O
) O
, O
2 O
) O
ntg O
immediately O
after O
learning O
, O
3 O
) O
ntg O
3 O
h O
after O
learning O
, O
4 O
) O
ntg O
and O
nimo O
, O
5 O
) O
vehicle O
, O
and O
6 O
) O
nimo O
alone O
. O

the O
extent O
of O
hypotension B-Disease
and O
changes O
in O
brain O
tissue O
oxygenation O
( O
pbto O
( O
2 O
) O
) O
and O
in O
cerebral O
blood O
flow O
were O
studied O
in O
a O
separate O
group O
of O
animals O
. O

results O
: O
all O
groups O
exhibited O
similar O
training O
latencies O
( O
17 O
. O
0 O
+ O
/ O
- O
4 O
. O
6 O
s O
) O
. O

mice O
subjected O
to O
hypotensive B-Disease
episodes O
showed O
a O
significant O
decrease O
in O
latency O
time O
( O
178 O
+ O
/ O
- O
156 O
s O
) O
compared O
with O
those O
injected O
with O
saline O
, O
ntg O
+ O
nimo O
, O
or O
delayed O
ntg O
( O
580 O
+ O
/ O
- O
81 O
s O
, O
557 O
+ O
/ O
- O
67 O
s O
, O
and O
493 O
+ O
/ O
- O
146 O
s O
, O
respectively O
) O
. O

a O
kruskal O
- O
wallis O
1 O
- O
way O
analysis O
of O
variance O
indicated O
a O
significant O
difference O
among O
the O
4 O
treatment O
groups O
( O
h O
= O
15 O
. O
34 O
; O
p O
< O
0 O
. O
001 O
) O
. O

in O
a O
separate O
group O
of O
mice O
not O
subjected O
to O
behavioral O
studies O
, O
the O
same O
dose O
of O
ntg O
( O
n O
= O
3 O
) O
and O
ntg O
+ O
nimo O
( O
n O
= O
3 O
) O
caused O
mean O
arterial O
blood O
pressure O
to O
decrease O
from O
85 O
. O
9 O
+ O
/ O
- O
3 O
. O
8 O
mm O
hg O
sem O
to O
31 O
. O
6 O
+ O
/ O
- O
0 O
. O
8 O
mm O
hg O
sem O
and O
from O
86 O
. O
2 O
+ O
/ O
- O
3 O
. O
7 O
mm O
hg O
sem O
to O
32 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
mm O
hg O
sem O
, O
respectively O
. O

mean O
arterial O
blood O
pressure O
in O
mice O
treated O
with O
nimo O
alone O
decreased O
from O
88 O
. O
1 O
+ O
/ O
- O
3 O
. O
8 O
mm O
hg O
to O
80 O
. O
0 O
+ O
/ O
- O
2 O
. O
9 O
mm O
hg O
. O

the O
intergroup O
difference O
was O
statistically O
significant O
( O
p O
< O
0 O
. O
05 O
) O
. O

pbto O
( O
2 O
) O
decreased O
from O
51 O
. O
7 O
+ O
/ O
- O
4 O
. O
5 O
mm O
hg O
sem O
to O
33 O
. O
8 O
+ O
/ O
- O
5 O
. O
2 O
mm O
hg O
sem O
in O
the O
ntg O
group O
and O
from O
38 O
. O
6 O
+ O
/ O
- O
6 O
. O
1 O
mm O
hg O
sem O
to O
25 O
. O
4 O
+ O
/ O
- O
2 O
. O
0 O
mm O
hg O
sem O
in O
the O
ntg O
+ O
nimo O
groups O
, O
respectively O
. O

there O
were O
no O
significant O
differences O
among O
groups O
. O

conclusion O
: O
in O
a O
pa O
retention O
paradigm O
, O
the O
injection O
of O
ntg O
immediately O
after O
learning O
produced O
a O
significant O
impairment O
of O
long O
- O
term O
associative O
memory O
in O
mice O
, O
whereas O
delayed O
induced O
hypotension B-Disease
had O
no O
effect O
. O

nimo O
attenuated O
the O
disruption O
in O
consolidation O
of O
long O
- O
term O
memory O
caused O
by O
ntg O
but O
did O
not O
improve O
latency O
in O
the O
absence O
of O
hypotension B-Disease
. O

the O
observed O
effect O
of O
nimo O
may O
have O
been O
attributable O
to O
the O
preservation O
of O
calcium O
homeostasis O
during O
hypotension B-Disease
, O
because O
there O
were O
no O
differences O
in O
the O
pbto O
( O
2 O
) O
indices O
among O
groups O
. O

metabotropic O
glutamate O
7 O
receptor O
subtype O
modulates O
motor O
symptoms O
in O
rodent O
models O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

metabotropic O
glutamate O
( O
mglu O
) O
receptors O
modulate O
synaptic O
transmission O
in O
the O
central O
nervous O
system O
and O
represent O
promising O
therapeutic O
targets O
for O
symptomatic O
treatment O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
( O
pd B-Disease
) O
. O

among O
the O
eight O
mglu O
receptor O
subtypes O
, O
mglu7 O
receptor O
is O
prominently O
expressed O
in O
the O
basal O
ganglia O
, O
but O
its O
role O
in O
restoring O
motor O
function O
in O
animal O
models O
of O
pd B-Disease
is O
not O
known O
. O

the O
effects O
of O
n O
, O
n O
' O
- O
dibenzhydrylethane O
- O
1 O
, O
2 O
- O
diamine O
dihydrochloride O
( O
amn082 O
) O
, O
the O
first O
selective O
allosteric O
activator O
of O
mglu7 O
receptors O
, O
were O
thus O
tested O
in O
different O
rodent O
models O
of O
pd B-Disease
. O

here O
, O
we O
show O
that O
oral O
( O
5 O
mg O
/ O
kg O
) O
or O
intrastriatal O
administration O
( O
0 O
. O
1 O
and O
0 O
. O
5 O
nmol O
) O
of O
amn082 O
reverses O
haloperidol O
- O
induced O
catalepsy B-Disease
in O
rats O
. O

amn082 O
( O
2 O
. O
5 O
and O
5 O
mg O
/ O
kg O
) O
reduces O
apomorphine O
- O
induced O
rotations O
in O
unilateral O
6 O
- O
hydroxydopamine O
( O
6 O
- O
ohda O
) O
- O
lesioned O
rats O
. O

in O
a O
more O
complex O
task O
commonly O
used O
to O
evaluate O
major O
akinetic B-Disease
symptoms O
of O
pd B-Disease
patients O
, O
5 O
mg O
/ O
kg O
amn082 O
reverses O
the O
increased O
reaction O
time O
to O
respond O
to O
a O
cue O
of O
bilateral O
6 O
- O
ohda O
- O
lesioned O
rats O
. O

in O
addition O
, O
amn082 O
reduces O
the O
duration O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
in O
a O
mglu7 O
receptor O
- O
dependent O
manner O
in O
wild O
- O
type O
but O
not O
mglu7 O
receptor O
knockout O
mice O
. O

higher O
doses O
of O
amn082 O
( O
10 O
and O
20 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
have O
no O
effect O
on O
the O
same O
models O
of O
pd B-Disease
. O

overall O
these O
findings O
suggest O
that O
mglu7 O
receptor O
activation O
can O
reverse O
motor O
dysfunction O
associated O
with O
reduced O
dopamine O
activity O
. O

selective O
ligands O
of O
mglu7 O
receptor O
subtypes O
may O
thus O
be O
considered O
as O
promising O
compounds O
for O
the O
development O
of O
antiparkinsonian O
therapeutic O
strategies O
. O

sorafenib O
- O
induced O
acute O
myocardial B-Disease
infarction B-Disease
due O
to O
coronary B-Disease
artery B-Disease
spasm B-Disease
. O

a O
65 O
- O
year O
- O
old O
man O
with O
advanced O
renal B-Disease
cell B-Disease
carcinoma B-Disease
was O
admitted O
due O
to O
continuing O
chest B-Disease
pain B-Disease
at O
rest O
. O

two O
weeks O
before O
his O
admission O
, O
sorafenib O
had O
been O
started O
. O

he O
was O
diagnosed O
with O
non O
- O
st O
- O
elevation O
myocardial B-Disease
infarction B-Disease
by O
laboratory O
data O
and O
electrocardiogram O
. O

enhanced O
heart O
magnetic O
resonance O
imaging O
also O
showed O
subendocardial B-Disease
infarction B-Disease
. O

however O
, O
there O
was O
no O
stenosis O
in O
coronary O
arteries O
on O
angiography O
. O

coronary B-Disease
artery B-Disease
spasm B-Disease
was O
induced O
by O
a O
provocative O
test O
. O

cessation O
of O
sorafenib O
and O
administration O
of O
ca O
- O
channel O
blocker O
and O
nitrates O
ameliorated O
his O
symptoms O
, O
but O
relapse O
occurred O
after O
resumption O
of O
sorafenib O
. O

addition O
of O
oral O
nicorandil O
reduced O
his O
symptoms O
and O
maintained O
stable B-Disease
angina B-Disease
status O
. O

we O
report O
the O
first O
case O
of O
sorafenib O
- O
induced O
coronary B-Disease
artery B-Disease
spasm B-Disease
. O

sorafenib O
is O
a O
multikinase O
inhibitor O
that O
targets O
signaling O
pathways O
necessary O
for O
cellular O
proliferation O
and O
survival O
. O

on O
the O
other O
hand O
, O
the O
rho O
/ O
rock O
pathway O
has O
an O
important O
role O
in O
the O
pathogenesis O
of O
coronary B-Disease
artery B-Disease
spasm B-Disease
. O

our O
report O
may O
show O
an O
adverse O
effect O
on O
the O
rho O
/ O
rock O
pathway O
by O
sorafenib O
use O
. O

a O
novel O
animal O
model O
to O
evaluate O
the O
ability O
of O
a O
drug O
delivery O
system O
to O
promote O
the O
passage O
through O
the O
bbb O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
explore O
the O
potentiality O
of O
a O
novel O
animal O
model O
to O
be O
used O
for O
the O
in O
vivo O
evaluation O
of O
the O
ability O
of O
a O
drug O
delivery O
system O
to O
promote O
the O
passage O
through O
the O
blood O
- O
brain O
barrier O
( O
bbb O
) O
and O
/ O
or O
to O
improve O
the O
brain O
localization O
of O
a O
bioactive O
compound O
. O

a O
tween O
80 O
- O
coated O
poly O
- O
l O
- O
lactid O
acid O
nanoparticles O
was O
used O
as O
a O
model O
of O
colloidal O
drug O
delivery O
system O
, O
able O
to O
trespass O
the O
bbb O
. O

tacrine O
, O
administered O
in O
licl O
pre O
- O
treated O
rats O
, O
induces O
electrocorticographic O
seizures B-Disease
and O
delayed O
hippocampal B-Disease
damage B-Disease
. O

the O
toxic O
effects O
of O
tacrine O
- O
loaded O
poly O
- O
l O
- O
lactid O
acid O
nanoparticles O
( O
5mg O
/ O
kg O
) O
, O
a O
saline O
solution O
of O
tacrine O
( O
5mg O
/ O
kg O
) O
and O
an O
empty O
colloidal O
nanoparticle O
suspension O
were O
compared O
following O
i O
. O
p O
. O
administration O
in O
licl O
- O
pre O
- O
treated O
wistar O
rats O
. O

all O
the O
animals O
treated O
with O
tacrine O
- O
loaded O
nanoparticles O
showed O
an O
earlier O
outcome O
of O
cns O
adverse O
symptoms O
, O
i O
. O
e O
. O
epileptic B-Disease
onset O
, O
with O
respect O
to O
those O
animals O
treated O
with O
the O
free O
compound O
( O
10 O
min O
vs O
. O
22 O
min O
respectively O
) O
. O

in O
addition O
, O
tacrine O
- O
loaded O
nanoparticles O
administration O
induced O
damage B-Disease
of B-Disease
neuronal B-Disease
cells B-Disease
in O
ca1 O
field O
of O
the O
hippocampus O
in O
all O
treated O
animals O
, O
while O
the O
saline O
solution O
of O
tacrine O
only O
in O
60 O
% O
of O
animals O
. O

empty O
nanoparticles O
provided O
similar O
results O
to O
control O
( O
saline O
- O
treated O
) O
group O
of O
animals O
. O

in O
conclusion O
, O
the O
evaluation O
of O
time O
- O
to O
- O
onset O
of O
symptoms O
and O
the O
severity O
of O
neurodegenerative O
processes O
induced O
by O
the O
tacrine O
- O
lithium O
model O
of O
epilepsy B-Disease
in O
the O
rat O
, O
could O
be O
used O
to O
evaluate O
preliminarily O
the O
capability O
of O
a O
drug O
delivery O
system O
to O
trespass O
( O
or O
not O
) O
the O
bbb O
in O
vivo O
. O

high O
- O
dose O
tranexamic O
acid O
is O
associated O
with O
nonischemic O
clinical O
seizures B-Disease
in O
cardiac O
surgical O
patients O
. O

background O
: O
in O
2 O
separate O
centers O
, O
we O
observed O
a O
notable O
increase O
in O
the O
incidence O
of O
postoperative O
convulsive B-Disease
seizures B-Disease
from O
1 O
. O
3 O
% O
to O
3 O
. O
8 O
% O
in O
patients O
having O
undergone O
major O
cardiac O
surgical O
procedures O
. O

these O
events O
were O
temporally O
coincident O
with O
the O
initial O
use O
of O
high O
- O
dose O
tranexamic O
acid O
( O
txa O
) O
therapy O
after O
withdrawal O
of O
aprotinin O
from O
general O
clinical O
usage O
. O

the O
purpose O
of O
this O
review O
was O
to O
perform O
a O
retrospective O
analysis O
to O
examine O
whether O
there O
was O
a O
relation O
between O
txa O
usage O
and O
seizures B-Disease
after O
cardiac O
surgery O
. O

methods O
: O
an O
in O
- O
depth O
chart O
review O
was O
undertaken O
in O
all O
24 O
patients O
who O
developed O
perioperative O
seizures B-Disease
. O

electroencephalographic O
activity O
was O
recorded O
in O
11 O
of O
these O
patients O
, O
and O
all O
patients O
had O
a O
formal O
neurological O
evaluation O
and O
brain O
imaging O
studies O
. O

results O
: O
twenty O
- O
one O
of O
the O
24 O
patients O
did O
not O
have O
evidence O
of O
new O
cerebral B-Disease
ischemic B-Disease
injury B-Disease
, O
but O
seizures B-Disease
were O
likely O
due O
to O
ischemic B-Disease
brain B-Disease
injury B-Disease
in O
3 O
patients O
. O

all O
patients O
with O
seizures B-Disease
did O
not O
have O
permanent O
neurological B-Disease
abnormalities B-Disease
. O

all O
24 O
patients O
with O
seizures B-Disease
received O
high O
doses O
of O
txa O
intraoperatively O
ranging O
from O
61 O
to O
259 O
mg O
/ O
kg O
, O
had O
a O
mean O
age O
of O
69 O
. O
9 O
years O
, O
and O
21 O
of O
24 O
had O
undergone O
open O
chamber O
rather O
than O
coronary O
bypass O
procedures O
. O

all O
but O
one O
patient O
were O
managed O
using O
cardiopulmonary O
bypass O
. O

no O
evidence O
of O
brain B-Disease
ischemic B-Disease
, O
metabolic O
, O
or O
hyperthermia B-Disease
- O
induced O
causes O
for O
their O
seizures B-Disease
was O
apparent O
. O

conclusion O
: O
our O
results O
suggest O
that O
use O
of O
high O
- O
dose O
txa O
in O
older O
patients O
in O
conjunction O
with O
cardiopulmonary O
bypass O
and O
open O
- O
chamber O
cardiac O
surgery O
is O
associated O
with O
clinical O
seizures B-Disease
in O
susceptible O
patients O
. O

electrocardiographic O
changes O
and O
cardiac B-Disease
arrhythmias B-Disease
in O
patients O
receiving O
psychotropic O
drugs O
. O

eight O
patients O
had O
cardiac O
manifestations O
that O
were O
life O
- O
threatening O
in O
five O
while O
taking O
psychotropic O
drugs O
, O
either O
phenothiazines O
or O
tricyclic O
antidepressants O
. O

although O
most O
patients O
were O
receiving O
several O
drugs O
, O
mellaril O
( O
thioridazine O
) O
appeared O
to O
be O
responsible O
for O
five O
cases O
of O
ventricular B-Disease
tachycardia B-Disease
, O
one O
of O
which O
was O
fatal O
in O
a O
35 O
year O
old O
woman O
. O

supraventricular B-Disease
tachycardia B-Disease
developed O
in O
one O
patient O
receiving O
thorazine O
( O
chlorpromazine O
) O
. O

aventyl O
( O
nortriptyline O
) O
and O
elavil O
( O
amitriptyline O
) O
each O
produced O
left B-Disease
bundle B-Disease
branch B-Disease
block B-Disease
in O
a O
73 O
year O
old O
woman O
. O

electrocardiographic O
t O
and O
u O
wave O
abnormalities O
were O
present O
in O
most O
patients O
. O

the O
ventricular B-Disease
arrhythmias B-Disease
responded O
to O
intravenous O
administration O
of O
lidocaine O
and O
to O
direct O
current O
electric O
shock O
; O
ventricular O
pacing O
was O
required O
in O
some O
instances O
and O
intravenous O
administration O
of O
propranolol O
combined O
with O
ventricular O
pacing O
in O
one O
. O

the O
tachyarrhythmias B-Disease
generally O
subsided O
within O
48 O
hours O
after O
administration O
of O
the O
drugs O
was O
stopped O
. O

five O
of O
the O
eight O
patients O
were O
50 O
years O
of O
age O
or O
younger O
; O
only O
one O
clearly O
had O
antecedent O
heart B-Disease
disease B-Disease
. O

major O
cardiac B-Disease
arrhythmias B-Disease
are O
a O
potential O
hazard O
in O
patients O
without O
heart B-Disease
disease B-Disease
who O
are O
receiving O
customary O
therapeutic O
doses O
of O
psychotropic O
drugs O
. O

a O
prospective O
clinical O
trial O
is O
suggested O
to O
quantify O
the O
risk O
of O
cardiac B-Disease
complications B-Disease
to O
patients O
receiving O
phenothiazines O
or O
tricyclic O
antidepressant O
drugs O
. O

sensitivity O
of O
erythroid O
progenitor O
colonies O
to O
erythropoietin O
in O
azidothymidine O
treated O
immunodeficient B-Disease
mice O
. O

the O
anaemia B-Disease
induced O
by O
3 O
' O
- O
azido O
- O
3 O
' O
dideoxythymidine O
( O
azt O
) O
is O
poorly O
understood O
. O

we O
have O
used O
a O
murine O
model O
of O
aids B-Disease
, O
infection B-Disease
of O
female O
c57bl O
/ O
6 O
mice O
with O
lp O
- O
bm5 O
murine O
leukaemia B-Disease
( O
mulv O
) O
virus O
, O
to O
determine O
if O
azt O
- O
induced O
anaemia B-Disease
is O
due O
, O
in O
part O
, O
to O
decreased O
responsiveness O
of O
erythropoietic O
precursors O
( O
bfu O
- O
e O
) O
to O
erythropoietin O
( O
epo O
) O
. O

mice O
in O
the O
early O
stage O
of O
lp O
- O
bm5 O
mulv O
disease O
were O
given O
azt O
in O
their O
drinking O
water O
at O
1 O
. O
0 O
and O
2 O
. O
5 O
mg O
/ O
ml O
. O

azt O
produced O
anaemia B-Disease
in O
both O
groups O
, O
in O
a O
dose O
- O
dependent O
fashion O
. O

despite O
the O
anaemia B-Disease
, O
the O
number O
of O
splenic O
and O
bone O
marrow O
bfu O
- O
e O
in O
azt O
treated O
mice O
increased O
up O
to O
five O
- O
fold O
over O
levels O
observed O
in O
infected O
untreated O
animals O
after O
15 O
d O
of O
treatment O
. O

colony O
formation O
by O
splenic O
and O
bone O
marrow O
bfue O
was O
stimulated O
at O
lower O
concentrations O
of O
epo O
in O
mice O
receiving O
azt O
for O
15 O
d O
than O
for O
infected O
, O
untreated O
mice O
. O

by O
day O
30 O
, O
sensitivity O
of O
both O
splenic O
and O
bone O
marrow O
bfu O
- O
e O
of O
treated O
animals O
returned O
to O
that O
observed O
from O
cells O
of O
infected O
untreated O
animals O
. O

the O
mean O
plasma O
levels O
of O
epo O
observed O
in O
azt O
treated O
mice O
were O
appropriate O
for O
the O
degree O
of O
anaemia B-Disease
observed O
when O
compared O
with O
phenylhydrazine O
( O
phz O
) O
treated O
mice O
. O

the O
numbers O
of O
bfu O
- O
e O
and O
the O
percentage O
of O
bone O
marrow O
erythroblasts O
observed O
were O
comparable O
in O
azt O
and O
phz O
treated O
mice O
with O
similar O
degrees O
of O
anaemia B-Disease
. O

however O
, O
reticulocytosis B-Disease
was O
inappropriate O
for O
the O
degree O
of O
anaemia B-Disease
observed O
in O
azt O
treated O
infected O
mice O
. O

azt O
- O
induced O
peripheral O
anaemia B-Disease
in O
the O
face O
of O
increased O
numbers O
of O
bfu O
- O
e O
and O
increased O
levels O
of O
plasma O
epo O
suggest O
a O
lesion O
in O
terminal O
differentiation O
. O

sedation O
depth O
during O
spinal O
anesthesia O
and O
the O
development O
of O
postoperative B-Disease
delirium B-Disease
in O
elderly O
patients O
undergoing O
hip B-Disease
fracture B-Disease
repair O
. O

objective O
: O
to O
determine O
whether O
limiting O
intraoperative O
sedation O
depth O
during O
spinal O
anesthesia O
for O
hip B-Disease
fracture B-Disease
repair O
in O
elderly O
patients O
can O
decrease O
the O
prevalence O
of O
postoperative B-Disease
delirium B-Disease
. O

patients O
and O
methods O
: O
we O
performed O
a O
double O
- O
blind O
, O
randomized O
controlled O
trial O
at O
an O
academic O
medical O
center O
of O
elderly O
patients O
( O
> O
or O
= O
65 O
years O
) O
without O
preoperative O
delirium B-Disease
or O
severe O
dementia B-Disease
who O
underwent O
hip B-Disease
fracture B-Disease
repair O
under O
spinal O
anesthesia O
with O
propofol O
sedation O
. O

sedation O
depth O
was O
titrated O
using O
processed O
electroencephalography O
with O
the O
bispectral O
index O
( O
bis O
) O
, O
and O
patients O
were O
randomized O
to O
receive O
either O
deep O
( O
bis O
, O
approximately O
50 O
) O
or O
light O
( O
bis O
, O
> O
or O
= O
80 O
) O
sedation O
. O

postoperative B-Disease
delirium B-Disease
was O
assessed O
as O
defined O
by O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders B-Disease
( O
third O
edition O
revised O
) O
criteria O
using O
the O
confusion O
assessment O
method O
beginning O
at O
any O
time O
from O
the O
second O
day O
after O
surgery O
. O

results O
: O
from O
april O
2 O
, O
2005 O
, O
through O
october O
30 O
, O
2008 O
, O
a O
total O
of O
114 O
patients O
were O
randomized O
. O

the O
prevalence O
of O
postoperative B-Disease
delirium B-Disease
was O
significantly O
lower O
in O
the O
light O
sedation O
group O
( O
11 O
/ O
57 O
[ O
19 O
% O
] O
vs O
23 O
/ O
57 O
[ O
40 O
% O
] O
in O
the O
deep O
sedation O
group O
; O
p O
= O
. O
02 O
) O
, O
indicating O
that O
1 O
incident O
of O
delirium B-Disease
will O
be O
prevented O
for O
every O
4 O
. O
7 O
patients O
treated O
with O
light O
sedation O
. O

the O
mean O
+ O
/ O
- O
sd O
number O
of O
days O
of O
delirium B-Disease
during O
hospitalization O
was O
lower O
in O
the O
light O
sedation O
group O
than O
in O
the O
deep O
sedation O
group O
( O
0 O
. O
5 O
+ O
/ O
- O
1 O
. O
5 O
days O
vs O
1 O
. O
4 O
+ O
/ O
- O
4 O
. O
0 O
days O
; O
p O
= O
. O
01 O
) O
. O

conclusion O
: O
the O
use O
of O
light O
propofol O
sedation O
decreased O
the O
prevalence O
of O
postoperative B-Disease
delirium B-Disease
by O
50 O
% O
compared O
with O
deep O
sedation O
. O

limiting O
depth O
of O
sedation O
during O
spinal O
anesthesia O
is O
a O
simple O
, O
safe O
, O
and O
cost O
- O
effective O
intervention O
for O
preventing O
postoperative B-Disease
delirium B-Disease
in O
elderly O
patients O
that O
could O
be O
widely O
and O
readily O
adopted O
. O

the O
protective O
role O
of O
nrf2 O
in O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy B-Disease
. O

objective O
: O
diabetic B-Disease
nephropathy B-Disease
is O
one O
of O
the O
major O
causes O
of O
renal B-Disease
failure B-Disease
, O
which O
is O
accompanied O
by O
the O
production O
of O
reactive O
oxygen O
species O
( O
ros O
) O
. O

nrf2 O
is O
the O
primary O
transcription O
factor O
that O
controls O
the O
antioxidant O
response O
essential O
for O
maintaining O
cellular O
redox O
homeostasis O
. O

here O
, O
we O
report O
our O
findings O
demonstrating O
a O
protective O
role O
of O
nrf2 O
against O
diabetic B-Disease
nephropathy B-Disease
. O

research O
design O
and O
methods O
: O
we O
explore O
the O
protective O
role O
of O
nrf2 O
against O
diabetic B-Disease
nephropathy B-Disease
using O
human O
kidney O
biopsy O
tissues O
from O
diabetic B-Disease
nephropathy B-Disease
patients O
, O
a O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy B-Disease
model O
in O
nrf2 O
( O
- O
/ O
- O
) O
mice O
, O
and O
cultured O
human O
mesangial O
cells O
. O

results O
: O
the O
glomeruli O
of O
human O
diabetic B-Disease
nephropathy B-Disease
patients O
were O
under O
oxidative O
stress O
and O
had O
elevated O
nrf2 O
levels O
. O

in O
the O
animal O
study O
, O
nrf2 O
was O
demonstrated O
to O
be O
crucial O
in O
ameliorating O
streptozotocin O
- O
induced O
renal B-Disease
damage B-Disease
. O

this O
is O
evident O
by O
nrf2 O
( O
- O
/ O
- O
) O
mice O
having O
higher O
ros O
production O
and O
suffering O
from O
greater O
oxidative O
dna O
damage O
and O
renal B-Disease
injury B-Disease
compared O
with O
nrf2 O
( O
+ O
/ O
+ O
) O
mice O
. O

mechanistic O
studies O
in O
both O
in O
vivo O
and O
in O
vitro O
systems O
showed O
that O
the O
nrf2 O
- O
mediated O
protection O
against O
diabetic B-Disease
nephropathy B-Disease
is O
, O
at O
least O
, O
partially O
through O
inhibition O
of O
transforming O
growth O
factor O
- O
beta1 O
( O
tgf O
- O
beta1 O
) O
and O
reduction O
of O
extracellular O
matrix O
production O
. O

in O
human O
renal O
mesangial O
cells O
, O
high O
glucose O
induced O
ros O
production O
and O
activated O
expression O
of O
nrf2 O
and O
its O
downstream O
genes O
. O

furthermore O
, O
activation O
or O
overexpression O
of O
nrf2 O
inhibited O
the O
promoter O
activity O
of O
tgf O
- O
beta1 O
in O
a O
dose O
- O
dependent O
manner O
, O
whereas O
knockdown O
of O
nrf2 O
by O
sirna O
enhanced O
tgf O
- O
beta1 O
transcription O
and O
fibronectin O
production O
. O

conclusions O
: O
this O
work O
clearly O
indicates O
a O
protective O
role O
of O
nrf2 O
in O
diabetic B-Disease
nephropathy B-Disease
, O
suggesting O
that O
dietary O
or O
therapeutic O
activation O
of O
nrf2 O
could O
be O
used O
as O
a O
strategy O
to O
prevent O
or O
slow O
down O
the O
progression O
of O
diabetic B-Disease
nephropathy B-Disease
. O

metformin O
prevents O
experimental O
gentamicin O
- O
induced O
nephropathy B-Disease
by O
a O
mitochondria O
- O
dependent O
pathway O
. O

the O
antidiabetic O
drug O
metformin O
can O
diminish O
apoptosis O
induced O
by O
oxidative O
stress O
in O
endothelial O
cells O
and O
prevent O
vascular B-Disease
dysfunction B-Disease
even O
in O
nondiabetic O
patients O
. O

here O
we O
tested O
whether O
it O
has O
a O
beneficial O
effect O
in O
a O
rat O
model O
of O
gentamicin O
toxicity B-Disease
. O

mitochondrial O
analysis O
, O
respiration O
intensity O
, O
levels O
of O
reactive O
oxygen O
species O
, O
permeability O
transition O
, O
and O
cytochrome O
c O
release O
were O
assessed O
3 O
and O
6 O
days O
after O
gentamicin O
administration O
. O

metformin O
treatment O
fully O
blocked O
gentamicin O
- O
mediated O
acute B-Disease
renal B-Disease
failure B-Disease
. O

this O
was O
accompanied O
by O
a O
lower O
activity O
of O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
, O
together O
with O
a O
decrease O
of O
lipid O
peroxidation O
and O
increase O
of O
antioxidant O
systems O
. O

metformin O
also O
protected O
the O
kidney O
from O
histological O
damage O
6 O
days O
after O
gentamicin O
administration O
. O

these O
in O
vivo O
markers O
of O
kidney B-Disease
dysfunction B-Disease
and O
their O
correction O
by O
metformin O
were O
complemented O
by O
in O
vitro O
studies O
of O
mitochondrial O
function O
. O

we O
found O
that O
gentamicin O
treatment O
depleted O
respiratory O
components O
( O
cytochrome O
c O
, O
nadh O
) O
, O
probably O
due O
to O
the O
opening O
of O
mitochondrial O
transition O
pores O
. O

these O
injuries O
, O
partly O
mediated O
by O
a O
rise O
in O
reactive O
oxygen O
species O
from O
the O
electron O
transfer O
chain O
, O
were O
significantly O
decreased O
by O
metformin O
. O

thus O
, O
our O
study O
suggests O
that O
pleiotropic O
effects O
of O
metformin O
can O
lessen O
gentamicin O
nephrotoxicity B-Disease
and O
improve O
mitochondrial O
homeostasis O
. O

risk O
of O
nephropathy B-Disease
after O
consumption O
of O
nonionic O
contrast O
media O
by O
children O
undergoing O
cardiac O
angiography O
: O
a O
prospective O
study O
. O

despite O
increasing O
reports O
on O
nonionic O
contrast O
media O
- O
induced O
nephropathy B-Disease
( O
cin B-Disease
) O
in O
hospitalized O
adult O
patients O
during O
cardiac O
procedures O
, O
the O
studies O
in O
pediatrics O
are O
limited O
, O
with O
even O
less O
focus O
on O
possible O
predisposing O
factors O
and O
preventive O
measures O
for O
patients O
undergoing O
cardiac O
angiography O
. O

this O
prospective O
study O
determined O
the O
incidence O
of O
cin B-Disease
for O
two O
nonionic O
contrast O
media O
( O
cm O
) O
, O
iopromide O
and O
iohexol O
, O
among O
80 O
patients O
younger O
than O
18 O
years O
and O
compared O
the O
rates O
for O
this O
complication O
in O
relation O
to O
the O
type O
and O
dosage O
of O
cm O
and O
the O
presence O
of O
cyanosis B-Disease
. O

the O
80 O
patients O
in O
the O
study O
consecutively O
received O
either O
iopromide O
( O
group O
a O
, O
n O
= O
40 O
) O
or O
iohexol O
( O
group O
b O
, O
n O
= O
40 O
) O
. O

serum O
sodium O
( O
na O
) O
, O
potassium O
( O
k O
) O
, O
and O
creatinine O
( O
cr O
) O
were O
measured O
24 O
h O
before O
angiography O
as O
baseline O
values O
, O
then O
measured O
again O
at O
12 O
- O
, O
24 O
- O
, O
and O
48 O
- O
h O
intervals O
after O
cm O
use O
. O

urine O
samples O
for O
na O
and O
cr O
also O
were O
checked O
at O
the O
same O
intervals O
. O

risk O
of O
renal B-Disease
failure B-Disease
, O
injury B-Disease
to B-Disease
the B-Disease
kidney B-Disease
, O
failure B-Disease
of B-Disease
kidney B-Disease
function B-Disease
, O
loss B-Disease
of B-Disease
kidney B-Disease
function B-Disease
, O
and O
end O
- O
stage O
renal B-Disease
damage B-Disease
( O
rifle O
criteria O
) O
were O
used O
to O
define O
cin B-Disease
and O
its O
incidence O
in O
the O
study O
population O
. O

accordingly O
, O
among O
the O
15 O
cin B-Disease
patients O
( O
18 O
. O
75 O
% O
) O
, O
7 O
. O
5 O
% O
of O
the O
patients O
in O
group O
a O
had O
increased O
risk O
and O
3 O
. O
75 O
% O
had O
renal B-Disease
injury B-Disease
, O
whereas O
5 O
% O
of O
group O
b O
had O
increased O
risk O
and O
2 O
. O
5 O
% O
had O
renal B-Disease
injury B-Disease
. O

whereas O
33 O
. O
3 O
% O
of O
the O
patients O
with O
cin B-Disease
were O
among O
those O
who O
received O
the O
proper O
dosage O
of O
cm O
, O
the O
percentage O
increased O
to O
66 O
. O
6 O
% O
among O
those O
who O
received O
larger O
doses O
, O
with O
a O
significant O
difference O
in O
the O
incidence O
of O
cin B-Disease
related O
to O
the O
different O
dosages O
of O
cm O
( O
p O
= O
0 O
. O
014 O
) O
. O

among O
the O
15 O
patients O
with O
cin B-Disease
, O
6 O
had O
cyanotic O
congenital B-Disease
heart B-Disease
diseases B-Disease
, O
but O
the O
incidence O
did O
not O
differ O
significantly O
from O
that O
for O
the O
noncyanotic O
patients O
( O
p O
= O
0 O
. O
243 O
) O
. O

although O
clinically O
silent O
, O
cin B-Disease
is O
not O
rare O
in O
pediatrics O
. O

the O
incidence O
depends O
on O
dosage O
but O
not O
on O
the O
type O
of O
consumed O
nonionic O
cm O
, O
nor O
on O
the O
presence O
of O
cyanosis B-Disease
, O
and O
although O
cin B-Disease
usually O
is O
reversible O
, O
more O
concern O
is O
needed O
for O
the O
prevention O
of O
such O
a O
complication O
in O
children O
. O

renal O
function O
and O
hemodynamics O
during O
prolonged O
isoflurane O
- O
induced O
hypotension B-Disease
in O
humans O
. O

the O
effect O
of O
isoflurane O
- O
induced O
hypotension B-Disease
on O
glomerular O
function O
and O
renal O
blood O
flow O
was O
investigated O
in O
20 O
human O
subjects O
. O

glomerular O
filtration O
rate O
( O
gfr O
) O
and O
effective O
renal O
plasma O
flow O
( O
erpf O
) O
were O
measured O
by O
inulin O
and O
para O
- O
aminohippurate O
( O
pah O
) O
clearance O
, O
respectively O
. O

anesthesia O
was O
maintained O
with O
fentanyl O
, O
nitrous O
oxide O
, O
oxygen O
, O
and O
isoflurane O
. O

hypotension B-Disease
was O
induced O
for O
236 O
. O
9 O
+ O
/ O
- O
15 O
. O
1 O
min O
by O
increasing O
the O
isoflurane O
inspired O
concentration O
to O
maintain O
a O
mean O
arterial O
pressure O
of O
59 O
. O
8 O
+ O
/ O
- O
0 O
. O
4 O
mmhg O
. O

gfr O
and O
erpf O
decreased O
with O
the O
induction O
of O
anesthesia O
but O
not O
significantly O
more O
during O
hypotension B-Disease
. O

postoperatively O
, O
erpf O
returned O
to O
preoperative O
values O
, O
whereas O
gfr O
was O
higher O
than O
preoperative O
values O
. O

renal O
vascular O
resistance O
increased O
during O
anesthesia O
but O
decreased O
when O
hypotension B-Disease
was O
induced O
, O
allowing O
the O
maintenance O
of O
renal O
blood O
flow O
. O

we O
conclude O
that O
renal O
compensatory O
mechanisms O
are O
preserved O
during O
isoflurane O
- O
induced O
hypotension B-Disease
and O
that O
renal O
function O
and O
hemodynamics O
quickly O
return O
to O
normal O
when O
normotension O
is O
resumed O
. O

brainstem B-Disease
dysgenesis B-Disease
in O
an O
infant O
prenatally O
exposed O
to O
cocaine O
. O

many O
authors O
described O
the O
effects O
on O
the O
fetus O
of O
maternal O
cocaine B-Disease
abuse B-Disease
during O
pregnancy O
. O

vasoconstriction O
appears O
to O
be O
the O
common O
mechanism O
of O
action O
leading O
to O
a O
wide O
range O
of O
fetal B-Disease
anomalies B-Disease
. O

we O
report O
on O
an O
infant O
with O
multiple B-Disease
cranial B-Disease
- B-Disease
nerve B-Disease
involvement B-Disease
attributable O
to O
brainstem B-Disease
dysgenesis B-Disease
, O
born O
to O
a O
cocaine B-Disease
- B-Disease
addicted B-Disease
mother O
. O

a O
cross O
- O
sectional O
evaluation O
of O
the O
effect O
of O
risperidone O
and O
selective O
serotonin O
reuptake O
inhibitors O
on O
bone O
mineral O
density O
in O
boys O
. O

objective O
: O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
on O
trabecular O
bone O
mineral O
density O
( O
bmd O
) O
in O
children O
and O
adolescents O
. O

method O
: O
medically O
healthy O
7 O
- O
to O
17 O
- O
year O
- O
old O
males O
chronically O
treated O
, O
in O
a O
naturalistic O
setting O
, O
with O
risperidone O
were O
recruited O
for O
this O
cross O
- O
sectional O
study O
through O
child O
psychiatry O
outpatient O
clinics O
between O
november O
2005 O
and O
june O
2007 O
. O

anthropometric O
measurements O
and O
laboratory O
testing O
were O
conducted O
. O

the O
clinical O
diagnoses O
were O
based O
on O
chart O
review O
, O
and O
developmental O
and O
treatment O
history O
was O
obtained O
from O
the O
medical O
record O
. O

volumetric O
bmd O
of O
the O
ultradistal O
radius O
was O
measured O
using O
peripheral O
quantitative O
computed O
tomography O
, O
and O
areal O
bmd O
of O
the O
lumbar O
spine O
was O
estimated O
using O
dual O
- O
energy O
x O
- O
ray O
absorptiometry O
. O

results O
: O
hyperprolactinemia B-Disease
was O
present O
in O
49 O
% O
of O
83 O
boys O
( O
n O
= O
41 O
) O
treated O
with O
risperidone O
for O
a O
mean O
of O
2 O
. O
9 O
years O
. O

serum O
testosterone O
concentration O
increased O
with O
pubertal O
status O
but O
was O
not O
affected O
by O
hyperprolactinemia B-Disease
. O

as O
expected O
, O
bone O
mineral O
content O
and O
bmd O
increased O
with O
sexual O
maturity O
. O

after O
adjusting O
for O
the O
stage O
of O
sexual O
development O
and O
height O
and O
bmi O
z O
scores O
, O
serum O
prolactin O
was O
negatively O
associated O
with O
trabecular O
volumetric O
bmd O
at O
the O
ultradistal O
radius O
( O
p O
< O
. O
03 O
) O
. O

controlling O
for O
relevant O
covariates O
, O
we O
also O
found O
treatment O
with O
selective O
serotonin O
reuptake O
inhibitors O
( O
ssris O
) O
to O
be O
associated O
with O
lower O
trabecular O
bmd O
at O
the O
radius O
( O
p O
= O
. O
03 O
) O
and O
bmd O
z O
score O
at O
the O
lumbar O
spine O
( O
p O
< O
. O
05 O
) O
. O

these O
findings O
became O
more O
marked O
when O
the O
analysis O
was O
restricted O
to O
non O
- O
hispanic O
white O
patients O
. O

of O
13 O
documented O
fractures B-Disease
, O
3 O
occurred O
after O
risperidone O
and O
ssris O
were O
started O
, O
and O
none O
occurred O
in O
patients O
with O
hyperprolactinemia B-Disease
. O

conclusions O
: O
this O
is O
the O
first O
study O
to O
link O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
and O
ssri O
treatment O
to O
lower O
bmd O
in O
children O
and O
adolescents O
. O

future O
research O
should O
evaluate O
the O
longitudinal O
course O
of O
this O
adverse O
event O
to O
determine O
its O
temporal O
stability O
and O
whether O
a O
higher O
fracture O
rate O
ensues O
. O

fear O
- O
potentiated O
startle B-Disease
, O
but O
not O
light O
- O
enhanced O
startle B-Disease
, O
is O
enhanced O
by O
anxiogenic O
drugs O
. O

rationale O
and O
objectives O
: O
the O
light O
- O
enhanced O
startle B-Disease
paradigm O
( O
les O
) O
is O
suggested O
to O
model O
anxiety B-Disease
, O
because O
of O
the O
non O
- O
specific O
cue O
and O
the O
long O
- O
term O
effect O
. O

in O
contrast O
, O
the O
fear O
- O
potentiated O
startle B-Disease
( O
fps O
) O
is O
suggested O
to O
model O
conditioned O
fear O
. O

however O
, O
the O
pharmacological O
profiles O
of O
these O
two O
paradigms O
are O
very O
similar O
. O

the O
present O
study O
investigated O
the O
effects O
of O
putative O
anxiogenic O
drugs O
on O
les O
and O
fps O
and O
aimed O
at O
determining O
the O
sensitivity O
of O
les O
for O
anxiogenic O
drugs O
and O
to O
potentially O
showing O
a O
pharmacological O
differentiation O
between O
these O
two O
paradigms O
. O

methods O
: O
male O
wistar O
rats O
received O
each O
dose O
of O
the O
alpha O
( O
2 O
) O
- O
adrenoceptor O
antagonist O
yohimbine O
( O
0 O
. O
25 O
- O
1 O
. O
0mg O
/ O
kg O
) O
, O
the O
5 O
- O
ht O
( O
2c O
) O
receptor O
agonist O
m O
- O
chlorophenylpiperazine O
( O
mcpp O
, O
0 O
. O
5 O
- O
2 O
. O
0mg O
/ O
kg O
) O
or O
the O
gaba O
( O
a O
) O
inverse O
receptor O
agonist O
pentylenetetrazole O
( O
ptz O
, O
3 O
- O
30mg O
/ O
kg O
) O
and O
were O
subsequently O
tested O
in O
either O
les O
or O
fps O
. O

results O
: O
none O
of O
the O
drugs O
enhanced O
les O
, O
whereas O
mcpp O
increased O
percentage O
fps O
and O
yohimbine O
increased O
absolute O
fps O
values O
. O

furthermore O
, O
yohimbine O
increased O
baseline O
startle B-Disease
amplitude O
in O
the O
les O
, O
while O
mcpp O
suppressed O
baseline O
startle B-Disease
in O
both O
the O
les O
and O
fps O
and O
ptz O
suppressed O
baseline O
startle B-Disease
in O
the O
fps O
. O

conclusions O
: O
in O
contrast O
to O
findings O
in O
the O
fps O
paradigm O
, O
none O
of O
the O
drugs O
were O
able O
to O
exacerbate O
the O
les O
response O
. O

thus O
, O
a O
clear O
pharmacological O
differentiation O
was O
found O
between O
les O
and O
fps O
. O

rosaceiform O
dermatitis B-Disease
associated O
with O
topical O
tacrolimus O
treatment O
. O

we O
describe O
herein O
3 O
patients O
who O
developed O
rosacea B-Disease
- O
like O
dermatitis B-Disease
eruptions B-Disease
while O
using O
0 O
. O
03 O
% O
or O
0 O
. O
1 O
% O
tacrolimus O
ointment O
for O
facial B-Disease
dermatitis B-Disease
. O

skin O
biopsy O
specimens O
showed O
telangiectasia B-Disease
and O
noncaseating O
epithelioid O
granulomatous O
tissue O
formation O
in O
the O
papillary O
to O
mid O
dermis O
. O

continuous O
topical O
use O
of O
immunomodulators O
such O
as O
tacrolimus O
or O
pimecrolimus O
should O
be O
regarded O
as O
a O
potential O
cause O
of O
rosaceiform O
dermatitis B-Disease
, O
although O
many O
cases O
have O
not O
been O
reported O
. O

coenzyme O
q10 O
treatment O
ameliorates O
acute O
cisplatin O
nephrotoxicity B-Disease
in O
mice O
. O

the O
nephroprotective O
effect O
of O
coenzyme O
q10 O
was O
investigated O
in O
mice O
with O
acute B-Disease
renal B-Disease
injury B-Disease
induced O
by O
a O
single O
i O
. O
p O
. O
injection O
of O
cisplatin O
( O
5 O
mg O
/ O
kg O
) O
. O

coenzyme O
q10 O
treatment O
( O
10 O
mg O
/ O
kg O
/ O
day O
, O
i O
. O
p O
. O
) O
was O
applied O
for O
6 O
consecutive O
days O
, O
starting O
1 O
day O
before O
cisplatin O
administration O
. O

coenzyme O
q10 O
significantly O
reduced O
blood O
urea O
nitrogen O
and O
serum O
creatinine O
levels O
which O
were O
increased O
by O
cisplatin O
. O

coenzyme O
q10 O
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced O
glutathione O
level O
and O
superoxide O
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
, O
nitric O
oxide O
and O
platinum O
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium O
and O
zinc O
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin O
administration O
. O

also O
, O
histopathological O
renal B-Disease
tissue B-Disease
damage B-Disease
mediated O
by O
cisplatin O
was O
ameliorated O
by O
coenzyme O
q10 O
treatment O
. O

immunohistochemical O
analysis O
revealed O
that O
coenzyme O
q10 O
significantly O
decreased O
the O
cisplatin O
- O
induced O
overexpression O
of O
inducible O
nitric O
oxide O
synthase O
, O
nuclear O
factor O
- O
kappab O
, O
caspase O
- O
3 O
and O
p53 O
in O
renal O
tissue O
. O

it O
was O
concluded O
that O
coenzyme O
q10 O
represents O
a O
potential O
therapeutic O
option O
to O
protect O
against O
acute O
cisplatin O
nephrotoxicity B-Disease
commonly O
encountered O
in O
clinical O
practice O
. O

reversible O
cholestasis B-Disease
with O
bile B-Disease
duct B-Disease
injury B-Disease
following O
azathioprine O
therapy O
. O

a O
case O
report O
. O

a O
67 O
- O
year O
- O
old O
patient O
, O
with O
primary O
polymyositis B-Disease
and O
without O
previous O
evidence O
of O
liver B-Disease
disease B-Disease
, O
developed O
clinical O
and O
biochemical O
features O
of O
severe O
cholestasis B-Disease
3 O
months O
after O
initiation O
of O
azathioprine O
therapy O
. O

liver O
biopsy O
showed O
cholestasis B-Disease
with O
both O
cytological O
and O
architectural O
alterations O
of O
interlobular O
bile O
ducts O
. O

azathioprine O
withdrawal O
resulted O
after O
7 O
weeks O
in O
the O
resolution O
of O
clinical O
and O
biochemical O
abnormalities O
. O

it O
is O
believed O
that O
this O
is O
the O
first O
reported O
case O
of O
reversible O
azathioprine O
- O
induced O
cholestasis B-Disease
associated O
with O
histological O
evidence O
of O
bile B-Disease
duct B-Disease
injury B-Disease
. O

dopamine O
is O
not O
essential O
for O
the O
development O
of O
methamphetamine O
- O
induced O
neurotoxicity B-Disease
. O

it O
is O
widely O
believed O
that O
dopamine O
( O
da O
) O
mediates O
methamphetamine O
( O
meth O
) O
- O
induced O
toxicity B-Disease
to O
brain O
dopaminergic O
neurons O
, O
because O
drugs O
that O
interfere O
with O
da O
neurotransmission O
decrease O
toxicity B-Disease
, O
whereas O
drugs O
that O
increase O
da O
neurotransmission O
enhance O
toxicity B-Disease
. O

however O
, O
temperature O
effects O
of O
drugs O
that O
have O
been O
used O
to O
manipulate O
brain O
da O
neurotransmission O
confound O
interpretation O
of O
the O
data O
. O

here O
we O
show O
that O
the O
recently O
reported O
ability O
of O
l O
- O
dihydroxyphenylalanine O
to O
reverse O
the O
protective O
effect O
of O
alpha O
- O
methyl O
- O
para O
- O
tyrosine O
on O
meth O
- O
induced O
da O
neurotoxicity B-Disease
is O
also O
confounded O
by O
drug O
effects O
on O
body O
temperature O
. O

further O
, O
we O
show O
that O
mice O
genetically O
engineered O
to O
be O
deficient O
in O
brain O
da O
develop O
meth O
neurotoxicity B-Disease
, O
as O
long O
as O
the O
thermic O
effects O
of O
meth O
are O
preserved O
. O

in O
addition O
, O
we O
demonstrate O
that O
mice O
genetically O
engineered O
to O
have O
unilateral O
brain O
da O
deficits O
develop O
meth O
- O
induced O
dopaminergic B-Disease
deficits B-Disease
that O
are O
of O
comparable O
magnitude O
on O
both O
sides O
of O
the O
brain O
. O

taken O
together O
, O
these O
findings O
demonstrate O
that O
da O
is O
not O
essential O
for O
the O
development O
of O
meth O
- O
induced O
dopaminergic O
neurotoxicity B-Disease
and O
suggest O
that O
mechanisms O
independent O
of O
da O
warrant O
more O
intense O
investigation O
. O

swallowing O
- O
induced O
atrial B-Disease
tachyarrhythmia B-Disease
triggered O
by O
salbutamol O
: O
case O
report O
and O
review O
of O
the O
literature O
. O

case O
: O
a O
49 O
- O
year O
- O
old O
patient O
experienced O
chest O
discomfort O
while O
swallowing O
. O

on O
electrocardiogram O
, O
episodes O
of O
atrial B-Disease
tachyarrhythmia B-Disease
were O
recorded O
immediately O
after O
swallowing O
; O
24 O
- O
hour O
holter O
monitoring O
recorded O
several O
events O
. O

the O
arrhythmia B-Disease
resolved O
after O
therapy O
with O
atenolol O
, O
but O
recurred O
a O
year O
later O
. O

the O
patient O
noticed O
that O
before O
these O
episodes O
he O
had O
been O
using O
an O
inhalator O
of O
salbutamol O
. O

after O
stopping O
the O
beta O
- O
agonist O
, O
and O
after O
a O
week O
with O
the O
atenolol O
, O
the O
arrhythmia B-Disease
disappeared O
. O

discussion O
: O
swallowing O
- O
induced O
atrial B-Disease
tachyarrhythmia B-Disease
( O
siat B-Disease
) O
is O
a O
rare O
phenomenon O
. O

fewer O
than O
50 O
cases O
of O
siat B-Disease
have O
been O
described O
in O
the O
literature O
. O

this O
article O
summarizes O
all O
the O
cases O
published O
, O
creating O
a O
comprehensive O
review O
of O
the O
current O
knowledge O
and O
approach O
to O
siat B-Disease
. O

it O
discusses O
demographics O
, O
clinical O
characteristics O
and O
types O
of O
arrhythmia B-Disease
, O
postulated O
mechanisms O
of O
siat B-Disease
, O
and O
different O
treatment O
possibilities O
such O
as O
medications O
, O
surgery O
, O
and O
radiofrequency O
catheter O
ablation O
( O
rfca O
) O
. O

conclusion O
: O
salbutamol O
is O
presented O
here O
as O
a O
possible O
trigger O
for O
siat B-Disease
. O

although O
it O
is O
difficult O
to O
define O
causality O
in O
a O
case O
report O
, O
it O
is O
logical O
to O
think O
that O
a O
beta O
- O
agonist O
like O
salbutamol O
( O
known O
to O
induce O
tachycardia B-Disease
) O
may O
be O
the O
trigger O
of O
adrenergic O
reflexes O
originating O
in O
the O
esophagus O
while O
swallowing O
and O
that O
a O
beta O
- O
blocker O
such O
as O
atenolol O
( O
that O
blocks O
the O
adrenergic O
activity O
) O
may O
relieve O
it O
. O

the O
ability O
of O
insulin O
treatment O
to O
reverse O
or O
prevent O
the O
changes O
in O
urinary O
bladder O
function O
caused O
by O
streptozotocin O
- O
induced O
diabetes B-Disease
mellitus B-Disease
. O

1 O
. O

the O
effects O
of O
insulin O
treatment O
on O
in O
vivo O
and O
in O
vitro O
urinary O
bladder O
function O
in O
streptozotocin O
- O
diabetic B-Disease
rats O
were O
investigated O
. O

2 O
. O

diabetes B-Disease
of O
2 O
months O
duration O
resulted O
in O
decreases O
in O
body O
weight O
and O
increases O
in O
fluid O
consumption O
, O
urine O
volume O
, O
frequency O
of O
micturition O
, O
and O
average O
volume O
per O
micturition O
; O
effects O
which O
were O
prevented O
by O
insulin O
treatment O
. O

3 O
. O

insulin O
treatment O
also O
prevented O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic B-Disease
rats O
to O
nerve O
stimulation O
, O
atp O
, O
and O
bethanechol O
. O

4 O
. O

diabetes B-Disease
of O
4 O
months O
duration O
also O
resulted O
in O
decreases O
in O
body O
weight O
, O
and O
increases O
in O
fluid O
consumption O
, O
urine O
volume O
, O
frequency O
of O
micturition O
, O
and O
average O
volume O
per O
micturition O
, O
effects O
which O
were O
reversed O
by O
insulin O
treatment O
for O
the O
final O
2 O
months O
of O
the O
study O
. O

5 O
. O

insulin O
treatment O
reversed O
the O
increases O
in O
contractile O
responses O
of O
bladder O
body O
strips O
from O
diabetic B-Disease
rats O
to O
nerve O
stimulation O
, O
atp O
, O
and O
bethanechol O
. O

6 O
. O

the O
data O
indicate O
that O
the O
effects O
of O
streptozotocin O
- O
induced O
diabetes B-Disease
on O
urinary O
bladder O
function O
are O
both O
prevented O
and O
reversed O
by O
insulin O
treatment O
. O

glutamatergic O
neurotransmission O
mediated O
by O
nmda O
receptors O
in O
the O
inferior O
colliculus O
can O
modulate O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

the O
inferior O
colliculus O
( O
ic O
) O
is O
primarily O
involved O
in O
the O
processing O
of O
auditory O
information O
, O
but O
it O
is O
distinguished O
from O
other O
auditory O
nuclei O
in O
the O
brainstem O
by O
its O
connections O
with O
structures O
of O
the O
motor O
system O
. O

functional O
evidence O
relating O
the O
ic O
to O
motor O
behavior O
derives O
from O
experiments O
showing O
that O
activation O
of O
the O
ic O
by O
electrical O
stimulation O
or O
excitatory O
amino O
acid O
microinjection O
causes O
freezing O
, O
escape O
- O
like O
behavior O
, O
and O
immobility O
. O

however O
, O
the O
nature O
of O
this O
immobility O
is O
still O
unclear O
. O

the O
present O
study O
examined O
the O
influence O
of O
excitatory O
amino O
acid O
- O
mediated O
mechanisms O
in O
the O
ic O
on O
the O
catalepsy B-Disease
induced O
by O
the O
dopamine O
receptor O
blocker O
haloperidol O
administered O
systemically O
( O
1 O
or O
0 O
. O
5 O
mg O
/ O
kg O
) O
in O
rats O
. O

haloperidol O
- O
induced O
catalepsy B-Disease
was O
challenged O
with O
prior O
intracollicular O
microinjections O
of O
glutamate O
nmda O
receptor O
antagonists O
, O
mk O
- O
801 O
( O
15 O
or O
30 O
mmol O
/ O
0 O
. O
5 O
microl O
) O
and O
ap7 O
( O
10 O
or O
20 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
, O
or O
of O
the O
nmda O
receptor O
agonist O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
, O
20 O
or O
30 O
nmol O
/ O
0 O
. O
5 O
microl O
) O
. O

the O
results O
showed O
that O
intracollicular O
microinjection O
of O
mk O
- O
801 O
and O
ap7 O
previous O
to O
systemic O
injections O
of O
haloperidol O
significantly O
attenuated O
the O
catalepsy B-Disease
, O
as O
indicated O
by O
a O
reduced O
latency O
to O
step O
down O
from O
a O
horizontal O
bar O
. O

accordingly O
, O
intracollicular O
microinjection O
of O
nmda O
increased O
the O
latency O
to O
step O
down O
the O
bar O
. O

these O
findings O
suggest O
that O
glutamate O
- O
mediated O
mechanisms O
in O
the O
neural O
circuits O
at O
the O
ic O
level O
influence O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
participate O
in O
the O
regulation O
of O
motor O
activity O
. O

severe O
congestive B-Disease
heart B-Disease
failure B-Disease
patient O
on O
amiodarone O
presenting O
with O
myxedemic B-Disease
coma B-Disease
: O
a O
case O
report O
. O

this O
is O
a O
case O
report O
of O
myxedema B-Disease
coma B-Disease
secondary O
to O
amiodarone O
- O
induced O
hypothyroidism B-Disease
in O
a O
patient O
with O
severe O
congestive B-Disease
heart B-Disease
failure B-Disease
( O
chf B-Disease
) O
. O

to O
our O
knowledge O
and O
after O
reviewing O
the O
literature O
there O
is O
one O
case O
report O
of O
myxedema B-Disease
coma B-Disease
during O
long O
term O
amiodarone O
therapy O
. O

myxedema B-Disease
coma B-Disease
is O
a O
life O
threatening O
condition O
that O
carries O
a O
mortality O
reaching O
as O
high O
as O
20 O
% O
with O
treatment O
. O

the O
condition O
is O
treated O
with O
intravenous O
thyroxine O
( O
t4 O
) O
or O
intravenous O
tri O
- O
iodo O
- O
thyronine O
( O
t3 O
) O
. O

patients O
with O
chf B-Disease
on O
amiodarone O
may O
suffer O
serious O
morbidity O
and O
mortality O
from O
hypothyroidism B-Disease
, O
and O
thus O
may O
deserve O
closer O
follow O
up O
for O
thyroid O
stimulating O
hormone O
( O
tsh O
) O
levels O
. O

this O
case O
report O
carries O
an O
important O
clinical O
application O
given O
the O
frequent O
usage O
of O
amiodarone O
among O
chf B-Disease
patients O
. O

the O
myriad O
clinical O
presentation O
of O
myxedema B-Disease
coma B-Disease
and O
its O
serious O
morbidity O
and O
mortality O
stresses O
the O
need O
to O
suspect O
this O
clinical O
syndrome O
among O
chf B-Disease
patients O
presenting O
with O
hypotension B-Disease
, O
weakness B-Disease
or O
other O
unexplained O
symptoms O
. O

effects O
of O
active O
constituents O
of O
crocus O
sativus O
l O
. O
, O
crocin O
on O
streptozocin O
- O
induced O
model O
of O
sporadic O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
in O
male O
rats O
. O

background O
: O
the O
involvement O
of O
water O
- O
soluble O
carotenoids O
, O
crocins O
, O
as O
the O
main O
and O
active O
components O
of O
crocus O
sativus O
l O
. O
extract O
in O
learning O
and O
memory O
processes O
has O
been O
proposed O
. O

in O
the O
present O
study O
, O
the O
effect O
of O
crocins O
on O
sporadic O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
induced O
by O
intracerebroventricular O
( O
icv O
) O
streptozocin O
( O
stz O
) O
in O
male O
rats O
was O
investigated O
. O

methods O
: O
male O
adult O
wistar O
rats O
( O
n O
= O
90 O
and O
260 O
- O
290 O
g O
) O
were O
divided O
into O
1 O
, O
control O
; O
2 O
and O
3 O
, O
crocins O
( O
15 O
and O
30 O
mg O
/ O
kg O
) O
; O
4 O
, O
stz O
; O
5 O
and O
6 O
, O
stz O
+ O
crocins O
( O
15 O
and O
30 O
mg O
/ O
kg O
) O
groups O
. O

in O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
groups O
, O
rats O
were O
injected O
with O
stz O
- O
icv O
bilaterally O
( O
3 O
mg O
/ O
kg O
) O
in O
first O
day O
and O
3 O
days O
later O
, O
a O
similar O
stz O
- O
icv O
application O
was O
repeated O
. O

in O
stz O
+ O
crocin O
animal O
groups O
, O
crocin O
was O
applied O
in O
doses O
of O
15 O
and O
30 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
one O
day O
pre O
- O
surgery O
and O
continued O
for O
three O
weeks O
. O

prescription O
of O
crocin O
in O
each O
dose O
was O
repeated O
once O
for O
two O
days O
. O

however O
, O
the O
learning O
and O
memory O
performance O
was O
assessed O
using O
passive O
avoidance O
paradigm O
, O
and O
for O
spatial O
cognition O
evaluation O
, O
y O
- O
maze O
task O
was O
used O
. O

results O
: O
it O
was O
found O
out O
that O
crocin O
( O
30 O
mg O
/ O
kg O
) O
- O
treated O
stz O
- O
injected O
rats O
show O
higher O
correct O
choices O
and O
lower O
errors O
in O
y O
- O
maze O
than O
vehicle O
- O
treated O
stz O
- O
injected O
rats O
. O

in O
addition O
, O
crocin O
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning B-Disease
and B-Disease
memory B-Disease
impairment B-Disease
in O
treated O
stz O
- O
injected O
group O
in O
passive O
avoidance O
test O
. O

conclusion O
: O
therefore O
, O
these O
results O
demonstrate O
the O
effectiveness O
of O
crocin O
( O
30 O
mg O
/ O
kg O
) O
in O
antagonizing O
the O
cognitive B-Disease
deficits B-Disease
caused O
by O
stz O
- O
icv O
in O
rats O
and O
its O
potential O
in O
the O
treatment O
of O
neurodegenerative B-Disease
diseases B-Disease
such O
as O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

serotonin O
6 O
receptor O
gene O
is O
associated O
with O
methamphetamine O
- O
induced O
psychosis B-Disease
in O
a O
japanese O
population O
. O

background O
: O
altered O
serotonergic O
neural O
transmission O
is O
hypothesized O
to O
be O
a O
susceptibility O
factor O
for O
psychotic B-Disease
disorders B-Disease
such O
as O
schizophrenia B-Disease
. O

the O
serotonin O
6 O
( O
5 O
- O
ht6 O
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine O
and O
olanzapine O
, O
and O
d O
- O
amphetamine O
- O
induced O
hyperactivity B-Disease
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5 O
- O
ht6 O
receptor O
antagonist O
. O

in O
addition O
, O
the O
disrupted O
prepulse O
inhibition O
induced O
by O
d O
- O
amphetamine O
or O
phencyclidine O
was O
restored O
by O
5 O
- O
ht6 O
receptor O
antagonist O
in O
an O
animal O
study O
using O
rats O
. O

these O
animal O
models O
were O
considered O
to O
reflect O
the O
positive O
symptoms O
of O
schizophrenia B-Disease
, O
and O
the O
above O
evidence O
suggests O
that O
altered O
5 O
- O
ht6 O
receptors O
are O
involved O
in O
the O
pathophysiology O
of O
psychotic B-Disease
disorders B-Disease
. O

the O
symptoms O
of O
methamphetamine O
( O
meth O
) O
- O
induced O
psychosis B-Disease
are O
similar O
to O
those O
of O
paranoid B-Disease
type B-Disease
schizophrenia B-Disease
. O

therefore O
, O
we O
conducted O
an O
analysis O
of O
the O
association O
of O
the O
5 O
- O
ht6 O
gene O
( O
htr6 O
) O
with O
meth O
- O
induced O
psychosis B-Disease
. O

method O
: O
using O
five O
tagging O
snps O
( O
rs6693503 O
, O
rs1805054 O
, O
rs4912138 O
, O
rs3790757 O
and O
rs9659997 O
) O
, O
we O
conducted O
a O
genetic O
association O
analysis O
of O
case O
- O
control O
samples O
( O
197 O
meth O
- O
induced O
psychosis B-Disease
patients O
and O
337 O
controls O
) O
in O
the O
japanese O
population O
. O

the O
age O
and O
sex O
of O
the O
control O
subjects O
did O
not O
differ O
from O
those O
of O
the O
methamphetamine O
dependence O
patients O
. O

results O
: O
rs6693503 O
was O
associated O
with O
meth O
- O
induced O
psychosis B-Disease
patients O
in O
the O
allele O
/ O
genotype O
- O
wise O
analysis O
. O

moreover O
, O
this O
association O
remained O
significant O
after O
bonferroni O
correction O
. O

in O
the O
haplotype O
- O
wise O
analysis O
, O
we O
detected O
an O
association O
between O
two O
markers O
( O
rs6693503 O
and O
rs1805054 O
) O
and O
three O
markers O
( O
rs6693503 O
, O
rs1805054 O
and O
rs4912138 O
) O
in O
htr6 O
and O
meth O
- O
induced O
psychosis B-Disease
patients O
, O
respectively O
. O

conclusion O
: O
htr6 O
may O
play O
an O
important O
role O
in O
the O
pathophysiology O
of O
meth O
- O
induced O
psychosis B-Disease
in O
the O
japanese O
population O
. O

neural O
correlates O
of O
s O
- O
ketamine O
induced O
psychosis B-Disease
during O
overt O
continuous O
verbal O
fluency O
. O

the O
glutamatergic O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
has O
been O
implicated O
in O
the O
pathophysiology O
of O
schizophrenia B-Disease
. O

administered O
to O
healthy O
volunteers O
, O
a O
subanesthetic O
dose O
of O
the O
non O
- O
competitive O
nmda O
receptor O
antagonist O
ketamine O
leads O
to O
psychopathological O
symptoms O
similar O
to O
those O
observed O
in O
schizophrenia B-Disease
. O

in O
patients O
with O
schizophrenia B-Disease
, O
ketamine O
exacerbates O
the O
core O
symptoms O
of O
illness O
, O
supporting O
the O
hypothesis O
of O
a O
glutamatergic B-Disease
dysfunction B-Disease
. O

in O
a O
counterbalanced O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
study O
design O
, O
healthy O
subjects O
were O
administered O
a O
continuous O
subanesthetic O
s O
- O
ketamine O
infusion O
while O
differences O
in O
bold O
responses O
measured O
with O
fmri O
were O
detected O
. O

during O
the O
scanning O
period O
, O
subjects O
performed O
continuous O
overt O
verbal O
fluency O
tasks O
( O
phonological O
, O
lexical O
and O
semantic O
) O
. O

ketamine O
- O
induced O
psychopathological O
symptoms O
were O
assessed O
with O
the O
positive O
and O
negative O
syndrome O
scale O
( O
panss O
) O
. O

ketamine O
elicited O
psychosis B-Disease
like O
psychopathology O
. O

post O
- O
hoc O
t O
- O
tests O
revealed O
significant O
differences O
between O
placebo O
and O
ketamine O
for O
the O
amounts O
of O
words O
generated O
during O
lexical O
and O
semantic O
verbal O
fluency O
, O
while O
the O
phonological O
domain O
remained O
unaffected O
. O

ketamine O
led O
to O
enhanced O
cortical O
activations O
in O
supramarginal O
and O
frontal O
brain O
regions O
for O
phonological O
and O
lexical O
verbal O
fluency O
, O
but O
not O
for O
semantic O
verbal O
fluency O
. O

ketamine O
induces O
activation O
changes O
in O
healthy O
subjects O
similar O
to O
those O
observed O
in O
patients O
with O
schizophrenia B-Disease
, O
particularly O
in O
frontal O
and O
temporal O
brain O
regions O
. O

our O
results O
provide O
further O
support O
for O
the O
hypothesis O
of O
an O
nmda O
receptor O
dysfunction O
in O
the O
pathophysiology O
of O
schizophrenia B-Disease
. O

long O
- O
term O
prognosis O
for O
transplant O
- O
free O
survivors O
of O
paracetamol O
- O
induced O
acute B-Disease
liver B-Disease
failure B-Disease
. O

background O
: O
the O
prognosis O
for O
transplant O
- O
free O
survivors O
of O
paracetamol O
- O
induced O
acute B-Disease
liver B-Disease
failure B-Disease
remains O
unknown O
. O

aim O
: O
to O
examine O
whether O
paracetamol O
- O
induced O
acute B-Disease
liver B-Disease
failure B-Disease
increases O
long O
- O
term O
mortality O
. O

methods O
: O
we O
followed O
up O
all O
transplant O
- O
free O
survivors O
of O
paracetamol O
- O
induced O
acute B-Disease
liver B-Disease
injury B-Disease
, O
hospitalized O
in O
a O
danish O
national O
referral O
centre O
during O
1984 O
- O
2004 O
. O

we O
compared O
age O
- O
specific O
mortality O
rates O
from O
1 O
year O
post O
- O
discharge O
through O
2008 O
between O
those O
in O
whom O
the O
liver B-Disease
injury B-Disease
led O
to O
an O
acute B-Disease
liver B-Disease
failure B-Disease
and O
those O
in O
whom O
it O
did O
not O
. O

results O
: O
we O
included O
641 O
patients O
. O

on O
average O
, O
age O
- O
specific O
mortality O
rates O
were O
slightly O
higher O
for O
the O
101 O
patients O
whose O
paracetamol O
- O
induced O
liver B-Disease
injury B-Disease
had O
caused O
an O
acute B-Disease
liver B-Disease
failure B-Disease
( O
adjusted O
mortality O
rate O
ratio O
= O
1 O
. O
70 O
, O
95 O
% O
ci O
1 O
. O
02 O
- O
2 O
. O
85 O
) O
, O
but O
the O
association O
was O
age O
- O
dependent O
, O
and O
no O
survivors O
of O
acute B-Disease
liver B-Disease
failure B-Disease
died O
of O
liver B-Disease
disease B-Disease
, O
whereas O
suicides O
were O
frequent O
in O
both O
groups O
. O

these O
observations O
speak O
against O
long O
- O
term O
effects O
of O
acute B-Disease
liver B-Disease
failure B-Disease
. O

more O
likely O
, O
the O
elevated O
mortality O
rate O
ratio O
resulted O
from O
incomplete O
adjustment O
for O
the O
greater O
prevalence O
of O
substance B-Disease
abuse B-Disease
among O
survivors O
of O
acute B-Disease
liver B-Disease
failure B-Disease
. O

conclusions O
: O
paracetamol O
- O
induced O
acute B-Disease
liver B-Disease
failure B-Disease
did O
not O
affect O
long O
- O
term O
mortality O
. O

clinical O
follow O
- O
up O
may O
be O
justified O
by O
the O
cause O
of O
the O
liver B-Disease
failure B-Disease
, O
but O
not O
by O
the O
liver B-Disease
failure B-Disease
itself O
. O

in O
vivo O
characterization O
of O
a O
dual O
adenosine O
a2a O
/ O
a1 O
receptor O
antagonist O
in O
animal O
models O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

the O
in O
vivo O
characterization O
of O
a O
dual O
adenosine O
a O
( O
2a O
) O
/ O
a O
( O
1 O
) O
receptor O
antagonist O
in O
several O
animal O
models O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
is O
described O
. O

discovery O
and O
scale O
- O
up O
syntheses O
of O
compound O
1 O
are O
described O
in O
detail O
, O
highlighting O
optimization O
steps O
that O
increased O
the O
overall O
yield O
of O
1 O
from O
10 O
. O
0 O
% O
to O
30 O
. O
5 O
% O
. O

compound O
1 O
is O
a O
potent O
a O
( O
2a O
) O
/ O
a O
( O
1 O
) O
receptor O
antagonist O
in O
vitro O
( O
a O
( O
2a O
) O
k O
( O
i O
) O
= O
4 O
. O
1 O
nm O
; O
a O
( O
1 O
) O
k O
( O
i O
) O
= O
17 O
. O
0 O
nm O
) O
that O
has O
excellent O
activity O
, O
after O
oral O
administration O
, O
across O
a O
number O
of O
animal O
models O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
including O
mouse O
and O
rat O
models O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
, O
mouse O
model O
of O
reserpine O
- O
induced O
akinesia B-Disease
, O
rat O
6 O
- O
hydroxydopamine O
( O
6 O
- O
ohda O
) O
lesion O
model O
of O
drug O
- O
induced O
rotation O
, O
and O

mptp O
- O
treated O
non O
- O
human O
primate O
model O
. O

effects O
of O
the O
hippocampal O
deep O
brain O
stimulation O
on O
cortical O
epileptic B-Disease
discharges O
in O
penicillin O
- O
induced O
epilepsy B-Disease
model O
in O
rats O
. O

aim O
: O
experimental O
and O
clinical O
studies O
have O
revealed O
that O
hippocampal O
dbs O
can O
control O
epileptic B-Disease
activity O
, O
but O
the O
mechanism O
of O
action O
is O
obscure O
and O
optimal O
stimulation O
parameters O
are O
not O
clearly O
defined O
. O

the O
aim O
was O
to O
evaluate O
the O
effects O
of O
high O
frequency O
hippocampal O
stimulation O
on O
cortical O
epileptic B-Disease
activity O
in O
penicillin O
- O
induced O
epilepsy B-Disease
model O
. O

material O
and O
methods O
: O
twenty O
- O
five O
sprague O
- O
dawley O
rats O
were O
implanted O
dbs O
electrodes O
. O

in O
group O
- O
1 O
( O
n O
= O
10 O
) O
hippocampal O
dbs O
was O
off O
and O
in O
the O
group O
- O
2 O
( O
n O
= O
10 O
) O
hippocampal O
dbs O
was O
on O
( O
185 O
hz O
, O
0 O
. O
5v O
, O
1v O
, O
2v O
, O
and O
5v O
for O
60 O
sec O
) O
following O
penicillin O
g O
injection O
intracortically O
. O

in O
the O
control O
group O
hippocampal O
dbs O
was O
on O
following O
8 O
l O
saline O
injection O
intracortically O
. O

eeg O
recordings O
were O
obtained O
before O
and O
15 O
minutes O
following O
penicillin O
- O
g O
injection O
, O
and O
at O
10th O
minutes O
following O
each O
stimulus O
for O
analysis O
in O
terms O
of O
frequency O
, O
amplitude O
, O
and O
power O
spectrum O
. O

results O
: O
high O
frequency O
hippocampal O
dbs O
suppressed O
the O
acute O
penicillin O
- O
induced O
cortical O
epileptic B-Disease
activity O
independent O
from O
stimulus O
intensity O
. O

in O
the O
control O
group O
, O
hippocampal O
stimulation O
alone O
lead O
only O
to O
diffuse O
slowing O
of O
cerebral O
bioelectrical O
activity O
at O
5v O
stimulation O
. O

conclusion O
: O
our O
results O
revealed O
that O
continuous O
high O
frequency O
stimulation O
of O
the O
hippocampus O
suppressed O
acute O
cortical O
epileptic B-Disease
activity O
effectively O
without O
causing O
secondary O
epileptic B-Disease
discharges O
. O

these O
results O
are O
important O
in O
terms O
of O
defining O
the O
optimal O
parameters O
of O
hippocampal O
dbs O
in O
patients O
with O
epilepsy B-Disease
. O

ccnu O
( O
lomustine O
) O
toxicity B-Disease
in O
dogs O
: O
a O
retrospective O
study O
( O
2002 O
- O
07 O
) O
. O

objective O
: O
to O
describe O
the O
incidence O
of O
haematological B-Disease
, B-Disease
renal B-Disease
, B-Disease
hepatic B-Disease
and B-Disease
gastrointestinal B-Disease
toxicities B-Disease
in O
tumour O
- O
bearing O
dogs O
receiving O
1 O
- O
( O
2 O
- O
chloroethyl O
) O
- O
3 O
- O
cyclohexyl O
- O
1 O
- O
nitrosourea O
( O
ccnu O
) O
. O

design O
: O
the O
medical O
records O
of O
206 O
dogs O
that O
were O
treated O
with O
ccnu O
at O
the O
melbourne O
veterinary O
specialist O
centre O
between O
february O
2002 O
and O
december O
2007 O
were O
retrospectively O
evaluated O
. O

results O
: O
of O
the O
206 O
dogs O
treated O
with O
ccnu O
, O
185 O
met O
the O
inclusion O
criteria O
for O
at O
least O
one O
class O
of O
toxicity B-Disease
. O

ccnu O
was O
used O
most O
commonly O
in O
the O
treatment O
of O
lymphoma B-Disease
, O
mast B-Disease
cell B-Disease
tumour B-Disease
, O
brain B-Disease
tumour B-Disease
, O
histiocytic B-Disease
tumours B-Disease
and O
epitheliotropic B-Disease
lymphoma B-Disease
. O

throughout O
treatment O
, O
56 O
. O
9 O
% O
of O
dogs O
experienced O
neutropenia B-Disease
, O
34 O
. O
2 O
% O
experienced O
anaemia B-Disease
and O
14 O
. O
2 O
% O
experienced O
thrombocytopenia B-Disease
. O

gastrointestinal B-Disease
toxicosis B-Disease
was O
detected O
in O
37 O
. O
8 O
% O
of O
dogs O
, O
the O
most O
common O
sign O
of O
which O
was O
vomiting B-Disease
( O
24 O
. O
3 O
% O
) O
. O

potential O
renal O
toxicity B-Disease
and O
elevated O
alanine O
transaminase O
( O
alt O
) O
concentration O
were O
reported O
in O
12 O
. O
2 O
% O
and O
48 O
. O
8 O
% O
of O
dogs O
, O
respectively O
. O

the O
incidence O
of O
hepatic B-Disease
failure B-Disease
was O
1 O
. O
2 O
% O
. O

conclusions O
: O
ccnu O
- O
associated O
toxicity B-Disease
in O
dogs O
is O
common O
, O
but O
is O
usually O
not O
life O
threatening O
. O

central O
vein B-Disease
thrombosis B-Disease
and O
topical O
dipivalyl O
epinephrine O
. O

a O
report O
is O
given O
on O
an O
83 O
- O
year O
- O
old O
female O
who O
acquired O
central O
vein B-Disease
thrombosis B-Disease
in O
her O
seeing O
eye O
one O
day O
after O
having O
started O
topical O
medication O
with O
dipivalyl O
epinephrine O
for O
advanced O
glaucoma B-Disease
discovered O
in O
the O
other O
eye O
. O

from O
present O
knowledge O
about O
the O
effects O
of O
adrenergic O
eye O
drops O
on O
ocular O
blood O
circulation O
, O
it O
is O
difficult O
to O
suggest O
an O
association O
between O
the O
two O
events O
, O
which O
may O
be O
coincidental O
only O
. O

benzylacyclouridine O
reverses O
azidothymidine O
- O
induced O
marrow B-Disease
suppression B-Disease
without O
impairment O
of O
anti O
- O
human O
immunodeficiency B-Disease
virus O
activity O
. O

increased O
extracellular O
concentrations O
of O
uridine O
( O
urd O
) O
have O
been O
reported O
to O
reduce O
, O
in O
vitro O
, O
azidothymidine O
( O
azt O
) O
- O
induced O
inhibition O
of O
human O
granulocyte O
- O
macrophage O
progenitor O
cells O
without O
impairment O
of O
its O
antihuman O
immunodeficiency B-Disease
virus O
( O
hiv O
) O
activity O
. O

because O
of O
the O
clinical O
toxicities B-Disease
associated O
with O
chronic O
urd O
administration O
, O
the O
ability O
of O
benzylacyclouridine O
( O
bau O
) O
to O
effect O
, O
in O
vivo O
, O
azt O
- O
induced O
anemia B-Disease
and O
leukopenia B-Disease
was O
assessed O
. O

this O
agent O
inhibits O
urd O
catabolism O
and O
, O
in O
vivo O
, O
increases O
the O
plasma O
concentration O
of O
urd O
in O
a O
dose O
- O
dependent O
manner O
, O
without O
urd O
- O
related O
toxicity B-Disease
. O

in O
mice O
rendered O
anemic B-Disease
and O
leukopenic B-Disease
by O
the O
administration O
of O
azt O
for O
28 O
days O
in O
drinking O
water O
( O
1 O
. O
5 O
mg O
/ O
ml O
) O
, O
the O
continued O
administration O
of O
azt O
plus O
daily O
bau O
( O
300 O
mg O
/ O
kg O
, O
orally O
) O
partially O
reversed O
azt O
- O
induced O
anemia B-Disease
and O
leukopenia B-Disease
( O
p O
less O
than O
. O
05 O
) O
, O
increased O
peripheral O
reticulocytes O
( O
to O
4 O
. O
9 O
% O
, O
p O
less O
than O
. O
01 O
) O
, O
increased O
cellularity O
in O
the O
marrow O
, O
and O
improved O
megaloblastosis B-Disease
. O

when O
coadministered O
with O
azt O
from O
the O
onset O
of O
drug O
administration O
, O
bau O
reduced O
azt O
- O
induced O
marrow B-Disease
toxicity B-Disease
. O

in O
vitro O
, O
at O
a O
concentration O
of O
100 O
mumol O
/ O
l O
, O
bau O
possesses O
minimal O
anti O
- O
hiv O
activity O
and O
has O
no O
effect O
on O
the O
ability O
of O
azt O
to O
reverse O
the O
hiv O
- O
induced O
cytopathic O
effect O
in O
mt4 O
cells O
. O

the O
clinical O
and O
biochemical O
implications O
of O
these O
findings O
are O
discussed O
. O

lethal O
anuria B-Disease
complicating O
high O
dose O
ifosfamide O
chemotherapy O
in O
a O
breast B-Disease
cancer B-Disease
patient O
with O
an O
impaired B-Disease
renal B-Disease
function B-Disease
. O

a O
sixty O
- O
year O
- O
old O
woman O
with O
advanced O
breast B-Disease
cancer B-Disease
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible O
lethal O
renal B-Disease
failure B-Disease
with O
anuria B-Disease
, O
the O
day O
after O
5 O
g O
/ O
m2 O
bolus O
ifosfamide O
. O

postrenal B-Disease
failure B-Disease
was O
excluded O
by O
echography O
. O

a O
prerenal O
component O
could O
have O
contributed O
to O
renal B-Disease
failure B-Disease
because O
of O
a O
transient O
hypotension B-Disease
, O
due O
to O
an O
increasing O
ascitis O
, O
occurring O
just O
before O
anuria B-Disease
. O

however O
, O
correction O
of O
the O
hemodynamic O
parameters O
did O
not O
improve O
renal O
function O
. O

ifosfamide O
is O
a O
known O
nephrotoxic B-Disease
drug O
with O
demonstrated O
tubulopathies B-Disease
. O

we O
strongly O
suspect O
that O
this O
lethal O
anuria B-Disease
was O
mainly O
due O
to O
ifosfamide O
, O
occurring O
in O
a O
patient O
having O
received O
previous O
cisplatin O
chemotherapy O
and O
with O
poor O
kidney O
perfusion O
due O
to O
transient O
hypotension B-Disease
. O

we O
recommend O
careful O
use O
of O
ifosfamide O
in O
patients O
pretreated O
with O
nephrotoxic B-Disease
chemotherapy O
and O
inadequate O
renal O
perfusion O
. O

nociceptive O
effects O
induced O
by O
intrathecal O
administration O
of O
prostaglandin O
d2 O
, O
e2 O
, O
or O
f2 O
alpha O
to O
conscious O
mice O
. O

the O
effects O
of O
intrathecal O
administration O
of O
prostaglandins O
on O
pain B-Disease
responses O
in O
conscious O
mice O
were O
evaluated O
by O
using O
hot O
plate O
and O
acetic O
acid O
writhing O
tests O
. O

prostaglandin O
d2 O
( O
0 O
. O
5 O
- O
3 O
ng O
/ O
mouse O
) O
had O
a O
hyperalgesic B-Disease
action O
on O
the O
response O
to O
a O
hot O
plate O
during O
a O
3 O
- O
60 O
min O
period O
after O
injection O
. O

prostaglandin O
e2 O
showed O
a O
hyperalgesic B-Disease
effect O
at O
doses O
of O
1 O
pg O
to O
10 O
ng O
/ O
mouse O
, O
but O
the O
effect O
lasted O
shorter O
( O
3 O
- O
30 O
min O
) O
than O
that O
of O
prostaglandin O
d2 O
. O

similar O
results O
were O
obtained O
by O
acetic O
acid O
writhing O
tests O
. O

the O
hyperalgesic B-Disease
effect O
of O
prostaglandin O
d2 O
was O
blocked O
by O
simultaneous O
injection O
of O
a O
substance O
p O
antagonist O
( O
greater O
than O
or O
equal O
to O
100 O
ng O
) O
but O
not O
by O
ah6809 O
, O
a O
prostanoid O
ep1 O
- O
receptor O
antagonist O
. O

conversely O
, O
prostaglandin O
e2 O
- O
induced O
hyperalgesia B-Disease
was O
blocked O
by O
ah6809 O
( O
greater O
than O
or O
equal O
to O
500 O
ng O
) O
but O
not O
by O
the O
substance O
p O
antagonist O
. O

prostaglandin O
f2 O
alpha O
had O
little O
effect O
on O
pain B-Disease
responses O
. O

these O
results O
demonstrate O
that O
both O
prostaglandin O
d2 O
and O
prostaglandin O
e2 O
exert O
hyperalgesia B-Disease
in O
the O
spinal O
cord O
, O
but O
in O
different O
ways O
. O

d O
- O
penicillamine O
in O
the O
treatment O
of O
localized B-Disease
scleroderma B-Disease
. O

localized B-Disease
scleroderma B-Disease
has O
no O
recognized O
internal O
organ O
involvement O
but O
may O
be O
disfiguring O
and O
disabling O
when O
the O
cutaneous O
lesions O
are O
extensive O
or O
affect O
children O
. O

there O
is O
no O
accepted O
or O
proven O
treatment O
for O
localized B-Disease
scleroderma B-Disease
. O

case O
reports O
of O
11 O
patients O
with O
severe O
, O
extensive O
localized B-Disease
scleroderma B-Disease
who O
were O
treated O
with O
d O
- O
penicillamine O
are O
summarized O
in O
this O
article O
. O

this O
drug O
was O
judged O
to O
have O
a O
favorable O
effect O
on O
the O
disease O
course O
in O
7 O
( O
64 O
% O
) O
of O
11 O
patients O
. O

improvement O
began O
within O
3 O
to O
6 O
months O
and O
consisted O
of O
cessation O
of O
active O
cutaneous O
lesions O
in O
all O
7 O
patients O
, O
skin O
softening O
in O
5 O
, O
and O
more O
normal O
growth O
of O
the O
affected O
limb O
in O
2 O
of O
3 O
children O
. O

joint O
stiffness O
and O
contractures B-Disease
also O
improved O
. O

the O
dose O
of O
d O
- O
penicillamine O
associated O
with O
a O
favorable O
response O
was O
as O
low O
as O
2 O
to O
5 O
mg O
/ O
kg O
per O
day O
given O
over O
a O
period O
ranging O
from O
15 O
to O
53 O
months O
. O

d O
- O
penicillamine O
caused O
nephrotic B-Disease
syndrome B-Disease
in O
1 O
patient O
and O
milder O
reversible O
proteinuria B-Disease
in O
3 O
other O
patients O
; O
none O
developed O
renal B-Disease
insufficiency B-Disease
. O

these O
data O
suggest O
that O
d O
- O
penicillamine O
may O
be O
effective O
in O
severe O
cases O
of O
localized B-Disease
scleroderma B-Disease
. O

cerebral B-Disease
sinus B-Disease
thrombosis B-Disease
as O
a O
potential O
hazard O
of O
antifibrinolytic O
treatment O
in O
menorrhagia B-Disease
. O

we O
describe O
a O
42 O
- O
year O
- O
old O
woman O
who O
developed O
superior O
sagittal B-Disease
and B-Disease
left B-Disease
transverse B-Disease
sinus B-Disease
thrombosis B-Disease
associated O
with O
prolonged O
epsilon O
- O
aminocaproic O
acid O
therapy O
for O
menorrhagia B-Disease
. O

this O
antifibrinolytic O
agent O
has O
been O
used O
in O
women O
with O
menorrhagia B-Disease
to O
promote O
clotting O
and O
reduce O
blood B-Disease
loss B-Disease
. O

although O
increased O
risk O
of O
thromboembolic B-Disease
disease B-Disease
has O
been O
reported O
during O
treatment O
with O
epsilon O
- O
aminocaproic O
acid O
, O
cerebral B-Disease
sinus B-Disease
thrombosis B-Disease
has O
not O
been O
previously O
described O
. O

careful O
use O
of O
epsilon O
- O
aminocaproic O
acid O
therapy O
is O
recommended O
. O

seizure B-Disease
activity O
with O
imipenem O
therapy O
: O
incidence O
and O
risk O
factors O
. O

two O
elderly O
patients O
with O
a O
history O
of O
either O
cerebral B-Disease
vascular B-Disease
accident B-Disease
( O
cva B-Disease
) O
or O
head B-Disease
trauma B-Disease
and O
no O
evidence O
of O
renal B-Disease
disease B-Disease
developed O
seizures B-Disease
while O
receiving O
maximum O
doses O
of O
imipenem O
/ O
cilastatin O
. O

neither O
patient O
had O
reported O
previous O
seizures B-Disease
or O
seizure B-Disease
- O
like O
activity O
nor O
was O
receiving O
anticonvulsant O
agents O
. O

all O
seizures B-Disease
were O
controlled O
with O
therapeutic O
doses O
of O
phenytoin O
. O

both O
patients O
had O
received O
maximum O
doses O
of O
other O
beta O
- O
lactam O
antibiotics O
without O
evidence O
of O
seizure B-Disease
activity O
. O

midline O
b3 O
serotonin O
nerves O
in O
rat O
medulla O
are O
involved O
in O
hypotensive B-Disease
effect O
of O
methyldopa O
. O

previous O
experiments O
in O
this O
laboratory O
have O
shown O
that O
microinjection O
of O
methyldopa O
onto O
the O
ventrolateral O
cells O
of O
the O
b3 O
serotonin O
neurons O
in O
the O
medulla O
elicits O
a O
hypotensive B-Disease
response O
mediated O
by O
a O
projection O
descending O
into O
the O
spinal O
cord O
. O

the O
present O
experiments O
were O
designed O
to O
investigate O
the O
role O
of O
the O
midline O
cells O
of O
the O
b3 O
serotonin O
neurons O
in O
the O
medulla O
, O
coinciding O
with O
the O
raphe O
magnus O
. O

in O
spontaneously O
hypertensive B-Disease
, O
stroke B-Disease
- O
prone O
rats O
, O
microinjection O
of O
methyldopa O
into O
the O
area O
of O
the O
midline O
b3 O
serotonin O
cell O
group O
in O
the O
ventral O
medulla O
caused O
a O
potent O
hypotension B-Disease
of O
30 O
- O
40 O
mm O
hg O
, O
which O
was O
maximal O
2 O
- O
3 O
h O
after O
administration O
and O
was O
abolished O
by O
the O
serotonin O
neurotoxin O
5 O
, O
7 O
- O
dihydroxytryptamine O
( O
5 O
, O
7 O
- O
dht O
) O
injected O
intracerebroventricularly O
. O

however O
, O
intraspinal O
injection O
of O
5 O
, O
7 O
- O
dht O
to O
produce O
a O
more O
selective O
lesion O
of O
only O
descending O
serotonin O
projections O
in O
the O
spinal O
cord O
did O
not O
affect O
this O
hypotension B-Disease
. O

further O
, O
5 O
, O
7 O
- O
dht O
lesion O
of O
serotonin O
nerves O
travelling O
in O
the O
median O
forebrain O
bundle O
, O
one O
of O
the O
main O
ascending O
pathways O
from O
the O
b3 O
serotonin O
cells O
, O
did O
not O
affect O
the O
fall O
in O
blood O
pressure O
associated O
with O
a O
midline O
b3 O
serotonin O
methyldopa O
injection O
. O

it O
is O
concluded O
therefore O
that O
, O
unlike O
the O
ventrolateral O
b3 O
cells O
which O
mediate O
a O
methyldopa O
- O
induced O
hypotension B-Disease
via O
descending O
projections O
, O
the O
midline O
serotonin O
b3 O
cells O
in O
the O
medulla O
contribute O
to O
the O
hypotensive B-Disease
action O
of O
methyldopa O
, O
either O
by O
way O
of O
an O
ascending O
projection O
which O
does O
not O
pass O
through O
the O
median O
forebrain O
bundle O
, O
or O
through O
a O
projection O
restricted O
to O
the O
caudal O
brainstem O
. O

antiarrhythmic O
plasma O
concentrations O
of O
cibenzoline O
on O
canine O
ventricular B-Disease
arrhythmias B-Disease
. O

using O
two O
- O
stage O
coronary O
ligation O
- O
, O
digitalis O
- O
, O
and O
adrenaline O
- O
induced O
canine O
ventricular B-Disease
arrhythmias B-Disease
, O
antiarrhythmic O
effects O
of O
cibenzoline O
were O
examined O
and O
the O
minimum O
effective O
plasma O
concentration O
for O
each O
arrhythmia B-Disease
model O
was O
determined O
. O

cibenzoline O
suppressed O
all O
the O
arrhythmias B-Disease
, O
and O
the O
minimum O
effective O
plasma O
concentrations O
for O
arrhythmias B-Disease
induced O
by O
24 O
- O
h O
coronary O
ligation O
, O
48 O
- O
h O
coronary O
ligation O
, O
digitalis O
, O
and O
adrenaline O
were O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
9 O
( O
by O
8 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
, O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
5 O
( O
by O
8 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
, O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
( O
by O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
, O
and O
3 O
. O
5 O
+ O
/ O
- O

1 O
. O
3 O
( O
by O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
sdm O
, O
n O
= O
6 O
- O
7 O
) O
. O

the O
concentration O
for O
adrenaline O
- O
induced O
arrhythmia B-Disease
was O
significantly O
higher O
than O
those O
for O
the O
other O
types O
of O
arrhythmias B-Disease
. O

this O
pharmacological O
profile O
is O
similar O
to O
those O
of O
mexiletine O
and O
tocainide O
, O
and O
all O
three O
drugs O
have O
central O
nervous O
system O
( O
cns O
) O
stimulant O
action O
. O

because O
cibenzoline O
had O
only O
weak O
hypotensive B-Disease
and O
sinus O
node O
depressive B-Disease
effects O
and O
was O
found O
to O
be O
orally O
active O
when O
given O
to O
coronary O
ligation O
arrhythmia B-Disease
dogs O
, O
its O
clinical O
usefulness O
is O
expected O
. O

continuous O
ambulatory O
ecg O
monitoring O
during O
fluorouracil O
therapy O
: O
a O
prospective O
study O
. O

although O
there O
have O
been O
anecdotal O
reports O
of O
cardiac B-Disease
toxicity B-Disease
associated O
with O
fluorouracil O
( O
5 O
- O
fu O
) O
therapy O
, O
this O
phenomenon O
has O
not O
been O
studied O
in O
a O
systematic O
fashion O
. O

we O
prospectively O
performed O
continuous O
ambulatory O
ecg O
monitoring O
on O
25 O
patients O
undergoing O
5 O
- O
fu O
infusion O
for O
treatment O
of O
solid O
tumors B-Disease
in O
order O
to O
assess O
the O
incidence O
of O
ischemic B-Disease
st O
changes O
. O

patients O
were O
monitored O
for O
23 O
+ O
/ O
- O
4 O
hours O
before O
5 O
- O
fu O
infusion O
, O
and O
98 O
+ O
/ O
- O
9 O
hours O
during O
5 O
- O
fu O
infusion O
. O

anginal B-Disease
episodes O
were O
rare O
: O
only O
one O
patient O
had O
angina B-Disease
( O
during O
5 O
- O
fu O
infusion O
) O
. O

however O
, O
asymptomatic O
st O
changes O
( O
greater O
than O
or O
equal O
to O
1 O
mm O
st O
deviation O
) O
were O
common O
: O
six O
of O
25 O
patients O
( O
24 O
% O
) O
had O
st O
changes O
before O
5 O
- O
fu O
infusion O
v O
17 O
( O
68 O
% O
) O
during O
5 O
- O
fu O
infusion O
( O
p O
less O
than O
. O
002 O
) O
. O

the O
incidence O
of O
ischemic B-Disease
episodes O
per O
patient O
per O
hour O
was O
0 O
. O
05 O
+ O
/ O
- O
0 O
. O
02 O
prior O
to O
5 O
- O
fu O
infusion O
v O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
03 O
during O
5 O
- O
fu O
infusion O
( O
p O
less O
than O
. O
001 O
) O
; O
the O
duration O
of O
ecg O
changes O
was O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
minutes O
per O
patient O
per O
hour O
before O
5 O
- O
fu O
v O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
minutes O
per O
patient O
per O
hour O
during O
5 O
- O
fu O
( O
p O
less O
than O
. O
01 O
) O
. O

ecg O
changes O
were O
more O
common O
among O
patients O
with O
known O
coronary B-Disease
artery B-Disease
disease B-Disease
. O

there O
were O
two O
cases O
of O
sudden B-Disease
death B-Disease
, O
both O
of O
which O
occurred O
at O
the O
end O
of O
the O
chemotherapy O
course O
. O

we O
conclude O
that O
5 O
- O
fu O
infusion O
is O
associated O
with O
a O
significant O
increase O
in O
silent O
st O
segment O
deviation O
suggestive O
of O
ischemia B-Disease
, O
particularly O
among O
patients O
with O
coronary B-Disease
artery B-Disease
disease B-Disease
. O

the O
mechanism O
and O
clinical O
significance O
of O
these O
ecg O
changes O
remain O
to O
be O
determined O
. O

nature O
, O
time O
course O
and O
dose O
dependence O
of O
zidovudine O
- O
related O
side O
effects O
: O
results O
from O
the O
multicenter O
canadian O
azidothymidine O
trial O
. O

to O
characterize O
the O
nature O
, O
time O
course O
and O
dose O
dependency O
of O
zidovudine O
- O
related O
side O
effects O
, O
we O
undertook O
a O
multicenter O
, O
prospective O
, O
dose O
- O
range O
finding O
study O
. O

our O
study O
group O
consisted O
of O
74 O
hiv O
- O
positive O
homosexual O
men O
belonging O
to O
groups O
ii O
b O
, O
iii O
and O
iv O
c2 O
from O
the O
centers O
for O
disease O
control O
( O
cdc O
) O
classification O
of O
hiv B-Disease
disease B-Disease
. O

following O
a O
3 O
- O
week O
observation O
period O
, O
volunteers O
were O
treated O
with O
zidovudine O
600 O
mg O
/ O
day O
for O
18 O
weeks O
, O
900 O
mg O
/ O
day O
for O
9 O
weeks O
and O
1200 O
mg O
/ O
day O
for O
9 O
weeks O
, O
followed O
by O
a O
washout O
period O
of O
6 O
weeks O
after O
which O
they O
were O
re O
- O
started O
on O
1200 O
mg O
/ O
day O
or O
the O
highest O
tolerated O
dose O
at O
8 O
- O
hourly O
intervals O
. O

subjects O
were O
randomly O
assigned O
to O
4 O
- O
hourly O
or O
8 O
- O
hourly O
regimens O
within O
cdc O
groups O
while O
taking O
600 O
and O
1200 O
mg O
/ O
day O
. O

clinical O
and O
laboratory O
evaluations O
were O
performed O
at O
3 O
- O
week O
intervals O
. O

symptomatic O
adverse O
effects O
were O
present O
in O
96 O
% O
of O
subjects O
, O
most O
commonly O
nausea B-Disease
( O
64 O
% O
) O
, O
fatigue B-Disease
( O
55 O
% O
) O
and O
headache B-Disease
( O
49 O
% O
) O
. O

these O
were O
generally O
self O
- O
limited O
, O
reappearing O
briefly O
at O
each O
dose O
increment O
. O

a O
decrease O
in O
hemoglobin O
occurred O
shortly O
after O
initiation O
of O
therapy O
. O

this O
was O
not O
dose O
dependent O
and O
reversed O
rapidly O
upon O
discontinuation O
of O
treatment O
. O

a O
red O
blood O
cell O
count O
decrease O
, O
a O
mean O
cell O
volume O
increase O
and O
a O
granulocyte O
count O
decrease O
developed O
early O
in O
a O
dose O
- O
independent O
fashion O
, O
reverting O
at O
least O
partially O
during O
the O
washout O
phase O
. O

the O
decrease O
in O
reticulocyte O
count O
was O
dose O
related O
between O
600 O
and O
900 O
mg O
/ O
day O
with O
no O
further O
change O
when O
the O
dose O
was O
escalated O
to O
1200 O
mg O
/ O
day O
. O

bone O
marrow O
changes O
occurred O
rapidly O
as O
demonstrated O
by O
megaloblastosis B-Disease
in O
95 O
% O
of O
65 O
specimens O
at O
week O
18 O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

national O
project O
on O
the O
prevention O
of O
mother O
- O
to O
- O
infant O
infection B-Disease
by B-Disease
hepatitis B-Disease
b B-Disease
virus B-Disease
in O
japan O
. O

in O
japan O
, O
a O
nationwide O
prevention O
program O
against O
mother O
- O
to O
- O
infant O
infection B-Disease
by B-Disease
hepatitis B-Disease
b B-Disease
virus B-Disease
( O
hbv O
) O
started O
in O
1985 O
. O

this O
program O
consists O
of O
double O
screenings O
of O
pregnant O
women O
and O
prophylactic O
treatment O
to O
the O
infants O
born O
to O
both O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
and O
hepatitis O
b O
e O
antigen O
( O
hbeag O
) O
positive O
mothers O
. O

these O
infants O
are O
treated O
with O
two O
injections O
of O
hepatitis B-Disease
b B-Disease
immune O
globulin O
( O
hbig O
) O
and O
at O
least O
three O
injections O
of O
plasma O
derived O
hepatitis O
b O
vaccine O
. O

we O
sent O
questionnaires O
about O
the O
numbers O
of O
each O
procedure O
or O
examination O
during O
nine O
months O
of O
investigation O
period O
to O
each O
local O
government O
in O
1986 O
and O
1987 O
. O

93 O
. O
4 O
% O
pregnant O
women O
had O
the O
chance O
to O
be O
examined O
for O
hbsag O
, O
and O
the O
positive O
rate O
was O
1 O
. O
4 O
to O
1 O
. O
5 O
% O
. O

the O
hbeag O
positive O
rate O
in O
hbsag O
positive O
was O
23 O
to O
26 O
% O
. O

the O
hbsag O
positive O
rate O
in O
neonates O
and O
in O
infants O
before O
two O
months O
were O
3 O
% O
and O
2 O
% O
respectively O
. O

some O
problems O
may O
arise O
, O
because O
27 O
to O
30 O
% O
of O
infants O
need O
the O
fourth O
vaccination O
in O
some O
restricted O
areas O
. O

involvement O
of O
the O
mu O
- O
opiate O
receptor O
in O
peripheral O
analgesia B-Disease
. O

the O
intradermal O
injection O
of O
mu O
( O
morphine O
, O
tyr O
- O
d O
- O
ala O
- O
gly O
- O
nme O
- O
phe O
- O
gly O
- O
ol O
and O
morphiceptin O
) O
, O
kappa O
( O
trans O
- O
3 O
, O
4 O
- O
dichloro O
- O
n O
- O
methyl O
- O
n O
[ O
2 O
- O
( O
1 O
- O
pyrrolidinyl O
) O
cyclohexyl O
] O
benzeneactemide O
) O
and O
delta O
( O
[ O
d O
- O
pen2 O
. O
5 O
] O
- O
enkephalin O
and O
[ O
d O
- O
ser2 O
] O
- O
[ O
leu O
] O
enkephalin O
- O
thr O
) O
selective O
opioid O
- O

agonists O
, O
by O
themselves O
, O
did O
not O
significantly O
affect O
the O
mechanical O
nociceptive O
threshold O
in O
the O
hindpaw O
of O
the O
rat O
. O

intradermal O
injection O
of O
mu O
, O
but O
not O
delta O
or O
kappa O
opioid O
- O
agonists O
, O
however O
, O
produced O
dose O
- O
dependent O
inhibition O
of O
prostaglandin O
e2 O
- O
induced O
hyperalgesia B-Disease
. O

the O
analgesic O
effect O
of O
the O
mu O
- O
agonist O
morphine O
was O
dose O
- O
dependently O
antagonized O
by O
naloxone O
and O
prevented O
by O
co O
- O
injection O
of O
pertussis O
toxin O
. O

morphine O
did O
not O
, O
however O
, O
alter O
the O
hyperalgesia B-Disease
induced O
by O
8 O
- O
bromo O
cyclic O
adenosine O
monophosphate O
. O

we O
conclude O
that O
the O
analgesic O
action O
of O
opioids O
on O
the O
peripheral O
terminals O
of O
primary O
afferents O
is O
via O
a O
binding O
site O
with O
characteristics O
of O
the O
mu O
- O
opioid O
receptor O
and O
that O
this O
action O
is O
mediated O
by O
inhibition O
of O
the O
cyclic O
adenosine O
monophosphate O
second O
messenger O
system O
. O

involvement O
of O
locus O
coeruleus O
and O
noradrenergic O
neurotransmission O
in O
fentanyl O
- O
induced O
muscular B-Disease
rigidity B-Disease
in O
the O
rat O
. O

whereas O
muscular B-Disease
rigidity B-Disease
is O
a O
well O
- O
known O
side O
effect O
that O
is O
associated O
with O
high O
- O
dose O
fentanyl O
anesthesia O
, O
a O
paucity O
of O
information O
exists O
with O
regard O
to O
its O
underlying O
mechanism O
( O
s O
) O
. O

we O
investigated O
in O
this O
study O
the O
possible O
engagement O
of O
locus O
coeruleus O
of O
the O
pons O
in O
this O
phenomenon O
, O
using O
male O
sprague O
- O
dawley O
rats O
anesthetized O
with O
ketamine O
. O

under O
proper O
control O
of O
respiration O
, O
body O
temperature O
and O
end O
- O
tidal O
co2 O
, O
intravenous O
administration O
of O
fentanyl O
( O
50 O
or O
100 O
micrograms O
/ O
kg O
) O
consistently O
promoted O
an O
increase O
in O
electromyographic O
activity O
recorded O
from O
the O
gastrocnemius O
and O
abdominal O
rectus O
muscles O
. O

such O
an O
induced O
muscular B-Disease
rigidity B-Disease
by O
the O
narcotic O
agent O
was O
significantly O
antagonized O
or O
even O
reduced O
by O
prior O
electrolytic O
lesions O
of O
the O
locus O
coeruleus O
or O
pretreatment O
with O
the O
alpha O
- O
adrenoceptor O
blocker O
, O
prazosin O
. O

microinjection O
of O
fentanyl O
( O
2 O
. O
5 O
micrograms O
/ O
50 O
nl O
) O
directly O
into O
this O
pontine O
nucleus O
, O
on O
the O
other O
hand O
, O
elicited O
discernible O
electromyographic O
excitation O
. O

it O
is O
speculated O
that O
the O
induction O
of O
muscular B-Disease
rigidity B-Disease
by O
fentanyl O
may O
involve O
the O
coerulospinal O
noradrenergic O
fibers O
to O
the O
spinal O
motoneurons O
. O

dexmedetomidine O
, O
acting O
through O
central O
alpha O
- O
2 O
adrenoceptors O
, O
prevents O
opiate O
- O
induced O
muscle B-Disease
rigidity B-Disease
in O
the O
rat O
. O

the O
highly O
- O
selective O
alpha O
- O
2 O
adrenergic O
agonist O
dexmedetomidine O
( O
d O
- O
med O
) O
is O
capable O
of O
inducing O
muscle B-Disease
flaccidity B-Disease
and O
anesthesia O
in O
rats O
and O
dogs O
. O

intense O
generalized O
muscle B-Disease
rigidity B-Disease
is O
an O
undesirable O
side O
effect O
of O
potent O
opiate O
agonists O
. O

although O
the O
neurochemistry O
of O
opiate O
- O
induced O
rigidity B-Disease
has O
yet O
to O
be O
fully O
elucidated O
, O
recent O
work O
suggests O
a O
role O
for O
a O
central O
adrenergic O
mechanism O
. O

in O
the O
present O
study O
, O
the O
authors O
determined O
if O
treatment O
with O
d O
- O
med O
prevents O
the O
muscle B-Disease
rigidity B-Disease
caused O
by O
high O
- O
dose O
alfentanil O
anesthesia O
in O
the O
rat O
. O

animals O
( O
n O
= O
42 O
) O
were O
treated O
intraperitoneally O
with O
one O
of O
the O
following O
six O
regimens O
: O
1 O
) O
l O
- O
med O
( O
the O
inactive O
l O
- O
isomer O
of O
medetomidine O
) O
, O
30 O
micrograms O
/ O
kg O
; O
2 O
) O
d O
- O
med O
, O
10 O
micrograms O
/ O
kg O
; O
3 O
) O
d O
- O
med O
, O
30 O
micrograms O
/ O
kg O
; O
4 O
) O
d O
- O
med O
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O
central O
- O
acting O
alpha O
- O
2 O
antagonist O
, O
idazoxan O
[ O
10 O
mg O
/ O
kg O
] O
; O
5 O
) O
d O
- O
med O
[ O
30 O
micrograms O
/ O
kg O
] O
and O
the O

peripheral O
- O
acting O
alpha O
- O
2 O
antagonist O
dg O
- O
5128 O
[ O
10 O
mg O
/ O
kg O
] O
, O
or O
; O
6 O
) O
saline O
. O

baseline O
electromyographic O
activity O
was O
recorded O
from O
the O
gastrocnemius O
muscle O
before O
and O
after O
drug O
treatment O
. O

each O
rat O
was O
then O
injected O
with O
alfentanil O
( O
alf O
, O
0 O
. O
5 O
mg O
/ O
kg O
sc O
) O
. O

alf O
injection O
resulted O
in O
a O
marked O
increase O
in O
hindlimb O
emg O
activity O
in O
the O
l O
- O
med O
treatment O
group O
which O
was O
indistinguishable O
from O
that O
seen O
in O
animals O
treated O
with O
saline O
. O

in O
contrast O
, O
d O
- O
med O
prevented O
alfentanil O
- O
induced O
muscle B-Disease
rigidity B-Disease
in O
a O
dose O
- O
dependent O
fashion O
. O

the O
small O
emg O
values O
obtained O
in O
the O
high O
- O
dose O
d O
- O
med O
group O
were O
comparable O
with O
those O
recorded O
in O
earlier O
studies O
from O
control O
animals O
not O
given O
any O
opiate O
. O

the O
high O
- O
dose O
d O
- O
med O
animals O
were O
flaccid O
, O
akinetic B-Disease
, O
and O
lacked O
a O
startle B-Disease
response O
during O
the O
entire O
experimental O
period O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

some O
central O
effects O
of O
repeated O
treatment O
with O
fluvoxamine O
. O

we O
investigated O
the O
effect O
of O
repeated O
treatment O
with O
fluvoxamine O
, O
a O
selective O
serotonin O
uptake O
inhibitor O
, O
on O
behavioral O
effects O
of O
dopaminomimetics O
and O
methoxamine O
and O
on O
the O
animal O
behavior O
in O
the O
" O
behavioral O
despair O
" O
test O
. O

a O
repeated O
treatment O
with O
fluvoxamine O
( O
twice O
daily O
for O
14 O
days O
) O
potentiated O
in O
mice O
and O
in O
rats O
( O
weaker O
) O
the O
amphetamine O
- O
induced O
hyperactivity B-Disease
. O

the O
hyperactivity B-Disease
induced O
by O
nomifensine O
in O
mice O
remained O
unaffected O
by O
fluvoxamine O
. O

the O
stimulation O
of O
locomotor O
activity O
by O
intracerebroventricularly O
administered O
methoxamine O
was O
not O
affected O
by O
repeated O
treatment O
with O
fluvoxamine O
. O

given O
three O
times O
fluvoxamine O
had O
no O
effect O
on O
the O
immobilization O
time O
in O
the O
" O
behavioral O
despair O
" O
test O
in O
rats O
. O

the O
results O
indicate O
that O
fluvoxamine O
given O
repeatedly O
acts O
differently O
than O
citalopram O
, O
another O
selective O
serotonin O
uptake O
inhibitor O
, O
and O
differs O
also O
from O
other O
antidepressant O
drugs O
. O

protective O
effect O
of O
a O
specific O
platelet O
- O
activating O
factor O
antagonist O
, O
bn O
52021 O
, O
on O
bupivacaine O
- O
induced O
cardiovascular B-Disease
impairments B-Disease
in O
rats O
. O

administration O
of O
the O
local O
anaesthetic O
bupivacaine O
( O
1 O
. O
5 O
or O
2 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
) O
to O
rats O
elicited O
a O
marked O
decrease B-Disease
of B-Disease
mean B-Disease
arterial B-Disease
blood B-Disease
pressure B-Disease
( B-Disease
mbp B-Disease
) B-Disease
and B-Disease
heart B-Disease
rate B-Disease
( B-Disease
hr B-Disease
) B-Disease
leading O
to O
death O
( O
in O
67 O
% O
or O
90 O
% O
of O
animals O
respectively O
) O
. O

intravenous O
injection O
of O
the O
specific O
platelet O
- O
activating O
factor O
( O
paf O
) O
antagonist O
bn O
52021 O
( O
10 O
mg O
/ O
kg O
) O
, O
30 O
min O
before O
bupivacaine O
administration O
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
suppressed O
both O
the O
decrease B-Disease
of B-Disease
mbp B-Disease
and B-Disease
hr B-Disease
. O

in O
contrast O
, O
doses O
of O
1 O
mg O
/ O
kg O
bn O
52021 O
given O
30 O
min O
before O
or O
10 O
mg O
/ O
kg O
administered O
5 O
min O
before O
i O
. O
v O
. O
injection O
of O
bupivacaine O
were O
ineffective O
. O

when O
bn O
52021 O
( O
20 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
was O
injected O
immediately O
after O
bupivacaine O
( O
2 O
mg O
/ O
kg O
) O
, O
a O
partial O
reversion O
of O
the O
decrease B-Disease
of B-Disease
mbp B-Disease
and B-Disease
hr B-Disease
was O
observed O
, O
whereas O
the O
dose O
of O
10 O
mg O
/ O
kg O
was O
ineffective O
. O

a O
partial O
recovery O
of O
bupivacaine O
- O
induced O
ecg O
alterations O
was O
observed O
after O
pretreatment O
of O
the O
rats O
with O
bn O
52021 O
. O

since O
the O
administration O
of O
bn O
52021 O
, O
at O
all O
doses O
studied O
, O
did O
not O
alter O
mbp O
and O
hr O
at O
the O
doses O
used O
, O
the O
bulk O
of O
these O
results O
clearly O
demonstrate O
a O
protective O
action O
of O
bn O
52021 O
, O
a O
specific O
antagonist O
of O
paf O
, O
against O
bupivacaine O
- O
induced O
cardiovascular B-Disease
toxicity B-Disease
. O

thus O
, O
consistent O
with O
its O
direct O
effect O
on O
heart O
, O
paf O
appears O
to O
be O
implicated O
in O
bupivacaine O
- O
induced O
cardiovascular B-Disease
alterations B-Disease
. O

the O
epidemiology O
of O
the O
acute O
flank B-Disease
pain B-Disease
syndrome O
from O
suprofen O
. O

suprofen O
, O
a O
new O
nonsteroidal O
anti O
- O
inflammatory O
drug O
, O
was O
marketed O
in O
early O
1986 O
as O
an O
analgesic O
agent O
. O

until O
physicians O
began O
reporting O
an O
unusual O
acute O
flank B-Disease
pain B-Disease
syndrome O
to O
the O
spontaneous O
reporting O
system O
, O
700 O
, O
000 O
persons O
used O
the O
drug O
in O
the O
united O
states O
. O

through O
august O
1986 O
, O
a O
total O
of O
163 O
cases O
of O
this O
syndrome O
were O
reported O
. O

to O
elucidate O
the O
epidemiology O
of O
the O
syndrome O
, O
a O
case O
- O
control O
study O
was O
performed O
, O
comparing O
62 O
of O
the O
case O
patients O
who O
had O
been O
reported O
to O
the O
spontaneous O
reporting O
system O
to O
185 O
suprofen O
- O
exposed O
control O
subjects O
who O
did O
not O
have O
the O
syndrome O
. O

case O
patients O
were O
more O
likely O
to O
be O
men O
( O
odds O
ratio O
, O
3 O
. O
8 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O
2 O
- O
12 O
. O
1 O
) O
, O
suffer O
from O
hay B-Disease
fever B-Disease
and O
asthma B-Disease
( O
odds O
ratio O
, O
3 O
. O
4 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O
0 O
- O
11 O
. O
9 O
) O
; O
to O
participate O
in O
regular O
exercise O
( O
odds O
ratio O
, O
5 O
. O
9 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O
1 O
- O
30 O
. O
7 O
) O
, O
especially O
in O
the O
use O
of O
nautilus O
equipment O
( O
p O
= O
0 O
. O
02 O
) O
; O
and O
to O
use O
alcohol O
( O
odds O
ratio O
, O
4 O
. O
4 O
; O
95 O
% O
confidence O
interval O
, O

1 O
. O
1 O
- O
17 O
. O
5 O
) O
. O

possible O
risk O
factors O
included O
young O
age O
, O
concurrent O
use O
of O
other O
analgesic O
agents O
( O
especially O
ibuprofen O
) O
, O
preexisting O
renal B-Disease
disease B-Disease
, O
a O
history O
of O
kidney B-Disease
stones B-Disease
, O
a O
history O
of O
gout B-Disease
, O
a O
recent O
increase O
in O
activity O
, O
a O
recent O
increase O
in O
sun O
exposure O
, O
and O
residence O
in O
the O
sunbelt O
. O

these O
were O
findings O
that O
were O
suggestive O
but O
did O
not O
reach O
conventional O
statistical O
significance O
. O

these O
findings O
are O
consistent O
with O
the O
postulated O
mechanism O
for O
this O
unusual O
syndrome O
: O
acute O
diffuse O
crystallization O
of O
uric O
acid O
in O
renal O
tubules O
. O

phlorizin O
- O
induced O
glycosuria B-Disease
does O
not O
prevent O
gentamicin O
nephrotoxicity B-Disease
in O
rats O
. O

because O
rats O
with O
streptozotocin O
- O
induced O
diabetes B-Disease
mellitus B-Disease
( O
dm B-Disease
) O
have O
a O
high O
solute O
diuresis O
( O
glycosuria B-Disease
of O
10 O
to O
12 O
g O
/ O
day O
) O
, O
we O
have O
suggested O
that O
this O
may O
in O
part O
be O
responsible O
for O
their O
resistance O
to O
gentamicin O
- O
induced O
acute B-Disease
renal B-Disease
failure B-Disease
( O
arf B-Disease
) O
. O

the O
protection O
from O
gentamicin O
nephrotoxicity B-Disease
was O
studied O
in O
non O
- O
diabetic B-Disease
rats O
with O
chronic O
solute O
diuresis O
induced O
by O
blockage O
of O
tubular O
glucose O
reabsorption O
with O
phlorizin O
( O
p O
) O
. O

dm B-Disease
rats O
with O
mild O
glycosuria B-Disease
( O
similar O
in O
degree O
to O
that O
of O
the O
p O
treated O
animals O
) O
were O
also O
studied O
. O

unanesthetized O
adult O
female O
, O
sprague O
- O
dawley O
rats O
were O
divided O
in O
four O
groups O
and O
studied O
for O
15 O
days O
. O

group O
1 O
( O
p O
alone O
) O
received O
p O
, O
360 O
mg O
/ O
day O
, O
for O
15 O
days O
; O
group O
ii O
( O
p O
+ O
gentamicin O
) O
; O
group O
iii O
( O
gentamicin O
alone O
) O
and O
group O
iv O
( O
mild O
dm B-Disease
+ O
gentamicin O
) O
. O

nephrotoxic B-Disease
doses O
( O
40 O
mg O
/ O
kg O
body O
wt O
/ O
day O
) O
of O
gentamicin O
were O
injected O
during O
the O
last O
nine O
days O
of O
study O
to O
the O
animals O
of O
groups O
ii O
to O
iv O
. O

in O
group O
i O
, O
p O
induced O
a O
moderate O
and O
stable O
glycosuria B-Disease
( O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
1 O
g O
/ O
day O
, O
se O
) O
, O
and O
no O
functional O
or O
morphologic O
evidence O
of O
renal B-Disease
dysfunction B-Disease
( O
baseline O
ccr O
2 O
. O
1 O
+ O
/ O
- O
0 O
. O
1 O
ml O
/ O
min O
, O
undetectable O
lysozymuria O
) O
or O
damage O
( O
tubular B-Disease
necrosis B-Disease
score O
[ O
maximum O
4 O
] O
, O
zero O
) O
. O

in O
group O
ii O
, O
p O
did O
not O
prevent O
gentamicin O
- O
arf B-Disease
( O
maximal O
decrease O
in O
ccr O
at O
day O
9 O
. O
89 O
% O
, O
p O
less O
than O
0 O
. O
001 O
; O
peak O
lysozymuria O
, O
1863 O
+ O
/ O
- O
321 O
micrograms O
/ O
day O
; O
and O
tubular B-Disease
necrosis B-Disease
score O
, O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
1 O
) O
. O

these O
values O
were O
not O
different O
from O
those O
of O
group O
iii O
: O
maximal O
decrease O
in O
ccr O
73 O
% O
( O
p O
less O
than O
0 O
. O
001 O
) O
; O
lysozymuria O
, O
2147 O
+ O
/ O
- O
701 O
micrograms O
/ O
day O
; O
tubular B-Disease
necrosis B-Disease
score O
, O
3 O
. O
8 O
+ O
/ O
- O
0 O
. O
1 O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

catalepsy B-Disease
induced O
by O
combinations O
of O
ketamine O
and O
morphine O
: O
potentiation O
, O
antagonism O
, O
tolerance O
and O
cross O
- O
tolerance O
in O
the O
rat O
. O

previous O
studies O
demonstrated O
that O
both O
ketamine O
and O
morphine O
induced O
analgesia B-Disease
and O
catalepsy B-Disease
in O
the O
rat O
. O

pre O
- O
treatment O
with O
ketamine O
produced O
cross O
- O
tolerance O
to O
morphine O
, O
whereas O
pretreatment O
with O
morphine O
did O
not O
induce O
cross O
- O
tolerance O
to O
ketamine O
but O
rather O
augmented O
the O
cataleptic B-Disease
response O
; O
this O
augmentation O
was O
attributed O
to O
residual O
morphine O
in O
the O
brain O
. O

the O
present O
studies O
explored O
the O
duration O
of O
the O
loss O
of O
righting O
reflex O
induced O
by O
sub O
- O
effective O
doses O
of O
ketamine O
and O
morphine O
, O
administered O
simultaneously O
. O

there O
was O
mutual O
potentiation O
between O
sub O
- O
effective O
doses O
of O
ketamine O
and O
morphine O
, O
but O
sub O
- O
effective O
doses O
of O
ketamine O
partly O
antagonized O
fully O
- O
effective O
doses O
of O
morphine O
. O

latency O
to O
the O
loss O
of O
righting O
reflex O
, O
rigidity B-Disease
and O
behavior O
on O
recovery O
, O
reflected O
the O
relative O
predominance O
of O
ketamine O
or O
morphine O
in O
each O
combination O
. O

naloxone O
inhibited O
the O
induced O
cataleptic B-Disease
effects O
. O

the O
degree O
and O
time O
course O
of O
development O
of O
tolerance O
to O
daily O
administration O
of O
sub O
- O
effective O
dose O
combinations O
of O
ketamine O
and O
morphine O
were O
similar O
. O

rats O
, O
tolerant O
to O
ketamine O
- O
dominant O
combinations O
, O
were O
cross O
- O
tolerant O
to O
both O
drugs O
, O
while O
those O
tolerant O
to O
morphine O
- O
dominant O
combinations O
were O
cross O
- O
tolerant O
to O
morphine O
but O
showed O
either O
no O
cross O
- O
tolerance O
or O
an O
augmented O
response O
to O
ketamine O
. O

while O
the O
mutual O
potentiation O
, O
antagonism O
and O
tolerance O
suggest O
common O
mechanisms O
for O
the O
induced O
catalepsy B-Disease
, O
differences O
in O
latency O
, O
rigidity B-Disease
and O
behavior O
, O
asymmetry O
of O
cross O
- O
tolerance O
and O
a O
widely O
- O
different O
id50 O
for O
naloxone O
would O
argue O
against O
an O
action O
at O
a O
single O
opioid O
site O
. O

hydrocortisone O
- O
induced O
hypertension B-Disease
in O
humans O
: O
pressor O
responsiveness O
and O
sympathetic O
function O
. O

oral O
hydrocortisone O
increases O
blood O
pressure O
and O
enhances O
pressor O
responsiveness O
in O
normal O
human O
subjects O
. O

we O
studied O
the O
effects O
of O
1 O
week O
of O
oral O
hydrocortisone O
( O
200 O
mg O
/ O
day O
) O
on O
blood O
pressure O
, O
cardiac O
output O
, O
total O
peripheral O
resistance O
, O
forearm O
vascular O
resistance O
, O
and O
norepinephrine O
spillover O
to O
plasma O
in O
eight O
healthy O
male O
volunteers O
. O

although O
diastolic O
blood O
pressure O
remained O
unchanged O
, O
systolic O
blood O
pressure O
increased O
from O
119 O
to O
135 O
mm O
hg O
( O
sed O
+ O
/ O
- O
3 O
. O
4 O
, O
p O
less O
than O
0 O
. O
01 O
) O
, O
associated O
with O
an O
increased B-Disease
cardiac B-Disease
output B-Disease
( O
5 O
. O
85 O
- O
7 O
. O
73 O
l O
/ O
min O
, O
sed O
+ O
/ O
- O
0 O
. O
46 O
, O
p O
less O
than O
0 O
. O
01 O
) O
. O

total O
peripheral O
vascular O
resistance O
fell O
from O
15 O
. O
1 O
to O
12 O
. O
2 O
mm O
hg O
/ O
l O
/ O
min O
( O
sed O
+ O
/ O
- O
1 O
. O
03 O
, O
p O
less O
than O
0 O
. O
05 O
) O
. O

resting O
forearm O
vascular O
resistance O
remained O
unchanged O
, O
but O
the O
reflex O
response O
to O
the O
cold O
pressor O
test O
was O
accentuated O
, O
the O
rise O
in O
resistance O
increasing O
from O
10 O
. O
5 O
mm O
hg O
/ O
ml O
/ O
100 O
ml O
/ O
min O
( O
r O
units O
) O
before O
treatment O
to O
32 O
. O
6 O
r O
units O
after O
treatment O
( O
sed O
+ O
/ O
- O
6 O
. O
4 O
, O
p O
less O
than O
0 O
. O
025 O
) O
. O

the O
rise O
in O
forearm O
vascular O
resistance O
accompanying O
intra O
- O
arterial O
norepinephrine O
( O
25 O
, O
50 O
, O
and O
100 O
ng O
/ O
min O
) O
was O
also O
significantly O
greater O
after O
hydrocortisone O
, O
increasing O
from O
an O
average O
of O
14 O
. O
9 O
+ O
/ O
- O
2 O
. O
4 O
r O
units O
before O
treatment O
to O
35 O
. O
1 O
+ O
/ O
- O
5 O
. O
5 O
r O
units O
after O
hydrocortisone O
( O
sed O
+ O
/ O
- O
6 O
. O
0 O
, O
p O
less O
than O
0 O
. O
05 O
) O
. O

a O
shift O
to O
the O
left O
in O
the O
dose O
- O
response O
relation O
and O
fall O
in O
threshold O
suggested O
increased O
sensitivity O
to O
norepinephrine O
after O
treatment O
. O

measurement O
of O
resting O
norepinephrine O
spillover O
rate O
to O
plasma O
and O
norepinephrine O
uptake O
indicated O
that O
overall O
resting O
sympathetic O
nervous O
system O
activity O
was O
not O
increased O
. O

the O
rise B-Disease
in B-Disease
resting B-Disease
blood B-Disease
pressure B-Disease
with O
hydrocortisone O
is O
associated O
with O
an O
increased B-Disease
cardiac B-Disease
output B-Disease
( O
presumably O
due O
to O
increased O
blood O
volume O
) O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

neuromuscular B-Disease
blockade B-Disease
with O
magnesium O
sulfate O
and O
nifedipine O
. O

a O
patient O
who O
received O
tocolysis O
with O
nifedipine O
developed O
neuromuscular B-Disease
blockade B-Disease
after O
500 O
mg O
of O
magnesium O
sulfate O
was O
administered O
. O

this O
reaction O
demonstrates O
that O
nifedipine O
can O
seriously O
potentiate O
the O
toxicity B-Disease
of O
magnesium O
. O

caution O
should O
be O
exercised O
when O
these O
two O
tocolytics O
are O
combined O
. O

chronic O
carbamazepine O
inhibits O
the O
development O
of O
local O
anesthetic O
seizures B-Disease
kindled O
by O
cocaine O
and O
lidocaine O
. O

the O
effects O
of O
carbamazepine O
( O
cbz O
) O
treatment O
on O
local O
anesthetic O
- O
kindled O
seizures B-Disease
and O
lethality O
were O
evaluated O
in O
different O
stages O
of O
the O
kindling O
process O
and O
under O
different O
methods O
of O
cbz O
administration O
. O

chronic O
oral O
cbz O
inhibited O
the O
development O
of O
both O
lidocaine O
- O
and O
cocaine O
- O
induced O
seizures B-Disease
, O
but O
had O
little O
effect O
on O
the O
fully O
developed O
local O
anesthetic O
seizures B-Disease
. O

chronic O
cbz O
also O
decreased O
the O
incidence O
of O
seizure B-Disease
- O
related O
mortality O
in O
the O
cocaine O
- O
injected O
rats O
. O

acute O
cbz O
over O
a O
range O
of O
doses O
( O
15 O
- O
50 O
mg O
/ O
kg O
) O
had O
no O
effect O
on O
completed O
lidocaine O
- O
kindled O
or O
acute O
cocaine O
- O
induced O
seizures B-Disease
. O

repeated O
i O
. O
p O
. O
injection O
of O
cbz O
( O
15 O
mg O
/ O
kg O
) O
also O
was O
without O
effect O
on O
the O
development O
of O
lidocaine O
- O
or O
cocaine O
- O
kindled O
seizures B-Disease
. O

the O
differential O
effects O
of O
cbz O
depending O
upon O
stage O
of O
seizure B-Disease
development O
suggest O
that O
distinct O
mechanisms O
underlie O
the O
development O
versus O
maintenance O
of O
local O
anesthetic O
- O
kindled O
seizures B-Disease
. O

the O
effectiveness O
of O
chronic O
but O
not O
repeated O
, O
intermittent O
injections O
of O
cbz O
suggests O
that O
different O
biochemical O
consequences O
result O
from O
the O
different O
treatment O
regimens O
. O

the O
possible O
utility O
of O
chronic O
cbz O
in O
preventing O
the O
development O
of O
toxic O
side O
effects O
in O
human O
cocaine O
users O
is O
suggested O
by O
these O
data O
, O
but O
remains O
to O
be O
directly O
evaluated O
. O

magnetic O
resonance O
imaging O
of O
cerebral O
venous B-Disease
thrombosis B-Disease
secondary O
to O
" O
low O
- O
dose O
" O
birth O
control O
pills O
. O

the O
clinical O
and O
radiographic O
features O
of O
cerebral O
deep B-Disease
venous B-Disease
thrombosis B-Disease
in O
a O
21 O
- O
year O
- O
old O
white O
woman O
are O
presented O
. O

this O
nulliparous O
patient O
presented O
with O
relatively O
mild O
clinical O
symptoms O
and O
progressing O
mental O
status O
changes O
. O

the O
only O
known O
risk O
factor O
was O
" O
low O
- O
dose O
" O
oral O
contraceptive O
pills O
. O

the O
magnetic O
resonance O
image O
( O
mri O
) O
showed O
increased O
signal O
intensity O
from O
the O
internal O
cerebral O
veins O
, O
vein O
of O
galen O
, O
and O
straight O
sinus O
. O

the O
diagnosis O
was O
confirmed O
by O
arterial O
angiography O
. O

beta O
- O
2 O
- O
adrenoceptor O
- O
mediated O
hypokalemia B-Disease
and O
its O
abolishment O
by O
oxprenolol O
. O

the O
time O
course O
and O
concentration O
- O
effect O
relationship O
of O
terbutaline O
- O
induced O
hypokalemia B-Disease
was O
studied O
, O
using O
computer O
- O
aided O
pharmacokinetic O
- O
dynamic O
modeling O
. O

subsequently O
we O
investigated O
the O
efficacy O
of O
oxprenolol O
in O
antagonizing O
such O
hypokalemia B-Disease
, O
together O
with O
the O
pharmacokinetic O
interaction O
between O
both O
drugs O
. O

six O
healthy O
subjects O
were O
given O
a O
0 O
. O
5 O
mg O
subcutaneous O
dose O
of O
terbutaline O
on O
two O
occasions O
: O
1 O
hour O
after O
oral O
administration O
of O
a O
placebo O
and O
1 O
hour O
after O
80 O
mg O
oxprenolol O
orally O
. O

in O
the O
7 O
- O
hour O
period O
after O
terbutaline O
administration O
, O
plasma O
samples O
were O
taken O
for O
determination O
of O
plasma O
potassium O
levels O
and O
drug O
concentrations O
. O

the O
sigmoid O
emax O
model O
offered O
a O
good O
description O
of O
the O
relation O
between O
terbutaline O
concentrations O
and O
potassium O
effects O
. O

oxprenolol O
caused O
decreases O
of O
65 O
% O
and O
56 O
% O
of O
terbutaline O
volume O
of O
distribution O
and O
clearance O
, O
respectively O
, O
and O
an O
increase O
of O
130 O
% O
of O
its O
auc O
. O

in O
spite O
of O
higher O
terbutaline O
concentrations O
after O
oxprenolol O
pretreatment O
, O
the O
hypokalemia B-Disease
was O
almost O
completely O
antagonized O
by O
the O
beta O
2 O
- O
blocking O
action O
. O

a O
dystonia B-Disease
- O
like O
syndrome O
after O
neuropeptide O
( O
msh O
/ O
acth O
) O
stimulation O
of O
the O
rat O
locus O
ceruleus O
. O

the O
movement B-Disease
disorder B-Disease
investigated O
in O
these O
studies O
has O
some O
features O
in O
common O
with O
human O
idiopathic O
dystonia B-Disease
, O
and O
information O
obtained O
in O
these O
studies O
may O
be O
of O
potential O
clinical O
benefit O
. O

the O
present O
experimental O
results O
indicated O
that O
peptidergic O
stimulation O
of O
the O
lc O
resulted O
in O
a O
ne O
- O
mediated O
inhibition O
of O
cerebellar O
purkinje O
cells O
located O
at O
terminals O
of O
the O
ceruleo O
- O
cerebellar O
pathway O
. O

however O
, O
it O
is O
not O
certain O
as O
to O
the O
following O
: O
( O
a O
) O
what O
receptors O
were O
stimulated O
by O
the O
acth O
n O
- O
terminal O
fragments O
at O
the O
lc O
that O
resulted O
in O
this O
disorder O
; O
( O
b O
) O
whether O
ne O
, O
released O
onto O
purkinje O
cell O
synapses O
located O
at O
terminals O
of O
the O
ceruleo O
- O
cerebellar O
pathway O
, O
did O
indeed O
cause O
the O
long O
- O
term O
depression B-Disease
at O
purkinje O
cell O
synapses O
( O
previously O
described O
by O
others O
) O
that O
resulted O
in O
the O
long O
duration O
of O
the O
movement B-Disease
disorder B-Disease
; O
( O
c O
) O
whether O
the O
inhibition O
of O
inhibitory O
purkinje O
cells O
resulted O
in O
disinhibition O
or O
increased O

excitability O
of O
the O
unilateral O
cerebellar O
fastigial O
or O
interpositus O
nuclei O
, O
the O
output O
targets O
of O
the O
purkinje O
cell O
axons O
, O
that O
may O
have O
been O
an O
important O
contributing O
factor O
to O
this O
disorder O
. O

these O
questions O
are O
currently O
being O
investigated O
. O

enhanced O
stimulus O
- O
induced O
neurotransmitter O
overflow O
in O
epinephrine O
- O
induced O
hypertensive B-Disease
rats O
is O
not O
mediated O
by O
prejunctional O
beta O
- O
adrenoceptor O
activation O
. O

the O
present O
study O
examines O
the O
effect O
of O
6 O
- O
day O
epinephrine O
treatment O
( O
100 O
micrograms O
/ O
kg O
per O
h O
, O
s O
. O
c O
. O
) O
on O
stimulus O
- O
induced O
( O
1 O
hz O
) O
endogenous O
neurotransmitter O
overflow O
from O
the O
isolated O
perfused O
kidney O
of O
vehicle O
- O
and O
epinephrine O
- O
treated O
rats O
. O

renal O
catecholamine O
stores O
and O
stimulus O
- O
induced O
overflow O
in O
the O
vehicle O
- O
treated O
group O
consisted O
of O
norepinephrine O
only O
. O

however O
, O
epinephrine O
treatment O
resulted O
in O
the O
incorporation O
of O
epinephrine O
into O
renal O
catecholamine O
stores O
such O
that O
approximately O
40 O
% O
of O
the O
catecholamine O
present O
was O
epinephrine O
while O
the O
norepinephrine O
content O
was O
reduced O
by O
a O
similar O
degree O
. O

total O
tissue O
catecholamine O
content O
of O
the O
kidney O
on O
a O
molar O
basis O
was O
unchanged O
. O

stimulus O
- O
induced O
fractional O
overflow O
of O
neurotransmitter O
from O
the O
epinephrine O
- O
treated O
kidneys O
was O
approximately O
twice O
normal O
and O
consisted O
of O
both O
norepinephrine O
and O
epinephrine O
in O
proportions O
similar O
to O
those O
found O
in O
the O
kidney O
. O

this O
difference O
in O
fractional O
overflow O
between O
groups O
was O
not O
affected O
by O
neuronal O
and O
extraneuronal O
uptake O
blockade O
. O

propranolol O
had O
no O
effect O
on O
stimulus O
- O
induced O
overflow O
in O
either O
group O
. O

phentolamine O
increased O
stimulus O
- O
induced O
overflow O
in O
both O
groups O
although O
the O
increment O
in O
overflow O
was O
greater O
in O
the O
epinephrine O
- O
treated O
group O
. O

in O
conclusion O
, O
chronic O
epinephrine O
treatment O
results O
in O
enhanced O
fractional O
neurotransmitter O
overflow O
. O

however O
, O
neither O
alterations O
in O
prejunctional O
beta O
- O
adrenoceptor O
influences O
nor O
alterations O
in O
neuronal O
and O
extraneuronal O
uptake O
mechanisms O
appear O
to O
be O
responsible O
for O
this O
alteration O
. O

furthermore O
, O
data O
obtained O
with O
phentolamine O
alone O
do O
not O
suggest O
alpha O
- O
adrenoceptor O
desensitization O
as O
the O
cause O
of O
the O
enhanced O
neurotransmitter O
overflow O
after O
epinephrine O
treatment O
. O

gaba O
involvement O
in O
naloxone O
induced O
reversal O
of O
respiratory B-Disease
paralysis B-Disease
produced O
by O
thiopental O
. O

no O
agent O
is O
yet O
available O
to O
reverse O
respiratory B-Disease
paralysis B-Disease
produced O
by O
cns O
depressants O
, O
such O
as O
general O
anesthetics O
. O

in O
this O
study O
naloxone O
reversed O
respiratory B-Disease
paralysis B-Disease
induced O
by O
thiopental O
in O
rats O
. O

25 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
thiopental O
produced O
anesthesia O
without O
altering O
respiratory O
rate O
, O
increased O
gaba O
, O
decreased O
glutamate O
, O
and O
had O
no O
effect O
on O
aspartate O
or O
glycine O
levels O
compared O
to O
controls O
in O
rat O
cortex O
and O
brain O
stem O
. O

pretreatment O
of O
rats O
with O
thiosemicarbazide O
for O
30 O
minutes O
abolished O
the O
anesthetic O
action O
as O
well O
as O
the O
respiratory O
depressant O
action O
of O
thiopental O
. O

50 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
thiopental O
produced O
respiratory B-Disease
arrest B-Disease
with O
further O
increase O
in O
gaba O
and O
decrease O
in O
glutamate O
again O
in O
cortex O
and O
brain O
stem O
without O
affecting O
any O
of O
the O
amino O
acids O
studied O
in O
four O
regions O
of O
rat O
brain O
. O

naloxone O
( O
2 O
. O
5 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
) O
reversed O
respiratory B-Disease
paralysis B-Disease
, O
glutamate O
and O
gaba O
levels O
to O
control O
values O
in O
brain O
stem O
and O
cortex O
with O
no O
changes O
in O
caudate O
or O
cerebellum O
. O

these O
data O
suggest O
naloxone O
reverses O
respiratory B-Disease
paralysis B-Disease
produced O
by O
thiopental O
and O
involves O
gaba O
in O
its O
action O
. O

diazepam O
facilitates O
reflex O
bradycardia B-Disease
in O
conscious O
rats O
. O

the O
effects O
of O
diazepam O
on O
cardiovascular O
function O
were O
assessed O
in O
conscious O
rats O
. O

intravenous O
administration O
of O
diazepam O
( O
1 O
- O
30 O
mg O
kg O
- O
1 O
) O
produced O
a O
dose O
- O
dependent O
decrease O
in O
both O
the O
mean O
arterial O
pressure O
and O
the O
heart O
rate O
. O

also O
, O
reflex O
bradycardia B-Disease
was O
produced O
in O
rats O
by O
intravenous O
infusion O
of O
adrenaline O
( O
1 O
. O
25 O
- O
2 O
. O
5 O
micrograms O
kg O
- O
1 O
) O
. O

intravenous O
pretreatment O
of O
the O
rats O
with O
diazepam O
, O
although O
causing O
no O
change O
in O
the O
adrenaline O
- O
induced O
pressor O
effect O
, O
did O
enhance O
the O
adrenaline O
- O
induced O
reflex O
bradycardia B-Disease
. O

however O
, O
the O
diazepam O
enhancement O
of O
adrenaline O
- O
induced O
reflex O
bradycardia B-Disease
was O
antagonized O
by O
pretreatment O
of O
rats O
with O
an O
intravenous O
dose O
of O
picrotoxin O
( O
an O
agent O
blocks O
chloride O
channels O
by O
binding O
to O
sites O
associated O
with O
the O
benzodiazepine O
- O
gaba O
- O
chloride O
channel O
macromolecular O
complex O
) O
. O

the O
data O
indicate O
that O
diazepam O
acts O
through O
the O
benzodiazepine O
- O
gaba O
- O
chloride O
channel O
macromolecular O
complex O
within O
the O
central O
nervous O
system O
to O
facilitate O
reflex O
bradycardia B-Disease
mediated O
through O
baroreceptor O
reflexes O
in O
response O
to O
an O
acute O
increase O
in O
arterial O
pressure O
. O

initial O
potassium O
loss O
and O
hypokalaemia B-Disease
during O
chlorthalidone O
administration O
in O
patients O
with O
essential O
hypertension B-Disease
: O
the O
influence O
of O
dietary O
sodium O
restriction O
. O

to O
investigate O
the O
initial O
potassium O
loss O
and O
development O
of O
hypokalaemia B-Disease
during O
the O
administration O
of O
an O
oral O
diuretic O
, O
metabolic O
balance O
studies O
were O
performed O
in O
ten O
patients O
with O
essential O
hypertension B-Disease
who O
had O
shown O
hypokalaemia B-Disease
under O
prior O
oral O
diuretic O
treatment O
. O

chlorthalidone O
( O
50 O
mg O
daily O
) O
was O
given O
for O
14 O
days O
. O

six O
patients O
received O
a O
normal O
- O
sodium O
diet O
and O
four O
a O
low O
- O
sodium O
( O
17 O
mmol O
/ O
day O
) O
diet O
. O

all O
patients O
had O
a O
normal O
initial O
total O
body O
potassium O
( O
40k O
) O
. O

the O
electrolyte O
balances O
, O
weight O
, O
bromide O
space O
, O
plasma O
renin O
activity O
, O
and O
aldosterone O
secretion O
rate O
were O
measured O
. O

in O
both O
groups O
a O
potassium O
deficit O
developed O
, O
with O
proportionally O
larger O
losses O
from O
the O
extracellular O
than O
from O
the O
intracellular O
compartment O
. O

in O
the O
normal O
- O
sodium O
group O
the O
highest O
mean O
potassium O
deficit O
was O
176 O
mmol O
on O
day O
9 O
, O
after O
which O
some O
potassium O
was O
regained O
; O
in O
the O
low O
- O
sodium O
group O
the O
highest O
deficit O
was O
276 O
mmol O
on O
day O
13 O
. O

the O
normal O
- O
sodium O
group O
showed O
an O
immediate O
but O
temporary O
rise O
of O
the O
renin O
and O
aldosterone O
levels O
; O
in O
the O
low O
- O
sodium O
group O
renin O
and O
aldosterone O
increased O
more O
slowly O
but O
remained O
elevated O
. O

it O
is O
concluded O
that O
dietary O
sodium O
restriction O
increases O
diuretic O
- O
induced O
potassium O
loss O
, O
presumably O
by O
an O
increased O
activity O
of O
the O
renin O
- O
angiotensin O
- O
aldosterone O
system O
, O
while O
sodium O
delivery O
to O
the O
distal O
renal O
tubules O
remains O
sufficiently O
high O
to O
allow O
increased O
potassium O
secretion O
. O

reversal O
of O
neuroleptic O
- O
induced O
catalepsy B-Disease
by O
novel O
aryl O
- O
piperazine O
anxiolytic O
drugs O
. O

the O
novel O
anxiolytic O
drug O
, O
buspirone O
, O
reverses O
catalepsy B-Disease
induced O
by O
haloperidol O
. O

a O
series O
of O
aryl O
- O
piperazine O
analogues O
of O
buspirone O
and O
other O
5 O
- O
hydroxytryptaminergic O
agonists O
were O
tested O
for O
their O
ability O
to O
reverse O
haloperidol O
induced O
catalepsy B-Disease
. O

those O
drugs O
with O
strong O
affinity O
for O
5 O
- O
hydroxytryptamine1a O
receptors O
were O
able O
to O
reverse O
catalepsy B-Disease
. O

drugs O
with O
affinity O
for O
other O
5 O
- O
ht O
receptors O
or O
weak O
affinity O
were O
ineffective O
. O

however O
, O
inhibition O
of O
postsynaptic O
5 O
- O
ht O
receptors O
neither O
inhibited O
nor O
potentiated O
reversal O
of O
catalepsy B-Disease
and O
leaves O
open O
the O
question O
as O
to O
the O
site O
or O
mechanism O
for O
this O
effect O
. O

glycopyrronium O
requirements O
for O
antagonism O
of O
the O
muscarinic O
side O
effects O
of O
edrophonium O
. O

we O
have O
compared O
, O
in O
60 O
adult O
patients O
, O
the O
cardiovascular O
effects O
of O
glycopyrronium O
5 O
micrograms O
kg O
- O
1 O
and O
10 O
micrograms O
kg O
- O
1 O
given O
either O
simultaneously O
or O
1 O
min O
before O
edrophonium O
1 O
mg O
kg O
- O
1 O
. O

significant O
differences O
between O
the O
four O
groups O
were O
detected O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

both O
groups O
receiving O
10 O
micrograms O
kg O
- O
1 O
showed O
increases O
in O
heart O
rate O
of O
up O
to O
30 O
beat O
min O
- O
1 O
( O
95 O
% O
confidence O
limits O
28 O
- O
32 O
beat O
min O
- O
1 O
) O
. O

use O
of O
glycopyrronium O
5 O
micrograms O
kg O
- O
1 O
provided O
greater O
cardiovascular O
stability O
and O
, O
given O
1 O
min O
before O
the O
edrophonium O
, O
was O
sufficient O
to O
minimize O
early O
, O
edrophonium O
- O
induced O
bradycardias B-Disease
. O

this O
low O
dose O
of O
glycopyrronium O
provided O
good O
control O
of O
oropharyngeal O
secretions O
. O

selective O
injection O
of O
iopentol O
, O
iohexol O
and O
metrizoate O
into O
the O
left O
coronary O
artery O
of O
the O
dog O
. O

induction O
of O
ventricular B-Disease
fibrillation B-Disease
and O
decrease O
of O
aortic O
pressure O
. O

in O
twenty O
beagle O
dogs O
selective O
injections O
were O
made O
into O
the O
left O
coronary O
artery O
with O
iopentol O
, O
iohexol O
and O
metrizoate O
in O
doses O
of O
4 O
ml O
, O
8 O
ml O
and O
16 O
ml O
. O

thirty O
- O
six O
iopentol O
injections O
, O
35 O
iohexol O
injections O
and O
37 O
metrizoate O
injections O
were O
made O
. O

frequencies O
of O
ventricular B-Disease
fibrillation B-Disease
were O
significantly O
lower O
( O
p O
less O
than O
0 O
. O
05 O
) O
after O
iopentol O
( O
0 O
% O
) O
and O
iohexol O
( O
3 O
% O
) O
than O
after O
metrizoate O
( O
22 O
% O
) O
. O

iopentol O
and O
iohexol O
also O
produced O
significantly O
less O
decrease O
in O
aortic O
blood O
pressure O
than O
metrizoate O
at O
the O
different O
doses O
. O

thyroid O
function O
and O
urine O
- O
concentrating O
ability O
during O
lithium O
treatment O
. O

it O
has O
been O
suggested O
that O
adenylate O
cyclase O
inhibition O
may O
be O
important O
in O
the O
development O
of O
both O
nephrogenic B-Disease
diabetes B-Disease
insipidus B-Disease
and O
hypothyroidism B-Disease
during O
lithium O
treatment O
. O

we O
measured O
serum O
thyroxine O
and O
urine O
- O
concentrating O
ability O
( O
umax O
) O
in O
response O
to O
desmopressin O
( O
ddavp O
) O
in O
85 O
patients O
receiving O
lithium O
. O

hypothyroidism B-Disease
developed O
in O
eight O
patients O
while O
they O
were O
taking O
lithium O
. O

impaired O
umax O
was O
found O
in O
both O
euthyroid O
and O
hypothyroid B-Disease
patients O
while O
some O
hypothyroid B-Disease
patients O
concentrated O
their O
urine O
well O
. O

it O
is O
concluded O
that O
the O
dominant O
mechanisms O
by O
which O
lithium O
exerts O
these O
two O
effects O
are O
different O
. O

remodelling O
of O
nerve O
structure O
in O
experimental O
isoniazid O
neuropathy B-Disease
in O
the O
rat O
. O

the O
neuropathy B-Disease
caused O
by O
a O
single O
dose O
of O
isoniazid O
in O
rats O
was O
studied O
with O
a O
computer O
- O
assisted O
morphometric O
method O
. O

scatter O
diagrams O
of O
the O
g O
ratio O
( O
quotient O
fibre O
diameter O
/ O
axon O
diameter O
) O
define O
regenerating O
fibres O
as O
a O
distinct O
population O
, O
distinguishable O
from O
the O
surviving O
fibres O
by O
reduced O
sheath O
thickness O
and O
reduced O
axon O
calibre O
. O

there O
was O
also O
evidence O
of O
a O
subtle O
direct O
toxic O
effect O
on O
the O
entire O
fibre O
population O
, O
causing O
axon O
shrinkage O
masked O
by O
readjustment O
of O
the O
myelin O
sheath O
. O

multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
efficacy O
and O
safety O
trial O
of O
azelastine O
, O
chlorpheniramine O
, O
and O
placebo O
in O
the O
treatment O
of O
spring B-Disease
allergic B-Disease
rhinitis B-Disease
. O

azelastine O
, O
a O
novel O
antiallergic O
medication O
, O
was O
compared O
with O
chlorpheniramine O
maleate O
and O
placebo O
for O
efficacy O
and O
safety O
in O
the O
treatment O
of O
spring B-Disease
allergic B-Disease
rhinitis B-Disease
in O
a O
multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
study O
. O

one O
hundred O
fifty O
- O
five O
subjects O
participated O
. O

subjects O
ranged O
in O
age O
from O
18 O
to O
60 O
years O
of O
age O
and O
had O
at O
least O
a O
2 O
- O
year O
history O
of O
spring B-Disease
allergic B-Disease
rhinitis B-Disease
, O
confirmed O
by O
positive O
skin O
test O
to O
spring O
aeroallergens O
. O

medications O
were O
given O
four O
times O
daily O
; O
the O
azelastine O
groups O
received O
0 O
. O
5 O
, O
1 O
. O
0 O
, O
or O
2 O
. O
0 O
mg O
in O
the O
morning O
and O
evening O
with O
placebo O
in O
the O
early O
and O
late O
afternoon O
; O
the O
chlorpheniramine O
group O
received O
4 O
. O
0 O
mg O
four O
times O
daily O
. O

daily O
subject O
symptom O
cards O
were O
completed O
during O
a O
screening O
period O
to O
assess O
pretreatment O
symptoms O
and O
during O
a O
4 O
- O
week O
treatment O
period O
while O
subjects O
received O
study O
medications O
. O

individual O
symptoms O
, O
total O
symptoms O
, O
and O
major O
symptoms O
were O
compared O
to O
determine O
efficacy O
of O
medication O
. O

elicited O
, O
volunteered O
, O
and O
observed O
adverse O
experiences O
were O
recorded O
for O
each O
subject O
and O
compared O
among O
groups O
. O

vital O
signs O
, O
body O
weights O
, O
serum O
chemistry O
values O
, O
complete O
blood O
cell O
counts O
, O
urine O
studies O
, O
and O
electrocardiograms O
were O
obtained O
for O
each O
subject O
and O
compared O
among O
groups O
. O

symptoms O
relief O
in O
the O
group O
receiving O
the O
highest O
concentration O
of O
azelastine O
( O
2 O
. O
0 O
mg O
twice O
daily O
) O
was O
statistically O
greater O
than O
in O
the O
placebo O
group O
during O
all O
weeks O
of O
the O
study O
. O

lower O
doses O
of O
azelastine O
were O
statistically O
more O
effective O
than O
placebo O
only O
during O
portions O
of O
the O
first O
3 O
weeks O
of O
the O
study O
. O

in O
contrast O
, O
although O
the O
chlorpheniramine O
group O
did O
have O
fewer O
symptoms O
than O
the O
placebo O
group O
during O
the O
study O
, O
the O
difference O
never O
reached O
statistical O
significance O
during O
any O
week O
of O
the O
study O
. O

there O
were O
no O
serious O
side O
effects O
in O
any O
of O
the O
treatment O
groups O
. O

drowsiness B-Disease
and O
altered B-Disease
taste B-Disease
perception B-Disease
were O
increased O
significantly O
over O
placebo O
only O
in O
the O
high O
- O
dose O
azelastine O
group O
. O

azelastine O
appears O
to O
be O
a O
safe O
, O
efficacious O
medication O
for O
seasonal B-Disease
allergic B-Disease
rhinitis B-Disease
. O

toxicity B-Disease
due O
to O
remission O
inducing O
drugs O
in O
rheumatoid B-Disease
arthritis B-Disease
. O

association O
with O
hla O
- O
b35 O
and O
cw4 O
antigens O
. O

twenty O
- O
five O
patients O
with O
rheumatoid B-Disease
arthritis B-Disease
( O
ra B-Disease
) O
who O
developed O
toxicity B-Disease
while O
taking O
remission O
inducing O
drugs O
and O
30 O
without O
toxicity B-Disease
were O
studied O
for O
possible O
associations O
with O
class O
i O
and O
ii O
hla O
antigens O
. O

a O
strong O
association O
has O
been O
found O
between O
nephritis B-Disease
and O
dermatitis B-Disease
due O
to O
tiopronin O
( O
a O
d O
- O
penicillamine O
like O
compound O
) O
and O
class O
i O
antigens O
b35 O
- O
cw4 O
, O
and O
between O
dermatitis B-Disease
due O
to O
gold O
thiosulphate O
and O
b35 O
. O

compared O
to O
healthy O
controls O
a O
lower O
dr5 O
frequency O
was O
observed O
in O
patients O
with O
ra B-Disease
except O
for O
the O
tiopronin O
related O
nephritis B-Disease
group O
. O

transient O
contralateral B-Disease
rotation B-Disease
following O
unilateral O
substantia B-Disease
nigra B-Disease
lesion B-Disease
reflects O
susceptibility O
of O
the O
nigrostriatal O
system O
to O
exhaustion O
by O
amphetamine O
. O

following O
unilateral O
6 O
- O
ohda O
induced O
sn B-Disease
lesion B-Disease
, O
a O
transient O
period O
of O
contralateral B-Disease
rotation B-Disease
has O
been O
reported O
to O
precede O
the O
predominant O
ipsilateral B-Disease
circling B-Disease
. O

in O
order O
to O
clarify O
the O
nature O
of O
this O
initial O
contralateral B-Disease
rotation B-Disease
we O
examined O
the O
effect O
of O
the O
duration O
of O
recovery O
period O
after O
the O
lesion O
, O
on O
amphetamine O
- O
induced O
rotational B-Disease
behavior B-Disease
. O

three O
days O
post O
lesion O
, O
most O
rats O
circled O
predominantly O
contralaterally O
to O
the O
lesion O
. O

such O
contralateral B-Disease
rotation B-Disease
may O
result O
from O
either O
degeneration O
- O
induced O
breakdown O
of O
the O
da O
pool O
, O
or O
lesion O
- O
induced O
increase O
of O
da O
turnover O
in O
the O
spared O
neurons O
. O

a O
substantial O
degree O
of O
contralateral O
preference O
was O
still O
evident O
when O
amphetamine O
was O
administered O
for O
the O
first O
time O
24 O
days O
after O
lesioning O
, O
indicating O
involvement O
of O
spared O
cells O
in O
the O
contralateral B-Disease
rotation B-Disease
. O

however O
, O
regardless O
of O
the O
duration O
of O
recovery O
( O
and O
irrespective O
of O
either O
lesion O
volume O
, O
amphetamine O
dose O
, O
or O
post O
- O
lesion O
motor O
exercise O
) O
, O
amphetamine O
- O
induced O
rotation B-Disease
tended O
to O
become O
gradually O
more O
ipsilateral O
as O
the O
observation O
session O
progressed O
, O
and O
all O
rats O
circled O
ipsilaterally O
to O
the O
lesion O
in O
response O
to O
further O
amphetamine O
injections O
. O

these O
findings O
suggest O
that O
amphetamine O
has O
an O
irreversible O
effect O
on O
the O
post O
- O
lesion O
da O
pool O
contributing O
to O
contralateral B-Disease
rotation B-Disease
. O

mitomycin O
c O
associated O
hemolytic B-Disease
uremic B-Disease
syndrome B-Disease
. O

mitomycin O
c O
associated O
hemolytic B-Disease
uremic B-Disease
syndrome B-Disease
( O
hus B-Disease
) O
is O
a O
potentially O
fatal O
but O
uncommon O
condition O
that O
is O
not O
yet O
widely O
recognised O
. O

it O
consists O
of O
microangiopathic O
hemolytic B-Disease
anemia B-Disease
, O
thrombocytopenia B-Disease
and O
progressive O
renal B-Disease
failure B-Disease
associated O
with O
mitomycin O
c O
treatment O
and O
affects O
about O
10 O
% O
of O
patients O
treated O
with O
this O
agent O
. O

the O
renal B-Disease
failure B-Disease
usually O
develops O
about O
8 O
- O
10 O
mth O
after O
start O
of O
mitomycin O
c O
treatment O
and O
the O
mortality O
is O
approximately O
60 O
% O
from O
renal B-Disease
failure B-Disease
or O
pulmonary B-Disease
edema B-Disease
. O

renal B-Disease
lesions B-Disease
are O
similar O
to O
those O
seen O
in O
idiopathic O
hus B-Disease
and O
include O
arteriolar O
fibrin O
thrombi B-Disease
, O
expanded O
subendothelial O
zones O
in O
glomerular O
capillary O
walls O
, O
ischemic B-Disease
wrinkling O
of O
glomerular O
basement O
membranes O
and O
mesangiolysis O
. O

the O
mechanism O
of O
action O
is O
postulated O
as O
mitomycin O
c O
- O
induced O
endothelial O
cell O
damage O
. O

we O
describe O
the O
clinical O
course O
and O
pathological O
findings O
in O
a O
65 O
yr O
- O
old O
man O
with O
gastric B-Disease
adenocarcinoma B-Disease
who O
developed O
renal B-Disease
failure B-Disease
and O
thrombocytopenia B-Disease
while O
on O
treatment O
with O
mitomycin O
c O
and O
died O
in O
pulmonary B-Disease
edema B-Disease
. O

ketanserin O
pretreatment O
reverses O
alfentanil O
- O
induced O
muscle B-Disease
rigidity B-Disease
. O

systemic O
pretreatment O
with O
ketanserin O
, O
a O
relatively O
specific O
type O
- O
2 O
serotonin O
receptor O
antagonist O
, O
significantly O
attenuated O
the O
muscle B-Disease
rigidity B-Disease
produced O
in O
rats O
by O
the O
potent O
short O
- O
acting O
opiate O
agonist O
alfentanil O
. O

following O
placement O
of O
subcutaneous O
electrodes O
in O
each O
animal O
' O
s O
left O
gastrocnemius O
muscle O
, O
rigidity B-Disease
was O
assessed O
by O
analyzing O
root O
- O
mean O
- O
square O
electromyographic O
activity O
. O

intraperitoneal O
ketanserin O
administration O
at O
doses O
of O
0 O
. O
63 O
and O
2 O
. O
5 O
mg O
/ O
kg O
prevented O
the O
alfentanil O
- O
induced O
increase O
in O
electromyographic O
activity O
compared O
with O
animals O
pretreated O
with O
saline O
. O

chlordiazepoxide O
at O
doses O
up O
to O
10 O
mg O
/ O
kg O
failed O
to O
significantly O
influence O
the O
rigidity B-Disease
produced O
by O
alfentanil O
. O

despite O
the O
absence O
of O
rigidity B-Disease
, O
animals O
that O
received O
ketanserin O
( O
greater O
than O
0 O
. O
31 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
followed O
by O
alfentanil O
were O
motionless O
, O
flaccid O
, O
and O
less O
responsive O
to O
external O
stimuli O
than O
were O
animals O
receiving O
alfentanil O
alone O
. O

rats O
that O
received O
ketanserin O
and O
alfentanil O
exhibited O
less O
rearing O
and O
exploratory O
behavior O
at O
the O
end O
of O
the O
60 O
- O
min O
recording O
period O
than O
did O
animals O
that O
received O
ketanserin O
alone O
. O

these O
results O
, O
in O
combination O
with O
previous O
work O
, O
suggest O
that O
muscle B-Disease
rigidity B-Disease
, O
a O
clinically O
relevant O
side O
- O
effect O
of O
parenteral O
narcotic O
administration O
, O
may O
be O
partly O
mediated O
via O
serotonergic O
pathways O
. O

pretreatment O
with O
type O
- O
2 O
serotonin O
antagonists O
may O
be O
clinically O
useful O
in O
attenuating O
opiate O
- O
induced O
rigidity B-Disease
, O
although O
further O
studies O
will O
be O
necessary O
to O
assess O
the O
interaction O
of O
possibly O
enhanced O
cns O
, O
cardiovascular B-Disease
, B-Disease
and B-Disease
respiratory B-Disease
depression B-Disease
. O

antagonism O
of O
diazepam O
- O
induced O
sedative O
effects O
by O
ro15 O
- O
1788 O
in O
patients O
after O
surgery O
under O
lumbar O
epidural O
block O
. O

a O
double O
- O
blind O
placebo O
- O
controlled O
investigation O
of O
efficacy O
and O
safety O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
ro15 O
- O
1788 O
and O
a O
placebo O
in O
reversing O
diazepam O
- O
induced O
effects O
after O
surgery O
under O
epidural O
block O
, O
and O
to O
evaluate O
the O
local O
tolerance O
and O
general O
safety O
of O
ro15 O
- O
1788 O
. O

fifty O
- O
seven O
patients O
were O
sedated O
with O
diazepam O
for O
surgery O
under O
epidural O
anaesthesia O
. O

antagonism O
of O
diazepam O
- O
induced O
effects O
by O
ro15 O
- O
1788 O
was O
investigated O
postoperatively O
in O
a O
double O
- O
blind O
placebo O
- O
controlled O
trial O
. O

the O
patient O
' O
s O
subjective O
assessment O
of O
mood O
rating O
, O
an O
objective O
test O
of O
performance O
, O
a O
test O
for O
amnesia B-Disease
, O
and O
vital O
signs O
were O
recorded O
for O
up O
to O
300 O
min O
after O
administration O
of O
the O
trial O
drug O
. O

no O
significant O
differences O
between O
the O
two O
groups O
were O
observed O
for O
mood O
rating O
, O
amnesia B-Disease
, O
or O
vital O
signs O
. O

the O
ro15 O
- O
1788 O
group O
showed O
a O
significant O
improvement O
in O
the O
performance O
test O
up O
to O
120 O
min O
after O
administration O
of O
the O
drug O
. O

there O
was O
no O
evidence O
of O
reaction O
at O
the O
injection O
site O
. O

chorea B-Disease
associated O
with O
oral O
contraception O
. O

three O
patients O
developed O
chorea B-Disease
while O
receiving O
oral O
contraceptives O
. O

two O
were O
young O
patients O
whose O
chorea B-Disease
developed O
long O
after O
treatment O
had O
been O
started O
and O
disappeared O
soon O
after O
it O
had O
been O
discontinued O
. O

the O
third O
patient O
had O
acute O
amphetamine O
- O
induced O
chorea B-Disease
after O
prolonged O
oral O
contraception O
. O

prolonged O
administration O
of O
female O
sex O
hormones O
is O
a O
possible O
cause O
of O
chorea B-Disease
in O
women O
who O
have O
not O
previously O
had O
chorea B-Disease
or O
rheumatic B-Disease
fever B-Disease
. O

co O
- O
carcinogenic B-Disease
effect O
of O
retinyl O
acetate O
on O
forestomach B-Disease
carcinogenesis B-Disease
of O
male O
f344 O
rats O
induced O
with O
butylated O
hydroxyanisole O
. O

the O
potential O
modifying O
effect O
of O
retinyl O
acetate O
( O
ra O
) O
on O
butylated O
hydroxyanisole O
( O
bha O
) O
- O
induced O
rat O
forestomach B-Disease
tumorigenesis B-Disease
was O
examined O
. O

male O
f344 O
rats O
, O
5 O
weeks O
of O
age O
, O
were O
maintained O
on O
diet O
containing O
1 O
% O
or O
2 O
% O
bha O
by O
weight O
and O
simultaneously O
on O
drinking O
water O
supplemented O
with O
ra O
at O
various O
concentrations O
( O
w O
/ O
v O
) O
for O
52 O
weeks O
. O

in O
groups O
given O
2 O
% O
bha O
, O
although O
marked O
hyperplastic O
changes O
of O
the O
forestomach O
epithelium O
were O
observed O
in O
all O
animals O
, O
co O
- O
administration O
of O
0 O
. O
25 O
% O
ra O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
increased O
the O
incidence O
of O
forestomach B-Disease
tumors B-Disease
( O
squamous B-Disease
cell B-Disease
papilloma B-Disease
and O
carcinoma B-Disease
) O
to O
60 O
% O
( O
9 O
/ O
15 O
, O
2 O
rats O
with O
carcinoma B-Disease
) O
from O
15 O
% O
( O
3 O
/ O
20 O
, O
one O
rat O
with O
carcinoma B-Disease
) O
in O
the O
group O
given O
ra O
- O
free O
water O
. O

in O
rats O
given O
1 O
% O
bha O
, O
ra O
co O
- O
administered O
at O
a O
dose O
of O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
or O
0 O
. O
25 O
% O
showed O
a O
dose O
- O
dependent O
enhancing O
effect O
on O
the O
development O
of O
the O
bha O
- O
induced O
epithelial B-Disease
hyperplasia B-Disease
. O

tumors B-Disease
, O
all O
papillomas B-Disease
, O
were O
induced O
in O
3 O
rats O
( O
17 O
% O
) O
with O
0 O
. O
25 O
% O
ra O
and O
in O
one O
rat O
( O
10 O
% O
) O
with O
0 O
. O
05 O
% O
ra O
co O
- O
administration O
. O

ra O
alone O
did O
not O
induce O
hyperplastic O
changes O
in O
the O
forestomach O
. O

these O
findings O
indicate O
that O
ra O
acted O
as O
a O
co O
- O
carcinogen O
in O
the O
bha O
forestomach B-Disease
carcinogenesis B-Disease
of O
the O
rat O
. O

a O
prospective O
study O
on O
the O
dose O
dependency O
of O
cardiotoxicity B-Disease
induced O
by O
mitomycin O
c O
. O

since O
1975 O
mitomycin O
c O
( O
mmc O
) O
has O
been O
suggested O
to O
be O
cardiotoxic B-Disease
, O
especially O
when O
combined O
with O
or O
given O
following O
doxorubicin O
. O

data O
on O
dose O
dependency O
or O
incidence O
concerning O
this O
side O
effect O
were O
not O
known O
. O

we O
have O
initiated O
a O
prospective O
study O
to O
obtain O
some O
more O
data O
on O
these O
subjects O
. O

forty O
- O
four O
mmc O
- O
treated O
patients O
were O
studied O
, O
37 O
of O
them O
could O
be O
evaluated O
. O

all O
patients O
were O
studied O
by O
repeated O
physical O
examinations O
, O
chest O
x O
- O
rays O
, O
electro O
- O
and O
echocardiography O
and O
radionuclide O
left O
ventricular O
ejection O
fraction O
( O
ef O
) O
determinations O
. O

the O
results O
were O
evaluated O
per O
cumulative O
dose O
level O
. O

one O
of O
the O
patients O
developed O
cardiac B-Disease
failure B-Disease
after O
30 O
mg O
m O
- O
2 O
mmc O
and O
only O
150 O
mg O
m O
- O
2 O
doxorubicin O
. O

the O
cardiac B-Disease
failure B-Disease
was O
predicted O
by O
a O
drop O
in O
ef O
determined O
during O
a O
cold O
pressor O
test O
. O

none O
of O
the O
other O
patients O
developed O
clinical O
cardiotoxicity B-Disease
, O
nor O
did O
the O
studied O
parameters O
change O
. O

the O
literature O
on O
this O
subject O
was O
also O
reviewed O
. O

based O
on O
the O
combined O
data O
from O
the O
present O
study O
and O
the O
literature O
, O
we O
suggest O
that O
mmc O
- O
related O
cardiotoxicity B-Disease
is O
dose O
dependent O
, O
occurring O
at O
cumulative O
dose O
levels O
of O
30 O
mg O
m O
- O
2 O
or O
more O
, O
mainly O
in O
patients O
also O
( O
previously O
or O
simultaneously O
) O
treated O
with O
doxorubicin O
. O

the O
incidence O
is O
likely O
to O
be O
less O
than O
10 O
% O
even O
for O
this O
risk O
group O
. O

reversible O
cerebral B-Disease
lesions B-Disease
associated O
with O
tiazofurin O
usage O
: O
mr O
demonstration O
. O

tiazofurin O
is O
an O
experimental O
chemotherapeutic O
agent O
currently O
undergoing O
clinical O
evaluation O
. O

we O
report O
our O
results O
with O
magnetic O
resonance O
( O
mr O
) O
in O
demonstrating O
reversible O
cerebral B-Disease
abnormalities B-Disease
concurrent O
with O
the O
use O
of O
this O
drug O
. O

the O
abnormalities O
on O
mr O
were O
correlated O
with O
findings O
on O
ct O
as O
well O
as O
with O
cerebral O
angiography O
. O

the O
utility O
of O
mr O
in O
the O
evaluation O
of O
patients O
receiving O
this O
new O
agent O
is O
illustrated O
. O

receptor O
mechanisms O
of O
nicotine O
- O
induced O
locomotor B-Disease
hyperactivity B-Disease
in O
chronic O
nicotine O
- O
treated O
rats O
. O

rats O
were O
pretreated O
with O
saline O
or O
nicotine O
( O
1 O
. O
5 O
mg O
/ O
kg O
per O
day O
) O
by O
subcutaneously O
implanting O
each O
animal O
with O
an O
alzet O
osmotic O
mini O
- O
pump O
which O
continuously O
released O
saline O
or O
nicotine O
for O
1 O
, O
5 O
and O
14 O
days O
. O

at O
the O
end O
of O
each O
pretreatment O
period O
, O
animals O
were O
used O
for O
( O
i O
) O
determining O
their O
locomotor O
response O
to O
acutely O
injected O
nicotine O
( O
0 O
. O
2 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
and O
( O
ii O
) O
measuring O
the O
density O
of O
l O
- O
[ O
3h O
] O
nicotine O
and O
[ O
3h O
] O
spiperone O
binding O
sites O
in O
the O
striatum O
. O

we O
observed O
no O
changes O
in O
nicotine O
- O
induced O
locomotor O
response O
, O
striatal O
l O
- O
[ O
3h O
] O
nicotine O
and O
[ O
3h O
] O
spiperone O
binding O
in O
the O
animals O
pretreated O
with O
nicotine O
for O
1 O
day O
. O

in O
rats O
which O
were O
pretreated O
with O
nicotine O
for O
5 O
days O
, O
there O
was O
a O
significant O
increase O
in O
the O
nicotine O
- O
stimulated O
locomotor O
response O
which O
was O
associated O
with O
an O
increase O
in O
the O
number O
of O
l O
- O
[ O
3h O
] O
nicotine O
binding O
sites O
and O
also O
with O
an O
elevated O
dopamine O
( O
da O
) O
level O
in O
the O
striatum O
. O

the O
number O
of O
striatal O
[ O
3h O
] O
spiperone O
binding O
sites O
was O
not O
affected O
. O

in O
animals O
pretreated O
with O
nicotine O
for O
14 O
days O
, O
the O
nicotine O
- O
induced O
locomotor O
response O
remained O
to O
be O
potentiated O
. O

however O
, O
this O
response O
was O
correlated O
with O
an O
elevated O
number O
of O
striatal O
[ O
3h O
] O
spiperone O
binding O
sites O
, O
whereas O
the O
number O
of O
striatal O
l O
- O
[ O
3h O
] O
nicotine O
binding O
sites O
and O
the O
striatal O
da O
level O
were O
normal O
. O

these O
results O
suggest O
that O
chronic O
nicotine O
- O
treated O
rats O
develop O
locomotor B-Disease
hyperactivity B-Disease
in O
response O
to O
nicotine O
initially O
due O
to O
increases O
of O
both O
the O
density O
of O
nicotinic O
receptors O
and O
da O
concentration O
, O
followed O
by O
inducing O
da O
receptor O
supersensitivity O
in O
the O
striatum O
. O

amelioration O
of O
bendrofluazide O
- O
induced O
hypokalemia B-Disease
by O
timolol O
. O

the O
beta O
adrenergic O
blocking O
drug O
, O
timolol O
, O
tended O
to O
correct O
the O
hypokalemia B-Disease
of O
short O
- O
term O
bendrofluazide O
treatment O
in O
6 O
healthy O
male O
subjects O
and O
although O
the O
effect O
was O
small O
it O
was O
significant O
. O

timolol O
also O
reduced O
the O
rise O
in O
plasma O
aldosterone O
and O
urine O
potassium O
excretion O
following O
bendrofluazide O
and O
increased O
the O
urine O
sodium O
/ O
potassium O
ratio O
. O

there O
was O
no O
evidence O
of O
a O
shift O
of O
potassium O
from O
the O
intracellular O
to O
the O
extracellular O
space O
. O

st B-Disease
. B-Disease

anthony B-Disease
' B-Disease
s B-Disease
fire B-Disease
, O
then O
and O
now O
: O
a O
case O
report O
and O
historical O
review O
. O

a O
rare O
case O
of O
morbid O
vasospasm B-Disease
, O
together O
with O
striking O
angiographic O
findings O
, O
is O
described O
secondary O
to O
the O
ingestion O
of O
methysergide O
by O
a O
48 O
- O
year O
- O
old O
woman O
. O

a O
brief O
review O
of O
the O
literature O
on O
similar O
cases O
is O
presented O
. O

a O
discussion O
of O
the O
history O
of O
ergot O
includes O
its O
original O
discovery O
, O
the O
epidemics O
of O
gangrene B-Disease
that O
it O
has O
caused O
through O
the O
ages O
and O
its O
past O
and O
present O
role O
in O
the O
management O
of O
migraine B-Disease
headache B-Disease
. O

despite O
the O
advent O
of O
calcium O
channel O
blockers O
and O
beta O
- O
adrenergic O
antagonists O
, O
ergot O
preparations O
continue O
to O
play O
a O
major O
role O
in O
migraine B-Disease
therapy O
, O
so O
that O
the O
danger O
of O
st B-Disease
. B-Disease

anthony B-Disease
' B-Disease
s B-Disease
fire B-Disease
persists O
. O

cardiac O
transplantation O
: O
improved O
quality O
of O
survival O
with O
a O
modified O
immunosuppressive O
protocol O
. O

the O
effects O
on O
renal O
function O
on O
two O
different O
immunosuppressive O
protocols O
were O
evaluated O
retrospectively O
in O
two O
subsequent O
groups O
of O
heart O
transplant O
recipients O
. O

in O
group O
i O
, O
cyclosporine O
was O
given O
before O
the O
procedure O
at O
a O
loading O
dose O
of O
17 O
. O
5 O
mg O
/ O
kg O
and O
then O
continued O
after O
the O
procedure O
to O
keep O
a O
whole O
blood O
level O
about O
1000 O
ng O
/ O
ml O
. O

in O
group O
ii O
, O
cyclosporine O
was O
started O
only O
after O
the O
procedure O
at O
a O
lower O
dosage O
and O
was O
complemented O
by O
azathioprine O
, O
which O
was O
used O
for O
the O
first O
postoperative O
week O
. O

group O
ii O
showed O
a O
better O
perioperative O
renal O
function O
as O
determined O
by O
serum O
blood O
urea O
nitrogen O
and O
serum O
creatinine O
levels O
. O

group O
ii O
also O
showed O
a O
significant O
decrease O
of O
chronic O
nephrotoxicity B-Disease
secondary O
to O
long O
- O
term O
therapy O
with O
cyclosporine O
. O

despite O
this O
improvement O
in O
late O
renal O
function O
, O
group O
ii O
still O
shows O
a O
slow O
rise O
in O
serum O
creatinine O
. O

we O
think O
that O
even O
these O
lower O
dosages O
of O
cyclosporine O
can O
cause O
chronic O
nephrotoxicity B-Disease
and O
that O
further O
modification O
of O
the O
immunosuppressive O
regimen O
is O
required O
to O
completely O
abolish O
this O
toxic O
side O
effect O
. O

ethopropazine O
and O
benztropine O
in O
neuroleptic O
- O
induced O
parkinsonism B-Disease
. O

in O
a O
12 O
- O
week O
controlled O
study O
ethopropazine O
was O
compared O
to O
benztropine O
in O
the O
treatment O
of O
parkinsonism B-Disease
induced O
by O
fluphenazine O
enanthate O
in O
60 O
schizophrenic B-Disease
outpatients O
. O

ethopropazine O
and O
benztropine O
were O
found O
to O
be O
equally O
effective O
in O
controlling O
parkinsonian B-Disease
symptoms B-Disease
and O
were O
as O
efficacious O
as O
procyclidine O
, O
their O
previous O
antiparkinsonian O
drug O
. O

however O
, O
benztropine O
treated O
patients O
had O
a O
significant O
increase O
in O
tardive B-Disease
dyskinesia B-Disease
compared O
to O
their O
condition O
during O
procyclindine O
treatment O
, O
and O
significantly O
more O
anxiety B-Disease
and O
depression B-Disease
than O
ethopropazine O
treated O
patients O
. O

this O
suggests O
that O
benztropine O
is O
not O
the O
anticholinergic O
drug O
of O
choice O
in O
the O
treatment O
of O
neuroleptic O
- O
induced O
parkinsonian B-Disease
symptoms B-Disease
, O
because O
of O
its O
more O
toxic O
central O
and O
peripheral O
atropinic O
effect O
. O

quinidine O
phenylethylbarbiturate O
- O
induced O
fulminant O
hepatitis B-Disease
in O
a O
pregnant O
woman O
. O

a O
case O
report O
. O

we O
report O
the O
case O
of O
a O
19 O
- O
year O
- O
old O
laotian O
patient O
affected O
by O
fulminant O
hepatitis B-Disease
during O
the O
third O
trimester O
of O
her O
pregnancy O
after O
a O
1 O
- O
month O
administration O
of O
quinidine O
phenylethylbarbiturate O
. O

after O
delivery O
, O
the O
patient O
underwent O
orthotopic O
liver O
transplantation O
. O

the O
patient O
was O
in O
good O
condition O
16 O
months O
after O
liver O
transplantation O
. O

quinidine O
itself O
or O
phenylethylbarbiturate O
may O
be O
responsible O
for O
fulminant O
hepatitis B-Disease
in O
this O
patient O
. O

mechanisms O
of O
myocardial B-Disease
ischemia B-Disease
induced O
by O
epinephrine O
: O
comparison O
with O
exercise O
- O
induced O
ischemia B-Disease
. O

the O
role O
of O
epinephrine O
in O
eliciting O
myocardial B-Disease
ischemia B-Disease
was O
examined O
in O
patients O
with O
coronary B-Disease
artery B-Disease
disease B-Disease
. O

objective O
signs O
of O
ischemia B-Disease
and O
factors O
increasing O
myocardial O
oxygen O
consumption O
were O
compared O
during O
epinephrine O
infusion O
and O
supine O
bicycle O
exercise O
. O

both O
epinephrine O
and O
exercise O
produced O
myocardial B-Disease
ischemia B-Disease
as O
evidenced O
by O
st O
segment O
depression B-Disease
and O
angina B-Disease
. O

however O
, O
the O
mechanisms O
of O
myocardial B-Disease
ischemia B-Disease
induced O
by O
epinephrine O
were O
significantly O
different O
from O
those O
of O
exercise O
. O

exercise O
- O
induced O
myocardial B-Disease
ischemia B-Disease
was O
marked O
predominantly O
by O
increased O
heart O
rate O
and O
rate O
- O
pressure O
product O
with O
a O
minor O
contribution O
of O
end O
- O
diastolic O
volume O
, O
while O
epinephrine O
- O
induced O
ischemia B-Disease
was O
characterized O
by O
a O
marked O
increase O
in O
contractility O
and O
a O
less O
pronounced O
increase O
in O
heart O
rate O
and O
rate O
- O
pressure O
product O
. O

these O
findings O
indicate O
that O
ischemia B-Disease
produced O
by O
epinephrine O
, O
as O
may O
occur O
during O
states O
of O
emotional O
distress O
, O
has O
a O
mechanism O
distinct O
from O
that O
due O
to O
physical O
exertion O
. O

recent O
preclinical O
and O
clinical O
studies O
with O
the O
thymidylate O
synthase O
inhibitor O
n10 O
- O
propargyl O
- O
5 O
, O
8 O
- O
dideazafolic O
acid O
( O
cb O
3717 O
) O
. O

cb O
3717 O
, O
n10 O
- O
propargyl O
- O
5 O
, O
8 O
- O
dideazafolic O
acid O
, O
is O
a O
tight O
- O
binding O
inhibitor O
of O
thymidylate O
synthase O
( O
ts O
) O
whose O
cytotoxicity B-Disease
is O
mediated O
solely O
through O
the O
inhibition O
of O
this O
enzyme O
. O

recent O
preclinical O
studies O
have O
focused O
on O
the O
intracellular O
formation O
of O
cb O
3717 O
polyglutamates O
. O

following O
a O
12 O
- O
hour O
exposure O
of O
l1210 O
cells O
to O
50 O
microm O
[ O
3h O
] O
cb O
3717 O
, O
30 O
% O
of O
the O
extractable O
radioactivity O
could O
be O
accounted O
for O
as O
cb O
3717 O
tetra O
- O
and O
pentaglutamate O
, O
as O
determined O
by O
high O
- O
pressure O
liquid O
chromatography O
( O
hplc O
) O
analyses O
. O

as O
inhibitors O
of O
isolated O
l1210 O
ts O
, O
cb O
3717 O
di O
- O
, O
tri O
- O
, O
tetra O
- O
and O
pentaglutamate O
are O
26 O
- O
, O
87 O
- O
, O
119 O
- O
and O
114 O
- O
fold O
more O
potent O
than O
cb O
3717 O
, O
respectively O
, O
and O
their O
formation O
may O
, O
therefore O
, O
be O
an O
important O
determinant O
of O
cb O
3717 O
cytotoxicity B-Disease
. O

in O
early O
clinical O
studies O
with O
cb O
3717 O
, O
activity O
has O
been O
seen O
in O
breast B-Disease
cancer B-Disease
, O
ovarian B-Disease
cancer B-Disease
, O
hepatoma B-Disease
, O
and O
mesothelioma B-Disease
. O

toxicities B-Disease
included O
hepatotoxicity B-Disease
, O
malaise B-Disease
, O
and O
dose O
- O
limiting O
nephrotoxicity B-Disease
. O

this O
latter O
effect O
is O
thought O
to O
be O
due O
to O
drug O
precipitation O
within O
the O
renal O
tubule O
as O
a O
result O
of O
the O
poor O
solubility O
of O
cb O
3717 O
under O
acidic O
conditions O
. O

in O
an O
attempt O
to O
overcome O
this O
problem O
, O
a O
clinical O
trial O
of O
cb O
3717 O
administered O
with O
alkaline O
diuresis O
is O
under O
way O
. O

preliminary O
results O
at O
400 O
and O
500 O
mg O
/ O
m2 O
suggest O
that O
a O
reduction O
in O
nephrotoxicity B-Disease
may O
have O
been O
achieved O
with O
only O
1 O
instance O
of O
renal B-Disease
toxicity B-Disease
in O
10 O
patients O
. O

hepatotoxicity B-Disease
and O
malaise B-Disease
are O
again O
the O
most O
frequent O
side O
effects O
. O

evidence O
of O
antitumor O
activity O
has O
been O
seen O
in O
3 O
patients O
. O

pharmacokinetic O
investigations O
have O
shown O
that O
alkaline O
diuresis O
does O
not O
alter O
cb O
3717 O
plasma O
levels O
or O
urinary O
excretion O
and O
that O
satisfactory O
urinary O
alkalinization O
can O
be O
readily O
achieved O
. O

type B-Disease
b B-Disease
hepatitis B-Disease
after O
needle O
- O
stick O
exposure O
: O
prevention O
with O
hepatitis B-Disease
b B-Disease
immune O
globulin O
. O

final O
report O
of O
the O
veterans O
administration O
cooperative O
study O
. O

hepatitis B-Disease
b B-Disease
immune O
globulin O
( O
hbig O
) O
and O
immune O
serum O
globulin O
( O
isg O
) O
were O
examined O
in O
a O
randomized O
, O
double O
- O
blind O
trial O
to O
assess O
their O
relative O
efficacies O
in O
preventing O
type B-Disease
b B-Disease
hepatitis B-Disease
after O
needle O
- O
stick O
exposure O
to O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
- O
positive O
donors O
. O

clinical O
hepatitis B-Disease
developed O
in O
1 O
. O
4 O
% O
of O
hbig O
and O
in O
5 O
. O
9 O
% O
of O
isg O
recipients O
( O
p O
= O
0 O
. O
016 O
) O
, O
and O
seroconversion O
( O
anti O
- O
hbs O
) O
occurred O
in O
5 O
. O
6 O
% O
and O
20 O
. O
7 O
% O
of O
them O
respectively O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

mild O
and O
transient O
side O
- O
effects O
were O
noted O
in O
3 O
. O
0 O
% O
of O
isg O
and O
in O
3 O
. O
2 O
% O
of O
hbig O
recipients O
. O

available O
donor O
sera O
were O
examined O
for O
dna O
polymerase O
( O
dnap O
) O
and O
e O
antigen O
and O
antibody O
( O
hbeag O
; O
anti O
- O
hbe O
) O
. O

both O
dnap O
and O
hbeag O
showed O
a O
highly O
statistically O
significant O
correlation O
with O
the O
infectivity O
of O
hbsag O
- O
positive O
donors O
. O

hepatitis B-Disease
b B-Disease
immune O
globulin O
remained O
significantly O
superior O
to O
isg O
in O
preventing O
type B-Disease
b B-Disease
hepatitis B-Disease
even O
when O
the O
analysis O
was O
confined O
to O
these O
two O
high O
- O
risk O
subgroups O
. O

the O
efficacy O
of O
isg O
in O
preventing O
type B-Disease
b B-Disease
hepatitis B-Disease
cannot O
be O
ascertained O
because O
a O
true O
placebo O
group O
was O
not O
included O
. O

production O
of O
autochthonous O
prostate B-Disease
cancer B-Disease
in O
lobund O
- O
wistar O
rats O
by O
treatments O
with O
n O
- O
nitroso O
- O
n O
- O
methylurea O
and O
testosterone O
. O

more O
than O
50 O
% O
of O
lobund O
- O
wistar O
( O
l O
- O
w O
) O
strain O
rats O
developed O
large O
, O
palpable O
prostate B-Disease
adenocarcinomas B-Disease
( O
pas B-Disease
) O
following O
treatments O
with O
n O
- O
nitroso O
- O
n O
- O
methylurea O
( O
cas O
: O
684 O
- O
93 O
- O
5 O
) O
and O
testosterone O
propionate O
[ O
( O
tp O
) O
cas O
: O
57 O
- O
85 O
- O
2 O
] O
, O
and O
most O
of O
the O
tumor B-Disease
- O
bearing O
rats O
manifested O
metastatic O
lesions O
. O

the O
incubation O
periods O
averaged O
10 O
. O
6 O
months O
. O

within O
the O
same O
timeframe O
, O
no O
l O
- O
w O
rat O
developed O
a O
similar O
palpable O
pa B-Disease
when O
treated O
only O
with O
tp O
. O

in O
l O
- O
w O
rats O
, O
tp O
acted O
as O
a O
tumor B-Disease
enhancement O
agent O
, O
with O
primary O
emphasis O
on O
the O
development O
of O
prostate B-Disease
cancer B-Disease
. O

relative O
efficacy O
and O
toxicity B-Disease
of O
netilmicin O
and O
tobramycin O
in O
oncology O
patients O
. O

we O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin O
sulfate O
or O
tobramycin O
sulfate O
in O
conjunction O
with O
piperacillin O
sodium O
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections B-Disease
. O

the O
two O
treatment O
regimens O
were O
equally O
efficacious O
. O

nephrotoxicity B-Disease
occurred O
in O
a O
similar O
proportion O
in O
patients O
treated O
with O
netilmicin O
and O
tobramycin O
( O
17 O
% O
vs O
11 O
% O
) O
. O

ototoxicity B-Disease
occurred O
in O
four O
( O
9 O
. O
5 O
% O
) O
of O
42 O
netilmicin O
and O
piperacillin O
and O
in O
12 O
( O
22 O
% O
) O
of O
54 O
tobramycin O
and O
piperacillin O
- O
treated O
patients O
. O

of O
those O
evaluated O
with O
posttherapy O
audiograms O
, O
three O
of O
four O
netilmicin O
and O
piperacillin O
- O
treated O
patients O
had O
auditory O
thresholds O
return O
to O
baseline O
compared O
with O
one O
of O
nine O
tobramycin O
and O
piperacillin O
- O
treated O
patients O
. O

the O
number O
of O
greater O
than O
or O
equal O
to O
15 O
- O
db O
increases O
in O
auditory O
threshold O
as O
a O
proportion O
of O
total O
greater O
than O
or O
equal O
to O
15 O
- O
db O
changes O
( O
increases O
and O
decreases O
) O
was O
significantly O
lower O
in O
netilmicin O
and O
piperacillin O
- O
vs O
tobramycin O
and O
piperacillin O
- O
treated O
patients O
( O
18 O
of O
78 O
vs O
67 O
of O
115 O
) O
. O

we O
conclude O
that O
aminoglycoside O
- O
associated O
ototoxicity B-Disease
was O
less O
severe O
and O
more O
often O
reversible O
with O
netilmicin O
than O
with O
tobramycin O
. O

urinary O
enzymes O
and O
protein O
patterns O
as O
indicators O
of O
injury B-Disease
to B-Disease
different B-Disease
regions B-Disease
of B-Disease
the B-Disease
kidney B-Disease
. O

acute B-Disease
experimental B-Disease
models B-Disease
of B-Disease
renal B-Disease
damage B-Disease
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro O
- O
1 O
: O
3 O
- O
butadiene O
( O
hcbd O
) O
, O
puromycin O
aminonucleoside O
( O
pan O
) O
, O
and O
2 O
- O
bromoethylamine O
( O
bea O
) O
, O
respectively O
. O

several O
routine O
indicators O
of O
nephrotoxicity B-Disease
, O
the O
enzymes O
alkaline O
phosphatase O
and O
n O
- O
acetyl O
- O
beta O
- O
glucosaminidase O
, O
and O
the O
molecular O
weight O
of O
protein B-Disease
excretion B-Disease
were O
determined O
on O
urine O
samples O
. O

tubular O
damage O
produced O
by O
hcbd O
or O
bea O
was O
discriminated O
both O
quantitatively O
and O
qualitatively O
from O
glomerular B-Disease
damage B-Disease
produced O
by O
pan O
. O

the O
latter O
was O
characterized O
by O
a O
pronounced O
increase O
in O
protein B-Disease
excretion B-Disease
, O
especially O
proteins O
with O
molecular O
weight O
greater O
than O
40 O
, O
000 O
da O
. O

in O
contrast O
, O
protein B-Disease
excretion B-Disease
in O
tubular O
damage O
was O
raised O
only O
slightly O
and O
characterized O
by O
excretion B-Disease
of B-Disease
proteins B-Disease
of O
a O
wide O
range O
of O
molecular O
weights O
. O

proximal O
tubular O
damage O
caused O
by O
hcbd O
and O
papillary O
damage O
caused O
by O
bea O
were O
distinguished O
both O
by O
conventional O
urinalysis O
( O
volume O
and O
specific O
gravity O
) O
and O
by O
measurement O
of O
the O
two O
urinary O
enzymes O
. O

alkaline O
phosphatase O
and O
glucose O
were O
markedly O
and O
transiently O
elevated O
in O
proximal O
tubular O
damage O
and O
n O
- O
acetyl O
- O
beta O
- O
glucosaminidase O
showed O
a O
sustained O
elevation O
in O
papillary O
damage O
. O

it O
is O
concluded O
that O
both O
selective O
urinary O
enzymes O
and O
the O
molecular O
weight O
pattern O
of O
urinary O
proteins O
can O
be O
used O
to O
provide O
diagnostic O
information O
about O
the O
possible O
site O
of O
renal B-Disease
damage B-Disease
. O

a O
catch O
in O
the O
reye B-Disease
. O

twenty O
- O
six O
cases O
of O
reye B-Disease
syndrome B-Disease
from O
the O
children O
' O
s O
hospital O
, O
camperdown O
, O
australia O
, O
occurring O
between O
1973 O
and O
1982 O
were O
reviewed O
. O

of O
these O
, O
20 O
cases O
met O
the O
us O
public O
health O
service O
centers O
for O
disease O
control O
criteria O
for O
the O
diagnosis O
of O
reye B-Disease
syndrome B-Disease
. O

aspirin O
or O
salicylate O
ingestion O
had O
occurred O
in O
only O
one O
of O
the O
20 O
cases O
( O
5 O
% O
) O
, O
and O
paracetamol O
( O
acetaminophen O
) O
had O
been O
administered O
in O
only O
six O
of O
the O
cases O
( O
30 O
% O
) O
. O

pathologic O
confirmation O
of O
the O
diagnosis O
of O
reye B-Disease
syndrome B-Disease
was O
accomplished O
in O
90 O
% O
of O
the O
cases O
. O

the O
incidence O
of O
reye B-Disease
syndrome B-Disease
in O
new O
south O
wales O
, O
australia O
, O
is O
estimated O
from O
this O
study O
to O
be O
approximately O
nine O
cases O
per O
1 O
million O
children O
compared O
with O
recent O
us O
data O
of O
ten O
to O
20 O
cases O
per O
1 O
million O
children O
and O
three O
to O
seven O
cases O
per O
1 O
million O
children O
in O
great O
britain O
. O

the O
mortality O
for O
these O
reye B-Disease
syndrome B-Disease
cases O
in O
australia O
was O
45 O
% O
as O
compared O
with O
a O
32 O
% O
case O
- O
fatality O
rate O
in O
the O
united O
states O
. O

in O
australia O
, O
the O
pediatric O
usage O
of O
aspirin O
has O
been O
extremely O
low O
for O
the O
past O
25 O
years O
( O
less O
than O
1 O
% O
of O
total O
dosage O
units O
sold O
) O
, O
with O
paracetamol O
( O
acetaminophen O
) O
dominating O
the O
pediatric O
analgesic O
and O
antipyretic O
market O
. O

reye B-Disease
syndrome B-Disease
may O
be O
disappearing O
from O
australia O
despite O
a O
total O
lack O
of O
association O
with O
salicylates O
or O
aspirin O
ingestion O
, O
since O
there O
were O
no O
cases O
found O
at O
the O
children O
' O
s O
hospital O
in O
1983 O
, O
1984 O
, O
or O
1985 O
. O

postpartum O
psychosis B-Disease
induced O
by O
bromocriptine O
. O

two O
multigravida O
patients O
with O
no O
prior O
psychiatric B-Disease
history O
were O
seen O
with O
postpartum O
psychosis B-Disease
, O
having O
received O
bromocriptine O
for O
inhibition B-Disease
of B-Disease
lactation B-Disease
. O

bromocriptine O
given O
in O
high O
doses O
has O
been O
associated O
with O
psychosis B-Disease
in O
patients O
receiving O
the O
drug O
for O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

these O
cases O
demonstrate O
that O
bromocriptine O
may O
cause O
psychosis B-Disease
even O
when O
given O
in O
low O
doses O
. O

hyperglycemic B-Disease
acidotic B-Disease
coma B-Disease
and O
death O
in O
kearns B-Disease
- B-Disease
sayre B-Disease
syndrome B-Disease
. O

this O
paper O
presents O
the O
clinical O
and O
metabolic O
findings O
in O
two O
young O
boys O
with O
long O
- O
standing O
kearns B-Disease
- B-Disease
sayre B-Disease
syndrome B-Disease
. O

following O
short O
exposure O
to O
oral O
prednisone O
, O
both O
boys O
developed O
lethargy B-Disease
, O
increasing O
somnolence B-Disease
, O
polydipsia B-Disease
, O
polyphagia B-Disease
, O
and O
polyuria B-Disease
. O

both O
presented O
in O
the O
emergency O
room O
with O
profound O
coma B-Disease
, O
hypotension B-Disease
, O
severe O
hyperglycemia B-Disease
, O
and O
acidosis B-Disease
. O

nonketotic O
lactic B-Disease
acidosis B-Disease
was O
present O
in O
one O
and O
ketosis B-Disease
without O
a O
known O
serum O
lactate O
level O
was O
present O
in O
the O
other O
. O

respiratory B-Disease
failure B-Disease
rapidly O
ensued O
and O
both O
patients O
expired O
in O
spite O
of O
efforts O
at O
resuscitation O
. O

we O
believe O
these O
two O
cases O
represent O
a O
newly O
described O
and O
catastrophic O
metabolic B-Disease
- B-Disease
endocrine B-Disease
failure B-Disease
in O
the O
kearns B-Disease
- B-Disease
sayre B-Disease
syndrome B-Disease
. O

experimental O
cyclosporine O
nephrotoxicity B-Disease
: O
risk O
of O
concomitant O
chemotherapy O
. O

the O
role O
of O
cyclosporine O
( O
csa O
) O
alone O
or O
in O
combination O
with O
various O
chemotherapeutics O
in O
the O
development O
of O
renal B-Disease
toxicity B-Disease
was O
evaluated O
in O
rats O
. O

administration O
of O
20 O
mg O
/ O
kg O
/ O
day O
csa O
for O
4 O
weeks O
caused O
renal O
functional O
and O
structural O
changes O
similar O
to O
those O
reported O
in O
man O
. O

the O
combined O
administration O
of O
csa O
and O
various O
chemotherapeutic O
drugs O
with O
a O
nephrotoxic B-Disease
potential O
, O
such O
as O
gentamicin O
( O
at O
therapeutic O
doses O
) O
, O
amphothericin O
b O
and O
ketoconazole O
, O
which O
are O
frequently O
used O
in O
immunosuppressed O
patients O
, O
did O
not O
aggravate O
the O
csa O
induced O
toxicity B-Disease
in O
the O
rat O
model O
. O

gentamicin O
at O
toxic O
doses O
, O
however O
, O
increased O
csa O
nephrotoxicity B-Disease
. O

thus O
, O
the O
nephrotoxicity B-Disease
induced O
by O
csa O
has O
a O
different O
pathogenetic O
mechanism O
. O

diuretics O
, O
potassium O
and O
arrhythmias B-Disease
in O
hypertensive B-Disease
coronary B-Disease
disease B-Disease
. O

it O
has O
been O
proposed O
that O
modest O
changes O
in O
plasma O
potassium O
can O
alter O
the O
tendency O
towards O
cardiac B-Disease
arrhythmias B-Disease
. O

if O
this O
were O
so O
, O
patients O
with O
coronary B-Disease
artery B-Disease
disease B-Disease
might O
be O
especially O
susceptible O
. O

thus O
, O
myocardial O
electrical O
excitability O
was O
measured O
in O
patients O
with O
mild O
essential O
hypertension B-Disease
and O
known O
coronary B-Disease
artery B-Disease
disease B-Disease
after O
8 O
weeks O
of O
treatment O
with O
a O
potassium O
- O
conserving O
diuretic O
( O
amiloride O
) O
and O
a O
similar O
period O
on O
a O
potassium O
- O
losing O
diuretic O
( O
chlorthalidone O
) O
in O
a O
randomised O
study O
. O

plasma O
potassium O
concentrations O
were O
on O
average O
1 O
mmol O
/ O
l O
lower O
during O
the O
chlorthalidone O
phase O
compared O
to O
amiloride O
therapy O
. O

blood O
pressure O
and O
volume O
states O
as O
assessed O
by O
bodyweight O
, O
plasma O
renin O
and O
noradrenaline O
( O
norepinephrine O
) O
concentrations O
were O
similar O
on O
the O
2 O
regimens O
. O

compared O
to O
amiloride O
treatment O
, O
the O
chlorthalidone O
phase O
was O
associated O
with O
an O
increased O
frequency O
of O
ventricular B-Disease
ectopic B-Disease
beats B-Disease
( O
24 O
- O
hour O
holter O
monitoring O
) O
and O
a O
higher O
lown O
grading O
, O
increased O
upslope O
and O
duration O
of O
the O
monophasic O
action O
potential O
, O
prolonged O
ventricular O
effective O
refractory O
period O
, O
and O
increased O
electrical O
instability O
during O
programmed O
ventricular O
stimulation O
. O

the O
above O
results O
indicate O
that O
because O
potassium O
- O
losing O
diuretic O
therapy O
can O
increase O
myocardial O
electrical O
excitability O
in O
patients O
with O
ischaemic B-Disease
heart B-Disease
disease B-Disease
, O
even O
minor O
falls O
in O
plasma O
potassium O
concentrations O
are O
probably O
best O
avoided O
in O
such O
patients O
. O

transketolase O
abnormality O
in O
tolazamide O
- O
induced O
wernicke B-Disease
' B-Disease
s B-Disease
encephalopathy B-Disease
. O

we O
studied O
a O
thiamine O
- O
dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic B-Disease
patient O
who O
developed O
wernicke B-Disease
' B-Disease
s B-Disease
encephalopathy B-Disease
when O
treated O
with O
tolazamide O
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[ O
high O
km O
for O
thiamine O
pyrophosphate O
( O
tpp O
) O
] O
, O
as O
previously O
reported O
in O
postalcoholic O
wernicke B-Disease
- B-Disease
korsakoff B-Disease
syndrome B-Disease
. O

in O
addition O
to O
this O
patient O
, O
we O
also O
studied O
this O
enzyme O
from O
three O
diabetic B-Disease
kindreds O
without O
any O
history O
of O
wernicke B-Disease
' B-Disease
s B-Disease
encephalopathy B-Disease
and O
from O
four O
normal O
controls O
. O

we O
found O
that O
the O
above O
- O
mentioned O
patient O
and O
one O
of O
the O
diabetic B-Disease
kindreds O
with O
no O
history O
of O
wernicke B-Disease
' B-Disease
s B-Disease
encephalopathy B-Disease
had O
abnormal O
transketolase O
as O
determined O
by O
its O
km O
for O
tpp O
. O

these O
data O
suggest O
a O
similarity O
between O
postalcoholic O
wernicke B-Disease
- B-Disease
korsakoff B-Disease
syndrome B-Disease
and O
the O
patient O
with O
tolazamide O
- O
induced O
wernicke B-Disease
' B-Disease
s B-Disease
encephalopathy B-Disease
from O
the O
standpoint O
of O
transketolase O
abnormality O
. O

bradycardia B-Disease
due O
to O
trihexyphenidyl O
hydrochloride O
. O

a O
chronic O
schizophrenic B-Disease
patient O
was O
treated O
with O
an O
anticholinergic O
drug O
, O
trihexyphenidyl O
hydrochloride O
. O

the O
patient O
developed O
, O
paradoxically O
, O
sinus O
bradycardia B-Disease
. O

the O
reaction O
was O
specific O
to O
trihexyphenidyl O
and O
not O
to O
other O
anticholinergic O
drugs O
. O

this O
antidyskinetic O
drug O
is O
widely O
used O
in O
clinical O
psychiatric B-Disease
practice O
and O
physicians O
should O
be O
aware O
of O
this O
side O
effect O
. O

post O
- O
operative O
rigidity B-Disease
after O
fentanyl O
administration O
. O

a O
case O
of O
thoraco O
- O
abdominal O
rigidity B-Disease
leading O
to O
respiratory B-Disease
failure B-Disease
is O
described O
in O
the O
post O
- O
operative O
period O
in O
an O
elderly O
patient O
who O
received O
a O
moderate O
dose O
of O
fentanyl O
. O

this O
was O
successfully O
reversed O
by O
naloxone O
. O

the O
mechanisms O
possibly O
implicated O
in O
this O
accident O
are O
discussed O
. O

anti O
- O
carcinogenic B-Disease
action O
of O
phenobarbital O
given O
simultaneously O
with O
diethylnitrosamine O
in O
the O
rat O
. O

the O
present O
work O
has O
been O
planned O
in O
order O
to O
elucidate O
the O
effect O
of O
phenobarbital O
( O
pb O
: O
15 O
mg O
per O
rat O
of O
ingested O
dose O
) O
on O
carcinogenesis B-Disease
when O
it O
is O
administered O
simultaneously O
with O
diethylnitrosamine O
( O
den O
: O
10 O
mg O
/ O
kg O
/ O
day O
) O
. O

wistar O
rats O
( O
180 O
g O
) O
were O
treated O
by O
den O
alone O
or O
by O
den O
+ O
pb O
during O
2 O
, O
4 O
and O
6 O
weeks O
according O
to O
our O
schedule O
for O
hepatocarcinogenesis B-Disease
. O

after O
the O
end O
of O
the O
treatment O
, O
the O
number O
and O
the O
size O
of O
induced O
pas O
positive O
preneoplastic B-Disease
foci B-Disease
was O
significantly O
reduced O
when O
pb O
was O
given O
simultaneously O
with O
den O
for O
4 O
and O
6 O
weeks O
. O

the O
mitotic O
inhibition O
and O
the O
production O
of O
micronuclei O
normally O
observed O
after O
partial O
hepatectomy O
in O
den O
treated O
rats O
were O
also O
significantly O
decreased O
in O
den O
+ O
pb O
treated O
rats O
. O

when O
the O
treatment O
last O
only O
2 O
weeks O
, O
the O
presence O
of O
pb O
did O
not O
change O
significantly O
the O
last O
parameters O
. O

in O
den O
+ O
pb O
treated O
rats O
, O
the O
survival O
was O
prolonged O
and O
the O
tumor B-Disease
incidence O
decreased O
as O
compared O
with O
the O
results O
obtained O
by O
den O
alone O
. O

it O
is O
concluded O
that O
pb O
, O
which O
promotes O
carcinogenesis B-Disease
when O
administered O
after O
the O
den O
treatment O
, O
reduces O
the O
carcinogen O
effect O
when O
given O
simultaneously O
with O
den O
. O

this O
' O
anti O
- O
carcinogen O
' O
effect O
acts O
on O
the O
initiation O
as O
well O
as O
on O
the O
promotion O
of O
the O
precancerous B-Disease
lesions B-Disease
. O

biochemical O
investigations O
are O
in O
progress O
to O
obtain O
more O
information O
about O
this O
' O
paradoxical O
' O
pb O
effect O
. O

bilateral B-Disease
optic B-Disease
neuropathy B-Disease
due O
to O
combined O
ethambutol O
and O
isoniazid O
treatment O
. O

the O
case O
of O
a O
40 O
- O
year O
- O
old O
patient O
who O
underwent O
an O
unsuccessful O
cadaver O
kidney O
transplantation O
and O
was O
treated O
with O
ethambutol O
and O
isoniazid O
is O
reported O
. O

a O
bilateral B-Disease
retrobulbar B-Disease
neuropathy B-Disease
with O
an O
unusual O
central O
bitemporal O
hemianopic O
scotoma B-Disease
was O
found O
. O

ethambutol O
was O
stopped O
and O
only O
small O
improvement O
of O
the O
visual O
acuity O
followed O
. O

isoniazid O
was O
discontinued O
later O
, O
followed O
by O
a O
dramatic O
improvement O
in O
the O
visual O
acuity O
. O

the O
hazards O
of O
optic O
nerve O
toxicity B-Disease
due O
to O
ethambutol O
are O
known O
. O

we O
emphasize O
the O
potential O
danger O
in O
the O
use O
of O
ethambutol O
and O
isoniazid O
. O

a O
prospective O
study O
of O
adverse O
reactions O
associated O
with O
vancomycin O
therapy O
. O

a O
prospective O
evaluation O
of O
the O
efficacy O
and O
safety O
of O
vancomycin O
was O
conducted O
in O
54 O
consecutive O
patients O
over O
a O
16 O
- O
month O
period O
. O

vancomycin O
was O
curative O
in O
95 O
% O
of O
43 O
patients O
with O
proven O
infection B-Disease
. O

drugs O
were O
ceased O
in O
six O
patients O
because O
of O
adverse O
reactions O
; O
in O
three O
of O
these O
vancomycin O
was O
considered O
the O
likely O
cause O
. O

reactions O
included O
thrombophlebitis B-Disease
( O
20 O
of O
54 O
patients O
) O
, O
rash B-Disease
( O
4 O
of O
54 O
) O
, O
nephrotoxicity B-Disease
( O
4 O
of O
50 O
) O
, O
proteinuria B-Disease
( O
1 O
of O
50 O
) O
and O
ototoxicity B-Disease
( O
1 O
of O
11 O
patients O
tested O
by O
audiometry O
) O
. O

thrombophlebitis B-Disease
occurred O
only O
with O
infusion O
through O
peripheral O
cannulae O
; O
nephrotoxicity B-Disease
and O
ototoxicity B-Disease
were O
confined O
to O
patients O
receiving O
an O
aminoglycoside O
plus O
vancomycin O
. O

we O
conclude O
that O
vancomycin O
, O
administered O
appropriately O
, O
constitutes O
safe O
, O
effective O
therapy O
for O
infections B-Disease
caused O
by O
susceptible O
bacteria O
. O

factors O
associated O
with O
nephrotoxicity B-Disease
and O
clinical O
outcome O
in O
patients O
receiving O
amikacin O
. O

data O
from O
60 O
patients O
treated O
with O
amikacin O
were O
analyzed O
for O
factors O
associated O
with O
nephrotoxicity B-Disease
. O

in O
42 O
of O
these O
patients O
, O
data O
were O
examined O
for O
factors O
associated O
with O
clinical O
outcome O
. O

variables O
evaluated O
included O
patient O
weight O
, O
age O
, O
sex O
, O
serum O
creatinine O
level O
, O
creatinine O
clearance O
, O
duration O
of O
therapy O
, O
total O
dose O
, O
mean O
daily O
dose O
, O
organism O
minimum O
inhibitory O
concentration O
( O
mic O
) O
, O
mean O
peak O
levels O
, O
mean O
trough O
levels O
, O
mean O
area O
under O
the O
serum O
concentration O
- O
time O
curve O
( O
auc O
) O
, O
total O
auc O
, O
mean O
auc O
greater O
than O
mic O
, O
total O
auc O
greater O
than O
mic O
, O
mean O
schumacher O
' O
s O
intensity O
factor O
( O
if O
) O
, O
total O
if O
, O
in O
( O
mean O
maximum O
concentration O
[ O
cmax O
] O
/ O
mic O
) O
. O

model O
- O
dependent O
pharmacokinetic O
parameters O
were O
calculated O
by O
computer O
based O
on O
a O
one O
- O
compartment O
model O
. O

when O
the O
parameters O
were O
examined O
individually O
, O
duration O
of O
therapy O
and O
total O
auc O
correlated O
significantly O
( O
p O
less O
than O
. O
05 O
) O
with O
nephrotoxicity B-Disease
. O

in O
contrast O
, O
a O
stepwise O
discriminant O
function O
analysis O
identified O
only O
duration O
of O
therapy O
( O
p O
less O
than O
. O
001 O
) O
as O
an O
important O
factor O
. O

based O
on O
this O
model O
and O
on O
bayes O
' O
theorem O
, O
the O
predictive O
accuracy O
of O
identifying O
" O
nephrotoxic B-Disease
" O
patients O
increased O
from O
0 O
. O
17 O
to O
0 O
. O
39 O
. O

when O
examined O
individually O
, O
mean O
if O
, O
mic O
, O
total O
dose O
, O
mean O
daily O
dose O
, O
and O
ln O
( O
mean O
cmax O
/ O
mic O
) O
correlated O
significantly O
( O
p O
less O
than O
. O
05 O
) O
with O
cure O
. O

in O
contrast O
, O
a O
simultaneous O
multivariable O
analysis O
identified O
if O
, O
mic O
, O
and O
total O
dose O
according O
to O
one O
model O
and O
ln O
( O
mean O
cmax O
/ O
mic O
) O
according O
to O
a O
second O
statistical O
model O
of O
parameters O
selected O
to O
have O
the O
greatest O
prospective O
value O
. O

based O
on O
bayes O
' O
theorem O
and O
the O
first O
model O
, O
the O
predictive O
accuracy O
of O
identifying O
patients O
not O
cured O
increased O
from O
0 O
. O
19 O
to O
0 O
. O
83 O
. O

for O
the O
second O
model O
, O
the O
predictive O
accuracy O
increased O
from O
0 O
. O
19 O
to O
0 O
. O
50 O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

cardiac B-Disease
toxicity B-Disease
of O
5 O
- O
fluorouracil O
. O

report O
of O
a O
case O
of O
spontaneous O
angina B-Disease
. O

we O
report O
a O
case O
of O
a O
patient O
with O
colon B-Disease
carcinoma B-Disease
and O
liver O
metastasis B-Disease
who O
presented O
chest B-Disease
pain B-Disease
after O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
administration O
. O

clinical O
electrocardiographic O
evolution O
was O
similar O
to O
that O
observed O
in O
prinzmetal B-Disease
' B-Disease
s B-Disease
angina B-Disease
, O
and O
chest B-Disease
pain B-Disease
promptly O
resolved O
with O
nifedipine O
. O

these O
data O
suggest O
that O
coronary B-Disease
spasm B-Disease
may O
be O
the O
cause O
of O
cardiotoxicity B-Disease
due O
to O
5 O
- O
fu O
, O
and O
that O
calcium O
antagonists O
may O
probably O
be O
used O
in O
the O
prevention O
or O
treatment O
of O
5 O
- O
fu O
cardiotoxicity B-Disease
. O

dose O
- O
related O
beneficial O
and O
adverse O
effects O
of O
dietary O
corticosterone O
on O
organophosphorus O
- O
induced O
delayed O
neuropathy B-Disease
in O
chickens O
. O

tri O
- O
ortho O
- O
tolyl O
phosphate O
( O
totp O
) O
, O
360 O
mg O
/ O
kg O
, O
po O
, O
and O
0 O
, O
0 O
' O
- O
diisopropyl O
phosphorofluoridate O
( O
dfp O
) O
, O
1 O
mg O
/ O
kg O
sc O
, O
were O
administered O
to O
adult O
white O
leghorn O
chickens O
24 O
hr O
after O
they O
were O
placed O
on O
diets O
containing O
0 O
to O
300 O
ppm O
corticosterone O
. O

supplemented O
diets O
were O
continued O
until O
clinical O
signs O
and O
lesions O
of O
delayed O
neuropathy B-Disease
appeared O
. O

although O
low O
concentrations O
( O
less O
than O
or O
equal O
to O
50 O
ppm O
) O
of O
corticosterone O
had O
beneficial O
effects O
on O
totp O
- O
induced O
neuropathy B-Disease
, O
greater O
than O
or O
equal O
to O
200 O
ppm O
exacerbated O
clinical O
signs O
in O
chickens O
given O
either O
totp O
or O
dfp O
. O

neurotoxic B-Disease
esterase O
activities O
24 O
hr O
after O
totp O
or O
dfp O
were O
less O
than O
20 O
% O
of O
values O
measured O
in O
chickens O
not O
given O
organophosphorous O
compounds O
. O

chickens O
given O
200 O
ppm O
corticosterone O
without O
totp O
or O
dfp O
had O
significantly O
elevated O
activity O
of O
plasma O
cholinesterase O
and O
significantly O
inhibited O
activity O
of O
liver O
carboxylesterase O
. O

degenerating B-Disease
myelinated B-Disease
fibers B-Disease
were O
also O
evident O
in O
distal O
levels O
of O
the O
peripheral O
nerves O
of O
chickens O
given O
totp O
or O
dfp O
. O

hepatotoxicity B-Disease
of O
amiodarone O
. O

amiodarone O
has O
proved O
very O
effective O
in O
the O
treatment O
of O
otherwise O
resistant O
cardiac O
tachyarrhythmias B-Disease
. O

the O
use O
of O
amiodarone O
has O
, O
however O
, O
been O
limited O
due O
to O
its O
serious O
side O
- O
effects O
. O

a O
patient O
with O
cholestatic B-Disease
hepatitis B-Disease
due O
to O
amiodarone O
treatment O
is O
presented O
below O
and O
a O
review O
of O
the O
hepatotoxicity B-Disease
of O
amiodarone O
is O
given O
. O

it O
is O
concluded O
that O
solid O
evidence O
exists O
of O
hepatic B-Disease
injury B-Disease
due O
to O
amiodarone O
treatment O
, O
including O
steatosis B-Disease
, O
alterations O
resembling O
alcoholic B-Disease
hepatitis B-Disease
, O
cholestatic B-Disease
hepatitis B-Disease
and O
micronodular O
cirrhosis B-Disease
of B-Disease
the B-Disease
liver B-Disease
. O

patients O
receiving O
amiodarone O
should O
be O
regularly O
screened O
with O
respect O
to O
hepatic O
enzyme O
levels O
. O

therapy O
should O
be O
discontinued O
on O
the O
suspicion O
of O
cholestatic B-Disease
injury B-Disease
or O
hepatomegaly B-Disease
. O

promotional O
effects O
of O
testosterone O
and O
dietary O
fat O
on O
prostate O
carcinogenesis B-Disease
in O
genetically O
susceptible O
rats O
. O

germfree O
( O
gf O
) O
lobund O
strain O
wistar O
( O
lw O
) O
rats O
, O
fed O
vegetable O
diet O
l O
- O
485 O
, O
have O
developed O
prostate B-Disease
adenocarcinomas B-Disease
spontaneously O
( O
10 O
% O
incidence O
) O
at O
average O
age O
34 O
months O
. O

conventional O
lw O
rats O
, O
implanted O
with O
testosterone O
at O
age O
4 O
months O
, O
developed O
a O
higher O
incidence O
of O
prostate B-Disease
cancer B-Disease
after O
an O
average O
interval O
of O
14 O
months O
: O
24 O
% O
had O
developed O
gross O
tumors B-Disease
, O
and O
40 O
% O
when O
it O
included O
microscopic O
tumors B-Disease
. O

preliminary O
results O
indicate O
that O
testosterone O
- O
treated O
lw O
rats O
that O
were O
fed O
the O
same O
diet O
, O
which O
was O
supplemented O
with O
corn O
oil O
up O
to O
20 O
% O
fat O
, O
developed O
prostate B-Disease
cancer B-Disease
after O
intervals O
of O
6 O
- O
12 O
months O
. O

aged O
gf O
sprague O
- O
dawley O
( O
sd O
) O
rats O
have O
not O
developed O
prostate B-Disease
cancer B-Disease
spontaneously O
. O

conventional O
sd O
rats O
fed O
diet O
l O
- O
485 O
and O
treated O
with O
testosterone O
developed O
only O
prostatitis B-Disease
. O

experimental O
designs O
should O
consider O
genetic O
susceptibility O
as O
a O
basic O
prerequisite O
for O
studies O
on O
experimental O
prostate B-Disease
cancer B-Disease
. O

time O
course O
alterations O
of O
qtc O
interval O
due O
to O
hypaque O
76 O
. O

sequential O
measurement O
of O
qt O
interval O
during O
left O
ventricular O
angiography O
was O
made O
30 O
seconds O
and O
one O
, O
three O
, O
five O
and O
ten O
minutes O
after O
injection O
of O
hypaque O
76 O
. O

the O
subjects O
were O
ten O
patients O
found O
to O
have O
normal O
left O
ventricles O
and O
coronary O
arteries O
. O

significant O
qtc B-Disease
prolongation B-Disease
occurred O
in O
30 O
seconds O
to O
one O
minute O
in O
association O
with O
marked O
hypotension B-Disease
and O
elevation O
of O
cardiac O
output O
. O

rat O
extraocular O
muscle O
regeneration O
. O

repair O
of O
local O
anesthetic O
- O
induced O
damage O
. O

local O
anesthetics O
that O
are O
commonly O
used O
in O
ophthalmic O
surgery O
( O
0 O
. O
75 O
% O
bupivacaine O
hydrochloride O
, O
2 O
. O
0 O
% O
mepivacaine O
hydrochloride O
, O
and O
2 O
. O
0 O
% O
lidocaine O
hydrochloride O
plus O
1 O
: O
100 O
, O
000 O
epinephrine O
) O
were O
injected O
into O
the O
retrobulbar O
area O
of O
rat O
eyes O
. O

controls O
were O
injected O
with O
physiological O
saline O
. O

all O
three O
anesthetics O
produced O
massive O
degeneration O
of O
the O
extraocular O
muscles O
. O

muscle B-Disease
degeneration B-Disease
is O
followed O
by O
regeneration O
of O
the O
damaged O
muscle O
fibers O
. O

in O
addition O
to O
muscle B-Disease
damage B-Disease
, O
severe O
damage O
was O
also O
seen O
in O
harderian O
glands O
, O
especially O
after O
exposure O
to O
mepivacaine O
and O
lidocaine O
plus O
epinephrine O
. O

with O
these O
findings O
in O
rats O
, O
it O
is O
hypothesized O
that O
the O
temporary O
diplopia B-Disease
sometimes O
seen O
in O
patients O
after O
ophthalmic O
surgery O
might O
be O
due O
to O
anesthetic O
- O
induced O
damage O
to O
the O
extraocular O
muscles O
. O

gentamicin O
nephropathy B-Disease
in O
a O
neonate O
. O

the O
clinical O
and O
autopsy O
findings O
in O
a O
premature O
baby O
who O
died O
of O
acute B-Disease
renal B-Disease
failure B-Disease
after O
therapy O
with O
gentamicin O
( O
5 O
mg O
/ O
kg O
/ O
day O
) O
and O
penicillin O
are O
presented O
. O

the O
serum O
gentamicin O
concentration O
had O
reached O
toxic O
levels O
when O
anuria B-Disease
developed O
. O

numerous O
periodic O
acid O
schiff O
( O
pas O
) O
positive O
, O
diastase O
resistant O
cytoplasmic O
inclusion O
bodies O
which O
appeared O
as O
myelin O
figures O
in O
cytosegresomes O
under O
the O
electron O
microscope O
were O
identified O
in O
the O
proximal O
convoluted O
tubules O
. O

the O
pathological O
changes O
induced O
by O
gentamicin O
in O
the O
human O
neonatal O
kidneys O
have O
not O
been O
previously O
reported O
. O

induction O
by O
paracetamol O
of O
bladder B-Disease
and B-Disease
liver B-Disease
tumours B-Disease
in O
the O
rat O
. O

effects O
on O
hepatocyte O
fine O
structure O
. O

groups O
of O
male O
and O
female O
inbred O
leeds O
strain O
rats O
were O
fed O
diets O
containing O
either O
0 O
. O
5 O
% O
or O
1 O
. O
0 O
% O
paracetamol O
by O
weight O
for O
up O
to O
18 O
months O
. O

at O
the O
1 O
. O
0 O
% O
dosage O
level O
, O
20 O
% O
of O
rats O
of O
both O
sexes O
developed O
neoplastic O
nodules O
of O
the O
liver O
, O
a O
statistically O
significant O
incidence O
. O

these O
rats O
also O
showed O
gross O
enlargement O
of O
their O
livers O
and O
an O
increase O
in O
foci O
of O
cellular O
alteration O
, O
the O
latter O
also O
being O
observed O
in O
the O
low O
dosage O
male O
rats O
. O

papillomas B-Disease
of O
the O
transitional O
epithelium O
of O
the O
bladder O
developed O
in O
all O
paracetamol O
- O
treated O
groups O
, O
and O
three O
rats O
bore O
bladder B-Disease
carcinomas B-Disease
. O

however O
, O
significant O
yields O
of O
bladder B-Disease
tumours B-Disease
were O
only O
obtained O
from O
low O
dosage O
females O
and O
high O
dosage O
males O
. O

additionally O
, O
20 O
to O
25 O
% O
of O
paracetamol O
- O
treated O
rats O
developed O
hyperplasia B-Disease
of O
the O
bladder O
epithelium O
, O
which O
was O
not O
coincident O
with O
the O
presence O
of O
bladder B-Disease
calculi B-Disease
. O

a O
low O
yield O
of O
tumours B-Disease
at O
various O
other O
sites O
also O
arose O
following O
paracetamol O
feeding O
. O

an O
electron O
microscope O
study O
of O
the O
livers O
of O
paracetamol O
- O
treated O
rats O
revealed O
ultrastructural O
changes O
in O
the O
hepatocytes O
that O
resemble O
those O
that O
result O
from O
exposure O
to O
a O
variety O
of O
known O
hepatocarcinogens B-Disease
. O

transient O
hemiparesis B-Disease
: O
a O
rare O
manifestation O
of O
diphenylhydantoin O
toxicity B-Disease
. O

report O
of O
two O
cases O
. O

among O
the O
common O
side O
effects O
of O
diphenylhydantoin O
( O
dph O
) O
overdose B-Disease
, O
the O
most O
frequently O
encountered O
neurological O
signs O
are O
those O
of O
cerebellar B-Disease
dysfunction B-Disease
. O

very O
rarely O
, O
the O
toxic O
neurological O
manifestations O
of O
this O
drug O
are O
of O
cerebral O
origin O
. O

two O
patients O
are O
presented O
who O
suffered O
progressive O
hemiparesis B-Disease
due O
to O
dph O
overdose B-Disease
. O

both O
had O
brain O
surgery O
before O
dph O
treatment O
. O

it O
is O
assumed O
that O
patients O
with O
some O
cerebral B-Disease
damage B-Disease
are O
liable O
to O
manifest O
dph O
toxicity B-Disease
as O
focal O
neurological O
signs O
. O

tiapride O
in O
levodopa O
- O
induced O
involuntary B-Disease
movements B-Disease
. O

tiapride O
, O
a O
substituted O
benzamide O
derivative O
closely O
related O
to O
metoclopramide O
, O
reduced O
levodopa O
- O
induced O
peak O
dose O
involuntary B-Disease
movements B-Disease
in O
16 O
patients O
with O
idiopathic B-Disease
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

however O
, O
an O
unacceptable O
increase O
in O
disability O
from O
parkinsonism B-Disease
with O
aggravation O
of O
end O
- O
of O
- O
dose O
akinesia B-Disease
led O
to O
its O
cessation O
in O
14 O
patients O
. O

tiapride O
had O
no O
effect O
on O
levodopa O
- O
induced O
early O
morning O
of O
" O
off O
- O
period O
" O
segmental O
dystonia B-Disease
. O

these O
results O
fail O
to O
support O
the O
notion O
that O
levodopa O
- O
induced O
dyskinesias B-Disease
are O
caused O
by O
overstimulation O
of O
a O
separate O
group O
of O
dopamine O
receptors O
. O

quinidine O
hepatitis B-Disease
. O

long O
- O
term O
administration O
of O
quinidine O
was O
associated O
with O
persistent O
elevation O
of O
serum O
concentrations O
of O
sgot O
, O
lactic O
acid O
dehydrogenase O
, O
and O
alkaline O
phosphatase O
. O

liver O
biopsy O
showed O
active O
hepatitis B-Disease
. O

discontinuance O
of O
quinidine O
therapy O
led O
to O
normalization O
of O
liver O
function O
tests O
. O

a O
challenge O
dose O
of O
quinidine O
caused O
clinical O
symptoms O
and O
abrupt O
elevation O
of O
sgot O
, O
alkaline O
phosphatase O
, O
and O
lactic O
acid O
dehydrogenase O
values O
. O

we O
concluded O
that O
this O
patient O
had O
quinidine O
hepatotoxicity B-Disease
and O
believe O
that O
this O
is O
the O
first O
case O
reported O
with O
liver O
biopsy O
documentation O
. O

this O
report O
also O
suggests O
that O
, O
even O
after O
long O
- O
term O
administration O
, O
the O
hepatic B-Disease
toxicity B-Disease
is O
reversible O
. O

arterial O
thromboembolism B-Disease
in O
patients O
receiving O
systemic O
heparin O
therapy O
: O
a O
complication O
associated O
with O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

arterial O
thromboembolism B-Disease
is O
a O
recognized O
complication O
of O
systemic O
heparin O
therapy O
. O

characteristic O
of O
the O
entity O
is O
arterial B-Disease
occlusion B-Disease
by O
platelet O
- O
fibrin O
thrombi B-Disease
with O
distal O
ischemia B-Disease
occurring O
four O
to O
twenty O
days O
after O
the O
initiation O
of O
heparin O
therapy O
, O
preceded O
by O
profound O
thrombocytopenia B-Disease
with O
platelet O
counts O
in O
the O
range O
of O
30 O
, O
000 O
to O
40 O
, O
000 O
per O
cubic O
millimeter O
. O

the O
clinically O
apparent O
occlusion O
may O
be O
preceded O
by O
gastrointestinal B-Disease
and B-Disease
musculoskeletal B-Disease
symptoms B-Disease
that O
appear O
to O
be O
ischemic B-Disease
in O
origin O
, O
and O
might O
serve O
to O
warn O
the O
clinician O
of O
these O
complications O
. O

previous O
reports O
of O
these O
phenomena O
as O
well O
as O
recent O
studies O
of O
the O
effect O
of O
heparin O
are O
reviewed O
. O

the O
common O
factor O
relating O
thromboembolism B-Disease
and O
thrombocytopenia B-Disease
is O
heparin O
- O
induced O
platelet B-Disease
aggregation B-Disease
. O

appropriate O
treatment O
consists O
of O
discontinuation O
of O
heparin O
, O
and O
anticoagulation O
with O
sodium O
warfarin O
if O
necessary O
. O

vascular O
procedures O
are O
performed O
as O
indicated O
. O

pharmacology O
of O
gyki O
- O
41 O
099 O
( O
chlorpropanol O
, O
tobanum O
) O
a O
new O
potent O
beta O
- O
adrenergic O
antagonist O
. O

the O
compound O
gyki O
- O
41 O
099 O
, O
as O
a O
beta O
- O
adrenergic O
antagonist O
, O
is O
3 O
- O
8 O
times O
more O
potent O
than O
propranolol O
in O
vitro O
and O
in O
vivo O
. O

its O
antiarrhythmic O
effectiveness O
surpasses O
that O
of O
propranolol O
and O
pindolol O
inhibiting O
the O
ouabain O
arrhythmia B-Disease
in O
dogs O
and O
cats O
. O

gyki O
- O
41 O
900 O
has O
a O
negligible O
cardiodepressant O
activity O
; O
it O
is O
not O
cardioselective O
. O

the O
compound O
shows O
a O
rapid O
and O
long O
lasting O
effect O
. O

there O
was O
a O
prolonged O
elimination O
of O
the O
radioactivity O
after O
the O
injection O
of O
14c O
- O
41 O
099 O
to O
rats O
and O
dogs O
. O

the O
half O
life O
of O
the O
unlabeled O
substance O
in O
humans O
was O
more O
than O
10 O
hours O
. O

adverse O
reactions O
to O
bendrofluazide O
and O
propranolol O
for O
the O
treatment O
of O
mild O
hypertension B-Disease
. O

report O
of O
medical O
research O
council O
working O
party O
on O
mild O
to O
moderate O
hypertension B-Disease
. O

participants O
in O
the O
medical O
research O
council O
treatment O
trial O
for O
mild O
hypertension B-Disease
are O
randomly O
allocated O
to O
one O
of O
four O
treatment O
groups O
: O
bendrofluazide O
, O
propranolol O
, O
or O
a O
placebo O
for O
either O
of O
these O
drugs O
. O

the O
trial O
is O
single O
- O
blind O
. O

23 O
582 O
patient O
- O
years O
of O
observation O
have O
been O
completed O
so O
far O
, O
10 O
684 O
on O
active O
drugs O
and O
12 O
898 O
on O
placebos O
. O

the O
results O
show O
an O
association O
between O
bendrofluazide O
treatment O
and O
impotence B-Disease
, O
and O
impotence B-Disease
also O
occurred O
more O
frequently O
in O
patients O
taking O
propranolol O
than O
in O
those O
taking O
placebos O
. O

other O
adverse O
reactions O
significantly O
linked O
with O
active O
drugs O
include O
impaired B-Disease
glucose B-Disease
tolerance B-Disease
in O
men O
and O
women O
and O
gout B-Disease
in O
men O
, O
associated O
with O
bendrofluazide O
treatment O
, O
and O
raynaud B-Disease
' B-Disease
s B-Disease
phenomenon B-Disease
and O
dyspnoea B-Disease
in O
men O
and O
women O
taking O
propranolol O
. O

no O
corneal B-Disease
disease B-Disease
is O
known O
to O
have O
occurred O
in O
the O
propranolol O
group O
. O

mean O
serum O
potassium O
level O
fell O
, O
and O
urea O
and O
uric O
acid O
levels O
rose O
, O
in O
men O
and O
women O
taking O
bendrofluazide O
. O

in O
the O
propranolol O
group O
, O
serum O
potassium O
and O
uric O
acid O
levels O
rose O
in O
both O
sexes O
, O
but O
the O
urea O
level O
rose O
significantly O
in O
women O
only O
. O

serotonergic O
drugs O
, O
benzodiazepines O
and O
baclofen O
block O
muscimol O
- O
induced O
myoclonic B-Disease
jerks B-Disease
in O
a O
strain O
of O
mice O
. O

in O
male O
swiss O
mice O
, O
muscimol O
produced O
myoclonic B-Disease
jerks B-Disease
. O

a O
3 O
mg O
/ O
kg O
( O
i O
. O
p O
. O
) O
dose O
induced O
this O
response O
in O
all O
of O
the O
mice O
tested O
and O
the O
peak O
response O
of O
73 O
jerks O
per O
min O
was O
observed O
between O
27 O
and O
45 O
min O
. O

increasing O
the O
brain O
serotonin O
levels O
by O
the O
administration O
of O
5 O
- O
hydroxytryptophan O
( O
80 O
- O
160 O
mg O
/ O
kg O
) O
in O
combination O
with O
a O
peripheral O
decarboxylase O
inhibitor O
resulted O
in O
an O
inhibition O
of O
the O
muscimol O
effect O
. O

however O
, O
in O
a O
similar O
experiment O
l O
- O
dopa O
( O
80 O
- O
160 O
mg O
/ O
kg O
) O
was O
without O
effect O
. O

in O
doses O
of O
3 O
- O
10 O
mg O
/ O
kg O
, O
the O
serotonin O
receptor O
agonist O
mk O
- O
212 O
caused O
a O
dose O
- O
dependent O
blockade O
of O
the O
response O
of O
muscimol O
. O

of O
the O
benzodiazepines O
, O
clonazepam O
( O
0 O
. O
1 O
- O
0 O
. O
3 O
mg O
/ O
kg O
) O
was O
found O
to O
be O
several O
fold O
more O
potent O
than O
diazepam O
( O
0 O
. O
3 O
- O
3 O
mg O
/ O
kg O
) O
in O
blocking O
the O
myoclonic B-Disease
jerks B-Disease
. O

while O
( O
- O
) O
- O
baclofen O
( O
1 O
- O
3 O
mg O
/ O
kg O
) O
proved O
to O
be O
an O
effective O
antagonist O
of O
muscimol O
, O
its O
( O
+ O
) O
- O
isomer O
( O
5 O
- O
20 O
mg O
/ O
kg O
) O
lacked O
this O
property O
. O

considering O
the O
fact O
that O
5 O
- O
htp O
and O
the O
benzodiazepines O
have O
been O
found O
to O
be O
beneficial O
in O
the O
management O
of O
clinical O
myoclonus B-Disease
, O
the O
muscimol O
- O
induced O
myoclonus B-Disease
seems O
to O
be O
a O
satisfactory O
animal O
model O
that O
may O
prove O
useful O
for O
the O
development O
of O
new O
drug O
treatments O
for O
this O
condition O
. O

our O
present O
study O
indicated O
the O
possible O
value O
of O
mk O
- O
212 O
and O
( O
- O
) O
- O
baclofen O
in O
the O
management O
of O
clinical O
myoclonus B-Disease
. O

adverse O
interaction O
between O
beta O
- O
adrenergic O
blocking O
drugs O
and O
verapamil O
- O
- O
report O
of O
three O
cases O
. O

three O
patients O
with O
ischaemic B-Disease
heart B-Disease
disease B-Disease
developed O
profound O
cardiac B-Disease
failure B-Disease
, O
hypotension B-Disease
and O
bradycardia B-Disease
during O
combined O
therapy O
with O
verapamil O
and O
beta O
- O
adrenergic O
blocking O
drugs O
. O

this O
clinical O
picture O
resolved O
completely O
with O
cessation O
of O
the O
combined O
therapy O
. O

baseline O
left O
ventricular O
function O
, O
assessed O
by O
cardiac O
catheterisation O
or O
nuclear O
angiography O
, O
was O
normal O
in O
two O
patients O
and O
only O
mildly O
reduced O
in O
the O
other O
. O

simultaneously O
administration O
of O
beta O
- O
adrenergic O
blocking O
drugs O
and O
verapamil O
may O
result O
in O
profound O
adverse O
interactions O
and O
should O
only O
be O
administered O
with O
great O
caution O
. O

comparison O
of O
the O
effectiveness O
of O
ranitidine O
and O
cimetidine O
in O
inhibiting O
acid O
secretion O
in O
patients O
with O
gastric O
hypersecretory O
states O
. O

the O
h2 O
- O
histamine O
receptor O
antagonists O
ranitidine O
and O
cimetidine O
were O
compared O
for O
their O
abilities O
to O
control O
gastric O
acid O
hypersecretion O
on O
a O
short O
- O
and O
long O
- O
term O
basis O
in O
22 O
patients O
with O
gastric O
acid O
hypersecretory O
states O
. O

nineteen O
patients O
had O
zollinger B-Disease
- B-Disease
ellison B-Disease
syndrome B-Disease
, O
one O
patient O
had O
systemic B-Disease
mastocytosis B-Disease
, O
and O
two O
patients O
had O
idiopathic O
hypersecretion O
. O

the O
rates O
of O
onset O
of O
the O
action O
of O
cimetidine O
and O
ranitidine O
were O
the O
same O
. O

the O
actions O
of O
both O
drugs O
were O
increased O
by O
anticholinergic O
agents O
, O
and O
there O
was O
a O
close O
correlation O
between O
the O
daily O
maintenance O
dose O
of O
each O
drug O
needed O
to O
control O
acid O
secretion O
. O

however O
, O
ranitidine O
was O
threefold O
more O
potent O
than O
cimetidine O
both O
in O
acute O
inhibition O
studies O
and O
in O
the O
median O
maintenance O
dose O
needed O
( O
1 O
. O
2 O
g O
per O
day O
for O
ranitidine O
and O
3 O
. O
6 O
g O
per O
day O
for O
cimetidine O
) O
. O

sixty O
percent O
of O
the O
males O
developed O
breast O
changes O
or O
impotence B-Disease
while O
taking O
cimetidine O
and O
in O
all O
cases O
these O
changes O
disappeared O
when O
cimetidine O
was O
replaced O
by O
ranitidine O
. O

treatment O
with O
high O
doses O
of O
cimetidine O
( O
one O
to O
60 O
months O
; O
median O
, O
11 O
months O
) O
or O
ranitidine O
( O
two O
to O
31 O
months O
; O
median O
, O
14 O
months O
) O
was O
not O
associated O
with O
hepatic B-Disease
or B-Disease
hematologic B-Disease
toxicity B-Disease
or O
alterations O
of O
serum O
gastrin O
concentrations O
, O
but O
ranitidine O
therapy O
was O
associated O
with O
a O
significantly O
lower O
serum O
creatinine O
level O
than O
seen O
with O
cimetidine O
therapy O
. O

the O
results O
show O
that O
both O
drugs O
can O
adequately O
inhibit O
acid O
secretion O
in O
patients O
with O
gastric O
hypersecretory O
states O
. O

both O
are O
safe O
at O
high O
doses O
, O
but O
ranitidine O
is O
threefold O
more O
potent O
and O
does O
not O
cause O
the O
antiandrogen O
side O
effects O
frequently O
seen O
with O
high O
doses O
of O
cimetidine O
. O

epileptogenic O
properties O
of O
enflurane O
and O
their O
clinical O
interpretation O
. O

three O
cases O
of O
eeg O
changes O
induced O
by O
single O
exposure O
to O
enflurane O
anesthesia O
are O
reported O
. O

in O
one O
patient O
, O
enflurane O
administered O
during O
a O
donor O
nephrectomy O
resulted O
in O
unexpected O
partial O
motor O
seizures B-Disease
. O

until O
the O
cause O
of O
the O
seizures B-Disease
was O
correctly O
identified O
, O
the O
patient O
was O
inappropriately O
treated O
with O
anticonvulsants O
. O

two O
other O
patients O
suffered O
from O
partial O
, O
complex O
and O
generalized O
seizures B-Disease
uncontrolled O
by O
medication O
. O

epileptic B-Disease
foci O
delineated O
and O
activated O
by O
enflurane O
were O
surgically O
ablated O
and O
the O
patients O
are O
now O
seizure B-Disease
- O
free O
. O

previous O
exposures O
to O
enflurane O
have O
to O
be O
disclosed O
to O
avoid O
mistakes O
in O
clinical O
interpretation O
of O
the O
eeg O
. O

on O
the O
other O
hand O
, O
enflurane O
may O
prove O
to O
be O
a O
safe O
fast O
acting O
activator O
of O
epileptic B-Disease
foci O
during O
corticography O
or O
depth O
electrode O
intraoperative O
recordings O
. O

development O
of O
isoproterenol O
- O
induced O
cardiac B-Disease
hypertrophy B-Disease
. O

the O
development O
of O
cardiac B-Disease
hypertrophy B-Disease
was O
studied O
in O
adult O
female O
wistar O
rats O
following O
daily O
subcutaneous O
injections O
of O
isoproterenol O
( O
iso O
) O
( O
0 O
. O
3 O
mg O
/ O
kg O
body O
weight O
) O
. O

a O
time O
course O
was O
established O
for O
the O
change O
in O
tissue O
mass O
, O
rna O
and O
dna O
content O
, O
as O
well O
as O
hydroxyproline O
content O
. O

heart O
weight O
increased O
44 O
% O
after O
8 O
days O
of O
treatment O
with O
a O
half O
time O
of O
3 O
. O
4 O
days O
. O

ventricular O
rna O
content O
was O
elevated O
26 O
% O
after O
24 O
h O
of O
a O
single O
injection O
and O
reached O
a O
maximal O
level O
following O
8 O
days O
of O
therapy O
. O

the O
half O
time O
for O
rna O
accumulation O
was O
2 O
. O
0 O
days O
. O

the O
total O
content O
of O
hydroxyproline O
remained O
stable O
during O
the O
first O
2 O
days O
of O
treatment O
but O
increased O
46 O
% O
after O
4 O
days O
of O
therapy O
. O

ventricular O
dna O
content O
was O
unchanged O
during O
the O
early O
stage O
( O
1 O
- O
4 O
days O
) O
of O
hypertrophic B-Disease
growth O
but O
increased O
to O
a O
new O
steady O
- O
state O
level O
19 O
% O
above O
the O
controls O
after O
8 O
days O
of O
treatment O
. O

intraventricular O
pressures O
and O
coronary O
flow O
measures O
were O
similar O
for O
control O
and O
experimental O
animals O
following O
4 O
days O
of O
developed O
hypertrophy B-Disease
. O

however O
, O
dp O
/ O
dt O
in O
the O
iso O
- O
treated O
hearts O
was O
slightly O
but O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
elevated O
. O

these O
data O
indicate O
that O
the O
adaptive O
response O
to O
iso O
shows O
an O
early O
hypertrophic B-Disease
phase O
( O
1 O
- O
4 O
days O
) O
characterized O
by O
a O
substantial O
increase O
in O
rna O
content O
and O
cardiac O
mass O
in O
the O
absence O
of O
changes O
in O
dna O
. O

however O
, O
prolonged O
stimulation O
( O
8 O
- O
12 O
days O
) O
appears O
to O
represent O
a O
complex O
integration O
of O
both O
cellular O
hypertrophy B-Disease
and O
hyperplasia B-Disease
within O
the O
heart O
. O

multiple O
side O
effects O
of O
penicillamine O
therapy O
in O
one O
patient O
with O
rheumatoid B-Disease
arthritis B-Disease
. O

skin B-Disease
rashes B-Disease
, O
proteinuria B-Disease
, O
systemic B-Disease
lupus B-Disease
erythematosus B-Disease
, O
polymyositis B-Disease
and O
myasthenia B-Disease
gravis B-Disease
have O
all O
been O
recorded O
as O
complications O
of O
penicillamine O
therapy O
in O
patients O
with O
rheumatoid B-Disease
arthritis B-Disease
. O

a O
patient O
who O
had O
developed O
all O
5 O
is O
now O
described O
. O

the O
skin B-Disease
lesion B-Disease
resembled O
elastosis B-Disease
perforans B-Disease
serpiginosa B-Disease
, O
which O
has O
been O
reported O
as O
a O
rare O
side O
effect O
in O
patients O
with O
wilson B-Disease
' B-Disease
s B-Disease
disease B-Disease
but O
not O
in O
patients O
with O
rheumatoid B-Disease
arthritis B-Disease
treated O
with O
penicillamine O
. O

obsolete O
but O
dangerous O
antacid O
preparations O
. O

one O
case O
of O
acute O
hypercalcaemia B-Disease
and O
two O
of O
recurrent O
nephrolithiasis B-Disease
are O
reported O
in O
patients O
who O
had O
regularly O
consumed O
large O
amounts O
of O
calcium O
carbon O
- O
ate O
- O
sodium O
bicarbonate O
powders O
for O
more O
than O
20 O
years O
. O

the O
powders O
had O
been O
obtained O
from O
pharmacists O
unknown O
to O
the O
patients O
' O
medical O
practitioners O
. O

it O
is O
suggested O
that O
these O
preparations O
were O
responsible O
for O
the O
patient O
' O
s O
problems O
, O
and O
that O
such O
powders O
should O
no O
longer O
be O
freely O
obtainable O
. O

doxorubicin O
cardiomyopathy B-Disease
in O
children O
with O
left O
- O
sided O
wilms B-Disease
tumor B-Disease
. O

two O
children O
with O
wilms B-Disease
tumor B-Disease
of O
the O
left O
kidney O
experienced O
severe O
anthracycline O
cardiomyopathy B-Disease
after O
irradiation O
to O
the O
tumor B-Disease
bed O
and O
conventional O
dosage O
of O
doxorubicin O
. O

the O
cardiomyopathy B-Disease
is O
attributed O
1 O
) O
to O
the O
fact O
that O
radiation O
fields O
for O
left O
wilms B-Disease
tumor B-Disease
include O
the O
lower O
portion O
of O
the O
heart O
and O
2 O
) O
to O
the O
interaction O
of O
doxorubicin O
and O
irradiation O
on O
cardiac O
muscle O
. O

it O
is O
recommended O
that O
doxorubicin O
dosage O
be O
sharply O
restricted O
in O
children O
with O
wilms B-Disease
tumor B-Disease
of O
the O
left O
kidney O
who O
receive O
postoperative O
irradiation O
. O

effects O
of O
calcitonin O
on O
rat O
extrapyramidal O
motor O
system O
: O
behavioral O
and O
biochemical O
data O
. O

the O
effects O
of O
i O
. O
v O
. O
c O
. O
injection O
of O
human O
and O
salmon O
calcitonin O
on O
biochemical O
and O
behavioral O
parameters O
related O
to O
the O
extrapyramidal O
motor O
system O
, O
were O
investigated O
in O
male O
rats O
. O

calcitonin O
injection O
resulted O
in O
a O
potentiation O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
a O
partial O
prevention O
of O
apomorphine O
- O
induced O
hyperactivity B-Disease
. O

moreover O
calcitonin O
induced O
a O
significant O
decrease O
in O
nigral O
gad O
activity O
but O
no O
change O
in O
striatal O
da O
and O
dopac O
concentration O
or O
gad O
activity O
. O

the O
results O
are O
discussed O
in O
view O
of O
a O
primary O
action O
of O
calcitonin O
on O
the O
striatonigral O
gabaergic O
pathway O
mediating O
the O
da O
- O
related O
behavioral O
messages O
of O
striatal O
origin O
. O

naloxazone O
pretreatment O
modifies O
cardiorespiratory O
, O
temperature O
, O
and O
behavioral O
effects O
of O
morphine O
. O

behavioral O
and O
cardiorespiratory O
responses O
to O
a O
lethal O
dose O
of O
morphine O
were O
evaluated O
in O
rats O
pretreated O
with O
saline O
or O
naloxazone O
, O
an O
antagonist O
of O
high O
- O
affinity O
mu O
1 O
opioid O
receptors O
. O

pretreatment O
with O
naloxazone O
significantly O
blocked O
morphine O
analgesia B-Disease
, O
catalepsy B-Disease
and O
hypothermia B-Disease
at O
a O
dose O
which O
completely O
eliminated O
high O
- O
affinity O
binding O
in O
brain O
membranes O
. O

moreover O
, O
naloxazone O
significantly O
attenuated O
the O
morphine O
- O
induced O
hypotension B-Disease
and O
respiratory B-Disease
depression B-Disease
, O
whereas O
morphine O
- O
induced O
bradycardia B-Disease
was O
less O
affected O
. O

results O
indicate O
that O
subpopulations O
of O
mu O
receptors O
may O
mediate O
selective O
behavioral O
and O
cardiorespiratory O
responses O
to O
morphine O
. O

modification O
of O
drug O
action O
by O
hyperammonemia B-Disease
. O

pretreatment O
with O
ammonium O
acetate O
( O
nh4ac O
) O
( O
6 O
mmol O
/ O
kg O
s O
. O
c O
. O
) O
approximately O
doubled O
the O
time O
morphine O
- O
treated O
mice O
remained O
on O
a O
hot O
surface O
and O
similarly O
increased O
muscular O
incoordination B-Disease
by O
diazepam O
, O
but O
nh4ac O
treatment O
alone O
had O
no O
effect O
. O

thus O
, O
hyperammonemia B-Disease
is O
capable O
of O
altering O
drug O
action O
and O
must O
be O
considered O
along O
with O
impaired O
drug O
metabolism O
in O
enhanced O
drug O
responses O
associated O
with O
liver B-Disease
disease B-Disease
. O

experiments O
in O
vitro O
showed O
that O
acetylcholine O
- O
induced O
catecholamine O
release O
from O
bovine O
adrenal O
medulla O
is O
depressed O
as O
much O
as O
50 O
% O
by O
0 O
. O
3 O
mm O
nh4ac O
and O
kcl O
- O
induced O
contractions O
of O
guinea O
- O
pig O
ileum O
were O
inhibited O
20 O
% O
by O
5 O
mm O
nh4ac O
. O

addition O
of O
excess O
calcium O
reversed O
the O
depression B-Disease
in O
both O
tissues O
, O
but O
calcium O
- O
independent O
catecholamine O
release O
by O
acetaldehyde O
was O
not O
blocked O
by O
nh4ac O
. O

these O
results O
suggested O
that O
ammonia O
blocks O
calcium O
channels O
. O

parallels O
in O
the O
actions O
of O
nh4ac O
and O
the O
calcium O
channel O
blocker O
verapamil O
support O
this O
concept O
. O

both O
verapamil O
( O
10 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
and O
nh4ac O
pretreatment O
enhanced O
morphine O
analgesia B-Disease
- O
and O
diazepam O
- O
induced O
muscular O
incoordination B-Disease
and O
antagonized O
amphetamine O
- O
induced O
motor O
activity O
, O
and O
neither O
verapamil O
nor O
nh4ac O
affected O
the O
convulsant O
action O
of O
metrazol O
. O

the O
data O
suggest O
that O
hyperammonemia B-Disease
exerts O
a O
calcium O
channel O
blocking O
action O
which O
enhances O
the O
effects O
of O
central O
nervous O
system O
depressants O
and O
certain O
opioid O
analgesics O
. O

levodopa O
- O
induced O
dyskinesia B-Disease
and O
thalamotomy O
. O

levodopa O
- O
induced O
dyskinesia B-Disease
of O
the O
limbs O
in O
thirteen O
cases O
of O
parkinsonism B-Disease
, O
which O
was O
choreic O
, O
ballistic O
or O
dystonic B-Disease
in O
type O
, O
was O
alleviated O
almost O
completely O
by O
stereotaxic O
surgery O
using O
a O
microelectrode O
technique O
for O
the O
ventralis O
oralis O
anterior O
and O
posterior O
nuclei O
of O
the O
thalamus O
, O
but O
much O
less O
by O
the O
ventralis O
intermedius O
nucleus O
. O

control O
of O
levodopa O
- O
induced O
dyskinesias B-Disease
by O
thalamic B-Disease
lesions B-Disease
in O
the O
course O
of O
routine O
treatment O
of O
parkinsonism B-Disease
is O
discussed O
. O

treatment O
of O
ifosfamide O
- O
induced O
urothelial B-Disease
toxicity B-Disease
by O
oral O
administration O
of O
sodium O
2 O
- O
mercaptoethane O
sulphonate O
( O
mesna O
) O
to O
patients O
with O
inoperable O
lung B-Disease
cancer B-Disease
. O

the O
protective O
effect O
of O
oral O
administration O
of O
the O
thiol O
compound O
sodium O
2 O
- O
mercaptoethane O
sulphonate O
( O
mesna O
) O
against O
urothelial B-Disease
toxicity B-Disease
induced O
by O
ifosfamide O
( O
if O
) O
was O
tested O
in O
a O
group O
of O
45 O
patients O
with O
inoperable O
lung B-Disease
cancer B-Disease
under O
treatment O
with O
if O
( O
2250 O
mg O
/ O
m2 O
on O
days O
2 O
- O
5 O
) O
as O
part O
of O
a O
polychemotherapy O
regimen O
repeated O
in O
a O
4 O
- O
week O
cycle O
. O

mesna O
was O
given O
orally O
on O
the O
days O
of O
treatment O
with O
if O
in O
3 O
doses O
of O
840 O
mg O
/ O
m2 O
, O
each O
administered O
at O
0 O
hr O
( O
= O
injection O
of O
if O
) O
, O
4 O
hr O
and O
8 O
hr O
p O
. O
i O
. O

out O
of O
a O
total O
of O
88 O
courses O
of O
this O
treatment O
we O
observed O
10 O
episodes O
of O
asymptomatic O
microscopic O
haematuria B-Disease
and O
no O
episodes O
of O
gross O
haematuria B-Disease
. O

in O
this O
group O
of O
45 O
patients O
under O
protection O
with O
mesna O
there O
were O
5 O
complete O
remissions O
and O
9 O
partial O
remissions O
( O
total O
31 O
% O
) O
. O

a O
further O
group O
of O
25 O
patients O
under O
polychemotherapy O
with O
if O
were O
treated O
by O
conventional O
prophylactic O
measures O
( O
raised O
fluid O
intake O
and O
forced O
diuresis O
) O
. O

in O
this O
group O
there O
were O
1 O
complete O
and O
5 O
partial O
remissions O
( O
total O
24 O
% O
) O
, O
but O
nearly O
all O
patients O
developed O
either O
gross O
haematuria B-Disease
and O
/ O
or O
symptoms O
of O
bladder B-Disease
irritation B-Disease
( O
cystitis B-Disease
and O
pollakisuria B-Disease
) O
. O

there O
were O
no O
appreciable O
differences O
between O
the O
mesna O
series O
and O
the O
conventional O
prophylaxis O
series O
with O
respect O
to O
either O
haematological O
or O
systemic O
toxicity B-Disease
of O
the O
cytostatic O
treatment O
. O

our O
results O
support O
the O
view O
that O
mesna O
, O
given O
orally O
in O
conjunction O
with O
combined O
cytostatic O
regimens O
which O
include O
if O
, O
simplifies O
the O
treatment O
and O
provides O
optimum O
protection O
for O
the O
urinary O
epithelium O
. O

protection O
with O
oral O
mesna O
is O
particularly O
suitable O
for O
outpatients O
. O

myoclonic B-Disease
, B-Disease
atonic B-Disease
, B-Disease
and B-Disease
absence B-Disease
seizures B-Disease
following O
institution O
of O
carbamazepine O
therapy O
in O
children O
. O

five O
children O
, O
aged O
3 O
to O
11 O
years O
, O
treated O
with O
carbamazepine O
for O
epilepsy B-Disease
, O
had O
an O
acute O
aberrant O
reaction O
characterized O
by O
the O
onset O
of O
myoclonic B-Disease
, B-Disease
atypical B-Disease
absence B-Disease
and B-Disease
/ B-Disease
or B-Disease
atonic B-Disease
( B-Disease
minor B-Disease
motor B-Disease
) B-Disease
seizures B-Disease
within O
a O
few O
days O
. O

when O
the O
carbamazepine O
was O
discontinued O
, O
two O
of O
the O
children O
returned O
to O
their O
former O
state O
very O
quickly O
, O
two O
had O
the O
minor O
motor O
seizures B-Disease
resolve O
in O
3 O
and O
6 O
months O
, O
and O
one O
had O
the O
seizures B-Disease
persist O
. O

the O
child O
in O
whom O
the O
seizures B-Disease
persisted O
was O
later O
found O
to O
have O
ceroid B-Disease
lipofuscinosis B-Disease
. O

the O
other O
children O
are O
doing O
well O
on O
other O
anticonvulsants O
. O

effect O
of O
prostaglandin O
synthetase O
inhibitors O
on O
experimentally O
induced O
convulsions B-Disease
in O
rats O
. O

to O
investigate O
the O
relationship O
of O
prostaglandins O
( O
pgs O
) O
to O
seizure B-Disease
induction O
, O
the O
effects O
of O
six O
pg O
synthetase O
inhibitors O
on O
convulsions B-Disease
induced O
by O
flurothyl O
, O
picrotoxin O
, O
pentetrazol O
( O
ptz O
) O
, O
electroshock O
or O
bicuculline O
were O
evaluated O
. O

ibuprofen O
, O
sulindac O
, O
mefenamic O
acid O
, O
and O
low O
dose O
meclofenamic O
acid O
increased O
the O
latency O
- O
to O
- O
onset O
in O
the O
flurothyl O
and O
/ O
or O
ptz O
models O
; O
the O
electroshock O
, O
picrotoxin O
and O
bicuculline O
models O
were O
not O
significantly O
affected O
by O
any O
of O
the O
pretreatment O
agents O
. O

these O
results O
suggest O
that O
pgs O
are O
involved O
in O
the O
mechanism O
( O
s O
) O
underlying O
fluorthyl O
- O
and O
ptz O
- O
induced O
convulsions B-Disease
, O
but O
not O
picrotoxin O
- O
, O
electroshock O
- O
, O
or O
bicuculline O
- O
induced O
convulsions B-Disease
. O

acute O
changes O
of O
blood O
ammonia O
may O
predict O
short O
- O
term O
adverse O
effects O
of O
valproic O
acid O
. O

valproic O
acid O
( O
vpa O
) O
was O
given O
to O
24 O
epileptic B-Disease
patients O
who O
were O
already O
being O
treated O
with O
other O
antiepileptic O
drugs O
. O

a O
standardized O
loading O
dose O
of O
vpa O
was O
administered O
, O
and O
venous O
blood O
was O
sampled O
at O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
hours O
. O

ammonia O
( O
nh3 O
) O
was O
higher O
in O
patients O
who O
, O
during O
continuous O
therapy O
, O
complained O
of O
drowsiness B-Disease
( O
7 O
patients O
) O
than O
in O
those O
who O
were O
symptom O
- O
free O
( O
17 O
patients O
) O
, O
although O
vpa O
plasma O
levels O
were O
similar O
in O
both O
groups O
. O

by O
measuring O
vpa O
- O
induced O
changes O
of O
blood O
nh3 O
content O
, O
it O
may O
be O
possible O
to O
identify O
patients O
at O
higher O
risk O
of O
obtundation O
when O
vpa O
is O
given O
chronically O
. O

effect O
of O
captopril O
on O
pre O
- O
existing O
and O
aminonucleoside O
- O
induced O
proteinuria B-Disease
in O
spontaneously O
hypertensive B-Disease
rats O
. O

proteinuria B-Disease
is O
a O
side O
effect O
of O
captopril O
treatment O
in O
hypertensive B-Disease
patients O
. O

the O
possibility O
of O
reproducing O
the O
same O
renal B-Disease
abnormality B-Disease
with O
captopril O
was O
examined O
in O
shr O
. O

oral O
administration O
of O
captopril O
at O
100 O
mg O
/ O
kg O
for O
14 O
days O
failed O
to O
aggravate O
proteinuria B-Disease
pre O
- O
existing O
in O
shr O
. O

also O
, O
captopril O
treatment O
failed O
to O
potentiate O
or O
facilitate O
development O
of O
massive O
proteinuria B-Disease
invoked O
by O
puromycin O
aminonucleoside O
in O
shr O
. O

captopril O
had O
little O
or O
no O
demonstrable O
effects O
on O
serum O
electrolyte O
concentrations O
, O
excretion O
of O
urine O
, O
sodium O
and O
potassium O
, O
endogenous O
creatinine O
clearance O
, O
body O
weight O
, O
and O
food O
and O
water O
consumption O
. O

however O
, O
ketone O
bodies O
were O
consistently O
present O
in O
urine O
and O
several O
lethalities O
occurred O
during O
multiple O
dosing O
of O
captopril O
in O
shr O
. O

complete O
heart B-Disease
block B-Disease
following O
a O
single O
dose O
of O
trazodone O
. O

forty O
minutes O
after O
receiving O
a O
single O
starting O
dose O
of O
trazodone O
, O
a O
patient O
developed O
complete O
heart B-Disease
block B-Disease
. O

the O
case O
illustrates O
that O
, O
despite O
the O
results O
of O
earlier O
studies O
, O
trazodone O
' O
s O
effect O
on O
cardiac O
conduction O
may O
be O
severe O
in O
individuals O
at O
risk O
for O
conduction O
delay O
. O

phenobarbital O
- O
induced O
dyskinesia B-Disease
in O
a O
neurologically B-Disease
- B-Disease
impaired B-Disease
child O
. O

a O
2 O
- O
year O
- O
old O
child O
with O
known O
neurologic B-Disease
impairment B-Disease
developed O
a O
dyskinesia B-Disease
soon O
after O
starting O
phenobarbital O
therapy O
for O
seizures B-Disease
. O

known O
causes O
of O
movement B-Disease
disorders B-Disease
were O
eliminated O
after O
evaluation O
. O

on O
repeat O
challenge O
with O
phenobarbital O
, O
the O
dyskinesia B-Disease
recurred O
. O

phenobarbital O
should O
be O
added O
to O
the O
list O
of O
anticonvulsant O
drugs O
that O
can O
cause O
movement B-Disease
disorders B-Disease
. O

effects O
of O
amine O
pretreatment O
on O
ketamine O
catatonia B-Disease
in O
pinealectomized O
or O
hypophysectomized O
animals O
. O

the O
present O
studies O
were O
designed O
to O
clarify O
the O
role O
of O
catecholamines O
and O
pineal O
idolamines O
on O
ketamine O
- O
induced O
catatonia B-Disease
in O
the O
intact O
, O
pinealectomized O
or O
hypophysectomized O
chick O
and O
rat O
. O

in O
the O
pinealectomized O
chick O
, O
pretreatment O
with O
dopamine O
increased O
the O
duration O
of O
catatonia B-Disease
( O
doc O
) O
after O
ketamine O
, O
but O
pretreatment O
with O
norepinephrine O
did O
not O
. O

the O
pineal O
indolamines O
exhibited O
mixed O
actions O
. O

serotonin O
and O
n O
- O
acetyl O
serotonin O
which O
augmented O
ketamine O
doc O
, O
did O
not O
do O
so O
in O
the O
absence O
of O
the O
pineal O
gland O
, O
whereas O
melatonin O
potentiated O
the O
ketamine O
doc O
in O
both O
the O
intact O
and O
pinealectomized O
chick O
. O

ketamine O
was O
more O
potent O
in O
the O
hypophysectomized O
chick O
and O
the O
circadian O
rhythm O
noted O
in O
the O
intact O
chick O
was O
absent O
; O
furthermore O
, O
melatonin O
did O
not O
augment O
the O
ketamine O
doc O
whereas O
dopamine O
continued O
to O
do O
so O
. O

this O
study O
did O
not O
demonstrate O
a O
species O
difference O
regarding O
the O
role O
of O
the O
amines O
on O
the O
pineal O
in O
spite O
of O
the O
immature O
blood O
- O
brain O
barrier O
in O
the O
young O
chick O
and O
the O
intact O
barrier O
in O
the O
rat O
. O

in O
addition O
, O
these O
data O
indicate O
a O
direct O
role O
of O
the O
pituitary O
in O
the O
augmentation O
of O
ketamine O
doc O
induced O
by O
melatonin O
. O

furthermore O
, O
dopamine O
appeared O
to O
act O
on O
systems O
more O
closely O
involved O
with O
the O
induction O
of O
ketamine O
catatonia B-Disease
rather O
than O
directly O
on O
the O
pituitary O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
, O
thrombosis B-Disease
, O
and O
hemorrhage B-Disease
. O

sixty O
- O
two O
patients O
with O
a O
heparin O
- O
induced O
thrombocytopenia B-Disease
are O
reported O
. O

clinical O
manifestations O
of O
this O
disorder O
include O
hemorrhage B-Disease
or O
, O
more O
frequently O
, O
thromboembolic B-Disease
events O
in O
patients O
receiving O
heparin O
. O

laboratory O
testing O
has O
revealed O
a B-Disease
falling B-Disease
platelet B-Disease
count B-Disease
, O
increased O
resistance O
to O
heparin O
, O
and O
aggregation O
of O
platelets O
by O
the O
patient O
' O
s O
plasma O
when O
heparin O
is O
added O
. O

immunologic O
testing O
has O
demonstrated O
the O
presence O
of O
a O
heparin O
- O
dependent O
platelet O
membrane O
antibody O
. O

the O
20 O
deaths O
, O
52 O
hemorrhagic B-Disease
and B-Disease
thromboembolic B-Disease
complications B-Disease
, O
and O
21 O
surgical O
procedures O
to O
manage O
the O
complications O
confirm O
the O
seriousness O
of O
the O
disorder O
. O

specific O
risk O
factors O
have O
not O
been O
identified O
; O
therefore O
, O
all O
patients O
receiving O
heparin O
should O
be O
monitored O
. O

if O
the O
platelet O
count O
falls O
to O
less O
than O
100 O
, O
000 O
/ O
mm3 O
, O
while O
the O
patient O
is O
receiving O
heparin O
, O
platelet B-Disease
aggregation B-Disease
testing O
, O
using O
the O
patient O
' O
s O
plasma O
, O
is O
indicated O
. O

management O
consists O
of O
cessation O
of O
heparin O
, O
platelet O
anti O
- O
aggregating O
agents O
, O
and O
alternate O
forms O
of O
anticoagulation O
when O
indicated O
. O

ventricular B-Disease
fibrillation B-Disease
from O
diatrizoate O
with O
and O
without O
chelating O
agents O
. O

the O
toxicity B-Disease
of O
renografin O
76 O
% O
was O
compared O
with O
that O
of O
hypaque O
76 O
% O
by O
selective O
injection O
of O
each O
into O
the O
right O
coronary O
artery O
of O
dogs O
. O

renografin O
contains O
the O
chelating O
agents O
sodium O
citrate O
and O
disodium O
edetate O
, O
while O
hypaque O
contains O
calcium O
disodium O
edetate O
and O
no O
sodium O
citrate O
. O

ventricular B-Disease
fibrillation B-Disease
occurred O
significantly O
more O
often O
with O
renografin O
, O
suggesting O
that O
chelating O
agents O
contribute O
to O
toxicity B-Disease
in O
coronary O
angiography O
. O

long O
- O
term O
efficacy O
and O
toxicity B-Disease
of O
high O
- O
dose O
amiodarone O
therapy O
for O
ventricular B-Disease
tachycardia B-Disease
or O
ventricular B-Disease
fibrillation B-Disease
. O

amiodarone O
was O
administered O
to O
154 O
patients O
who O
had O
sustained O
, O
symptomatic O
ventricular B-Disease
tachycardia B-Disease
( O
vt B-Disease
) O
( O
n O
= O
118 O
) O
or O
a O
cardiac B-Disease
arrest B-Disease
( O
n O
= O
36 O
) O
and O
who O
were O
refractory O
to O
conventional O
antiarrhythmic O
drugs O
. O

the O
loading O
dose O
was O
800 O
mg O
/ O
day O
for O
6 O
weeks O
and O
the O
maintenance O
dose O
was O
600 O
mg O
/ O
day O
. O

sixty O
- O
nine O
percent O
of O
patients O
continued O
treatment O
with O
amiodarone O
and O
had O
no O
recurrence O
of O
symptomatic O
vt B-Disease
or O
ventricular B-Disease
fibrillation B-Disease
( O
vf B-Disease
) O
over O
a O
follow O
- O
up O
of O
6 O
to O
52 O
months O
( O
mean O
+ O
/ O
- O
standard O
deviation O
14 O
. O
2 O
+ O
/ O
- O
8 O
. O
2 O
) O
. O

six O
percent O
of O
the O
patients O
had O
a O
nonfatal O
recurrence O
of O
vt B-Disease
and O
were O
successfully O
managed O
by O
continuing O
amiodarone O
at O
a O
higher O
dose O
or O
by O
the O
addition O
of O
a O
conventional O
antiarrhythmic O
drug O
. O

one O
or O
more O
adverse O
drug O
reactions O
occurred O
in O
51 O
% O
of O
patients O
. O

adverse O
effects O
forced O
a O
reduction O
in O
the O
dose O
of O
amiodarone O
in O
41 O
% O
and O
discontinuation O
of O
amiodarone O
in O
10 O
% O
of O
patients O
. O

the O
most O
common O
symptomatic O
adverse O
reactions O
were O
tremor B-Disease
or O
ataxia B-Disease
( O
35 O
% O
) O
, O
nausea B-Disease
and O
anorexia B-Disease
( O
8 O
% O
) O
, O
visual B-Disease
halos B-Disease
or B-Disease
blurring B-Disease
( O
6 O
% O
) O
, O
thyroid B-Disease
function B-Disease
abnormalities B-Disease
( O
6 O
% O
) O
and O
pulmonary B-Disease
interstitial B-Disease
infiltrates B-Disease
( O
5 O
% O
) O
. O

although O
large O
- O
dose O
amiodarone O
is O
highly O
effective O
in O
the O
long O
- O
term O
treatment O
of O
vt B-Disease
or O
vf B-Disease
refractory O
to O
conventional O
antiarrhythmic O
drugs O
, O
it O
causes O
significant O
toxicity B-Disease
in O
approximately O
50 O
% O
of O
patients O
. O

however O
, O
when O
the O
dose O
is O
adjusted O
based O
on O
clinical O
response O
or O
the O
development O
of O
adverse O
effects O
, O
75 O
% O
of O
patients O
with O
vt B-Disease
or O
vf B-Disease
can O
be O
successfully O
managed O
with O
amiodarone O
. O

why O
may O
epsilon O
- O
aminocaproic O
acid O
( O
eaca O
) O
induce O
myopathy B-Disease
in O
man O
? O

report O
of O
a O
case O
and O
literature O
review O
. O

a O
case O
of O
necrotizing B-Disease
myopathy B-Disease
due O
to O
a O
short O
epsilon O
- O
aminocaproic O
acid O
( O
eaca O
) O
treatment O
in O
a O
72 O
year O
- O
old O
patient O
with O
subarachnoid B-Disease
haemorrhage B-Disease
( O
sah B-Disease
) O
is O
described O
. O

pathogenetic O
hypotheses O
are O
discussed O
. O

cerebral B-Disease
hemorrhage B-Disease
associated O
with O
phenylpropanolamine O
in O
combination O
with O
caffeine O
. O

phenylpropanolamine O
( O
ppa O
) O
is O
a O
drug O
that O
has O
been O
associated O
with O
serious O
side O
effects O
including O
stroke B-Disease
. O

it O
is O
often O
combined O
with O
caffeine O
in O
diet O
preparations O
and O
" O
look O
- O
alike O
" O
pills O
. O

in O
order O
to O
determine O
if O
ppa O
/ O
caffeine O
can O
lead O
to O
stroke B-Disease
in O
normotensive O
and O
/ O
or O
hypertensive B-Disease
rats O
, O
we O
administered O
the O
combination O
in O
six O
times O
the O
allowed O
human O
dose O
calculated O
on O
a O
per O
weight O
basis O
for O
the O
rats O
two O
times O
per O
day O
for O
five O
days O
. O

subarachnoid B-Disease
and B-Disease
cerebral B-Disease
hemorrhage B-Disease
was O
noted O
in O
18 O
% O
of O
the O
hypertensive B-Disease
rats O
. O

a O
single O
ppa O
/ O
caffeine O
administration O
( O
same O
dose O
) O
lead O
to O
acute O
hypertension B-Disease
in O
both O
the O
normotensive O
and O
hypertensive B-Disease
animals O
. O

these O
results O
suggest O
that O
ppa O
/ O
caffeine O
can O
lead O
to O
cerebral B-Disease
hemorrhage B-Disease
in O
previously O
hypertensive B-Disease
animals O
when O
administered O
in O
greater O
than O
the O
allowed O
dosage O
. O

an O
acute O
elevation O
in O
blood O
pressure O
may O
be O
a O
contributing O
factor O
. O

renal B-Disease
papillary B-Disease
necrosis B-Disease
due O
to O
naproxen O
. O

a O
31 O
- O
year O
- O
old O
man O
with O
rheumatoid B-Disease
arthritis B-Disease
, O
who O
had O
previously O
been O
treated O
with O
sulindac O
, O
fenoprofen O
calcium O
, O
high O
dose O
salicylates O
and O
gold O
salts O
, O
developed O
renal B-Disease
papillary B-Disease
necrosis B-Disease
( O
rpn B-Disease
) O
4 O
months O
after O
institution O
of O
naproxen O
therapy O
. O

no O
other O
factor O
predisposing O
to O
rpn B-Disease
could O
be O
discovered O
. O

sulindac O
was O
substituted O
for O
naproxen O
and O
no O
further O
adverse O
renal O
effects O
occurred O
over O
the O
next O
12 O
months O
. O

we O
review O
previous O
reports O
linking O
rpn B-Disease
to O
antiinflammatory O
drug O
use O
and O
discuss O
possible O
advantages O
of O
sulindac O
in O
patients O
who O
have O
experienced O
renal B-Disease
toxicity B-Disease
from O
other O
antiinflammatory O
agents O
. O

nephrotoxic B-Disease
effects O
of O
aminoglycoside O
treatment O
on O
renal O
protein O
reabsorption O
and O
accumulation O
. O

to O
quantify O
the O
effects O
of O
gentamicin O
, O
kanamycin O
and O
netilmicin O
on O
renal O
protein O
reabsorption O
and O
accumulation O
, O
these O
drugs O
were O
administered O
to O
rats O
intraperitoneally O
( O
30 O
mg O
/ O
kg O
/ O
day O
) O
for O
7 O
, O
14 O
or O
21 O
days O
. O

scanning O
electron O
microscopy O
of O
the O
glomerular O
endothelia O
, O
urinary O
measurements O
of O
sodium O
, O
potassium O
, O
endogenous O
lysozyme O
, O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
nag O
) O
as O
well O
as O
clearance O
and O
accumulation O
experiments O
after O
i O
. O
v O
. O
administration O
of O
egg O
- O
white O
lysozyme O
and O
measurements O
of O
inulin O
clearance O
( O
gfr O
) O
were O
done O
in O
each O
treatment O
group O
. O

gentamicin O
administration O
decreased O
diameter O
, O
density O
and O
shape O
of O
endothelial O
fenestrae O
. O

kanamycin O
and O
netilmicin O
appeared O
to O
have O
no O
effect O
at O
the O
dose O
used O
. O

all O
three O
aminoglycosides O
decreased O
gfr O
and O
increased O
urinary O
excretion O
of O
sodium O
and O
potassium O
. O

while O
gentamicin O
and O
kanamycin O
decreased O
the O
percentage O
reabsorption O
and O
accumulation O
of O
lysozyme O
after O
i O
. O
v O
. O
administration O
of O
egg O
- O
white O
lysozyme O
netilmicin O
had O
no O
effect O
. O

daily O
excretion O
of O
total O
protein O
, O
endogenous O
lysozyme O
and O
nag O
increased O
only O
after O
treatment O
with O
kanamycin O
and O
gentamicin O
. O

thus O
, O
aminoglycosides O
may O
act O
as O
nephrotoxicants O
at O
glomerular O
and O
/ O
or O
tubular O
level O
inducing O
impairment B-Disease
of B-Disease
renal B-Disease
reabsorption B-Disease
and O
accumulation O
of O
proteins O
. O

induction O
of O
the O
obstructive B-Disease
sleep B-Disease
apnea B-Disease
syndrome B-Disease
in O
a O
woman O
by O
exogenous O
androgen O
administration O
. O

we O
documented O
airway O
occlusion O
during O
sleep O
and O
an O
abnormally O
high O
supraglottic O
resistance O
while O
awake O
in O
a O
54 O
- O
yr O
- O
old O
woman O
who O
had O
developed O
physical O
changes O
and O
the O
syndrome B-Disease
of B-Disease
obstructive B-Disease
sleep B-Disease
apnea B-Disease
while O
being O
administered O
exogenous O
androgens O
. O

when O
the O
androgens O
were O
withdrawn O
, O
the O
patient O
' O
s O
physical O
changes O
, O
symptoms O
, O
sleep O
study O
, O
and O
supraglottic O
resistance O
all O
returned O
to O
normal O
. O

a O
rechallenge O
with O
androgen O
produced O
symptoms O
of O
obstructive B-Disease
sleep B-Disease
apnea B-Disease
that O
abated O
upon O
withdrawal O
of O
the O
hormone O
. O

previous O
reports O
have O
favored O
a O
role O
of O
androgens O
in O
the O
pathogenesis O
of O
sleep B-Disease
apnea B-Disease
. O

our O
report O
provides O
direct O
evidence O
for O
this O
role O
. O

structural O
and O
functional O
measurements O
indicate O
that O
androgens O
exert O
a O
permissive O
or O
necessary O
action O
on O
the O
structural O
configuration O
of O
the O
oropharynx O
that O
predisposes O
to O
obstruction O
during O
sleep O
. O

development O
of O
the O
obstructive B-Disease
sleep B-Disease
apnea B-Disease
syndrome B-Disease
must O
be O
considered O
a O
possible O
side O
effect O
of O
androgen O
therapy O
. O

cardiotoxic B-Disease
and O
possible O
leukemogenic O
effects O
of O
adriamycin O
in O
nonhuman O
primates O
. O

10 O
monkeys O
( O
macaques O
) O
received O
adriamycin O
by O
monthly O
intravenous O
injections O
at O
12 O
mg O
/ O
m2 O
( O
1 O
mg O
/ O
kg O
) O
. O

8 O
of O
the O
10 O
monkeys O
developed O
congestive B-Disease
heart B-Disease
failure B-Disease
at O
an O
average O
cumulative O
adriamycin O
dose O
( O
310 O
mg O
/ O
m2 O
) O
well O
below O
that O
considered O
the O
safe O
upper O
limit O
( O
550 O
mg O
/ O
m2 O
) O
in O
man O
. O

histologically O
, O
the O
myocardial B-Disease
lesions B-Disease
resembled O
those O
found O
in O
human O
anthracycline O
- O
induced O
cardiomyopathy B-Disease
. O

1 O
of O
the O
10 O
monkeys O
developed O
acute B-Disease
myeloblastic B-Disease
leukemia B-Disease
after O
receiving O
324 O
mg O
/ O
m2 O
of O
adriamycin O
; O
the O
10th O
monkey O
is O
alive O
and O
well O
26 O
months O
after O
the O
last O
dose O
of O
drug O
. O

our O
results O
suggest O
that O
adriamycin O
is O
a O
more O
potent O
cardiotoxin O
in O
monkeys O
than O
in O
man O
, O
and O
that O
leukemia B-Disease
may O
be O
a O
consequence O
of O
prolonged O
treatment O
with O
this O
drug O
. O

tricuspid B-Disease
valve B-Disease
regurgitation B-Disease
and O
lithium O
carbonate O
toxicity B-Disease
in O
a O
newborn O
infant O
. O

a O
newborn O
with O
massive O
tricuspid B-Disease
regurgitation B-Disease
, O
atrial B-Disease
flutter B-Disease
, O
congestive B-Disease
heart B-Disease
failure B-Disease
, O
and O
a O
high O
serum O
lithium O
level O
is O
described O
. O

this O
is O
the O
first O
patient O
to O
initially O
manifest O
tricuspid B-Disease
regurgitation B-Disease
and O
atrial B-Disease
flutter B-Disease
, O
and O
the O
11th O
described O
patient O
with O
cardiac B-Disease
disease B-Disease
among O
infants O
exposed O
to O
lithium O
compounds O
in O
the O
first O
trimester O
of O
pregnancy O
. O

sixty O
- O
three O
percent O
of O
these O
infants O
had O
tricuspid O
valve O
involvement O
. O

lithium O
carbonate O
may O
be O
a O
factor O
in O
the O
increasing O
incidence O
of O
congenital B-Disease
heart B-Disease
disease B-Disease
when O
taken O
during O
early O
pregnancy O
. O

it O
also O
causes O
neurologic B-Disease
depression B-Disease
, O
cyanosis B-Disease
, O
and O
cardiac B-Disease
arrhythmia B-Disease
when O
consumed O
prior O
to O
delivery O
. O

effects O
of O
the O
novel O
compound O
aniracetam O
( O
ro O
13 O
- O
5057 O
) O
upon O
impaired B-Disease
learning B-Disease
and B-Disease
memory B-Disease
in O
rodents O
. O

the O
effect O
of O
aniracetam O
( O
ro O
13 O
- O
5057 O
, O
1 O
- O
anisoyl O
- O
2 O
- O
pyrrolidinone O
) O
was O
studied O
on O
various O
forms O
of O
experimentally O
impaired B-Disease
cognitive B-Disease
functions B-Disease
( O
learning O
and O
memory O
) O
in O
rodents O
and O
produced O
the O
following O
effects O
: O
( O
1 O
) O
almost O
complete O
prevention O
of O
the O
incapacity O
to O
learn O
a O
discrete O
escape O
response O
in O
rats O
exposed O
to O
sublethal O
hypercapnia B-Disease
immediately O
before O
the O
acquisition O
session O
; O
( O
2 O
) O
partial O
( O
rats O
) O
or O
complete O
( O
mice O
) O
prevention O
of O
the O
scopolamine O
- O
induced O
short O
- O
term O
amnesia B-Disease
for O
a O
passive O
avoidance O
task O
; O
( O

3 O
) O
complete O
protection O
against O
amnesia B-Disease
for O
a O
passive O
avoidance O
task O
in O
rats O
submitted O
to O
electroconvulsive O
shock O
immediately O
after O
avoidance O
acquisition O
; O
( O
4 O
) O
prevention O
of O
the O
long O
- O
term O
retention O
- O
or O
retrieval O
- O
deficit O
for O
a O
passive O
avoidance O
task O
induced O
in O
rats O
and O
mice O
by O
chloramphenicol O
or O
cycloheximide O
administered O
immediately O
after O
acquisition O
; O
( O
5 O
) O
reversal O
, O
when O
administered O
as O
late O
as O
1 O
h O
before O
the O
retention O
test O
, O
of O
the O
deficit O
in O
retention O
or O
retrieval O
of O
a O
passive O
avoidance O
task O
induced O
by O
cycloheximide O

injected O
2 O
days O
previously O
; O
( O
6 O
) O
prevention O
of O
the O
deficit O
in O
the O
retrieval O
of O
an O
active O
avoidance O
task O
induced O
in O
mice O
by O
subconvulsant O
electroshock O
or O
hypercapnia B-Disease
applied O
immediately O
before O
retrieval O
testing O
( O
24 O
h O
after O
acquisition O
) O
. O

these O
improvements O
or O
normalizations O
of O
impaired B-Disease
cognitive B-Disease
functions B-Disease
were O
seen O
at O
oral O
aniracetam O
doses O
of O
10 O
- O
100 O
mg O
/ O
kg O
. O

generally O
, O
the O
dose O
- O
response O
curves O
were O
bell O
- O
shaped O
. O

the O
mechanisms O
underlying O
the O
activity O
of O
aniracetam O
and O
its O
' O
therapeutic O
window O
' O
are O
unknown O
. O

piracetam O
, O
another O
pyrrolidinone O
derivative O
was O
used O
for O
comparison O
. O

it O
was O
active O
only O
in O
six O
of O
nine O
tests O
and O
had O
about O
one O
- O
tenth O
the O
potency O
of O
aniracetam O
. O

the O
results O
indicate O
that O
aniracetam O
improves O
cognitive O
functions O
which O
are O
impaired O
by O
different O
procedure O
and O
in O
different O
phases O
of O
the O
learning O
and O
memory O
process O
. O

effect O
of O
calcium O
chloride O
on O
gross O
behavioural O
changes O
produced O
by O
carbachol O
and O
eserine O
in O
cats O
. O

the O
effect O
of O
calcium O
chloride O
injected O
into O
the O
cerebral O
ventricles O
of O
group O
- O
housed O
unanaesthetized O
cats O
upon O
vocalization O
( O
rage O
, O
hissing O
and O
snarling O
) O
, O
fighting O
( O
attack O
with O
paws O
and O
claws O
, O
defense O
with O
paws O
and O
claws O
and O
biting O
) O
, O
mydriasis B-Disease
, O
tremor B-Disease
and O
clonic B-Disease
- B-Disease
tonic B-Disease
convulsions B-Disease
produced O
by O
carbachol O
and O
eserine O
injected O
similarly O
was O
investigated O
. O

calcium O
chloride O
depressed O
or O
almost O
completely O
abolished O
the O
vocalization O
and O
fighting O
due O
to O
carbachol O
and O
eserine O
. O

on O
the O
other O
hand O
, O
mydriasis B-Disease
, O
tremor B-Disease
and O
clonic B-Disease
- B-Disease
tonic B-Disease
convulsions B-Disease
evoked O
by O
carbachol O
and O
eserine O
were O
not O
significantly O
changed O
by O
calcium O
chloride O
. O

it O
is O
apparent O
that O
calcium O
chloride O
can O
" O
dissociate O
" O
vocalization O
and O
fighting O
from O
autonomic O
and O
motor O
phenomena O
such O
as O
mydriasis B-Disease
, O
tremor B-Disease
and O
clonic B-Disease
- B-Disease
tonic B-Disease
convulsions B-Disease
caused O
by O
carbachol O
and O
eserine O
. O

calcium O
chloride O
inhibited O
the O
vocalization O
and O
fighting O
produced O
by O
carbachol O
and O
eserine O
most O
probably O
by O
a O
nonspecific O
stabilizing O
action O
on O
central O
muscarinic O
cholinoceptive O
sites O
. O

these O
results O
further O
support O
the O
view O
that O
calcium O
ions O
in O
excess O
have O
an O
atropine O
- O
like O
action O
also O
in O
the O
central O
nervous O
system O
. O

thiazide O
diuretics O
, O
hypokalemia B-Disease
and O
cardiac B-Disease
arrhythmias B-Disease
. O

thiazide O
diuretics O
are O
widely O
accepted O
as O
the O
cornerstone O
of O
antihypertensive O
treatment O
programs O
. O

hypokalemia B-Disease
is O
a O
commonly O
encountered O
metabolic O
consequence O
of O
chronic O
thiazide O
therapy O
. O

we O
treated O
38 O
patients O
( O
22 O
low O
renin O
, O
16 O
normal O
renin O
) O
with O
moderate O
diastolic B-Disease
hypertension B-Disease
with O
hydrochlorothiazide O
( O
hctc O
) O
administered O
on O
a O
twice O
daily O
schedule O
. O

initial O
dose O
was O
50 O
mg O
and O
the O
dose O
was O
increased O
at O
monthly O
intervals O
to O
100 O
mg O
, O
150 O
mg O
and O
200 O
mg O
daily O
until O
blood O
pressure O
normalized O
. O

the O
serum O
k O
during O
the O
control O
period O
was O
4 O
. O
5 O
+ O
/ O
- O
0 O
. O
2 O
meq O
/ O
l O
an O
on O
50 O
, O
100 O
, O
150 O
and O
200 O
mg O
hctz O
daily O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
3 O
, O
3 O
. O
4 O
+ O
/ O
- O
0 O
. O
2 O
, O
2 O
. O
9 O
+ O
/ O
- O
0 O
. O
2 O
, O
and O
2 O
. O
4 O
+ O
/ O
- O
0 O
. O
3 O
meq O
/ O
l O
, O
respectively O
. O

corresponding O
figures O
for O
whole O
body O
k O
were O
4107 O
+ O
/ O
- O
208 O
, O
3722 O
+ O
/ O
- O
319 O
, O
3628 O
+ O
/ O
- O
257 O
, O
3551 O
+ O
/ O
- O
336 O
, O
and O
3269 O
+ O
/ O
- O
380 O
meq O
, O
respectively O
. O

in O
13 O
patients O
we O
observed O
the O
effects O
of O
hctz O
therapy O
( O
100 O
mg O
daily O
) O
on O
the O
occurrence O
of O
pvc O
' O
s O
during O
rest O
as O
well O
as O
during O
static O
and O
dynamic O
exercise O
. O

during O
rest O
we O
observed O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
08 O
pvc O
beats O
/ O
min O
+ O
/ O
- O
sem O
and O
during O
static O
and O
dynamic O
exercise O
0 O
. O
6 O
+ O
/ O
- O
0 O
. O
06 O
and O
0 O
. O
8 O
+ O
/ O
- O
0 O
. O
15 O
, O
respectively O
. O

corresponding O
figures O
during O
hctz O
therapy O
100 O
mg O
daily O
were O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
, O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
7 O
and O
5 O
. O
7 O
4 O
/ O
- O
0 O
. O
8 O
, O
respectively O
. O

the O
occurrence O
of O
pvc O
' O
s O
correlated O
significantly O
with O
the O
fall O
in O
serum O
k O
+ O
observed O
r O
= O
0 O
. O
72 O
, O
p O
less O
than O
0 O
. O
001 O
. O

in O
conclusion O
we O
found O
that O
thiazide O
diuretics O
cause O
hypokalemia B-Disease
and O
depletion O
of O
body O
potassium O
. O

the O
more O
profound O
hypokalemia B-Disease
, O
the O
greater O
the O
propensity O
for O
the O
occurrence O
of O
pvc O
' O
s O
. O

circulating O
lysosomal O
enzymes O
and O
acute B-Disease
hepatic B-Disease
necrosis B-Disease
. O

the O
activities O
of O
the O
lysosomal O
enzymes O
acid O
and O
neutral O
protease O
, O
n O
- O
acetylglucosaminidase O
, O
and O
acid O
phosphatase O
were O
measured O
in O
the O
serum O
of O
patients O
with O
fulminant B-Disease
hepatic B-Disease
failure B-Disease
. O

acid O
protease O
( O
cathepsin O
d O
) O
activity O
was O
increased O
about O
tenfold O
in O
patients O
who O
died O
and O
nearly O
fourfold O
in O
those O
who O
survived O
fulminant B-Disease
hepatic B-Disease
failure B-Disease
after O
paracetamol O
overdose B-Disease
, O
whereas O
activities O
were O
increased O
equally O
in O
patients O
with O
fulminant B-Disease
hepatic B-Disease
failure B-Disease
due O
to O
viral B-Disease
hepatitis B-Disease
whether O
or O
not O
they O
survived O
. O

a O
correlation O
was O
found O
between O
serum O
acid O
protease O
activity O
and O
prothrombin O
time O
, O
and O
the O
increase O
in O
cathepsin O
d O
activity O
was O
sustained O
over O
several O
days O
compared O
with O
aspartate O
aminotransferase O
, O
which O
showed O
a O
sharp O
early O
peak O
and O
then O
a O
fall O
. O

circulating O
lysosomal O
proteases O
can O
damage O
other O
organs O
, O
and O
measurement O
of O
their O
activity O
may O
therefore O
be O
of O
added O
value O
in O
assessing O
prognosis O
in O
this O
condition O
. O

hepatic B-Disease
veno B-Disease
- B-Disease
occlusive B-Disease
disease B-Disease
caused O
by O
6 O
- O
thioguanine O
. O

clinically O
reversible O
veno B-Disease
- B-Disease
occlusive B-Disease
disease B-Disease
of B-Disease
the B-Disease
liver B-Disease
developed O
in O
a O
23 O
- O
year O
- O
old O
man O
with O
acute B-Disease
lymphocytic B-Disease
leukemia B-Disease
after O
10 O
months O
of O
maintenance O
therapy O
with O
6 O
- O
thioguanine O
. O

serial O
liver O
biopsies O
showed O
the O
development O
and O
resolution O
of O
intense O
sinusoidal O
engorgement O
. O

although O
this O
disease O
was O
clinically O
reversible O
, O
some O
subintimal O
fibrosis B-Disease
about O
the O
terminal O
hepatic O
veins O
persisted O
. O

this O
case O
presented O
a O
unique O
opportunity O
to O
observe O
the O
histologic O
features O
of O
clinically O
reversible O
hepatic B-Disease
veno B-Disease
- B-Disease
occlusive B-Disease
disease B-Disease
over O
time O
, O
and O
may O
be O
the O
first O
case O
of O
veno O
- O
occlusive O
related O
solely O
to O
6 O
- O
thioguanine O
. O

chlorpropamide O
- O
induced O
optic B-Disease
neuropathy B-Disease
. O

a O
65 O
- O
year O
- O
old O
woman O
with O
adult B-Disease
- B-Disease
onset B-Disease
diabetes B-Disease
treated O
with O
chlorpropamide O
( O
diabenese O
) O
had O
a O
toxic B-Disease
optic B-Disease
neuropathy B-Disease
that O
resolved O
with O
discontinuation O
of O
chlorpropamide O
therapy O
. O

visual B-Disease
loss B-Disease
occurs O
in O
diabetics B-Disease
for O
a O
variety O
of O
reasons O
, O
and O
accurate O
diagnosis O
is O
necessary O
to O
institute O
appropriate O
therapy O
. O

the O
possibility O
of O
a O
drug O
- O
induced O
optic B-Disease
neuropathy B-Disease
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
visual B-Disease
loss B-Disease
in O
diabetics B-Disease
. O

plasma O
and O
urinary O
lipids O
and O
lipoproteins O
during O
the O
development O
of O
nephrotic B-Disease
syndrome B-Disease
induced O
in O
the O
rat O
by O
puromycin O
aminonucleoside O
. O

this O
study O
was O
undertaken O
to O
ascertain O
whether O
the O
alterations O
of O
plasma O
lipoproteins O
found O
in O
nephrotic B-Disease
syndrome B-Disease
induced O
by O
puromycin O
aminonucleoside O
were O
due O
to O
nephrotic B-Disease
syndrome B-Disease
per O
se O
, O
or O
, O
at O
least O
in O
part O
, O
to O
the O
aminonucleoside O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
changes O
in O
plasma O
and O
urinary O
lipoproteins O
during O
the O
administration O
of O
puromycin O
aminonucleoside O
( O
20 O
mg O
/ O
kg O
for O
7 O
days O
) O
and O
the O
subsequent O
development O
of O
nephrotic B-Disease
syndrome B-Disease
. O

since O
massive O
albuminuria B-Disease
occurred O
after O
6 O
days O
of O
treatment O
, O
the O
time O
- O
course O
study O
was O
divided O
into O
two O
stages O
: O
pre O
- O
nephrotic B-Disease
stage O
( O
day O
1 O
- O
5 O
) O
and O
nephrotic B-Disease
stage O
( O
day O
6 O
- O
11 O
) O
. O

in O
pre O
- O
nephrotic B-Disease
stage O
the O
plasma O
level O
of O
fatty O
acids O
, O
triacylglycerol O
and O
vldl O
decreased O
while O
that O
of O
phospholipid O
, O
cholesteryl O
esters O
and O
hdl O
remained O
constant O
. O

plasma O
apolipoprotein O
a O
- O
i O
tended O
to O
increase O
( O
40 O
% O
increase O
at O
day O
5 O
) O
. O

at O
the O
beginning O
of O
nephrotic B-Disease
stage O
( O
day O
6 O
) O
the O
concentration O
of O
plasma O
albumin O
dropped O
to O
a O
very O
low O
level O
, O
while O
that O
of O
apolipoprotein O
a O
- O
i O
increased O
abruptly O
( O
4 O
- O
fold O
increase O
) O
and O
continued O
to O
rise O
, O
although O
less O
steeply O
, O
in O
the O
following O
days O
. O

the O
plasma O
concentration O
of O
hdl O
followed O
the O
same O
pattern O
. O

plasma O
vldl O
and O
ldl O
increased O
at O
a O
later O
stage O
( O
day O
9 O
) O
. O

plasma O
apolipoprotein O
a O
- O
i O
was O
found O
not O
only O
in O
hdl O
( O
1 O
. O
063 O
- O
1 O
. O
210 O
g O
/ O
ml O
) O
but O
also O
in O
the O
ldl O
density O
class O
( O
1 O
. O
025 O
- O
1 O
. O
050 O
g O
/ O
ml O
) O
. O

in O
the O
pre O
- O
nephrotic B-Disease
stage O
lipoproteinuria O
was O
negligible O
, O
while O
in O
the O
early O
nephrotic B-Disease
stage O
the O
urinary O
loss O
of O
plasma O
lipoproteins O
consisted O
mainly O
of O
hdl O
. O

these O
observations O
indicate O
that O
puromycin O
aminonucleoside O
alters O
plasma O
lipoproteins O
by O
lowering O
vldl O
and O
increasing O
hdl O
. O

it O
is O
likely O
that O
the O
early O
and O
striking O
increase O
of O
plasma O
hdl O
found O
in O
nephrotic B-Disease
rats O
is O
related O
to O
a O
direct O
effect O
of O
the O
drug O
on O
hdl O
metabolism O
. O

fatal O
aplastic B-Disease
anemia B-Disease
following O
topical O
administration O
of O
ophthalmic O
chloramphenicol O
. O

a O
73 O
- O
year O
- O
old O
woman O
died O
of O
aplastic B-Disease
anemia B-Disease
less O
than O
two O
months O
after O
undergoing O
cataract B-Disease
extraction O
and O
beginning O
topical O
therapy O
with O
chloramphenicol O
. O

the O
first O
signs O
of O
pancytopenia B-Disease
began O
within O
one O
month O
of O
the O
surgery O
. O

the O
pattern O
of O
the O
aplastic B-Disease
anemia B-Disease
was O
associated O
with O
an O
idiosyncratic O
response O
to O
chloramphenicol O
. O

this O
was O
the O
second O
report O
of O
fatal O
aplastic B-Disease
anemia B-Disease
after O
topical O
treatment O
with O
chloramphenicol O
for O
ocular O
conditions O
, O
although O
two O
cases O
of O
reversible O
bone B-Disease
marrow B-Disease
hypoplasia B-Disease
have O
also O
been O
reported O
. O

any O
other O
suspected O
cases O
of O
ocular B-Disease
toxicity B-Disease
associated O
with O
topically O
applied O
chloramphenicol O
should O
be O
reported O
to O
the O
national O
registry O
of O
drug O
- O
induced O
ocular O
side O
effects O
, O
oregon O
health O
sciences O
university O
, O
portland O
, O
or O
97201 O
. O

midazolam O
compared O
with O
thiopentone O
as O
an O
induction O
agent O
. O

in O
patients O
premedicated O
with O
scopolamine O
+ O
morphine O
( O
+ O
5 O
mg O
nitrazepam O
the O
evening O
before O
surgery O
) O
, O
the O
sleep O
- O
inducing O
effect O
of O
midazolam O
0 O
. O
15 O
mg O
/ O
kg O
i O
. O
v O
. O
was O
clearly O
slower O
in O
onset O
than O
that O
of O
thiopentone O
4 O
. O
67 O
mg O
/ O
kg O
i O
. O
v O
. O
somewhat O
fewer O
cardiovascular O
and O
local O
sequelae O
were O
found O
in O
the O
midazolam O
group O
, O
but O
, O
although O
apnoea B-Disease
occurred O
less O
often O
in O
the O
midazolam O
group O
it O
lasted O
longer O
. O

on O
the O
whole O
, O
the O
differences O
between O
midazolam O
and O
thiopentone O
had O
no O
apparent O
clinical O
consequences O
. O

midazolam O
is O
a O
new O
alternative O
agent O
for O
induction O
in O
combination O
anaesthesia O
. O

extrapyramidal O
side O
effects O
and O
oral O
haloperidol O
: O
an O
analysis O
of O
explanatory O
patient O
and O
treatment O
characteristics O
. O

the O
incidence O
of O
extrapyramidal O
side O
effects O
( O
eps O
) O
was O
evaluated O
in O
98 O
patients O
treated O
with O
haloperidol O
. O

the O
incidence O
of O
parkinsonism B-Disease
was O
higher O
at O
higher O
doses O
of O
haloperidol O
and O
in O
younger O
patients O
. O

prophylactic O
antiparkinsonian O
medication O
was O
effective O
in O
younger O
but O
not O
in O
older O
patients O
. O

however O
, O
these O
medications O
were O
more O
effective O
in O
both O
young O
and O
old O
patients O
when O
given O
after O
parkinsonism B-Disease
developed O
. O

akathisia B-Disease
was O
controlled O
by O
the O
benzodiazepine O
lorazepam O
in O
14 O
out O
of O
16 O
patients O
, O
while O
prophylactic O
antiparkinsonians O
were O
ineffective O
. O

the O
present O
study O
points O
to O
patient O
characteristics O
that O
may O
be O
of O
significance O
in O
the O
development O
of O
eps O
due O
to O
haloperidol O
. O

deaths O
from O
local O
anesthetic O
- O
induced O
convulsions B-Disease
in O
mice O
. O

median O
convulsant O
( O
cd50 O
) O
and O
median O
lethal O
( O
ld50 O
) O
doses O
of O
three O
representative O
local O
anesthetics O
were O
determined O
in O
adult O
mice O
to O
evaluate O
the O
threat O
to O
life O
of O
local O
anesthetic O
- O
induced O
convulsions B-Disease
. O

the O
cd50 O
and O
ld50 O
, O
respectively O
, O
were O
57 O
. O
7 O
and O
58 O
. O
7 O
mg O
/ O
kg O
for O
bupivacaine O
, O
111 O
. O
0 O
and O
133 O
. O
1 O
mg O
/ O
kg O
for O
lidocaine O
, O
and O
243 O
. O
4 O
and O
266 O
. O
5 O
mg O
/ O
kg O
for O
chloroprocaine O
. O

when O
given O
intraperitoneally O
, O
bupivacaine O
thus O
was O
only O
about O
twice O
as O
toxic O
as O
lidocaine O
and O
four O
times O
as O
toxic O
as O
chloroprocaine O
. O

convulsions B-Disease
always O
preceded O
death O
, O
except O
after O
precipitous O
cardiopulmonary B-Disease
arrest B-Disease
from O
extreme O
doses O
. O

a O
cd50 O
dose O
of O
local O
anesthetic O
( O
causing O
convulsions B-Disease
in O
50 O
% O
of O
mice O
) O
was O
fatal O
in O
90 O
% O
of O
bupivacaine O
- O
induced O
seizures B-Disease
, O
in O
57 O
% O
of O
the O
chloroprocaine O
group O
, O
and O
in O
6 O
% O
of O
the O
lidocaine O
group O
. O

the O
narrow O
gap O
between O
convulsant O
and O
lethal O
doses O
of O
local O
anesthetics O
indicates O
that O
untreated O
convulsions B-Disease
present O
much O
more O
of O
a O
threat O
to O
life O
than O
heretofore O
appreciated O
. O

rem B-Disease
sleep B-Disease
deprivation B-Disease
changes O
behavioral O
response O
to O
catecholaminergic O
and O
serotonergic O
receptor O
activation O
in O
rats O
. O

the O
effects O
of O
rem B-Disease
sleep B-Disease
deprivation B-Disease
( O
remd B-Disease
) O
on O
apomorphine O
- O
induced O
aggressiveness B-Disease
and O
quipazine O
- O
induced O
head B-Disease
twitches B-Disease
in O
rats O
were O
determined O
. O

forty O
- O
eight O
hr O
of O
remd B-Disease
increased O
apomorphine O
- O
induced O
aggressiveness B-Disease
, O
and O
reduced O
( O
immediately O
after O
completing O
of O
remd B-Disease
) O
or O
increased O
( O
96 O
hr O
after O
completing O
of O
remd B-Disease
) O
quipazine O
- O
induced O
head B-Disease
twitches B-Disease
. O

results O
are O
discussed O
in O
terms O
of O
similarity O
to O
pharmacological O
effects O
of O
other O
antidepressive O
treatments O
. O

fatal O
aplastic B-Disease
anemia B-Disease
due O
to O
indomethacin O
- O
- O
lymphocyte O
transformation O
tests O
in O
vitro O
. O

although O
indomethacin O
has O
been O
implicated O
as O
a O
possible O
cause O
of O
aplastic B-Disease
anemia B-Disease
on O
the O
basis O
of O
a O
few O
clinical O
observations O
, O
its O
role O
has O
not O
been O
definitely O
established O
. O

a O
case O
of O
fatal O
aplastic B-Disease
anemia B-Disease
is O
described O
in O
which O
no O
drugs O
other O
than O
allopurinol O
and O
indomethacin O
were O
given O
. O

indomethacin O
was O
first O
given O
four O
weeks O
prior O
to O
the O
onset O
of O
symptoms O
. O

a O
positive O
lymphocyte O
transformation O
test O
with O
indomethacin O
in O
vitro O
further O
substantiates O
the O
potential O
role O
of O
this O
drug O
in O
causing O
aplastic B-Disease
anemia B-Disease
in O
a O
susceptible O
patient O
. O

fortunately O
, O
this O
seems O
to O
be O
a O
very O
rare O
complication O
. O

dose O
- O
effect O
and O
structure O
- O
function O
relationships O
in O
doxorubicin O
cardiomyopathy B-Disease
. O

the O
cardiomyopathy B-Disease
( O
cm B-Disease
) O
produced O
by O
the O
anticancer O
drug O
doxorubicin O
( O
dxr O
) O
( O
adriamycin O
) O
provides O
a O
unique O
opportunity O
to O
analyze O
dose O
- O
effect O
and O
structure O
- O
function O
relationships O
during O
development O
of O
myocardial B-Disease
disease B-Disease
. O

we O
measured O
the O
degree O
of O
morphologic O
damage O
by O
ultrastructural O
examination O
of O
endomyocardial O
biopsy O
and O
the O
degree O
of O
performance O
abnormally O
by O
right O
heart O
catheterization O
in O
patients O
receiving O
dxr O
. O

morphologic O
damage O
was O
variable O
but O
was O
proportional O
to O
the O
total O
cumulative O
dxr O
dose O
between O
100 O
and O
600 O
mg O
/ O
m2 O
. O

performance O
abnormalities O
correlated O
weakly O
with O
dose O
, O
exhibited O
a O
curvilinear O
relationship O
, O
and O
had O
a O
" O
threshold O
" O
for O
expression O
. O

catheterization O
abnormalities O
correlated O
well O
with O
morphologic O
damage O
( O
r O
= O
0 O
. O
57 O
to O
0 O
. O
78 O
) O
in O
a O
subgroup O
of O
patients O
in O
whom O
exercise O
hemodynamics O
were O
measured O
, O
and O
this O
relationship O
also O
exhibited O
a O
curvilinear O
, O
threshold O
configuration O
. O

in O
dxr O
- O
cm B-Disease
myocardial B-Disease
damage B-Disease
is O
proportional O
to O
the O
degree O
of O
cytotoxic O
insult O
( O
dxr O
dose O
) O
while O
myocardial O
function O
is O
preserved O
until O
a O
critical O
dose O
or O
degree O
of O
damage O
is O
reached O
, O
after O
which O
myocardial O
performance O
deteriorates O
rapidly O
. O

massive O
cerebral B-Disease
edema B-Disease
associated O
with O
fulminant O
hepatic B-Disease
failure B-Disease
in O
acetaminophen O
overdose B-Disease
: O
possible O
role O
of O
cranial O
decompression O
. O

cerebral B-Disease
edema B-Disease
may O
complicate O
the O
course O
of O
fulminant B-Disease
hepatic B-Disease
failure B-Disease
. O

response O
to O
conventional O
therapy O
has O
been O
disappointing O
. O

we O
present O
a O
patient O
with O
fatal O
acetaminophen O
- O
induced O
fulminant B-Disease
hepatic B-Disease
failure B-Disease
, O
with O
signs O
and O
symptoms O
of O
cerebral B-Disease
edema B-Disease
, O
unresponsive O
to O
conventional O
medical O
therapy O
. O

cranial O
decompression O
was O
carried O
out O
. O

a O
justification O
of O
the O
need O
for O
further O
evaluation O
of O
cranial O
decompression O
in O
such O
patients O
is O
presented O
. O

subjective O
assessment O
of O
sexual B-Disease
dysfunction B-Disease
of O
patients O
on O
long O
- O
term O
administration O
of O
digoxin O
. O

various O
data O
suggest O
that O
male O
patients O
who O
have O
received O
digoxin O
on O
a O
longterm O
basis O
have O
increased O
levels O
of O
serum O
estrogen O
and O
decreased O
levels O
of O
plasma O
testosterone O
and O
luteinizing O
hormone O
( O
lh O
) O
. O

this O
study O
was O
undertaken O
to O
investigate O
the O
links O
between O
the O
long O
- O
term O
administration O
of O
digoxin O
therapy O
and O
sexual O
behavior O
, O
and O
the O
effect O
of O
digoxin O
on O
plasma O
levels O
of O
estradiol O
, O
testosterone O
, O
and O
lh O
. O

the O
patients O
of O
the O
study O
and O
control O
group O
( O
without O
digoxin O
) O
were O
of O
similar O
cardiac O
functional O
capacity O
and O
age O
( O
25 O
- O
40 O
years O
) O
and O
were O
randomly O
selected O
from O
the O
rheumatic B-Disease
heart B-Disease
disease B-Disease
patients O
. O

a O
subjective O
assessment O
of O
sexual O
behavior O
in O
the O
study O
and O
control O
groups O
was O
carried O
out O
, O
using O
parameters O
such O
as O
sexual O
desire O
, O
sexual O
excitement O
, O
and O
frequency O
of O
sexual O
relations O
. O

personal O
interviews O
and O
a O
questionnaire O
were O
also O
used O
for O
the O
evaluation O
of O
sexual O
behavior O
. O

the O
findings O
support O
the O
reports O
concerning O
digoxin O
effect O
on O
plasma O
estradiol O
, O
testosterone O
, O
and O
lh O
. O

the O
differences O
in O
the O
means O
were O
significant O
. O

tests O
used O
to O
evaluate O
the O
changes O
in O
sexual O
behavior O
showed O
a O
significant O
decrease B-Disease
in B-Disease
sexual B-Disease
desire B-Disease
, O
sexual O
excitement O
phase O
( O
erection O
) O
, O
and O
frequency O
of O
sexual O
relations O
in O
the O
study O
group O
. O

endometrial B-Disease
carcinoma B-Disease
after O
hodgkin B-Disease
disease B-Disease
in O
childhood O
. O

a O
34 O
- O
year O
- O
old O
patient O
developed O
metastic O
endometrial B-Disease
carcinoma B-Disease
after O
hodgkin B-Disease
disease B-Disease
in O
childhood O
. O

she O
had O
ovarian B-Disease
failure B-Disease
after O
abdominal O
irradiation O
and O
chemotherapy O
for O
hodgkin B-Disease
disease B-Disease
, O
and O
received O
exogenous O
estrogens O
, O
a O
treatment O
implicated O
in O
the O
development O
of O
endometrial B-Disease
cancer B-Disease
in O
menopausal O
women O
. O

young O
women O
on O
replacement O
estrogens O
for O
ovarian B-Disease
failure B-Disease
after O
cancer B-Disease
therapy O
may O
also O
have O
increased O
risk O
of O
endometrial B-Disease
carcinoma B-Disease
and O
should O
be O
examined O
periodically O
. O

long O
- O
term O
lithium O
treatment O
and O
the O
kidney O
. O

interim O
report O
on O
fifty O
patients O
. O

this O
is O
a O
report O
on O
the O
first O
part O
of O
our O
study O
of O
the O
effects O
of O
long O
- O
term O
lithium O
treatment O
on O
the O
kidney O
. O

creatinine O
clearance O
, O
maximum O
urinary O
osmolality O
and O
24 O
hour O
urine O
volume O
have O
been O
tested O
in O
50 O
affectively O
ill O
patients O
who O
have O
been O
on O
long O
- O
term O
lithium O
for O
more O
than O
one O
year O
. O

these O
findings O
have O
been O
compared O
with O
norms O
and O
with O
values O
of O
the O
same O
tests O
from O
screening O
prior O
to O
lithium O
, O
available O
for O
most O
of O
our O
patients O
. O

no O
evidence O
was O
found O
for O
any O
reduction O
of O
glomerular O
filtration O
during O
lithium O
treatment O
. O

low O
clearance O
values O
found O
in O
several O
patients O
could O
be O
accounted O
for O
by O
their O
age O
and O
their O
pre O
- O
lithium O
values O
. O

urinary O
concentration O
defect O
appeared O
frequent O
but O
the O
extent O
of O
the O
impairment O
is O
difficult O
to O
assess O
because O
of O
the O
uncertainty O
about O
the O
norms O
applicable O
to O
this O
group O
of O
patients O
. O

the O
concentration O
defect O
appeared O
reversible O
, O
at O
least O
in O
part O
. O

polyuria B-Disease
above O
3 O
litres O
/ O
24 O
hours O
was O
found O
in O
10 O
% O
of O
patients O
. O

an O
attempt O
is O
made O
to O
draw O
practical O
conclusions O
from O
the O
preliminary O
findings O
. O

nephrotoxicity B-Disease
of O
cyclosporin O
a O
and O
fk506 O
: O
inhibition O
of O
calcineurin O
phosphatase O
. O

cyclosporin O
a O
( O
csa O
; O
50 O
mg O
/ O
kg O
) O
and O
fujimycine O
( O
fk506 O
; O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
the O
related O
macrolide O
immunosuppressant O
rapamycin O
( O
5 O
mg O
/ O
kg O
) O
, O
caused O
a O
reduction O
of O
glomerular O
filtration O
rate O
, O
degenerative O
changes O
of O
proximal O
tubular O
epithelium O
, O
and O
hypertrophy B-Disease
of O
the O
juxtaglomerular O
apparatus O
in O
male O
wistar O
rats O
when O
given O
for O
10 O
days O
. O

the O
molecular O
mechanisms O
of O
csa O
and O
fk506 O
toxicity B-Disease
were O
investigated O
. O

cyclophilin O
a O
and O
fk506 O
- O
binding O
protein O
, O
the O
main O
intracytoplasmic O
receptors O
for O
csa O
and O
fk506 O
, O
respectively O
, O
were O
each O
detected O
in O
renal O
tissue O
extract O
. O

in O
the O
kidney O
, O
high O
levels O
of O
immunoreactive O
and O
enzymatically O
active O
calcineurin O
were O
found O
which O
were O
inhibited O
by O
the O
immunosuppressants O
csa O
and O
fk506 O
, O
but O
not O
by O
rapamycin O
. O

finally O
, O
specific O
immunophilin O
- O
drug O
- O
calcineurin O
complexes O
formed O
only O
in O
the O
presence O
of O
csa O
and O
fk506 O
, O
but O
not O
rapamycin O
. O

these O
results O
suggest O
that O
the O
nephrotoxic B-Disease
effects O
of O
csa O
and O
fk506 O
is O
likely O
mediated O
through O
binding O
to O
renal O
immunophilin O
and O
inhibiting O
calcineurin O
phosphatase O
. O

acute B-Disease
renal B-Disease
failure B-Disease
in O
high O
dose O
carboplatin O
chemotherapy O
. O

carboplatin O
has O
been O
reported O
to O
cause O
acute B-Disease
renal B-Disease
failure B-Disease
when O
administered O
in O
high O
doses O
to O
adult O
patients O
. O

we O
report O
a O
4 O
1 O
/ O
2 O
- O
year O
- O
old O
girl O
who O
was O
treated O
with O
high O
- O
dose O
carboplatin O
for O
metastatic O
parameningeal O
embryonal B-Disease
rhabdomyosarcoma B-Disease
. O

acute B-Disease
renal B-Disease
failure B-Disease
developed O
followed O
by O
a O
slow O
partial O
recovery O
of O
renal O
function O
. O

possible O
contributing O
factors O
are O
discussed O
. O

clinical O
evaluation O
on O
combined O
administration O
of O
oral O
prostacyclin O
analogue O
beraprost O
and O
phosphodiesterase O
inhibitor O
cilostazol O
. O

among O
various O
oral O
antiplatelets O
, O
a O
combination O
of O
a O
novel O
prostacyclin O
analogue O
beraprost O
( O
bpt O
) O
and O
a O
potent O
phosphodiesterase O
inhibitor O
cilostazol O
( O
clz O
) O
may O
result O
in O
untoward O
clinical O
effects O
due O
to O
possible O
synergistic O
elevation O
of O
intracellular O
camp O
( O
cyclic O
adenosine O
3 O
' O
, O
5 O
' O
- O
monophosphate O
) O
. O

thereby O
, O
a O
clinical O
study O
of O
the O
combined O
administration O
of O
the O
two O
agents O
was O
attempted O
. O

twelve O
healthy O
volunteers O
were O
assigned O
to O
take O
bpt O
/ O
clz O
in O
the O
following O
schedule O
; O
bpt O
: O
40 O
micrograms O
at O
day O
1 O
and O
120 O
micrograms O
t O
. O
i O
. O
d O
. O
from O
day O
7 O
to O
14 O
, O
clz O
: O
200 O
mg O
t O
. O
i O
. O
d O
. O
from O
day O
3 O
to O
14 O
. O

at O
various O
time O
intervals O
, O
physical O
examination O
and O
blood O
collection O
for O
ex O
vivo O
platelet B-Disease
aggregation B-Disease
and O
determination O
of O
intraplatelet O
camp O
were O
performed O
. O

throughout O
the O
observation O
period O
, O
no O
significant O
alteration O
in O
vital O
signs O
was O
observed O
. O

seven O
out O
of O
12 O
subjects O
experienced O
headache B-Disease
of O
a O
short O
duration O
accompanying O
facial B-Disease
flush B-Disease
in O
one O
and O
nausea B-Disease
in O
one O
, O
especially O
after O
ingestion O
of O
clz O
. O

all O
of O
these O
symptoms O
, O
probably O
caused O
by O
the O
vasodilating O
effect O
of O
the O
two O
agents O
, O
were O
of O
mild O
degree O
and O
no O
special O
treatment O
was O
required O
. O

intraplatelet O
camp O
content O
was O
gradually O
but O
significantly O
increased O
to O
9 O
. O
84 O
+ O
/ O
- O
4 O
. O
59 O
pmol O
per O
10 O
( O
9 O
) O
platelets O
at O
day O
14 O
in O
comparison O
with O
the O
initial O
value O
( O
6 O
. O
87 O
+ O
/ O
- O
2 O
. O
25 O
pmol O
) O
. O

the O
platelet O
aggregability O
was O
significantly O
suppressed O
at O
various O
time O
intervals O
but O
no O
additive O
or O
synergistic O
inhibitory O
effect O
by O
the O
combined O
administration O
was O
noted O
. O

in O
conclusion O
, O
the O
combined O
administration O
of O
bpt O
/ O
clz O
is O
safe O
at O
doses O
used O
in O
the O
study O
, O
though O
the O
beneficial O
clinical O
effect O
of O
the O
combined O
administration O
has O
yet O
to O
be O
elucidated O
. O

pravastatin O
- O
associated O
myopathy B-Disease
. O

report O
of O
a O
case O
. O

a O
case O
of O
acute O
inflammatory B-Disease
myopathy B-Disease
associated O
with O
the O
use O
of O
pravastatin O
, O
a O
new O
hydrophilic O
3 O
- O
hydroxy O
- O
3 O
methylglutaril O
coenzyme O
a O
reductase O
inhibitor O
, O
is O
reported O
. O

the O
patient O
, O
a O
69 O
- O
year O
- O
old O
man O
was O
affected O
by O
non B-Disease
- B-Disease
insulin B-Disease
- B-Disease
dependent B-Disease
diabetes B-Disease
mellitus B-Disease
and O
hypertension B-Disease
. O

he O
assumed O
pravastatin O
( O
20 O
mg O
/ O
day O
) O
because O
of O
hypercholesterolemia B-Disease
. O

he O
was O
admitted O
with O
acute O
myopathy B-Disease
of O
the O
lower O
limbs O
which O
resolved O
in O
a O
few O
days O
after O
pravastatin O
discontinuation O
. O

a O
previously O
unknown O
hypothyroidism B-Disease
, O
probably O
due O
to O
chronic O
autoimmune B-Disease
thyroiditis B-Disease
, O
was O
evidenced O
. O

muscle O
biopsy O
( O
left O
gastrocnemius O
) O
revealed O
a O
perimysial O
and O
endomysial O
inflammatory O
infiltrate O
with O
a O
prevalence O
of O
cd4 O
+ O
lymphocytes O
. O

while O
lovastatin O
and O
simvastatin O
have O
been O
associated O
with O
toxic O
myopathy B-Disease
, O
pravastatin O
- O
associated O
myopathy B-Disease
could O
represent O
a O
distinct O
, O
inflammatory O
entity O
. O

reversal O
of O
ammonia O
coma B-Disease
in O
rats O
by O
l O
- O
dopa O
: O
a O
peripheral O
effect O
. O

ammonia O
coma B-Disease
was O
produced O
in O
rats O
within O
10 O
to O
15 O
minutes O
of O
an O
intraperitonealinjection O
of O
1 O
. O
7 O
mmol O
nh4cl O
. O

this O
coma B-Disease
was O
prevented O
with O
1 O
. O
68 O
mmol O
l O
- O
dopa O
given O
by O
gastric O
intubation O
15 O
minutes O
before O
the O
ammonium O
salt O
injection O
. O

the O
effect O
of O
l O
- O
dopa O
was O
correlated O
with O
a O
decrease O
in O
blood O
and O
brain O
ammonia O
, O
an O
increase O
in O
brain O
dopamine O
, O
and O
an O
increase O
in O
renal O
excretion O
of O
ammonia O
and O
urea O
. O

intraventricular O
infusion O
of O
dopamine O
sufficient O
to O
raise O
the O
brain O
dopamine O
to O
the O
same O
extent O
did O
not O
prevent O
the O
ammonia O
coma B-Disease
nor O
affect O
the O
blood O
and O
brain O
ammonia O
concentrations O
. O

bilateral O
nephrectomy O
eliminated O
the O
beneficial O
effect O
of O
l O
- O
dopa O
on O
blood O
and O
brain O
ammonia O
and O
the O
ammonia O
coma B-Disease
was O
not O
prevented O
. O

thus O
, O
the O
reduction O
in O
blood O
and O
brain O
ammonia O
and O
the O
prevention O
of O
ammonia O
coma B-Disease
after O
l O
- O
dopa O
, O
can O
be O
accounted O
for O
by O
the O
peripheral O
effect O
of O
dopamine O
on O
renal O
function O
rather O
than O
its O
central O
action O
. O

these O
results O
provide O
a O
reasonable O
explanation O
for O
the O
beneficial O
effects O
observed O
in O
some O
encephalopathic B-Disease
patients O
receiving O
l O
- O
dopa O
. O

etoposide O
- O
related O
myocardial B-Disease
infarction B-Disease
. O

the O
occurrence O
of O
a O
myocardial B-Disease
infarction B-Disease
is O
reported O
after O
chemotherapy O
containing O
etoposide O
, O
in O
a O
man O
with O
no O
risk O
factors O
for O
coronary B-Disease
heart B-Disease
disease B-Disease
. O

possible O
causal O
mechanisms O
are O
discussed O
. O

halogenated O
anesthetics O
form O
liver O
adducts O
and O
antigens O
that O
cross O
- O
react O
with O
halothane O
- O
induced O
antibodies O
. O

two O
halogenated O
anesthetics O
, O
enflurane O
and O
isoflurane O
, O
have O
been O
associated O
with O
an O
allergic O
- O
type O
hepatic B-Disease
injury B-Disease
both O
alone O
and O
following O
previous O
exposure O
to O
halothane O
. O

halothane O
hepatitis B-Disease
appears O
to O
involve O
an O
aberrant O
immune O
response O
. O

an O
antibody O
response O
to O
a O
protein O
- O
bound O
biotransformation O
product O
( O
trifluoroacetyl O
adduct O
) O
has O
been O
detected O
on O
halothane O
hepatitis B-Disease
patients O
. O

this O
study O
was O
performed O
to O
determine O
cross O
- O
reactivity O
between O
enflurane O
and O
isoflurane O
with O
the O
hypersensitivity B-Disease
induced O
by O
halothane O
. O

the O
subcellular O
and O
lobular O
production O
of O
hepatic O
neoantigens O
recognized O
by O
halothane O
- O
induced O
antibodies O
following O
enflurane O
and O
isoflurane O
, O
and O
the O
biochemical O
nature O
of O
these O
neoantigens O
was O
investigated O
in O
two O
animal O
models O
. O

enflurane O
administration O
resulted O
in O
neoantigens O
detected O
in O
both O
the O
microsomal O
and O
cytosolic O
fraction O
of O
liver O
homogenates O
and O
in O
the O
centrilobular O
region O
of O
the O
liver O
. O

in O
the O
same O
liver O
, O
biochemical O
analysis O
detected O
fluorinated O
liver O
adducts O
that O
were O
up O
to O
20 O
- O
fold O
greater O
in O
guinea O
pigs O
than O
in O
rats O
. O

this O
supports O
and O
extends O
previous O
evidence O
for O
a O
mechanism O
by O
which O
enflurane O
and O
/ O
or O
isoflurane O
could O
produce O
a O
hypersensitivity B-Disease
condition O
similar O
to O
that O
of O
halothane O
hepatitis B-Disease
either O
alone O
or O
subsequent O
to O
halothane O
administration O
. O

the O
guinea O
pig O
would O
appear O
to O
be O
a O
useful O
model O
for O
further O
investigations O
of O
the O
immunological O
response O
to O
these O
antigens O
. O

cholinergic O
toxicity B-Disease
resulting O
from O
ocular O
instillation O
of O
echothiophate O
iodide O
eye O
drops O
. O

a O
patient O
developed O
a O
severe O
cholinergic O
syndrome O
from O
the O
use O
of O
echothiophate O
iodide O
ophthalmic O
drops O
, O
presented O
with O
profound O
muscle B-Disease
weakness B-Disease
and O
was O
initially O
given O
the O
diagnosis O
of O
myasthenia B-Disease
gravis B-Disease
. O

red O
blood O
cell O
and O
serum O
cholinesterase O
levels O
were O
severely O
depressed O
and O
symptoms O
resolved O
spontaneously O
following O
discontinuation O
of O
the O
eye O
drops O
. O

seizure B-Disease
after O
flumazenil O
administration O
in O
a O
pediatric O
patient O
. O

flumazenil O
is O
a O
benzodiazepine O
receptor O
antagonist O
used O
to O
reverse O
sedation O
and O
respiratory B-Disease
depression B-Disease
induced O
by O
benzodiazepines O
. O

seizures B-Disease
and O
cardiac B-Disease
arrhythmias B-Disease
have O
complicated O
its O
use O
in O
adult O
patients O
. O

overdose B-Disease
patients O
who O
have O
coingested O
tricyclic O
antidepressants O
have O
a O
higher O
risk O
of O
these O
complications O
. O

little O
information O
exists O
concerning O
adverse O
effects O
of O
flumazenil O
in O
children O
. O

we O
report O
the O
occurrence O
of O
a O
generalized O
tonic B-Disease
- B-Disease
clonic B-Disease
seizure B-Disease
in O
a O
pediatric O
patient O
following O
the O
administration O
of O
flumazenil O
. O

phase O
i O
trial O
of O
13 O
- O
cis O
- O
retinoic O
acid O
in O
children O
with O
neuroblastoma B-Disease
following O
bone O
marrow O
transplantation O
. O

purpose O
: O
treatment O
of O
neuroblastoma B-Disease
cell O
lines O
with O
13 O
- O
cis O
- O
retinoic O
acid O
( O
cis O
- O
ra O
) O
can O
cause O
sustained O
inhibition O
of O
proliferation O
. O

since O
cis O
- O
ra O
has O
demonstrated O
clinical O
responses O
in O
neuroblastoma B-Disease
patients O
, O
it O
may O
be O
effective O
in O
preventing O
relapse O
after O
cytotoxic O
therapy O
. O

this O
phase O
i O
trial O
was O
designed O
to O
determine O
the O
maximal O
- O
tolerated O
dosage O
( O
mtd O
) O
, O
toxicities B-Disease
, O
and O
pharmacokinetics O
of O
cis O
- O
ra O
administered O
on O
an O
intermittent O
schedule O
in O
children O
with O
neuroblastoma B-Disease
following O
bone O
marrow O
transplantation O
( O
bmt O
) O
. O

patients O
and O
methods O
: O
fifty O
- O
one O
assessable O
patients O
, O
2 O
to O
12 O
years O
of O
age O
, O
were O
treated O
with O
oral O
cis O
- O
ra O
administered O
in O
two O
equally O
divided O
doses O
daily O
for O
2 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
, O
for O
up O
to O
12 O
courses O
. O

the O
dose O
was O
escalated O
from O
100 O
to O
200 O
mg O
/ O
m2 O
/ O
d O
until O
dose O
- O
limiting O
toxicity B-Disease
( O
dlt O
) O
was O
observed O
. O

a O
single O
intrapatient O
dose O
escalation O
was O
permitted O
. O

results O
: O
the O
mtd O
of O
cis O
- O
ra O
was O
160 O
mg O
/ O
m2 O
/ O
d O
. O

dose O
- O
limiting O
toxicities B-Disease
in O
six O
of O
nine O
patients O
at O
200 O
mg O
/ O
m2 O
/ O
d O
included O
hypercalcemia B-Disease
( O
n O
= O
3 O
) O
, O
rash B-Disease
( O
n O
= O
2 O
) O
, O
and O
anemia B-Disease
/ O
thrombocytopenia B-Disease
/ O
emesis B-Disease
/ O
rash B-Disease
( O
n O
= O
1 O
) O
. O

all O
toxicities B-Disease
resolved O
after O
cis O
- O
ra O
was O
discontinued O
. O

three O
complete O
responses O
were O
observed O
in O
marrow O
metastases B-Disease
. O

serum O
levels O
of O
7 O
. O
4 O
+ O
/ O
- O
3 O
. O
0 O
mumol O
/ O
l O
( O
peak O
) O
and O
4 O
. O
0 O
+ O
/ O
- O
2 O
. O
8 O
mumol O
/ O
l O
( O
trough O
) O
at O
the O
mtd O
were O
maintained O
during O
14 O
days O
of O
therapy O
. O

the O
dlt O
correlated O
with O
serum O
levels O
> O
or O
= O
10 O
mumol O
/ O
l O
. O

conclusion O
: O
the O
mtd O
of O
cis O
- O
ra O
given O
on O
this O
intermittent O
schedule O
was O
160 O
mg O
/ O
m2 O
/ O
d O
. O

serum O
levels O
known O
to O
be O
effective O
against O
neuroblastoma B-Disease
in O
vitro O
were O
achieved O
at O
this O
dose O
. O

the O
dlt O
included O
hypercalcemia B-Disease
, O
and O
may O
be O
predicted O
by O
serum O
cis O
- O
ra O
levels O
. O

monitoring O
of O
serum O
calcium O
and O
cis O
- O
ra O
levels O
is O
indicated O
in O
future O
trials O
. O

time O
dependence O
of O
plasma O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
during O
incomplete O
cerebral B-Disease
ischemia B-Disease
in O
the O
rat O
. O

incomplete O
cerebral B-Disease
ischemia B-Disease
( O
30 O
min O
) O
was O
induced O
in O
the O
rat O
by O
bilaterally O
clamping O
the O
common O
carotid O
arteries O
. O

peripheral O
venous O
blood O
samples O
were O
withdrawn O
from O
the O
femoral O
vein O
four O
times O
( O
once O
every O
5 O
min O
) O
before O
ischemia B-Disease
( O
0 O
time O
) O
and O
5 O
, O
15 O
, O
and O
30 O
min O
after O
ischemia B-Disease
. O

plasma O
extracts O
were O
analyzed O
by O
a O
highly O
sensitive O
high O
- O
performance O
liquid O
chromatographic O
method O
for O
the O
direct O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
. O

during O
ischemia B-Disease
, O
a O
time O
- O
dependent O
increase O
of O
plasma O
oxypurines O
and O
nucleosides O
was O
observed O
. O

plasma O
malondialdehyde O
, O
which O
was O
present O
in O
minimal O
amount O
at O
zero O
time O
( O
0 O
. O
058 O
mumol O
/ O
liter O
plasma O
; O
sd O
0 O
. O
015 O
) O
, O
increased O
after O
5 O
min O
of O
ischemia B-Disease
, O
resulting O
in O
a O
fivefold O
increase O
after O
30 O
min O
of O
carotid O
occlusion O
( O
0 O
. O
298 O
mumol O
/ O
liter O
plasma O
; O
sd O
0 O
. O
078 O
) O
. O

increased O
plasma O
malondialdehyde O
was O
also O
recorded O
in O
two O
other O
groups O
of O
animals O
subjected O
to O
the O
same O
experimental O
model O
, O
one O
receiving O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
of O
the O
cyclooxygenase O
inhibitor O
acetylsalicylate O
intravenously O
immediately O
before O
ischemia B-Disease
, O
the O
other O
receiving O
650 O
micrograms O
/ O
kg O
b O
. O
w O
. O
of O
the O
hypotensive B-Disease
drug O
nitroprusside O
at O
a O
flow O
rate O
of O
103 O
microliters O
/ O
min O
intravenously O
during O
ischemia B-Disease
, O
although O
in O
this O
latter O
group O
malondialdehyde O
was O
significantly O
higher O
. O

the O
present O
data O
indicate O
that O
the O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides O
in O
peripheral O
blood O
, O
may O
be O
used O
to O
monitor O
the O
metabolic O
alterations O
of O
tissues O
occurring O
during O
ischemic B-Disease
phenomena O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

acute O
renal B-Disease
toxicity B-Disease
of O
doxorubicin O
( O
adriamycin O
) O
- O
loaded O
cyanoacrylate O
nanoparticles O
. O

acute O
doxorubicin O
- O
loaded O
nanoparticle O
( O
dxnp O
) O
renal B-Disease
toxicity B-Disease
was O
explored O
in O
both O
normal O
rats O
and O
rats O
with O
experimental O
glomerulonephritis B-Disease
. O

in O
normal O
rats O
, O
2 O
/ O
6 O
rats O
given O
free O
doxorubicin O
( O
dx O
) O
( O
5 O
mg O
/ O
kg O
) O
died O
within O
one O
week O
, O
whereas O
all O
control O
animals O
and O
all O
rats O
having O
received O
free O
np O
or O
dxnp O
survived O
. O

a O
3 O
times O
higher O
proteinuria B-Disease
appeared O
in O
animals O
treated O
with O
dxnp O
than O
in O
those O
treated O
with O
dx O
. O

free O
np O
did O
not O
provoke O
any O
proteinuria B-Disease
. O

two O
hr O
post O
- O
injection O
, O
dxnp O
was O
2 O
. O
7 O
times O
more O
concentrated O
in O
kidneys O
than O
free O
dx O
( O
p O
< O
0 O
. O
025 O
) O
. O

in O
rats O
with O
immune O
experimental O
glomerulonephritis B-Disease
, O
5 O
/ O
6 O
rats O
given O
dx O
died O
within O
7 O
days O
, O
in O
contrast O
to O
animals O
treated O
by O
dxnp O
, O
np O
, O
or O
untreated O
, O
which O
all O
survived O
. O

proteinuria B-Disease
appeared O
in O
all O
series O
, O
but O
was O
2 O
- O
5 O
times O
more O
intense O
( O
p O
> O
0 O
. O
001 O
) O
and O
prolonged O
after O
doxorubicin O
treatment O
( O
400 O
- O
700 O
mg O
/ O
day O
) O
, O
without O
significant O
difference O
between O
dxnp O
and O
dx O
. O

rats O
treated O
by O
unloaded O
np O
behaved O
as O
controls O
. O

these O
results O
demonstrate O
that O
, O
in O
these O
experimental O
conditions O
, O
dxnp O
killed O
less O
animals O
than O
free O
dx O
, O
despite O
of O
an O
enhanced O
renal B-Disease
toxicity B-Disease
of O
the O
former O
. O

both O
effects O
( O
better O
survival O
and O
nephrosis B-Disease
) O
are O
most O
probably O
related O
to O
an O
enhanced O
capture O
of O
dxnp O
by O
cells O
of O
the O
mononuclear O
phagocyte O
system O
, O
including O
mesangial O
cells O
. O

prostaglandin O
e2 O
- O
induced O
bladder B-Disease
hyperactivity B-Disease
in O
normal O
, O
conscious O
rats O
: O
involvement O
of O
tachykinins O
? O

in O
normal O
conscious O
rats O
investigated O
by O
continuous O
cystometry O
, O
intravesically O
instilled O
prostaglandin O
( O
pg O
) O
e2 O
facilitated O
micturition O
and O
increased O
basal O
intravesical O
pressure O
. O

the O
effect O
was O
attenuated O
by O
both O
the O
nk1 O
receptor O
selective O
antagonist O
rp O
67 O
, O
580 O
and O
the O
nk2 O
receptor O
selective O
antagonist O
sr O
48 O
, O
968 O
, O
given O
intra O
- O
arterially O
, O
suggesting O
that O
it O
was O
mediated O
by O
stimulation O
of O
both O
nk1 O
and O
nk2 O
receptors O
. O

intra O
- O
arterially O
given O
pge2 O
produced O
a O
distinct O
increase O
in O
bladder O
pressure O
before O
initiating O
a O
micturition O
reflex O
, O
indicating O
that O
the O
pg O
had O
a O
direct O
contractant O
effect O
on O
the O
detrusor O
smooth O
muscle O
. O

the O
effect O
of O
intra O
- O
arterial O
pge2 O
could O
not O
be O
blocked O
by O
intra O
- O
arterial O
rp O
67 O
, O
580 O
or O
sr O
48 O
, O
968 O
, O
which O
opens O
the O
possibility O
that O
the O
micturition O
reflex O
elicited O
by O
intra O
- O
arterial O
pge2 O
was O
mediated O
by O
pathways O
other O
than O
the O
reflex O
initiated O
when O
the O
pg O
was O
given O
intravesically O
. O

the O
present O
results O
thus O
suggest O
that O
intra O
- O
arterial O
pge2 O
, O
given O
near O
the O
bladder O
, O
may O
initiate O
micturition O
in O
the O
normal O
rat O
chiefly O
by O
directly O
contracting O
the O
smooth O
muscle O
of O
the O
detrusor O
. O

however O
, O
when O
given O
intravesically O
, O
pge2 O
may O
stimulate O
micturition O
by O
releasing O
tachykinins O
from O
nerves O
in O
and O
/ O
or O
immediately O
below O
the O
urothelium O
. O

these O
tachykinins O
, O
in O
turn O
, O
initiate O
a O
micturition O
reflex O
by O
stimulating O
nk1 O
and O
nk2 O
receptors O
. O

prostanoids O
may O
, O
via O
release O
of O
tachykinins O
, O
contribute O
to O
both O
urge O
and O
bladder B-Disease
hyperactivity B-Disease
seen O
in O
inflammatory O
conditions O
of O
the O
lower O
urinary O
tract O
. O

refractory O
cardiogenic B-Disease
shock B-Disease
and O
complete O
heart B-Disease
block B-Disease
after O
verapamil O
sr O
and O
metoprolol O
treatment O
. O

a O
case O
report O
. O

a O
seventy O
- O
eight O
- O
year O
- O
old O
woman O
presented O
with O
complete O
heart B-Disease
block B-Disease
and O
refractory O
hypotension B-Disease
two O
days O
after O
a O
therapeutic O
dose O
of O
sustained O
- O
release O
verapamil O
with O
concomitant O
use O
of O
metoprolol O
. O

the O
patient O
continued O
to O
remain O
hypotensive B-Disease
with O
complete O
heart B-Disease
block B-Disease
, O
even O
with O
multiple O
uses O
of O
intravenous O
atropine O
as O
well O
as O
high O
doses O
of O
pressor O
agents O
such O
as O
dopamine O
and O
dobutamine O
. O

however O
, O
shortly O
after O
the O
use O
of O
intravenous O
calcium O
chloride O
, O
the O
refractory O
hypotension B-Disease
and O
complete O
heart B-Disease
block B-Disease
resolved O
. O

protective O
effect O
of O
misoprostol O
on O
indomethacin O
induced O
renal B-Disease
dysfunction B-Disease
in O
elderly O
patients O
. O

objective O
: O
to O
evaluate O
the O
possible O
protective O
effects O
of O
misoprostol O
on O
renal O
function O
in O
hospitalized O
elderly O
patients O
treated O
with O
indomethacin O
. O

methods O
: O
forty O
- O
five O
hospitalized O
elderly O
patients O
( O
> O
65 O
years O
old O
) O
who O
required O
therapy O
with O
nonsteroidal O
antiinflammatory O
drugs O
( O
nsaid O
) O
were O
randomly O
assigned O
to O
receive O
either O
indomethacin O
, O
150 O
mg O
/ O
day O
( O
group O
a O
) O
, O
or O
indomethacin O
150 O
mg O
/ O
day O
plus O
misoprostol O
at O
0 O
. O
6 O
mg O
/ O
day O
( O
group O
b O
) O
. O

laboratory O
variables O
of O
renal O
function O
[ O
serum O
creatinine O
, O
blood O
urea O
nitrogen O
( O
bun O
) O
and O
electrolytes O
] O
were O
evaluated O
before O
initiation O
of O
therapy O
and O
every O
2 O
days O
, O
until O
termination O
of O
the O
study O
( O
a O
period O
of O
at O
least O
6 O
days O
) O
. O

response O
to O
treatment O
was O
estimated O
by O
the O
visual O
analog O
scale O
for O
severity O
of O
pain B-Disease
. O

results O
: O
forty O
- O
two O
patients O
completed O
the O
study O
, O
22 O
in O
group O
a O
and O
20 O
in O
group O
b O
. O

bun O
and O
creatinine O
increased O
by O
> O
50 O
% O
of O
baseline O
levels O
in O
54 O
and O
45 O
% O
of O
group O
a O
patients O
, O
respectively O
, O
compared O
to O
only O
20 O
and O
10 O
% O
of O
group O
b O
patients O
( O
p O
< O
0 O
. O
05 O
) O
. O

potassium O
( O
k O
) O
increment O
of O
0 O
. O
6 O
meq O
/ O
l O
or O
more O
was O
observed O
in O
50 O
% O
of O
group O
a O
, O
but O
in O
only O
15 O
% O
of O
group O
b O
patients O
( O
p O
< O
0 O
. O
05 O
) O
. O

the O
mean O
increments O
in O
bun O
, O
creatinine O
, O
and O
k O
were O
reduced O
by O
63 O
, O
80 O
, O
and O
42 O
% O
, O
respectively O
, O
in O
group O
b O
patients O
compared O
to O
group O
a O
. O
response O
to O
treatment O
did O
not O
differ O
significantly O
between O
the O
2 O
groups O
. O

conclusion O
: O
hospitalized O
elderly O
patients O
are O
at O
risk O
for O
developing O
indomethacin O
related O
renal B-Disease
dysfunction B-Disease
. O

addition O
of O
misoprostol O
can O
minimize O
this O
renal B-Disease
impairment B-Disease
without O
affecting O
pain B-Disease
control O
. O

cognitive B-Disease
deterioration B-Disease
from O
long O
- O
term O
abuse O
of O
dextromethorphan O
: O
a O
case O
report O
. O

dextromethorphan O
( O
dm O
) O
, O
the O
dextrorotatory O
isomer O
of O
3 O
- O
hydroxy O
- O
n O
- O
methylmorphinan O
, O
is O
the O
main O
ingredient O
in O
a O
number O
of O
widely O
available O
, O
over O
- O
the O
- O
counter O
antitussives O
. O

initial O
studies O
( O
bornstein O
1968 O
) O
showed O
that O
it O
possessed O
no O
respiratory O
suppressant O
effects O
and O
no O
addiction O
liability O
. O

subsequently O
, O
however O
, O
several O
articles O
reporting O
abuse O
of O
this O
drug O
have O
appeared O
in O
the O
literature O
. O

the O
drug O
is O
known O
to O
cause O
a O
variety O
of O
acute O
toxic O
effects O
, O
ranging O
from O
nausea B-Disease
, O
restlessness B-Disease
, O
insomnia B-Disease
, O
ataxia B-Disease
, O
slurred O
speech O
and O
nystagmus B-Disease
to O
mood O
changes O
, O
perceptual O
alterations O
, O
inattention O
, O
disorientation O
and O
aggressive B-Disease
behavior B-Disease
( O
rammer O
et O
al O
1988 O
; O
katona O
and O
watson O
1986 O
; O
isbell O
and O
fraser O
1953 O
; O
devlin O
et O
al O
1985 O
; O
mccarthy O
1971 O
; O
dodds O
and O
revai O
1967 O
; O
degkwitz O
1964 O
; O
hildebrand O
et O
al O
1989 O
) O
. O

there O
have O
also O
been O
two O
reported O
fatalities O
from O
dm O
overdoses O
( O
fleming O
1986 O
) O
. O

however O
, O
there O
are O
no O
reports O
describing O
the O
effects O
of O
chronic O
abuse O
. O

this O
report O
describes O
a O
case O
of O
cognitive B-Disease
deterioration B-Disease
resulting O
from O
prolonged O
use O
of O
dm O
. O

effects O
of O
ouabain O
on O
myocardial O
oxygen O
supply O
and O
demand O
in O
patients O
with O
chronic O
coronary B-Disease
artery B-Disease
disease B-Disease
. O

a O
hemodynamic O
, O
volumetric O
, O
and O
metabolic O
study O
in O
patients O
without O
heart B-Disease
failure B-Disease
. O

the O
effects O
of O
digitalis O
glycosides O
on O
myocardial O
oxygen O
supply O
and O
demand O
are O
of O
particular O
interest O
in O
the O
presence O
of O
obstructive O
coronary B-Disease
artery B-Disease
disease B-Disease
, O
but O
have O
not O
been O
measured O
previously O
in O
man O
. O

we O
assessed O
the O
effects O
of O
ouabain O
( O
0 O
. O
015 O
mg O
/ O
kg O
body O
weight O
) O
on O
hemodynamic O
, O
volumetric O
, O
and O
metabolic O
parameters O
in O
11 O
patients O
with O
severe O
chronic O
coronary B-Disease
artery B-Disease
disease B-Disease
without O
clinical O
congestive B-Disease
heart B-Disease
failure B-Disease
. O

because O
the O
protocol O
was O
long O
and O
involved O
interventions O
which O
might O
affect O
the O
determinations O
, O
we O
also O
studied O
in O
nine O
patients O
using O
an O
identical O
protocol O
except O
that O
ouabain O
administration O
was O
omitted O
. O

left O
ventricular O
end O
- O
diastolic O
pressure O
and O
left O
ventricular O
end O
- O
diastolic O
volume O
fell O
in O
each O
patient O
given O
ouabain O
, O
even O
though O
they O
were O
initially O
elevated O
in O
only O
two O
patients O
. O

left O
ventricular O
end O
- O
diastolic O
pressure O
fell O
from O
11 O
. O
5 O
+ O
/ O
- O
1 O
. O
4 O
( O
mean O
+ O
/ O
- O
se O
) O
to O
5 O
. O
6 O
+ O
/ O
- O
0 O
. O
9 O
mm O
hg O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
left O
ventricular O
end O
- O
diastolic O
volume O
fell O
from O
100 O
+ O
/ O
- O
17 O
to O
82 O
+ O
/ O
- O
12 O
ml O
/ O
m2 O
( O
p O
less O
than O
0 O
. O
01 O
) O
1 O
h O
after O
ouabain O
infusion O
was O
completed O
. O

the O
maximum O
velocity O
of O
contractile O
element O
shortening O
increased O
from O
1 O
. O
68 O
+ O
/ O
- O
0 O
. O
11 O
ml O
/ O
s O
to O
2 O
. O
18 O
+ O
/ O
- O
0 O
. O
21 O
muscle O
- O
lengths O
/ O
s O
( O
p O
less O
than O
0 O
. O
05 O
) O
and O
is O
consistent O
with O
an O
increase O
in O
contractility O
. O

no O
significant O
change O
in O
these O
parameters O
occurred O
in O
the O
control O
patients O
. O

no O
significant O
change O
in O
myocardial O
oxygen O
consumption O
occurred O
after O
ouabain O
administration O
but O
this O
may O
be O
related O
to O
a O
greater O
decrease O
in O
mean O
arterial O
pressure O
in O
the O
ouabain O
patients O
than O
in O
the O
control O
patients O
. O

we O
conclude O
that O
in O
patients O
with O
chronic O
coronary B-Disease
artery B-Disease
disease B-Disease
who O
are O
not O
in O
clinical O
congestive B-Disease
heart B-Disease
failure B-Disease
left B-Disease
ventricular B-Disease
end B-Disease
- B-Disease
diastolic B-Disease
volume B-Disease
falls B-Disease
after O
ouabain O
administration O
even O
when O
it O
is O
initially O
normal O
. O

though O
this O
fall O
would O
be O
associated O
with O
a O
decrease O
in O
wall O
tension O
, O
and O
, O
therefore O
, O
of O
myocardial O
oxygen O
consumption O
, O
it O
may O
not O
be O
of O
sufficient O
magnitude O
to O
prevent O
a O
net O
increase O
in O
myocardial O
oxygen O
consumption O
. O

nevertheless O
, O
compensatory O
mechanisms O
prevent O
a O
deterioration O
of O
resting O
myocardial O
metabolism O
. O

dexamethasone O
- O
induced O
ocular B-Disease
hypertension B-Disease
in O
perfusion O
- O
cultured O
human O
eyes O
. O

purpose O
: O
glucocorticoid O
administration O
can O
lead O
to O
the O
development O
of O
ocular B-Disease
hypertension B-Disease
and O
corticosteroid B-Disease
glaucoma B-Disease
in O
a O
subset O
of O
the O
population O
through O
a O
decrease O
in O
the O
aqueous O
humor O
outflow O
facility O
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
glucocorticoid O
treatment O
can O
directly O
affect O
the O
outflow O
facility O
of O
isolated O
, O
perfusion O
- O
cultured O
human O
eyes O
. O

methods O
: O
the O
anterior O
segments O
of O
human O
donor O
eyes O
from O
regional O
eye O
banks O
were O
placed O
in O
a O
constant O
flow O
, O
variable O
pressure O
perfusion O
culture O
system O
. O

paired O
eyes O
were O
perfused O
in O
serum O
- O
free O
media O
with O
or O
without O
10 O
( O
- O
7 O
) O
m O
dexamethasone O
for O
12 O
days O
. O

intraocular O
pressure O
was O
monitored O
daily O
. O

after O
incubation O
, O
the O
eyes O
were O
morphologically O
characterized O
by O
light O
microscopy O
, O
transmission O
and O
scanning O
electron O
microscopy O
, O
and O
scanning O
laser O
confocal O
microscopy O
. O

results O
: O
a O
significant O
increase O
in O
intraocular O
pressure O
developed O
in O
13 O
of O
the O
44 O
pairs O
of O
eyes O
perfused O
with O
dexamethasone O
with O
an O
average O
pressure O
rise O
of O
17 O
. O
5 O
+ O
/ O
- O
3 O
. O
8 O
mm O
hg O
after O
12 O
days O
of O
dexamethasone O
exposure O
. O

the O
contralateral O
control O
eyes O
, O
which O
did O
not O
receive O
dexamethasone O
, O
maintained O
a O
stable O
intraocular O
pressure O
during O
the O
same O
period O
. O

the O
outflow O
pathway O
of O
the O
untreated O
eyes O
appeared O
morphologically O
normal O
. O

in O
contrast O
, O
the O
dexamethasone O
- O
treated O
hypertensive B-Disease
eyes B-Disease
had O
thickened O
trabecular O
beams O
, O
decreased O
intertrabecular O
spaces O
, O
thickened O
juxtacanalicular O
tissue O
, O
activated O
trabecular O
meshwork O
cells O
, O
and O
increased O
amounts O
of O
amorphogranular O
extracellular O
material O
, O
especially O
in O
the O
juxtacanalicular O
tissue O
and O
beneath O
the O
endothelial O
lining O
of O
the O
canal O
of O
schlemm O
. O

the O
dexamethasone O
- O
treated O
nonresponder O
eyes O
appeared O
to O
be O
morphologically O
similar O
to O
the O
untreated O
eyes O
, O
although O
several O
subtle O
dexamethasone O
- O
induced O
morphologic O
changes O
were O
evident O
. O

conclusion O
: O
dexamethasone O
treatment O
of O
isolated O
, O
perfusion O
- O
cultured O
human O
eyes O
led O
to O
the O
generation O
of O
ocular B-Disease
hypertension B-Disease
in O
approximately O
30 O
% O
of O
the O
dexamethasone O
- O
treated O
eyes O
. O

steroid O
treatment O
resulted O
in O
morphologic O
changes O
in O
the O
trabecular O
meshwork O
similar O
to O
those O
reported O
for O
corticosteroid B-Disease
glaucoma B-Disease
and O
open B-Disease
angle B-Disease
glaucoma B-Disease
. O

this O
system O
may O
provide O
an O
acute O
model O
in O
which O
to O
study O
the O
pathogenic O
mechanisms O
involved O
in O
steroid B-Disease
glaucoma B-Disease
and O
primary B-Disease
open B-Disease
angle B-Disease
glaucoma B-Disease
. O

auditory O
disturbance O
associated O
with O
interscalene O
brachial O
plexus O
block O
. O

we O
performed O
an O
audiometric O
study O
in O
20 O
patients O
who O
underwent O
surgery O
of O
the O
shoulder O
region O
under O
an O
interscalene O
brachial O
plexus O
block O
( O
ibpb O
) O
. O

bupivacaine O
0 O
. O
75 O
% O
with O
adrenaline O
was O
given O
followed O
by O
a O
24 O
- O
hr O
continuous O
infusion O
of O
0 O
. O
25 O
% O
bupivacaine O
. O

three O
audiometric O
threshold O
measurements O
( O
0 O
. O
25 O
- O
18 O
khz O
) O
were O
made O
: O
the O
first O
before O
ibpb O
, O
the O
second O
2 O
- O
6 O
h O
after O
surgery O
and O
the O
third O
on O
the O
first O
day O
after O
operation O
. O

in O
four O
patients O
hearing B-Disease
impairment B-Disease
on O
the O
side O
of O
the O
block O
was O
demonstrated O
after O
operation O
, O
in O
three O
measurements O
on O
the O
day O
of O
surgery O
and O
in O
one O
on O
the O
following O
day O
. O

the O
frequencies O
at O
which O
the O
impairment O
occurred O
varied O
between O
patients O
; O
in O
one O
only O
low O
frequencies O
( O
0 O
. O
25 O
- O
0 O
. O
5 O
khz O
) O
were O
involved O
. O

the O
maximum O
change O
in O
threshold O
was O
35 O
db O
at O
6 O
khz O
measured O
at O
the O
end O
of O
the O
continuous O
infusion O
of O
bupivacaine O
. O

this O
patient O
had O
hearing O
threshold O
changes O
( O
15 O
- O
20 O
db O
) O
at O
6 O
- O
10 O
khz O
on O
the O
opposite O
side O
also O
. O

ibpb O
may O
cause O
transient O
auditory B-Disease
dysfunction B-Disease
in O
the O
ipsilateral O
ear O
, O
possibly O
via O
an O
effect O
on O
sympathetic O
innervation O
. O

the O
safety O
and O
efficacy O
of O
combination O
n O
- O
butyl O
- O
deoxynojirimycin O
( O
sc O
- O
48334 O
) O
and O
zidovudine O
in O
patients O
with O
hiv B-Disease
- B-Disease
1 B-Disease
infection B-Disease
and O
200 O
- O
500 O
cd4 O
cells O
/ O
mm3 O
. O

we O
conducted O
a O
double O
- O
blind O
, O
randomized O
phase O
ii O
study O
to O
evaluate O
the O
safety O
and O
activity O
of O
combination O
therapy O
with O
n O
- O
butyl O
- O
deoxynojirimycin O
( O
sc O
- O
48334 O
) O
( O
an O
alpha O
- O
glucosidase O
i O
inhibitor O
) O
and O
zidovudine O
versus O
zidovudine O
alone O
. O

patients O
with O
200 O
to O
500 O
cd4 O
cells O
/ O
mm3 O
who O
tolerated O
< O
or O
= O
12 O
weeks O
of O
prior O
zidovudine O
therapy O
received O
sc O
- O
48334 O
( O
1000 O
mg O
every O
8 O
h O
) O
and O
zidovudine O
( O
100 O
mg O
every O
8 O
h O
) O
or O
zidovudine O
and O
placebo O
. O

sixty O
patients O
received O
combination O
therapy O
and O
58 O
, O
zidovudine O
and O
placebo O
. O

twenty O
- O
three O
patients O
( O
38 O
% O
) O
and O
15 O
( O
26 O
% O
) O
, O
in O
the O
combination O
and O
zidovudine O
groups O
, O
respectively O
, O
discontinued O
therapy O
( O
p O
= O
0 O
. O
15 O
) O
. O

the O
mean O
sc O
- O
48334 O
steady O
- O
state O
trough O
level O
( O
4 O
. O
04 O
+ O
/ O
- O
0 O
. O
99 O
micrograms O
/ O
ml O
) O
was O
below O
the O
in O
vitro O
inhibitory O
concentration O
for O
human O
immunodeficiency B-Disease
virus O
( O
hiv O
) O
. O

the O
mean O
increase O
in O
cd4 O
cells O
at O
week O
4 O
was O
73 O
. O
8 O
cells O
/ O
mm3 O
and O
52 O
. O
4 O
cells O
/ O
mm3 O
for O
the O
combination O
and O
zidovudine O
groups O
, O
respectively O
( O
p O
> O
0 O
. O
36 O
) O
. O

for O
patients O
with O
prior O
zidovudine O
therapy O
, O
the O
mean O
change O
in O
cd4 O
cells O
in O
the O
combination O
and O
zidovudine O
groups O
was O
63 O
. O
7 O
cells O
/ O
mm3 O
and O
4 O
. O
9 O
cells O
/ O
mm3 O
at O
week O
8 O
and O
6 O
. O
8 O
cells O
/ O
mm3 O
and O
- O
45 O
. O
1 O
cells O
/ O
mm3 O
at O
week O
16 O
, O
respectively O
. O

the O
number O
of O
patients O
with O
suppression O
of O
hiv O
p24 O
antigenemia O
in O
the O
combination O
and O
zidovudine O
groups O
was O
six O
( O
40 O
% O
) O
and O
two O
( O
11 O
% O
) O
at O
week O
4 O
( O
p O
= O
0 O
. O
10 O
) O
and O
five O
( O
45 O
% O
) O
and O
two O
( O
14 O
% O
) O
at O
week O
24 O
( O
p O
= O
0 O
. O
08 O
) O
, O
respectively O
. O

diarrhea B-Disease
, O
flatulence B-Disease
, O
abdominal B-Disease
pain B-Disease
, O
and O
weight B-Disease
loss B-Disease
were O
common O
for O
combination O
recipients O
. O
( O
abstract O
truncated O
at O
250 O
words O
) O

prolonged O
paralysis B-Disease
due O
to O
nondepolarizing O
neuromuscular O
blocking O
agents O
and O
corticosteroids O
. O

the O
long O
- O
term O
use O
of O
nondepolarizing O
neuromuscular O
blocking O
agents O
( O
nd O
- O
nmba O
) O
has O
recently O
been O
implicated O
as O
a O
cause O
of O
prolonged O
muscle B-Disease
weakness B-Disease
, O
although O
the O
site O
of O
the O
lesion O
and O
the O
predisposing O
factors O
have O
been O
unclear O
. O

we O
report O
3 O
patients O
( O
age O
37 O
- O
52 O
years O
) O
with O
acute O
respiratory B-Disease
insufficiency B-Disease
who O
developed O
prolonged O
weakness B-Disease
following O
the O
discontinuation O
of O
nd O
- O
nmbas O
. O

two O
patients O
also O
received O
intravenous O
corticosteroids O
. O

renal O
function O
was O
normal O
but O
hepatic O
function O
was O
impaired O
in O
all O
patients O
, O
and O
all O
had O
acidosis B-Disease
. O

electrophysiologic O
studies O
revealed O
low O
amplitude O
compound O
motor O
action O
potentials O
, O
normal O
sensory O
studies O
, O
and O
fibrillations O
. O

repetitive O
stimulation O
at O
2 O
hz O
showed O
a O
decremental O
response O
in O
2 O
patients O
. O

the O
serum O
vecuronium O
level O
measured O
in O
1 O
patient O
14 O
days O
after O
the O
drug O
had O
been O
discontinued O
was O
172 O
ng O
/ O
ml O
. O

a O
muscle O
biopsy O
in O
this O
patient O
showed O
loss B-Disease
of B-Disease
thick B-Disease
, B-Disease
myosin B-Disease
filaments B-Disease
. O

the O
weakness B-Disease
in O
these O
patients O
is O
due O
to O
pathology B-Disease
at B-Disease
both B-Disease
the B-Disease
neuromuscular B-Disease
junction B-Disease
( O
most O
likely O
due O
to O
nd O
- O
nmba O
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids O
) O
. O

hepatic B-Disease
dysfunction B-Disease
and O
acidosis B-Disease
are O
contributing O
risk O
factors O
. O

failure O
of O
ancrod O
in O
the O
treatment O
of O
heparin O
- O
induced O
arterial O
thrombosis B-Disease
. O

the O
morbidity O
and O
mortality O
associated O
with O
heparin O
- O
induced O
thrombosis B-Disease
remain O
high O
despite O
numerous O
empirical O
therapies O
. O

ancrod O
has O
been O
used O
successfully O
for O
prophylaxis O
against O
development O
of O
thrombosis B-Disease
in O
patients O
with O
heparin O
induced O
platelet B-Disease
aggregation B-Disease
who O
require O
brief O
reexposure O
to O
heparin O
, O
but O
its O
success O
in O
patients O
who O
have O
developed O
the O
thrombosis B-Disease
syndrome O
is O
not O
well O
defined O
. O

the O
authors O
present O
a O
case O
of O
failure O
of O
ancrod O
treatment O
in O
a O
patient O
with O
heparin O
- O
induced O
thrombosis B-Disease
. O

water B-Disease
intoxication B-Disease
associated O
with O
oxytocin O
administration O
during O
saline O
- O
induced O
abortion B-Disease
. O

four O
cases O
of O
water B-Disease
intoxication B-Disease
in O
connection O
with O
oxytocin O
administration O
during O
saline O
- O
induced O
abortions B-Disease
are O
described O
. O

the O
mechanism O
of O
water B-Disease
intoxication B-Disease
is O
discussed O
in O
regard O
to O
these O
cases O
. O

oxytocin O
administration O
during O
midtrimester O
- O
induced O
abortions B-Disease
is O
advocated O
only O
if O
it O
can O
be O
carried O
out O
under O
careful O
observations O
of O
an O
alert O
nursing O
staff O
, O
aware O
of O
the O
symptoms O
of O
water B-Disease
intoxication B-Disease
and O
instructed O
to O
watch O
the O
diuresis O
and O
report O
such O
early O
signs O
of O
the O
syndrome O
as O
asthenia B-Disease
, O
muscular O
irritability B-Disease
, O
or O
headaches B-Disease
. O

the O
oxytocin O
should O
be O
given O
only O
in O
ringers O
lactate O
or O
, O
alternately O
, O
in O
ringers O
lactate O
and O
a O
5 O
per O
cent O
dextrose O
and O
water O
solutions O
. O

the O
urinary O
output O
should O
be O
monitored O
and O
the O
oxytocin O
administration O
discontinued O
and O
the O
serum O
electrolytes O
checked O
if O
the O
urinary O
output O
decreases O
. O

the O
oxytocin O
should O
not O
be O
administered O
in O
excess O
of O
36 O
hours O
. O

if O
the O
patient O
has O
not O
aborted O
by O
then O
the O
oxytocin O
should O
be O
discontinued O
for O
10 O
to O
12 O
hours O
in O
order O
to O
perform O
electrolyte O
determinations O
and O
correct O
any O
electrolyte O
imbalance O
. O

light O
chain O
proteinuria B-Disease
and O
cellular O
mediated O
immunity O
in O
rifampin O
treated O
patients O
with O
tuberculosis B-Disease
. O

light O
chain O
proteinuria B-Disease
was O
found O
in O
9 O
of O
17 O
tuberculosis B-Disease
patients O
treated O
with O
rifampin O
. O

concomitant O
assay O
of O
cellular O
mediated O
immunity O
in O
these O
patients O
using O
skin O
test O
antigen O
and O
a O
lymphokine O
in O
vitro O
test O
provided O
results O
that O
were O
different O
. O

response O
to O
varidase O
skin O
test O
antigen O
was O
negative O
for O
all O
eight O
tuberculosis B-Disease
patients O
tested O
, O
but O
there O
occurred O
a O
hyper O
- O
responsiveness O
of O
the O
lymphocytes O
of O
these O
eight O
patients O
to O
phytomitogen O
( O
pha O
- O
p O
) O
. O
as O
well O
as O
of O
those O
of O
seven O
other O
tuberculous B-Disease
patients O
. O

this O
last O
finding O
may O
be O
related O
to O
time O
of O
testing O
and O
/ O
or O
endogenous O
serum O
binding O
of O
rifampin O
which O
could O
have O
inhibited O
mitogen O
activity O
for O
the O
lymphocyte O
. O

kf17837 O
: O
a O
novel O
selective O
adenosine O
a2a O
receptor O
antagonist O
with O
anticataleptic O
activity O
. O

kf17837 O
is O
a O
novel O
selective O
adenosine O
a2a O
receptor O
antagonist O
. O

oral O
administration O
of O
kf17837 O
( O
2 O
. O
5 O
, O
10 O
. O
0 O
and O
30 O
. O
0 O
mg O
/ O
kg O
) O
significantly O
ameliorated O
the O
cataleptic B-Disease
responses O
induced O
by O
intracerebroventricular O
administration O
of O
an O
adenosine O
a2a O
receptor O
agonist O
, O
cgs O
21680 O
( O
10 O
micrograms O
) O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

kf17837 O
also O
reduced O
the O
catalepsy B-Disease
induced O
by O
haloperidol O
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
and O
by O
reserpine O
( O
5 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

these O
anticataleptic O
effects O
were O
exhibited O
dose O
dependently O
at O
doses O
from O
0 O
. O
625 O
and O
2 O
. O
5 O
mg O
/ O
kg O
p O
. O
o O
. O
, O
respectively O
. O

moreover O
, O
kf17837 O
( O
0 O
. O
625 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
potentiated O
the O
anticataleptic O
effects O
of O
a O
subthreshold O
dose O
of O
l O
- O
3 O
, O
4 O
- O
dihydroxyphenylalanine O
( O
l O
- O
dopa O
; O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
plus O
benserazide O
( O
6 O
. O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

these O
results O
suggested O
that O
kf17837 O
is O
a O
centrally O
active O
adenosine O
a2a O
receptor O
antagonist O
and O
that O
the O
dopaminergic O
function O
of O
the O
nigrostriatal O
pathway O
is O
potentiated O
by O
adenosine O
a2a O
receptor O
antagonists O
. O

furthermore O
, O
kf17837 O
may O
be O
a O
useful O
drug O
in O
the O
treatment O
of O
parkinsonism B-Disease
. O

effect O
of O
nondopaminergic O
drugs O
on O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
in O
mptp O
- O
treated O
monkeys O
. O

a O
group O
of O
four O
monkeys O
was O
rendered O
parkinsonian B-Disease
with O
the O
toxin O
mptp O
. O

they O
were O
then O
treated O
chronically O
with O
l O
- O
dopa O
/ O
benserazide O
50 O
/ O
12 O
. O
5 O
mg O
/ O
kg O
given O
orally O
daily O
for O
2 O
months O
. O

this O
dose O
produced O
a O
striking O
antiparkinsonian O
effect O
, O
but O
all O
animals O
manifested O
dyskinesia B-Disease
. O

a O
series O
of O
agents O
acting O
primarily O
on O
neurotransmitters O
other O
than O
dopamine O
were O
then O
tested O
in O
combination O
with O
l O
- O
dopa O
to O
see O
if O
the O
dyskinetic B-Disease
movements O
would O
be O
modified O
. O

several O
drugs O
, O
including O
clonidine O
, O
physostigmine O
, O
methysergide O
, O
5 O
- O
mdot O
, O
propranolol O
, O
and O
mk O
- O
801 O
, O
markedly O
reduced O
the O
dyskinetic B-Disease
movements O
but O
at O
the O
cost O
of O
a O
return O
of O
parkinsonian B-Disease
symptomatology O
. O

however O
, O
yohimbine O
and O
meperidine O
reduced O
predominantly O
the O
dyskinetic B-Disease
movements O
. O

baclofen O
was O
also O
useful O
in O
one O
monkey O
against O
a O
more O
dystonic B-Disease
form O
of O
dyskinesia B-Disease
. O

atropine O
converted O
the O
dystonic B-Disease
movements O
into O
chorea B-Disease
. O

hallucinations B-Disease
and O
ifosfamide O
- O
induced O
neurotoxicity B-Disease
. O

background O
: O
hallucinations B-Disease
as O
a O
symptom O
of O
central O
neurotoxicity B-Disease
are O
a O
known O
but O
poorly O
described O
side O
effect O
of O
ifosfamide O
. O

most O
cases O
of O
ifosfamide O
- O
induced O
hallucinations B-Disease
have O
been O
reported O
with O
other O
mental O
status O
changes O
. O

methods O
: O
the O
authors O
interviewed O
six O
persons O
with O
ifosfamide O
- O
induced O
hallucinations B-Disease
in O
the O
presence O
of O
a O
clear O
sensorium O
. O

all O
patients O
were O
receiving O
high O
- O
dose O
ifosfamide O
as O
part O
of O
their O
bone O
marrow O
transplant O
procedure O
. O

results O
: O
hallucinations B-Disease
occurred O
only O
when O
the O
patient O
' O
s O
eyes O
were O
closed O
and O
, O
in O
all O
but O
one O
case O
, O
were O
reported O
as O
disturbing O
or O
frightening O
. O

underreporting O
of O
these O
hallucinations B-Disease
by O
patients O
is O
likely O
. O

conclusions O
: O
hallucinations B-Disease
may O
be O
the O
sole O
or O
first O
manifestation O
of O
neurotoxicity B-Disease
. O

the O
incidence O
may O
be O
dose O
and O
infusion O
- O
time O
related O
. O

the O
clinician O
should O
be O
alerted O
for O
possible O
ifosfamide O
- O
induced O
hallucinations B-Disease
, O
which O
may O
occur O
without O
other O
signs O
of O
neurotoxicity B-Disease
. O

" O
eyes O
- O
closed O
" O
hallucinatory B-Disease
experiences O
appear O
to O
be O
an O
unusual O
feature O
of O
this O
presentation O
. O

patients O
anxious O
about O
this O
experience O
respond O
well O
to O
support O
and O
education O
about O
this O
occurrence O
. O

optimal O
pharmacologic O
management O
of O
disturbed O
patients O
is O
unclear O
. O

if O
agitation B-Disease
becomes O
marked O
, O
high O
- O
potency O
neuroleptics O
( O
i O
. O
e O
. O
, O
haloperidol O
) O
may O
be O
effective O
. O

photodistributed O
nifedipine O
- O
induced O
facial O
telangiectasia B-Disease
. O

five O
months O
after O
starting O
nifedipine O
( O
adalat O
) O
, O
two O
patients O
developed O
photodistributed O
facial O
telangiectasia B-Disease
, O
which O
became O
more O
noticeable O
with O
time O
. O

neither O
patient O
complained O
of O
photosensitivity O
or O
flushing B-Disease
. O

both O
patients O
reported O
a O
significant O
cosmetic O
improvement O
after O
discontinuing O
the O
drug O
. O

one O
commenced O
the O
closely O
related O
drug O
amlodipine O
3 O
years O
later O
, O
with O
recurrence O
of O
telangiectasia B-Disease
. O

the O
photodistribution O
of O
the O
telangiectasia B-Disease
suggests O
a O
significant O
drug O
/ O
light O
interaction O
. O

penicillamine O
- O
induced O
rapidly O
progressive O
glomerulonephritis B-Disease
in O
a O
patient O
with O
rheumatoid B-Disease
arthritis B-Disease
. O

a O
67 O
- O
year O
- O
old O
woman O
with O
rheumatoid B-Disease
arthritis B-Disease
presented O
rapidly O
progressive O
glomerulonephritis B-Disease
( O
rpgn B-Disease
) O
after O
5 O
months O
of O
d O
- O
penicillamine O
( O
250 O
mg O
/ O
day O
) O
treatment O
. O

light O
microscopy O
study O
showed O
severe O
glomerulonephritis B-Disease
with O
crescent O
formation O
in O
60 O
% O
of O
the O
glomeruli O
and O
infiltration O
of O
inflammatory O
cells O
in O
the O
wall O
of O
an O
arteriole O
. O

immunofluorescence O
revealed O
scanty O
granular O
igg O
, O
iga O
and O
c3 O
deposits O
along O
the O
capillary O
walls O
and O
mesangium O
. O

the O
patient O
was O
treated O
with O
steroid O
pulse O
, O
plasmapheresis O
, O
cyclophosphamide O
and O
antiplatelet O
agents O
. O

a O
complete O
recovery O
of O
renal O
function O
was O
achieved O
in O
a O
few O
weeks O
. O

this O
new O
case O
of O
rpgn B-Disease
in O
the O
course O
of O
d O
- O
penicillamine O
treatment O
emphasizes O
the O
need O
for O
frequent O
monitoring O
of O
renal O
function O
and O
evaluation O
of O
urinary O
sediment O
and O
proteinuria B-Disease
in O
these O
patients O
. O

the O
prompt O
discontinuation O
of O
d O
- O
penicillamine O
and O
vigorous O
treatment O
measures O
could O
allow O
for O
a O
good O
prognosis O
as O
in O
this O
case O
. O

a O
case O
of O
polymyositis B-Disease
in O
a O
patient O
with O
primary B-Disease
biliary B-Disease
cirrhosis B-Disease
treated O
with O
d O
- O
penicillamine O
. O

although O
d O
- O
penicillamine O
has O
been O
used O
for O
many O
rheumatologic B-Disease
diseases B-Disease
, O
toxicity B-Disease
limits O
its O
usefulness O
in O
many O
patients O
. O

polymyositis B-Disease
/ O
dermatomyositis B-Disease
can O
develop O
as O
one O
of O
the O
autoimmune O
complications O
of O
d O
- O
penicillamine O
treatment O
, O
but O
its O
exact O
pathogenesis O
remains O
unclear O
. O

we O
report O
a O
patient O
with O
primary B-Disease
biliary B-Disease
cirrhosis B-Disease
, O
who O
developed O
polymyositis B-Disease
while O
receiving O
d O
- O
penicillamine O
therapy O
. O

we O
described O
the O
special O
clinical O
course O
of O
the O
patient O
. O

patients O
receiving O
d O
- O
penicillamine O
therapy O
should O
be O
followed O
carefully O
for O
the O
development O
of O
autoimmune O
complications O
like O
polymyositis B-Disease
/ O
dermatomyositis B-Disease
. O

hyperalgesia B-Disease
and O
myoclonus B-Disease
in O
terminal O
cancer B-Disease
patients O
treated O
with O
continuous O
intravenous O
morphine O
. O

eight O
cancer B-Disease
patients O
in O
the O
terminal O
stages O
of O
the O
disease O
treated O
with O
high O
doses O
of O
intravenous O
morphine O
developed O
hyperalgesia B-Disease
. O

all O
cases O
were O
retrospectively O
sampled O
from O
three O
different O
hospitals O
in O
copenhagen O
. O

five O
patients O
developed O
universal O
hyperalgesia B-Disease
and O
hyperesthesia B-Disease
which O
in O
2 O
cases O
were O
accompanied O
by O
myoclonus B-Disease
. O

in O
3 O
patients O
a O
pre O
- O
existing O
neuralgia B-Disease
increased O
to O
excruciating O
intensity O
and O
in O
2 O
of O
these O
cases O
myoclonus B-Disease
occurred O
simultaneously O
. O

although O
only O
few O
clinical O
descriptions O
of O
the O
relationship O
between O
hyperalgesia B-Disease
/ O
myoclonus B-Disease
and O
high O
doses O
of O
morphine O
are O
available O
, O
experimental O
support O
from O
animal O
studies O
indicates O
that O
morphine O
, O
or O
its O
metabolites O
, O
plays O
a O
causative O
role O
for O
the O
observed O
behavioural O
syndrome O
. O

the O
possible O
mechanisms O
are O
discussed O
and O
treatment O
proposals O
given O
suggesting O
the O
use O
of O
more O
efficacious O
opioids O
with O
less O
excitatory O
potency O
in O
these O
situations O
. O

liposomal O
daunorubicin O
in O
advanced O
kaposi B-Disease
' B-Disease
s B-Disease
sarcoma B-Disease
: O
a O
phase O
ii O
study O
. O

we O
report O
a O
non O
- O
randomized O
phase O
ii O
clinical O
trial O
to O
assess O
the O
efficacy O
and O
safety O
of O
liposomal O
daunorubicin O
( O
daunoxome O
) O
in O
the O
treatment O
of O
aids B-Disease
related O
kaposi B-Disease
' B-Disease
s B-Disease
sarcoma B-Disease
. O

eleven O
homosexual O
men O
with O
advanced O
kaposi B-Disease
' B-Disease
s B-Disease
sarcoma B-Disease
were O
entered O
in O
the O
trial O
. O

changes O
in O
size O
, O
colour O
and O
associated O
oedema B-Disease
of O
selected O
' O
target O
' O
lesions O
were O
measured O
. O

clinical O
, O
biochemical O
and O
haematological O
toxicities B-Disease
were O
assessed O
. O

ten O
subjects O
were O
evaluated O
. O

a O
partial O
response O
was O
achieved O
in O
four O
, O
of O
whom O
two O
subsequently O
relapsed O
. O

stabilization O
of O
kaposi B-Disease
' B-Disease
s B-Disease
sarcoma B-Disease
occurred O
in O
the O
remaining O
six O
, O
maintained O
until O
the O
end O
of O
the O
trial O
period O
in O
four O
. O

the O
drug O
was O
generally O
well O
tolerated O
, O
with O
few O
mild O
symptoms O
of O
toxicity B-Disease
. O

the O
main O
problem O
encountered O
was O
haematological O
toxicity B-Disease
, O
with O
three O
subjects O
experiencing O
severe O
neutropenia B-Disease
( O
neutrophil O
count O
< O
0 O
. O
5 O
x O
10 O
( O
9 O
) O
/ O
l O
) O
. O

there O
was O
no O
evidence O
of O
cardiotoxicity B-Disease
. O

in O
this O
small O
patient O
sample O
, O
liposomal O
daunorubicin O
was O
an O
effective O
and O
well O
tolerated O
agent O
in O
the O
treatment O
of O
kaposi B-Disease
' B-Disease
s B-Disease
sarcoma B-Disease
. O

long O
- O
term O
effects O
of O
vincristine O
on O
the O
peripheral O
nervous O
system O
. O

forty O
patients O
with O
non B-Disease
- B-Disease
hodgkin B-Disease
' B-Disease
s B-Disease
lymphoma B-Disease
treated O
with O
vincristine O
between O
1984 O
and O
1990 O
( O
cumulative O
dose O
12 O
mg O
in O
18 O
- O
24 O
weeks O
) O
were O
investigated O
in O
order O
to O
evaluate O
the O
long O
term O
effects O
of O
vincristine O
on O
the O
peripheral O
nervous O
system O
. O

the O
patients O
were O
interviewed O
with O
emphasis O
on O
neuropathic B-Disease
symptoms B-Disease
. O

physical O
and O
quantitative O
sensory O
examination O
with O
determination O
of O
vibratory O
perception O
and O
thermal O
discrimination O
thresholds O
were O
performed O
, O
four O
to O
77 O
months O
( O
median O
34 O
months O
) O
after O
vincristine O
treatment O
. O

twenty O
- O
seven O
patients O
reported O
neuropathic B-Disease
symptoms B-Disease
. O

in O
13 O
of O
these O
27 O
patients O
symptoms O
were O
still O
present O
at O
the O
time O
of O
examination O
. O

in O
these O
patients O
sensory O
signs O
and O
symptoms O
predominated O
. O

in O
the O
other O
14 O
patients O
symptoms O
had O
been O
present O
in O
the O
past O
. O

symptoms O
persisted O
maximally O
40 O
months O
since O
cessation O
of O
therapy O
. O

there O
was O
no O
age O
difference O
between O
patients O
with O
and O
without O
complaints O
at O
the O
time O
of O
examination O
. O

normal O
reflexes O
were O
found O
in O
two O
third O
of O
patients O
. O

neuropathic O
complaints O
were O
not O
very O
troublesome O
on O
the O
long O
term O
. O

it O
is O
concluded O
that O
with O
the O
above O
mentioned O
vincristine O
dose O
schedule O
signs O
and O
symptoms O
of O
vincristine O
neuropathy B-Disease
are O
reversible O
for O
a O
great O
deal O
and O
prognosis O
is O
fairly O
good O
. O

hepatic O
adenomas B-Disease
and O
focal B-Disease
nodular B-Disease
hyperplasia B-Disease
of O
the O
liver O
in O
young O
women O
on O
oral O
contraceptives O
: O
case O
reports O
. O

two O
cases O
of O
hepatic O
adenoma B-Disease
and O
one O
of O
focal B-Disease
nodular B-Disease
hyperplasia B-Disease
presumably O
associated O
with O
the O
use O
of O
oral O
contraceptives O
, O
are O
reported O
. O

special O
reference O
is O
made O
to O
their O
clinical O
presentation O
, O
which O
may O
be O
totally O
asymptomatic O
. O

liver O
- O
function O
tests O
are O
of O
little O
diagnostic O
value O
, O
but O
valuable O
information O
may O
be O
obtained O
from O
both O
liver O
scanning O
and O
hepatic O
angiography O
. O

histologic O
differences O
and O
clinical O
similarities O
between O
hepatic O
adenoma B-Disease
and O
focal B-Disease
nodular B-Disease
hyperplasia B-Disease
of O
the O
liver O
are O
discussed O
. O

loss O
of O
glutamate O
decarboxylase O
mrna O
- O
containing O
neurons O
in O
the O
rat O
dentate O
gyrus O
following O
pilocarpine O
- O
induced O
seizures B-Disease
. O

in O
situ O
hybridization O
methods O
were O
used O
to O
determine O
if O
glutamic O
acid O
decarboxylase O
( O
gad O
) O
mrna O
- O
containing O
neurons O
within O
the O
hilus O
of O
the O
dentate O
gyrus O
are O
vulnerable O
to O
seizure B-Disease
- O
induced O
damage O
in O
a O
model O
of O
chronic O
seizures B-Disease
. O

sprague O
- O
dawley O
rats O
were O
injected O
intraperitoneally O
with O
pilocarpine O
, O
and O
the O
hippocampal O
formation O
was O
studied O
histologically O
at O
1 O
, O
2 O
, O
4 O
, O
and O
8 O
week O
intervals O
after O
pilocarpine O
- O
induced O
seizures B-Disease
. O

in O
situ O
hybridization O
histochemistry O
, O
using O
a O
digoxigenin O
- O
labeled O
gad O
crna O
probe O
, O
demonstrated O
a O
substantial O
decrease O
in O
the O
number O
of O
gad O
mrna O
- O
containing O
neurons O
in O
the O
hilus O
of O
the O
dentate O
gyrus O
in O
the O
pilocarpine O
- O
treated O
rats O
as O
compared O
to O
controls O
at O
all O
time O
intervals O
. O

additional O
neuronanatomical O
studies O
, O
including O
cresyl O
violet O
staining O
, O
neuronal B-Disease
degeneration B-Disease
methods O
, O
and O
histochemical O
localization O
of O
glial O
fibrillary O
acidic O
protein O
, O
suggested O
that O
the O
decrease O
in O
the O
number O
of O
gad O
mrna O
- O
containing O
neurons O
was O
related O
to O
neuronal B-Disease
loss B-Disease
rather O
than O
to O
a O
decrease O
in O
gad O
mrna O
levels O
. O

the O
loss O
of O
gad O
mrna O
- O
containing O
neurons O
in O
the O
hilus O
contrasted O
with O
the O
relative O
preservation O
of O
labeled O
putative O
basket O
cells O
along O
the O
inner O
margin O
of O
the O
granule O
cell O
layer O
. O

quantitative O
analyses O
of O
labeled O
neurons O
in O
three O
regions O
of O
the O
dentate O
gyrus O
in O
the O
1 O
and O
2 O
week O
groups O
showed O
statistically O
significant O
decreases O
in O
the O
mean O
number O
of O
gad O
mrna O
- O
containing O
neurons O
in O
the O
hilus O
of O
both O
groups O
of O
experimental O
animals O
. O

no O
significant O
differences O
were O
found O
in O
the O
molecular O
layer O
or O
the O
granule O
cell O
layer O
, O
which O
included O
labeled O
neurons O
along O
the O
lower O
margin O
of O
the O
granule O
cell O
layer O
. O

the O
results O
indicate O
that O
, O
in O
this O
model O
, O
a O
subpopulation O
of O
gad O
mrna O
- O
containing O
neurons O
within O
the O
dentate O
gyrus O
is O
selectively O
vulnerable O
to O
seizure B-Disease
- O
induced O
damage O
. O

such O
differential O
vulnerability O
appears O
to O
be O
another O
indication O
of O
the O
heterogeneity O
of O
gaba O
neurons O
. O

effects O
of O
deliberate O
hypotension B-Disease
induced O
by O
labetalol O
with O
isoflurane O
on O
neuropsychological O
function O
. O

the O
effect O
of O
deliberate O
hypotension B-Disease
on O
brain O
function O
measured O
by O
neuropsychological O
tests O
was O
studied O
in O
41 O
adult O
patients O
. O

twenty O
- O
four O
patients O
were O
anaesthetized O
for O
middle O
- O
ear O
surgery O
with O
deliberate O
hypotension B-Disease
induced O
by O
labetalol O
with O
isoflurane O
( O
hypotensive B-Disease
group O
) O
. O

seventeen O
patients O
without O
hypotension B-Disease
served O
as O
a O
control O
group O
. O

the O
mean O
arterial O
pressure O
was O
77 O
+ O
/ O
- O
2 O
mmhg O
( O
10 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
kpa O
) O
before O
hypotension B-Disease
and O
50 O
+ O
/ O
- O
0 O
mmhg O
( O
6 O
. O
7 O
+ O
/ O
- O
0 O
. O
0 O
kpa O
) O
during O
hypotension B-Disease
in O
the O
hypotensive B-Disease
group O
, O
and O
86 O
+ O
/ O
- O
2 O
mmhg O
( O
11 O
. O
5 O
+ O
/ O
- O
0 O
. O
3 O
kpa O
) O
during O
anaesthesia O
in O
the O
control O
group O
. O

the O
following O
psychological O
tests O
were O
performed O
: O
four O
subtests O
of O
the O
wechsler O
adult O
intelligence O
scale O
( O
similarities O
, O
digit O
span O
, O
vocabulary O
and O
digit O
symbol O
) O
, O
trail O
- O
making O
tests O
a O
and O
b O
, O
zung O
tests O
( O
self O
- O
rating O
anxiety B-Disease
scale O
and O
self O
- O
rating O
depression B-Disease
scale O
) O
and O
two O
- O
part O
memory O
test O
battery O
with O
immediate O
and O
delayed O
recall O
. O

the O
tests O
were O
performed O
preoperatively O
and O
2 O
days O
postoperatively O
. O

there O
were O
no O
statistically O
significant O
differences O
between O
the O
groups O
in O
any O
of O
the O
tests O
in O
the O
changes O
from O
preoperative O
value O
to O
postoperative O
value O
. O

the O
results O
indicate O
that O
hypotension B-Disease
induced O
by O
labetalol O
with O
isoflurane O
has O
no O
significant O
harmful O
effects O
on O
mental O
functions O
compared O
to O
normotensive O
anaesthesia O
. O

apparent O
cure O
of O
rheumatoid B-Disease
arthritis B-Disease
by O
bone O
marrow O
transplantation O
. O

we O
describe O
the O
induction O
of O
sustained O
remissions O
and O
possible O
cure O
of O
severe O
erosive O
rheumatoid B-Disease
arthritis B-Disease
( O
ra B-Disease
) O
by O
bone O
marrow O
transplantation O
( O
bmt O
) O
in O
2 O
patients O
. O

bmt O
was O
used O
to O
treat O
severe O
aplastic B-Disease
anemia B-Disease
which O
was O
caused O
by O
gold O
in O
one O
case O
and O
d O
- O
penicillamine O
in O
the O
other O
. O

in O
the O
8 O
and O
6 O
years O
since O
the O
transplants O
( O
representing O
8 O
and O
4 O
years O
since O
cessation O
of O
all O
immunosuppressive O
therapy O
, O
respectively O
) O
, O
the O
ra B-Disease
in O
each O
case O
has O
been O
completely O
quiescent O
. O

although O
short O
term O
remission O
of O
severe O
ra B-Disease
following O
bmt O
has O
been O
reported O
, O
these O
are O
the O
first O
cases O
for O
which O
prolonged O
followup O
has O
been O
available O
. O

this O
experience O
raises O
the O
question O
of O
the O
role O
of O
bmt O
itself O
as O
a O
therapeutic O
option O
for O
patients O
with O
uncontrolled O
destructive O
synovitis B-Disease
. O

seizures B-Disease
induced O
by O
combined O
levomepromazine O
- O
fluvoxamine O
treatment O
. O

we O
report O
a O
case O
of O
combined O
levomepromazine O
- O
fluvoxamine O
treatment O
- O
induced O
seizures B-Disease
. O

it O
seems O
that O
combined O
treatment O
of O
fluvoxamine O
with O
phenothiazines O
may O
possess O
proconvulsive O
activity O
. O

case O
report O
: O
pentamidine O
and O
polymorphic O
ventricular B-Disease
tachycardia B-Disease
revisited O
. O

pentamidine O
isethionate O
has O
been O
associated O
with O
ventricular B-Disease
tachyarrhythmias B-Disease
, O
including O
torsade B-Disease
de B-Disease
pointes B-Disease
. O

this O
article O
reports O
two O
cases O
of O
this O
complication O
and O
reviews O
all O
reported O
cases O
to O
date O
. O

pentamidine O
- O
induced O
torsade B-Disease
de B-Disease
pointes B-Disease
may O
be O
related O
to O
serum O
magnesium O
levels O
and O
hypomagnesemia B-Disease
may O
synergistically O
induce O
torsade O
. O

torsade B-Disease
de B-Disease
pointes B-Disease
occurred O
after O
an O
average O
of O
10 O
days O
of O
treatment O
with O
pentamidine O
. O

in O
these O
patients O
, O
no O
other O
acute O
side O
effects O
of O
pentamidine O
were O
observed O
. O

torsade B-Disease
de B-Disease
pointes B-Disease
can O
be O
treated O
when O
recognized O
early O
, O
possibly O
without O
discontinuation O
of O
pentamidine O
. O

when O
qtc B-Disease
interval B-Disease
prolongation B-Disease
is O
observed O
, O
early O
magnesium O
supplementation O
is O
advocated O
. O

efficacy O
and O
tolerability O
of O
lovastatin O
in O
3390 O
women O
with O
moderate O
hypercholesterolemia B-Disease
. O

objective O
: O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
lovastatin O
in O
women O
with O
moderate O
hypercholesterolemia B-Disease
. O

design O
: O
the O
expanded O
clinical O
evaluation O
of O
lovastatin O
( O
excel O
) O
study O
, O
a O
multicenter O
, O
double O
- O
blind O
, O
diet O
- O
and O
placebo O
- O
controlled O
trial O
, O
in O
which O
participants O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
lovastatin O
at O
doses O
of O
20 O
or O
40 O
mg O
once O
daily O
, O
or O
20 O
or O
40 O
mg O
twice O
daily O
for O
48 O
weeks O
. O

setting O
: O
ambulatory O
patients O
recruited O
by O
362 O
participating O
centers O
throughout O
the O
united O
states O
. O

patients O
: O
women O
( O
n O
= O
3390 O
) O
from O
the O
total O
cohort O
of O
8245 O
volunteers O
. O

measurements O
: O
plasma O
total O
, O
low O
- O
density O
lipoprotein O
( O
ldl O
) O
, O
and O
high O
- O
density O
lipoprotein O
( O
hdl O
) O
cholesterol O
, O
and O
triglycerides O
; O
and O
laboratory O
and O
clinical O
evidence O
of O
adverse O
events O
monitored O
periodically O
throughout O
the O
study O
. O

results O
: O
among O
women O
, O
lovastatin O
( O
20 O
to O
80 O
mg O
/ O
d O
) O
produced O
sustained O
( O
12 O
- O
to O
48 O
- O
week O
) O
, O
dose O
- O
related O
changes O
( O
p O
< O
0 O
. O
001 O
) O
: O
decreases O
in O
ldl O
cholesterol O
( O
24 O
% O
to O
40 O
% O
) O
and O
triglycerides O
( O
9 O
% O
to O
18 O
% O
) O
, O
and O
increases O
in O
hdl O
cholesterol O
( O
6 O
. O
7 O
% O
to O
8 O
. O
6 O
% O
) O
. O

depending O
on O
the O
dose O
, O
from O
82 O
% O
to O
95 O
% O
of O
lovastatin O
- O
treated O
women O
achieved O
the O
national O
cholesterol O
education O
program O
goal O
of O
ldl O
cholesterol O
levels O
less O
than O
4 O
. O
14 O
mmol O
/ O
l O
( O
160 O
mg O
/ O
dl O
) O
, O
and O
40 O
% O
to O
87 O
% O
achieved O
the O
goal O
of O
3 O
. O
36 O
mmol O
/ O
l O
( O
130 O
mg O
/ O
dl O
) O
. O

successive O
transaminase O
elevations O
greater O
than O
three O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0 O
. O
1 O
% O
of O
women O
and O
were O
dose O
dependent O
above O
the O
20 O
- O
mg O
dose O
. O

myopathy B-Disease
, O
defined O
as O
muscle O
symptoms O
with O
creatine O
kinase O
elevations O
greater O
than O
10 O
times O
the O
upper O
limit O
of O
normal O
, O
was O
rare O
and O
associated O
with O
the O
highest O
recommended O
daily O
dose O
of O
lovastatin O
( O
80 O
mg O
) O
. O

estrogen O
- O
replacement O
therapy O
appeared O
to O
have O
no O
effect O
on O
either O
the O
efficacy O
or O
safety O
profile O
of O
lovastatin O
. O

conclusion O
: O
lovastatin O
is O
highly O
effective O
and O
generally O
well O
tolerated O
as O
therapy O
for O
primary O
hypercholesterolemia B-Disease
in O
women O
. O

tetany B-Disease
and O
rhabdomyolysis B-Disease
due O
to O
surreptitious O
furosemide O
- O
- O
importance O
of O
magnesium O
supplementation O
. O

diuretics O
may O
induce O
hypokalemia B-Disease
, O
hypocalcemia B-Disease
and O
hypomagnesemia B-Disease
. O

while O
severe O
hypokalemia B-Disease
may O
cause O
muscle B-Disease
weakness B-Disease
, O
severe O
hypomagnesemia B-Disease
is O
associated O
with O
muscle B-Disease
spasms B-Disease
and O
tetany B-Disease
which O
cannot O
be O
corrected O
by O
potassium O
and O
calcium O
supplementation O
alone O
( O
1 O
, O
2 O
) O
. O

surreptitious O
diuretic O
ingestion O
has O
been O
described O
, O
mainly O
in O
women O
who O
are O
concerned O
that O
they O
are O
obese B-Disease
or O
edematous B-Disease
. O

symptomatic O
hypokalemia B-Disease
has O
been O
reported O
in O
such O
patients O
( O
3 O
- O
7 O
) O
and O
in O
one O
case O
hypocalcemia B-Disease
was O
observed O
( O
8 O
) O
, O
but O
the O
effects O
of O
magnesium O
depletion O
were O
not O
noted O
in O
these O
patients O
. O

ciprofloxacin O
- O
induced O
nephrotoxicity B-Disease
in O
patients O
with O
cancer B-Disease
. O

nephrotoxicity B-Disease
associated O
with O
ciprofloxacin O
is O
uncommon O
. O

five O
patients O
with O
cancer B-Disease
who O
developed O
acute B-Disease
renal B-Disease
failure B-Disease
that O
followed O
treatment O
with O
ciprofloxacin O
are O
described O
and O
an O
additional O
15 O
cases O
reported O
in O
the O
literature O
are O
reviewed O
. O

other O
than O
elevation O
of O
serum O
creatinine O
levels O
, O
characteristic O
clinical O
manifestations O
and O
abnormal O
laboratory O
findings O
are O
not O
frequently O
present O
. O

allergic O
interstitial B-Disease
nephritis B-Disease
is O
believed O
to O
be O
the O
underlying O
pathological O
- O
process O
. O

definitive O
diagnosis O
requires O
performance O
of O
renal O
biopsy O
, O
although O
this O
is O
not O
always O
feasible O
. O

an O
improvement O
in O
renal O
function O
that O
followed O
the O
discontinuation O
of O
the O
offending O
antibiotic O
supports O
the O
presumptive O
diagnosis O
of O
ciprofloxacin O
- O
induced O
acute B-Disease
renal B-Disease
failure B-Disease
. O

venous B-Disease
complications B-Disease
of O
midazolam O
versus O
diazepam O
. O

although O
some O
studies O
have O
suggested O
fewer O
venous B-Disease
complications B-Disease
are O
associated O
with O
midazolam O
than O
with O
diazepam O
for O
endoscopic O
procedures O
, O
this O
variable O
has O
not O
been O
well O
documented O
. O

we O
prospectively O
evaluated O
the O
incidence O
of O
venous B-Disease
complications B-Disease
after O
intravenous O
injection O
of O
diazepam O
or O
midazolam O
in O
122 O
consecutive O
patients O
undergoing O
colonoscopy O
and O
esophagogastroduodenoscopy O
. O

overall O
, O
venous B-Disease
complications B-Disease
were O
more O
frequent O
with O
diazepam O
( O
22 O
of O
62 O
patients O
) O
than O
with O
midazolam O
( O
4 O
of O
60 O
patients O
) O
( O
p O
< O
0 O
. O
001 O
) O
. O

a O
palpable O
venous O
cord O
was O
present O
in O
23 O
% O
( O
14 O
of O
62 O
) O
of O
patients O
in O
the O
diazepam O
group O
, O
compared O
with O
2 O
% O
( O
1 O
of O
60 O
patients O
) O
in O
the O
midazolam O
group O
( O
p O
< O
0 O
. O
002 O
) O
. O

pain B-Disease
at O
the O
injection O
site O
occurred O
in O
35 O
% O
( O
22 O
of O
62 O
) O
of O
patients O
in O
the O
diazepam O
group O
compared O
with O
7 O
% O
( O
4 O
of O
60 O
patients O
) O
in O
the O
midazolam O
group O
( O
p O
< O
0 O
. O
001 O
) O
. O

swelling B-Disease
and O
warmth O
at O
the O
injection O
site O
were O
not O
significantly O
different O
between O
the O
two O
groups O
. O

smoking O
, O
nonsteroidal O
anti O
- O
inflammatory O
drug O
use O
, O
intravenous O
catheter O
site O
, O
dwell O
time O
of O
the O
needle O
, O
alcohol O
use O
, O
and O
pain B-Disease
during O
the O
injection O
had O
no O
effect O
on O
the O
incidence O
of O
venous B-Disease
complications B-Disease
. O

clarithromycin O
- O
associated O
visual B-Disease
hallucinations B-Disease
in O
a O
patient O
with O
chronic B-Disease
renal B-Disease
failure B-Disease
on O
continuous O
ambulatory O
peritoneal O
dialysis O
. O

visual B-Disease
hallucinations B-Disease
are O
a O
rare O
event O
in O
chronic B-Disease
renal B-Disease
failure B-Disease
and O
not O
related O
to O
uremia B-Disease
per O
se O
. O

unreported O
in O
the O
literature O
is O
visual B-Disease
hallucinations B-Disease
occurring O
in O
association O
with O
the O
new O
macrolide O
antibiotic O
, O
clarithromycin O
. O

we O
describe O
such O
a O
case O
in O
a O
patient O
with O
end B-Disease
- B-Disease
stage B-Disease
renal B-Disease
disease B-Disease
( O
esrd B-Disease
) O
maintained O
on O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
capd O
) O
. O

the O
combination O
of O
a O
relatively O
high O
dose O
of O
clarithromycin O
in O
face O
of O
chronic B-Disease
renal B-Disease
failure B-Disease
in O
a O
functionally O
anephric O
patient O
, O
with O
underlying O
aluminum O
intoxication O
, O
may O
have O
facilitated O
the O
appearance O
of O
this O
neurotoxic B-Disease
side O
effect O
. O

it O
is O
important O
to O
understand O
the O
pharmacokinetics O
of O
medications O
in O
face O
of O
chronic B-Disease
renal B-Disease
failure B-Disease
, O
the O
possibility O
of O
drug O
interactions O
, O
and O
how O
these O
factors O
should O
help O
guide O
medication O
therapy O
in O
the O
esrd B-Disease
patient O
. O

changes O
in O
peroxisomes O
in O
preneoplastic O
liver O
and O
hepatoma B-Disease
of O
mice O
induced O
by O
alpha O
- O
benzene O
hexachloride O
. O

peroxisomes O
in O
hepatomas B-Disease
and O
hyperplastic O
preneoplastic O
liver B-Disease
lesions B-Disease
induced O
in O
mice O
by O
500 O
ppm O
alpha O
- O
benzene O
hexachloride O
were O
examined O
histochemically O
and O
electron O
microscopically O
. O

although O
most O
of O
the O
hepatomas B-Disease
were O
well O
- O
differentiated O
tumors B-Disease
and O
contained O
a O
considerable O
number O
of O
peroxisomes O
, O
the O
tumor B-Disease
cells O
did O
not O
respond O
to O
ethyl O
- O
alpha O
- O
p O
- O
chlorophenoxyisobutyrate O
with O
proliferation O
of O
peroxisomes O
. O

at O
the O
16th O
week O
of O
carcinogen O
feeding O
, O
hyperplastic O
nodules O
appeared O
and O
advanced O
to O
further O
stages O
. O

a O
majority O
of O
the O
nodules O
showed O
a O
considerable O
number O
of O
peroxisomes O
and O
the O
inductive O
proliferation O
of O
peroxisomes O
. O

within O
the O
nodules O
, O
foci O
of O
proliferation O
of O
the O
cells O
that O
showed O
no O
inducibility O
of O
proliferation O
of O
peroxisomes O
appeared O
. O

these O
cells O
proliferated O
further O
, O
replacing O
the O
most O
part O
of O
the O
nodules O
, O
and O
with O
this O
process O
hepatomas B-Disease
appeared O
to O
have O
been O
formed O
. O

no O
abnormal O
matrical O
inclusions O
of O
peroxisomes O
were O
formed O
in O
the O
cells O
of O
hyperplastic O
nodules O
by O
ethyl O
- O
alpha O
- O
p O
- O
chlorophenoxyisobutyrate O
unlike O
in O
the O
case O
of O
rats O
. O

contribution O
of O
the O
sympathetic O
nervous O
system O
to O
salt O
- O
sensitivity O
in O
lifetime O
captopril O
- O
treated O
spontaneously O
hypertensive B-Disease
rats O
. O

objective O
: O
to O
test O
the O
hypothesis O
that O
, O
in O
lifetime O
captopril O
- O
treated O
spontaneously O
hypertensive B-Disease
rats O
( O
shr O
) O
, O
the O
sympathetic O
nervous O
system O
contributes O
importantly O
to O
the O
hypertensive B-Disease
effect O
of O
dietary O
sodium O
chloride O
supplementation O
. O

methods O
: O
male O
shr O
( O
aged O
6 O
weeks O
) O
that O
had O
been O
treated O
from O
conception O
onward O
with O
either O
captopril O
or O
vehicle O
remained O
on O
a O
basal O
sodium O
chloride O
diet O
or O
were O
fed O
a O
high O
sodium O
chloride O
diet O
. O

after O
2 O
weeks O
, O
the O
rats O
were O
subjected O
to O
ganglionic O
blockade O
and O
2 O
days O
later O
, O
an O
infusion O
of O
clonidine O
. O

results O
: O
lifetime O
captopril O
treatment O
significantly O
lowered O
mean O
arterial O
pressure O
in O
both O
groups O
. O

intravenous O
infusion O
of O
the O
ganglionic O
blocker O
hexamethonium O
resulted O
in O
a O
rapid O
decline O
in O
map O
that O
eliminated O
the O
dietary O
sodium O
chloride O
- O
induced O
increase B-Disease
in B-Disease
map B-Disease
in O
both O
groups O
. O

infusion O
of O
the O
central O
nervous O
system O
alpha2 O
- O
adrenergic O
receptor O
agonist O
clonidine O
also O
resulted O
in O
a O
greater O
reduction O
in O
map O
in O
both O
groups O
of O
shr O
that O
were O
fed O
the O
high O
( O
compared O
with O
the O
basal O
) O
sodium O
chloride O
diet O
. O

conclusions O
: O
in O
both O
lifetime O
captopril O
- O
treated O
and O
control O
shr O
, O
the O
sympathetic O
nervous O
system O
contributes O
to O
the O
pressor O
effects O
of O
a O
high O
sodium O
chloride O
diet O
. O

angioedema B-Disease
associated O
with O
droperidol O
administration O
. O

angioedema B-Disease
, O
also O
known O
as O
angioneurotic B-Disease
edema B-Disease
or O
quincke B-Disease
' B-Disease
s B-Disease
disease B-Disease
, O
is O
a O
well O
- O
demarcated O
, O
localized O
edema B-Disease
involving O
the O
subcutaneous O
tissues O
that O
may O
cause O
upper B-Disease
- B-Disease
airway B-Disease
obstruction B-Disease
. O

we O
report O
the O
case O
of O
a O
previously O
healthy O
19 O
- O
year O
- O
old O
man O
with O
no O
known O
drug B-Disease
allergies B-Disease
in O
whom O
angioedema B-Disease
with O
significant O
tongue B-Disease
swelling B-Disease
and O
protrusion O
developed O
within O
10 O
minutes O
of O
the O
administration O
of O
a O
single O
iv O
dose O
of O
droperidol O
. O

late O
cardiotoxicity B-Disease
after O
treatment O
for O
a O
malignant O
bone B-Disease
tumor B-Disease
. O

cardiac O
function O
was O
assessed O
in O
long O
- O
term O
survivors O
of O
malignant O
bone B-Disease
tumors B-Disease
who O
were O
treated O
according O
to O
rosen O
' O
s O
t5 O
or O
t10 O
protocol O
, O
both O
including O
doxorubicin O
. O

thirty O
- O
one O
patients O
, O
age O
10 O
- O
45 O
years O
( O
median O
age O
17 O
. O
8 O
years O
) O
were O
evaluated O
2 O
. O
3 O
- O
14 O
. O
1 O
years O
( O
median O
8 O
. O
9 O
years O
) O
following O
completion O
of O
treatment O
. O

cumulative O
doses O
of O
doxorubicin O
were O
225 O
- O
550 O
mg O
/ O
m2 O
( O
median O
dose O
360 O
) O
. O

the O
evaluation O
consisted O
of O
a O
history O
, O
physical O
examination O
, O
electrocardiogram O
( O
ecg O
) O
, O
signal O
averaged O
ecg O
, O
24 O
- O
hour O
ambulatory O
ecg O
, O
echocardiography O
and O
radionuclide O
angiography O
. O

eighteen O
of O
31 O
( O
58 O
% O
) O
patients O
showed O
cardiac B-Disease
toxicity B-Disease
, O
defined O
as O
having O
one O
or O
more O
of O
the O
following O
abnormalities O
: O
late O
potentials O
, O
complex O
ventricular B-Disease
arrhythmias B-Disease
, O
left O
ventricular B-Disease
dilation B-Disease
, O
decreased O
shortening O
fraction O
, O
or O
decreased O
ejection O
fraction O
. O

the O
incidence O
of O
cardiac B-Disease
abnormalities B-Disease
increased O
with O
length O
of O
follow O
- O
up O
( O
p O
< O
or O
= O
. O
05 O
) O
. O

no O
correlation O
could O
be O
demonstrated O
between O
cumulative O
dose O
of O
doxorubicin O
and O
cardiac O
status O
, O
except O
for O
heart O
rate O
variability O
. O

when O
adjusted O
to O
body O
surface O
area O
, O
the O
left O
ventricular O
posterior O
wall O
thickness O
( O
lvpw O
index O
) O
was O
decreased O
in O
all O
patients O
. O

the O
incidence O
of O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
is O
high O
and O
increases O
with O
follow O
- O
up O
, O
irrespective O
of O
cumulative O
dose O
. O

life O
- O
long O
cardiac O
follow O
- O
up O
in O
these O
patients O
is O
warranted O
. O

the O
results O
of O
our O
study O
suggest O
that O
heart O
rate O
variability O
and O
lvpw O
index O
could O
be O
sensitive O
indicators O
for O
cardiotoxicity B-Disease
. O

acute O
blood O
pressure O
elevations O
with O
caffeine O
in O
men O
with O
borderline O
systemic O
hypertension B-Disease
. O

whether O
the O
vasoconstrictive O
actions O
of O
caffeine O
are O
enhanced O
in O
hypertensive B-Disease
persons O
has O
not O
been O
demonstrated O
. O

thus O
, O
caffeine O
( O
3 O
. O
3 O
mg O
/ O
kg O
) O
versus O
placebo O
was O
tested O
in O
48 O
healthy O
men O
( O
aged O
20 O
to O
35 O
years O
) O
selected O
after O
screening O
on O
2 O
separate O
occasions O
. O

borderline O
hypertensive B-Disease
men O
( O
n O
= O
24 O
) O
were O
selected O
with O
screening O
systolic O
blood O
pressure O
( O
bp O
) O
of O
140 O
to O
160 O
mm O
hg O
and O
/ O
or O
diastolic O
bp O
90 O
to O
99 O
mm O
hg O
. O

low O
- O
risk O
controls O
( O
n O
= O
24 O
) O
reported O
no O
parental O
history O
of O
hypertension B-Disease
and O
had O
screening O
bp O
< O
130 O
/ O
85 O
mm O
hg O
. O

participants O
were O
then O
tested O
on O
2 O
occasions O
after O
12 O
- O
hour O
abstinence O
from O
caffeine O
in O
each O
of O
2 O
protocols O
; O
this O
required O
a O
total O
of O
4 O
laboratory O
visits O
. O

caffeine O
- O
induced O
changes O
in O
diastolic O
bp O
were O
2 O
to O
3 O
times O
larger O
in O
borderline O
subjects O
than O
in O
controls O
( O
+ O
8 O
. O
4 O
vs O
+ O
3 O
. O
8 O
mm O
hg O
, O
p O
< O
0 O
. O
0001 O
) O
, O
and O
were O
attributable O
to O
larger O
changes O
in O
impedance O
- O
derived O
measures O
of O
systemic O
vascular O
resistance O
( O
+ O
135 O
vs O
+ O
45 O
dynes O
. O
s O
. O
cm O
- O
5 O
, O
p O
< O
0 O
. O
004 O
) O
. O

these O
findings O
were O
consistent O
and O
reached O
significance O
in O
both O
protocols O
. O

the O
percentage O
of O
borderline O
subjects O
in O
whom O
diastolic O
bp O
changes O
exceeded O
the O
median O
control O
response O
was O
96 O
% O
. O

consequently O
, O
whereas O
all O
participants O
exhibited O
normotensive O
levels O
during O
the O
resting O
predrug O
baseline O
, O
33 O
% O
of O
borderline O
subjects O
achieved O
hypertensive B-Disease
bp O
levels O
after O
caffeine O
ingestion O
. O

thus O
, O
in O
borderline O
hypertensive B-Disease
men O
, O
exaggerated O
responses O
to O
caffeine O
were O
: O
selective O
for O
diastolic O
bp O
, O
consistent O
with O
greater O
vasoconstriction O
, O
replicated O
in O
2 O
protocols O
, O
and O
representative O
of O
nearly O
all O
borderline O
hypertensives B-Disease
. O

we O
suspect O
that O
the O
potential O
for O
caffeine O
to O
stabilize O
high O
resistance O
states O
in O
susceptible O
persons O
suggests O
that O
its O
use O
may O
facilitate O
their O
disease O
progression O
, O
as O
well O
as O
hinder O
accurate O
diagnosis O
and O
treatment O
. O

absence O
of O
effect O
of O
sertraline O
on O
time O
- O
based O
sensitization O
of O
cognitive B-Disease
impairment B-Disease
with O
haloperidol O
. O

this O
double O
- O
blind O
, O
randomized O
, O
placebo O
- O
controlled O
study O
evaluated O
the O
effects O
of O
haloperidol O
alone O
and O
haloperidol O
plus O
sertraline O
on O
cognitive O
and O
psychomotor O
function O
in O
24 O
healthy O
male O
subjects O
. O

method O
: O
all O
subjects O
received O
placebo O
on O
day O
1 O
and O
haloperidol O
2 O
mg O
on O
days O
2 O
and O
25 O
. O

from O
days O
9 O
to O
25 O
, O
subjects O
were O
randomly O
assigned O
to O
either O
sertraline O
( O
12 O
subjects O
) O
or O
placebo O
( O
12 O
subjects O
) O
; O
the O
sertraline O
dose O
was O
titrated O
from O
50 O
to O
200 O
mg O
/ O
day O
from O
days O
9 O
to O
16 O
, O
and O
remained O
at O
200 O
mg O
/ O
day O
for O
the O
final O
10 O
days O
of O
the O
drug O
administration O
period O
. O

cognitive O
function O
testing O
was O
performed O
before O
dosing O
and O
over O
a O
24 O
- O
hour O
period O
after O
dosing O
on O
days O
1 O
, O
2 O
, O
and O
25 O
. O

results O
: O
impairment B-Disease
of B-Disease
cognitive B-Disease
function B-Disease
was O
observed O
6 O
to O
8 O
hours O
after O
administration O
of O
haloperidol O
on O
day O
2 O
but O
was O
not O
evident O
23 O
hours O
after O
dosing O
. O

when O
single O
- O
dose O
haloperidol O
was O
given O
again O
25 O
days O
later O
, O
greater O
impairment O
with O
earlier O
onset O
was O
noted O
in O
several O
tests O
in O
both O
treatment O
groups O
, O
suggesting O
enhancement O
of O
this O
effect O
. O

there O
was O
no O
indication O
that O
sertraline O
exacerbated O
the O
impairment O
produced O
by O
haloperidol O
since O
an O
equivalent O
effect O
also O
occurred O
in O
the O
placebo O
group O
. O

three O
subjects O
( O
2 O
on O
sertraline O
and O
1 O
on O
placebo O
) O
withdrew O
from O
the O
study O
because O
of O
side O
effects O
. O

ten O
subjects O
in O
each O
group O
reported O
side O
effects O
related O
to O
treatment O
. O

the O
side O
effect O
profiles O
of O
sertraline O
and O
of O
placebo O
were O
similar O
. O

conclusion O
: O
haloperidol O
produced O
a O
clear O
profile O
of O
cognitive B-Disease
impairment B-Disease
that O
was O
not O
worsened O
by O
concomitant O
sertraline O
administration O
. O

coexistence O
of O
cerebral B-Disease
venous B-Disease
sinus B-Disease
and B-Disease
internal B-Disease
carotid B-Disease
artery B-Disease
thrombosis B-Disease
associated O
with O
exogenous O
sex O
hormones O
. O

a O
case O
report O
. O

a O
forty O
- O
six O
year O
- O
old O
premenopausal O
woman O
developed O
headache B-Disease
, O
nausea B-Disease
and O
vomiting B-Disease
, O
left O
hemiparesis B-Disease
and O
seizure B-Disease
two O
days O
after O
parenteral O
use O
of O
progesterone O
and O
estradiol O
. O

diabetes B-Disease
mellitus B-Disease
( O
dm B-Disease
) O
was O
found O
during O
admission O
. O

computed O
tomography O
showed O
a O
hemorrhagic B-Disease
infarct B-Disease
in O
the O
right O
frontal O
lobe O
and O
increased O
density O
in O
the O
superior O
sagittal O
sinus O
( O
sss O
) O
. O

left O
carotid O
angiography O
found O
occlusion B-Disease
of B-Disease
the B-Disease
left B-Disease
internal B-Disease
carotid B-Disease
artery B-Disease
( O
ica O
) O
. O

right O
carotid O
angiograms O
failed O
to O
show O
the O
sss O
and O
inferior O
sagittal O
sinus O
, O
suggestive O
of O
venous B-Disease
sinus B-Disease
thrombosis B-Disease
. O

coexistence O
of O
the O
cerebral B-Disease
artery B-Disease
and B-Disease
the B-Disease
venous B-Disease
sinus B-Disease
occlusion B-Disease
has O
been O
described O
infrequently O
. O

in O
this O
case O
, O
the O
authors O
postulate O
that O
the O
use O
of O
estradiol O
and O
progesterone O
and O
the O
underlying O
dm B-Disease
increased O
vascular O
thrombogenicity O
, O
which O
provided O
a O
common O
denominator O
for O
thrombosis B-Disease
of B-Disease
both B-Disease
the B-Disease
ica B-Disease
and B-Disease
the B-Disease
venous B-Disease
sinus B-Disease
. O

chemotherapy O
of O
advanced O
inoperable O
non B-Disease
- B-Disease
small B-Disease
cell B-Disease
lung B-Disease
cancer B-Disease
with O
paclitaxel O
: O
a O
phase O
ii O
trial O
. O

paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
has O
demonstrated O
significant O
antineoplastic O
activity O
against O
different O
tumor B-Disease
types O
, O
notably O
ovarian B-Disease
and B-Disease
breast B-Disease
carcinoma B-Disease
. O

two O
phase O
ii O
trials O
of O
24 O
- O
hour O
paclitaxel O
infusions O
in O
chemotherapy O
- O
naive O
patients O
with O
stage O
iiib O
or O
iv O
non B-Disease
- B-Disease
small B-Disease
cell B-Disease
lung B-Disease
cancer B-Disease
( O
nsclc B-Disease
) O
reported O
response O
rates O
of O
21 O
% O
and O
24 O
% O
. O

leukopenia B-Disease
was O
dose O
limiting O
: O
as O
many O
as O
62 O
. O
5 O
% O
of O
patients O
experienced O
grade O
4 O
leukopenia B-Disease
. O

we O
investigated O
the O
efficacy O
and O
toxicity B-Disease
of O
a O
3 O
- O
hour O
paclitaxel O
infusion O
in O
a O
phase O
ii O
trial O
in O
patients O
with O
inoperable O
stage O
iiib O
or O
iv O
nsclc B-Disease
. O

the O
58 O
patients O
treated O
( O
41 O
men O
and O
17 O
women O
) O
had O
a O
median O
age O
of O
59 O
years O
( O
age O
range O
, O
25 O
to O
75 O
) O
and O
a O
performance O
status O
of O
0 O
through O
2 O
. O

most O
patients O
( O
72 O
. O
4 O
% O
) O
had O
stage O
iv O
nsclc B-Disease
. O

paclitaxel O
225 O
mg O
/ O
m2 O
was O
infused O
over O
3 O
hours O
every O
3 O
weeks O
with O
standard O
prophylactic O
premedication O
. O

of O
50 O
patients O
evaluable O
for O
response O
, O
12 O
( O
24 O
% O
) O
had O
partial O
remission O
, O
26 O
( O
52 O
% O
) O
had O
no O
change O
, O
and O
12 O
had O
disease O
progression O
( O
24 O
% O
) O
. O

hematologic O
toxicities B-Disease
were O
mild O
: O
only O
one O
patient O
( O
2 O
% O
) O
developed O
grade O
3 O
or O
4 O
neutropenia B-Disease
, O
while O
29 O
% O
had O
grade O
1 O
or O
2 O
. O

grade O
1 O
or O
2 O
polyneuropathy B-Disease
affected O
56 O
% O
of O
patients O
while O
only O
one O
( O
2 O
% O
) O
experienced O
severe O
polyneuropathy B-Disease
. O

similarly O
, O
grade O
1 O
or O
2 O
myalgia B-Disease
/ O
arthralgia B-Disease
was O
observed O
in O
63 O
. O
2 O
% O
of O
patients O
, O
but O
only O
14 O
. O
3 O
% O
experienced O
grade O
3 O
or O
4 O
. O

nausea B-Disease
and O
vomiting B-Disease
were O
infrequent O
, O
with O
14 O
% O
of O
patients O
experiencing O
grade O
1 O
or O
2 O
and O
only O
2 O
% O
experiencing O
grade O
3 O
or O
4 O
. O

paclitaxel O
is O
thus O
an O
active O
single O
agent O
in O
this O
patient O
population O
, O
with O
a O
3 O
- O
hour O
infusion O
proving O
comparably O
effective O
to O
a O
24 O
- O
hour O
infusion O
and O
superior O
in O
terms O
of O
the O
incidence O
of O
hematologic O
and O
nonhematologic O
toxicity B-Disease
. O

further O
phase O
ii O
studies O
with O
paclitaxel O
combined O
with O
other O
drugs O
active O
against O
nsclc B-Disease
are O
indicated O
, O
and O
phase O
iii O
studies O
comparing O
paclitaxel O
with O
standard O
chemotherapy O
remain O
to O
be O
completed O
. O

paclitaxel O
combined O
with O
carboplatin O
in O
the O
first O
- O
line O
treatment O
of O
advanced O
ovarian B-Disease
cancer B-Disease
. O

in O
a O
phase O
i O
study O
to O
determine O
the O
maximum O
tolerated O
dose O
of O
paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
given O
as O
a O
3 O
- O
hour O
infusion O
in O
combination O
with O
carboplatin O
administered O
every O
21 O
days O
to O
women O
with O
advanced O
ovarian B-Disease
cancer B-Disease
, O
paclitaxel O
doses O
were O
escalated O
as O
follows O
: O
level O
1 O
, O
135 O
mg O
/ O
m2 O
; O
level O
2 O
, O
160 O
mg O
/ O
m2 O
; O
level O
3 O
, O
185 O
mg O
/ O
m2 O
; O
and O
level O
4 O
, O
210 O
mg O
/ O
m2 O
. O

the O
fixed O
dose O
of O
carboplatin O
at O
levels O
1 O
through O
4 O
was O
given O
to O
achieve O
an O
area O
under O
the O
concentration O
- O
time O
curve O
( O
auc O
) O
of O
5 O
using O
the O
calvert O
formula O
. O

in O
levels O
5 O
and O
6 O
the O
carboplatin O
dose O
was O
targeted O
at O
aucs O
of O
6 O
and O
7 O
. O
5 O
, O
respectively O
, O
combined O
with O
a O
fixed O
paclitaxel O
dose O
of O
185 O
mg O
/ O
m2 O
. O

to O
date O
, O
30 O
previously O
untreated O
patients O
, O
all O
with O
a O
good O
performance O
status O
( O
eastern O
cooperative O
oncology O
group O
0 O
to O
2 O
) O
have O
been O
entered O
into O
this O
ongoing O
study O
. O

the O
dose O
- O
limiting O
toxicity B-Disease
of O
the O
combination O
was O
myelosuppression B-Disease
( O
leukopenia B-Disease
, O
granulocytopenia B-Disease
, O
and O
thrombocytopenia B-Disease
) O
. O

neurotoxicity B-Disease
was O
largely O
moderate O
. O

so O
far O
, O
14 O
patients O
are O
evaluable O
for O
response O
; O
of O
these O
, O
eight O
( O
57 O
% O
) O
showed O
objective O
( O
complete O
or O
partial O
) O
response O
and O
disease O
stabilized O
in O
six O
patients O
. O

no O
patient O
had O
disease O
progression O
. O

we O
conclude O
that O
the O
combination O
of O
paclitaxel O
185 O
mg O
/ O
m2 O
administered O
as O
a O
3 O
- O
hour O
infusion O
followed O
immediately O
by O
a O
1 O
- O
hour O
infusion O
of O
carboplatin O
at O
an O
auc O
of O
6 O
can O
be O
administered O
safely O
in O
a O
21 O
- O
day O
schedule O
in O
the O
outpatient O
setting O
. O

the O
recommended O
dose O
for O
phase O
iii O
studies O
is O
paclitaxel O
185 O
mg O
/ O
m2 O
and O
carboplatin O
auc O
6 O
. O

effects O
of O
acute O
steroid O
administration O
on O
ventilatory O
and O
peripheral O
muscles O
in O
rats O
. O

occasional O
case O
reports O
have O
shown O
that O
acute O
myopathy B-Disease
may O
occur O
in O
patients O
treated O
with O
massive O
doses O
of O
corticosteroids O
. O

the O
mechanism O
of O
this O
myopathy B-Disease
is O
poorly O
understood O
. O

therefore O
, O
60 O
male O
rats O
were O
randomly O
assigned O
to O
receive O
daily O
injection O
of O
saline O
( O
c O
) O
, O
methylprednisolone O
( O
m O
) O
, O
or O
triamcinolone O
( O
t O
) O
80 O
mg O
/ O
kg O
/ O
d O
for O
5 O
d O
. O

nutritional O
intake O
, O
measured O
daily O
in O
15 O
animals O
, O
showed O
a O
significant O
reduction B-Disease
of B-Disease
food B-Disease
intake B-Disease
in O
the O
steroid O
- O
treated O
groups O
( O
- O
50 O
and O
- O
79 O
% O
in O
m O
and O
t O
, O
respectively O
) O
. O

this O
was O
associated O
with O
a O
similar O
loss B-Disease
in B-Disease
body B-Disease
weight B-Disease
. O

in O
the O
45 O
remaining O
animals O
, O
diaphragm O
contractility O
and O
histopathologic O
features O
of O
several O
muscles O
were O
studied O
. O

weights O
of O
respiratory O
and O
peripheral O
muscles O
were O
similarly O
decreased O
after O
steroid O
treatment O
. O

maximal O
twitches O
of O
the O
diaphragm O
were O
lower O
in O
the O
c O
group O
( O
653 O
+ O
/ O
- O
174 O
g O
/ O
cm O
( O
2 O
) O
) O
than O
in O
the O
m O
group O
( O
837 O
+ O
/ O
- O
171 O
g O
/ O
cm O
( O
2 O
) O
; O
p O
< O
0 O
. O
05 O
) O
and O
the O
t O
group O
( O
765 O
+ O
/ O
- O
145 O
g O
/ O
cm O
( O
2 O
) O
, O
ns O
) O
. O

half O
- O
relaxation O
time O
was O
prolonged O
in O
both O
steroid O
groups O
, O
and O
time O
to O
peak O
tension O
was O
longer O
with O
m O
, O
whereas O
tetanic B-Disease
tensions O
were O
similar O
. O

steroid O
treatment O
also O
induced O
a O
leftward O
shift O
of O
the O
force O
- O
frequency O
curve O
at O
25 O
and O
50 O
hz O
when O
compared O
with O
saline O
treatment O
( O
p O
< O
0 O
. O
05 O
) O
. O

atpase O
staining O
of O
the O
diaphragm O
, O
scalenus O
medius O
, O
and O
gastrocnemius O
showed O
type O
iib O
fiber O
atrophy B-Disease
in O
the O
steroid O
groups O
and O
also O
diaphragmatic O
type O
iia O
atrophy B-Disease
with O
t O
, O
whereas O
histologic O
examinations O
revealed O
a O
normal O
muscular O
pattern O
with O
absence O
of O
necrosis B-Disease
. O

finally O
, O
a O
pair O
- O
fed O
( O
pf O
) O
study O
, O
performed O
in O
18 O
rats O
( O
c O
, O
t O
, O
and O
pf O
) O
, O
showed O
that O
muscle B-Disease
atrophy B-Disease
was O
considerably O
less O
pronounced O
in O
pf O
animals O
than O
in O
t O
- O
treated O
animals O
. O

we O
conclude O
that O
( O
1 O
) O
short O
- O
term O
treatment O
with O
massive O
doses O
of O
steroids O
induced O
severe O
respiratory O
and O
limb O
muscle O
wasting O
; O
( O
2 O
) O
both O
types O
of O
steroids O
induced O
predominantly O
type O
iib O
atrophy B-Disease
, O
resulting O
in O
the O
expected O
alterations O
in O
diaphragm O
contractile O
properties O
; O
( O
3 O
) O
neither O
steroid O
caused O
muscle O
necrosis B-Disease
; O
( O
4 O
) O
type O
iib O
atrophy B-Disease
was O
not O
caused O
by O
acute O
nutritional O
deprivation O
alone O
. O

continuous O
subcutaneous O
administration O
of O
mesna O
to O
prevent O
ifosfamide O
- O
induced O
hemorrhagic B-Disease
cystitis B-Disease
. O

hemorrhagic B-Disease
cystitis B-Disease
is O
a O
major O
potential O
toxicity B-Disease
of O
ifosfamide O
that O
can O
be O
prevented O
by O
administering O
mesna O
along O
with O
the O
cytotoxic O
agent O
. O

mesna O
is O
generally O
administered O
by O
the O
intravenous O
route O
, O
although O
experience O
with O
oral O
delivery O
of O
the O
drug O
has O
increased O
. O

the O
continuous O
subcutaneous O
administration O
of O
mesna O
has O
the O
advantage O
of O
not O
requiring O
intravenous O
access O
. O

in O
addition O
, O
subcutaneous O
delivery O
of O
the O
neutralizing O
agent O
will O
not O
be O
associated O
with O
the O
risk O
of O
inadequate O
urinary O
mesna O
concentrations O
, O
such O
as O
in O
a O
patient O
taking O
oral O
mesna O
who O
experiences O
severe O
ifosfamide O
- O
induced O
emesis B-Disease
and O
is O
unable O
to O
absorb O
the O
drug O
. O

limited O
clinical O
experience O
with O
continuous O
subcutaneous O
mesna O
administration O
suggests O
it O
is O
a O
safe O
, O
practical O
, O
and O
economic O
method O
of O
drug O
delivery O
that O
permits O
ifosfamide O
to O
be O
administered O
successfully O
in O
the O
outpatient O
setting O
. O

leg B-Disease
and B-Disease
back B-Disease
pain B-Disease
after O
spinal O
anaesthesia O
involving O
hyperbaric O
5 O
% O
lignocaine O
. O

fifty O
- O
four O
patients O
, O
aged O
27 O
- O
90 O
years O
, O
who O
were O
given O
lignocaine O
5 O
% O
in O
6 O
. O
8 O
% O
glucose O
solution O
for O
spinal O
anaesthesia O
were O
studied O
. O

thirteen O
of O
these O
patients O
experienced O
pain B-Disease
in B-Disease
the B-Disease
legs B-Disease
and B-Disease
/ B-Disease
or B-Disease
back B-Disease
after O
recovery O
from O
anaesthesia O
. O

the O
patients O
affected O
were O
younger O
( O
p O
< O
0 O
. O
05 O
) O
and O
the O
site O
of O
the O
dural O
puncture O
was O
higher O
( O
p O
< O
0 O
. O
01 O
) O
than O
those O
individuals O
without O
pain B-Disease
. O

five O
of O
the O
13 O
patients O
( O
38 O
% O
) O
with O
pain B-Disease
and O
seven O
of O
the O
41 O
patients O
( O
17 O
% O
) O
without O
pain B-Disease
admitted O
to O
a O
high O
alcohol O
intake O
, O
which O
might O
be O
a O
contributing O
factor O
. O

leg B-Disease
and B-Disease
/ B-Disease
or B-Disease
back B-Disease
pain B-Disease
is O
associated O
with O
the O
intrathecal O
use O
of O
hyperbaric O
5 O
% O
lignocaine O
. O

the O
use O
of O
serum O
cholinesterase O
in O
succinylcholine O
apnoea B-Disease
. O

fifteen O
patients O
demonstrating O
unexpected O
prolonged O
apnoea B-Disease
lasting O
several O
hours O
after O
succinylcholine O
have O
been O
treated O
by O
a O
new O
preparation O
of O
human O
serum O
cholinesterase O
. O

adequate O
spontaneous O
respiration O
was O
re O
- O
established O
in O
an O
average O
period O
of O
ten O
minutes O
after O
the O
injection O
. O

in O
12 O
patients O
biochemical O
genetic O
examinations O
confirmed O
the O
presence O
of O
an O
atypical O
serum O
cholinesterase O
. O

in O
three O
patients O
none O
of O
the O
usual O
variants O
were O
found O
. O

it O
is O
therefore O
supposed O
that O
other O
unknown O
variants O
of O
serum O
cholinesterase O
exist O
which O
cannot O
hydrolyze O
succinylcholine O
. O

the O
use O
of O
serum O
cholinesterase O
in O
succinylcholine O
apnoea B-Disease
provided O
considerable O
relief O
to O
both O
patient O
and O
anaesthetist O
. O

increased O
sulfation O
and O
decreased O
7alpha O
- O
hydroxylation O
of O
deoxycholic O
acid O
in O
ethinyl O
estradiol O
- O
induced O
cholestasis B-Disease
in O
rats O
. O

deoxycholic O
acid O
conjugation O
, O
transport O
capacity O
, O
and O
metabolism O
were O
compared O
in O
control O
and O
ethinyl O
estradiol O
- O
treated O
rats O
. O

control O
rats O
were O
found O
to O
have O
a O
lower O
capacity O
to O
transport O
deoxycholic O
acid O
than O
taurodeoxycholic O
acid O
, O
and O
both O
were O
decreased O
by O
ethinyl O
estradiol O
treatment O
. O

during O
[ O
24 O
- O
14c O
] O
sodium O
deoxycholate O
infusion O
, O
[ O
14c O
] O
biliary O
bile O
acid O
secretion O
increased O
, O
but O
bile O
flow O
did O
not O
change O
significantly O
in O
either O
control O
or O
ethinyl O
estradiol O
- O
treated O
rats O
. O

ethinyl O
estradiol O
- O
treated O
animals O
excreted O
significantly O
less O
14c O
as O
taurocholic O
acid O
than O
did O
control O
animals O
, O
consistent O
with O
an O
impairment O
of O
7alpha O
- O
hydroxylation O
of O
taurodeoxycholic O
acid O
. O

ethinyl O
estradiol O
treatment O
did O
not O
impair O
conjugation O
of O
deoxycholic O
acid O
, O
but O
did O
result O
in O
an O
increase O
in O
sulfation O
of O
taurodeoxycholic O
acid O
from O
1 O
. O
5 O
% O
in O
controls O
to O
nearly O
4 O
. O
0 O
% O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

these O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
rat O
has O
a O
poorer O
tolerance O
for O
deoxycholic O
acid O
than O
do O
certain O
other O
species O
. O

furthermore O
, O
the O
rat O
converts O
deoxycholic O
acid O
, O
a O
poor O
choleretic O
, O
to O
taurocholic O
acid O
, O
a O
good O
choleretic O
. O

when O
this O
conversion O
is O
impaired O
with O
ethinyl O
estradiol O
treatment O
, O
sulfation O
may O
be O
an O
important O
alternate O
pathway O
for O
excretion O
of O
this O
potentially O
harmful O
bile O
acid O
. O

influence O
of O
diet O
free O
of O
nad O
- O
precursors O
on O
acetaminophen O
hepatotoxicity B-Disease
in O
mice O
. O

recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic O
acid O
amide O
, O
a O
selective O
inhibitor O
of O
poly O
( O
adp O
- O
ribose O
) O
polymerase O
( O
parp O
; O
ec O
2 O
. O
4 O
. O
2 O
. O
30 O
) O
on O
mice O
suffering O
from O
acetaminophen O
( O
aap O
) O
- O
hepatitis B-Disease
, O
suggesting O
that O
the O
aap O
- O
induced O
liver B-Disease
injury B-Disease
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

the O
present O
study O
investigates O
the O
effects O
of O
a O
diet O
free O
of O
precursors O
of O
nad O
, O
the O
substrate O
on O
which O
parp O
acts O
, O
in O
female O
nmri O
mice O
with O
aap O
hepatitis B-Disease
and O
evaluates O
the O
influence O
of O
simultaneous O
ethanol O
consumption O
in O
these O
animals O
. O

liver B-Disease
injuries B-Disease
were O
quantified O
as O
serum O
activities O
of O
glutamate O
- O
oxaloacetate O
transaminase O
( O
got O
) O
and O
glutamate O
- O
pyruvate O
transaminase O
( O
gpt O
) O
. O

while O
aap O
caused O
a O
117 O
- O
fold O
elevation O
of O
serum O
transaminase O
activities O
in O
mice O
kept O
on O
a O
standard O
laboratory O
diet O
, O
which O
was O
significantly O
exacerbated O
by O
ethanol O
and O
inhibited O
by O
nicotinic O
acid O
amide O
( O
naa O
) O
, O
adverse O
effects O
were O
noted O
in O
animals O
fed O
a O
diet O
free O
of O
precursors O
of O
nad O
. O

in O
these O
animals O
, O
only O
minor O
increases O
of O
serum O
transaminase O
activities O
were O
measured O
in O
the O
presence O
of O
aap O
, O
and O
unlike O
the O
exacerbation O
caused O
by O
ethanol O
in O
mice O
on O
a O
standard O
diet O
, O
the O
liver B-Disease
damage B-Disease
was O
inhibited O
by O
50 O
% O
by O
ethanol O
. O

a O
further O
64 O
% O
reduction O
of O
hepatitis B-Disease
was O
observed O
, O
when O
naa O
was O
given O
to O
ethanol O
/ O
aap O
- O
mice O
. O

our O
results O
provide O
evidence O
that O
the O
aap O
- O
induced O
hepatitis B-Disease
and O
its O
exacerbation O
by O
ethanol O
can O
either O
be O
reduced O
by O
end O
- O
product O
inhibition O
of O
parp O
by O
naa O
or O
by O
dietary O
depletion O
of O
the O
enzyme O
' O
s O
substrate O
nad O
. O

we O
see O
the O
main O
application O
of O
naa O
as O
for O
the O
combinational O
use O
in O
pharmaceutical O
preparations O
of O
acetaminophen O
in O
order O
to O
avoid O
hepatic B-Disease
damage B-Disease
in O
patients O
treated O
with O
this O
widely O
used O
analgesic O
. O

nightmares O
and O
hallucinations B-Disease
after O
long O
- O
term O
intake O
of O
tramadol O
combined O
with O
antidepressants O
. O

tramadol O
is O
a O
weak O
opioid O
with O
effects O
on O
adrenergic O
and O
serotonergic O
neurotransmission O
that O
is O
used O
to O
treat O
cancer B-Disease
pain B-Disease
and O
chronic O
non O
malignant O
pain B-Disease
. O

this O
drug O
was O
initiated O
in O
association O
with O
paroxetine O
and O
dosulepine O
hydrochloride O
in O
a O
tetraparetic B-Disease
patient O
with O
chronic B-Disease
pain B-Disease
. O

fifty O
- O
six O
days O
after O
initiation O
of O
the O
treatment O
the O
patient O
presented O
hallucinations B-Disease
that O
only O
stopped O
after O
the O
withdrawal O
of O
psycho O
- O
active O
drugs O
and O
tramadol O
. O

the O
case O
report O
questions O
the O
long O
term O
use O
of O
pain B-Disease
killers O
combined O
with O
psycho O
- O
active O
drugs O
in O
chronic O
non O
malignant O
pain B-Disease
, O
especially O
if O
pain B-Disease
is O
under O
control O
. O

effect O
of O
calcium O
chloride O
and O
4 O
- O
aminopyridine O
therapy O
on O
desipramine O
toxicity B-Disease
in O
rats O
. O

background O
: O
hypotension B-Disease
is O
a O
major O
contributor O
to O
mortality O
in O
tricyclic O
antidepressant O
overdose B-Disease
. O

recent O
data O
suggest O
that O
tricyclic O
antidepressants O
inhibit O
calcium O
influx O
in O
some O
tissues O
. O

this O
study O
addressed O
the O
potential O
role O
of O
calcium O
channel O
blockade O
in O
tricyclic O
antidepressant O
- O
induced O
hypotension B-Disease
. O

methods O
: O
two O
interventions O
were O
studied O
that O
have O
been O
shown O
previously O
to O
improve O
blood O
pressure O
with O
calcium O
channel O
blocker O
overdose B-Disease
. O

cacl2 O
and O
4 O
- O
aminopyridine O
. O

anesthetized O
rats O
received O
the O
tricyclic O
antidepressant O
desipramine O
ip O
to O
produce O
hypotension B-Disease
, O
qrs O
prolongation O
, O
and O
bradycardia B-Disease
. O

fifteen O
min O
later O
, O
animals O
received O
cacl2 O
, O
nahco3 O
, O
or O
saline O
. O

in O
a O
second O
experiment O
, O
rats O
received O
tricyclic O
antidepressant O
desipramine O
ip O
followed O
in O
15 O
min O
by O
4 O
- O
aminopyridine O
or O
saline O
. O

results O
: O
nahco3 O
briefly O
( O
5 O
min O
) O
reversed O
hypotension B-Disease
and O
qrs O
prolongation O
. O

cacl2 O
and O
4 O
- O
aminopyridine O
failed O
to O
improve O
blood O
pressure O
. O

the O
incidence O
of O
ventricular B-Disease
arrhythmias B-Disease
( O
p O
= O
0 O
. O
004 O
) O
and O
seizures B-Disease
( O
p O
= O
0 O
. O
03 O
) O
in O
the O
cacl2 O
group O
was O
higher O
than O
the O
other O
groups O
. O

conclusion O
: O
the O
administration O
of O
cacl2 O
or O
4 O
- O
aminopyridine O
did O
not O
reverse O
tricyclic O
antidepressant O
- O
induced O
hypotension B-Disease
in O
rats O
. O

cacl2 O
therapy O
may O
possibly O
worsen O
both O
cardiovascular B-Disease
and B-Disease
central B-Disease
nervous B-Disease
system B-Disease
toxicity B-Disease
. O

these O
findings O
do O
not O
support O
a O
role O
for O
calcium O
channel O
inhibition O
in O
the O
pathogenesis O
of O
tricyclic O
antidepressant O
- O
induced O
hypotension B-Disease
. O

valsartan O
, O
a O
new O
angiotensin O
ii O
antagonist O
for O
the O
treatment O
of O
essential O
hypertension B-Disease
: O
a O
comparative O
study O
of O
the O
efficacy O
and O
safety O
against O
amlodipine O
. O

objective O
: O
to O
compare O
the O
antihypertensive O
efficacy O
of O
a O
new O
angiotensin O
ii O
antagonist O
, O
valsartan O
, O
with O
a O
reference O
therapy O
, O
amlodipine O
. O

methods O
: O
one O
hundred O
sixty O
- O
eight O
adult O
outpatients O
with O
mild O
to O
moderate O
hypertension B-Disease
were O
randomly O
allocated O
in O
double O
- O
blind O
fashion O
and O
equal O
number O
to O
receive O
80 O
mg O
valsartan O
or O
5 O
mg O
amlodipine O
for O
12 O
weeks O
. O

after O
8 O
weeks O
of O
therapy O
, O
in O
patients O
whose O
blood O
pressure O
remained O
uncontrolled O
, O
5 O
mg O
amlodipine O
was O
added O
to O
the O
initial O
therapy O
. O

patients O
were O
assessed O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
. O

the O
primary O
efficacy O
variable O
was O
change O
from O
baseline O
in O
mean O
sitting O
diastolic O
blood O
pressure O
at O
8 O
weeks O
. O

secondary O
variables O
included O
change O
in O
sitting O
systolic O
blood O
pressure O
and O
responder O
rates O
. O

results O
: O
both O
valsartan O
and O
amlodipine O
were O
effective O
at O
lowering O
blood O
pressure O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
. O

similar O
decreases O
were O
observed O
in O
both O
groups O
, O
with O
no O
statistically O
significant O
differences O
between O
the O
groups O
for O
any O
variable O
analyzed O
. O

for O
the O
primary O
variable O
the O
difference O
was O
0 O
. O
5 O
mm O
hg O
in O
favor O
of O
valsartan O
( O
p O
= O
0 O
. O
68 O
; O
95 O
% O
confidence O
interval O
, O
- O
2 O
. O
7 O
to O
1 O
. O
7 O
) O
. O

responder O
rates O
at O
8 O
weeks O
were O
66 O
. O
7 O
% O
for O
valsartan O
and O
60 O
. O
2 O
% O
for O
amlodipine O
( O
p O
= O
0 O
. O
39 O
) O
. O

both O
treatments O
were O
well O
tolerated O
. O

the O
incidence O
of O
drug O
- O
related O
dependent O
edema B-Disease
was O
somewhat O
higher O
in O
the O
amlodipine O
group O
, O
particularly O
at O
a O
dose O
of O
10 O
mg O
per O
day O
( O
2 O
. O
4 O
% O
for O
80 O
mg O
valsartan O
; O
3 O
. O
6 O
% O
for O
5 O
mg O
amlodipine O
; O
0 O
% O
for O
valsartan O
plus O
5 O
mg O
amlodipine O
; O
14 O
. O
3 O
% O
for O
10 O
mg O
amlodipine O
) O
. O

conclusions O
: O
the O
data O
show O
that O
valsartan O
is O
at O
least O
as O
effective O
as O
amlodipine O
in O
the O
treatment O
of O
mild O
to O
moderate O
hypertension B-Disease
. O

the O
results O
also O
show O
valsartan O
to O
be O
well O
tolerated O
and O
suggest O
that O
it O
is O
not O
associated O
with O
side O
effects O
characteristic O
of O
this O
comparator O
class O
, O
dihydropyridine O
calcium O
antagonists O
. O

a O
measure O
of O
pupillary B-Disease
oscillation B-Disease
as O
a O
marker O
of O
cocaine O
- O
induced O
paranoia B-Disease
. O

cocaine O
- O
induced O
paranoia B-Disease
( O
cip B-Disease
) O
remains O
an O
important O
drug O
- O
induced O
model O
of O
idiopathic O
paranoia B-Disease
for O
which O
no O
psychophysiologic O
marker O
has O
yet O
emerged O
. O

measures O
of O
pupillary B-Disease
oscillation B-Disease
were O
able O
to O
significantly O
distinguish O
a O
group O
of O
abstinent O
crack O
cocaine O
abusers O
endorsing O
past O
cip B-Disease
( O
n O
= O
32 O
) O
from O
another O
group O
of O
crack O
addicts O
who O
denied O
past O
cip B-Disease
( O
n O
= O
29 O
) O
. O

serotonin B-Disease
syndrome B-Disease
from O
venlafaxine O
- O
tranylcypromine O
interaction O
. O

excessive O
stimulation O
of O
serotonin O
5ht1a O
receptors O
causes O
a O
syndrome O
of O
serotonin O
excess O
that O
consists O
of O
shivering O
, O
muscle B-Disease
rigidity B-Disease
, O
salivation B-Disease
, O
confusion B-Disease
, O
agitation B-Disease
and O
hyperthermia B-Disease
. O

the O
most O
common O
cause O
of O
this O
syndrome O
is O
an O
interaction O
between O
a O
monoamine O
oxidase O
inhibitor O
( O
maoi O
) O
and O
a O
specific O
serotonin O
reuptake O
inhibitor O
. O

venlafaxine O
is O
a O
new O
antidepressant O
agent O
that O
inhibits O
the O
reuptake O
of O
serotonin O
and O
norepinephrine O
. O

we O
report O
a O
venlafaxine O
- O
maoi O
interaction O
that O
resulted O
in O
the O
serotonin B-Disease
syndrome B-Disease
in O
a O
23 O
- O
y O
- O
old O
male O
who O
was O
taking O
tranylcypromine O
for O
depression B-Disease
. O

he O
had O
been O
well O
until O
the O
morning O
of O
presentation O
when O
he O
took O
1 O
/ O
2 O
tab O
of O
venlafaxine O
. O

within O
2 O
h O
he O
became O
confused O
with O
jerking O
movements O
of O
his O
extremities O
, O
tremors B-Disease
and O
rigidity B-Disease
. O

he O
was O
brought O
directly O
to O
a O
hospital O
where O
he O
was O
found O
to O
be O
agitated O
and O
confused O
with O
shivering O
, O
myoclonic B-Disease
jerks B-Disease
, O
rigidity B-Disease
, O
salivation B-Disease
and O
diaphoresis O
. O

his O
pupils O
were O
7 O
mm O
and O
sluggishly O
reactive O
to O
light O
. O

vital O
signs O
were O
: O
blood O
pressure O
120 O
/ O
67 O
mm O
hg O
, O
heart O
rate O
127 O
/ O
min O
, O
respiratory O
rate O
28 O
/ O
min O
, O
and O
temperature O
97 O
f O
. O

after O
180 O
mg O
of O
diazepam O
i O
. O
v O
. O
he O
remained O
tremulous O
with O
muscle B-Disease
rigidity B-Disease
and O
clenched O
jaws O
. O

he O
was O
intubated O
for O
airway O
protection O
and O
because O
of O
hypoventilation B-Disease
, O
and O
was O
paralyzed B-Disease
to O
control O
muscle B-Disease
rigidity B-Disease
. O

his O
subsequent O
course O
was O
remarkable O
for O
non O
- O
immune O
thrombocytopenia B-Disease
which O
resolved O
. O

the O
patient O
' O
s O
maximal O
temperature O
was O
101 O
. O
2 O
f O
and O
his O
cpk O
remained O
< O
500 O
units O
/ O
l O
with O
no O
other O
evidence O
of O
rhabdomyolysis B-Disease
. O

his O
mental O
status O
normalized O
and O
he O
was O
transferred O
to O
a O
psychiatry O
ward O
. O

this O
patient O
survived O
without O
sequelae O
due O
to O
the O
aggressive O
sedation O
and O
neuromuscular O
paralysis B-Disease
. O

cyclophosphamide O
associated O
bladder B-Disease
cancer B-Disease
- O
- O
a O
highly O
aggressive O
disease O
: O
analysis O
of O
12 O
cases O
. O

purpose O
: O
we O
gained O
knowledge O
of O
the O
etiology O
, O
treatment O
and O
prevention O
of O
cyclophosphamide O
associated O
urothelial B-Disease
cancer B-Disease
. O

materials O
and O
methods O
: O
the O
medical O
records O
of O
6 O
men O
and O
6 O
women O
( O
mean O
age O
55 O
years O
) O
with O
cyclophosphamide O
associated O
bladder B-Disease
cancer B-Disease
were O
reviewed O
. O

results O
: O
all O
tumors B-Disease
were O
grade O
3 O
or O
4 O
transitional O
cell O
carcinoma B-Disease
. O

of O
the O
5 O
patients O
initially O
treated O
with O
endoscopic O
resection O
alone O
only O
1 O
is O
alive O
without O
disease O
. O

of O
the O
6 O
patients O
who O
underwent O
early O
cystectomy O
4 O
were O
alive O
at O
24 O
to O
111 O
months O
. O

the O
remaining O
patient O
with O
extensive O
cancer B-Disease
underwent O
partial O
cystectomy O
for O
palliation O
and O
died O
3 O
months O
later O
. O

conclusions O
: O
cyclophosphamide O
associated O
bladder B-Disease
tumor B-Disease
is O
an O
aggressive O
disease O
. O

however O
, O
long O
- O
term O
survival O
is O
possible O
when O
radical O
cystectomy O
is O
performed O
for O
bladder B-Disease
tumors B-Disease
with O
any O
sign O
of O
invasion O
and O
for O
recurrent O
high O
grade O
disease O
, O
even O
when O
noninvasive O
. O

a O
phase O
i O
clinical O
study O
of O
the O
antipurine O
antifolate O
lometrexol O
( O
ddathf O
) O
given O
with O
oral O
folic O
acid O
. O

lometrexol O
is O
an O
antifolate O
which O
inhibits O
glycinamide O
ribonucleotide O
formyltransferase O
( O
garft O
) O
, O
an O
enzyme O
essential O
for O
de O
novo O
purine O
synthesis O
. O

extensive O
experimental O
and O
limited O
clinical O
data O
have O
shown O
that O
lometrexol O
has O
activity O
against O
tumours B-Disease
which O
are O
refractory O
to O
other O
drugs O
, O
notably O
methotrexate O
. O

however O
, O
the O
initial O
clinical O
development O
of O
lometrexol O
was O
curtailed O
because O
of O
severe O
and O
cumulative O
antiproliferative O
toxicities B-Disease
. O

preclinical O
murine O
studies O
demonstrated O
that O
the O
toxicity B-Disease
of O
lometrexol O
can O
be O
prevented O
by O
low O
dose O
folic O
acid O
administration O
, O
i O
. O
e O
. O
for O
7 O
days O
prior O
to O
and O
7 O
days O
following O
a O
single O
bolus O
dose O
. O

this O
observation O
prompted O
a O
phase O
i O
clinical O
study O
of O
lometrexol O
given O
with O
folic O
acid O
supplementation O
which O
has O
confirmed O
that O
the O
toxicity B-Disease
of O
lometrexol O
can O
be O
markedly O
reduced O
by O
folic O
acid O
supplementation O
. O

thrombocytopenia B-Disease
and O
mucositis B-Disease
were O
the O
major O
toxicities B-Disease
. O

there O
was O
no O
clear O
relationship O
between O
clinical O
toxicity B-Disease
and O
the O
extent O
of O
plasma O
folate O
elevation O
. O

associated O
studies O
demonstrated O
that O
lometrexol O
plasma O
pharmacokinetics O
were O
not O
altered O
by O
folic O
acid O
administration O
indicating O
that O
supplementation O
is O
unlikely O
to O
reduce O
toxicity B-Disease
by O
enhancing O
lometrexol O
plasma O
clearance O
. O

the O
work O
described O
in O
this O
report O
has O
identified O
for O
the O
first O
time O
a O
clinically O
acceptable O
schedule O
for O
the O
administration O
of O
a O
garft O
inhibitor O
. O

this O
information O
will O
facilitate O
the O
future O
evaluation O
of O
this O
class O
of O
compounds O
in O
cancer B-Disease
therapy O
. O

fatal O
excited O
delirium B-Disease
following O
cocaine O
use O
: O
epidemiologic O
findings O
provide O
new O
evidence O
for O
mechanisms O
of O
cocaine O
toxicity B-Disease
. O

we O
describe O
an O
outbreak O
of O
deaths O
from O
cocaine O
- O
induced O
excited O
delirium B-Disease
( O
edds B-Disease
) O
in O
dade O
county O
, O
florida O
between O
1979 O
and O
1990 O
. O

from O
a O
registry O
of O
all O
cocaine O
- O
related O
deaths O
in O
dade O
county O
, O
florida O
, O
from O
1969 O
- O
1990 O
, O
58 O
edds B-Disease
were O
compared O
with O
125 O
victims O
of O
accidental O
cocaine O
overdose B-Disease
without O
excited O
delirium B-Disease
. O

compared O
with O
controls O
, O
edds B-Disease
were O
more O
frequently O
black O
, O
male O
, O
and O
younger O
. O

they O
were O
less O
likely O
to O
have O
a O
low O
body O
mass O
index O
, O
and O
more O
likely O
to O
have O
died O
in O
police O
custody O
, O
to O
have O
received O
medical O
treatment O
immediately O
before O
death O
, O
to O
have O
survived O
for O
a O
longer O
period O
, O
to O
have O
developed O
hyperthermia B-Disease
, O
and O
to O
have O
died O
in O
summer O
months O
. O

edds B-Disease
had O
concentrations O
of O
cocaine O
and O
benzoylecgonine O
in O
autopsy O
blood O
that O
were O
similar O
to O
those O
for O
controls O
. O

the O
epidemiologic O
findings O
are O
most O
consistent O
with O
the O
hypothesis O
that O
chronic O
cocaine O
use O
disrupts O
dopaminergic O
function O
and O
, O
when O
coupled O
with O
recent O
cocaine O
use O
, O
may O
precipitate O
agitation B-Disease
, O
delirium B-Disease
, O
aberrant O
thermoregulation O
, O
rhabdomyolysis B-Disease
, O
and O
sudden B-Disease
death B-Disease
. O

pemoline O
induced O
acute O
choreoathetosis B-Disease
: O
case O
report O
and O
review O
of O
the O
literature O
. O

background O
: O
pemoline O
is O
an O
oxazolidine O
derivative O
that O
is O
structurally O
different O
from O
amphetamines O
and O
used O
in O
the O
treatment O
of O
attention B-Disease
deficit B-Disease
disorder B-Disease
. O

pemoline O
has O
not O
been O
commonly O
associated O
in O
the O
literature O
as O
a O
cause O
of O
acute O
movement B-Disease
disorders B-Disease
. O

the O
following O
case O
describes O
two O
children O
acutely O
poisoned O
with O
pemoline O
who O
experienced O
profound O
choreoathetosis B-Disease
. O

case O
report O
: O
two O
, O
3 O
- O
year O
- O
old O
male O
, O
identical O
twin O
siblings O
presented O
to O
the O
emergency O
department O
after O
found O
playing O
with O
a O
an O
empty O
bottle O
of O
pemoline O
originally O
containing O
59 O
tablets O
. O

the O
children O
had O
a O
medical O
history O
significant O
for O
attention B-Disease
deficit B-Disease
disorder B-Disease
previously O
treated O
with O
methylphenidate O
without O
success O
. O

this O
was O
their O
first O
day O
of O
pemoline O
therapy O
. O

the O
choreoathetoid B-Disease
movements O
began O
45 O
min O
to O
1 O
h O
after O
ingestion O
. O

the O
children O
gave O
no O
history O
of O
prior O
movement B-Disease
disorders B-Disease
and O
there O
was O
no O
family O
history O
of O
movement B-Disease
disorders B-Disease
. O

the O
children O
received O
gastrointestinal O
decontamination O
and O
high O
doses O
of O
intravenous O
benzodiazepines O
in O
an O
attempt O
to O
control O
the O
choreoathetoid B-Disease
movements O
. O

despite O
treatment O
, O
the O
children O
continued O
to O
have O
choreoathetosis B-Disease
for O
approximately O
24 O
hours O
. O

forty O
- O
eight O
hours O
after O
admission O
, O
the O
children O
appeared O
to O
be O
at O
their O
baseline O
and O
were O
discharged O
home O
. O

conclusion O
: O
pemoline O
associated O
movement B-Disease
disorder B-Disease
has O
been O
rarely O
reported O
in O
the O
acute O
toxicology O
literature O
. O

the O
possibility O
of O
choreoathetoid B-Disease
movements O
should O
be O
considered O
in O
patients O
presenting O
after O
pemoline O
overdose B-Disease
. O

effect O
of O
myopic O
excimer O
laser O
photorefractive O
keratectomy O
on O
the O
electrophysiologic O
function O
of O
the O
retina O
and O
optic O
nerve O
. O

purpose O
: O
to O
assess O
by O
electrophysiologic O
testing O
the O
effect O
of O
photorefractive O
keratectomy O
( O
prk O
) O
on O
the O
retina O
and O
optic O
nerve O
. O

setting O
: O
eye O
clinic O
, O
s O
. O

salvatore O
hospital O
, O
l O
' O
aquila O
university O
, O
italy O
. O

methods O
: O
standard O
pattern O
electroretinograms O
( O
p O
- O
ergs O
) O
and O
standard O
pattern O
visual O
evoked O
potentials O
( O
p O
- O
veps O
) O
were O
done O
in O
25 O
eyes O
of O
25 O
patients O
who O
had O
myopic O
prk O
for O
an O
attempted O
correction O
between O
5 O
. O
00 O
and O
15 O
. O
00 O
diopters O
( O
d O
) O
( O
mean O
8 O
. O
00 O
d O
) O
. O

testing O
was O
done O
preoperatively O
and O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
postoperatively O
. O

the O
contralateral O
eyes O
served O
as O
controls O
. O

during O
the O
follow O
- O
up O
, O
3 O
patients O
( O
12 O
% O
) O
developed O
steroid O
- O
induced O
elevated B-Disease
intraocular B-Disease
pressure B-Disease
( O
iop O
) O
that O
resolved O
after O
corticosteroid O
therapy O
was O
discontinued O
. O

results O
: O
no O
statistically O
significant O
differences O
were O
seen O
between O
treated O
and O
control O
eyes O
nor O
between O
treated O
eyes O
preoperatively O
and O
postoperatively O
. O

conclusion O
: O
myopic O
excimer O
laser O
prk O
did O
not O
seem O
to O
affect O
the O
posterior O
segment O
. O

the O
transient O
steroid O
- O
induced O
iop B-Disease
rise B-Disease
did O
not O
seem O
to O
cause O
functional O
impairment O
. O

neutrophil O
superoxide O
and O
hydrogen O
peroxide O
production O
in O
patients O
with O
acute B-Disease
liver B-Disease
failure B-Disease
. O

defects O
in O
superoxide O
and O
hydrogen O
peroxide O
production O
may O
be O
implicated O
in O
the O
high O
incidence O
of O
bacterial B-Disease
infections B-Disease
in O
patients O
with O
acute B-Disease
liver B-Disease
failure B-Disease
( O
alf B-Disease
) O
. O

in O
the O
present O
study O
, O
oxygen O
radical O
production O
in O
patients O
with O
alf B-Disease
due O
to O
paracetamol O
overdose B-Disease
was O
compared O
with O
that O
of O
healthy O
volunteers O
. O

neutrophils O
from O
14 O
alf B-Disease
patients O
were O
stimulated O
via O
the O
complement O
receptors O
using O
zymosan O
opsonized O
with O
alf B-Disease
or O
control O
serum O
. O

superoxide O
and O
hydrogen O
peroxide O
production O
by O
alf B-Disease
neutrophils O
stimulated O
with O
zymosan O
opsonized O
with O
alf B-Disease
serum O
was O
significantly O
reduced O
compared O
with O
the O
control O
subjects O
( O
p O
< O
0 O
. O
01 O
) O
. O

this O
defect O
persisted O
when O
zymosan O
opsonized O
by O
control O
serum O
was O
used O
( O
p O
< O
0 O
. O
05 O
) O
. O

superoxide O
and O
hydrogen O
peroxide O
production O
in O
neutrophils O
stimulated O
with O
formyl O
- O
methionyl O
- O
leucyl O
- O
phenylalanine O
( O
fmlp O
) O
from O
a O
further O
18 O
alf B-Disease
patients O
was O
unaffected O
compared O
with O
control O
neutrophils O
. O

serum O
c3 O
complement O
levels O
were O
significantly O
reduced O
in O
alf B-Disease
patients O
compared O
with O
control O
subjects O
( O
p O
< O
0 O
. O
0005 O
) O
. O

these O
results O
demonstrate O
a O
neutrophil O
defect O
in O
alf B-Disease
due O
to O
paracetamol O
overdose B-Disease
, O
that O
is O
complement O
dependent O
but O
independent O
of O
serum O
complement O
, O
possibly O
connected O
to O
the O
complement O
receptor O
. O

cholesteryl O
hemisuccinate O
treatment O
protects O
rodents O
from O
the O
toxic O
effects O
of O
acetaminophen O
, O
adriamycin O
, O
carbon O
tetrachloride O
, O
chloroform O
and O
galactosamine O
. O

in O
addition O
to O
its O
use O
as O
a O
stabilizer O
/ O
rigidifier O
of O
membranes O
, O
cholesteryl O
hemisuccinate O
, O
tris O
salt O
( O
cs O
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic B-Disease
effects O
of O
carbon O
tetrachloride O
( O
ccl4 O
) O
. O

to O
further O
our O
understanding O
of O
the O
mechanism O
of O
cs O
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
cs O
and O
the O
non O
- O
hydrolyzable O
ether O
form O
of O
cs O
, O
gamma O
- O
cholesteryloxybutyric O
acid O
, O
tris O
salt O
( O
cse O
) O
against O
acetaminophen O
- O
, O
adriamycin O
- O
, O
carbon O
tetrachloride O
- O
, O
chloroform O
- O
and O
galactosamine O
- O
induced O
toxicity B-Disease
. O

the O
results O
of O
these O
studies O
demonstrated O
that O
cs O
- O
mediated O
protection O
is O
not O
selective O
for O
a O
particular O
species O
, O
organ O
system O
or O
toxic O
chemical O
. O

a O
24 O
- O
h O
pretreatment O
of O
both O
rats O
and O
mice O
with O
a O
single O
dose O
of O
cs O
( O
100mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
resulted O
in O
significant O
protection O
against O
the O
hepatotoxic B-Disease
effects O
of O
ccl4 O
, O
chcl3 O
, O
acetaminophen O
and O
galactosamine O
and O
against O
the O
lethal O
( O
and O
presumably O
cardiotoxic B-Disease
) O
effect O
of O
adriamycin O
administration O
. O

maximal O
cs O
- O
mediated O
protection O
was O
observed O
in O
experimental O
animals O
pretreated O
24 O
h O
prior O
to O
the O
toxic O
insult O
. O

these O
data O
suggest O
that O
cs O
intervenes O
in O
a O
critical O
cellular O
event O
that O
is O
an O
important O
common O
pathway O
to O
toxic O
cell O
death O
. O

the O
mechanism O
of O
cs O
protection O
does O
not O
appear O
to O
be O
dependent O
on O
the O
inhibition O
of O
chemical O
bioactivation O
to O
a O
toxic O
reactive O
intermediate O
( O
in O
light O
of O
the O
protection O
observed O
against O
galactosamine O
hepatotoxicity B-Disease
) O
. O

however O
, O
based O
on O
the O
data O
presented O
, O
we O
can O
not O
exclude O
the O
possibility O
that O
cs O
administration O
inhibits O
chemical O
bioactivation O
. O

our O
findings O
do O
suggest O
that O
cs O
- O
mediated O
protection O
is O
dependent O
on O
the O
action O
of O
the O
intact O
anionic O
cs O
molecule O
( O
non O
- O
hydrolyzable O
cse O
was O
as O
protective O
as O
cs O
) O
, O
whose O
mechanism O
has O
yet O
to O
be O
defined O
. O

a O
murine O
model O
of O
adenomyosis B-Disease
: O
the O
effects O
of O
hyperprolactinemia B-Disease
induced O
by O
fluoxetine O
hydrochloride O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
on O
adenomyosis B-Disease
induction O
in O
wistar O
albino O
rats O
. O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
fluoxetine O
given O
to O
castrated O
and O
noncastrated O
rats O
caused O
hyperprolactinemia B-Disease
and O
its O
effects O
with O
respect O
to O
adenomyosis B-Disease
. O

design O
: O
fluoxetine O
, O
a O
serotonin O
reuptake O
inhibitor O
, O
was O
given O
to O
wistar O
albino O
rats O
for O
98 O
days O
to O
produce O
hyperprolactinemia B-Disease
. O

the O
drug O
was O
given O
to O
two O
groups O
consisting O
of O
castrated O
and O
noncastrated O
rats O
and O
compared O
to O
two O
groups O
of O
castrated O
and O
noncastrated O
controls O
. O

prolactin O
levels O
were O
measured O
and O
the O
uteri O
of O
the O
rats O
were O
removed O
for O
histopathological O
analysis O
at O
the O
end O
of O
98 O
days O
. O

setting O
: O
marmara O
university O
school O
of O
medicine O
, O
department O
of O
histology O
and O
embryology O
, O
zeynep O
kamil O
women O
and O
children O
' O
s O
hospital O
. O

main O
outcome O
measures O
: O
serum O
prolactin O
levels O
, O
uterine O
histopathology O
. O

results O
: O
the O
prolactin O
levels O
of O
castrated O
and O
noncastrated O
groups O
treated O
with O
fluoxetine O
were O
statistically O
significantly O
higher O
when O
compared O
to O
their O
respective O
control O
groups O
. O

histological O
studies O
revealed O
11 O
cases O
of O
adenomyosis B-Disease
, O
all O
within O
the O
noncastrated O
group O
receiving O
fluoxetine O
. O

conclusion O
: O
it O
was O
suggested O
that O
high O
serum O
prolactin O
levels O
cause O
degeneration O
of O
myometrial O
cells O
in O
the O
presence O
of O
ovarian O
steroids O
that O
results O
in O
a O
myometrial O
invasion O
by O
endometrial O
stroma O
. O

this O
invasion O
eventually O
progresses O
to O
adenomyosis B-Disease
. O

postinfarction O
ventricular B-Disease
septal B-Disease
defect B-Disease
associated O
with O
long O
- O
term O
steroid O
therapy O
. O

two O
cases O
of O
postinfarction O
ventricular B-Disease
septal B-Disease
rupture B-Disease
in O
patients O
on O
long O
- O
term O
steroid O
therapy O
are O
presented O
and O
the O
favourable O
outcome O
in O
both O
cases O
described O
. O

a O
possible O
association O
between O
steroid O
therapy O
and O
subsequent O
postinfarction O
septal B-Disease
rupture B-Disease
is O
discussed O
. O

neuroactive O
steroids O
protect O
against O
pilocarpine O
- O
and O
kainic O
acid O
- O
induced O
limbic O
seizures B-Disease
and O
status B-Disease
epilepticus B-Disease
in O
mice O
. O

several O
structurally O
related O
metabolites O
of O
progesterone O
( O
3 O
alpha O
- O
hydroxy O
pregnane O
- O
20 O
- O
ones O
) O
and O
deoxycorticosterone O
( O
3 O
alpha O
- O
hydroxy O
pregnane O
- O
21 O
- O
diol O
- O
20 O
- O
ones O
) O
and O
their O
3 O
beta O
- O
epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine O
- O
, O
kainic O
acid O
- O
and O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
- O
induced O
seizures B-Disease
in O
mice O
. O

steroids O
with O
the O
3 O
- O
hydroxy O
group O
in O
the O
alpha O
- O
position O
and O
5 O
- O
h O
in O
the O
alpha O
- O
or O
beta O
- O
configurations O
were O
highly O
effective O
in O
protecting O
against O
pilocarpine O
( O
416 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
- O
induced O
limbic O
motor O
seizures B-Disease
and O
status B-Disease
epilepticus B-Disease
( O
ed50 O
values O
, O
7 O
. O
0 O
- O
18 O
. O
7 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

the O
corresponding O
epimers O
with O
the O
3 O
- O
hydroxy O
group O
in O
the O
beta O
- O
position O
were O
also O
effective O
but O
less O
potent O
( O
ed50 O
values O
, O
33 O
. O
8 O
- O
63 O
. O
5 O
, O
i O
. O
p O
. O
) O
. O

although O
the O
neuroactive O
steroids O
were O
considerably O
less O
potent O
than O
the O
benzodiazepine O
clonazepam O
in O
protecting O
against O
pilocarpine O
seizures B-Disease
, O
steroids O
with O
the O
5 O
alpha O
, O
3 O
alpha O
- O
configuration O
had O
comparable O
or O
higher O
protective O
index O
values O
( O
td50 O
for O
motor O
impairment O
divided O
by O
ed50 O
for O
seizure B-Disease
protection O
) O
than O
clonazepam O
, O
indicating O
that O
some O
neuroactive O
steroids O
may O
have O
lower O
relative O
toxicity B-Disease
. O

steroids O
with O
the O
5 O
alpha O
, O
3 O
alpha O
- O
or O
5 O
beta O
, O
3 O
alpha O
- O
configurations O
also O
produced O
a O
dose O
- O
dependent O
delay O
in O
the O
onset O
of O
limbic O
seizures B-Disease
induced O
by O
kainic O
acid O
( O
32 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
but O
did O
not O
completely O
protect O
against O
the O
seizures B-Disease
. O

however O
, O
when O
a O
second O
dose O
of O
the O
steroid O
was O
administered O
1 O
hr O
after O
the O
first O
dose O
, O
complete O
protection O
from O
the O
kainic O
acid O
- O
induced O
limbic O
seizures B-Disease
and O
status B-Disease
epilepticus B-Disease
was O
obtained O
. O

the O
steroids O
also O
caused O
a O
dose O
- O
dependent O
delay O
in O
nmda O
( O
257 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
- O
induced O
lethality O
, O
but O
did O
not O
completely O
protect O
against O
nmda O
seizures B-Disease
or O
lethality O
. O

we O
conclude O
that O
neuroactive O
steroids O
are O
highly O
effective O
in O
protecting O
against O
pilocarpine O
- O
and O
kainic O
acid O
- O
induced O
seizures B-Disease
and O
status B-Disease
epilepticus B-Disease
in O
mice O
, O
and O
may O
be O
of O
utility O
in O
the O
treatment O
of O
some O
forms O
of O
status B-Disease
epilepticus B-Disease
in O
humans O
. O

hepatic O
and O
extrahepatic O
angiotensinogen O
gene O
expression O
in O
rats O
with O
acute O
nephrotic B-Disease
syndrome B-Disease
. O

plasma O
concentration O
and O
urine O
excretion O
of O
the O
renin O
- O
angiotensin O
system O
proteins O
are O
altered O
in O
rats O
with O
nephrotic B-Disease
syndrome B-Disease
( O
ns B-Disease
) O
. O

in O
this O
work O
the O
messenger O
ribonucleic O
acid O
( O
mrna O
) O
levels O
of O
angiotensinogen O
( O
ao O
) O
were O
analyzed O
with O
the O
slot O
- O
blot O
hybridization O
technique O
in O
liver O
and O
other O
extrahepatic O
tissues O
: O
kidney O
, O
heart O
, O
brain O
, O
and O
adrenal O
gland O
from O
control O
, O
nephrotic B-Disease
, O
and O
pair O
- O
fed O
( O
pf O
) O
rats O
. O

ns B-Disease
was O
induced O
by O
a O
single O
injection O
of O
puromycin O
amino O
- O
nucleoside O
( O
pan O
) O
. O

although O
a O
great O
urinary O
excretion O
and O
half O
- O
normal O
plasma O
levels O
of O
ao O
were O
observed O
on O
day O
6 O
after O
pan O
injection O
, O
when O
ns B-Disease
was O
clearly O
established O
, O
hepatic O
ao O
mrna O
levels O
did O
not O
change O
. O

furthermore O
, O
the O
ao O
mrna O
levels O
did O
not O
change O
in O
any O
of O
the O
extrahepatic O
tissues O
studied O
on O
day O
6 O
, O
nor O
did O
its O
hepatic O
levels O
at O
days O
1 O
, O
3 O
, O
5 O
, O
or O
7 O
after O
pan O
injection O
. O

these O
data O
suggest O
that O
the O
hepatic O
and O
extrahepatic O
ao O
mrna O
levels O
are O
unaltered O
during O
the O
development O
of O
the O
acute O
ns B-Disease
induced O
by O
pan O
. O

neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
with O
risperidone O
. O

neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
is O
thought O
to O
be O
a O
result O
of O
dopamine O
d2 O
receptor O
blockade O
in O
the O
striatum O
of O
the O
basal O
ganglia O
. O

risperidone O
, O
a O
benzisoxazole O
derivative O
antipsychotic O
, O
has O
high O
serotonin O
5 O
- O
ht2 O
receptor O
blockade O
and O
dose O
- O
related O
d2 O
receptor O
blockade O
. O

the O
high O
ratio O
is O
believed O
to O
impart O
the O
low O
frequency O
of O
extrapyramidal B-Disease
symptoms B-Disease
with O
risperidone O
at O
low O
dosages O
. O

with O
this O
low O
frequency O
of O
extrapyramidal B-Disease
symptoms B-Disease
, O
it O
was O
thought O
the O
frequency O
of O
neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
might O
also O
be O
lowered O
. O

a O
73 O
- O
year O
- O
old O
woman O
developed O
neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
after O
monotherapy O
with O
risperidone O
. O

the O
syndrome O
reversed O
after O
discontinuing O
risperidone O
and O
starting O
treatment O
with O
dantrolene O
and O
bromocriptine O
. O

it O
appears O
that O
the O
protection O
from O
extrapyramidal O
side O
effects O
observed O
with O
risperidone O
does O
not O
ensure O
protection O
from O
neuroleptic B-Disease
malignant B-Disease
syndrome B-Disease
. O

the O
attenuating O
effect O
of O
carteolol O
hydrochloride O
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
neuroleptic O
- O
induced O
catalepsy B-Disease
in O
rats O
. O

it O
is O
known O
that O
beta O
- O
adrenoceptor O
antagonists O
are O
effective O
in O
the O
treatment O
of O
akathisia B-Disease
, O
one O
of O
the O
extrapyramidal O
side O
effects O
that O
occur O
during O
neuroleptic O
treatment O
. O

neuroleptic O
- O
induced O
catalepsy B-Disease
, O
a O
model O
of O
neuroleptic O
- O
induced O
extrapyramidal O
side O
effects O
, O
was O
considered O
suitable O
as O
a O
model O
for O
predicting O
neuroleptic O
- O
induced O
akathisia B-Disease
in O
humans O
, O
although O
neuroleptic O
- O
induced O
catalepsy B-Disease
was O
not O
considered O
a O
specific O
test O
for O
neuroleptic O
- O
induced O
akathisia B-Disease
. O

therefore O
, O
the O
effects O
of O
carteolol O
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
haloperidol O
- O
induced O
catalepsy B-Disease
in O
rats O
were O
behaviorally O
studied O
and O
compared O
with O
those O
of O
propranolol O
and O
biperiden O
, O
a O
muscarinic O
receptor O
antagonist O
. O

carteolol O
, O
as O
well O
as O
propranolol O
and O
biperiden O
, O
inhibited O
the O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

the O
inhibitory O
effect O
of O
carteolol O
was O
almost O
comparable O
to O
that O
of O
propranolol O
, O
but O
was O
weaker O
than O
that O
of O
biperiden O
. O

carteolol O
did O
not O
evoke O
postsynaptic O
dopamine O
receptor O
- O
stimulating O
behavioral O
signs O
such O
as O
stereotypy O
and O
hyperlocomotion B-Disease
in O
rats O
. O

carteolol O
did O
not O
antagonize O
the O
inhibitory O
effects O
of O
haloperidol O
on O
apomorphine O
- O
induced O
stereotypy O
and O
locomotor O
activity O
in O
rats O
. O

in O
addition O
, O
carteolol O
did O
not O
evoke O
5 O
- O
ht1a O
receptor O
- O
stimulating O
behavioral O
signs O
such O
as O
flat O
body O
posture O
and O
forepaw O
treading O
and O
did O
not O
inhibit O
5 O
- O
hydroxytryptophan O
- O
induced O
head O
twitch O
in O
rats O
. O

finally O
, O
carteolol O
did O
not O
inhibit O
physostigmine O
- O
induced O
lethality O
in O
rats O
. O

these O
results O
strongly O
suggest O
that O
carteolol O
improves O
haloperidol O
- O
induced O
catalepsy B-Disease
via O
its O
beta O
- O
adrenoceptor O
antagonistic O
activity O
and O
is O
expected O
to O
be O
effective O
in O
the O
treatment O
of O
akathisia B-Disease
without O
attenuating O
neuroleptic O
- O
induced O
antipsychotic O
effects O
due O
to O
its O
postsynaptic O
dopamine O
receptor O
antagonistic O
activity O
. O

granulosa B-Disease
cell B-Disease
tumor B-Disease
of B-Disease
the B-Disease
ovary B-Disease
associated O
with O
antecedent O
tamoxifen O
use O
. O

background O
: O
increased O
attention O
has O
been O
focused O
recently O
on O
the O
estrogenic O
effects O
of O
tamoxifen O
. O

review O
of O
the O
literature O
reveals O
an O
association O
between O
tamoxifen O
use O
and O
gynecologic O
tumors B-Disease
. O

case O
: O
a O
52 O
- O
year O
- O
old O
postmenopausal O
woman O
was O
treated O
with O
tamoxifen O
for O
stage O
ii O
estrogen O
receptor O
- O
positive O
breast B-Disease
carcinoma B-Disease
. O

her O
aspartate O
transaminase O
and O
alanine O
transaminase O
levels O
increase O
markedly O
after O
6 O
months O
of O
tamoxifen O
use O
. O

after O
an O
additional O
17 O
months O
of O
elevated O
serum O
transaminases O
, O
the O
patient O
was O
found O
to O
have O
a O
stage O
ic O
granulosa B-Disease
cell B-Disease
tumor B-Disease
of B-Disease
the B-Disease
ovary B-Disease
. O

conclusion O
: O
patients O
with O
tamoxifen O
- O
induced O
liver B-Disease
dysfunction B-Disease
may O
be O
at O
increased O
risk O
for O
granulosa B-Disease
cell B-Disease
tumors B-Disease
because O
of O
alterations O
in O
tamoxifen O
metabolism O
. O

lifetime O
treatment O
of O
mice O
with O
azidothymidine O
( O
azt O
) O
produces O
myelodysplasia B-Disease
. O

azt O
has O
induced O
a O
macrocytic B-Disease
anemia B-Disease
in O
aids B-Disease
patients O
on O
long O
term O
azt O
therapy O
. O

it O
is O
generally O
assumed O
that O
dna O
elongation O
is O
stopped O
by O
the O
insertion O
of O
azt O
into O
the O
chain O
in O
place O
of O
thymidine O
thus O
preventing O
the O
phosphate O
hydroxyl O
linkages O
and O
therefore O
suppresses O
hemopoietic O
progenitor O
cell O
proliferation O
in O
an O
early O
stage O
of O
differentiation O
. O

cba O
/ O
ca O
male O
mice O
started O
on O
azt O
0 O
. O
75 O
mg O
/ O
ml O
h2o O
at O
84 O
days O
of O
age O
and O
kept O
on O
it O
for O
687 O
days O
when O
dosage O
reduced O
to O
0 O
. O
5 O
mg O
/ O
ml O
h2o O
for O
a O
group O
, O
another O
group O
removed O
from O
azt O
to O
see O
recovery O
, O
and O
third O
group O
remained O
on O
0 O
. O
75 O
mg O
. O

at O
687 O
days O
mice O
that O
had O
been O
on O
0 O
. O
75 O
mg O
had O
average O
platelet O
counts O
of O
2 O
. O
5 O
x O
10 O
( O
6 O
) O
. O

histological O
examination O
on O
9 O
of O
10 O
mice O
with O
such O
thrombocytopenia B-Disease
showed O
changes O
compatible O
with O
myelodysplastic B-Disease
syndrome B-Disease
( O
mds B-Disease
) O
. O

a O
variety O
of O
histological O
patterns O
was O
observed O
. O

there O
were O
two O
cases O
of O
hypocellular O
myelodysplasia B-Disease
, O
two O
cases O
of O
hypersegmented O
myelodysplastic B-Disease
granulocytosis O
, O
two O
cases O
of O
hypercellular O
marrow O
with O
abnormal O
megakaryocytes O
with O
bizarre O
nuclei O
, O
one O
case O
of O
megakaryocytic O
myelosis O
associated O
with O
a O
hyperplastic B-Disease
marrow B-Disease
, O
dysmyelopoiesis B-Disease
and O
a O
hypocellular B-Disease
marrow B-Disease
and O
two O
cases O
of O
myelodysplasia B-Disease
with O
dyserythropoiesis B-Disease
, O
hemosiderosis B-Disease
and O
a O
hypocellular B-Disease
marrow B-Disease
. O

above O
mentioned O
azt O
incorporation O
may O
have O
induced O
an O
ineffective O
hemopoiesis O
in O
the O
primitive O
hemopoietic O
progenitor O
cells O
, O
which O
is O
known O
to O
be O
seen O
commonly O
in O
the O
myelodysplastic B-Disease
syndrome B-Disease
. O

biphasic O
response O
of O
the O
sa O
node O
of O
the O
dog O
heart O
in O
vivo O
to O
selective O
administration O
of O
ketamine O
. O

effect O
of O
ketamine O
on O
the O
sa O
node O
of O
the O
dog O
heart O
was O
studied O
in O
vivo O
using O
a O
selective O
perfusion O
technique O
of O
the O
sa O
node O
artery O
. O

injections O
of O
ketamine O
in O
doses O
from O
100 O
microgram O
to O
3 O
mg O
into O
the O
artery O
produced O
a O
depression B-Disease
of O
the O
sa O
nodal O
activity O
by O
a O
direct O
action O
. O

this O
depression B-Disease
was O
followed O
by O
the O
sudden O
appearance O
of O
a O
stimulatory O
phase O
. O

bilateral O
vagotomy O
and O
sympathectomy O
or O
prior O
administration O
of O
a O
ganglion O
blocker O
failed O
to O
inhibit O
the O
occurrence O
of O
the O
ketamine O
- O
induced O
tachycardia B-Disease
, O
while O
it O
was O
completely O
abolished O
in O
the O
reserpinized O
dogs O
or O
by O
a O
prior O
injection O
of O
a O
beta O
- O
blocking O
agent O
into O
the O
sa O
node O
artery O
. O

this O
may O
indicate O
that O
an O
activation O
of O
the O
peripheral O
adrenergic O
mechanism O
plays O
an O
important O
role O
in O
the O
induction O
of O
the O
excitatory O
effect O
of O
ketamine O
injected O
in O
the O
sa O
node O
artery O
. O

over O
expression O
of O
vascular O
endothelial O
growth O
factor O
and O
its O
receptor O
during O
the O
development O
of O
estrogen O
- O
induced O
rat O
pituitary B-Disease
tumors B-Disease
may O
mediate O
estrogen O
- O
initiated O
tumor B-Disease
angiogenesis O
. O

estrogens O
, O
which O
have O
been O
associated O
with O
several O
types O
of O
human O
and O
animal O
cancers B-Disease
, O
can O
induce O
tumor B-Disease
angiogenesis O
in O
the O
pituitary O
of O
fischer O
344 O
rats O
. O

the O
mechanistic O
details O
of O
tumor B-Disease
angiogenesis O
induction O
, O
during O
estrogen O
carcinogenesis B-Disease
, O
are O
still O
unknown O
. O

to O
elucidate O
the O
role O
of O
estrogen O
in O
the O
regulation O
of O
tumor B-Disease
angiogenesis O
in O
the O
pituitary O
of O
female O
rats O
, O
the O
density O
of O
blood O
vessels O
was O
analysed O
using O
factor O
viii O
related O
antigen O
( O
fviiirag O
) O
immunohistochemistry O
and O
the O
expression O
of O
vascular O
endothelial O
growth O
factor O
/ O
vascular O
permeability O
factor O
( O
vegf O
/ O
vpf O
) O
was O
examined O
by O
western O
blot O
and O
immunohistochemical O
analysis O
. O

the O
expression O
of O
vegf O
receptor O
( O
vegfr O
- O
2 O
/ O
flk O
- O
1 O
/ O
kdr O
) O
was O
also O
examined O
by O
immunohistochemistry O
. O

the O
results O
demonstrated O
that O
17beta O
- O
estradiol O
( O
e2 O
) O
induces O
neovascularization O
, O
as O
well O
as O
the O
growth O
and O
enlargement O
of O
blood O
vessels O
after O
7 O
days O
of O
exposure O
. O

the O
high O
tumor B-Disease
angiogenic O
potential O
was O
associated O
with O
an O
elevated O
vegf O
/ O
vpf O
protein O
expression O
in O
the O
e2 O
exposed O
pituitary O
of O
ovariectomized O
( O
ovex O
) O
rats O
. O

vegf O
/ O
vpf O
and O
fviiirag O
immunohistochemistry O
and O
endothelial O
specific O
lectin O
( O
uea1 O
) O
binding O
studies O
, O
indicate O
that O
the O
elevation O
of O
vegf O
protein O
expression O
initially O
occurred O
in O
both O
blood O
vessels O
and O
non O
- O
endothelial O
cells O
. O

after O
15 O
days O
of O
e2 O
exposure O
, O
vegf O
/ O
vpf O
protein O
expression O
, O
in O
the O
non O
- O
endothelial O
cell O
population O
, O
sharply O
declined O
and O
was O
restricted O
to O
the O
blood O
vessels O
. O

the O
function O
of O
non O
- O
endothelial O
- O
derived O
vegf O
is O
not O
clear O
. O

furthermore O
, O
immunohistochemical O
studies O
demonstrated O
that O
vegfr O
- O
2 O
( O
flk O
- O
1 O
/ O
kdr O
) O
, O
expression O
was O
elevated O
significantly O
in O
the O
endothelial O
cells O
of O
microblood O
vessels O
after O
7 O
days O
of O
e2 O
exposure O
. O

these O
findings O
suggest O
that O
over O
expression O
of O
vegf O
and O
its O
receptor O
( O
vegfr O
- O
2 O
) O
may O
play O
an O
important O
role O
in O
the O
initial O
step O
of O
the O
regulation O
of O
estrogen O
induced O
tumor B-Disease
angiogenesis O
in O
the O
rat O
pituitary O
. O

persistent O
nephrogenic B-Disease
diabetes B-Disease
insipidus B-Disease
following O
lithium O
therapy O
. O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
severe O
hypernatraemic O
dehydration B-Disease
following O
a O
head B-Disease
injury B-Disease
. O

ten O
years O
previously O
he O
had O
been O
diagnosed O
to O
have O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes B-Disease
insipidus B-Disease
, O
and O
lithium O
therapy O
had O
been O
discontinued O
. O

he O
remained O
thirsty O
and O
polyuric B-Disease
despite O
cessation O
of O
lithium O
and O
investigations O
on O
admission O
showed O
him O
to O
have O
normal O
osmoregulated O
thirst O
and O
vasopressin O
secretion O
, O
with O
clear O
evidence O
of O
nephrogenic B-Disease
diabetes B-Disease
insipidus B-Disease
. O

lithium O
induced O
nephrogenic B-Disease
diabetes B-Disease
insipidus B-Disease
is O
considered O
to O
be O
reversible O
on O
cessation O
of O
therapy O
but O
polyuria B-Disease
persisted O
in O
this O
patient O
for O
ten O
years O
after O
lithium O
was O
stopped O
. O

we O
discuss O
the O
possible O
renal O
mechanisms O
and O
the O
implications O
for O
management O
of O
patients O
with O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes B-Disease
insipidus B-Disease
. O

effects O
of O
nik O
- O
247 O
on O
cholinesterase O
and O
scopolamine O
- O
induced O
amnesia B-Disease
. O

the O
effects O
of O
nik O
- O
247 O
on O
cholinesterase O
, O
scopolamine O
- O
induced O
amnesia B-Disease
and O
spontaneous O
movement O
were O
examined O
and O
compared O
with O
those O
of O
the O
well O
- O
known O
cholinesterase O
inhibitors O
tacrine O
and O
e O
- O
2020 O
. O

nik O
- O
247 O
, O
tacrine O
and O
e O
- O
2020 O
all O
strongly O
inhibited O
acetylcholinesterase O
( O
ache O
) O
in O
human O
red O
blood O
cells O
( O
ic50s O
= O
1 O
. O
0 O
x O
10 O
( O
- O
6 O
) O
, O
2 O
. O
9 O
x O
10 O
( O
- O
7 O
) O
and O
3 O
. O
7 O
x O
10 O
( O
- O
8 O
) O
m O
, O
respectively O
) O
. O

in O
addition O
, O
nik O
- O
247 O
and O
tacrine O
, O
but O
not O
e O
- O
2020 O
, O
strongly O
inhibited O
butyrylcholinestrase O
( O
buche O
) O
in O
human O
serum O
. O

all O
three O
drugs O
produced O
mixed O
inhibition O
of O
ache O
activity O
. O

moreover O
, O
the O
inhibitory O
effect O
of O
nik O
- O
247 O
on O
ache O
was O
reversible O
. O

all O
compounds O
at O
0 O
. O
1 O
- O
1 O
mg O
/ O
kg O
p O
. O
o O
. O
significantly O
improved O
the O
amnesia B-Disease
induced O
by O
scopolamine O
( O
0 O
. O
5 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
in O
rats O
performing O
a O
passive O
avoidance O
task O
. O

the O
three O
compounds O
at O
1 O
and O
3 O
mg O
/ O
kg O
p O
. O
o O
. O
did O
not O
significantly O
decrease O
spontaneous O
movement O
by O
rats O
. O

these O
findings O
suggest O
that O
nik O
- O
247 O
at O
a O
low O
dose O
( O
0 O
. O
1 O
- O
1 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
improves O
scopolamine O
- O
induced O
amnesia B-Disease
but O
does O
not O
affect O
spontaneous O
movement O
. O

the O
findings O
suggest O
that O
nik O
- O
247 O
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
alzheimer B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

potential O
therapeutic O
use O
of O
the O
selective O
dopamine O
d1 O
receptor O
agonist O
, O
a O
- O
86929 O
: O
an O
acute O
study O
in O
parkinsonian B-Disease
levodopa O
- O
primed O
monkeys O
. O

the O
clinical O
utility O
of O
dopamine O
( O
da O
) O
d1 O
receptor O
agonists O
in O
the O
treatment O
of O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
( O
pd B-Disease
) O
is O
still O
unclear O
. O

the O
therapeutic O
use O
of O
selective O
da O
d1 O
receptor O
agonists O
such O
as O
skf O
- O
82958 O
( O
6 O
- O
chloro O
- O
7 O
, O
8 O
- O
dihydroxy O
- O
3 O
- O
allyl O
- O
1 O
- O
phenyl O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrahydro O
- O
1h O
- O
3 O
- O
benzaze O
pine O
hydrobromide O
) O
and O
a O
- O
77636 O
( O
[ O
1r O
, O
3s O
] O
3 O
- O
[ O
1 O
' O
- O
admantyl O
] O
- O
1 O
- O
aminomethyl O
- O
3 O
, O
4 O
- O
dihydro O
- O
5 O
, O
6 O
- O
dihydroxy O
- O
1h O
- O

2 O
- O
benzo O
pyran O
hydrochloride O
) O
seems O
limited O
because O
of O
their O
duration O
of O
action O
, O
which O
is O
too O
short O
for O
skf O
- O
82958 O
( O
< O
1 O
hr O
) O
and O
too O
long O
for O
a O
- O
77636 O
( O
> O
20 O
hr O
, O
leading O
to O
behavioral O
tolerance O
) O
. O

we O
therefore O
conducted O
the O
present O
acute O
dose O
- O
response O
study O
in O
four O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
mptp O
) O
- O
exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa O
- O
induced O
dyskinesias B-Disease
to O
evaluate O
the O
locomotor O
and O
dyskinetic B-Disease
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0 O
. O
03 O
to O
1 O
. O
0 O
mg O
/ O
kg O
) O
of O
a O
- O
86929 O
( O
[ O
- O
] O
- O
[ O
5ar O
, O
11bs O
] O
- O
4 O
, O
5 O
, O
5a O
, O
6 O
, O
7 O

, O
11b O
- O
hexahydro O
- O
2 O
- O
propyl O
- O
3 O
- O
thia O
- O
5 O
- O
+ O
+ O
+ O
azacyclopent O
- O
1 O
- O
ena O
[ O
c O
] O
phenathrene O
- O
9 O
- O
10 O
- O
diol O
) O
, O
a O
selective O
and O
full O
da O
d1 O
- O
like O
receptor O
agonist O
with O
an O
intermediate O
duration O
of O
action O
. O

levodopa O
and O
the O
da O
d2 O
- O
like O
receptor O
agonist O
, O
ly O
- O
171555 O
( O
[ O
4ar O
- O
trans O
] O
- O
4 O
, O
4a O
, O
5 O
, O
6 O
, O
7 O
, O
8 O
, O
8a O
, O
9 O
- O
o O
- O
dihydro O
- O
5n O
- O
propyl O
- O
2h O
- O
pyrazo O
lo O
- O
3 O
- O
4 O
- O
quinoline O
hydrochloride O
) O
were O
also O
used O
for O
comparison O
. O

acute O
administration O
of O
a O
- O
86929 O
was O
as O
efficacious O
in O
alleviating O
mptp O
- O
induced O
parkinsonism B-Disease
as O
levodopa O
and O
ly O
- O
171555 O
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa O
- O
induced O
dyskinesias B-Disease
in O
these O
animals O
than O
with O
either O
ly O
- O
171555 O
or O
subsequent O
challenge O
of O
levodopa O
. O

selective O
stimulation O
of O
the O
da O
d1 O
receptor O
may O
provide O
better O
integration O
of O
neural O
inputs O
transmitted O
to O
the O
internal O
segment O
of O
the O
globus O
pallidus O
( O
referred O
to O
as O
the O
basal O
ganglia O
output O
) O
compared O
with O
levodopa O
and O
selective O
da O
d2 O
receptor O
agonist O
. O

potent O
da O
d1 O
receptor O
agents O
with O
an O
intermediate O
duration O
of O
efficacy O
such O
as O
a O
- O
86929 O
( O
approximately O
4 O
hr O
at O
higher O
doses O
tested O
) O
are O
potential O
therapeutic O
tools O
in O
pd B-Disease
and O
merit O
further O
attention O
. O

neuropeptide O
- O
y O
immunoreactivity O
in O
the O
pilocarpine O
model O
of O
temporal B-Disease
lobe B-Disease
epilepsy B-Disease
. O

neuropeptide O
- O
y O
( O
npy O
) O
is O
expressed O
by O
granule O
cells O
and O
mossy O
fibres O
of O
the O
hippocampal O
dentate O
gyrus O
during O
experimental O
temporal B-Disease
lobe B-Disease
epilepsy B-Disease
( O
tle B-Disease
) O
. O

this O
expression O
may O
represent O
an O
endogenous O
damping O
mechanism O
since O
npy O
has O
been O
shown O
to O
block O
seizure B-Disease
- O
like O
events O
following O
high O
- O
frequency O
stimulation O
in O
hippocampal O
slices O
. O

the O
pilocarpine O
( O
pilo O
) O
model O
of O
epilepsy B-Disease
is O
characterized O
by O
an O
acute O
period O
of O
status B-Disease
epilepticus B-Disease
followed O
by O
spontaneous O
recurrent O
seizures B-Disease
and O
related O
brain B-Disease
damage B-Disease
. O

we O
report O
peroxidase O
- O
antiperoxidase O
immunostaining O
for O
npy O
in O
several O
brain O
regions O
in O
this O
model O
. O

pilo O
- O
injected O
animals O
exhibited O
npy O
immunoreactivity O
in O
the O
region O
of O
the O
mossy O
fibre O
terminals O
, O
in O
the O
dentate O
gyrus O
inner O
molecular O
layer O
and O
, O
in O
a O
few O
cases O
, O
within O
presumed O
granule O
cells O
. O

npy O
immunoreactivity O
was O
also O
dramatically O
changed O
in O
the O
entorhinal O
cortex O
, O
amygdala O
and O
sensorimotor O
areas O
. O

in O
addition O
, O
pilo O
injected O
animals O
exhibited O
a O
reduction O
in O
the O
number O
of O
npy O
- O
immunoreactive O
interneurons O
compared O
with O
controls O
. O

the O
results O
demonstrate O
that O
changes O
in O
npy O
expression O
, O
including O
expression O
in O
the O
granule O
cells O
and O
mossy O
fibres O
and O
the O
loss O
of O
vulnerable O
npy O
neurons O
, O
are O
present O
in O
the O
pilo O
model O
of O
tle B-Disease
. O

however O
, O
the O
significance O
of O
this O
changed O
synthesis O
of O
npy O
remains O
to O
be O
determined O
. O

posteroventral O
medial O
pallidotomy O
in O
advanced O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
. O

background O
: O
posteroventral O
medial O
pallidotomy O
sometimes O
produces O
striking O
improvement O
in O
patients O
with O
advanced O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
, O
but O
the O
studies O
to O
date O
have O
involved O
small O
numbers O
of O
patients O
and O
short O
- O
term O
follow O
- O
up O
. O

methods O
: O
forty O
patients O
with O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
underwent O
serial O
, O
detailed O
assessments O
both O
after O
drug O
withdrawal O
( O
" O
off O
" O
period O
) O
and O
while O
taking O
their O
optimal O
medical O
regimens O
( O
" O
on O
" O
period O
) O
. O

all O
patients O
were O
examined O
preoperatively O
and O
39 O
were O
examined O
at O
six O
months O
; O
27 O
of O
the O
patients O
were O
also O
examined O
at O
one O
year O
, O
and O
11 O
at O
two O
years O
. O

results O
: O
the O
percent O
improvements O
at O
six O
months O
were O
as O
follows O
: O
off O
- O
period O
score O
for O
overall O
motor O
function O
, O
28 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
19 O
to O
38 O
percent O
) O
, O
with O
most O
of O
the O
improvement O
in O
the O
contralateral O
limbs O
; O
off O
- O
period O
score O
for O
activities O
of O
daily O
living O
, O
29 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
19 O
to O
39 O
percent O
) O
; O
on O
- O
period O
score O
for O
contralateral O
dyskinesias B-Disease
, O
82 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
72 O
to O
91 O
percent O
) O
; O
and O
on O
- O
period O
score O
for O
ipsilateral O
dyskinesias B-Disease
, O
44 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
29 O
to O
59 O

percent O
) O
. O

the O
improvements O
in O
dyskinesias B-Disease
and O
the O
total O
scores O
for O
off O
- O
period O
parkinsonism B-Disease
, O
contralateral O
bradykinesia B-Disease
, O
and O
rigidity B-Disease
were O
sustained O
in O
the O
11 O
patients O
examined O
at O
two O
years O
. O

the O
improvement O
in O
ipsilateral O
dyskinesias B-Disease
was O
lost O
after O
one O
year O
, O
and O
the O
improvements O
in O
postural O
stability O
and O
gait O
lasted O
only O
three O
to O
six O
months O
. O

approximately O
half O
the O
patients O
who O
had O
been O
dependent O
on O
assistance O
in O
activities O
of O
daily O
living O
in O
the O
off O
period O
before O
surgery O
became O
independent O
after O
surgery O
. O

the O
complications O
of O
surgery O
were O
generally O
well O
tolerated O
, O
and O
there O
were O
no O
significant O
changes O
in O
the O
use O
of O
medication O
. O

conclusions O
: O
in O
late O
- O
stage O
parkinson B-Disease
' B-Disease
s B-Disease
disease B-Disease
, O
pallidotomy O
significantly O
reduces O
levodopa O
- O
induced O
dyskinesias B-Disease
and O
off O
- O
period O
disability O
. O

much O
of O
the O
benefit O
is O
sustained O
at O
two O
years O
, O
although O
some O
improvements O
, O
such O
as O
those O
on O
the O
ipsilateral O
side O
and O
in O
axial O
symptoms O
, O
wane O
within O
the O
first O
year O
. O

the O
on O
- O
period O
symptoms O
that O
are O
resistant O
to O
dopaminergic O
therapy O
do O
not O
respond O
to O
pallidotomy O
. O

clarithromycin O
- O
induced O
ventricular B-Disease
tachycardia B-Disease
. O

clarithromycin O
is O
a O
relatively O
new O
macrolide O
antibiotic O
that O
offers O
twice O
- O
daily O
dosing O
. O

it O
differs O
from O
erythromycin O
only O
in O
the O
methylation O
of O
the O
hydroxyl O
group O
at O
position O
6 O
. O

although O
the O
side O
- O
effect O
profile O
of O
erythromycin O
is O
established O
, O
including O
gastroenteritis B-Disease
and O
interactions O
with O
other O
drugs O
subject O
to O
hepatic O
mixed O
- O
function O
oxidase O
metabolism O
, O
experience O
with O
the O
newer O
macrolides O
is O
still O
being O
recorded O
. O

cardiotoxicity B-Disease
has O
been O
demonstrated O
after O
both O
intravenous O
and O
oral O
administration O
of O
erythromycin O
but O
has O
never O
been O
reported O
with O
the O
newer O
macrolides O
. O

we O
report O
a O
case O
of O
ventricular B-Disease
dysrhythmias B-Disease
that O
occurred O
after O
six O
therapeutic O
doses O
of O
clarithromycin O
. O

the O
dysrhythmias B-Disease
resolved O
after O
discontinuation O
of O
the O
drug O
. O

effect O
of O
glyceryl O
trinitrate O
on O
the O
sphincter B-Disease
of B-Disease
oddi B-Disease
spasm B-Disease
evoked O
by O
prostigmine O
- O
morphine O
administration O
. O

objective O
: O
in O
this O
study O
the O
effect O
of O
glyceryl O
trinitrate O
on O
the O
prostigmine O
- O
morphine O
- O
induced O
sphincter B-Disease
of B-Disease
oddi B-Disease
spasm B-Disease
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter B-Disease
of B-Disease
oddi B-Disease
dyskinesia B-Disease
. O

method O
: O
sphincter B-Disease
of B-Disease
oddi B-Disease
spasm B-Disease
was O
induced O
by O
prostigmine O
- O
morphine O
administration O
( O
0 O
. O
5 O
mg O
prostigmine O
intramuscularly O
and O
10 O
mg O
morphine O
subcutaneously O
) O
and O
visualized O
by O
quantitative O
hepatobiliary O
scintigraphy O
. O

the O
entire O
procedure O
was O
repeated O
during O
glyceryl O
trinitrate O
infusion O
( O
nitrolingual O
1 O
microg O
/ O
kg O
/ O
min O
for O
120 O
min O
) O
. O

results O
: O
prostigmine O
- O
morphine O
provocation O
caused O
significant O
increases O
in O
the O
time O
to O
peak O
activity O
( O
tmax O
) O
over O
the O
hepatic O
hilum O
( O
hh O
: O
34 O
. O
33 O
+ O
/ O
- O
5 O
. O
05 O
vs O
. O
22 O
. O
77 O
+ O
/ O
- O
3 O
. O
26 O
) O
and O
the O
common O
bile O
duct O
( O
cbd O
: O
60 O
. O
44 O
+ O
/ O
- O
5 O
. O
99 O
vs O
. O
40 O
. O
0 O
+ O
/ O
- O
2 O
. O
88 O
) O
and O
in O
the O
half O
- O
time O
of O
excretion O
( O
t1 O
/ O
2 O
) O
over O
the O
liver O
parenchyma O
( O
lp O
: O
120 O
. O
04 O
+ O
/ O
- O
16 O
. O
01 O
vs O
. O
27 O
. O

37 O
+ O
/ O
- O
2 O
. O
19 O
) O
, O
hh O
( O
117 O
. O
61 O
+ O
/ O
- O
14 O
. O
71 O
vs O
. O
31 O
. O
85 O
+ O
/ O
- O
3 O
. O
99 O
) O
and O
cbd O
( O
158 O
. O
11 O
+ O
/ O
- O
9 O
. O
18 O
vs O
. O
40 O
. O
1 O
+ O
/ O
- O
6 O
. O
24 O
) O
, O
indicating O
a O
complete O
spasm B-Disease
at O
the O
level O
of O
the O
sphincter O
of O
oddi O
. O

glyceryl O
trinitrate O
infusion O
completely O
normalized O
the O
prostigmine O
- O
morphine O
- O
induced O
alterations O
in O
these O
quantitative O
parameters O
( O
tmax O
over O
the O
lp O
: O
11 O
. O
33 O
+ O
/ O
- O
1 O
. O
13 O
; O
over O
the O
hh O
: O
18 O
. O
88 O
+ O
/ O
- O
1 O
. O
48 O
; O
and O
over O
the O
cbd O
: O
36 O
. O
22 O
+ O
/ O
- O
1 O
. O
92 O
; O
and O
t1 O
/ O
2 O
over O
the O
lp O
: O
28 O
. O
21 O
+ O
/ O
- O
1 O
. O
83 O
; O
over O
the O
hh O
: O
33 O
. O
42 O
+ O
/ O
- O
3 O
. O
10 O
; O
and O
over O
the O
cbd O
: O
41 O
. O
66 O
+ O
/ O

- O
6 O
. O
33 O
) O
, O
suggesting O
an O
effective O
sphincter O
- O
relaxing O
effect O
of O
glyceryl O
trinitrate O
. O

conclusion O
: O
these O
results O
provide O
the O
first O
evidence O
of O
the O
effectiveness O
of O
glyceryl O
trinitrate O
on O
the O
morphine O
- O
induced O
sphincter B-Disease
of B-Disease
oddi B-Disease
spasm B-Disease
in O
humans O
. O

since O
glyceryl O
trinitrate O
is O
able O
to O
overcome O
even O
the O
drastic O
effect O
of O
morphine O
, O
it O
might O
be O
of O
relevance O
in O
the O
treatment O
of O
sphincter B-Disease
of B-Disease
oddi B-Disease
dyskinesia B-Disease
. O

immunopathology O
of O
penicillamine O
- O
induced O
glomerular B-Disease
disease B-Disease
. O

four O
patients O
with O
rheumatoid B-Disease
arthritis B-Disease
developed O
heavy O
proteinuria B-Disease
after O
five O
to O
12 O
months O
of O
treatment O
with O
d O
- O
penicillamine O
. O

light O
microscopy O
of O
renal O
biopsy O
samples O
showed O
minimal O
glomerular O
capillary O
wall O
thickening O
and O
mesangial O
matrix O
increase O
, O
or O
no O
departure O
from O
normal O
. O

electron O
microscopy O
, O
however O
, O
revealed O
subepithelial O
electron O
- O
dense O
deposits O
, O
fusion O
of O
epithelial O
cell O
foot O
processes O
, O
and O
evidence O
of O
mesangial O
cell O
hyperactivity O
. O

immunofluorescence O
microscopy O
demonstrated O
granular O
capillary O
wall O
deposits O
of O
igg O
and O
c3 O
. O

the O
findings O
were O
similar O
to O
those O
in O
early O
membranous B-Disease
glomerulonephritis B-Disease
, O
differences O
being O
observed O
however O
in O
the O
results O
of O
staining O
for O
the O
early O
- O
acting O
complement O
components O
c1q O
and O
c4 O
. O

it O
is O
tentatively O
concluded O
that O
complement O
was O
activated O
by O
the O
classical O
pathway O
. O

experimental O
cranial O
pain B-Disease
elicited O
by O
capsaicin O
: O
a O
pet O
study O
. O

using O
a O
positron O
emission O
tomography O
( O
pet O
) O
study O
it O
was O
shown O
recently O
that O
in O
migraine B-Disease
without O
aura O
certain O
areas O
in O
the O
brain O
stem O
were O
activated O
during O
the O
headache B-Disease
state O
, O
but O
not O
in O
the O
headache B-Disease
free O
interval O
. O

it O
was O
suggested O
that O
this O
brain O
stem O
activation O
is O
inherent O
to O
the O
migraine B-Disease
attack O
itself O
and O
represents O
the O
so O
called O
' O
migraine B-Disease
generator O
' O
. O

to O
test O
this O
hypothesis O
we O
performed O
an O
experimental O
pain B-Disease
study O
in O
seven O
healthy O
volunteers O
, O
using O
the O
same O
positioning O
in O
the O
pet O
scanner O
as O
in O
the O
migraine B-Disease
patients O
. O

a O
small O
amount O
of O
capsaicin O
was O
administered O
subcutaneously O
in O
the O
right O
forehead O
to O
evoke O
a O
burning O
painful B-Disease
sensation O
in O
the O
first O
division O
of O
the O
trigeminal O
nerve O
. O

increases O
of O
regional O
cerebral O
blood O
flow O
( O
rcbf O
) O
were O
found O
bilaterally O
in O
the O
insula O
, O
in O
the O
anterior O
cingulate O
cortex O
, O
the O
cavernous O
sinus O
and O
the O
cerebellum O
. O

using O
the O
same O
stereotactic O
space O
limits O
as O
in O
the O
above O
mentioned O
migraine B-Disease
study O
no O
brain O
stem O
activation O
was O
found O
in O
the O
acute O
pain B-Disease
state O
compared O
to O
the O
pain B-Disease
free O
state O
. O

the O
increase O
of O
activation O
in O
the O
region O
of O
the O
cavernous O
sinus O
however O
, O
suggests O
that O
this O
structure O
is O
more O
likely O
to O
be O
involved O
in O
trigeminal O
transmitted O
pain B-Disease
as O
such O
, O
rather O
than O
in O
a O
specific O
type O
of O
headache B-Disease
as O
was O
suggested O
for O
cluster B-Disease
headache B-Disease
. O

value O
of O
methylprednisolone O
in O
prevention O
of O
the O
arthralgia B-Disease
- O
myalgia B-Disease
syndrome O
associated O
with O
the O
total O
dose O
infusion O
of O
iron O
dextran O
: O
a O
double O
blind O
randomized O
trial O
. O

the O
safety O
and O
efficacy O
of O
total O
dose O
infusion O
( O
tdi O
) O
of O
iron O
dextran O
has O
been O
well O
documented O
. O

in O
40 O
% O
of O
treated O
patients O
, O
an O
arthralgia B-Disease
- O
myalgia B-Disease
syndrome O
develops O
. O

the O
purpose O
of O
this O
randomized O
, O
double O
- O
blind O
, O
prospective O
study O
was O
to O
investigate O
whether O
intravenous O
( O
i O
. O
v O
. O
) O
administration O
of O
methylprednisolone O
( O
mp O
) O
prevents O
this O
complication O
. O

sixty O
- O
five O
patients O
, O
34 O
women O
and O
31 O
men O
, O
ages O
36 O
to O
80 O
years O
, O
received O
either O
normal O
saline O
before O
and O
after O
tdi O
( O
group O
1 O
) O
, O
125 O
mg O
i O
. O
v O
. O
mp O
before O
and O
saline O
after O
tdi O
( O
group O
2 O
) O
, O
or O
125 O
mg O
i O
. O
v O
. O
mp O
before O
and O
after O
tdi O
( O
group O
3 O
) O
. O

patients O
were O
observed O
for O
72 O
hours O
and O
reactions O
were O
recorded O
and O
graded O
according O
to O
severity O
. O

fifty O
- O
eight O
percent O
of O
group O
1 O
patients O
, O
33 O
% O
of O
group O
2 O
, O
and O
26 O
% O
of O
group O
3 O
had O
reactions O
to O
tdi O
. O

the O
severity O
of O
reactions O
( O
minimal O
, O
mild O
, O
and O
moderate O
, O
respectively O
) O
was O
as O
follows O
: O
group O
1 O
- O
- O
6 O
, O
6 O
, O
and O
2 O
; O
group O
2 O
- O
- O
1 O
, O
5 O
, O
and O
0 O
; O
group O
3 O
- O
- O
5 O
, O
1 O
, O
and O
0 O
. O

data O
were O
analyzed O
by O
the O
two O
- O
sided O
fisher O
' O
s O
exact O
test O
using O
95 O
% O
confidence O
intervals O
with O
the O
approximation O
of O
woolf O
. O

these O
data O
demonstrate O
that O
administration O
of O
mp O
before O
and O
after O
tdi O
reduces O
the O
frequency O
and O
severity O
of O
the O
arthralgia B-Disease
- O
myalgia B-Disease
syndrome O
. O

we O
conclude O
that O
125 O
mg O
i O
. O
v O
. O
mp O
should O
be O
given O
routinely O
before O
and O
after O
tdi O
of O
iron O
dextran O
. O

prolongation B-Disease
of B-Disease
the B-Disease
qt B-Disease
interval B-Disease
related O
to O
cisapride O
- O
diltiazem O
interaction O
. O

cisapride O
, O
a O
cytochrome O
p450 O
3a4 O
( O
cyp3a4 O
) O
substrate O
, O
is O
widely O
prescribed O
for O
the O
treatment O
of O
gastrointestinal B-Disease
motility B-Disease
disorders B-Disease
. O

prolongation B-Disease
of B-Disease
qt B-Disease
interval B-Disease
, O
torsades B-Disease
de B-Disease
pointes B-Disease
, O
and O
sudden B-Disease
cardiac B-Disease
death B-Disease
have O
been O
reported O
after O
concomitant O
administration O
with O
erythromycin O
or O
azole O
antifungal O
agents O
, O
but O
not O
with O
other O
cyp3a4 O
inhibitors O
. O

a O
possible O
drug O
interaction O
occurred O
in O
a O
45 O
- O
year O
- O
old O
woman O
who O
was O
taking O
cisapride O
for O
gastroesophageal B-Disease
reflux B-Disease
disorder B-Disease
and O
diltiazem O
, O
an O
agent O
that O
has O
inhibitory O
effect O
on O
cyp3a4 O
, O
for O
hypertension B-Disease
. O

the O
patient O
was O
in O
near O
syncope B-Disease
and O
had O
qt B-Disease
- B-Disease
interval B-Disease
prolongation B-Disease
. O

after O
discontinuing O
cisapride O
, O
the O
qt O
interval O
returned O
to O
normal O
and O
symptoms O
did O
not O
recur O
. O

we O
suggest O
that O
caution O
be O
taken O
when O
cisapride O
is O
prescribed O
with O
any O
potent O
inhibitor O
of O
cyp3a4 O
, O
including O
diltiazem O
. O

cortical O
motor O
overactivation O
in O
parkinsonian B-Disease
patients O
with O
l O
- O
dopa O
- O
induced O
peak O
- O
dose O
dyskinesia B-Disease
. O

we O
have O
studied O
the O
regional O
cerebral O
blood O
flow O
( O
rcbf O
) O
changes O
induced O
by O
the O
execution O
of O
a O
finger O
- O
to O
- O
thumb O
opposition O
motor O
task O
in O
the O
supplementary O
and O
primary O
motor O
cortex O
of O
two O
groups O
of O
parkinsonian B-Disease
patients O
on O
l O
- O
dopa O
medication O
, O
the O
first O
one O
without O
l O
- O
dopa O
induced O
dyskinesia B-Disease
( O
n O
= O
23 O
) O
and O
the O
other O
with O
moderate O
peak O
- O
dose O
dyskinesia B-Disease
( O
n O
= O
15 O
) O
, O
and O
of O
a O
group O
of O
14 O
normal O
subjects O
. O

single O
photon O
emission O
tomography O
with O
i O
. O
v O
. O
133xe O
was O
used O
to O
measure O
the O
rcbf O
changes O
. O

the O
dyskinetic B-Disease
parkinsonian B-Disease
patients O
exhibited O
a O
pattern O
of O
response O
which O
was O
markedly O
different O
from O
those O
of O
the O
normal O
subjects O
and O
non O
- O
dyskinetic B-Disease
parkinsonian B-Disease
patients O
, O
with O
a O
significant O
overactivation O
in O
the O
supplementary O
motor O
area O
and O
the O
ipsi O
- O
and O
contralateral O
primary O
motor O
areas O
. O

these O
results O
are O
compatible O
with O
the O
hypothesis O
that O
an O
hyperkinetic B-Disease
abnormal B-Disease
involuntary B-Disease
movement B-Disease
, O
like O
l O
- O
dopa O
- O
induced O
peak O
dose O
dyskinesia B-Disease
, O
is O
due O
to O
a O
disinhibition O
of O
the O
primary O
and O
associated O
motor O
cortex O
secondary O
to O
an O
excessive O
outflow O
of O
the O
pallidothalamocortical O
motor O
loop O
. O

open O
- O
label O
assessment O
of O
levofloxacin O
for O
the O
treatment O
of O
acute O
bacterial O
sinusitis B-Disease
in O
adults O
. O

purpose O
: O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
levofloxacin O
( O
500 O
mg O
orally O
once O
daily O
for O
10 O
to O
14 O
days O
) O
in O
treating O
adult O
outpatients O
with O
acute O
bacterial O
sinusitis B-Disease
. O

patients O
and O
methods O
: O
a O
total O
of O
329 O
patients O
enrolled O
in O
the O
study O
at O
24 O
centers O
. O

all O
patients O
had O
a O
pre O
- O
therapy O
gram O
' O
s O
stain O
and O
culture O
of O
sinus O
exudate O
obtained O
by O
antral O
puncture O
or O
nasal O
endoscopy O
. O

clinical O
response O
was O
assessed O
on O
the O
basis O
of O
signs O
and O
symptoms O
and O
sinus O
radiograph O
or O
computed O
tomography O
results O
. O

microbiologic O
cure O
rates O
were O
determined O
on O
the O
basis O
of O
presumed O
plus O
documented O
eradication O
of O
the O
pre O
- O
therapy O
pathogen O
( O
s O
) O
. O

results O
: O
the O
most O
common O
pathogens O
were O
haemophilus O
influenzae O
, O
streptococcus O
pneumoniae O
, O
staphylococcus O
aureus O
, O
and O
moraxella O
catarrhalis O
. O

of O
300 O
clinically O
evaluable O
patients O
, O
175 O
( O
58 O
% O
) O
were O
cured O
and O
90 O
( O
30 O
% O
) O
were O
improved O
at O
the O
post O
- O
therapy O
evaluation O
, O
resulting O
in O
a O
clinical O
success O
rate O
of O
88 O
% O
. O

thirty O
- O
five O
patients O
( O
12 O
% O
) O
clinically O
failed O
treatment O
. O

the O
microbiologic O
eradication O
rate O
( O
presumed O
plus O
documented O
) O
among O
138 O
microbiologically O
evaluable O
patients O
was O
92 O
% O
. O

microbiologic O
eradication O
rates O
( O
presumed O
plus O
documented O
) O
of O
the O
most O
common O
pathogens O
ranged O
from O
93 O
% O
( O
m O
. O
catarrhalis O
) O
to O
100 O
% O
( O
s O
. O
pneumoniae O
) O
at O
the O
post O
- O
therapy O
visit O
. O

all O
but O
one O
of O
the O
265 O
patients O
who O
were O
cured O
or O
improved O
at O
post O
- O
therapy O
returned O
for O
a O
long O
- O
term O
follow O
- O
up O
visit O
; O
243 O
( O
92 O
% O
) O
remained O
well O
4 O
to O
6 O
weeks O
after O
therapy O
; O
and O
21 O
( O
8 O
% O
) O
had O
a O
relapse O
of O
symptoms O
. O

adverse O
events O
considered O
to O
be O
related O
to O
levofloxacin O
administration O
were O
reported O
by O
29 O
patients O
( O
9 O
% O
) O
. O

the O
most O
common O
drug O
- O
related O
adverse O
events O
were O
diarrhea B-Disease
, O
flatulence B-Disease
, O
and O
nausea B-Disease
; O
most O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

conclusion O
: O
the O
results O
of O
this O
study O
indicate O
that O
levofloxacin O
500 O
mg O
once O
daily O
is O
an O
effective O
and O
safe O
treatment O
for O
acute O
bacterial O
sinusitis B-Disease
. O

iatrogenic O
risks O
of O
endometrial B-Disease
carcinoma B-Disease
after O
treatment O
for O
breast B-Disease
cancer B-Disease
in O
a O
large O
french O
case O
- O
control O
study O
. O

f O
d O
ration O
nationale O
des O
centres O
de O
lutte O
contre O
le O
cancer O
( O
fnclcc O
) O
. O

since O
tamoxifen O
is O
widely O
used O
in O
breast B-Disease
cancer B-Disease
treatment O
and O
has O
been O
proposed O
for O
the O
prevention O
of O
breast B-Disease
cancer B-Disease
, O
its O
endometrial O
iatrogenic O
effects O
must O
be O
carefully O
examined O
. O

we O
have O
investigated O
the O
association O
between O
endometrial B-Disease
cancer B-Disease
and O
tamoxifen O
use O
or O
other O
treatments O
in O
women O
treated O
for O
breast B-Disease
cancer B-Disease
in O
a O
case O
- O
control O
study O
. O

cases O
of O
endometrial B-Disease
cancer B-Disease
diagnosed O
after O
breast B-Disease
cancer B-Disease
( O
n O
= O
135 O
) O
and O
467 O
controls O
matched O
for O
age O
, O
year O
of O
diagnosis O
of O
breast B-Disease
cancer B-Disease
and O
hospital O
and O
survival O
time O
with O
an O
intact O
uterus O
were O
included O
. O

women O
who O
had O
received O
tamoxifen O
were O
significantly O
more O
likely O
to O
have O
endometrial B-Disease
cancer B-Disease
diagnosed O
than O
those O
who O
had O
not O
( O
crude O
relative O
risk O
= O
4 O
. O
9 O
, O
p O
= O
0 O
. O
0001 O
) O
. O

univariate O
and O
adjusted O
analyses O
showed O
that O
the O
risk O
increased O
with O
the O
length O
of O
treatment O
( O
p O
= O
0 O
. O
0001 O
) O
or O
the O
cumulative O
dose O
of O
tamoxifen O
received O
( O
p O
= O
0 O
. O
0001 O
) O
, O
irrespective O
of O
the O
daily O
dose O
. O

women O
who O
had O
undergone O
pelvic O
radiotherapy O
also O
had O
a O
higher O
risk O
( O
crude O
relative O
risk O
= O
7 O
. O
8 O
, O
p O
= O
0 O
. O
0001 O
) O
. O

after O
adjusting O
for O
confounding O
factors O
, O
the O
risk O
was O
higher O
for O
tamoxifen O
users O
( O
p O
= O
0 O
. O
0012 O
) O
, O
treatment O
for O
more O
than O
3 O
years O
( O
all O
p O
< O
0 O
. O
03 O
) O
and O
pelvic O
radiotherapy O
( O
p O
= O
0 O
. O
012 O
) O
. O

women O
who O
had O
endometrial B-Disease
cancer B-Disease
and O
had O
received O
tamoxifen O
had O
more O
advanced B-Disease
disease B-Disease
and O
poorer O
prognosis O
than O
those O
with O
endometrial B-Disease
cancer B-Disease
who O
had O
not O
received O
this O
treatment O
. O

our O
results O
suggest O
a O
causal O
role O
of O
tamoxifen O
in O
endometrial B-Disease
cancer B-Disease
, O
particularly O
when O
used O
as O
currently O
proposed O
for O
breast B-Disease
cancer B-Disease
prevention O
. O

pelvic O
radiotherapy O
may O
be O
an O
additional O
iatrogenic O
factor O
for O
women O
with O
breast B-Disease
cancer B-Disease
. O

endometrial B-Disease
cancers B-Disease
diagnosed O
in O
women O
treated O
with O
tamoxifen O
have O
poorer O
prognosis O
. O

women O
who O
receive O
tamoxifen O
for O
breast B-Disease
cancer B-Disease
should O
be O
offered O
gynaecological O
surveillance O
during O
and O
after O
treatment O
. O

a O
long O
- O
term O
evaluation O
of O
the O
risk O
- O
benefit O
ratio O
of O
tamoxifen O
as O
a O
preventive O
treatment O
for O
breast B-Disease
cancer B-Disease
is O
clearly O
warranted O
. O

contribution O
of O
the O
glycine O
site O
of O
nmda O
receptors O
in O
rostral O
and O
intermediate O
- O
caudal O
parts O
of O
the O
striatum O
to O
the O
regulation O
of O
muscle O
tone O
in O
rats O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
contribution O
of O
the O
glycine O
site O
of O
nmda O
receptors O
in O
the O
striatum O
to O
the O
regulation O
of O
muscle O
tone O
. O

muscle O
tone O
was O
examined O
using O
a O
combined O
mechanoand O
electromyographic O
method O
, O
which O
measured O
simultaneously O
the O
muscle O
resistance O
( O
mmg O
) O
of O
the O
rat O
' O
s O
hind O
foot O
to O
passive O
extension O
and O
flexion O
in O
the O
ankle O
joint O
and O
the O
electromyographic O
activity O
( O
emg O
) O
of O
the O
antagonistic O
muscles O
of O
that O
joint O
: O
gastrocnemius O
and O
tibialis O
anterior O
. O

muscle B-Disease
rigidity B-Disease
was O
induced O
by O
haloperidol O
( O
2 O
. O
5 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

5 O
, O
7 O
- O
dichlorokynurenic O
acid O
( O
5 O
, O
7 O
- O
dcka O
) O
, O
a O
selective O
glycine O
site O
antagonist O
, O
injected O
in O
doses O
of O
2 O
. O
5 O
and O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
bilaterally O
, O
into O
the O
rostral O
region O
of O
the O
striatum O
, O
decreased O
both O
the O
haloperidol O
- O
induced O
muscle B-Disease
rigidity B-Disease
( O
mmg O
) O
and O
the O
enhanced O
electromyographic O
activity O
( O
emg O
) O
. O

5 O
, O
7 O
- O
dcka O
injected O
bilaterally O
in O
a O
dose O
of O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
into O
the O
intermediate O
- O
caudal O
region O
of O
the O
striatum O
of O
rats O
not O
pretreated O
with O
haloperidol O
had O
no O
effect O
on O
the O
muscle O
tone O
. O

the O
present O
results O
suggest O
that O
blockade O
of O
the O
glycine O
site O
of O
nmda O
receptors O
in O
the O
rostral O
part O
of O
the O
striatum O
may O
be O
mainly O
responsible O
for O
the O
antiparkinsonian O
action O
of O
this O
drug O
. O

carboplatin O
toxic O
effects O
on O
the O
peripheral O
nervous O
system O
of O
the O
rat O
. O

background O
: O
the O
most O
striking O
of O
carboplatin O
' O
s O
advantages O
( O
cbdca O
) O
over O
cisplatin O
( O
cddp O
) O
is O
its O
markedly O
reduced O
rate O
of O
neurotoxic B-Disease
effects O
. O

however O
, O
the O
use O
of O
cbdca O
higher O
- O
intensity O
schedules O
and O
the O
association O
with O
other O
neurotoxic B-Disease
drugs O
in O
polychemotherapy O
may O
cause O
some O
concern O
about O
its O
safety O
with O
respect O
to O
peripheral B-Disease
nervous B-Disease
system B-Disease
damage B-Disease
. O

materials O
and O
methods O
: O
two O
different O
schedules O
of O
cbdca O
administration O
( O
10 O
mg O
/ O
kg O
and O
15 O
mg O
/ O
kg O
i O
. O
p O
. O
twice O
a O
week O
for O
nine O
times O
) O
were O
evaluated O
in O
wistar O
rats O
. O

neurotoxicity B-Disease
was O
assessed O
for O
behavioral O
( O
tail O
- O
flick O
test O
) O
, O
neurophysiological O
( O
nerve O
conduction O
velocity O
in O
the O
tail O
nerve O
) O
, O
morphological O
, O
morphometrical O
and O
analytical O
effects O
. O

results O
: O
cbdca O
administration O
induced O
dose O
- O
dependent O
peripheral B-Disease
neurotoxicity B-Disease
. O

pain B-Disease
perception O
and O
nerve O
conduction O
velocity O
in O
the O
tail O
were O
significantly O
impaired O
, O
particularly O
after O
the O
high O
- O
dose O
treatment O
. O

the O
dorsal O
root O
ganglia O
sensory O
neurons O
and O
, O
to O
a O
lesser O
extent O
, O
satellite O
cells O
showed O
the O
same O
changes O
as O
those O
induced O
by O
cddp O
, O
mainly O
affecting O
the O
nucleus O
and O
nucleolus O
of O
ganglionic O
sensory O
neurons O
. O

moreover O
, O
significant O
amounts O
of O
platinum O
were O
detected O
in O
the O
dorsal O
root O
ganglia O
and O
kidney O
after O
cbdca O
treatment O
. O

conclusions O
: O
cbdca O
is O
neurotoxic B-Disease
in O
our O
model O
, O
and O
the O
type O
of O
pathological O
changes O
it O
induces O
are O
so O
closely O
similar O
to O
those O
caused O
by O
cddp O
that O
it O
is O
probable O
that O
neurotoxicity B-Disease
is O
induced O
in O
the O
two O
drugs O
by O
the O
same O
mechanism O
. O

this O
model O
can O
be O
used O
alone O
or O
in O
combination O
with O
other O
drugs O
to O
explore O
the O
effect O
of O
cbdca O
on O
the O
peripheral O
nervous O
system O
. O

effects O
of O
cisapride O
on O
symptoms O
and O
postcibal O
small O
- O
bowel O
motor O
function O
in O
patients O
with O
irritable B-Disease
bowel B-Disease
syndrome B-Disease
. O

background O
: O
irritable B-Disease
bowel B-Disease
syndrome B-Disease
is O
a O
common O
cause O
of O
abdominal B-Disease
pain B-Disease
and O
discomfort O
and O
may O
be O
related O
to O
disordered B-Disease
gastrointestinal B-Disease
motility B-Disease
. O

our O
aim O
was O
to O
assess O
the O
effects O
of O
long O
- O
term O
treatment O
with O
a O
prokinetic O
agent O
, O
cisapride O
, O
on O
postprandial O
jejunal O
motility O
and O
symptoms O
in O
the O
irritable B-Disease
bowel B-Disease
syndrome B-Disease
( O
ibs B-Disease
) O
. O

methods O
: O
thirty O
- O
eight O
patients O
with O
ibs B-Disease
( O
constipation B-Disease
- O
predominant O
, O
n O
= O
17 O
; O
diarrhoea B-Disease
- O
predominant O
, O
n O
= O
21 O
) O
underwent O
24 O
- O
h O
ambulatory O
jejunal O
manometry O
before O
and O
after O
12 O
week O
' O
s O
treatment O
[ O
cisapride O
, O
5 O
mg O
three O
times O
daily O
( O
n O
= O
19 O
) O
or O
placebo O
( O
n O
= O
19 O
) O
] O
. O

results O
: O
in O
diarrhoea B-Disease
- O
predominant O
patients O
significant O
differences O
in O
contraction O
characteristics O
were O
observed O
between O
the O
cisapride O
and O
placebo O
groups O
. O

in O
cisapride O
- O
treated O
diarrhoea B-Disease
- O
predominant O
patients O
the O
mean O
contraction O
amplitude O
was O
higher O
( O
29 O
. O
3 O
+ O
/ O
- O
3 O
. O
2 O
versus O
24 O
. O
9 O
+ O
/ O
- O
2 O
. O
6 O
mm O
hg O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O
001 O
) O
; O
pretreatment O
, O
25 O
. O
7 O
+ O
/ O
- O
6 O
. O
0 O
mm O
hg O
) O
, O
the O
mean O
contraction O
duration O
longer O
( O
3 O
. O
4 O
+ O
/ O
- O
0 O
. O
2 O
versus O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
2 O
sec O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O
001 O
) O
; O

pretreatment O
, O
3 O
. O
1 O
+ O
/ O
- O
0 O
. O
5 O
sec O
) O
, O
and O
the O
mean O
contraction O
frequency O
lower O
( O
2 O
. O
0 O
+ O
/ O
- O
0 O
. O
2 O
versus O
2 O
. O
5 O
+ O
/ O
- O
0 O
. O
4 O
cont O
. O
/ O
min O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O
001 O
) O
; O
pretreatment O
, O
2 O
. O
5 O
+ O
/ O
- O
1 O
. O
1 O
cont O
. O
/ O
min O
] O
than O
patients O
treated O
with O
placebo O
. O

no O
significant O
differences O
in O
jejunal O
motility O
were O
found O
in O
the O
constipation B-Disease
- O
predominant O
ibs B-Disease
group O
. O

symptoms O
were O
assessed O
by O
using O
a O
visual O
analogue O
scale O
before O
and O
after O
treatment O
. O

symptom O
scores O
relating O
to O
the O
severity O
of O
constipation B-Disease
were O
lower O
in O
cisapride O
- O
treated O
constipation B-Disease
- O
predominant O
ibs B-Disease
patients O
[ O
score O
, O
54 O
+ O
/ O
- O
5 O
versus O
67 O
+ O
/ O
- O
14 O
mm O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O
05 O
) O
; O
pretreatment O
, O
62 O
+ O
/ O
- O
19 O
mm O
] O
. O

diarrhoea B-Disease
- O
predominant O
ibs B-Disease
patients O
had O
a O
higher O
pain B-Disease
score O
after O
cisapride O
therapy O
[ O
score O
, O
55 O
+ O
/ O
- O
15 O
versus O
34 O
+ O
/ O
- O
12 O
mm O
, O
cisapride O
versus O
placebo O
( O
p O
< O
0 O
. O
05 O
) O
; O
pretreatment O
, O
67 O
+ O
/ O
- O
19 O
mm O
] O
. O

conclusion O
: O
cisapride O
affects O
jejunal O
contraction O
characteristics O
and O
some O
symptoms O
in O
ibs B-Disease
. O

prevention O
of O
breast B-Disease
cancer B-Disease
with O
tamoxifen O
: O
preliminary O
findings O
from O
the O
italian O
randomised O
trial O
among O
hysterectomised O
women O
. O

italian O
tamoxifen O
prevention O
study O
. O

background O
: O
tamoxifen O
is O
a O
candidate O
chemopreventive O
agent O
in O
breast B-Disease
cancer B-Disease
, O
although O
the O
drug O
may O
be O
associated O
with O
the O
development O
of O
endometrial B-Disease
cancer B-Disease
. O

therefore O
we O
did O
a O
trial O
in O
hysterectomised O
women O
of O
tamoxifen O
as O
a O
chemopreventive O
. O

methods O
: O
in O
october O
, O
1992 O
, O
we O
started O
a O
double O
- O
blind O
placebo O
- O
controlled O
, O
randomised O
trial O
of O
tamoxifen O
in O
women O
( O
mainly O
in O
italy O
) O
who O
did O
not O
have O
breast B-Disease
cancer B-Disease
and O
who O
had O
had O
a O
hysterectomy O
. O

women O
were O
randomised O
to O
receive O
tamoxifen O
20 O
mg O
per O
day O
or O
placebo O
, O
both O
orally O
for O
5 O
years O
. O

the O
original O
plan O
was O
to O
follow O
the O
intervention O
phase O
by O
5 O
years O
' O
follow O
- O
up O
. O

in O
june O
, O
1997 O
, O
the O
trialists O
and O
the O
data O
- O
monitoring O
committee O
decided O
to O
end O
recruitment O
primarily O
because O
of O
the O
number O
of O
women O
dropping O
out O
of O
the O
study O
. O

recruitment O
ended O
on O
july O
11 O
, O
1997 O
, O
and O
the O
study O
will O
continue O
as O
planned O
. O

the O
primary O
endpoints O
are O
the O
occurrence O
of O
and O
deaths O
from O
breast B-Disease
cancer B-Disease
. O

this O
preliminary O
interim O
analysis O
is O
based O
on O
intention O
- O
to O
- O
treat O
. O

findings O
: O
5408 O
women O
were O
randomised O
; O
participating O
women O
have O
a O
median O
follow O
- O
up O
of O
46 O
months O
for O
major O
endpoints O
. O

41 O
cases O
of O
breast B-Disease
cancer B-Disease
occurred O
so O
far O
; O
there O
have O
been O
no O
deaths O
from O
breast B-Disease
cancer B-Disease
. O

there O
is O
no O
difference O
in O
breast B-Disease
- B-Disease
cancer B-Disease
frequency O
between O
the O
placebo O
( O
22 O
cases O
) O
and O
tamoxifen O
( O
19 O
) O
arms O
. O

there O
is O
a O
statistically O
significant O
reduction O
of O
breast B-Disease
cancer B-Disease
among O
women O
receiving O
tamoxifen O
who O
also O
used O
hormone O
- O
replacement O
therapy O
during O
the O
trial O
: O
among O
390 O
women O
on O
such O
therapy O
and O
allocated O
to O
placebo O
, O
we O
found O
eight O
cases O
of O
breast B-Disease
cancer B-Disease
compared O
with O
one O
case O
among O
362 O
women O
allocated O
to O
tamoxifen O
. O

compared O
with O
the O
placebo O
group O
, O
there O
was O
a O
significantly O
increased O
risk O
of O
vascular B-Disease
events B-Disease
and O
hypertriglyceridaemia B-Disease
among O
women O
on O
tamoxifen O
. O

interpretation O
: O
although O
this O
preliminary O
analysis O
has O
low O
power O
, O
in O
this O
cohort O
of O
women O
at O
low O
- O
to O
- O
normal O
risk O
of O
breast B-Disease
cancer B-Disease
, O
the O
postulated O
protective O
effects O
of O
tamoxifen O
are O
not O
yet O
apparent O
. O

women O
using O
hormone O
- O
replacement O
therapy O
appear O
to O
have O
benefited O
from O
use O
of O
tamoxifen O
. O

there O
were O
no O
deaths O
from O
breast B-Disease
cancer B-Disease
recorded O
in O
women O
in O
the O
study O
. O

it O
is O
essential O
to O
continue O
follow O
- O
up O
to O
quantify O
the O
long O
- O
term O
risks O
and O
benefits O
of O
tamoxifen O
therapy O
. O

epileptogenic O
activity O
of O
folic O
acid O
after O
drug O
induces O
sle B-Disease
( O
folic O
acid O
and O
epilepsy B-Disease
) O

objective O
: O
to O
study O
the O
effect O
of O
folic O
acid O
- O
containing O
multivitamin O
supplementation O
in O
epileptic B-Disease
women O
before O
and O
during O
pregnancy O
in O
order O
to O
determine O
the O
rate O
of O
structural O
birth B-Disease
defects B-Disease
and O
epilepsy B-Disease
- O
related O
side O
effects O
. O

study O
design O
: O
first O
a O
randomised O
trial O
, O
later O
periconception O
care O
including O
in O
total O
12225 O
females O
. O

results O
: O
of O
60 O
epileptic B-Disease
women O
with O
periconceptional O
folic O
acid O
( O
0 O
. O
8 O
mg O
) O
- O
containing O
multivitamin O
supplementation O
, O
no O
one O
developed O
epilepsy B-Disease
- O
related O
side O
effects O
during O
the O
periconception O
period O
. O

one O
epileptic B-Disease
woman O
delivered O
a O
newborn O
with O
cleft B-Disease
lip B-Disease
and B-Disease
palate B-Disease
. O

another O
patient O
exhibited O
with O
a O
cluster O
of O
seizures B-Disease
after O
the O
periconception O
period O
using O
another O
multivitamin O
. O

this O
22 O
- O
year O
- O
old O
epileptic B-Disease
woman O
was O
treated O
continuously O
by O
carbamazepine O
and O
a O
folic O
acid O
( O
1 O
mg O
) O
- O
containing O
multivitamin O
from O
the O
20th O
week O
of O
gestation O
. O

she O
developed O
status B-Disease
epilepticus B-Disease
and O
later O
symptoms O
of O
systemic B-Disease
lupus B-Disease
erythematodes B-Disease
. O

her O
pregnancy O
ended O
with O
stillbirth B-Disease
. O

conclusions O
: O
the O
epileptic B-Disease
pregnant O
patient O
' O
s O
autoimmune B-Disease
disease B-Disease
( O
probably O
drug O
- O
induced O
lupus B-Disease
) O
could O
damage O
the O
blood O
- O
brain O
barrier O
, O
therefore O
the O
therapeutic O
dose O
( O
> O
or O
= O
1 O
mg O
) O
of O
folic O
acid O
triggered O
a O
cluster O
of O
seizures B-Disease
. O

physiological O
dose O
( O
< O
1 O
mg O
) O
of O
folic O
acid O
both O
in O
healthy O
and O
60 O
epileptic B-Disease
women O
, O
all O
without O
any O
autoimmune B-Disease
disease B-Disease
, O
did O
not O
increase O
the O
risk O
for O
epileptic B-Disease
seizures B-Disease
. O

stroke B-Disease
and O
cocaine O
or O
amphetamine O
use O
. O

the O
association O
of O
cocaine O
and O
amphetamine O
use O
with O
hemorrhagic O
and O
ischemic B-Disease
stroke B-Disease
is O
based O
almost O
solely O
on O
data O
from O
case O
series O
. O

the O
limited O
number O
of O
epidemiologic O
studies O
of O
stroke B-Disease
and O
use O
of O
cocaine O
and O
/ O
or O
amphetamine O
have O
been O
done O
in O
settings O
that O
serve O
mostly O
the O
poor O
and O
/ O
or O
minorities O
. O

this O
case O
- O
control O
study O
was O
conducted O
in O
the O
defined O
population O
comprising O
members O
of O
kaiser O
permanente O
of O
northern O
and O
southern O
california O
. O

we O
attempted O
to O
identify O
all O
incident O
strokes B-Disease
in O
women O
ages O
15 O
- O
44 O
years O
during O
a O
3 O
- O
year O
period O
using O
hospital O
admission O
and O
discharge O
records O
, O
emergency O
department O
logs O
, O
and O
payment O
requests O
for O
out O
- O
of O
- O
plan O
hospitalizations O
. O

we O
selected O
controls O
, O
matched O
on O
age O
and O
facility O
of O
usual O
care O
, O
at O
random O
from O
healthy O
members O
of O
the O
health O
plan O
. O

we O
obtained O
information O
in O
face O
- O
to O
- O
face O
interviews O
. O

there O
were O
347 O
confirmed O
stroke B-Disease
cases O
and O
1 O
, O
021 O
controls O
. O

the O
univariate O
matched O
odds O
ratio O
for O
stroke B-Disease
in O
women O
who O
admitted O
to O
using O
cocaine O
and O
/ O
or O
amphetamine O
was O
8 O
. O
5 O
( O
95 O
% O
confidence O
interval O
= O
3 O
. O
6 O
- O
20 O
. O
0 O
) O
. O

after O
further O
adjustment O
for O
potential O
confounders O
, O
the O
odds O
ratio O
in O
women O
who O
reported O
using O
cocaine O
and O
/ O
or O
amphetamine O
was O
7 O
. O
0 O
( O
95 O
% O
confidence O
interval O
= O
2 O
. O
8 O
- O
17 O
. O
9 O
) O
. O

the O
use O
of O
cocaine O
and O
/ O
or O
amphetamine O
is O
a O
strong O
risk O
factor O
for O
stroke B-Disease
in O
this O
socioeconomically O
heterogeneous O
, O
insured O
urban O
population O
. O

acute B-Disease
renal B-Disease
failure B-Disease
subsequent O
to O
the O
administration O
of O
rifampicin O
. O

a O
follow O
- O
up O
study O
of O
cases O
reported O
earlier O
. O

a O
clinical O
presentation O
is O
made O
of O
a O
2 O
- O
3 O
year O
follow O
- O
up O
of O
six O
cases O
of O
acute B-Disease
renal B-Disease
failure B-Disease
that O
have O
been O
reported O
earlier O
. O

the O
patients O
had O
developed O
transient O
renal B-Disease
failure B-Disease
after O
the O
intermittent O
administration O
of O
rifampicin O
. O

the O
stage O
of O
olig O
- O
anuria B-Disease
lasted O
for O
1 O
- O
3 O
weeks O
, O
and O
five O
of O
the O
patients O
were O
treated O
by O
hemodialysis O
. O

two O
of O
the O
patients O
died O
due O
to O
unrelated O
causes O
during O
the O
follow O
- O
up O
period O
. O

the O
four O
patients O
re O
- O
examined O
were O
clinically O
cured O
. O

pathologic O
findings O
by O
light O
microscopy O
and O
immunofluorescence O
at O
biopsy O
were O
scarce O
. O

nothing O
abnormal O
was O
seen O
by O
electron O
microscopy O
in O
two O
of O
the O
cases O
studied O
. O

renal O
function O
was O
normal O
. O

in O
three O
cases O
the O
excretion O
at O
131i O
- O
hippuran O
renography O
was O
slightly O
slowed O
. O

although O
in O
the O
acute O
stage O
the O
renal B-Disease
lesions B-Disease
histologically O
appeared O
toxic O
, O
evidence O
suggestive O
of O
an O
immunological O
mechanism O
cannot O
be O
excluded O
. O

chronic O
effects O
of O
a O
novel O
synthetic O
anthracycline O
derivative O
( O
sm O
- O
5887 O
) O
on O
normal O
heart O
and O
doxorubicin O
- O
induced O
cardiomyopathy B-Disease
in O
beagle O
dogs O
. O

this O
study O
was O
designed O
to O
investigate O
the O
chronic O
cardiotoxic B-Disease
potential O
of O
sm O
- O
5887 O
and O
a O
possible O
deteriorating O
effect O
of O
sm O
- O
5887 O
on O
low O
- O
grade O
cardiotoxicity B-Disease
pre O
- O
induced O
by O
doxorubicin O
in O
beagle O
dogs O
. O

in O
the O
chronic O
treatment O
, O
beagle O
dogs O
of O
each O
sex O
were O
given O
intravenously O
once O
every O
3 O
weeks O
, O
either O
a O
sublethal O
dose O
of O
doxorubicin O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
or O
sm O
- O
5887 O
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
. O

the O
experiment O
was O
terminated O
3 O
weeks O
after O
the O
ninth O
dosing O
. O

animals O
which O
received O
over O
six O
courses O
of O
doxorubicin O
demonstrated O
the O
electrocardiogram O
( O
ecg O
) O
changes O
, O
decrease O
of O
blood O
pressure O
and O
high O
- O
grade O
histopathological O
cardiomyopathy B-Disease
, O
while O
animals O
which O
were O
terminally O
sacrificed O
after O
the O
sm O
- O
5887 O
administration O
did O
not O
show O
any O
changes O
in O
ecg O
, O
blood O
pressure O
and O
histopathological O
examinations O
. O

to O
examine O
a O
possibly O
deteriorating O
cardiotoxic B-Disease
effect O
of O
sm O
- O
5887 O
, O
low O
- O
grade O
cardiomyopathy B-Disease
was O
induced O
in O
dogs O
by O
four O
courses O
of O
doxorubicin O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
. O

nine O
weeks O
after O
pre O
- O
treatment O
, O
dogs O
were O
given O
four O
courses O
of O
either O
doxorubicin O
( O
1 O
. O
5 O
mg O
/ O
kg O
) O
or O
sm O
- O
5887 O
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
once O
every O
3 O
weeks O
. O

the O
low O
- O
grade O
cardiotoxic B-Disease
changes O
were O
enhanced O
by O
the O
additional O
doxorubicin O
treatment O
. O

on O
the O
contrary O
, O
the O
sm O
- O
5887 O
treatment O
did O
not O
progress O
the O
grade O
of O
cardiomyopathy B-Disease
. O

in O
conclusion O
, O
sm O
- O
5887 O
does O
not O
have O
any O
potential O
of O
chronic O
cardiotoxicity B-Disease
and O
deteriorating O
effect O
on O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
in O
dogs O
. O

risk O
for O
valvular B-Disease
heart B-Disease
disease B-Disease
among O
users O
of O
fenfluramine O
and O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
use O
of O
medication O
. O

background O
: O
because O
uncontrolled O
echocardiographic O
surveys O
suggested O
that O
up O
to O
30 O
% O
to O
38 O
% O
of O
users O
of O
fenfluramine O
and O
dexfenfluramine O
had O
valvular B-Disease
disease B-Disease
, O
these O
drugs O
were O
withdrawn O
from O
the O
market O
. O

objective O
: O
to O
determine O
the O
risk O
for O
new O
or O
worsening O
valvular B-Disease
abnormalities B-Disease
among O
users O
of O
fenfluramine O
or O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
they O
began O
to O
take O
these O
medications O
. O

design O
: O
cohort O
study O
. O

setting O
: O
academic O
primary O
care O
practices O
. O

patients O
: O
46 O
patients O
who O
used O
fenfluramine O
or O
dexfenfluramine O
for O
14 O
days O
or O
more O
and O
had O
echocardiograms O
obtained O
before O
therapy O
. O

measurements O
: O
follow O
- O
up O
echocardiography O
. O

the O
primary O
outcome O
was O
new O
or O
worsening O
valvulopathy B-Disease
, O
defined O
as O
progression O
of O
either O
aortic B-Disease
or B-Disease
mitral B-Disease
regurgitation B-Disease
by O
at O
least O
one O
degree O
of O
severity O
and O
disease O
that O
met O
u O
. O
s O
. O

food O
and O
drug O
administration O
criteria O
( O
at O
least O
mild O
aortic B-Disease
regurgitation B-Disease
or O
moderate O
mitral B-Disease
regurgitation B-Disease
) O
. O

results O
: O
two O
patients O
( O
4 O
. O
3 O
% O
[ O
95 O
% O
ci O
, O
0 O
. O
6 O
% O
to O
14 O
. O
8 O
% O
] O
) O
receiving O
fenfluramine O
- O
phentermine O
developed O
valvular B-Disease
heart B-Disease
disease B-Disease
. O

one O
had O
baseline O
bicuspid B-Disease
aortic B-Disease
valve B-Disease
and O
mild O
aortic B-Disease
regurgitation B-Disease
that O
progressed O
to O
moderate O
regurgitation O
. O

the O
second O
patient O
developed O
new O
moderate O
aortic B-Disease
insufficiency B-Disease
. O

conclusion O
: O
users O
of O
diet O
medications O
are O
at O
risk O
for O
valvular B-Disease
heart B-Disease
disease B-Disease
. O

however O
, O
the O
incidence O
may O
be O
lower O
than O
that O
reported O
previously O
. O

therapeutic O
drug O
monitoring O
of O
tobramycin O
: O
once O
- O
daily O
versus O
twice O
- O
daily O
dosage O
schedules O
. O

objective O
: O
to O
evaluate O
the O
effect O
of O
dosage O
regimen O
( O
once O
- O
daily O
vs O
. O
twice O
- O
daily O
) O
of O
tobramicyn O
on O
steady O
- O
state O
serum O
concentrations O
and O
toxicity B-Disease
. O

materials O
and O
methods O
: O
patients O
undergoing O
treatment O
with O
i O
. O
v O
. O
tobramycin O
( O
4 O
mg O
/ O
kg O
/ O
day O
) O
were O
randomised O
to O
two O
groups O
. O

group O
od O
( O
n O
= O
22 O
) O
received O
a O
once O
- O
daily O
dose O
of O
tobramycin O
and O
group O
td O
( O
n O
= O
21 O
) O
received O
the O
same O
dose O
divided O
into O
two O
doses O
daily O
. O

tobramycin O
serum O
concentrations O
( O
peak O
and O
trough O
) O
were O
measured O
by O
enzyme O
multiplied O
immunoassay O
. O

the O
renal O
and O
auditory O
functions O
of O
the O
patients O
were O
monitored O
before O
, O
during O
and O
immediately O
after O
treatment O
. O

results O
: O
the O
two O
groups O
were O
comparable O
with O
respect O
to O
sex O
, O
age O
, O
body O
weight O
and O
renal O
function O
. O

no O
statistically O
significant O
differences O
were O
found O
in O
mean O
daily O
dose O
, O
duration O
of O
treatment O
, O
or O
cumulative O
dose O
. O

trough O
concentrations O
were O
< O
2 O
g O
/ O
ml O
in O
the O
two O
groups O
( O
100 O
% O
) O
. O

peak O
concentrations O
were O
> O
6 O
microg O
/ O
ml O
in O
100 O
% O
of O
the O
od O
group O
and O
in O
67 O
% O
of O
the O
td O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

mean O
peak O
concentrations O
were O
markedly O
different O
: O
11 O
. O
00 O
+ O
/ O
- O
2 O
. O
89 O
microg O
/ O
ml O
in O
od O
vs O
. O
6 O
. O
53 O
+ O
/ O
- O
1 O
. O
45 O
microg O
/ O
ml O
in O
td O
( O
p O
< O
0 O
. O
01 O
) O
. O

the O
pharmacokinetics O
parameters O
were O
: O
ke O
, O
( O
0 O
. O
15 O
+ O
/ O
- O
0 O
. O
03 O
/ O
h O
in O
od O
vs O
. O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
06 O
/ O
h O
in O
td O
) O
, O
t1 O
/ O
2 O
, O
( O
4 O
. O
95 O
+ O
/ O
- O
1 O
. O
41 O
h O
in O
od O
vs O
. O
3 O
. O
07 O
+ O
/ O
- O
0 O
. O
71 O
h O
in O
td O
) O
, O
vd O
( O
0 O
. O
35 O
+ O
/ O
- O
0 O
. O
11 O
l O
/ O
kg O
in O
od O
vs O
. O
0 O
. O
33 O
+ O
/ O
- O
0 O
. O
09 O
l O
/ O
kg O
in O
td O
) O
, O
cl O
( O
0 O
. O
86 O
+ O
/ O
- O
0 O
. O
29 O

ml O
/ O
min O
/ O
kg O
in O
od O
vs O
. O
1 O
. O
28 O
+ O
/ O
- O
0 O
. O
33 O
ml O
/ O
min O
/ O
kg O
in O
td O
) O
. O

increased O
serum O
creatinine O
was O
observed O
in O
73 O
% O
of O
patients O
in O
od O
versus O
57 O
% O
of O
patients O
in O
td O
, O
without O
evidence O
of O
nephrotoxicity B-Disease
. O

in O
td O
group O
, O
three O
patients O
developed O
decreased B-Disease
auditory B-Disease
function B-Disease
, O
of O
which O
one O
presented O
with O
an O
auditory B-Disease
loss B-Disease
of O
- O
30 O
db O
, O
whereas O
in O
the O
od O
group O
only O
one O
patient O
presented O
decreased B-Disease
auditory B-Disease
function B-Disease
. O

conclusion O
: O
this O
small O
study O
suggests O
that O
a O
once O
- O
daily O
dosing O
regimen O
of O
tobramycin O
is O
at O
least O
as O
effective O
as O
and O
is O
no O
more O
and O
possibly O
less O
toxic O
than O
the O
twice O
- O
daily O
regimen O
. O

using O
a O
single O
- O
dose O
therapy O
, O
peak O
concentration O
determination O
is O
not O
necessary O
, O
only O
trough O
samples O
should O
be O
monitored O
to O
ensure O
levels O
below O
2 O
microg O
/ O
ml O
. O

enhanced O
bradycardia B-Disease
induced O
by O
beta O
- O
adrenoceptor O
antagonists O
in O
rats O
pretreated O
with O
isoniazid O
. O

high O
doses O
of O
isoniazid O
increase O
hypotension B-Disease
induced O
by O
vasodilators O
and O
change O
the O
accompanying O
reflex O
tachycardia B-Disease
to O
bradycardia B-Disease
, O
an O
interaction O
attributed O
to O
decreased O
synthesis O
of O
brain O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
) O
. O

in O
the O
present O
study O
, O
the O
possible O
enhancement O
by O
isoniazid O
of O
bradycardia B-Disease
induced O
by O
beta O
- O
adrenoceptor O
antagonists O
was O
determined O
in O
rats O
anaesthetised O
with O
chloralose O
- O
urethane O
. O

isoniazid O
significantly O
increased O
bradycardia B-Disease
after O
propranolol O
, O
pindolol O
, O
labetalol O
and O
atenolol O
, O
as O
well O
as O
after O
clonidine O
, O
but O
not O
after O
hexamethonium O
or O
carbachol O
. O

enhancement O
was O
not O
observed O
in O
rats O
pretreated O
with O
methylatropine O
or O
previously O
vagotomised O
. O

these O
results O
are O
compatible O
with O
interference O
by O
isoniazid O
with O
gabaergic O
inhibition O
of O
cardiac O
parasympathetic O
tone O
. O

such O
interference O
could O
be O
exerted O
centrally O
, O
possibly O
at O
the O
nucleus O
ambiguus O
, O
or O
peripherally O
at O
the O
sinus O
node O
. O

structural B-Disease
and B-Disease
functional B-Disease
impairment B-Disease
of B-Disease
mitochondria B-Disease
in O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
in O
mice O
: O
suppression O
of O
cytochrome O
c O
oxidase O
ii O
gene O
expression O
. O

the O
use O
of O
adriamycin O
( O
adr O
) O
in O
cancer B-Disease
chemotherapy O
has O
been O
limited O
due O
to O
its O
cumulative O
cardiovascular B-Disease
toxicity B-Disease
. O

earlier O
observations O
that O
adr O
interacts O
with O
mitochondrial O
cytochrome O
c O
oxidase O
( O
cox O
) O
and O
suppresses O
its O
enzyme O
activity O
led O
us O
to O
investigate O
adr O
' O
s O
action O
on O
the O
cardiovascular O
functions O
and O
heart O
mitochondrial O
morphology O
in O
balb O
- O
c O
mice O
i O
. O
p O
. O
treated O
with O
adr O
for O
several O
weeks O
. O

at O
various O
times O
during O
treatment O
, O
the O
animals O
were O
assessed O
for O
cardiovascular O
functions O
by O
electrocardiography O
and O
for O
heart O
tissue O
damage O
by O
electron O
microscopy O
. O

in O
parallel O
, O
total O
rna O
was O
extracted O
from O
samples O
of O
dissected O
heart O
and O
analyzed O
by O
northern O
blot O
hybridization O
to O
determine O
the O
steady O
- O
state O
level O
of O
three O
rna O
transcripts O
encoded O
by O
the O
coxii O
, O
coxiii O
, O
and O
coxiv O
genes O
. O

similarly O
, O
samples O
obtained O
from O
the O
liver O
of O
the O
same O
animals O
were O
analyzed O
for O
comparative O
studies O
. O

our O
results O
indicated O
that O
1 O
) O
treatment O
of O
mice O
with O
adr O
caused O
cardiovascular B-Disease
arrhythmias B-Disease
characterized O
by O
bradycardia B-Disease
, O
extension O
of O
ventricular O
depolarization O
time O
( O
tqrs O
) O
, O
and O
failure O
of O
qrs O
at O
high O
concentrations O
( O
10 O
- O
14 O
mg O
/ O
kg O
body O
weight O
cumulative O
dose O
) O
; O
2 O
) O
the O
heart O
mitochondria O
underwent O
swelling B-Disease
, O
fusion O
, O
dissolution O
, O
and O
/ O
or O
disruption O
of O
mitochondrial O
cristae O
after O
several O
weeks O
of O
treatment O
. O

such O
abnormalities O
were O
not O
observed O
in O
the O
mitochondria O
of O
liver O
tissue O
; O
and O
3 O
) O
among O
the O
three O
genes O
of O
cox O
enzyme O
examined O
, O
only O
coxii O
gene O
expression O
was O
suppressed O
by O
adr O
treatment O
, O
mainly O
after O
8 O
weeks O
in O
both O
heart O
and O
liver O
. O

knowing O
that O
heart O
mitochondria O
represent O
almost O
40 O
% O
of O
heart O
muscle O
by O
weight O
, O
we O
conclude O
that O
the O
deteriorating O
effects O
of O
adr O
on O
cardiovascular O
function O
involve O
mitochondrial B-Disease
structural B-Disease
and B-Disease
functional B-Disease
impairment B-Disease
. O
